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Dear ASHM Members, friends and colleagues,
It is our great pleasure to welcome delegates to Perth, Western Australia for the 20th Annual ASHM 
Conference to be held from Wednesday 17 to Saturday 20 September 2008.
The ASHM Conference is Australasia’s premier conference in the HIV, hepatitis and related diseases 
sector. It brings together the range of disciplines involved in HIV and hepatitis management, including 
basic science, clinical medicine, community programs, education, epidemiology, Indigenous health, 
international and regional issues, nursing and allied health, policy, primary care, public health and 
prevention, and social research.
We are pleased to announce that the 2008 ASHM Conference will again be run back-to-back with the 
Australasian Sexual Health Conference with one full day of overlap on Wednesday 17 September.  
The Annual Consensus Conference is this year incorporated into the clinical stream of the main ASHM 
Conference program. The Australian Antiretroviral Guidelines sessions will be held on the afternoons 
of Thursday 18 and Friday 19 September. These sessions include evidence-based presentations from 
international and local experts on the latest research and developments in HIV treatment and provide 
the opportunity for discussion. 
Take this opportunity to explore Perth.  The conference venue is the Perth Convention Centre, within 
Perth CBD.  
Levinia Crooks, Chief Executive Officer
Australasian Society for HIV Medicine 
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Convenor:	John	Dyer
Fremantle Hospital
Lisa	Bastian
WA Health
Scott	Bowden
Victorian Infectious Diseases Reference 
Laboratory
Peter	Canavan	
National Association of People Living with 
HIV/AIDS
Tony	Cunningham
Australian Centre for HIV and Hepatitis 
Virology Research
Francine	Eades
Aboriginal Health Council of WA
Jeffrey	Grierson
Australian Research Centre in Sex, Health 
and Society (ARCSHS)
Andrew	Grulich
National Centre in HIV Epidemiology and 
Clinical Research (NCHECR)
Vickie	Knight
Sydney Sexual Health Centre
Johnson	Mak
MacFarlane Burnet Institute 
Lewis	Marshall
Fremantle Hospital – Sexual Health Clinic
Darrel	O’Donnell
New South Wales Health – AIDS and 
Infectious Diseases Branch
Heather	Worth
National Centre in HIV Social Research
Tim	Wotton
Australian Government Department of 
Health and Ageing
Levinia	Crooks,	Marina	Carman,	
Nadine	Giatras,	Daliah	Szwarc,	
Nicole	Robertson
Australasian Society for HIV Medicine
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  AusAID
  Australasian Chapter of Sexual Health Medicine
  Australian Centre in HIV and Hepatitis 
 Virology Research
  Australian Federation of AIDS Organisations
 Australian Government Department of Health 
 and Ageing
 Australian Haemophilia Foundation
  Australian Research Centre in Sex, Health 
 and Society
  Family Planning NSW
  Macfarlane Burnet Institute
  National Association of People Living with HIV/AIDS
  National Centre in HIV Epidemiology and
 Clinical Research
  National Centre in HIV Social Research
  NSW Health
  New Zealand AIDS Foundation
  Nossal Institute for Global Health
  Sexually Transmitted Infections Research Centre
  VicHealth
SECTORAL PARTNERS
The following organisations support the aims of the conference and encourage their members and 
associates to attend:
Many other organisations also contribute to the success of the ASHM conferences; we appreciate their 
support.
ENVIRONMENT POLICy
	ASHM implements a waste-reduction policy that addresses – Reduce, Reuse, Recycle. This is done before, 
during and after each conference 
	ASHM reduces the number of printed materials by using electronic communication means wherever possible, 
including the website, email, online registration and abstract submission 
	ASHM monitors final delegate numbers for an accurate forecast of catering requirements in order to avoid waste. 
Where possible, ASHM will organise leftover food to be picked up by local charities to distribute accordingly 
	ASHM aims to research and prioritise purchasing items and equipment that support the use of recycled 
materials or can be recycled after use 
	ASHM will aim to ensure that recycling bins are available onsite at all events 
	ASHM will endeavour to minimise travel through the use of teleconferences instead of face-to-face meetings 
and holding meetings only when necessary 
	ASHM encourages all conference stakeholders to consider the environment by suggesting the following: 
reduction in printing requirements; recycling conference materials; and reusing conference merchandise.  
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First Name Last Name Organisation
Lisa Bastian WA Health
Holly Beasley Prison Health Services, Dept of Corrective Services
Timothy Blackmore Wellington Hospital / Clinical Leader Laboratories and Infection Control
Karen Blyth Victorian HIV Consultancy, The Alfred 
Marcus Bogie AIDS Action Council of the ACT
Scott Bowden Victorian Infectious Diseases Reference Laboratory
Mark Boyd National Centre in HIV Epidemiology and Clinical Research 
Graham Brown WA Centre for Health Promotion Research/Community (AFAO President)
Joanne Bryant National Centre in HIV Social Research
Chris Burrell Head of Division HIV/AIDS Research Laboratory
Allison Cain Royal Perth Hospital 
Peter Canavan National Association of People Living with HIV/AIDS
Marina Carman ASHM - International Division
Stevie Clayton AIDS Council of NSW
Barry Combs Department of Health
Damian Conway Australasian Society for HIV Medicine
June Crawford National Centre in HIV Social Research        
Levinia Crooks Australasian Society for HIV Medicine
Denise Cummins Redfern Community Health Centre
Philip Cunningham St Vincent’s Hospital
Tony Cunningham Australian Centre for HIV and Hepatitis Virology Research
Elizabeth Dax National Serology Reference Laboratory
Erol Digiusto National Centre in HIV Social Research
Kate Dolan National Drug and Alcohol Research Centre
Greg Dore National Centre in HIV Epidemiology and Clinical Research
Gary Dowsett Australian Research Centre in Sex, Health and Society
Heidi Drummer Macfarlane Burnet Institute
John Dyer Fremantle Hospital
Barry Edwards Cambodian HIV/AIDS Education & Care
Suzanne Fraser National Centre in HIV Social Research  
Martyn French Royal Perth Hospital
Rosemary Ffrench Macfarlane Burnet Institute
Roger Garsia Royal Prince Alfred Hospital
Paul Goldwater Women’s and Children’s Hospital
Jeffrey Grierson Australian Research Centre in Sex, Health and Society
Andrew Grulich National Centre in HIV Epidemiology and Clinical Research
Philip Habel Interchange General Practice
David Harrich Queensland Institute of Medical Research   
Martin Holt National Centre in HIV Social Research 
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First Name Last Name Organisation
Max Hopwood National Centre in HIV Social Research   
Jennifer Hoy Alfred Hospital
John Imrie National Centre in HIV Social Research    
Anthony Jaworowski Burnet Institute
John Kaldor National Centre in HIV Epidemiology and Clinical Research
Adeeba Kamarulzaman University of Malaya 
Tony Kelleher St Vincent’s Hospital - Centre for Immunology
Stephen Kent University of Melbourne
Alison Kesson The Childrens Hospital at Westmead
Vickie Knight Clinical Nurse Consultant Sydney Sexual Health Centre 
Henrike Korner National Centre in HIV Social Research   
Sue Laing Department of Health Western Australia
Stephen Lambert The University of Queensland
Sharon Lewin Alfred Hospital - Infectious Disease Unit  
Sam Libertino Fremantle Hospital
Lisa Maher National Centre in HIV Epidemiology and Clinical Research
Donna Mak Notre Dame and Department of Health
Johnson Mak Burnet Institute
Limin Mao National Centre in HIV Social Research       
Deborah Marriott St Vincent’s Hospital
Lewis Marshall Fremantle Hospital
Dale McPhee National Serology Reference Laboratory
Graham Mills Waikato Hospital - Sexual Health Clinic
Christy Newman National Centre in HIV Social Research      
Catherine O’Connor Livingstone Road Sexual Health Centre
Alan Pithie Christchurch Hospital - Infectious Diseases Department         
Marian Pitts Australian Research Centre in Sex, Health and Society
Jeffrey Post Prince of Wales Hospital
Andy Poumbourios Macfarlane Burnet Institute
Patricia Price Royal Perth Hospital
Damian Purcell University of Melbourne - Department of Microbiology and  Immunology     
John Quin Bigge Park Centre Interferon Treatment Unit
Patrick Rawstorne National Centre in HIV Social Research      
Nigel Raymond Capital Coast Health
Vanessa Read Department of Corrective Services
Jacqui Richmond St Vincent’s Hospital - Dept of Gastroenterology
Gary Rogers Secretariat of the Pacific Community 
John Rule National Association of People Living with HIV/AIDS
Darren Russell Sexual Health Cairns Sexual Health Service
REVIEW
ERS
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First Name Last Name Organisation
Joe Sasadeusz Victorian Infectious Disease Service, Alfred Hospital
Cindy Shannon Shannon Consulting Services
David Shaw Royal Adelaide Hospital
Tuck Meng Soo Interchange General Practice
Chad Stewart Aboriginal Health Council of WA                  
Alan Street Royal Melbourne Hospital - Victorian Infectious Diseases Service
Gilda Tachedjian MacFarlane Burnet Institute
Mark Thomas Auckland Hospital - Adult Infectious Diseases Unit    
Carla Treloar National Centre in HIV Social Research    
Ashley Watson Canberra Sexual Health Centre       
Jo Watson National Association of People Living with HIV/AIDS
John Wilkinson Westmead Hospital - Millennium Institute - Centre of Virus Research      
Jon Wills Australian Research Centre in Sex, Health and Society 
Ian Woolley Monash Medical Centre
Heather Worth National Centre in HIV Social Research 
Edwina Wright Alfred Hospital    
Rudyard yap Palmerston North Hospital
John Ziegler Sydney Childrens Hospital
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A heritage of rich scientific vision 
A future of broad scientific scope
innovAtions in Hiv cAre focused on tHe pAtient
GlaxoSmithKline is proud to be a Gold Sponsor 
of the ASHM 20th Annual Conference.
Come and see our team at the GSK Booth
GlaxoSmithKline Australia Pty Ltd. 1061 Mountain Hwy, Boronia, Victoria, 3155. 
ABN 47 100 162 481. For all enquiries, please phone: 1800 033 109. PC0807410 GSKA 7/08
PC0807410_v1.1.indd   1 24/7/08   12:06:53 PM
Program 
at a glance

17-20 SepteMber 2008 @ pertH ConVentIon Centre, WeStern AuStrAlIA                           13
W
ED
N
ES
D
AY
	1
7	
SE
PT
EM
BE
R	
20
08
	
PR
O
G
RA
M
	A
T	
A
	G
LA
N
C
E
WEDNESDAy 17 SEPTEMBER
7.30am Registration Opens
8.00am 
- 9.00am
Arrival Coffee/Tea in Pavillion 1 
8.30am - 
10.30am
ASHM Opening Ceremony and Plenary 1 9.00am 
- 10.30am
Sexual Health Plenary 5:
A Mixed Bag of Jewels
Riverside Theatre/Auditorium Meeting Room 1,2,3
10.30am 
- 
11.00am
Morning Tea in Exhibition & Poster Area in Pavilion 1 
11.00am - 
12.30pm
Women Risk HIV - 
International 11.00am 
- 12.30pm
ACH2 Bench to Bed: 1 11.00am 
- 12.30pm
Sexual Health Plenary 6: 
Drugs and Sex
Riverside Theatre/Auditorium Meeting Room 8 Meeting Room 1,2,3
12.30pm 
- 1.30pm
Lunch in Exhibition & Poster Area in Pavilion 1 
12.45pm 
- 1.15pm
Launch of the Annual Surveillance Report and the Annual Report of Trends in Behaviour from the National Centre 
in HIV Epidemiology and Clinical Research 
Meeting Room 8; Lunch will be provided there for attendees from 12.30pm
1.30pm 
- 3.00pm
IDU - Domestic 1.30pm 
- 3.00pm
ACH2 Bench to Bed: 2 1.30pm 
- 3.00pm
Sexual Health Plenary 7: 
Out of Sight Out of Mind
Riverside Theatre/Auditorium Meeting Room 8 Meeting Room 1,2,3
3.00pm 
- 3.30pm
Afternoon Tea in Exhibition & Poster Area in Pavilion 1 
3.30pm 
- 5.00pm
Virology/Immunology 3.30pm 
- 5.00pm
Planning Requires 
Economic and Quality 
Review
3.30pm 
- 5.00pm
Sexual Health Conference 
Closing
Riverside Theatre/Auditorium Meeting Room 8 Meeting Room 1,2,3
5.15pm 
- 6.15pm
Circumcision: Crown Jewels 5.15pm 
- 6.15pm
Diagnostics and Assay 
Development
Riverside Theatre/Auditorium Meeting Room 1,2,3
7.30pm - 
11.30pm
Joint Conference Dinner, ‘Diamonds are Forever’ - Bellevue Ballroom, Perth Convention Centre 
Sponsored by the Australian Government Department of Health and Ageing, WA Health, Gilead, GlaxoSmithKline, 
Boehringer Ingelheim and Merck Sharp & Dohme
14                17-20 SepteMber 2008 @ pertH ConVentIon Centre, WeStern AuStrAlIA
TH
U
RS
D
AY
	1
8	
SE
PT
EM
BE
R	
20
08
	
PR
O
G
RA
M
	A
T	
A
	G
LA
N
C
E
THURSDAy 18 SEPTEMBER
7.00am Registration Opens
7.30am 
- 8.45am
Breakfast Session - ‘Meet the Experts’ - Clinical 8.00am 
- 8.45am
Oral Poster Session - Social Research, International, 
Community, Indigenous Health
Riverview 4 Meeting Room 1,2,3
8.00am 
- 9.00am Arrival Coffee/Tea in Exhibition & Poster Area in Pavilion 1 
9.00am- 
10.30am
HIV and Ageing
Riverside Theatre/Auditorium
10.30am 
- 11.00am Morning Tea in Exhibition & Poster Area in Pavilion 1 
11.00am - 
12.30pm
Hot Topics: Top 
Papers of 2008
11.00am 
- 12.30pm
Community 
Research into 
Practice 11.00am - 
12.30pm
International: Global 
HIV Initiatives vs 
Local Response 11.00am - 
12.30pm
Margaret 
Macdonald 
Memorial Session 
- Epidemiology 
Population
Riverside 
Theatre/
Auditorium
Riverview 4 Meeting Room 1,2,3 Meeting Room 8
12.30pm 
- 1.30pm Lunch in Exhibition & Poster Area in Pavilion 1 
12.30pm 
- 1.30pm ASHM AGM in Meeting Room 6; Lunch will be provided here to attendees 
1.30pm 
- 3.00pm
Australian 
Antiretroviral 
Guidelines: 
Consensus 
Session
1.30pm 
- 3.00pm
Social Research 
- Desire
1.30pm 
- 3.00pm
AusAID Session 
- Indonesia
1.30pm 
- 3.00pm
HIV Immunology
Riverside 
Theatre/
Auditorium
Riverview 4 Meeting Room 1,2,3 Meeting Room 8
3.00pm 
- 3.30pm Afternoon Tea in Exhibition & Poster Area in Pavilion 1 
3.30pm 
- 4.55pm
Ian Thompson 
Memorial 
Session 
- Clinical Anti 
Retroviral 
Therapy
3.30pm 
- 5.00pm
Epidemiology 
- Morbidity and 
Mortality 3.30pm 
- 5.00pm
CALD Media
3.30pm 
- 5.00pm
Prevention and 
Treatment Issues 
for Older Gay Men 
- Sponsored by 
NSW Health and 
ACON
Riverside 
Theatre/
Auditorium
Riverview 4 Meeting Room 1,2,3 Meeting Room 8
5.00pm 
- 6.30pm
Policy: Australia’s Response to HIV in Asia 
and the Pacific: New Partnerships and 
Collaborations 5.00pm 
- 6.30pm
Response and 
Predictions in ART 5.00pm 
- 6.30pm
Adherence to 
Antiretroviral 
Therapy
Riverside Theatre/Auditorium Riverview 4 Meeting Room 1,2,3
6.30pm 
- 7.00pm
Launch of the Prison Entrants’ Blood Borne Virus Report in Riverside Theatre/Auditorium
Sponsored by WA Health on behalf of the National Drug Research Institute
Free Evening 
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FRIDAy 19 SEPTEMBER
7.00am Registration
7.00am - 
8.45am
Case Presentation Breakfast 7.45am 
- 8.45am
Oral Poster Session - Public Health and 
Epidemiology
Riverview 4 Meeting Room 1,2,3
8.00am - 
9.00am Arrival coffee/tea in Exhibition & Poster Area in Pavilion 1 
9.00am- 
10.30am
Plenary - Prevention 
Riverside Theatre/Auditorium
10.30am 
- 
11.00am
Morning Tea in Exhibition & Poster Area in Pavilion 1 
11.00am 
- 
12.30pm
Peter Meese 
Memorial 
Session - Clinical 
- Associated 
Conditions 
Complications
11.00am - 
12.30pm
Indigenous 
Health 11.00am - 
12.30pm
Epidemiology 
- Transmission/ 
Acquisition 11.00am - 
12.30pm
International: 
Where to for Testing 
and Counselling 
in Resource-Poor 
Settings?
Riverside Theatre/
Auditorium Riverview 4
Meeting Room 
1,2,3 Meeting Room 8
12.30pm 
- 1.30pm Lunch in Exhibition & Poster Area in Pavilion 1 
1.30pm - 
3.00pm
Australian 
Antiretroviral 
Guidelines: 
Consensus 
Session
1.30pm - 
3.00pm
Social Research 
- Sexual Risk in 
Space and Time 1.30pm - 
3.00pm
International: 
PNG 1.30pm 
- 3.00pm
Phillip Medcalf 
Memorial Session 
- Community, 
Health Choices and 
Communication
Riverside Theatre/
Auditorium Riverview 4
Meeting Room 
1,2,3 Meeting Room 8
3.00pm - 
3.30pm Afternoon Tea in Exhibition & Poster Area in Pavilion 1 
3.30pm Exhibition Closes
3.30pm - 
5.00pm
Clinical - Toxicity
3.30pm - 
5.00pm
Network Sex
3.30pm - 
5.00pm
International 
-  Harm 
Reduction in 
Asia
3.30pm 
- 5.00pm
Social Research - 
Lives Worth Living
Riverside Theatre/
Auditorium Riverview 4
Meeting Room 
1,2,3 Meeting Room 8
5.15pm - 
6.30pm
Swiss Statement 5.15pm - 
6.30pm
Media Event - HIV Epidemiology and Public Health 
Response in WA 
Riverside Theatre/Auditorium Meeting Room 1,2,3
Free Evening
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SATURDAy 20 SEPTEMBER
7.00am Registration
7.30am 
- 8.45am
Breakfast Session - ‘Meet the Experts’ - Basic 
Science/Immunology
Riverview 4
7.45am 
- 8.45am 
Oral Poster Session - Clinical, Allied Health and 
Basic Science
Meeting Room 1,2,3
8.00am 
- 9.00am Arrival coffee/tea in Foyer, Level 2 
9.00am- 
10.30am
Clinical 
Epidemiology
9.00am- 
10.30am
Social Research 
- Listen Up: 
International 
Perspective on 
young People and 
HIV Risk
9.00am- 
10.30am
Blood-
Borne 
Viruses: Co-
Infection 9.00am- 
10.30am
Program Delivery
Riverside 
Theatre/
Auditorium
Riverview 4 Meeting Room 1,2,3 Meeting Room 8
10.30am 
- 11.00am Morning Tea in Foyer, Level 2
11.00am 
- 12.45pm
Plenary - HIV AND TB Coinfection and Conference Closing
Riverside Theatre/Auditorium
12.45pm 
- 1.45pm Lunch in Foyer, Level 2 
1.45pm Conference Close
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ACON  Presents:
Prevention and Treatment Issues for Older Gay Men.
A sponsored ASHM conference session on differences in risk, 
behaviour and health promotion need in men over 40 
The average age of seroconversions is 
increasing; people with HIV are living longer 
and more men in their 40s and 50s are 
becoming HIV positive. This 90 minute session 
brings together a range of researchers, 
service delivery and health promotion 
professionals to explore appropriate HIV 
prevention and health promotion responses 
for older gay men.
The session will include an examination 
of available data - both nationally and 
internationally - that highlight issues in 
relation to risk behaviour impacting on 
seroconversions amongst this group. 
Additionally, the session will explore aspects 
of sex cultures and the framing of prevention 
messages, specific interventions targeted to 
older HIV positive men, as well as explore  the 
implications for an ageing GLBT community, 
including workforce development needs in the 
medical and aged care sectors. 
Thursday 18 September 3.30pm – 5.00pm Meeting Room 8
Chairs:
Stevie Clayton
ACON
Geoff Honnor 
NSW Health 
Panellists:
Garrett Prestage
NCHECR
John Imrie
NCHSR
Dermot Ryan
ACON
Russell Westacott
ACON
Rob Lake
Positive Life NSW
Supported by a funding grant from:
invited sPeakers
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MARTYN	FRENCH
Clinical Professor of Pathology and Laboratory 
Medicine at the University of Western Australia and 
a Clinical Immunologist at Royal Perth Hospital and 
PathWest Laboratory Medicine, Perth, Australia. 
Martyn French has been interested in the 
management of patients with acquired and 
primary immunodeficiency disorders since 1980 
and has conducted research on the immunology 
of HIV infection since 1986. He is currently a 
member of INSIGHT Network Immunology Group. 
He has participated in the Australian HIV clinical 
trials program since the late 1980s and is currently 
Chair of the Antiretroviral Working Group of 
The National Centre in HIV Epidemiology and 
Clinical Research. His particular area of  expertise 
is disorders of immune reconstitution in HIV 
patients receiving antiretroviral therapy and he 
first described immune restoration disease in 
1992. He is an author of over 170 publications 
and a member of the editorial boards of AIDS and 
Clinical Immunology.
PAUL	GORRY
Head, HIV Molecular Pathogenesis Laboratory, 
Burnet Principal Fellow, Macfarlane Burnet Institute 
for Medical Research & Public Health. Associate 
Professor of Medicine, Monash University, 
Melbourne
Paul Gorry completed his PhD in 1998, which 
examined mechanisms controlling HIV replication 
in brain astrocytes. From 1999 to 2002 he undertook 
postdoctoral studies at the Dana-Farber Cancer 
Institute at Harvard Medical School in Boston, 
where he researched mechanisms contributing 
to neurotropism and neurovirulence of HIV and 
host factors contributing to HIV transmission and 
persistence. In 2002 he returned to the Burnet 
Institute to head the HIV Molecular Pathogenesis 
Laboratory. Paul is presently Principal Fellow of the 
Burnet Institute Faculty, Associate Professor in the 
Department of Medicine at Monash University, 
and Associate Professor in the Department of 
Microbiology and Immunology at the University 
of Melbourne. His major research interests are 
pathogenesis of CCR5-restricted HIV variants, 
structure-function relationships of the HIV Env 
glycoproteins, and HIV neuropathogenesis.
CHRIS	BURRELL
After graduation, Prof Burrell trained at Prince 
Henry and Prince of Wales Hospitals in Sydney 
and completed a PhD on virus replication at ANU. 
He then spent 8 years as Lecturer in Bacteriology 
at Edinburgh University and the Royal Infirmary, 
Edinburgh, where he led a research laboratory 
on hepatitis B and trained in clinical virology. He 
moved to IMVS in 1979, and since 1990 has been 
Professor of Virology in the University of Adelaide 
and concurrently head of the Infectious Diseases 
Laboratories, IMVS. His research interests have 
included the molecular biology and pathogenesis 
of virus infections, particularly hepatitis B, HIV 
and papillomavirus; diagnostic virology; virus 
epidemiology and prevention. He has been active 
in NHMRC since 1980’s, and has been member 
or chair of various advisory committees in the 
Government and private sector.
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ROY	GULICK
Professor of Medicine at Weill Medical College 
of Cornell University, Director of the Cornell HIV 
Clinical Trials Unit of the Division of International 
Medicine and Infectious Diseases, and Attending 
Physician at the New york Presbyterian Hospital in 
New york City
Dr Gulick is Director of the Cornell HIV Clinical Trials 
Unit and Professor of Medicine at Weill Medical 
College of Cornell University in New york City.  His 
research interests include designing, conducting 
and analysing clinical trials to refine antiretroviral 
therapy strategies and assess antiretroviral drugs 
with new mechanisms of action.  He currently 
serves as Principal Investigator of the Cornell Clinical 
Trials Unit and as Chairman of the Optimization 
of Antiretroviral Therapy Committee of the AIDS 
Clinical Trials Group (ACTG), sponsored by the 
National Institutes of Health.   He also serves as a 
board member of the International AIDS Society-
USA and as a member of the Panel on Clinical 
Practices for Treatment of HIV Infection of the US. 
Department of Health and Human Services.  He 
is a member of the American Society of Clinical 
Investigation and the International AIDS Society 
and has presented at national and international 
meetings and published widely in the field of HIV/
AIDS.IN
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ADEEBA	KAMARULzAMAN
Head, Infectious Diseases Unit, Department 
of Medicine, University of Malaya Medical Centre, 
Malaysia
Professor Adeeba Kamarulzaman is presently 
the Head and Professor of Infectious Diseases 
at the University of Malaya where she oversees 
the running of an HIV/AIDS tertiary referral and 
research centre in Kuala Lumpur. 
In addition to her clinical and academic 
commitments, she has been actively involved 
in the community response to HIV/AIDS in 
Malaysia. As convenor of the Malaysian Harm 
Reduction Working Group of the Malaysian AIDS 
Council, she successfully led the advocacy for the 
implementation of harm reduction, including oral 
substitution therapy and needle syringe programs 
in Malaysia in 2005. In January 2006 she was 
elected President of the Malaysian AIDS Council, 
the umbrella organization for all AIDS NGOs in 
Malaysia. In this capacity, she has been further 
involved in advocating for and overseeing the 
implementation of community-based HIV/AIDS 
programmes across the country.  She is presently 
the Chair of the TREAT Asia Steering Committee, 
and is a member of the Executive Committee 
and Advisory Boards of the International Harm 
Reduction Association and the International 
Harm Reduction Development, as well as the 
American Foundation for AIDS Research (amfAR). 
Additionally, she is an Executive Committee 
member of the United Nations Regional Task 
Force on HIV Prevention Amongst Drug Users, and 
a member of the United Nations Reference Group 
on HIV and Injecting Drug Use. 
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ANTHONY	KELLEHER	
Associate Professor of Medicine at the University 
of New South Wales and Group Head of the 
Immunovirology and Pathogenesis Program of the 
National Centre in HIV and Epidemiology Clinical 
Research. He is also a Clinical Immunologist and 
Immunopathologist at Saint Vincent’s Hospital, n 
Sydney, Australia. 
Over the last 16 years Professor Kelleher has 
conducted extensive clinical and laboratory- based 
research into the immunopathogenesis of HIV-
infection, particularly with regards CD4 and CD8 T-
cell responses during primary infection and in long-
term non-progressors. He has conducted studies 
describing the impact of various therapeutic 
interventions on these responses. These studies 
complement his interest in the impact of immune 
responses on viral evolution and escape. He has 
been responsible for the conduct of several trials of 
immunotherapeutics and has been involved with 
each of the prophylactic HIV vaccine trials so far 
conducted in Australia. He works collaboratively 
with other Australian and international groups 
in the USA, Europe and Thailand. This work has 
resulted in a large number of peer-reviewed 
publications.  In 2007 he was awarded a National 
Health and Medical Research Council Practitioner 
Fellowship.
SIMON	MALLAL
Director of the Institute for Immunology and 
Infectious Diseases at Murdoch University and 
Royal Perth Hospital, Western Australia.  
Simon Mallal studied medicine at the University of 
Western Australia and has managed patients with 
HIV, auto-immune and allergic disease in Perth 
since 1987, and supervises the associated routine 
diagnostic immunology and molecular biology 
laboratory.  He is a Clinical Immunologist trained in 
Internal Medicine and Pathology and completed a 
Post-Doctoral Fellowship in Infectious Diseases at 
the Johns Hopkins School of Medicine, Baltimore, 
Maryland.  
He has had a longstanding research interest in 
the genes which influence the outcomes of HIV 
and other diseases.  More recently, he has focused 
on the way viruses adapt to the immune system 
of the patient and the implications of this for 
HIV vaccine design and other newly emerging 
infectious disease threats.  His group also studies 
the genetics and mechanisms by which drugs 
may cause severe side effects.  Their discovery of a 
genetic test to predict those patients predisposed 
to develop a potentially life-threatening reaction 
to the important anti-HIV drug abacavir has been 
taken up globally and represents one of the first 
successful implementations of personalised 
medicine.  
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GITA	RAMJEE
Medical Research Council HIV/AIDS Lead 
Programme and HIV Prevention Research Unit 
Durban, South Africa
Gita Ramjee is the Director of the South African 
Medical Research Council’s HIV Prevention Research 
Unit and Director of the HIV/AIDS lead program. 
She was awarded distinguished visiting professor 
by Tamil Nadu Medical University in Chennai, India. 
In 1988, she joined the Department of Pediatrics 
at the University of Kwazulu Natal to complete 
a masters degree, studying fungal diseases in 
malnourished children. She then completed her 
PhD in kidney diseases of childhood.  In the early 
1990s, she joined the Medical Research Council 
to work on HIV/AIDS, and in particular women-
initiated HIV prevention options.  She is well known 
for her work on HIV prevention trials.  Her unit is the 
only one worldwide which conducted 4 Phase III 
and 1 Phase IIB trial of women-initiated prevention 
methods consecutively. She has authored over 
50 peer-reviewed publications and serves as 
a reviewer for many international journals and 
research organisations. In 2006, she was a finalist 
in the science category of the Woman of the year 
award in South Africa.  She is an invited member of 
several societies in recognition of her contribution 
to the field of HIV prevention.
SARAH	ROWLAND-JONES
Human Immunology Unit, John Radcliffe Hospital, 
Oxford, United Kingdom
Sarah Rowland-Jones qualified in medicine from 
the universities of Cambridge and Oxford, and 
trained in Infectious Diseases in London and 
Oxford. She began her research career in Oxford 
with Professor Andrew McMichael on the role of 
cellular immune responses to viral infections. Since 
1995 she has led a research group in the Medical 
Research Council (MRC) Human Immunology Unit 
in Oxford, studying the role played by cytotoxic T-
cells in determining the outcome of HIV infection, 
as well as dengue and influenza virus infections. A 
key focus of the work has been the study of immune 
responses to HIV in people with an unusually good 
outcome of their exposure to the virus.  Since 2004 
she has worked as Director of Research in the MRC 
laboratories in the Gambia, the UK’s oldest and 
largest overseas research unit, which has led to a 
shift in her research focus towards understanding 
the pathogenesis of and immune response to HIV-
2 infection in West Africa.
BRUNO	SPIRE
Social Researcher, Marseilles, France
Bruno Spire got his MD degree in 1985 and his 
PhD in virology in 1990. In the early 1980s he 
worked in the laboratory at the Institut Pasteur 
with Françoise Barré-Sinoussi and participated in 
the first studies aimed at characterising HIV. In the 
1990s he worked in HIV molecular virology on the 
role of the vif accessory gene. In 1999, he switched 
to social sciences and public health issues and 
focused on adherence to antiretroviral treatment, 
quality of life and risky behaviours of people living 
with HIV/AIDS. He has a permanent position at 
the French National Research Institute for Medical 
Research and leads his own group in the field of 
public health applied to HIV. Dr Spire is openly 
HIV-positive and is the new president of AIDES, the 
French community-based NGO.
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DAVID	WILSON
Senior Lecturer, Curtin University of Technology, 
Perth
David has worked in the field of HIV prevention for 
over 20 years as an academic and practitioner. He is 
currently Acting Director and Lead Health Specialist 
in the Global HIV/AIDS Program of the World Bank. 
He holds an adjunct professorial position at the 
Centre for International Health at Curtin University 
of Technology in Perth, Western Australia. He has 
worked in over 50 countries in Africa, Asia, Eastern 
Europe, the Middle East and the Caribbean. He 
has also consulted on HIV prevention for several 
international agencies, including AusAID, DFID, 
EU, USAID, UNAIDS, UNICEF, USAID and the World 
Bank. His major research and applied interests are 
in the use of surveillance systems to characterise 
HIV epidemics, understand critical HIV/AIDS 
transmission dynamics and intervention priorities 
and to promote HIV prevention responses that are 
grounded in a thorough understanding of national 
and local HIV epidemics – an understanding of the 
“last 1,000 infections in a given context.
PIETRO	VERNAzzA
Division of Infectious Diseases of a tertiary hospital 
in Eastern Switzerland, St. Gallen and President of 
the Swiss Federal Commission on AIDS 
              
Pietro Vernazza trained in internal medicine and 
infectious diseases in St.Gallen, Switzerland and 
at the University of North Carolina at Chapel 
Hill. Since the early 1990s he focused his clinical 
research on co-factors of sexual transmission of HIV 
and  in the past six years has begun to investigate 
options for simplified maintenance treatment 
with PI monotherapy for HIV. Dr Vernazza is 
a member of the Swiss HIV Cohort where he 
chaired the Scientific Board from 2001 to 2007. 
Since 2000 he has been head of the Division of 
Infectious Diseases of a tertiary hospital in Eastern 
Switzerland, St. Gallen. He is currently president of 
the Swiss Federal Commission on AIDS.
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ROBIN	WOOD
Director of the Desmond Tutu HIV Centre Institute 
of Infectious Disease and Molecular Medicine, 
University of Cape Town Faculty of Health Sciences 
Observatory, South Africa
Professor Robin Wood completed his 
undergraduate training at the universities of 
Oxford and London and carried out post-graduate 
training in internal medicine at the University of 
Cape Town, and infectious diseases training at 
Stanford Medical School, California. Since 1993 
he supervised the first dedicated HIV clinic in the 
Western Cape at Somerset Hospital (Cape Town, 
South Africa). He has overseen the development 
of HIV care services within the public sector 
at secondary hospital, community health and 
primary health clinic levels. 
Professor Wood is currently the Director of the 
Desmond Tutu HIV Centre. He supervises the largest 
community ART clinic in the Western Cape and the 
TB/HIV Research programme in Masiphumelele, a 
local township.His major research interests are in 
the fields of infectious diseases and HIV. He has 
published widely in the areas of HIV management, 
tuberculosis interaction with HIV and new drug 
development.
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MARGARET	MACDONALD
Dr Margaret MacDonald, a Senior Lecturer at the 
National Centre for Epidemiology and Clinical 
Research, died on 29 September 2003 after a 
very brief illness. She had made a substantial 
contribution to Australia’s remarkable response 
to the threat of an HIV epidemic. Dr MacDonald 
was a nurse before developing her career as 
a public health researcher. She devised and 
established a series of inexpensive, timely and 
effective epidemiological monitoring techniques, 
especially for populations of injecting drug 
users. Her influence extended beyond Australia 
through this work. Dr MacDonald is best known 
for developing in 1995 an annual survey of 
demographic characteristics, drug consumption, 
risk behaviour, and hepatitis C and HIV serology. 
She had recently contributed substantially to the 
official evaluation of the Medically Supervised 
Injecting Centre in Kings Cross, Sydney. Despite 
her considerable contribution and international 
reputation, Dr MacDonald remained the same 
unassuming and self-effacing figure. Her work was 
influenced by a strong concern for social justice. 
Dr MacDonald had a wide range of interests and 
enjoyed many pursuits.M
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PHILLIP	MEDCALF	
Phillip Medcalf, President of NAPWA, died on 22 
February 2003. In the Australia Day Awards of 2003, 
Phillip James Medcalf (deceased) was awarded 
the Medal of the Order of Australia for service to 
the community as a supporter and promoter of 
the interests of people living with HIV/AIDS. Phillip 
had been a volunteer in the sector since he retired 
from full-time work as the General Manager at 
Sydney Sexual Health Centre in 1996. From 1996, 
Phillip had state-based roles in PLWH/A (NSW), The 
AIDS Council of NSW and the Bobby Goldsmith 
Foundation as representative on the boards and 
committee membership of the NSW HIV Agencies 
Forum, and the NSW Rural HIV Conferences. In 
May 1999 Phillip joined the National Association 
of People living with HIV/AIDS (NAPWA) Executive 
Committee, nominating for Vice President after 
several years as a PLWH/A (NSW) representative 
to the national body. In 2001 Phillip became 
President of NAPWA, a position he held until 
his death. Over this period he also represented 
in a variety of national positions, including the 
Commonwealth World AIDS Day Committee, the 
NAPWA nominee on the Board of Governors of 
the AIDS Trust of Australia (ATA), and the Board 
of Directors of the Australian Federation of AIDS 
Organisations (AFAO).
He was also working in a part-time capacity at the 
Australasian Society for HIV Medicine (ASHM) from 
August 2000 to March 2002. In a year when he was 
the  Executive Assistant to the Executive Officer of 
ASHM, he was also the NAPWA President and was 
invited to be part of the opening session of the 
2001 ASHM  Conference. Phillip leaves behind a 
legacy that was valued and appreciated by people 
all around Australia.
MEMORIAL	SESSIONS
ASHM has a commitment to ensure that at each annual ASHM Conference we honour the memory 
of those people who have contributed greatly to the sector. Four memorial sessions are held each 
year. These include: an Epidemiology Session on behalf of Margaret MacDonald; a Community Session 
on behalf of Phillip Medcalf; a Primary Care Session on behalf of Peter Meese; and a Clinical Medicine 
Session on behalf of Ian Thompson.
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PETER	MEESE
Dr Peter Meese, a physician in the Infectious 
Diseases Unit of the Alfred Hospital, Melbourne, 
died on 23 February 2000. He graduated from the 
University of Melbourne and began working at 
Middle Park Clinic in 1976.
Peter was a dedicated GP. His gifts of optimism, 
empathy and intelligence were available to all who 
consulted him. His patients had every confidence in 
him. Peter also worked very hard for advancement 
in his profession. He was affiliated with many 
medical organisations, but worked particularly 
hard in the pursuit of excellence in the field of HIV 
and Sexual Health and was a very active HIV/STI 
clinician and ASHM Member. Peter was a Senior 
Fellow of the Australasian College of Sexual Health 
Physicians, contributing articles and being involved 
in the examination process of its doctors. He was 
one of the editors of the Management Guidelines 
for Sexually Transmissible Infections. Peter was a 
long-term committee member and past chairman 
of the Venereology Society of Victoria and a past 
president of the National Venereology Council of 
Australia. He taught and examined the students 
of the Diploma of Venereology, and was always 
contributing to furthering the knowledge in the 
field of STIs. He was also an examiner for the Royal 
Australian College of General Practitioners.
Peter had worked in the Infectious Diseases Unit 
of the Alfred Hospital for almost a decade. He was 
instrumental in ASHM and the National Centre in 
HIV Epidemiology and Clinical Research. He was 
always involved in clinical trials - for the benefit of 
his patients. He made an invaluable contribution 
to this field of medicine.
IAN	THOMPSON
Dr Ian Lyall Thompson FRCP FRACP, consultant 
physician and haematologist, died in Sydney in
August 1989 at the age of 59. He was educated at 
Scots College, Sydney and the Faculty of Medicine 
of the University of Sydney. He became a member 
of the Royal College of Physicians in 1959 and 
subsequently a Fellow of the Royal College of 
Physicians and the Royal Australasian College of 
Physicians. In Sydney, his main appointments were 
consultant physician at Sydney Hospital, Crown 
Street Women’s Hospital, St Luke’s Hospital and later 
at St Vincent’s Hospital, Darlinghurst, where he was 
consultant physician to the Haematology and HIV 
Medicine Units. Dr Thompson was known by all for 
his enormous breadth and depth of knowledge, 
his rapier-sharp wit and his ever-present sense of 
humour. A compassionate and disciplined man, 
he was dedicated to the care of his patients and 
as a diagnostician he was unsurpassed. He was 
a much-loved teacher of medical students and 
of physician trainees. He devoted an enormous 
amount of time to and unending support for his 
younger colleagues, encouraging them in the 
pursuit of their careers in medicine. But it is not 
only within medicine that he will be remembered 
- his great knowledge covered the fields of art, 
literature, music and travel. He was a consummate 
conversationalist and entertainer. His enthusiasm 
for life itself made him a truly remarkable man, for 
which he will always be remembered.
Advancing Therapeutics. Improving Lives.
'ILEAD RECOGNIZES THE 
URGENT NEED FOR ACCESS  
TO HEALTHCARE CAPACITY  
AS WELL AS ()6 MEDICATIONS 
WORLDWIDE PARTICULARLY 
IN DEVELOPING COUNTRIES 
WHERE THE !)$3 EPIDEMIC 
IS DEVASTATING COMMUNITIES 
7E BELIEVE THAT THE 
MEDICINES WE DEVELOP 
SHOULD BE ACCESSIBLE TO  
ALL PATIENTS WHO NEED  
THEM WORLDWIDE REGARDLESS 
OF INCOME OR LOCATION
Our heart 
is in the right place.
We are undertaking the following initiatives locally and globally to help further expand 
access to our medicines and build healthcare capacity in resource-limited settings:
Gilead Access Program – to provide Viread® (tenofovir disoproxil fumarate) and Truvada®
(emtricitabine/tenofovir disoproxil fumarate) at substantially reduced prices in many low 
and middle income countries. This has been ongoing since 2003.
Partnerships with Generic Manufacturers – Gilead has signed non-exclusive 
licenses with multiple Indian generic manufactures to provide low cost high-quality 
generic versions of Viread® in 95 resource-limited countries, which are home to 
95% of the world’s HIV infected people. 
The Gilead Foundation – focused on improving health infrastructure 
in the developing world.
A member of the Collaboration for Health in Papua New Guinea (CHPNG)*
– to create sustainability and capacity in HIV management in PNG and meet the 
needs identified by our primary stakeholders and partners – ASHM and NAPWA. 
*Gilead, Boehringer Ingelheim, Merck Sharpe & Dohme, GSK, Pfizer Australia.
general 
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DISCLAIMER
All information disclosed in the Conference 
Program is correct at the time of printing. The 
Conference Secretariat reserves the right to 
alter the Conference Program in the event of 
unforeseen circumstances. All speakers were 
invited to contribute abstracts for inclusion in 
the Conference Handbook. Unfortunately, not 
all speakers were able to provide us with their 
abstracts at the time of printing. The Conference 
Secretariat accepts no responsibility for errors, 
misprints or other issues with abstracts contained 
in this handbook.
VENUE
Perth Convention Centre
21 Mounts Bay Road, Perth 
Western Australia 6000 
PO Box 7451, Cloisters Square, Perth 
Western Australia 6850 
Ph:  +61 8 9338 0300 
Fax:  +61 8 9338 0309 
 
The venue will host the conference sessions, poster 
presentations, the breakfast session, conference 
day catering, the trade exhibition and the Gala 
Dinner.
REGISTRATION	DESK
All enquiries should be directed to the registration 
desk, located on Level 2 of the Perth Convention 
and Exhibition Centre.  The desk will be open at 
the following times:
Wednesday 17 September 2008:  7.30am to 6.30pm 
Thursday 18 September 2008:  7.00am to 6.30pm
Friday 19 September 2008:  7.00am to  6.30pm
Saturday 20 September 2008:  7.00am to 2.00pm
SPEAKER	PREPARATION	ROOM
A speaker preparation room will be located in 
Meeting Room 12. This room will be open at the 
following times:
Tuesday 16 September 2008:  3.30pm to 6.00pm
Wednesday 17 September:  7.30am to 6.00pm
Thursday 18 September 2008:  7.00am to  6.00pm
Friday 19 September 2008:  7.00am to 6.00pm
Saturday 20 September 2008:  7.00am to 12.00pm 
All speakers must take their presentation to the 
speaker preparation room a minimum of four
hours prior to their presentation or the day before 
if presenting at a breakfast or morning session.
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An exhibition will be held in Pavilion 1 of the Perth 
Convention Centre.  
The Australasian Sexual Health Conference 
exhibition concludes on Wednesday 17 September 
at 5.00pm. 
The exhibition will open for the ASHM Conference 
on Wednesday 17 September 2008 at 8.00am and 
conclude on Friday 19 September at 3.30pm.
The exhibition will be open during the following 
hours: 
Wednesday 17 September 2008:  8.00am – 5.00pm   
Thursday 18 September 2008:  8.00am – 5.00pm
Friday 19 September 2008:  8.00am – 3.30pm
POSTER	DISPLAY
Posters will be displayed, grouped in their 
disciplines, for the duration of the exhibition in 
Pavilion 1 of the Perth Convention Centre.
There are dedicated poster viewing times for each 
theme area.  These are:
• Wednesday 17 September at 12.30pm - 1.30pm: 
Basic Science, Clinical Medicine, Community 
Program and Education Posters.
• Thursday 18 September at 12.30pm - 1.30pm: 
Epidemiology, Indigenous Health and International 
& Regional Issues Posters.
• Friday 19 September at 12.30pm - 1.30pm:
Nursing & Allied Health, Primary Care, Public Health 
& Prevention and Social Research Posters.
INTERNET	CAFé
The Internet café, proudly sponsored by Janssen-
Cilag Tibotec will be available in Pavilion 1, at 
Booths 31 and 32. This will be available from 
Wednesday 17 September 2008 at 8.00am until 
Friday 19 September 2008 at 3.30pm. 
JUICE	BAR
A Juice Bar, proudly sponsored by Boehringer 
Ingelheim, will be available in Pavilion 1, at Booths 
3 and 4. This will be available from Wednesday 17 
September at 8.30am until Friday 19 September 
2008 at 3.30pm.
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N INFORMATION	HUBThe Information Hub will be located on Level 2 next to the registration desk.  Three computers will 
be available for: 
•  Completing an online conference evaluation 
survey
•  Printing a certificate of attendance
•  Viewing the Australasian Chapter of Sexual Health 
Medicine Mock Exit Assessment Presentation
•  Viewing the abstract search database
•  Viewing delegate lists
HIV	PRESCRIBER	CME	POINTS
HIV s100 prescribers who are accredited in NSW/
ACT/VIC will receive 5 Prescriber CME points for 
their attendance at the conference.
RACGP/RACP/ACHSHM:	
CME	&	MOPS	POINTS
Application has been made to have attendance 
recognised for Quality Assurance & Continuing 
Professional Development. If you wish to claim 
CME points please ensure that you sign the 
attendance sheet at the Information Hub.  you will 
be able to print a certificate of attendance at the 
Information Hub. 
SMOKING
This conference has a no smoking policy.
MOBILE	PHONES/BEEPERS
As a courtesy to all delegates and speakers, please 
switch off, or set to silent, your mobile phones and 
beepers during all sessions.
NAME	BADGES
For security purposes, all attendees must wear their 
name badge at all times while in the conference 
venue. Entrance to the exhibition will be limited 
to badge-holders only. If you misplace your name 
badge, please advise staff at the registration desk.
PERSONAL	MAIL
The conference organisers do not accept 
responsibility for personal mail. Please have all 
mail sent to your accommodation address.
EVALUATION	SURVEYS
Evaluation Surveys will be available on-line at 
the Information Hub.  We ask that all delegates 
complete this survey electronically to go into 
a prize draw to win two tickets for the Sydney 
Harbour Bridge Climb.  
DELEGATE	LIST
A delegate list will be viewable at the Information 
Hub. 
  
LIABILITY/INSURANCE
In the event of industrial disruptions or natural 
disasters  ASHM cannot accept responsibility for 
any financial or other losses incurred by delegates. 
Nor can the Secretariat take responsibility for 
injury or damage to property or persons occurring 
during the conference or associated activities. 
Insurance is the responsibility of the individual 
delegate.
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MEDIA	EVENT:	
HIV Epidemiology and Public Health 
Response in WA 
Friday 19 September 2008:  5.00pm to 6.30pm
ASHM will be holding a media event in conjunction 
with the Western Australian Department of Health, 
exploring the impact of the Western Australian 
economic boom on HIV infection rates among 
WA’s heterosexual population. This session will be 
held Friday 19 September 2008.  
The session will feature a panel including: 
Paul Van Buynder, WA Public Health Division; Trish 
Langdon, WA AIDS Council; Don Baxter, Australian 
Federation of AIDS Organisations; and Darren 
Russell, Cairns Sexual Health.
Open to all delegates.
CONSENSUS	CONFERENCE
The	Perth	Convention	Exhibition	Centre
The Annual Consensus Conference is this year 
incorporated into the clinical stream of the main 
ASHM 08 Conference program. Previously, the 
Annual Consensus Conference has been held on 
the Saturday afternoon immediately following the 
close of the ASHM Conference. Feedback from 
previous years has suggested that attendance and 
participation would be maximised if the Australian 
Antiretroviral Guideline sessions were moved into 
the ASHM program.
This year, the Australian Antiretroviral Guidelines 
sessions will be held on the afternoons of 
Thursday 18 and Friday 19 September. These 
sessions include evidence-based presentations 
from international and local experts on the latest 
research and developments in HIV treatment and 
provide the opportunity for discussion. 
Dr Roy Gulick is a member of the US Department 
of Health and Human Services (DHSS) Panel on 
Antiretroviral Guidelines for Adults and Adolescents 
and will represent DHHS at these sessions. The 
DHSS Guidelines for the Use of Antiretroviral Agents 
HIV-1 Infected Adults and Adolescents have been 
endorsed by Australia and form the basis on which 
the Australian commentary is developed. The 
Australian commentary to the latest Guidelines for 
the Use of Antiretroviral Agents in HIV-1 Infected 
Adults and Adolescents is available at: http://www.
ashm.org.au/aust-guidelines/.
CONFERENCE	GALA	DINNER
Wednesday 17 September 2008: 7.30pm to 11.30pm
Bellevue Ballroom, Level 3
The Perth Convention Exhibition Centre
The theme of the dinner is ‘Diamonds are Forever’. 
Tickets will be required for entry to all associated 
events. All tickets will be given out on registration. 
No tickets for the Conference Gala Dinner are 
available on-site. 
The dinner is supported by the Australian 
Government Department of Health and Ageing, 
WA Health, Gilead, GlaxoSmithKline, Boehringer 
Ingelheim and Merck Sharp & Dohme.  
CASE	PRESENTATION	BREAKFAST
Friday 19 September 2008:  7.00am 
Riverview 4, Level 2
The Perth Convention Exhibition Centre
Case presentations will be supported by brief 
literature reviews and open to audience questions. 
Breakfast will be served during this session. The 
best case presentation will be awarded a cash 
prize.  
Tickets will be required for entry to all associated 
events. All tickets will be given out on registration. 
If you would like to purchase tickets to the Case 
Presentation Breakfast you may do so up until 
12 noon on Wednesday 17 September at the 
registration desk.
The Case Presentation Breakfast is optional and is 
not included in any of the registration fees.
Ticket cost: A$22.00 for all registrants.
TICKETS	TO	ASSOCIATED	EVENTS
Tickets will be required for entry to all associated 
events. All tickets will be given out on registration. 
A no-refund policy operates for cancellation of 
function tickets.
•  Silver Sponsor
•  Conference Scholarship Supporter
•  CD-rom Handbook Sponsor 
exhibitor 
directory
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Company Name  Booth Number
Abbott............................................................................................................................................................................ 24,25
Australasian Chapter of Sexual Health Medicine ....................................................................................... 6
Australasian Society for HIV Medicine ............................................................................................................ 11,12
Boehringer Ingelheim ............................................................................................................................................ 3,4
Bristol-Myers Squibb ............................................................................................................................................... 19,20,21,22
CaraData ....................................................................................................................................................................... 5 
Gilead............................................................................................................................................................................. 15,16,17, 18
GlaxoSmithKline ....................................................................................................................................................... 7,8,9,10
HIV & HCV Education Projects, The University of QLD............................................................................... 28
HIV Consortium ......................................................................................................................................................... 41
iNova .............................................................................................................................................................................. 35,36,37,38
International Congress on AIDS in Asia and the Pacific (Thurs 18 to Fri 19 Sep only) ....................... 45
Janssen-Cilag Tibotec ............................................................................................................................................. 31, 32
Merck Sharp & Dohme........................................................................................................................................... 29,30
National Association of People Lliving with HIV/AIDS  ............................................................................. 44
National Centre in HIV Social Research/ARCSHS......................................................................................... 34
Novartis ........................................................................................................................................................................ 13,14
Pfizer Australia ........................................................................................................................................................... 27
Schering-Plough ....................................................................................................................................................... 42
The UnderView Collection - Glen Cowans .................................................................................................... 33
WA Health ................................................................................................................................................................... 23
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The following organisations are exhibiting during the Sexual Health Conference and will be available to visit on 
Wednesday 17 September only.
CSL Biotherapies.............................................................................................................................................................................................................. 45
Marie Stopes International........................................................................................................................................................................................ 39                 
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ABBOTT	(24,	25)
We are a global health care company devoted to 
discovering new medicines, new technologies 
and new ways to manage health. Our products 
span the continuum of care, from nutritional 
products and laboratory diagnostics through 
medical devices and pharmaceutical therapies 
including Kaletra, Humira and Reductil. 
Throughout our 100+ year history, Abbott people 
have been driven by a constant goal: to advance 
medical science to help people live healthier lives. 
It’s part of our heritage. And, it continues to drive 
our work. Today, 65,000 Abbott employees around 
the world share the passion for “ Turning Science 
Into Caring.”
AUSTRALASIAN	CHAPTER	OF	SExUAL	
HEALTH	MEDICINE	(6)
The Australasian Chapter of Sexual Health 
Medicine is the professional body responsible for 
the education and training of doctors wishing 
to specialise in sexual health. It contributes to 
the professional development of other health 
professionals through its training courses, and the 
development and dissemination of guidelines 
and other educational products. It provides expert 
advice to government and other agencies on 
sexual health matters and its Fellows contribute to 
policy development at state and national level.
Australasian Chapter of 
Sexual Health Medicine 
145 Macquarie Street 
Sydney NSW 2000
Australia 
Ph:  (+61 2) 9256 9643 
Fax:  (+61 2) 9256 9693 
Email: sexualhealthmed@racp.edu.au
Australasian Chapter of Sexual Health Medicine 
AUSTRALASIAN	SOCIETY	FOR	HIV	MEDICINE	
(11,12)	
The Australasian Society for HIV Medicine (ASHM) 
is a peak representative professional body for 
medical practitioners and other health care workers 
in Australasia who work in HIV, viral hepatitis and 
related disease areas. 
It was formed in 1988 (as the Australian Society 
of AIDS Physicians). It changed its name in 1989 
to reflect a broader membership base and was 
incorporated in New South Wales in 1990. ASHM 
became a registered charity in 2003.
ASHM is a key partner in the Australasian and 
regional response to HIV, viral hepatitis and 
related diseases. It works closely with government, 
advisory bodies, community agencies and other 
professional organisations in Australia and the 
Asia Pacific region. It conducts broad education 
programs in HIV and viral hepatitis for medical 
practitioners, health care providers and allied 
health workers and manages programs of 
continuing medical education. 
ASHM is governed by an elected voluntary board 
and managed by a secretariat. It receives support 
from the Australian Government Department of 
Health and Ageing, the Australian Government’s 
Agency for International Development (AusAID), 
State and Territory Departments of Health and 
the private sector, and has established the ASHM 
Foundation which raises funds in support of 
educational activities. ASHM works on a range of 
issues affecting its members, including education 
and training, resources, HIV treatment, viral 
hepatitis, international/development issues and 
professional affairs. ASHM conducts an annual 
medical scientific conference. In addition, the 
ASHM conference division provides professional 
conference organisation to third parties.
Australasian Society for HIV Medicine (ASHM)
LMB 5057
DARLINGHURST NSW 1300
Australia
Ph:  61 2 8204 0700
Fax:  61 2 9212 2382
Email:  ashm@ashm.org.au
Web:  www.ashm.org.au
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BOEHRINGER	INGELHEIM	(3,	4)
Boehringer Ingelheim is committed to active 
involvement and practical answers for people 
living with HIV. The fight against HIV/AIDS extends 
to resource-poor settings. where Viramune® 
(nevirapine) has been donated to treat more 
than 1,000,000 mother-child pairs through 162 
programmes in 59 countries through the Viramune 
Donation Programme.
Boehringer Ingelheim is also proud to be a member 
of the Collaboration for Health in PNG (CHPNG).
The CHPNG is the initiative of a group of Australian 
pharmaceutical companies who are dedicated 
to making a philanthropic contribution towards 
improving the health and wellbeing, and political
and social stability of Australia’s nearest neighbour 
and is currently working with its partners to provide 
education and support to health care workers in
PNG.
Contact:
PO Box 1969
Macquarie Centre
NORTH RyDE NSW 2113
Phone:  61 2 8875 8833
Fax: 61 2 8875 8712
BRISTOL-MYERS	SqUIBB		(19,	22)
Bristol-Myers Squibb is a global biopharmaceutical 
company with a mission to extend and enhance 
human life.
Operating in Australia since 1930, Bristol-Myers 
Squibb is dedicated to discovering and developing 
innovative and cost-effective medicines 
addressing significant unmet medical needs. 
The Bristol-Myers Squibb R&D organisation is 
working on treatments for cancer, atherosclerosis/
thrombosis, diabetes, obesity, psychiatric 
disorders, Alzheimer’s disease, hepatitis, HIV/AIDS, 
rheumatoid arthritis, and solid organ transplant 
rejection.
For many years Bristol-Myers Squibb has been 
a leader in the area of HIV/AIDS and currently 
provides Reyataz® (atazanavir sulfate) to thousands 
of Australians.
CARADATA	(5)
CaraData is a successful Queensland based 
technology company that specialises in the 
development of health informatics software 
for use in the management and surveillance of 
sexual health, communicable diseases, HIV/AIDS, 
Hepatitis C and Family Planning clinics. CaraData’s 
core product is SHIP – Sexual Health Information 
Program. SHIP has been designed to reduce the 
workload for Medical, Administration, Nursing and 
Laboratory staff and to support the transition to a 
full electronic patient record. SHIP is user friendly, 
flexible and adaptable to meet minimum data set 
requirements. In 2004 CaraData took over from 
Dickson Computer Services (DCS) where SHIP was 
first developed by CEO Bridget Dickson in 1992. 
Since then SHIP is now installed in more then 68 
clinics throughout the world including Malaysia, 
New Zealand, Barbados, Ireland and six states 
in Australia – Queensland, New South Wales, 
Australian Capital Territory, Tasmania, Northern 
Territory and Western Australia. In 2005 CaraData 
established another branch over in Dublin, Ireland. 
Through this CaraData is able to provide 24/7 
support to all its clients.
Contact Details: 
Email: info@caradata.com
Ph:   +61 7 5594 9328
  Fax: +61 7 5571 5376
  Web: www.caradata.com
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GILEAD		(15-18)
Gilead’s mission is to advance patient care by 
developing ground-breaking therapeutics to 
treat life-threatening infectious diseases. We apply 
the best of biopharmaceutical science to create 
innovative medicines that bring new hope in 
the battles against HIV/AIDS (Truvada®, Emtriva®, 
Viread®), chronic hepatitis B (Hepsera®), and 
serious bacterial and systemic fungal infections 
(AmBisome®). 
Company name: Gilead Sciences
Address: Level 1, 128 Jolimont Road, East 
Melbourne, Victoria, 3002, Australia
Phone:  +61 (0)3 9272 4400
Fax:   +61 (0)3 9272 4411
We look forward to seeing you at the Gilead 
Sciences booth at Sexual Health & ASHM.
GLAxOSMITHKLINE	(7-10)
GSK Australia (GSK) is one of the largest research 
based pharmaceutical companies in Australia. 
GSK’s vision is to “help people to do more, feel 
better and live longer”.
The company’s product portfolio is closely aligned 
with the country’s key health priorities of asthma, 
immunisation, depression, diabetes, oncology, 
indigenous health and infectious diseases. GSK 
also supplies 25% of the world’s medicinal opiate 
needs from its Australian operations. 
GSK invests more than $35 million a year in 
Australian research and development, confirming 
the company’s place as one of the largest and 
most active innovators in the country.  
Through a series of cooperative partnerships - with 
government, the scientific research sector and the 
broader Australian community – GSK makes a 
substantial contribution to important economic, 
social and health initiatives.  
HIV	&	HCV	EDUCATION	PROJECTS	THE	
UNIVERSITY	OF	qLD		(28)
The HIV & HCV Education Projects is based 
within the School of Medicine, The University of 
Queensland and has been operating since the 
beginning of 1998.  It is recognised at a state 
level, nationally and internationally as a centre 
of expertise in clinical education, facilitation, 
monitoring and evaluation, and resourcing.
Originally, the primary responsibility of the 
projects was to design, develop, implement and 
evaluate courses for medical practitioners who 
wished to prescribe HIV antiretroviral therapies 
in Queensland, Australia. This remains a core 
component of the organisation. By 2003, the HIV 
& HCV Education Projects was providing clinical 
education, facilitation, monitoring and evaluation, 
and resourcing in its three core domains of HIV, 
Sexual Health and Viral Hepatitis across a range of 
health disciplines, including medical practitioners, 
nurses, dentists, allied health and community 
health workers.   By 2006 this expanded to include 
other domains.
School of Medicine-
The University of Queensland
288 Herston Road
HERSTON  QLD  4006
Australia
Ph:  07 3346 4813
Fax:  07 3346 4757
Email:  hivandhcvprojects@uq.edu.au
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HIV	CONSORTIUM	(41)
The HIV Consortium for Capacity Building in 
Asia and the Pacific is funded by AusAID to 
strengthen the capacity of organisations and 
individuals to respond effectively to HIV by 
fostering strategic partnerships and linkages in 
the health care, research and community sectors. 
 
Membership includes:
Albion Street Centre 
Australasian Society for HIV Medicine 
Australian Federation of AIDS Organisations 
Australian Injecting and Illicit Drug Users League 
Australian Research Centre in Sex, Health and 
Society 
National Serology Reference Laboratory
 National Centre in HIV Epidemiology and Clinical 
Research 
National Centre in HIV Social Research 
 Scarlet Alliance, Australian Sex Workers 
Association 
www.hivconsortium.org 
02 8204 0751
iNOVA	PHARMACEUTICALS	(35-38)
iNova Pharmaceuticals develops and markets 
a range of over-the-counter and prescription 
medicines to Australasia, Asia-Pacific, South Africa, 
the Americas and other international markets 
directly and also through other pharmaceutical 
companies and agents. These include prescription 
medicines in the areas of weight management, 
dermatology, heart conditions, asthma and pain 
management. 
To learn more about iNova Pharmaceuticals, go to 
http://www.inovapharma.com
JANSSEN-CILAG	TIBOTEC	(31,	32)
Tibotec, a division of Janssen-Cilag, is at the 
forefront of human immunodeficiency virus (HIV) 
research.  With several active discovery programs 
in HIV, hepatitis C and other life-threatening 
infectious diseases, Tibotec’s mission is to be a 
world leader in the discovery and development of 
innovative HIV/AIDS drugs and anti-infectives for 
diseases of high unmet medical need. PREZISTAÒ 
(darunavir) gained PBS approval in December 
2007.
Tibotec, a division of Janssen-Cilag Pty Ltd	
1 - 5 Khartoum Road, North Ryde,
NSW 2113 Australia
Ph:  61 2 8875 3333 
Toll Free 1800 800806
MERCK	SHARP	&	DOHME	(29,	30)
Merck Sharp & Dohme (MSD) Australia is a 
research based pharmaceutical company and 
has been looking after the health of Australians 
since 1952, a history of which MSD is extremely 
proud.  MSD invests a considerable amount into 
Australian research and development.  Over 90% 
of MSD products are manufactured and packaged 
in Australia, which leads to new investment 
and infrastructure opportunities.  The ongoing 
commitment of MSD in Australia is evidenced 
by its achievement in becoming the largest 
pharmaceutical exporter in the country, exporting 
to more than 16 countries throughout the world.
HIV CONSORTIUM
For Capacity Building in Asia and the Pacic 
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ArCSHS
The Australian Research Centre in Sex, Health and 
Society was established in 1993 as an independent 
unit within the Faculty of Health Sciences at 
La Trobe University.  It has a multi-disciplinary 
team of staff with qualifications and expertise in 
psychology, anthropology, sociology, public health, 
health promotion, methodology, epidemiology, 
education, women’s health, consumer advocacy 
and health policy.  The Centre is dedicated to the 
advancement of knowledge and applied skills in 
sexual health; locally, nationally and internationally. 
Through our research, teaching and community 
activities we strive to develop and sustain a direct 
and organic link with the wider community. The 
Centre has had since its inception a dedicated 
Community Liaison and Education Unit to ensure 
the research is disseminated widely and informs 
policy and practice.
NOVARTIS	(13,	14)		
Novartis is a world leader in the research, 
development and supply of products to protect 
and improve health and well-being. 
Novartis Pharmaceuticals researches and supplies 
a broad range of innovative and effective 
prescription medicines to treat patients in both 
general and specialist practice and hospitals. 
Created in 1996 from the merger of Swiss 
companies, Ciba and Sandoz, Novartis has a history 
in Australia going back over fifty years. Novartis 
employs about 98 000 people and operates in 
over 140 countries around the world.
In Australia the company now employs more 
than 600 people, and invests over AUD $30million 
annually in local research. This research not only 
assures the effectiveness of the company’s current 
range of treatments, but also secures the promise 
of improving health for the future.
Novartis medicines treat some of the most 
serious health conditions confronting healthcare 
professionals and their patients.  The company’s 
work is spread across many diseases in the areas 
of Primary Care, Oncology, Transplantation, and 
Ophthalmics.
NATIONAL	ASSOCIATION	OF	PEOPLE	LIVING	
WITH	HIV/AIDS	(44)	
The National Association of People Living with 
HIV/AIDS is Australia’s peak 
non-government organisation representing 
community-based groups of people living
 with HIV. NAPWA provides advocacy, policy, 
education and outreach on a national
 level.
We work across a range of health and education 
initiatives to promote the highest quality standard 
of care for HIV positive people and contribute 
to clinical and social research into the causes 
and prevention of HIV. We strive to minimise 
the adverse personal and social effects of HIV by 
championing the participation of positive people 
at all levels.
NATIONAL	CENTRE	IN	HIV	SOCIAL	
RESEARCH/ARCSHS	(34)
The National Centre in HIV Social Research 
(NCHSR) was established in 1990 with funding 
from the Commonwealth Department of Health 
and Ageing, Australia. We are located within the 
Faculty of Arts and Social Sciences at The University 
of New South Wales, Sydney.
NCHSR is internationally recognised for its 
contribution to the Australian response to HIV 
and hepatitis C. While the core of its work has 
been in social aspects of HIV, particularly in regard 
to sexual practice, in recent years the NCHSR 
research program has expanded to include social 
research related to hepatitis C, injecting and illicit 
drug use, sexual health, Aboriginal health and the 
Asia-Pacific region.
NCHSR is highly regarded for its multidisciplinary 
approach, quality and range of work, timeliness 
of research findings, and engagement with 
those communities most affected by HIV, STIs 
and hepatitis C. NCHSR’s core-funded strategic 
research has been strengthened by its location 
within an academic environment and the 
attendant scholarship and culture that entails. This 
has ensured research that is intellectually rigorous 
and valued by key decision makers.
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PFIzER	AUSTRALIA	(27)
With a history dating back to 1886, Pfizer Australia 
has grown to become the nation’s leading 
provider of prescription medicines. Pfizer Australia 
exports $600 million worth of product around 
the region annually from three manufacturing 
plants across the nation. Our researchers are 
part of the world’s largest private sector medical 
research program with more than 580 projects in 
discovery and development. In Australia, we spent 
more than $45 million in 2006 on local research 
and development across our business, helping to 
keep some of the nation’s leading researchers here 
in Australia working on conditions that have the 
potential to impact every Australian family.
SCHERING	PLOUGH	(42)
Schering-Plough is an innovation-driven, 
science-centred global health care company. 
Through its own biopharmaceutical research and 
collaborations with partners, Schering-Plough 
creates therapies that help save and improve lives 
around the world. Schering-Plough applies its 
research-and-development platform to human 
prescription and consumer products as well as 
to animal health products. Schering-Plough’s 
vision is to “Earn Trust, Every Day” with the doctors, 
patients, customers and other stakeholders served 
by its colleagues around the world. 
As part of its long-term commitment to working 
with doctors to support patients with hepatitis, 
Schering-Plough’s PEGATRON is now the first and 
only pegylated interferon approved for retreatment 
of chronic hepatitis C.
THE	UNDERVIEW	COLLECTION	-	GLEN	
COWANS	(33)
Glen Cowans is a unique and passionate 
photographer. His inspiration is our ocean. His 
subjects are the beautiful life forms that live there. 
Born in Western Australia, Cowans developed his 
passion for the ocean while snorkelling at the age 
of ten.  In 1995 he began his pursuit of underwater 
photography, and in 2005 left his trade as an 
electrician to become a full-time photographer. 
With over 13 years’ experience in underwater 
photography --- ranging through all the mediums 
of film, transparency and digital ---, Cowans has 
had more than 26 exhibitions. His work has found 
favour with collectors across Australia and around 
the world. Cowans’ takes photography to a new 
level by bridging the gap between photography 
and art. His philosophy is to allow nature to be the 
artist and let the shapes, colours and life forms of 
the ocean create the masterpiece. Cowans’ work 
offers viewers a rare experience, one where they 
can contemplate the wondrous life found in the 
underwater world.
WA	HEALTH	(23)	
Using a partnership approach, the Sexual Health 
and Blood-borne Virus Program of the WA 
Department of Health directs and coordinates the 
prevention and control of sexually transmitted 
infections, human immunodeficiency virus 
and blood-borne viruses (STI/HIV/BBV) for the 
population of WA.  Priority populations within WA 
include: young people; Aboriginal people; people 
who inject drugs; gay and other homosexually 
active men; sex workers (including opportunistic 
sex workers) and clients of sex workers; people 
living with HIV/AIDS and hepatitis C; and health 
care workers.
UndergradUate 
aWards
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LEON	BOTES
Leon is a Sexual Health Nurse who has worked in Sexual 
Health and HIV/AIDs in South Africa, New Zealand and 
Australia. He has also worked for the National Centre in 
HIV Epidemiology and Clinical Research and completed 
his Masters in Health Science (Sexual Health) at the 
University of Sydney in 2005. Since then, Leon has been 
a tutor on the online learning Postgraduate Program 
in Sexual Health. Leon was awarded the Novartis 2008 
Scholarship for Sexual Health Research, offered through 
the Royal College of Physicians. This scholarship has 
enabled him to begin his PhD project focused on Anal 
Squamous Intraepithelial Lesions (ASILs).
Poster Number 121  
MING	LIANG	CHAN
Ming Liang Chan’s research is focused on understanding 
the homeostatic control of CD4+ T cell numbers in 
chronic HIV infection. In HIV and in experimental models 
of SIV in rhesus macaques, chronic infection is associated 
with progressive CD4+ T cell depletion. However, in 
natural infection of some species, described as natural 
hosts, infection is largely asymptomatic. Ming Liang’s 
current research involves the use of mathematical and 
statistical tools to study viral pathogenesis in SIV and 
gain a deeper understanding about the lack of disease 
progression in natural hosts. In his latest work, he used a 
model to explain how the non-pathogenic SIV infection 
of natural hosts can be caused by lower levels of CD4+ 
T lymphocyte activation. This dynamic understanding of 
infection provides valuable insights into the pathogenesis 
of AIDS in HIV-infected individuals. 
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HEIDI	COUPLAND
Heidi is a PhD candidate in the National Centre in HIV 
Epidemiology and Clinical Research, University of New 
South Wales. Her supervisors are Associate Professor 
Lisa Maher and Dr Carolyn Day. Few studies have 
explored cultural differences in injecting drug users’ 
(IDUs) vulnerability to hepatitis C (HCV) infection and 
barriers to accessing services for HCV-related issues. 
This ethnographic study explored Indo-Chinese IDUs’ 
explanatory models of HCV prevention and management 
and examined their influence on health-seeking behaviour, 
in particular, access to HCV treatment. Field work and 
in-depth interviews were conducted with Cambodian, 
Lao and Vietnamese-background IDUs (n=72) in South 
Western Sydney. Twenty-three were involved in a pilot 
of a culturally-informed brief intervention regarding HCV 
treatment. Following a baseline interview and provision of 
the brief intervention, participants were offered facilitated 
referral to a tertiary liver clinic and were followed up and 
interviewed again at three and six months. Preliminary 
results indicate that explanatory models of HCV influence 
decision-making and patterns of service access in relation 
to hepatitis C testing and treatment. However, cultural 
meanings of injecting drug use and notions of family 
obligations, particularly in the context of immigration 
and resettlement, also shape responses to HCV among 
this group.  
Oral Presentation: Wednesday 17 September: ASHM IDU: 
Domestic; 2.45pm - 3.00pm
Poster Number 151
BENJAMIN	COWIE
Dr Ben Cowie is an Infectious Diseases Physician from 
Melbourne. He is writing his Doctoral Thesis through the 
University of Melbourne on the seroepidemiology of 
hepatitis B virus infection in Victoria and the development 
of a mathematical model of HBV infection in Australia, 
research which was conducted at VIDRL in Melbourne. A 
serosurvey of a randomised, age-structured sample 
of over 3200 serum specimens stored at VIDRL from 
1995-2005 has enabled examination of the changing 
prevalence of infection and vaccination uptake over 
time, and analysis by age-group and geographic area 
has been undertaken. Both simple linear regression 
and complex deterministic models of HBV infection in 
Australia have been constructed, allowing an assessment 
of the impact of existing control strategies and describing 
the evolution of the burden of HBV infection in Australia 
to date and into the future.
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ASHLEY	FREEMAN
Ashley Freeman is an undergraduate student of Dental 
Surgery at the University of Adelaide, completing a 
concurrent honours degree in dental science. His 
research investigates the oral health and treatment 
needs of patients at a specialised dental institution for 
individuals with HIV. The introduction of highly-active 
anti-retroviral therapy (HAART) has allowed HIV positive 
individuals to experience a greater life expectancy but 
with the potential for an increased risk of medical co-
morbidities including non-HIV related oral conditions. 
Little data is available describing prevalence and severity 
of oral manifestations and little evidence available for 
appropriate dental management in a post-HAART 
cohort of patients. This retrospective study of patient 
case records from 2001 to 2008 aims to describe the oral 
health needs and oral manifestations of HIV amongst 
a South Australia population. Emphasis is placed on 
changes in the prevalence of HIV-related oral lesions since 
the introduction of highly active anti-retroviral therapy 
(HAART) in the late 1990s. The increase life expectancy 
of HIV patients as a result of HAART has also led to the 
increase prevalence of medical comorbidities. The nature 
and severity of these problems, as they relate to the 
prevalence of any oral lesions and necessity for dental 
care will also be assessed. Information provided will help 
establish the current oral health needs for people with HIV. 
These findings provide information on the prevalence of 
oral conditions and demonstrate the need to identify and 
address oral health needs for people with HIV. 
Poster Number 126
SUzANNE	POLIS
Suzanne Polis is working full time as a Clinical Nurse 
Consultant in HIV/ Hepatitis at St George Hospital, and 
a part time PhD student at University of Technology 
Sydney, Faculty of Nursing, Midwifery & Family Health. 
Suzanne’s research focuses on individual’s adherence 
to HIV and hepatitis B virus (HBV) medications. Initial 
studies aim to identify factors that are associated with 
non-adherence in intellectually challenged HIV positive 
people having clinical evidence of non-adherence and 
virological resistance to antiviral therapies. Factors that 
are found to be associated with non-adherence will be 
used to implement individualized, and developmentally 
appropriate, adherence strategies, and to develop 
educational tools and written information. Future 
quantitative and qualitative studies are planned to 
investigate adherence to HBV medications within the 
general population. Anecdotal evidence suggests 
that patients have limited knowledge and understanding 
of chronic HBV treatments, treatment adherence, and the 
development of drug resistance, and that they risk long 
term liver sequelae including hepatocellular carcinoma. 
Study findings aim to improve anti-viral medication 
adherence and long term health outcomes within these 
population groups.
SHARMILA	REDDY
Eliciting broadly neutralizing antibodies (nab) against HIV-
1 has been a major limiting factor in the development of 
successful vaccines against HIV-1. The HIV-1 envelope 
glycoprotein is the sole viral protein available for nab 
to target and hence would be an ideal candidate for 
vaccine development. However variations in envelope 
protein sequences driven by high error rate of HIV-
1 reverse transcriptase during the course of infection 
can mediate escape from humoral immune responses. 
Studies show that protein sequences of transmitting 
strains are consistently different from those derived after 
seroconversion, have structural variations which lead to 
greater exposure of conserved domains and are highly 
sensitive to neutralization. Hence studying the envelope 
protein of viral isolates derived from patients prior to 
seroconversion may allow identification of envelope 
proteins with well exposed neutralization-sensitive 
epitopes - potentially useful information for developing 
vaccine candidates. Samples from preseroconversion 
cohort were selected, envelope region cloned and 
sequences were analyzed. The clones will be used for 
immunogenicity trials in animals and the neutralization 
activity of the resulting sera will be assessed. The aim is 
to induce high titers of broadly neutralizing antibodies 
capable of blocking HIV-1 transmission and to assess 
the relative contribution of different epitopes to virus 
neutralization.
Oral Poster Presentation: Saturday 20 September; Oral 
Poster Session: Clinical, Allied Health and Basic Science; 
8.45am - 8.50am. Poster Number 109
RUBY	UDDIN
Ruby Uddin is a Sexual Health Registrar, who has been 
training in Sydney with a particular interest in the clinical 
care for women living with HIV and the challenges they 
face. The rising rate of HIV infection in women in Australia, 
will heighten the need for HIV/Sexual Health services 
to focus further on developing a specific approach for 
management of HIV in women, particularly with emphasis 
on reproductive and maternal health.  Notified cases 
of newly diagnosed HIV infection in females resident 
in NSW increased from 31 of 391 (7.9%) in 2005, to 45 
of 369 (12.1%) in 2006, and a corresponding significant 
national increase has been observed from 5.8% to 14.3%, 
in 2005 and 2006, respectively. During her Sexual Health 
training at the Short Street Sexual Health Service, St 
George Hospital, Kogarah, where increasing numbers of 
HIV positive women are being seen, Ruby was able to 
document and investigate specific issues pertaining to 
management of HIV in women, particularly in relation to 
disclosure to partners, contraception, access to care and 
HIV management in pregnancy.    Results of the study 
could be helpful in developing local service policy to 
optimise provision of services for HIV positive women.
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THE	APPLICATION	PROCESS:
Applications are invited from all relevant disciplines, 
with priority given to medicine, nursing, dentistry and 
allied health, and must relate to a degree, diploma 
or award program at the undergraduate level (not 
available for post-doctoral programs). Applications 
can be received for residents of Australia and New 
Zealand only and can be for new work or work in 
progress. The awards program is funded by ASHM and 
the ASHM Tax Deductible Domestic Gift Fund. The 
Australian Government Department of Health and 
Ageing provides support for the administration of this 
program.
Abstracts of no more than 350 words should be 
submitted in writing along with the application form 
overleaf. Please note that applications which reflect the 
national priority action areas for research as outlined 
in the National HIV/AIDS Strategy and the National 
Hepatitis C Strategy will be given precedence. These 
research areas can be found on the Commonwealth 
Health website at www.health.gov.au or via the ASHM 
website at www.ashm.org.au. A Sub-Committee of the 
ASHM Board will review the applications and applicants 
will be notified of the outcome of their application by 
20 March 2009. 
For further information please review the website or 
contact Scott Chambers at scott.chambers@ashm.org.au. 
Tel: 02 8204 0704.
ASHM is offering up to eight support awards in 2009. 
The awards are available to promote research interest 
in HIV and viral hepatitis. Applications should be made 
in writing via the application form on the reverse of 
this flyer, and must be received in the ASHM Office by 
COB 1 February 2009. Please attach your abstract and a 
photocopy of your most recent academic transcript.
THE	AWARDS	WILL	COMPRISE:
 Annual ASHM associate membership for 2009
 Linkages between the student and ASHM members 
in the designated area of research interest
 Access to the ASHM website to allow students to 
place information about their research project
 Participation in relevant ASHM Committees
 Access to ASHM library, resources and archives
 First option to take on part-time research assistant 
positions offered by ASHM
 Registration at the 21st Annual ASHM Conference, to 
be held in Brisbane in September 2009, or registration 
at the 2010 Viral Hepatitis 
 Australasian Conference
 Presentation of a poster following abstract 
submission to the chosen conference in a special 
poster session (required)
 Scholarship for recipients requiring travel and/or 
accommodation to assist with attendance at the 
Conference to a value of A$400
 Publication of a short report on the research initiative 
in an edition of ASHMNews
ASHM UNDERGRADUATE AND JUNIOR  RESEARCHER SUPPORT AWARDS IN HIV  
AND VIRAL HEPATITIS 2009
post to: ASHM office, lMb 5057, DArlInGHurSt nSW 1300
 Fax:  02   9212 2382  or  register online at: www.ashm.org.au
Please attach your abstract (max. 350 words) and a photocopy of your most recent academic transcript. 
You may attach any extra notes or supporting documentation.
name:
postal address:
phone:  email:
Course in which you are enrolled:
Department/faculty:  Institution:
SUPERVISOR CONTACT DETAILS:
name:
postal address:
phone:  email:
please describe your area of research interest (and attach abstract):
What do you hope to achieve?
What is your interest in HIV or viral hepatitis?
How could ASHM assist you?
Supervisor’s signature:  Date:
Applicant’s signature:  Date:
APPLICANT:
Form deadline: 
COB	1	February	2009
ApplICAtIon ForM 
ASHM	UNDERGRADUATE	AND	JUNIOR	RESEARCHER	
SUPPORT	AWARDS	IN	HIV	&	VIRAL	HEPATITIS	2009
fUll conference 
Program
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7.30am Registration
8.00am 
- 9.00am Arrival Coffee/Tea in Exhibition and Poster Area in Pavilion 1 
8.30am	
-	10.30am
ASHM	Opening	Ceremony	and	Plenary	1
9.00am	
-	10.30am
Sexual	Health	Plenary	5:	
A	Mixed	Bag	of	Jewels
Riverside	Theatre/Auditorium Meeting	Room	1,2,3
Chairs:	John	Dyer	and	Levinia	Crooks Chairs:	John	Chuah	and	Alexandra	Marceglia
8.35am 
- 8.40am Welcome to Country by Janet Hayden
9.00am 
- 9.30am 
Matthew Law - Head Biostatics 
and Database, National Centre 
in HIV Epidemiology and 
Clinical Research, Sydney, New 
South Wales, Australia
8.40am 
- 8.45am
Welcome by Jonathan Anderson - President, Australasian Society for HIV 
Medicine, Australia
8.45am 
- 8.50am Government Representative Should we be Vaccinating Boys 
as well as Girls with the HPV 
Vaccine? 8.50am 
- 8.55am
Welcome by Graham Brown - President, Australian Federation of AIDS 
Organisations, Australia
8.55am 
- 9.00am
Welcome by Robert Mitchell - President, National Association of People 
Living with HIV/AIDS, Australia
9.30am 
- 10.00am
Kathleen Mazzella - Founder, 
Gynaecological Awareness 
Information Network, Western 
Australia
9.00am 
- 9.45am
Gita	Ramjee	-	Director,	South	African	Medical	Research	Council	
HIV/AIDS	Lead	Programme,	South	Africa	   
A Woman’s Personal Perspective 
and Experience of what is 
Missing in Sexual Health and 
Society, the Vulva 
HIV Prevention: Hypothesis to Facts
10.00am 
- 10.30am
David Speers – Infectious 
Diseases Physician, Sir Charles 
Gairdner Hospital, Western 
Australia 
9.45am 
- 10.30am
Sarah	Rowland-Jones	-	Human	Immunology	Unit,	John	Radcliffe	
Hospital,	Oxford,	United	Kingdom
Towards a HIV Vaccine - What is Protective Immunity Against HIV 
Infection?
Sexual Transmission of Hepatitis 
B and C
10.30am 
- 11.00am Morning Tea in Exhibition and Poster Area in Pavilion 1 
11.00am	
-	12.30pm
Women	Risk	HIV	
-	International
11.00am	
-	12.30pm
ACH2	Bench	to	Bed:	1
11.00am	
-	12.30pm
Sexual	Health	Plenary	6:	
Drugs	and	Sex
Riverside	Theatre/
Auditorium Meeting	Room	8 Meeting	Room	1,2,3
Chairs:	Susan	Kippax	
and	Gita	Ramjee
Chairs:	Tony	Cunningham	
and	Scott	Bowden
Chairs:	Fraser	Drummond	
and	Richard	Teague
56                17-20 SepteMber 2008 @ pertH ConVentIon Centre, WeStern AuStrAlIA
W
ED
N
ES
D
AY
	1
7	
SE
PT
EM
BE
R	
20
08
	
FU
LL
	C
O
N
FE
RE
N
C
E	
PR
O
G
RA
M
11.00am 
- 11.15am
Holmes W - A Novel 
Approach to Antenatal 
Risk Assessment in Very 
Low HIV Prevalence 
Settings in Resource-
Poor Countries
11.00am 
- 11.20am
Damian Purcell - Senior 
Lecturer, Virology, Department 
of Microbiology and 
Immunology, University 
of Melbourne, Melbourne, 
Victoria, Australia
11.00am 
- 11.45am
Jeffrey Klausner - Director, 
Sexually Transmitted Disease 
Prevention and Control 
Services, San Francisco, USA 
Towards Vaccines Eliciting 
Broad Neutralising Antibody 
Responses by Selecting for 
HIV-1 ENV Immunogens 
that Prominently Expose 
Conserved Neutralisation 
Epitopes
11.15am 
- 11.30am
Ofasia E - Addressing 
Gender-Based Violence 
in Settlement Areas of 
Port Moresby
11.20am 
- 11.40am
Patricia Price - University 
Academic, School Of 
Pathology And Laboratory 
Medicine, University of 
Western Australia, Perth, 
Western Australia
Sex, Drugs and Disease 
Transmission
11.30am 
- 11.45am
Kupul M -  Tribal 
Fighting, Violence 
Against Women and 
Girls and HIV in Papua 
New Guinea
Understanding Susceptibility 
to CMV Immune 
Restoration Disease and the 
Immunological Consequences 
of Extreme Immunodeficiency
11.45am 
- 12.00pm
Rawstorne P - Female 
Sex Workers in Sri Lanka: 
Why are Women who 
Work on the Street More 
Likely to use Condoms 
Compared with Women 
who Work in other 
Locations?
11.40am 
- 12.00pm
Kate Cherry - Physician and 
Senior Research Fellow, Alfred 
Hospital and Burnet Institute, 
Melbourne, Victoria, Australia           
11.45am 
- 12.30pm
Joel Palefsky - Professor 
of Medicine, University of 
California, San Francisco, USA
Predicting Neuropathy Risk 
Before Stavudine Prescription: 
An Algorithm For Minimizing 
Neurotoxicity In Resource-
Limited Settings
12.00pm 
- 12.15pm
Ghaly S - Alcohol 
Consumption, HIV 
Transmission and 
Implications for Women 
in South Africa
12.00pm 
- 12.20pm
Nitin Saksena - Chief Scientist, 
Head of the Retroviral 
Genetics Division, Westmead 
Millennium Institute, and 
Senior Research Fellow, 
University of Sydney,  New 
South Wales, Australia Natural History of HPV in the 
Anal Canal
Biological Characterisation of a 
Novel Anti-HIV Activity 
12.15pm 
- 12.30pm
Fawkes J - Enabling HIV 
Prevention Outcomes 
for Sex Workers, Papua 
New Guinea
12.20pm 
- 12.30pm Discussion
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- 1.30pm Lunch in Exhibition and Poster Area in Pavilion 1 
12.45pm 
- 1.15pm
Launch of the Annual Surveillance Report, Aboriginal and Torres Strait Islander Surveillance Report and the Annual 
Report of Trends in Behaviour from the NCHECR and NCHSR 
Meeting Room 8; Lunch will be provided there for attendees from 12.30pm
1.30pm	
-	3.00pm
IDU	-	Domestic
1.30pm	
-	3.00pm
ACH2	Bench	to	Bed:	2
1.30pm	
-	3.00pm
Sexual	Health	Plenary	7:	
Out	of	Sight	Out	of	Mind	
Riverside	Theatre/
Auditorium Meeting	Room	8 Meeting	Room	1,2,3
Chairs:	Ingrid	Van	Beek	
and	Tamara	Speed
Chairs:	Damian	Purcell	and	
Nitin	Saksena
Chairs:	Katrina	Allen	and	
David	Smith
1.30pm 
- 1.45pm
Prestage G - Illicit Drug 
Use and Risk of HIV 
Seroconversion among 
Gay Men in Sydney: Data 
from the Him Cohort
1.30pm 
- 1.50pm
Paul Gorry - Head, HIV 
Molecular Pathogenesis 
Laboratory, Burnet Principal 
Fellow, Macfarlane Burnet 
Institute for Medical Research 
& Public Health, Melbourne, 
Victoria, Australia 1.30pm 
- 2.00pm
Elizabeth Phillips - Clinical 
Pharmacologist and Infectious 
Disease Physician, Royal 
Perth Hospital and Sir Charles 
Gairdner Hospital, Perth, 
Western Australia 
1.45pm 
- 2.00pm
Deacon RM - Results 
from the 2008 Periodic 
Survey of NSW Needle 
and Syringe Program 
Attendees
Tissue-Specific Adaptive 
Changes in V3 of gp120 Enable 
Persistence of Maraviroc-
Sensitive R5x4 HIV-1 in Brain
Management of Penicillin 
Allergy in the Syphilitic Patient
2.00pm 
- 2.15pm
Kwon AJS - Continued 
Increases in Syringe 
Distribution are 
Required to Restrain Viral 
Transmissions among 
Injecting Drug Users in 
Australia: Results from a 
Modelling Study
1.50pm 
- 2.10pm
Bin Wang - Research Fellow, 
Retroviral Genetics Division, 
Westmead Millennium 
Institute, Sydney, New South 
Wales, Australia
2.00pm 
- 2.30pm
Richard Hillman - Senior 
Lecturer, Sexually Transmitted 
Infections Research Centre, 
The University of Sydney, 
Sydney, New South Wales, 
Australia                                
Genomic and Proteomic 
Characterisation of Novel Anti-
HIV Activity 
2.15pm 
- 2.30pm
Spooner C - The Role 
of Needle Syringe 
Programs in Preventing 
Transmission to Injecting 
by young People
2.10pm 
- 2.30pm
Jillian Carr - Senior Research 
Officer, South Australia 
Pathology, Adelaide, South 
Australia, Australia       Anal Dysplasia and Cancer. An 
Australian Experience
HIV DNA Levels in PBMC 
Decline in Patients 
Receiving Integrase Inhibitor 
Combination Therapy
2.30pm 
-2.45pm
Gahan G - A Gap 
Analysis of People with 
a History of Injecting 
Drug Use who are not 
Currently Accessing 
HIV and Sexual Health 
Services in South 
Eastern Sydney Illawarra 
Area Health
2.30pm 
-2.50pm
Anthony Cunningham 
- Director, Australian Centre 
for HIV and Hepatitis Virology 
Research, Sydney, New South 
Wales, Australia          
2.30pm 
- 3.00pm
Basil Donovan - Professor of 
Sexual Health, National Centre 
in HIV Epidemiology and 
Clinical Research, Sydney, New 
South Wales, AustraliaInhibition of HIV Binding to 
Langerin on Langerhan’s Cells 
as a Strategy for Microbicide 
Development 
2.45pm 
- 3.00pm
Coupland H - 
Increasing Hepatitis C 
Treatment Uptake by 
Injecting Drug Users 
from Culturally and 
Linguistically Diverse 
Backgrounds: Outcomes 
of a Pilot Study of 
Indochinese Injectors
2.50pm 
- 3.00pm Discussion It’s only a cold sore, Love....”
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3.00pm 
- 3.30pm Afternoon Tea in Exhibition and Poster Area in Pavilion 1 
3.30pm	
-	5.00pm
Virology/Immunology
3.30pm	
-	5.00pm
Planning	Requires	Economic	
and	quality	Review
3.30pm	
-	5.00pm
Sexual	Health	Conference	
Closing
Riverside	Theatre/
Auditorium Meeting	Room	8 Meeting	Room	1,2,3
Chairs:	Patricia	Price	
and	Rosemary	Ffrench
Chairs:	Jim	Hyde	and	Lisa	
Bastian
Chairs:	Jenny	McCloskey	and	
David	Jardine
3.30pm 
- 3.45pm
Keane NM - An HLA-
C*0702 Restricted T-Cell 
Response Directed 
Against an Immune 
Escaped HIV NEF Ky11 
Epitope Exhibits Higher 
Functional Avidity but 
Lesser Cytolytic Activity 
when Compared with 
the Anti-Wild Type 
Response
3.30pm 
- 3.45pm
Anderson J - A Critical 
Analysis of the Quality 
and Transferability of 
Economic Evaluations of HIV 
Interventions for Australian 
Decision-Making 3.30pm  
- 4.00pm
Basil Donovan - Professor of 
Sexual Health, National Centre 
in HIV Epidemiology and 
Clinical Research, Sydney, New 
South Wales, Australia
3.45pm 
- 4.00pm
Stratov I - Robust NK-Cell 
Mediated HIV-Specific 
Antibody-Dependent 
Responses in HIV-
Infected Subjects
3.45pm 
- 4.00pm
Hillman R - Cost Effectiveness 
of Screening for Anal Cancer in 
HIV-Positive MSM
LASH Study - Law and 
Sexworker Health 
4.00pm 
- 4.15pm
Fernandez S - CMV-
Specific Effector 
Memory CD4+ T-Cells 
in HIV Patients on 
Long-Term Art are 
Predominantly ‘CD28 
Null’ Immunosenescent 
Cells
4.00pm 
- 4.15pm
Bernard D - Effective 
Partnership and Adequate 
Investment Underpin a 
Successful Response: Key 
Factors in Dealing with HIV 
Increases 4.00pm 
- 4.30pm
Peter Leone - Associate 
Professor of Medicine, 
University of North Carolina, 
and Director, North Carolina 
HIV/STD Prevention and Control 
Branch, USA 
4.15pm 
- 4.30pm
Lim A - Phenotypic 
Analyses of FOxP3-
Expressing CD4+ And 
CD8+ T Cells in HIV-
Infected Patients
4.15pm 
- 4.30pm
Savage J - Models of Access 
and Clinical Service Delivery in 
Australia Today
Acute HIV and STDs: Screening 
and Co-infection
4.30pm 
- 4.45pm
Seddiki N - Identification 
of Human Antigen-
Specific Regulatory T 
Cells, Phenotyping and 
Functional Analysis
4.30pm 
- 4.45pm
Anderson J - Measuring 
Quality of Life for Economic 
Evaluation in HIV
4.30pm 
- 4.50pm
Prize Presentations and Closing 
Remarks by Darren Russell 
- President of the Australasian 
Chapter of Sexual Health 
Medicine Committee
4.45pm 
- 5.00pm
Seddiki N - Regulatory 
T Cell Abnormalities 
are Associated with 
Aberrant CD4+ 
T-Cell Responses in 
Patients with Immune 
Inflammatory Syndrome 
(IRIS)
4.45pm 
- 5.00pm Discussion
4.50pm 
- 5.00pm
Presentation of Next year’s 
Conference by David Jardine 
- Committee Convenor, 2009 
Australasian Sexual Health 
Conference, Brisbane 
5.15pm	
-	6.15pm
Circumcision:	Crown	Jewels
5.15pm	
-	6.15pm
Diagnostics	and	Assay	
Development
Riverside	Theatre/Auditorium Meeting	Room	1,2,3
Chairs:	Graham	Brown	and	Andrew	Grulich Chairs:	Elizabeth	Dax	and	Andrew	Lloyd
5.15pm 
- 5.30pm
Templeton D - Reduced Risk of HIV Seroconversion Among Circumcised 
Homosexual Men who Report a Preference for the Insertive Role in Anal 
Intercourse
5.15pm 
- 5.30pm
Guy R - The Accuracy of HIV 
Incidence Assays in Estimating 
the Population Rate of New 
Infections: A Systematic ReviewW
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5.30pm 
- 5.45pm
Londish G - Small Population Health Benefits on HIV by Circumcising 
Men who have Sex with Men
5.30pm 
- 5.45pm
Gold J - Sensitivity and 
Specificity of HIV Incidence 
Assays: A Systematic Review
5.45pm 
- 6.00pm
Anderson J - Cost-effectiveness of Circumcision for the Prevention of HIV 
in Gay Men in Australia
5.45pm 
- 6.00pm
Plate M - Evaluation of the New 
Version 3 Cavidi Exavir™ Load 
Quantitative HIV RT Load Kit as 
an Alternative HIV Viral Load 
Monitoring Assay for use in 
Both Resource-Constrained and 
Developed Countries
6.00pm 
- 6.15pm
Donohue S - Promoting Circumcision within the Australian HIV 
Prevention Response
6.00pm 
- 6.15pm
Zaunders J - Persistence of High 
Levels of HIV Antigen-Specific 
CD4+ T Cells in Untreated 
Chronic Infection, Detected by 
a Novel Flow Cytometric Assay
7.30pm	
-	11.30pm
Joint	Conference	Dinner,	‘Diamonds	are	Forever’	-	Bellevue	Ballroom,	Level	3,	Perth	Convention	Centre	
Sponsored	by	the	Australian	Government	Department	of	Health	and	Ageing,	WA	Health,	Gilead,	
GlaxoSmithKline,	Boehringer	Ingelheim,	and	Merck	Sharp	&	Dohme	
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THURSDAY 18 SEPTEMBER
7.00am Registration
7.30am	-	
8.45am
Breakfast	Session	-	‘Meet	the	Experts’	-	Clinical
8.00am	-	
8.45am
Oral	Poster	Session	-	Social	Research,	
International,	Community,	Indigenous	Health
Riverview	4 Meeting	Room	1,2,3
Chairs:	Miles	Beaman	and	Martyn	French Chairs:	Jeffrey	Grierson	and	Francine	Eades
7.30am 
- 7.40am
Martyn	French	-	Clinical	Professor,	Pathology	and	
Laboratory	Medicine,	University	of	Western	Australia,	
Perth,	Western	Australia 8.00am 
- 8.05am
Scott-Visser B - Enhanced Primary Care (EPC) and 
Care Coordination as a Cooperative Model
Life-threatening Immune Reconstitution Inflammatory 
Disease 
7.40am 
- 7.50am
Roy	Gulick	-	Professor	of	Medicine,	Weill	Medical	
College	of	Cornell	University,	USA 8.05am 
- 8.10am
McGowan A - ‘We have Infections Zapped!’ Offering 
Testing for Chlamydia and Gonorrhoea in Targeted 
youth SettingsContemporary Approach to Management of 
Antiretroviral Treatment Failure or Toxicity 
7.50am 
- 8.00am
Robin	Wood	-	Director,	Desmond	Tutu	HIV-Research	
Centre,	South	Africa 8.10am 
- 8.15am
Reeders D - User-Centred Design in a Resource for 
Positive TravellersManagement of Late Presenting Patients with Severe 
Opportunistic Infection 
8.00am 
- 8.10am
David	Nolan	-	Royal	Perth	Hospital	and	Murdoch	
University,	Western	Australia
8.15am 
- 8.20am
Brown G - Evaluation of a Health Promotion Short 
Course for the HIV Community Sector
Prevention and Management Strategies for Metabolic 
Syndrome and Cardiovascular Risk in Patients Taking 
Antiretroviral Therapy
8.20am 
- 8.25am
Brown G - Netreach: Online Peer Outreach to Virtual 
Communities Across Australia
8.10am 
- 8.45am Questions and Panel Discussion
8.25am 
- 8.30am
Lake R - Are Hospitals Biohazards for People with 
HIV?
8.30am 
- 8.35am
Clayton S - Sero-Sorting: What is the Impact on HIV 
Transmission in Gay Men and How Do We Reduce 
it?
8.35am 
- 8.40am
Sarangapany J - Potential Difficulties and Barriers: 
Findings from a Knowledge, Attitudes and Practice 
Survey in Papua New Guinea
8.35am 
- 8.45am Discussion
8.00am 
- 9.00am Arrival Coffee/Tea in Exhibition and Poster Area in Pavilion 1 
9.00am	
-	10.30am
HIV	and	Ageing
Riverside	Theatre/Auditorium
Chairs:	Bill	Whittaker	and	Patti	Martinez
9.00am 
- 9.20am
Bruce	Brew	-	Head,	Department	of	Neurology,	St	Vincents	Hospital,	Sydney,	New	South	Wales,	Australia		
Neurodegeneration and Ageing in the HAART Era
9.20am 
- 9.40am
Marian Pitts, Director, Australian Research Centre in Sex, Health and Society, La Trobe University, Melbourne, 
Victoria, Australia 
Growing Old Disgracefully with HIV
9.40am 
- 10.00am
Andrew	Grulich	-	Professor,	National	Centre	in	HIV	Epidemiology	and	Clinical	Research,	Sydney,	New	South	Wales,	
Australia
HIV, Cancer, and Immune Deficiency
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10.00am - 
10.30am
David	Nolan	-	Senior	Clinical	Research	Fellow,	Centre	for	Clinical	Immunology	and	Biomedical	Statistics,	Royal	Perth	
Hospital	and	Murdoch	University,	Perth,	Western	Australia
HIV Infection and Healthy Ageing: Is There a Need For HIV-Specific Management Guidelines for the Protection of Hearts, 
Bones, Minds and More?
10.30am - 
11.00am Morning Tea in Exhibition and Poster Area in Pavilion 1 
11.00am	-	
12.30pm
Hot	Topics:	Top	
Papers	of	2008
11.00am	-	
12.30pm
Community	
Research	into	
Practice
11.00am	-	
12.30pm
International:	
Global	HIV	
Initiatives	vs	Local	
Response
11.00am	
-	
12.30pm
Margaret	
Macdonald	
Memorial	
Session	-	
Epidemiology	
Population
Riverside	Theatre/
Auditorium Riverview	4
Meeting	Room	
1,2,3 Meeting	Room	8
Chairs:	Susan	
Kippax	and	Chris	
Birch	
Chairs:	Jo	Watson	
and	Marian	Pitts	
Chairs:	John	
Milan	and	Marina	
Carman
Chairs:	Andrew	
Grulich	and	
Margaret	
Hellard
11.00am - 
11.30am
Martyn French 
- Clinical Professor, 
Pathology and 
Laboratory 
Medicine, 
University of 
Western Australia, 
Perth, Western 
Australia
11.00am - 
11.15am
Bruno Spire 
- Communities 
and Research: The 
Necessity for Dialogue
11.00am - 
11.15am
Wilson D - Tailoring 
Global Responses 
to Local Epidemics
11.00am - 
11.15am
Mcdonald A 
- Trends in Newly 
Acquired HIV 
Infection in 
Australia, 1994 
– 2007
11.15am- 
11.30am
Canavan P - The Shock 
of Ethical Community 
Research
11.15am- 
11.30am
Priohutomo S 
- Impact of the 
Global Fund in 
Indonesia  
11.15am- 
11.30am
Wand H - 
Increasing HIV 
Transmission 
through Male 
Homosexual and 
Heterosexual 
Contact in 
Australia: Results 
from an Extended 
Back-Projection 
Approach
11.30am - 
12.00pm
Mary Crewe 
- Director, Centre 
for the Study of 
AIDS, University 
of Pretoria, South 
Africa    
11.30am - 
11.45am
Imrie J - The Feasibility 
of a National Gay 
Men’s Internet-
Based Cohort 
and Prospective 
Behavioural 
Surveillance Platform 
in Australia -What are 
the Issues?
11.30am - 
11.45am
Worth H - Exploring 
the Links between 
HIV and Poverty: 
Are the Analyses 
Correct?
11.30am - 
11.45am
Ward J - How is 
the Aboriginal 
and Torres 
Strait Islander 
Population Faring 
in the Australian 
HIV Epidemic? 
- An Analysis of 
Data from 1993-
2007
11.45am - 
12.00pm
Whittaker B - Special 
Access Schemes - An 
Analysis of the Last 
Four Programs 
11.45am - 
12.00pm
Bebbington M 
- Capacity Building 
through Long-term 
Partnerships
11.45am - 
12.00pm
Horyniak D 
- The Impact of 
Migration on 
the Burden of 
HIV Infection in 
Victoria, Australia
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12.00pm - 
12.30pm
John Kaldor - 
Deputy Director, 
National Centre In 
HIV Epidemiology 
and Clinical 
Research, Sydney, 
New South Wales, 
Australia 
12.00pm - 
12.15pm
Ogier A - Towards 
more Equitable 
Access to HIV Clinical 
Trials
12.00pm - 
12.15pm
Menon A - Building 
Clinical Capacity 
to Manage Human 
Immunodeficiency 
Virus (HIV) Infection 
in Resource 
Constrained 
Environments: 
Reflections from 
Experience with 
Clinical Mentoring 
in Papua New 
Guinea (PNG)
12.00pm - 
12.15pm
Manopaiboon C 
- Unexpectedly 
High HIV 
Prevalence 
Among Thai 
Sex Workers in 
a Respondent-
Driven Sampling 
Survey
12.15pm - 
12.30pm Discussion
12.15pm - 
12.30pm Discussion
12.15pm - 
12.30pm
Ryan CE - The 
Molecular 
Characterization 
of the HIV-1 
Epidemic in Fiji
12.30pm 
- 1.30pm Lunch in Exhibition and Poster Area in Pavilion 1 
12.30pm 
- 1.30pm ASHM AGM in Meeting Room 6; Lunch will be provided at Meeting Room 6 for attendees 
1.30pm	-	
3.00pm
Australian	
Antiretroviral	
Guidelines:	
Consensus	
Session
1.30pm	-	
3.00pm
Social	Research	-	
Desire
1.30pm	-	
3.00pm
AusAID	Session	
-	Indonesia
1.30pm	-	
3.00pm
HIV	
Immunology
Riverside	Theatre/
Auditorium Riverview	4
Meeting	Room	
1,2,3 Meeting	Room	8
Chairs:	Alan	Street	
and	Ron	McCoy	
Chairs:	Diana	
Bernard	and	
Anthony	Smith
Chairs:	Murray	
Proctor	and	David	
Wilson	
Chairs:	Stephen	
Kent	and	
Michael	Boyle
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1.30pm 
- 2.15pm
Roy	Gulick	
–			Professor	of	
Medicine,	Weill	
Medical	College,	
Cornell	University,	
New	York	
1.30pm 
- 1.45pm
De Wit J - Increasing 
the Contribution 
of Social Research 
to HIV Prevention: 
Developing and 
Testing a Theory-
Driven Intervention 
to Reduce 
Unpremeditated Risk-
Taking in MSM
1.30pm 
- 1.45pm
Sigit Priohutomo, 
Head HIV/AIDS 
Program Ministry of 
Health, Republic of 
Indonesia 
1.30pm 
- 1.50pm
Paul Gorry - Head, 
HIV Molecular 
Pathogenesis 
Laboratory, 
Burnet Principal 
Fellow, 
Macfarlane 
Burnet Institute 
for Medical 
Research & 
Public Health, 
Melbourne, 
Victoria, Australia 
Report on the 
Integrated Bio 
Behavioural 
Surveillance ( IBBS) 
Study for at Risk 
Populations in 
Indonesia
Heterogeneity in 
Primary R5 HIV-1 
gp120 Structures 
Affecting CD4 
and CCR5 
Interactions 
and Exposure 
of Neutralising 
Antibody 
Epitopes
How to Use the 
Newer Agents in 
the Treatment-
Experienced Patient 
and What Drugs 
Are in the Pipeline 
 
1.45pm 
- 2.00pm
Triffit KA - Sex Pigs 
- A Rough Guide to 
Dirty Sex
1.45pm 
- 2.00pm
Tim Mackay, Head,  
HIV Co-operation 
Program Indonesia  
1.50pm 
- 2.10pm
Simon Mallal 
- Clinical 
Immunologist, 
Royal Perth 
Hospital - Clinical 
Immunology 
Department, 
Perth, Western 
Australia
AusAID Indonesia 
HIV Program 
Support, 
Responsiveness and 
Building Capacity
2.00pm 
- 2.15pm
Prestage G - Gay 
Men who Engage 
in Group Sex are at 
Increased Risk of HIV 
Infection and Onward 
Transmission: Data 
from the Three or 
More Study
2.00pm 
- 2.15pm
Ms Wulan Sekar 
Sari, Director, 
Stigma Foundation, 
Indonesia 
How Might 
Understanding of 
the Co-Evolution 
Of HLA and 
Viruses Inform 
Contemporary 
Clinical Issues
Harm Reduction in 
Indonesia
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2.15pm 
- 3.00pm
Tim	Read	-	Sexual	
Health	Physician,	
Melbourne	Sexual	
Health	Centre	
and	Victorian	
infectious	
Diseases	Service	
(Royal	Melbourne	
Hospital),	
Melbourne,	
Victoria,	Australia
2.15pm 
-2.30pm
Grierson J - Walking 
after Midnight: 
Trajectories of Sex on 
Premises Visits
2.15pm 
-2.30pm
Carolyn Thomas 
- Supervisor, 
Spiritia Foundation, 
Indonesia
2.10pm - 
2.30pm
Alan Landay 
- Professor 
and Chairman, 
Department of 
Immunology/
Microbiology, 
Rush University 
Medical Center, 
Chicago , USA 
Catriona	Ooi	-	
Director	of	Sexual	
Health,	Hunter	
New	England	Area	
Health,	Newcastle,	
New	South	Wales,	
Australia	
Delivering 
Community 
Support Across 
Different Epidemics 
and Settings
Innate Immunity 
in HIV Disease: 
Friend or Foe
The	Guidelines	in	
Action	-	Treatment	
Dilemmas	in	
Clinical	Practice 2.30pm 
- 2.45pm
Adam PCG - Sexual 
Desires, Sexual 
Control and Sexual 
Risk-Taking in Men 
who have Sex with 
Men.
2.30pm 
- 3.00pm Discussion
2.30pm - 
2.50pm
Tony Kelleher 
- Associate 
Professor, 
National Centre in 
HIV Epidemiology 
& Clinical 
Research, Sydney, 
New South Wales, 
Australia 
Two case based 
presentations:          
                                    
    Case 1: Managing 
Suspected Early 
Virologic Failure
                            
 Case 2: Juggling 
Antiretroviral 
Therapy and 
Cardiovascular Risk
What Do T Cell 
Responses Mean: 
A Post Step 
Perspective
2.45pm 
- 3.00pm
Holt M - Medicine, 
Risk Factor, Pleasure 
Enhancer or Safe 
Sex Aid? The Use 
of Viagra and other 
Sexuopharmaceuticals 
by Gay Men
2.50pm - 
3.00pm Discussion
3.00pm 
- 3.30pm Afternoon Tea in Exhibition and Poster Area in Pavilion 1 
3.30pm	-	
5.00pm
Ian	Thompson	
Memorial	Session	
-	Clinical	Anti	
Retroviral	Therapy
3.30pm	-	
5.00pm
Epidemiology	
-	Morbidity	and	
Mortality
3.30pm	-	
5.00pm
Working	
with	CALD	
Communities	/	
Working	with	
Media	
3.30pm	-	
5.00pm
Prevention	
and	Treatment	
Issues	for	
Older	Gay	Men	
-	Sponsored	by	
NSW	Health	and	
ACON
Riverside	Theatre/
Auditorium Riverview	4
Meeting	Room	
1,2,3 Meeting	Room	8
Chairs:	Elizabeth	
Phillips	and	Greg	
Dore
Chairs:	John	Kaldor	
and	Sue	Laing
Chairs:	Trish	
Langdon	and	Lisa	
Bastian
Chairs:	Stevie	
Clayton	and	
Geoff	Honnor	
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3.30pm 
- 3.35pm
Introduction by 
David Cooper, 
Director, National 
Centre in HIV 
Epidemiology and 
Clinical Research, 
Sydney, New South 
Wales, Australia
3.30pm 
- 3.45pm
Murray JM - A Faster 
Decrease in CD4+ 
T Cell Counts after 
HIV Infection for 
Older Individuals 
Contributes 
to Levels of 
Immunosuppression 
at HIV Diagnosis
3.30pm 
- 3.45pm
Crawford G - Safe 
Sex No Regrets: 
Sexual Health in the 
Mainstream Media 
in WA
3.30pm 
- 3.45pm
Garrett Prestage 
- Senior Lecturer, 
National Centre in 
HIV Epidemiology 
& Clinical 
Research, Sydney, 
New South Wales, 
Australia 
3.35pm 
- 3.45pm
Pett S - Changes 
in Circulating 
CCR5+ T-Cells and 
Antigen-Specific 
CD4+ T-Cells during 
Monotherapy with 
a Small Molecule 
CCR5 Antagonist 
Sch532706, 
compared with 
Combination 
Antiretroviral 
Therapy (CART)
An Overview 
of Risk and 
Behaviour in 
Older Gay Men
3.45pm 
-4.00pm
Read T - Efavirenz 
(EFV) Plasma 
Concentrations in 
Patients Stopping 
Therapy after 
at Least One 
Month due to 
Neuropsychiatric 
Disturbances: An 
Initio Substudy
3.45pm 
-4.00pm
Petoumenos K 
- Predictors of Long-
Term Changes in 
Mean CD4 Cell Counts 
Amongst HIV Infected 
Patients from the Asia-
Pacific Region During 
Active Combination 
Antiretroviral Therapy
3.45pm 
-4.00pm
Shaw MJ - Different 
Communities, 
Different Needs: 
Shaping HIV/AIDS 
Messages for 
Six New South 
Wales Culturally 
and Linguistically 
Diverse 
Communities
3.45pm 
- 4.00pm
John Imrie 
- Associate 
Professor, 
National Centre 
in HIV Social 
Research, 
University of New 
South Wales, 
Sydney, New 
South Wales, 
Australia
Risk, Realities 
and HIV 
Seroconversions 
in Old Gay Men: 
Qualitative 
Results from an 
Investigation of 
Seroconversions 
in Gay Men 
Who HIV Test in 
England (Insight 
Study)
4.00pm 
- 4.15pm
Seneviratne N - 
ESPRIT (Evaluation 
Of Subcutaneous 
Proleukin® In 
A Randomised 
International 
Trial): Factors 
Associated with 
Ongoing Cycling 
with Recombinant 
Interleukin-2 (RIL-2)
4.00pm 
- 4.15pm
McDonald A - Who 
gets AIDS in the 
HAART Era?
4.00pm 
- 4.15pm
Newman CE - The 
Making of HIV as 
a Public Concern: 
Three Themes in 
the Contemporary 
Australian News 
Media Coverage 
of HIV
4.00pm - 
4.15pm
Dermot Ryan 
- Acting Director, 
Community 
Health, AIDS 
Council of New 
South Wales, 
Sydney, New 
South Wales, 
Australia
Prevention Issues 
and Responses
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4.15pm 
- 4.30pm
Zhou J - Deferred 
Modification of 
Antiretroviral 
Regimen Following 
Treatment Failure 
in Asia: Results 
from the Treat Asia 
HIV Observational 
Database (TAHOD)
4.15pm 
- 4.30pm
Grebely J - High 
Mortality Associated 
with HIV Infection 
Among Illicit Drug 
Users in the HAART 
Era
4.15pm 
- 4.30pm
Sabri W - Radio 
Dramas, HIV/AIDS 
& the Vietnamese 
Community in 
Sydney
4.15pm - 
4.30pm
Russell Westacott 
- Director, Client 
Services, AIDS 
Council of New 
South Wales, 
Sydney, New 
South Wales, 
Australia
 Ageing GLBT 
Populations
4.30pm 
- 4.35pm
Oral Poster: 
McLellan D 
- Efavirenz and 
Positive Urinary 
Drug Screen for 
Cannabinoids
4.30pm 
- 4.45pm
Van Leeuwen MT 
- Cancer and HIV 
in Australia: A 
Comparison Across 
Early and Late HAART 
Periods
4.30pm 
- 4.45pm
Katsaros E - 
Reflections on 
Improving Health 
Outcomes
4.30pm - 
4.45pm
Rob Lake - Chief 
Executive Officer, 
Positive Life NSW, 
Sydney, New 
South Wales, 
Australia4.35pm 
- 4.40pm
Oral Poster: 
Byakwaga H 
- HIV Disease 
Progression in HIV-1 
Patients Initiating 
Combination 
Antiretroviral 
Therapy with 
Advanced Disease 
in the Asia-Pacific 
Region: Results 
from the Treat Asia 
HIV Observational 
Database (TAHOD)      
4.40pm 
- 4.45pm
Oral Poster: Bloch 
M - Triple Class 
HIV Antiretroviral 
(ARV) Failure in an 
Australian Primary 
Care Setting
Treatment Issues 
and Responses
4.45pm 
- 4.50pm
Oral Poster: Chibo 
- Resistance to the 
HIV-1 Integrase 
Inhibitor Raltegravir: 
A Case Study
4.45pm 
- 5.00pm
Gelgor L - Update of 
the Australian Long-
Term Non-Progressor 
(LTNP) Cohort
4.45pm 
- 5.00pm
O’Connor CC 
- Acculturation, 
Sexual Behaviour, 
Risk And 
Knowledge In 
Vietnamese 
Men Living In 
Metropolitan 
Sydney
4.45pm - 
5.00pm Discussion
4.50pm 
- 5.00pm Discussion
5.00pm	
-	6.30pm
Policy:	Australia’s	Response	to	HIV	in	Asia	and	the	
Pacific:	New	Partnerships	and	Collaborations
5.00pm	
-	6.15pm
Response	and	
Predictions	in	ART
5.00pm	
-	6.30pm
Adherence	to	
Antiretroviral	
Therapy
Riverside	Theatre/Auditorium Riverview	4 Meeting	Room	1,2,3
Chairs:	Levinia	Crooks	and	Dr	Bagus	Widjaja	
Chairs:	Gail	
Matthews	and	Jill	
Carr
Chairs:	Angela	
Kelly	and	Ric	
Chaney
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5.00pm 
- 5.15pm
Bob	McMullan,	MP	-	Parliamentary	Secretary	for	
International	Development	Assistance,	Braddon,	
Australian	Capital	Territory,	Australia
5.00pm 
- 5.15pm
Warner MS 
- Evaluation of 
the Relationship 
between HLA-
B*5701 Status 
and HIV Reverse 
Transcriptase 
Codon 245 
Variation in South 
Australian HIV-
Infected Individuals
5.00pm 
- 5.15pm
Kerr SJ - Assessing 
Adherence in Thai 
Patients Taking 
HAART
A New Aid Policy on HIV/AIDS:  Issues for Consideration
5.15pm 
- 5.30pm
Dr	Tarun	Weeramanthri	-	Executive	Director,	Public	
Health	Division,	WA	Health,	Perth,	Western	Australia
5.15pm 
- 5.30pm
Chew C SN - 
Characterisation 
of TNF Block 
Haplotypes 
and Genotypes 
that Predict an 
Individual’s Risk 
of Stavudine-
Associated Sensory 
Neuropathy
5.15pm 
- 5.30pm
Herrmann S - Side 
Effects, Dosing 
Schedules, Pill 
Burden and 
Perceived Stress: 
Interaction 
and Influence 
on Medication 
Adherence
How to Overcome PIF (Policy Implementation Fatigue)
5.30pm 
- 5.40pm
James	Ward	-	Program	Manager,	Aboriginal	and	
Torres	Strait	Islander	Health,	National	Centre	in	HIV	
Epidemiology	and	Clinical	Research,	Sydney,	New	
South	Wales,	Australia 5.30pm 
- 5.45pm
Tschochner M - 
Naturally Occurring 
Polymorphisms in 
HIV-1 Integrase: 
Relationship to HIV 
Subtype, Integrase 
Inhibitor Resistance 
and Immune 
Selection
5.30pm 
- 5.45pm
Baker D 
- Improved 
Treatment 
Adherence 
Associated 
with Treatment 
Simplification 
Is it Luck or Persistence on the Ground? - Aboriginal and 
Torres Strait Islander Australians and HIV.  What Should 
a Future Policy Response Look Like for Indigenous 
Australia?
5.40pm 
- 5.50pm
David	Cooper	-	Director,	National	Centre	in	HIV	
Epidemiology	and	Clinical	Research,	Sydney,	New	
South	Wales,	Australia	 
5.45pm 
- 6.00pm
Grey P - Patient 
Characteristics and 
Predictors of Time 
to Commence 
Antiretroviral 
Treatment in a 
Prospective Cohort 
Identified at Primary 
HIV Infection (PHI). 
(The Phaedra 
Collaborative 
Cohort)
5.45pm 
- 6.00pm
O’Connor MB 
- Adherence to 
Anti-Retroviral 
Therapy Among 
Patients in 
Bangalore, IndiaNew Policies for Clinical and Operations Research in 
Resource Limited Settings
5.50pm 
- 6.00pm
Don	Baxter	-	Executive	Director,	Australian	
Federation	of	AIDS	Organisations,	Sydney,	New	
South	Wales,	Australia	
6.00pm 
- 6.15pm Discussion
6.00pm 
- 6.15pm
Ibrahim D - 
AIDS Dementia 
Complex (ADC) 
and Mental 
Illness: The Role 
of the NSW 
Mental Health 
Act in Managing 
Compliance with 
Highly Active Anti 
Retroviral Therapy 
(HAART)
Re-shaping Australia’s Response to Emerging Trends in 
the HIV Epidemic in Asia and the Pacific
6.00pm 
- 6.30pm Discussion
6.15pm 
- 6.30pm Discussion
6.30pm 
- 7.00pm
Launch of the Prison Entrants’ Blood Borne Virus Report in Meeting Room 6
Sponsored by WA Health on behalf of the National Drug Research Institute
Free Evening 
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FRIDAY 19 SEPTEMBER
7.00am Registration Opens
7.00am	
-	8.45am
Case	Presentation	Breakfast
7.45am	
-	8.45am
Oral	Poster	Session	-	Public	Health	and	Epidemiology
Riverview	4	 Meeting	Room	1,2,3
Chairs:	Tony	Allworth	and	Pietro	Vernazza Chairs:	Fengyi	Jin	and	Barry	Combs
7.30am 
- 7.45am
Sherry N - Autoimmune Haemolytic Anaemia: An 
Unusual Presentation of HIV Seroconversion
7.45am 
- 7.50am Introduction to Session
7.45am 
- 8.00am
Peel T - Steroid-Dependent Cryptococcal Immune 
Restoration Disease in a HIV-Positive Patient
7.50am 
- 7.55am
Roth N - A Comparative Study of Syphilis & HIV from a 
Melbourne General Practice Perspective
7.55am 
- 8.00am
Stoove M - Local HIV Information Testing and Support 
(HITS) Pilot Program: Improving the Capacity of General 
Practitioners
8.00am 
- 8.15am
Barber B - A Case of Tenofovir-Associated Renal 
Tubular Acidosis with Neurological Impairment
8.00am 
- 8.05am 
Allison W - Clinical Features Associated with HIV Infection 
in Children at Port Moresby General Hospital - Interim 
Analysis of a Prospective Study to Ascertain Predictors of 
HIV Infection
8.05am 
- 8.10am 
Hsu D - Combination Antiretroviral Therapy in HIV 
Patients at a Sydney Sexual Health Clinic
8.10am 
- 8.15am Jin F- Renewing the Seroconversion Study
8.15am 
- 8.30am
Rogers B - Three’s a Crowd: The Relationship 
between CA-MRSA, HIV and MSM
8.15am 
- 8.20am
Pedrana A - Estimating HIV Prevalence of HIV among 
Men who have Sex with Men (MSM); A Review of 
Methodological Options
8.20am 
- 8.25am
O’Connor M - A Comparative Study of Human 
Immunodeficiency Virus Antibody-Positive Patients in 
Ireland and Australia
8.25am 
- 8.30am
Prihaswan P - Sexo Latino. Sexo Caliente. Sexo Seguro. A 
Safe Sex Campaign for Spanish Speaking Gay Men
8.30am 
- 8.45am
Chang C - Fatal Acute Varicella-Zoster Virus 
Haemorrhagic Meningomyelitis with Necrotising 
Vasculitis in an HIV-Infected Patient
8.30am 
- 8.35am
Connelly C - The Effect of Introducing Specialist Blood 
-Borne Virus Nurses into Prison Health Centres 
8.35am 
- 8.45am Discussion 
8.00am 
- 9.00am Arrival Coffee/Tea in Exhibition and Poster Area in Pavilion 1 
9.00am-	
10.30am
Plenary	-	Prevention	
Riverside	Theatre/Auditorium
Chairs:	Gita	Ramjee	and	John	De	Wit
9.00am 
- 9.25am
Bruno	Spire	-	President,	French	NGO	AIDES,	Public	Health	and	Social	Science	in	Clinical	Research,	Marseilles,	France
Public Health and Social Science in Clinical Research: The Interest of a Multdisciplinary Approach 
9.25am 
- 9.50am
Sarah	Rowland-Jones	-	Human	Immunology	Unit,	John	Radcliffe	Hospital,	Oxford,	United	Kingdom		
The Role of T-cells in HIV Immunity: Lessons from China and West Africa
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9.50am 
- 10.10am
David	Wilson	-	Lead	Health	Specialist,	the	World	Bank	and	Adjunct	Professor,	Centre	for	International	Health,	
Curtin	University	of	Technology,	Perth,	Western	Australia		
Understanding Our Last 1,000 Infections - Knowing our Epidemics for more Effective Programming
10.10am 
- 10.30am
Pietro	Vernazza	-	Head,	Division	of	Infectious	Diseases	and	Hospital	Epidemiology,	Cantonal	Hospital,	St	Gallen,	
Switzerland 
Biological Factors of Sexual Transmission of HIV
10.30am 
- 11.00am Morning Tea in Exhibition and Poster Area in Pavilion 1 
11.00am	-	
12.30pm
Peter	Meese	
Memorial	
Session	-	Clinical	
-	Associated	
Conditions	
Complications
11.00am	
-	12.30pm
Indigenous	
Health
11.00am	-	
12.30pm
Epidemiology	
-	Transmission/	
Acquisition
11.00am	
-	12.30pm
International:	
Where	to	for	
Testing	and	
Counselling	in	
Resource-Poor	
Settings?
Riverside	Theatre/
Auditorium Riverview	4 Meeting	Room	1,2,3 Meeting	Room	8
Chairs:	Moira	
Wilson	and	David	
Shaw
Chairs:	
Heather	
D’Antoine	and	
Ted	Wilkes	
Chairs:	Andrew	
Grulich	and	
Margaret	Hellard
Chairs:	Edward	
Reis	and	Sigit	
Priohutomo
11.00am 
- 11.15am
Kidd M - Primary 
Healthcare and HIV 
as a Chronic Disease
11.00am 
- 11.15am
Huang R 
- Managing 
Data to Guide 
a Long-Term 
STI Control 
Response in 
some Remote 
Central 
Australian 
Aboriginal 
Communities
11.00am 
- 11.15am
Pierce AB - Rates of 
HIV Seroconversion 
in Patients who have 
Previously used 
NPEP: Data Linkage 
of the Victorian NPEP 
Service Database 
with the Victorian HIV 
Surveillance Registry
11.00am 
- 11.15am
Ankus J - Minimum 
Standards for HIV 
Counselling and 
Testing for the 
Pacific
11.15am- 
11.30am
Agarwal U - Profile 
of HIV Associated 
Tuberculosis in the 
Setting of Free Anti-
Retroviral Therapy 
at a Tuberculosis 
Hospital in India
11.15am- 
11.30am
Slater A 
- Barriers to 
Hepatitis 
C Services 
for Rural 
Aboriginal 
People
11.15am- 
11.30am
Jin F - Risk 
Reduction Patterns 
of Unprotected 
Anal Intercourse: 
Relative Risk for HIV 
Acquisition in the 
Health in Men (HIM) 
Study
11.15am
- 11.30am
Sri Kartika A - VCT, 
lessons learnt from 
Indonesia after ‘3x5’
11.30am 
- 11.45am
Newman C - 
General Practitioner 
Descriptions of 
Challenges in the 
Management of 
Depression in Gay 
Men and Men with 
HIV
11.30am 
- 11.45am
Webb D - A 
Cultural World 
AIDS Day in 
the Aboriginal 
Community
11.30am 
- 11.45am
Jin F - Sexual 
Partners’ Age as a 
Risk Factor for HIV 
Seroconversion in the 
Health in Men (HIM) 
Study
11.30am 
- 11.45am
Kelly A - Policing 
Women’s Bodies: Are 
we Ready to Move 
Beyond Critiquing 
PICT yet?
11.45am 
- 12.00pm
Carey C - 
Determination of 
the Underlying 
Cause of Death in 
Three Multicentre 
International HIV 
Clinical Trials
11.45am 
- 12.00pm
Smith M 
- Berrima 
Women’s 
Project
11.45am 
- 12.00pm
Wilson DP 
- Importance 
of Promoting 
HIV Testing for 
Preventing Secondary 
Transmissions: 
Modelling the 
Australian HIV 
Epidemic Among 
Men who have Sex 
with Men
11.45am 
- 12.00pm
Poolsawat M 
- Providing HIV 
Services to Prisoners 
in Thailand: Peer 
Outreach Voluntary 
Counselling and 
Testing (VCT) and 
Linkages to Care
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12.00pm 
- 12.15pm
Hoy J - Re-Initiation 
of Antiretroviral 
Therapy (ART) in the 
CD4 Cell-Guided 
ART Interruption 
Group in the Smart 
Study Lowers Risk 
of Opportunistic 
Disease or Death
12.00pm 
- 12.15pm
Gilles M 
- Willingness 
to Pay: What is 
the True Cost 
of Providing 
Equitable 
Health 
Care in a 
Disadvantaged 
Community?
12.00pm 
- 12.15pm
Wilson DP - The 
Paradoxical Effects 
of using Antiretroviral-
Based Microbicides to 
Control HIV Epidemics
12.00pm 
- 12.15pm
Dax E - Proposed 
Appraisal of HIV 
Testing Strategies 
Employing Simple/
Rapid Tests 
12.15pm 
- 12.23pm
Oral Poster: Rotty 
J - Incidence and 
Characteristics of 
HIV-Associated 
Lymphoma in the 
Era of HAART at Four 
Major Australian 
Treatment Centres
12.15pm 
- 12.30pm
Cain A - The 
Process of 
Managing an 
HIV-Positive 
Indigenous 
Woman with 
a Chaotic 
Lifestyle in a 
Rural Setting
12.15pm 
- 12.30pm
Sirivongrangson P 
- HIV Risk Behaviour 
Among HIV-Infected 
Men who have Sex 
with Men in Bangkok, 
Thailand
12.15pm 
- 12.30pm
Allison WE - Use of 
Dry Blood Spots 
(DBS) to Aid Human 
Immunodeficiency 
Virus (HIV) Diagnosis 
in Children in the 
Absence of Local 
Nucleic Acid Testing 
Laboratory Capacity12.23pm 
- 12.30pm
Oral Poster: Furner V 
- Complications: The 
TB + HIV Connection
12.30pm 
- 1.30pm Lunch in Exhibition and Poster Area in Pavilion 1 
1.30pm	
-	3.00pm
Australian	
Antiretroviral	
Guidelines:	
Consensus	Session
1.30pm	
-	3.00pm
Social	
Research:	
Sexual	Risk	
in	Space	and	
Time
1.30pm	
-	3.00pm
International:	PNG
1.30pm	
-	3.00pm
Phillip	Medcalf	
Memorial	Session	
-	Community,	
Health	
Choices	and	
Communication
Riverside	Theatre/
Auditorium Riverview	4 Meeting	Room	1,2,3 Meeting	Room	8
Chairs:	Jenny	
Hoy	and	Fraser	
Drummond
Chairs:	Jeffrey	
Grierson	and	
John	Imrie
Chairs:	Joachim	
Pantumari	and	Goa	
Tau
Chairs:	Robert	
Mitchell	and	John	
Daye	
1.30pm 
- 2.00pm
Dr.	Sarah	Pett	-	
Infectious	Diseases	
Physician	and	
Lecturer,	National	
Centre	for	HIV	
Epidemiology	&	
Clinical	Research,	
Sydney,	New	South	
Wales,	Australia
1.30pm 
- 1.45pm
Smith A - I Met 
Him at the 
Candy Store: 
Community 
Attitudes 
to Sex on 
Premises 
Venues and 
their Patrons
1.30pm 
- 1.45pm
Presenter To be 
advised 
1.30pm 
- 1.45pm
Martinez C - Life 
Coaching - Mission 
Not Impossible
Initiation of 
Combination 
Antiretroviral 
Therapy in Adults 
with HIV-1-infection, 
What CD4 Threshold 
to Use - Overview 
of Clinical Trial Data 
2008
1.45pm 
- 2.00pm
Reynolds R 
- HIV/AIDS 
and Australian 
Gay Life: A 
Generational 
Overview
1.45pm 
- 2.00pm
Kitur I - Human 
Immunodeficiency 
Virus (HIV) and 
Sexually Transmitted 
Infections (STI) 
Surveillance in Papua 
New Guinea 
1.45pm 
- 2.00pm
Niggl M - HIV-
Positive Speakers 
Bureaux a Model for 
Sustainability and 
Relevance in 2008 
and Beyond
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2.00pm 
- 2.30pm
Roy	Gulick	
-	Professor	of	
Medicine,	Weill	
Medical	College,	
Cornell	University,	
New	York	
2.00pm 
- 2.15pm
Prestage G - 
Age and Sexual 
Behaviour 
Among Gay 
Men in Sydney, 
Melbourne and 
Brisbane
2.00pm 
- 2.15pm
Gideon N and 
Sawiya G - Education 
Sessions Support 
Adherence and 
Improve Clinical 
Outcome, Heduru 
Clinic Port Moresby, 
PNG
2.00pm 
- 2.15pm
Green C - Treatment 
Questions? Answers 
by Internet and SMS 
in Indonesia
Emerging Issues 
about Potency 
and Toxicity of the 
Preferred Agents for 
Initial Therapy 
2.15pm 
-2.30pm
Lee J - Sex 
Between Men 
in Timor-Leste: 
What does it 
Mean?
2.15pm 
-2.30pm
Dala M  - The 
Development, 
Delivery and 
Outcome of Patient 
Care for Individuals 
with HIV/AIDS 
attending MAC from 
2004 to 2008
2.15pm 
-2.30pm
DeMaere K - The 
Treataware Infoline: 
A National HIV 
Treatment Health 
Promotion Service 
for People Living 
with HIV
2.30pm 
- 3.00pm
Jeffrey	Post	
-	Infectious	
Diseases	Physician,	
Prince	of	Wales	
Hospital,	Sydney,	
New	South	Wales,	
Australia																	
and																					
Alan	Street,	
Deputy	Director	
and	Head,	HIV	
Service,	Victorian	
Infectious	Diseases	
Service,		
Royal	Melbourne	
Hospital,	and	
Visiting	Physician,	
Infectious	
Diseases	Unit,	The	
Alfred	Hospital,	
Melbourne,	
Victoria,	Australia 
2.30pm 
- 2.45pm
Holt M - ‘1 Msg 
Then Sex’: 
Temporality, 
Spatiality, 
Safety and Risk 
In Gay and 
Bisexual Men’s 
Accounts of 
Online Sex-
Seeking
2.30pm 
- 2.45pm
Rondopali R and 
Gaudentia Sr 
- HIV/AIDS Awareness 
and Access to 
Antiretroviral Therapy 
(ART) Makes a 
Difference in People’s 
Lives in Southern 
Highlands, PNG 
2.30pm 
- 2.45pm
Sabri W - Dance, 
Theatre Drama, HIV/
AIDS & the African 
Communities in 
Sydney
Testing for Latent TB 
in HIV Patients - The 
Old or the New?
2.45pm 
- 3.00pm Discussion
2.45pm 
- 3.00pm Discussion
2.45pm 
- 3.00pm
Triffitt K - Getting 
on with it again 
- Responding to the 
Needs of People 
Living Longer with 
HIV
3.00pm 
- 3.30pm Afternoon Tea in Exhibition and Poster Area in Pavilion 1 
3.30pm Exhibition Closes
3.30pm	
-	5.00pm
Clinical	-	Toxicity
3.30pm	
-	5.00pm
Network	Sex
3.30pm	
-	5.00pm
International	
-		Harm	Reduction	
in	Asia
3.30pm	
-	5.00pm
Social	Research	-	
Lives	Worth	Living
Riverside	Theatre/
Auditorium Riverview	4 Meeting	Room	1,2,3 Meeting	Room	8
Chairs:	Ronan	
Murray	and	
Andrew	Carr
Chairs:	Basil	
Donovan	and	
Kate	Ward	
Chairs:	Nick	
Medland	and	
Catherine	Spooner
Chairs:	Peter	
Canavan	and	
Marian	Pitts
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3.30pm 
- 3.45pm
Drummond F 
- Elevated Levels 
of Interleukin-6 
and D-Dimer are 
Associated with an 
Increased Risk of 
Death in Patients 
with HIV
3.30pm 
- 3.45pm
Laing SC 
- Impact 
of a Non-
Occupational 
Post-Exposure 
Prophylaxis 
Program for 
HIV in Western 
Australia
3.30pm 
- 3.45pm
Kamarulzaman A 
- Harm Reduction 
in Asia - A Clinician’s 
Perspective
3.30pm 
- 3.45pm
Herrmann S 
- Development 
of a New Health-
Related Quality of 
Life Questionnaire 
Specific to HIV/AIDS: 
An International 
and Cross-Cultural 
Initiative
3.45pm 
-4.00pm
Bloch M 
- Cardiovascular 
Disease (CVD) Risk 
in the STEAL Study 
Cohort
3.45pm 
-4.00pm
Kaye MB 
- Extensive 
Transmission 
Links amongst 
Newly HIV-
Infected 
Patients 
Contribute 
Significantly to 
the Incidence 
of HIV-1 
Infection in 
Melbourne
3.45pm 
-4.00pm
Sari SW - Seeing Harm 
Reduction from a 
Gender Perspective
3.45pm 
-4.00pm
Bavinton B and Gray 
J - Assessing the 
Needs of younger 
HIV-Positive Men
4.00pm 
- 4.15pm
Carey D - Poly-L-
Lactic Acid for HIV-1 
Facial Lipoatrophy: 
48-Week Follow-Up
4.00pm 
- 4.15pm
Poynten 
IM - Non-
Occupational 
Post Exposure 
Prophylaxis 
Against HIV 
(NPEP) and 
Subsequent 
HIV Infection 
in Homosexual 
Men: Final Data 
from the HIM 
Cohort
4.00pm 
- 4.15pm
Kab V - Risk Lifestyle 
of Drug Users 
in Phnom Penh, 
Cambodia
4.00pm 
- 4.15pm
Grierson J - Being 
HIV Positive in 
Aotearoa /New 
Zealand: A Two 
Study Comparison 
2001-2007
4.15pm 
- 4.25pm
Oral Poster: Knox 
D - A Public Access 
Program of Sculptra® 
Polylactic Therapy 
to Treat People with 
Facial Lipoatrophy
4.15pm 
- 4.30pm
Langdon 
PA - ‘Sex in 
Other Cities’ 
- Responding 
to Increases 
in Overseas 
Acquired HIV 
Diagnoses in 
WA
4.15pm 
- 4.30pm
Crofts N - Harm 
Reduction in Asia 
– Australia’s Role
4.15pm 
- 4.30pm
Zablotska IB 
- Current Care and 
Support Needs of 
HIV-Positive Gay 
Men: What Factors 
Limit Access to 
Available Services?
4.25pm 
- 4.35pm
Oral Poster: Mackie 
K - Interaction 
Between Inhaled 
Corticosteroids and 
Protease Inhibitors 
(PI) in HIV-Infected 
Individuals 
- Which is the 
Preferred Inhaled 
Corticosteroid?
4.30pm 
- 4.45pm
Harper RE 
and Russell 
D - North 
Queensland 
Travellers 
Project: 
Heterosexual 
HIV Cluster
4.30pm 
- 4.45pm
Speed T - This is the 
Real World - Not as 
We Know It
4.30pm 
- 4.45pm
Murphy D - Viral 
Families: Analysing 
Kinship Discourse in 
HIV Transmission
4.35pm 
- 4.45pm
Oral Poster: Hooker 
D - Monitoring and 
Understanding 
Apoptosis in 
HIV Patients by 
Ligation-Mediated 
Polymerase Chain 
Reaction
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4.45pm 
- 4.55pm
Oral Poster: Russell 
D - Transient Sick 
Sinus Syndrome 
Related to Lopinavir-
Ritonavir in a Patient 
with AIDS
4.45pm 
- 5.00pm Discussion
4.45pm 
- 5.00pm Discussion
4.45pm 
- 5.00pm
Fawkes J - National 
Needs Assessment 
of Sex Workers who 
Live with HIV 2008
5.15pm	
-	6.30pm
Swiss	Statement
5.15pm	
-	6.30pm
Media	Event	-	HIV	Epidemiology	and	Public	Health	
Response	in	WA	
Riverside	Theatre/Auditorium Meeting	Room	1,2,3
Chairs:	Geoff	Honnor	and	Jonathan	Anderson Chairs:	Paul	Van	Buynder	and	Trish	Langdon	
5.15pm 
- 5.35pm
Pietro	Vernazza	-	President,	Swiss	Federal	
Commission	on	AIDS,	St.	Gallen,	Switzerland 
Background and Rationale - Normalising Sex in 
Stable Serodiscordant Relationships 
5.35pm 
- 5.50pm
David	Wilson	-	Mathematical	Modelling	Expert,	
The	National	Centre	in	HIV	Epidemiology	and	
Clinical	Research,	Sydney,	New	South	Wales,	
Australia	
Modelling of Data on Viral Load and Transmission
5.50pm 
- 6.05pm
Susan	Kippax,	Professorial	Research	Fellow,	
National	Centre	in	HIV	Social	Research,	Sydney,	
New	South	Wales,	Australia
Understandings of Viral Load in Negotiating 
Unprotected Sex
6.05pm 
- 6.20pm
Simon	Donohoe	-	Manager,	Education	Team,	
Australian	Federation	of	AIDS	Organisations,	
Sydney,	New	South	Wales,	Australia
Implications for HIV Education and Health 
Promotion
6.20pm 
- 6.30pm Debate 
Free Evening
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7.00am Registration
7.30am	
-	8.45am
Breakfast	Session	-	‘Meet	the	Experts’	-	Basic	
Science/Immunology
Riverview	4
Chairs:	Scott	Bowden	and	Tony	Cunningham
7.30am 
- 7.40am
Paul	Gorry	-	Head,	HIV	Molecular	
Pathogenesis	Laboratory,	Burnet	Principal	
Fellow,	Macfarlane	Burnet	Institute	
for	Medical	Research	&	Public	Health,	
Melbourne,	Victoria,	Australia	
Adaptive Changes in CCR5-Restricted HIV-1 
Affecting Entry Inhibitor Potency
7.45am	
-	8.45am	
Oral	Poster	Session	-	Clinical,	Allied	Health	and	
Basic	Science
7.40am 
- 7.50am
Chris	Burrell	-	Head,	Infectious	Diseases	
Laboratories,	Institute	of	Medical	and	
Veterinary	Science,	Adelaide,	South	
Australia
Meeting	Room	1,2,3
Natural History of Hepatitis B Infection Chairs:	Lewis	Marshall	and	Christopher	Fairley
7.50am 
- 8.00am
Anthony	Cunningham	-	Director,	Australian	
Centre	for	HIV	and	Hepatitis	Virology	
Research,	Sydney,	New	South	Wales,	
Australia
7.50am 
- 7.55am
Purnomo J - Reduced Energy and Increased Saturated 
Fat Intake in a Cohort of HIV-Positive Clients in Sydney
HIV Microbicides and Vaccines 7.55am - 8.00am Crooks L - The Support Focus is on Independent Living!
8.00am 
- 8.10am
Mina	John	-	Clinical	Immunologist,	Clinical	
Immunology	Department,	Royal	Perth	
Hospital,	Western	Australia
8.00am 
- 8.05am
Di Guilmi A - Validating an Abridged Symptoms Distress 
Questionnaire in an HIV-Positive Population to Facilitate 
Dietetic Referral and Improve Nutrition Outcomes
Genetic Factors and HIV & Hepatitis C 8.05am - 8.10am
Di Guilmi A - Validating a Two-Question Depression 
Screening Tool in an HIV-Positive Population to Use in 
Improving Nutrition Outcomes and Prognosis
8.10am 
- 8.45am Questions and Panel Discussion
8.10am 
- 8.15am 
Earle M - Complex Psychological Factors Contributing 
to Sexual Risk Behaviour Among HIV Negative Men 
who have Sex with Men (MSM): Informing Sexual Risk-
Reduction Initiatives for the Future
8.15am 
- 8.20am
Emori R - Physical and Social Benefits of Antiretroviral 
Therapy (ART) on the Lives of People Living with HIV 
and AIDS (PLWHA) in Papua New Guinea (PNG)
8.20am 
- 8.25am
Hoare A - Modelling the Emergence of Drug-Resistant 
HIV in Bangkok
8.25am 
- 8.30am
Tan D - Do Natural Killer Cells Compensate for Impaired 
CD4+ T-Cell Responses to CMV in HIV Patients 
Responding to Antiretroviral Therapy?
8.30am 
- 8.35am
Reddy S - Molecular Cloning and Characterisation of 
Envelope from HIV-1 Pre-Seroconversion Strains
8.35am 
-8.40am
Gorton C - HIV in the Tropics: An Analysis of New HIV 
Infections in Far North Queensland December 2006 
- March 2008
8.00am 
- 9.00am Arrival Coffee/Tea in Foyer, Level 2 
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9.00am-	
10.30am
Clinical	
Epidemiology
9.00am-	
10.30am
Social	Research	
-	Listen	Up:	
International	
Perspective	on	
Young	People	
and	HIV	Risk
9.00am-	
10.30am
Blood-Borne	Viruses:	
Co-Infection
9.00am-	
10.30am
Program	
Delivery
Riverside	
Theatre/
Auditorium
Riverview	4 Meeting	Room	1,2,3 Meeting	Room	8
Chairs:	Chris	
Bourne	and	
Lisa	Bastian
Chairs:	
Heather	Worth	
and	Patrick	
Rawstorne
Chairs:	Gail	Matthews	
and	Scott	Bowden	
Chairs:	Sam	
Libertino	
and	Suzanne	
Hermann
9.00am 
- 9.15am
Goller Jl - HIV, 
Syphilis and 
Chlamydia in 
MSM in Victoria: 
Risk Behaviour 
and Prevalence 
at Clinic Sentinel 
Surveillance 
Sites
9.00am 
- 9.15am
Power R 
- Zimbabwe, 
Adolescent 
Sexual Health 
and the Power of 
Narratives
9.00am 
- 9.20am
Matthews G - HIV/
Hepatitis B Co-Infection
9.00am 
- 9.15am
Ward K - Who is 
Diagnosing HIV 
in NSW?
9.15am 
- 9.30am
Higgins N 
- Rise in Syphilis 
Notifications in 
Victoria - A Case 
Series Study
9.15am 
- 9.30am
McMillan KE 
- Pacific Specific: 
young People 
and Condom 
Use in Tonga 
and Vanuatu
9.20am 
- 9.35am
Oliver BG - 
Immunopathogenesis 
of Hepatic Flare in 
HIV-Hepatitis B Virus 
(HBV) Co-Infected 
Individuals Following 
Initiation of HBV-Active 
Antiretroviral Therapy
9.15am 
- 9.30am
Boddy G - 
Queensland HIV 
Models of Care 
Project 2008
9.30am 
- 9.45am
Srirajalingam 
M - 
Seroprevalence 
and Incidence 
of HSV-1 and 
HSV-2 in an HIV 
Seropositive 
Cohort       
9.30am 
- 9.45am
Akuani F 
- Adequate 
Supply of Food 
and its Impact 
on Adherence to 
ART Treatment 
in Papua New 
Guinea
9.35am 
- 9.50am
Matthews G - Tenofovir 
Based HAART is 
Associated with High 
Rates of HBV DNA 
Suppression and 
HBEAG Seroconversion 
in Thai HIV-HBV 
Coinfected Patients
9.30am 
- 9.45am
Cain A 
- The Western 
Australian Rural 
and Remote 
HIV Program: 
A 10-year 
Experience
9.45am 
- 10.00am
Bradstreet 
B - Clinical 
Outcome of 
a Community 
Based Response 
to a Syphilis 
Outbreak 
Among Gay 
Men in WA
9.45am 
- 10.00am
Walizopa L - The 
Role of Comfort 
in young People 
Talking and 
Learning about 
Sex and HIV 
in Papua New 
Guinea
9.50am 
- 10.05am
Lo G - Screening 
for Hepatocellular 
Carcinoma (HCC) 
in Hepatitis/HIV 
Co-Infection using 
Ultrasound Imaging 
and Alfa-Feto Protein 
Levels
9.45am 
- 10.00am
Chuah J 
- Comparison 
of Clinical HIV 
Performance 
Indicators 
(Post-HAART) 
between AHOD 
and a Regional 
Sexual Health 
Clinic 1996-
2007
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10.00am 
- 10.15am
Moyer J - The 
Role of the 
Nurse in Syphilis 
(and Other STI) 
Risk Assessment 
in a Subacute 
Inpatient 
Setting at the 
Alfred Hospital, 
Melbourne, 
Victoria
10.00am 
- 10.15am
Regmi K 
- Adolescence 
Sexual Behaviour 
and Risks of 
Contracting 
Sexually 
Transmitted 
Infections: A 
Cross-Sectional 
Study in Nepal
10.05am 
- 10.20am
Jung S - GBV-C vs. HIV-1 
Several GBV-C Proteins 
Inhibit Different HIV 
Replication Steps
10.00am 
- 10.10am
Oral Poster: 
Saloner KL 
- Enhancing 
the GP’s 
Primary Care: 
Acon Sydney’s 
Enhanced 
Primary Care 
Project
10.15am 
- 10.30am Discussion
10.15am 
- 10.30am Discussion
10.10am 
- 10.20am
Oral Poster: 
Lienert TM 
- Living Long 
Term with HIV 
in the Rainbow 
Region
10.20am 
- 10.30am
Riley R - HIV and 
Hepatitis C Co-
Infection: From Patient 
to Educator 
10.20am 
- 10.30am Discussion
10.30am 
- 11.00am Morning Tea in Foyer, Level 2
11.00am	
-	12.45pm
Plenary	-	HIV	and	TB	Co-infection	and	Conference	Closing
Riverside	Theatre/Auditorium
Chairs:	Debbie	Marriott	and	Jonathon	Anderson
11.00am 
- 11.30am
Robin	Wood	-	Principal	Investigator,	Desmond	Tutu	HIV-Research	Centre,	Institute	of	Infectious	Disease	and	
Molecular	Medicine,	Faculty	Of	Health	Sciences	Observatory,	University	of	Cape	Town,	South	Africa 
HIV AND TB Co-infection
11.30am 
- 12.00pm
Martyn	French	-	Clinical	Professor,	Pathology	and	Laboratory	Medicine,	University	of	Western	Australia,	Perth,	
Western	Australia
Restoration of Immune Responses to M.tuberculosis in Patients with HIV and M.tuberculosis Infection is a Double-
Edged Sword
12.00pm 
- 12.30pm
Adeeba	Kamarulzaman	-	Head,	Infectious	Diseases	Unit,	Department	of	Medicine,	University	of	Malaya	
Medical	Centre,	Malaysia	
Opportunistic Infections in Asia – The Unmet Needs
12.30pm 
- 12.45pm
Levinia	Crooks	-	Chief	Executive	Officer,	Australasian	Society	for	HIV	Medicine,	Sydney,	New	South	Wales,	
Australia
Closing Remarks, Prize Announcements and Future Conferences
12.45pm 
- 1.45pm Lunch in Foyer, Level 2 
1.45pm Conference Close
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ASHM Opening Ceremony 
and Plenary 1 
8.30am – 10.30am
HIV	PREVENTION	RESEARCH
Gita Ramjee
South African Medical Research Council HIV/AIDS Lead 
Programme         
   
The HIV Prevention field has faced a number of set backs 
in the past year. Currently we have the ABC option of 
abstinence, being faithful and condomize (male and 
female), behavioural change and treatment of sexually 
transmitted infections.  More recently, three randomized 
control trials showed that male circumcision is likely to 
reduce the risk of female to male transmission of HIV 
by up to 60%. With the rising infection rates in many 
countries, the current efforts for HIV prevention are clearly 
not adequate.
Our recent efforts to expand HIV prevention options 
through a variety of technologies (microbicides, vaccines, 
HSV2 suppressive therapy, and vaginal diaphragm) have 
had no success and in some cases there was a potential 
of the intervention to increase the risk of HIV acquisition. 
One of the challenges in the field has been in that the 
theoretical concepts that have been scientifically sound 
with adequate support from observational studies for 
many of these novel intervention technologies, are not 
supported by the same outcomes in randomized control 
trials. With growing infection rates in many parts of the 
world especially subSharan Africa, scientists in the HIV 
prevention field need to come together to strategies and 
ascertain why theoretical concepts and observational 
studies are not proven effective in randomized control 
trials, giving up on HIV prevention is not an option.
TOWARDS	AN	HIV	VACCINE	-	WHAT	IS	
PROTECTIVE	IMMUNITY	AGAINST	HIV	
INFECTION?
Sarah Rowland-Jones, Nuffield Department of Medicine, 
Oxford University, John Radcliffe Hospital, Oxford Ox3 
9DU, UK
Following the disappointment experienced after the 
failure of the STEP HIV phase II vaccine trial last year, 
questions have bee raised about whether or not an 
effective vaccine to prevent HIV-1 infection can ever be 
achieved. Some have contended that the trial should 
be seen as a product failure rather than a failure of the 
entire T-cell vaccine concept, and that clinical vaccine 
studies should continue on an empirical basis. Others 
have suggested that there needs to be a return to basic 
science in order to define genuine correlates of protective 
immunity against HIV-1 infection. This presentation 
will review the current efforts towards HIV vaccines 
and discuss our understanding of the requirements 
for a successful HIV-1 vaccine. Relevant studies of HIV 
resistance or control of infection from studies in Kenya 
and West Africa will be presented to provide support for 
the concept of protective immunity.
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A	NOVEL	APPROACH	TO	ANTENATAL	RISK	
ASSESSMENT	IN	VERY	LOW	HIV	PREVALENCE	
SETTINGS	IN	RESOURCE-POOR	COUNTRIES
Holmes WR, Centre for International Health, Burnet 
Institute, Melbourne, VIC,  Australia
In very low HIV prevalence settings in resource-poor 
countries the relative cost-effectiveness of routine 
provider-initiated offer of HIV testing for all pregnant 
women is low.  A strategy of offering the test to pregnant 
women who may be more vulnerable to HIV infection 
is problematic because it is difficult to identify pregnant 
women at greater risk.  Women at risk because of their 
partner’s behaviour are often unaware of their risk, 
and undertaking risk assessment is a sensitive task for 
busy antenatal care staff to conduct in a confidential, 
inoffensive and non-stigmatising manner. 
However, there are often opportunities to reach 
expectant fathers with information and risk assessment. 
These opportunities may include pre-conception couple 
visits, antenatal couple visits, and ‘parentcraft’ classes for 
pregnant women and expectant fathers.
We have developed a novel risk assessment quiz for 
expectant fathers in the entertaining style typical of 
women’s magazine personality quizzes.  Because the 
men do not need to fill in a checklist or questionnaire 
they can be completely honest in their answers because 
no one will know the result except themselves.  The quiz 
includes ‘comments’ for each risk category.  Those in the 
‘low or no exposure risk category’ are congratulated and 
encouraged to continue their safe behaviours to protect 
themselves and their families.  Those in higher exposure 
risk categories are informed that if they find they are HIV 
positive it is possible to protect their wife from infection if 
she is not yet infected, and that if she is already infected 
the risk of transmission to their baby can be greatly 
reduced.  This provides a strong motivation for the father 
to request a confidential HIV test.  A commitment to 
disclose a positive result to his wife would be obtained 
during the pre-test counselling. 
It is planned to evaluate the risk assessment quiz for 
expectant fathers in Sri Lanka, where HIV prevalence 
remains very low.
Women Risk HIV – International
11.00am – 12.30pm
ADDRESSING	GENDER-BASED	VIOLENCE	IN	
SETTLEMENT	AREAS	OF	PORT	MORESBY	
Ofasia E1, Duffy SM2
1World Vision Pacific Development Group; 2World Vision 
Australia
Gender-based violence (GBV) is prioritised in Papua New 
Guinea’s (PNG) National Gender Policy and Plan on HIV/
AIDS 2006-2010.  Various studies indicate an association 
between GBV and Human Immunodeficiency Virus 
(HIV). High incidence of GBV in PNG is associated with 
rapid social, cultural and economic change, social 
dislocation and erosion of the wantok system, especially 
in Port Moresby’s informal settlement areas.  Victims of 
physical and sexual violence exhibit higher rates of HIV 
and sexually transmitted infections.  The National AIDS 
Council estimates nearly 60% of new HIV infections 
in adults in 2007 occurred in women.  Alarming rates 
of domestic abuse (two out of three married women) 
and sexual violence (over 50% of women) have been 
recorded in PNG.  In addition to HIV transmission caused 
directly by violent sexual contact, GBV is symptomatic 
of disempowerment and denial of a woman’s right to 
exercise control over sexuality, and to sustain safe sexual 
practices.  
In 2007 World Vision commenced implementation of 
the Ol Meri Igat Numba project to reduce GBV and HIV 
transmission in four settlement areas.  The project takes 
an appreciative, rights-based and collaborative approach, 
encouraging positive attitudes and behaviours as well 
as challenging abusive ones.  Project strategies combine 
behaviour change communication (BCC), engagement 
with service providers, and community forums.  BCC 
activities include theatre, dance, media campaigns, 
and information, education and communication (IEC) 
materials developed in partnership with women and 
men in settlement areas.  BCC messages raise awareness 
of HIV, safer sex, rights, health and welfare services, 
and strategies for action against perpetrators of GBV. 
Community forums provide opportunities for women to 
express concerns about GBV to men, community leaders 
and service providers.  To lessen women’s economic 
dependence, women receive training in vocational and 
business skills.  
Project methodology and early project results will be 
discussed, including successes and challenges.  Anecdotal 
evidence indicates that real change has occurred in both 
men’s and women’s attitudes, but suggest long-term 
engagement is required for sustainable change.  
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TRIBAL	FIGHTING,	VIOLENCE	AGAINST	
WOMEN	AND	GIRLS	AND	HIV	IN	PAPUA	NEW	
GUINEA
Kupul M1, Mek A1, Kepa B1, Kelly A2 
1Papua New Guinea Institute of Medical Research, 
Goroka, Papua New Guinea; 2National Centre in HIV Social 
Research, UNSW, Australia
There are many drivers of the epidemic and in the 
Highlands of PNG tribal fighting may be one. While killing 
men, tribal fighting creates a breeding ground for many 
form of violence against women and girls. Women and 
children are forced to be refugees in other ethnic areas, 
women and girls are exchanged for guns and/or forced 
into marriage and are raped and murdered. Women and 
children go without food, girls are denied education 
because they are refugees and pregnant women are 
deprived of antenatal care during pregnancy and labour. 
In these contexts women and girls are more vulnerable 
to HIV. 
Concerned with such high rates of violence in Melanesia 
and East Timor a research of best practices was 
commissioned by AusAID and carried out by Program for 
Appropriate Technology in Health (PATH) utilizing local 
researchers. Drawn from the PNG country evaluation, 
which using participatory research methods, this paper 
addresses how two communities in Chimbu Province 
effectively addressing violence against women and girls 
by first combating tribal fighting. 
The success of these communities indicates that in order 
for social change to occur there must be the desire for 
such change. There must also be ownership of the 
problem and the solutions. These communities and 
other which want to change must also be prepared AND 
supported to challenge cultural norms including violence, 
leadership and relationships within and between men 
and women and across ethnic groups. Two community 
organisations have initiated gender equity training, 
community policing by both men and women, and the 
involvement of women in decision making.
Where communities are working to help themselves, 
efforts must be made to help make them sustainable. 
To address violence against women and girls, gender 
relations need not be the direct entry point. Addressing 
other social issues such as tribal fighting can lead to 
change in gender relations and a reduction in violence 
against women and girls which in turn will make them 
less vulnerable to HIV. Communities have the power to 
transform themselves providing sanctuaries for women 
and girl from both violence and HIV.
FEMALE	SEx	WORKERS	IN	SRI	LANKA:	WHY	
ARE	WOMEN	WHO	WORK	ON	THE	SREET	
MORE	LIKELY	TO	USE	CONDOMS	COMPARED	
WITH	WOMEN	WHO	WORK	IN	OTHER	
LOCATIONS?
Rawstorne P, Worth H, Kippax S
National Centre in HIV Social Research, The University of 
New South Wales, Sydney, New South Wales, Australia
Sri Lanka has a low-level HIV epidemic. The first large scale 
behavioural surveillance survey (BSS) in Sri Lanka was 
conducted in 2006/2007. More than 7,000 people were 
sampled from six sub-population groups: female sex 
workers; factory workers; drivers of three-wheel taxis; men 
who have sex with men; ‘beach boys’; and drug users. This 
paper is focussed on female sex workers. 
Sampling female sex workers (FSW) was done according 
to the type of work context: streets, brothels, massage-
parlours, casinos, and karaoke bars. There were exactly 900 
FSW who had vaginal intercourse with a paying client in 
the previous twelve months, 488 of whom were working 
on the street. (Note: anal intercourse is not included in 
these analyses as it was rarely practiced).
In comparison with all other categories of FSW, women 
working on the streets were more likely to have always 
used condoms for vaginal intercourse in the last twelve 
months (82.0 % versus 62.3 %, p=.000) and on the last 
occasion (95.1 % versus 85.0 %, p=.000). These findings 
were contrary to expectation and prompted further 
analyses to explore the possible reasons why street-
based FSW are more likely to use condoms for vaginal 
intercourse. 
Multiple logistic regression analyses were conducted to 
examine the factors that distinguished FSW working on 
the street from other FSW. The final model showed that 
street FSW were more likely to: carry condoms with them; 
have found out about HIV through government health 
services; decide themselves how much the client pays 
for sex; and accurately believe that people can protect 
themselves from getting HIV sexually by using a condom 
every time they have intercourse. Street FSW were less 
likely than other FSW to: read and write; and to have 
found out about HIV through television.
Although less educated, FSW working on the street are 
better prepared to prevent HIV transmission by the use of 
condoms. These women are accessing important health 
information from government health services and appear 
to be taking greater responsibility for their health. Why 
these women have better access to government health 
services requires further exploration. 
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ALCOHOL	CONSUMPTION,	HIV	
TRANSMISSION	AND	IMPLICATIONS	FOR	
WOMEN	IN	SOUTH	AFRICA
Ghaly, S
The aim of this paper is to examine the HIV epidemic 
in South Africa and to explore the role that alcohol 
consumption plays in HIV transmission. The paper will 
include a critical appraisal of various interventions that 
aim to reduce alcohol abuse and in so doing, reduce HIV 
incidence. 
In several studies, alcohol consumption has shown to 
negatively impact on HIV prevention and treatment 
programs in South Africa. High levels of alcohol 
consumption are often attributed to factors such 
as unemployment, abuse and as resistance against 
oppression. High alcohol consumption was found to be 
one of the predominant causes of risky sexual behaviour, 
and a correlate of increasing levels of violence. The 
association between increased risky sexual behaviour 
and high levels of alcohol consumption has been 
demonstrated through studies conducted in South 
Africa by the South African Community Epidemiological 
Network on Drug Use (SACENDU).
After working with local HIV clinics in townships with 
the Organisation Friends of Africa, it became evident 
that underdevelopment, high unemployment, lack of 
recreational activities and the access to illegal alcohol 
outlets impacts on the risk of disease transmission, rape, 
teenage pregnancies and other forms of violence against 
women, all of which may contribute to increasing HIV 
rates. Intervention strategies such as the 2003 National 
Liquor Act have been established to reduce levels of 
alcohol consumption, by including a liquor outlet policy; 
regulating the physical availability of alcohol; and placing 
restrictions on alcohol marketing. Increasing employment 
opportunities and the availability of recreational activities 
are strategies that can also aid in reducing alcohol misuse 
and high risk sexual behaviour. However, many of these 
strategies have not yet been implemented. Consequently 
alcohol remains the highest abused substance causing 
irreversible social and physical damage for people living 
in South Africa. 
This paper reports on the effects that the misuse of 
alcohol can have on the increasing rates of HIV and the 
fact that women are predominantly affected and provides 
a critical appraisal on some of the current alcohol related 
interventions aimed at reducing HIV/AIDS transmission in 
South Africa.
ENABLING	HIV	PREVENTION	OUTCOMES	
FOR	SEx	WORKERS,	PAPUA	NEW	GUINEA
Janelle Fawkes, Chief Executive Officer, Scarlet Alliance, 
Australian Sex Workers Association,
When sex work is criminalised sex workers ability to 
access justice and services are reduced including: HIV 
prevention, testing, treatment and care; general sexual 
health. Laws regulating sex work in Papua New Guinea 
have been interpreted to mean sex work per se is illegal. 
This paper reviews the Papua New Guinea laws and 
reports on the impact of stigma and discrimination 
on HIV prevention along with the direct impacts on 
individuals. Anecdotal evidence collected during a three 
year capacity development project working directly with 
Papua New Guinea sex workers has identified the need 
for enabling legal environments for the success of future 
HIV prevention, testing, treatment and care services for 
sex workers in Papua New Guinea.
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TOWARDS	VACCINES	ELICITING	BROAD	
NEUTRALISING	ANTIBODY	RESPONSES	BY	
SELECTING	FOR	HIV-1	ENV	IMMUNOGENS	
THAT	PROMINENTLY	ExPOSE	CONSERVED	
NEUTRALISATION	EPITOPES
 
Purcell DF1, Tan J1, Siebentritt C1, Sterjovski J2, Gray LR2, 
Churchill MJ2, Reddy SM1, Ramsland PA3, Gorry PR2 and 
Center RJ1
1Department of Microbiology and Immunology, 
University of Melbourne, Parkville VIC 3010; 2Macfarlane 
Burnet Institute for Medical Research and Public 
Health, Prahran VIC 3004; 3Structural Immunology 
Laboratory, Macfarlane Burnet Institute for Medical 
Research and Public Health, Heidelberg, VIC 3084
  
The recent failure of HIV vaccines eliciting potent T-cell 
responses in humans has highlighted the need to also 
stimulate broadly neutralising antibodies against HIV-1 
envelope protein (Env), but this has proven a difficult task. 
While antibodies can be non-neutralising or enhancing 
for HIV infection, the desired broad neutralising antibodies 
bind conserved conformations such as the CD4 receptor 
and chemokine coreceptor binding sites on Env 
oligomers. We hypothesised that environments where 
target cells display low levels of receptor/coreceptor and 
negligible neutralising-antibody levels may select for 
HIV isolates that highly expose neutralisation-sensitive 
Env structures required for viral entry. We sought to 
rationally screen a panel of oligomeric Env for candidate 
neutralising-antibody immunogens by ranking them 
for binding affinity for soluble CD4 receptor (sCD4) and 
affinity for a reference panel of broadly neutralising 
monoclonal antibodies (mNAb). We assessed Env from 
two sources: 1) the brain, where antibody levels are 
typically low and 2) blood from late-stage AIDS patients 
when HIV-specific antibodies diminish. In general, Env 
from brain-derived clones showed higher affinity for 
mNAb and sCD4 than did Env from control clones derived 
from matched patient spleen. While some Env variants 
from late AIDS patients showed high affinity for sCD4 or 
mNAb this was not consistently different compared to 
Env derived from pre-symptomatic patients in the same 
cohort. A group of 6 Env clones with higher affinity for 
mNAb and/or sCD4 were selected for a DNA prime with a 
recombinant soluble gp140 oligomeric Env protein boost 
immunisation trial in mice. Most mice developed high 
anti-Env specific antibody titres measured by ELISA. Sera 
were pooled within groups and assessed for the ability to 
neutralise virus pseudotyped with Env derived from the 
AD8 (CCR5-restricted, relatively neutralisation resistant), 
89.6 (dual CCR5/CxCR4 tropic) and NL4.3 (CxCR4-
restricted, relatively neutralisation sensitive) strains. Env 
from one brain-derived clone elicited antibodies that 
neutralised reporter virus pseudotyped with heterotypic 
B-clade AD8 and 89.6 Env, but surprisingly not NL4.3 Env. 
The systematic screening of Env variants may provide 
further useful Env candidates for evaluation as broad 
NAb-eliciting vaccines in animals
ACH2 Bench to Bed: 1
11.00am – 12.30pm
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UNDERSTANDING	SUSCEPTIBILITY	TO	CMV	
IMMUNE	RESTORATION	DISEASE	AND	THE	
IMMUNOLOGICAL	CONSEqUENCES	OF	
ExTREME	IMMUNODEFICIENCY
Patricia Price; Pathology and Laboratory Medicine, 
University of Western Australia
CMV disease is a common complication of late-stage 
HIV disease and recurs as immune restoration disease 
(IRD) in some patients. Here immunological and genetic 
factors assayed by our group are used to profile patients 
who experience CMV disease`. CD4 T-cell responses 
were assessed by IFNγ ELISpot assay and antibody was 
quantitated by ELISA using a whole CMV antigen. 
We tested all available samples from patients who had 
begun ART with advanced immunodeficiency (nadir < 50 
CD4 T-cells/µl) in Perth (1996-8) and achieved a sustained 
virological and immunological response (n=50 patients). 
These criteria imply selection of patients on the basis of 
survival before ART and a favorable outcome thereafter. 
Although CD4 T-cell counts increased during the first 
year on ART, IFNγ responses to CMV were low before ART, 
rose slowly and never reached levels seen with cells from 
uninfected donors. Within this patient cohort, the lowest 
nadir CD4 T-cell counts associated with persistently low 
CD4 T cell IFNγ responses to CMV antigen, higher IFNγ 
responses to an NK-cell target (K562) and characteristic 
TNFA and IL12B genotypes. In a broader cohort, the TNFA 
genotype and high numbers of activating KIR genes were 
associated with a history of CMV as an AIDS–defining 
illness.
Patients who developed CMV IRD (retinitis or encephalitis, 
n=7) had a history of CMV-AIDS. Their CMV IRD paralleled 
a rise in anti-CMV antibody and markers of immune 
activation (eg: plasma IL-6). Longitudinal studies of IFNγ 
responses were not possible, but responses were low 2-
3 years after the IRD. CMV IRD patients all had very low 
nadir CD4 T-cell counts and the characteristic TNFA / 
IL12B and KIR genotypes. These genotypes may promote 
extreme immunodeficiency and/or CMV-AIDS or may 
allow patients to survive these conditions to experience 
an IRD and join our study. Activating KIR may promote 
an NK response able to compensate for poor CD4 T-cell 
responses to CMV. A corollary of this model is that CMV 
IRD may not be a T-cell cytokine storm, as implicated in 
IRD associated with mycobacteria.
A different scenario emerges in Kuala Lumpur. Patients 
beginning therapy with <200 CD4 T-cells all experienced 
a rise in CMV antibody and CD4 T-cell IFNγ responses. 
Associations with CMV IRD are now under investigation.
 
PREDICTING	NEUROPATHY	RISK	BEFORE	
STAVUDINE	PRESCRIPTION:	AN	ALGORITHM	
FOR	MINIMIzING	NEUROTOxICITY	IN	
RESOURCE-LIMITED	SETTINGS
Cherry CL1, Affandi JS2, Imran D3, yunihastuti E 3, Smyth K4, 
Vanar S5, Price P2, Kamarulzaman A5
1Burnet Institute, Monash University, and The Alfred 
Hospital, Melbourne, Victoria, Australia; 2Royal Perth 
Hospital and University of Western Australia, Perth, Western 
Australia, Australia; 3Pokdisus Clinic, Cipto Mangunkusumo 
Hospital  and University of Indonesia, Jakarta, Indonesia; 
4Australian National University, Canberra, ACT, Australia; 
5University of Malaya, Kuala Lumpur, Malaysia.
Sensory neuropathy (SN) is a common, disabling 
complication of stavudine (d4T) therapy, with prevalence 
rates >40% reported from d4T-treated cohorts of patients 
with HIV. Despite its toxicity, d4T is an effective, relatively 
inexpensive HIV treatment and remains important in 
resource-limited centres.  Methods of predicting SN risk 
are needed to guide antiretroviral prescribing in countries 
where some use of d4T remains an economic necessity.
We undertook SN screening programs in Melbourne 
(low d4T use), Kuala Lumpur (intermediate d4T use) 
and Jakarta (routine d4T use) in 2006 to describe SN 
risk factors among HIV patients in our region.  SN was 
defined by the presence of symptom/s and sign/s on 
the AIDS Clinical Trials Group Brief Peripheral Neuropathy 
Screen.  Patients’ height, age and weight were recorded 
and demographic, laboratory and treatment data were 
obtained from the medical file. Statistical analysis using 
Stata 9.2 defined factors associated with SN. The role of 
patient demographics in predicting SN was then assessed 
in patients who had ever used d4T.
294 patients were assessed (100 Australians, 98 Malaysians 
and 96 Indonesians).  Prevalence rates of SN were 42%, 
19% and 34% respectively and 32% overall.  In addition 
to treatment exposures, increasing age (p=0.002) and 
height (p=0.001) were independently associated with SN 
risk.  Receiver operating characteristic analysis suggested 
“cut offs” of ≥170cm and/or ≥40 years for predicting 
patients at risk of SN.  These were applied to the 181 d4T-
exposed patients, yielding an SN risk of 20% in younger, 
shorter patients, 33% in younger but taller patients, 38% 
in older but shorter patients, and 66% in those older than 
40 years and taller than 170 cm. 
Stavudine is infrequently prescribed in Australia due 
to high rates of toxicity, but remains an important HIV 
treatment in our region.  Rates of SN, a common d4T 
toxicity that impairs quality of life and may reduce 
patients’ ability to work, vary with patient age and height. 
These data support prioritizing patients taller than 170 
cm and/or older than 40 years (factors measurable at no 
extra cost) for access to antiretrovirals other than d4T.W
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BIOLOGICAL	CHARACTERIzATION	OF	NOVEL	
HIV-SPECIFIC	ACTIVITY
Nitin Saksena1, Maly Soedjono1, Wayne Dyer2, and John 
Zaunders3 and  Bin Wang1,
1Retroviral Genetics Labs, Westmead Millennium Institute, 
USyD, Westmead, Sydney; 2Australian RedCross, Clarence 
Street, Sydney; 3Center For Immunology,Darlinghurst, 
Sydney 
Human Immunodeficiency virus type-1 has led to global 
AIDS pandemic. Currently, there are 40 million people 
infected with HIV and with 14,000 new infections occurring 
each day. Although there are several lines of anti-retroviral 
drugs available in the market and have provided better life 
standards to HIV-infected individuals, there are continuing 
problems associated with these drugs-such as toxicity 
and emergence of resistance. All HIV vaccines have failed 
to date. Thus, fresh approaches and strategies are needed 
for controlling HIV. Recently, we have discovered a novel 
HIV-specific cellular differentiation activity in the soluble 
factor secreted by the CD4+ T cells from a unique HIV+ 
elite controller. This cellular differentiation activity leads to 
the induction of CD14+ monocytes to their differentiation 
to antigen presenting cells displaying CD40, CD86, CD11b 
and CD14 markers. This activity was observed to occur in 
both autologous and non-autologous fashion. This new 
approach has shown promise on cells from HIV+ positive 
individuals with low viral loads, suggesting its possible 
future use as a therapeutic vaccine in conjunction with 
currently prescribed therapy. The biology of these findings 
will be findings will be discussed in detail.
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ILLICIT	DRUG	USE	AND	RISK	OF	HIV	
SEROCONVERSION	AMONG	GAY	MEN	IN	
SYDNEY:	DATA	FROM	THE	HIM	COHORT
Prestage G1, Jin F1, Imrie J2, Zablotska I2, Kippax S2, 
Kaldor J1, Grulich A1
1National Centre in HIV Epidemiology & Clinical Research, 
UNSW; 2National Centre in HIV Social Research, UNSW.
Background: Illicit drug use has been associated with risk 
behaviour among gay men. We examined frequency of 
use of illicit drugs as a risk factor for HIV seroconversion in 
a community-based cohort of HIV negative homosexually 
active men in Sydney, Australia.
Methods: From June 2001 to June 2007, participants 
underwent annual HIV testing and were interviewed 
twice a year. Detailed information about sexual, drug-
using and other behaviour was collected. 
Results: Among 1,427 participants enrolled, 53 HIV 
seroconverters were identified by June 2007. 
At baseline, 62.7% reported using illicit drugs in the 
previous six months, including 10.7% who reported at 
least weekly use. Illicit drug use was associated with 
unprotected anal intercourse with casual partners 
(UAIC) (p<.001). Use of illicit drugs was associated with 
increased risk of HIV infection at a univariate level and 
this risk increased with greater frequency of use. This was 
also true of the use of Viagra. Use of methamphetamine, 
amyl nitrite and Viagra were highly intercorrelated. Use 
of each type of illicit drug was included in multivariate 
analysis, but after including Viagra only amyl nitrite and 
Viagra remained significant. After controlling for sexual 
risk behaviours, only use of Viagra remained significant 
(AOR=1.75, CI=1.31-2.33, p<0.001), although amyl nitrite 
was borderline significant (AOR=1.26, CI=0.98-1.62, 
p=0.074).
Conclusion: While drug use may not be a directly 
causative factor for UAIC, in this cohort of HIV-negative 
gay men frequent drug use is independently associated 
with HIV seroconversion. Viagra, amyl nitrite and 
methamphetamine are often used specifically, and 
explicitly, to enhance sexual pleasure among gay men, 
especially in the context of ‘partying’. The association 
between these drugs and UAIC among gay men suggests 
that intensive sex partying, where both these activities 
often occur, is an appropriate priority in HIV-prevention 
efforts in this population.
RESULTS	FROM	THE	2008	PERIODIC	SURVEY	
OF	NSW	NEEDLE	AND	SYRINGE	PROGRAM	
ATTENDEES
Deacon RM1, Iversen J1, Mason R2, Maher L1,3
1National Centre in HIV Epidemiology and Clinical 
Research, University of New South Wales, Sydney, NSW, 
Australia; 2AIDS/Infectious Diseases Branch, NSW Health 
Department, Sydney, NSW, Australia; 3School of Public 
Health and Community Medicine, University of New 
South Wales, Sydney, NSW, Australia
In April 2008, the NSW Department of Health requested 
that staff at Needle and Syringe Programs (NSPs) collect 
demographic and drug use data from clients of NSP 
services.  The National Centre in HIV Epidemiology 
and Clinical Research (NCHECR) was commissioned to 
analyse and report on the results.  All clients attending 
participating NSPs during a two week period were asked 
to provide information on their gender, age, ethnicity, 
age of first drug injection, last drug injected, frequency 
of injecting, syringe disposal and where syringes were 
obtained.
A total of 6047 data collection forms were returned from 
the 52 NSPs who participated in the data collection.  Of 
these, 3197 were clients who had not previously attended 
the NSP during the two week period. The number of repeat 
clients was 2009 giving an overall repeat ratio of 1.6.  The 
median age of non-repeat clients was 36 years, 66% were 
male, 5.9% were from a non-English speaking background 
and 13% self-identified as Aboriginal and/or Torres Strait 
Islanders.  The median duration of injecting drug use was 
15 years and the most common drug last injected was 
heroin (33%), followed by methamphetamine (28%). 
Approximately 41% of clients reported injecting daily or 
more frequently.  
This project provides an important snapshot of the NSW 
NSP client base and a useful mechanism for comparing 
the characteristics of clients across different geographic 
areas in NSW, as well as guiding estimates of the total IDU 
population in NSW for service coverage evaluation.
IDU – Domestic
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CONTINUED	INCREASES	IN	SYRINGE	
DISTRIBUTION	ARE	REqUIRED	TO	RESTRAIN	
VIRAL	TRANSMISSIONS	AMONG	INJECTING	
DRUG	USERS	IN	AUSTRALIA:	RESULTS	FROM	
A	MODELLING	STUDY
Kwon AJS,Iverson J, Maher L, Law M, Wilson DP 
National Centre in HIV Epidemiology and Clinical Research, 
University of New South Wales, Sydney, Australia
Sharing syringes by injecting drug users (IDUs) is an 
important mode of worldwide transmission of blood 
borne viruses, such as HIV and HCV. In Australia, the 
current coverage of sterile syringes is approximately 
50% and annually there are ~30-40 HIV notifications and 
~9,500 cases of HCV due to syringe sharing by IDUs. 
We address the following research questions: (i) what 
are the driving behavioural factors in differential HIV and 
HCV incidence among IDUs in Australia? (ii) What impact 
will changes in needle-syringe programs (NSPs) have on 
HIV and HCV incidence? (iii) How much reduction in the 
proportion of injections that are shared and number of 
time a syringe is used before disposal is required in order 
to theoretically eradicate HIV and HCV epidemics among 
IDUs? 
These questions are addressed through the development 
of a novel mathematical model based on risk equations, 
calibrated to the Australian population of IDUs. Differential 
incidence rates for the two epidemics are due to 
differences in transmission probabilities but also because 
syringe sharing behaviour and syringe distribution in 
Australia are at levels that sustain high levels of HCV 
incidence but not HIV. We provide predictions of the 
changes in incidence of both epidemics due to changes 
in intervention strategies. 
If Australia had not implemented NSP from the late 1980s, 
then HIV notifications could have increased substantially 
and moderate increases in HCV would also have been 
observed. We predict that interventions due to NSP are 
very effective in reducing HIV and HCV. An increase of in 
the coverage rate to 90% could theoretically eradicate 
HCV transmission among IDUs. Alternatively, if the 
proportion of injections that are shared decreased from 
15% to 2.5% then the HCV epidemic among IDUs could 
be eradicated. This research highlights the large benefits 
of NSPs and recommends that increased coverage can 
result in significant reductions in viral transmissions 
among IDUs.
THE	ROLE	OF	NEEDLE	SYRINGE	PROGRAMS	
IN	PREVENTING	TRANSMISSION	TO	
INJECTING	BY	YOUNG	PEOPLE
Spooner C1, Brenner L1, Treloar C1
1National Centre for HIV Social Research, University of 
NSW, Sydney, NSW, Australia
There is evidence that drug users in Australia are making 
transitions to injecting at younger ages. Needle and 
syringe programs (NSPs) play important roles in services 
for injecting drug users (IDU), and have the potential to 
assist in prevention of transition to injecting methods. 
However, their potential to access young people at risk of 
initiating injection is affected by the reluctance of young 
people to use health services. 
How can NSPs be better accessed by young people and 
play a role in prevention? What are the issues around 
young people accessing NSPs? 
To answer these questions, a literature review and 
key informant consultations were conducted. Using 
this research, an overview of existing and potential 
strategies and an outline the significant issues for NSPs 
in implementing such strategies will be presented. Issues 
include concerns about exposure of young people to 
drug users, normalisation of drug use, and NSP workforce 
capacity to work with young people and implement 
interventions.
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A	GAP	ANALYSIS	OF	PEOPLE	WITH	A	
HISTORY	OF	INJECTING	DRUG	USE	WHO	
ARE	NOT	CURRENTLY	ACCESSING	HIV	
AND	SExUAL	HEALTH	SERVICES	IN	SOUTH	
EASTERN	SYDNEY	ILLAWARRA	AREA	HEALTH	
Gahan G1, Malcolm A2, Purchas J3, Darlison L4, 
Narayanan P5
1HIV/AIDS & Related Programs Unit, South Eastern Sydney 
Illawarra Area Health; 2, 3, 4, 5 The Millar Group Public Health 
Consultants, Sydney
People with a history of injecting drug use are documented 
as one of the priority groups in the NSW HIV/AIDS 
Strategy 2006-2009 and receive special reference in the 
NSW Sexually Transmitted Infection Strategy 2006-2009. 
Despite this, access to specialist HIV and sexual health 
services by people who inject drugs remains low. 
This paper describes a gap analysis commissioned 
by South Eastern Sydney Illawarra Health to identify 
characteristics and needs of people with a history of 
injecting drug use and who are not accessing HIV/AIDS 
and STI services; and to Identify service support strategies 
for how SESIH services can better target these populations 
to improve access. 
The paper describes innovative strategies used to contact 
key informants, the role of informatics in analysing service 
utilisation data and the development of service re-
orientation processes to increase access to not only HIV 
and sexual health promotion, screening, prevention and 
testing services but also to treatment and care services. 
INCREASING	HEPATITIS	C	TREATMENT	
UPTAKE	BY	INJECTING	DRUG	USERS	FROM	
CULTURALLY	AND	LINGUISTICALLY	DIVERSE	
BACKGROUNDS:	OUTCOMES	OF	A	PILOT	
STUDY	OF	INDOCHINESE	INJECTORS	
  
Coupland H1, Levy, M2, Day, C3, & Maher L1
1National Centre in HIV Epidemiology and Clinical 
Research and School of Public Health and Community 
Medicine, University of New South Wales; 2Sydney South 
West Area Health Service; 3Drug Health Services, Faculty 
of Medicine, University of Sydney
Background: There has been limited research exploring 
hepatitis C (HCV) treatment- seeking from the perspective 
of injecting drug users (IDUs), particularly those from 
culturally and linguistically diverse backgrounds. 
Methods: Between 2003 and 2007 ethnographic fieldwork 
and in-depth interviews were conducted with Indo-
Chinese IDUs in South Western Sydney (n=72) recruited 
using theoretical and snowball sampling. Eligibility criteria 
for the pilot study (n=23) included being aged 18 years 
and over, ability to complete interviews in English, being 
of Cambodian, Lao or Vietnamese cultural background 
and having injected drugs in the last six months. Following 
a baseline interview about HCV, a culturally-informed 
brief intervention about HCV treatment was provided 
and participants offered facilitated referral to a tertiary 
liver clinic. Participants were followed up and interviewed 
again at three and six months. 
Results: At baseline, most participants were unclear about 
what treatment involved and its potential outcomes. 
Participants responded to the brief intervention with 
numerous, detailed questions but while most expressed 
interest in having treatment at some stage, few (n=3) 
attended the clinic. Factors influencing treatment-
seeking included the cultural significance of “curing” HCV, 
perceived capacity to adhere to treatment in the event of 
experiencing side effects, patterns of injecting drug use, 
precarious personal circumstances and lack of support, 
imprisonment and past experiences with health services. 
Some participants experienced difficulties accessing 
the liver clinic, particularly with the system for making 
appointments. Those who accessed the clinic and 
disclosed current drug use felt that they were discouraged 
from initiating treatment until they stopped injecting 
drugs. Cultural factors influenced interactions with clinic 
staff, particularly disclosure of drug and treatment-related 
concerns. 
Conclusions: Findings suggest that the brief intervention 
increased participants’ knowledge levels and interest in 
seeking treatment at some stage in the future. However, 
in addition to raising awareness of treatment, issues W
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identified regarding the assessment process and options 
for assistance and support during treatment, need to be 
addressed to promote treatment uptake by this group. 
Models of service delivery in tertiary settings need to 
include staff capacity to address drug dependence 
issues, streamlined referral and assessment processes and 
mechanisms for linking clients with culturally-appropriate 
support.
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TISSUE-SPECIFIC	ADAPTIVE	CHANGES	IN	
V3	OF	GP120	ENABLE	PERSISTENCE	OF	
MARAVIROC-SENSITIVE	R5x4	HIV-1	IN	BRAIN	
Paul R. Gorry.
Centre for Virology, Macfarlane Burnet Institute for 
Medical Research and Public Health, Melbourne, Victoria, 
Australia.
Most neurotropic HIV-1 strains are CCR5-restricted, but 
R5x4 variants have been identified infrequently in brain. 
In this study, HIV-1 Envs were cloned from R5x4 primary 
viruses isolated from brain (n=6) and spleen (n=6) of 
subject MACS1. Single R5x4 Envs cloned from brain 
and blood of another subject were included (aBR01, 
aBL01). Envs were sequenced and structural modeling 
was performed to analyze amino acid variants. Env 
fusogenicity was tested in fusion assays with wild type 
and mutant coreceptors. Sensitivity to inhibition by the 
CCR5 and CxCR4 inhibitors, Maraviroc and AMD3100 
respectively, was tested in single-round entry assays.
MACS1 brain (M1br) and the brain-derived aBR01 Envs 
were more fusogenic than Envs from matched spleen 
or blood in cells expressing CD4/CCR5, whereas MACS1 
spleen (M1sp) and the blood-derived aBL01 Envs were 
more fusogenic than Envs from matched brain in cells 
expressing CD4/CxCR4. Entry assays showed brain/
spleen R5x4 Envs had preferential usage of CCR5/CxCR4 
for entry, respectively. Studies with coreceptor mutants 
showed that, compared to M1sp Envs, M1br Envs had 
reduced dependence on residues in the CCR5 N-terminus 
(y15), ECL1 (H88), and ECL3 regions (E262, F264) for CCR5-
mediated fusion. Compared to M1br Envs, M1sp Envs had 
reduced dependence on residues 4-36 in the CxCR4 N-
terminus and R183 in the ECL2 region for CxCR4-mediated 
fusion. Sequence analysis identified R306 in the V3 loop 
of 6/6 M1sp Envs and S306 in 6/6 M1br Envs. Mutagenesis 
studies showed R/S306 was solely responsible for the 
spleen/brain phenotypes, respectively. Whilst entry of 
spleen R5x4 Envs was not inhibited by the CCR5 inhibitor 
Maraviroc, entry of brain R5x4 Envs was potently inhibited 
by Maraviroc; a phenotype also conferred by R/S306. 
Thus, tissue-specific adaptive changes resulting in altered 
mode of coreceptor usage may enhance the tropism of 
compartmentalized R5x4 strains for cells expressing CCR5 
in brain and CxCR4 in lymphoid tissues. Furthermore, 
the results suggest CCR5 inhibitors may be effective in 
suppressing certain R5x4 HIV-1 variants.
GENOMIC	AND	PROTEOMIC	
CHARACTERIzATION	OF	A	NOVEL	HIV-
SPECIFIC	ACTIVIITY
Bin Wang1, Maly Soedjono1, Wayne Dyer2, Amit Kapur3 
and Nitin Saksena1
1Retroviral Genetics Labs, Westmead Millennium Institute, 
USyD, Westmead, Sydney
2Australian RedCross, Clarence Street, Sydney
3Australian Proteomic Facility, Macquarie University, 
Sydney 
Virus-specific CD4+T cells play a critical role in antiviral 
immunity. HIV-1-specific CD4+T cells in chronically-
infected adults are mostly composed of IFN-g secreting 
cells and IL-2-secreting CD4+T cells, while in other HIV-
infected progressors there appears to be a defect in IL-
2-secreting cells. The HIV-infected non-progressors differ 
from other HIV+patients in displaying strong proliferative 
responses to viral antigen, which are thought to be 
highly protective. As discussed in the first talk, we have 
identified a rare HIV-infected non-progressor, in whom 
this proliferative response was coupled with strong 
HIV-specific cellular differentiation activity, which has 
not been observed before. This differentiation activity 
was mediated by a soluble factor secreted by CD4+T 
cells in response to HIV antigen. This soluble factor, 
in vitro, induces a potent and rapid differentiation of 
CD14+ monocytes to antigen presenting cells in both 
autologous and non-autologous fashion. In this study, 
using quantitative superarray, whole human genome 
microarray (>47,000 genes) and mass spectrometry, we 
have elucidated possible immunological mechanism of 
this novel HIV-specific bioactivity.
ACH2 Bench to Bed: 2
1.30pm – 3.00pm
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HIV	DNA	LEVELS	IN	PBMC	DECLINE	IN	
PATIENTS	RECEIVING	INTEGRASE	INHIBITOR	
COMBINATION	THERAP
Carr JM1,2, Daly L3, Shaw D3, Burrell CJ1,2 and Li P1,2
1SA Pathology, Adelaide, SA, 5000; 2School of Molecular 
and Biomedical Science, University of Adelaide, Adelaide, 
SA, 5005; 3Infectious Diseases Unit, Royal Adelaide 
Hospital, Adelaide, SA, 5000
HIV DNA can persist for years in circulating cells from 
patients on successful anti-retroviral therapy and presents 
a circulating latent reservoir of virus.  New drugs to treat 
HIV infection are targeted at the HIV integrase (IN) enzyme. 
We assessed changes in HIV DNA in patients treated with 
an IN inhibitor, to assess if these new drugs can clear this 
circulating reservoir.
PBMC were isolated from patients recruited for Raltegravir 
(Ral) combination therapy based on special access 
guidelines, DNA extracted and HIV DNA quantitated (1). 
IN DNA sequence was obtained by consensus sequence 
analysis.  HIV DNA was detected in all patients prior to 
Ral therapy and declined to undetectable levels within 4 
wks in 5/6 patients and 8 wks in the 6th patient.  Patients 
concurrently showed a rise in CD4+ cells and a decline 
in circulating plasma viral load.  The increase in CD4+ 
cells without accompanied increased HIV DNA, indicates 
reconstitution with HIV negative cells and prevention 
of further re-infection of these cells.  Successful therapy 
was maintained for at least 6 mths.  A minor transient 
viremia was observed in one patient with a brief 
treatment intermission at 3 mth post-therapy which was 
accompanied by an increase in HIV DNA.  Ral-induced 
drug resistance mutations in the IN gene were not 
observed in either the circulating virus or PBMC DNA.
In conclusion, Ral combination therapy successfully 
and rapidly reduced HIV viral load and cellular DNA and 
increased CD4+ without drug resistance.  Prevention of 
HIV DNA integration may promote decay and clearance 
of unintegrated latent HIV DNA forms, while the turn-over 
of cells harbouring integrated DNA without re-population 
of new infected cells may subsequently purge the HIV 
DNA containing reservoir.  Thus, IN inhibitor therapy may 
reduce the circulating HIV reservoir above that seen with 
traditional protease and RT inhibitor based combination 
therapies.
This work was supported by funding from ACH2
(1) Carr, J.M., et al.,  (2007)  J Clin Micro, 45(4): 1288-97
INHIBITION	OF	HIV	BINDING	TO	LANGERIN	
ON	LANGERHAN’S	CELLS	AS	A	STRATEGY	
FOR	MICROBICIDE	DEVELOPMENT
Anthony L. Cunningham
Centre for Virus Research, Westmead Millennium Institute, 
Westmead NSW Sydney Australia 2145
The interaction of HIV with immature Langerhans cells 
(iLCs) in the female genital tract is of key importance for 
sexual transmission, as these cells are the major cells able 
to transport virus through epithelium to T cells in the 
submucosa or lymph node. HIV binds initially to langerin 
on iLCs. Then the virus is probably either  endocytosed or 
cause true infection. Therefore inhibition of HIV binding to 
langerin is likely to be a successful strategy for prevention 
of infection by microbicides (but probably requires 
combination with an inhibitor of the HIV fusion receptor 
(CCR5)). 
To test this hypothesis we initially used skin/mucosa 
derived immature (i)LCs but yields were too low for 
screening inhibitors, only for final validation of results. 
However with the model iLCs, Mutz 3 cells, derived from 
acute myelomonocytic leukaemia (5) and cultured in 
GM-CSF, TNFα, TGF-β,  99% expressed Langerin and <2% 
DC-SIGN and mannose receptor (MR), after cell sorting 
to deplete DC-SIGN/MR+ cells. 80-95% of these cells also 
expressed CD4 and 25-30% expressed CCR5. They were 
infectable by HIV at similar levels to iLCs.
Meanwhile parallel studies on the oligomeric status of 
langerin on the surface of langerin transfected QT6 and 
Mutz3 cells showed Langerin to equilibrate between 
monomeric and tetrameric states and that HIV gp120 
trimer bound more strongly to the tetramer. The first 
inhibitors tested were the generic C Type Lectin Receptor 
inhibitor, mannan, and also blocking monoclonal 
antibodies to the carbohydrate recognition domain 
(CRD) and/or full extracellular domain (ECD) of langerin. 
All inhibited gp120 monomer/trimer binding to langerin 
as a monomer but not as a tetramer, indicating the 
need to develop inhibitors of gp120-langerin oligomer 
imteractions, such as soluble langerins. The latter were 
tested for toxicity to monocyte derived DCs, Mutz 3 cells 
and keratinocytes and shown to be toxic only at high 
concentrations of  >25μg/ml, using trypan blue dye 
exclusion or, for DCs in an antigen presentation assays. 
We will now examine the efficacy of soluble langerins in 
inhibiting binding of gp120 to langerin (oligomers) on 
Mutz 3 cells and iLCs, infection of these cells and finally 
transfer of HIV from these cells to CD4 lymphocytes.
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AN	HLA-C*0702	RESTRICTED	T-CELL	
RESPONSE	DIRECTED	AGAINST	AN	IMMUNE	
ESCAPED	HIV	NEF	KY11	EPITOPE	ExHIBITS	
HIGHER	FUNCTIONAL	AVIDITY	BUT	LESSER	
CYTOLYTIC	ACTIVITY	WHEN	COMPARED	
WITH	THE	ANTI-WILD	TYPE	RESPONSE	
Keane NM, Laird R, Chopra A, Maiden T, Almeida C, Mallal 
S, John M
HIV-1 mutational escape from a suppressive epitope-
specific T-cell response has been well described. Analysis 
of HLA allele associated HIV polymorphism in population-
based studies (n>800) suggests that HIV may also adapt to 
favour induction of certain epitopes that actively enhance 
viral replication. We therefore sought to investigate the 
presence and functionality of the HLA-restricted T-cell 
responses driving one such adaptation identified by the 
genetic analysis (Nef D108E in the HLA-C*0702 restricted 
Nef Ky11 epitope). 
Cryopreserved PBMC samples from 32 HIV-infected 
patients with HLA-C*0702 allele were assayed for IFN-γ 
production upon stimulation with the adapted and non-
adapted (‘wild type’) Ky11 peptides by ELISpot assay. 
The functional avidity of wild type and variant-specific 
T-cell directed responses were compared using serial 
peptide dilutions. Autologous epitope sequences were 
determined from contemporaneous plasma samples in 
patients with detectable HIV viral load (n=4). CTL killing of 
peptide-pulsed EBV transformed B-cells was determined 
using the Chromium release assay. 
IFN-γ was detected in PBMC samples from all patients 
after stimulation with anti-CD3 or CEF. IFN-γ responses to 
the wild type or adapted Ky11 epitopes were detected 
in 13 patients. The adapted epitope induced IFN-γ 
responses in 11 HLA-C*0702 patients (median-500, 
range 150-1110 spots/million cells). In 3 samples from 2 
cases, the adapted peptide-specific response had greater 
functional avidity than the wild type peptide. Autologous 
sequence contained the D108E adaptation in 1 patient 
who concurrently demonstrated IFN-γ responses. In 
initial assessments of T-cell killing, HLA-C*0702 B-cells 
pulsed with wild type peptide were killed more readily by 
adapted peptide CTLs than wild type peptide CTLs. 
Despite modest levels of epitope-specific IFN-γresponses 
overall in this treatment-experienced patient group, HLA-
restricted responses against an HLA-adapted epitope 
were demonstrable, including with higher avidity than the 
wild type form in 3 samples, suggesting a functional basis 
for adaptation driving creation of epitopes. In addition, 
preliminary data on CTL killing suggests lesser cytolytic 
activity of the variant specific T-cell response would favour 
persistence of the adapted virus. These data support the 
possibility of HIV adapting to actively exploit rather than 
simply evade T-cell responses and have implications for 
epitope inclusion criteria in HIV vaccine design.
Virology / Immunology
3.30pm – 5.00pm
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ROBUST	NK-CELL	MEDIATED	HIV-SPECIFIC	
ANTIBODY-DEPENDENT	RESPONSES	IN	HIV-
INFECTED	SUBJECTS
Stratov I¹, Kent S², Chung A ² 
¹Burnet Institute; ²University of Melbourne      
Antibody-dependent cellular cytotoxicity (ADCC) is 
a potentially effective adaptive immune response to 
HIV-infection. The study of ADCC responses has been 
hampered by the lack of simple methods to quantify these 
responses and map effective epitopes. We serendipitously 
observed that standard intracellular cytokine assays 
on fresh whole blood from a cohort of 26 HIV-infected 
subjects identified non-T lymphocytes expressing IFN-γ 
in response to overlapping linear peptides spanning HIV-
1 proteins. The effector cells were CD3-4-8-14-2+56+/- NK 
lymphocytes and degranulated Granzyme B and Perforin 
in response to antigen stimulation. Serum transfer assays 
demonstrated that the specific response was mediated 
by IgG. Fresh blood samples from half of the HIV-infected 
cohort demonstrated robust HIV peptide-specific IFN-
γ expression by NK cells; predominately to Env, Pol and 
Vpu HIV-1 proteins. Responses were readily mapped to 
define minimal epitopes utilizing this assay. Antibody-
dependent, HIV-specific NK cell recognition, involving 
components of both innate and adaptive immune 
systems, represents a novel and potentially effective 
immune responses to induce by vaccination.
CMV-SPECIFIC	EFFECTOR	MEMORY	CD4+	
T-CELLS	IN	HIV	PATIENTS	ON	LONG-TERM	
ART	ARE	PREDOMINANTLY	‘CD28	NULL’	
IMMUNOSENESCENT	CELLS
Fernandez S, Price P, French MA
Department of Clinical Immunology and Immunogenetics, 
Royal Perth Hospital and School of Pathology and 
Laboratory Medicine, University of Western Australia. 
Perth, WA, Australia
HIV-infected individuals who achieve a long-term 
virological response to combination antiretroviral 
therapy (ART) experience variable recovery of CD4+ T-cell 
responses to the antigens of opportunistic pathogens. 
This does not reflect current CD4+ T-cell numbers but is 
particularly evident amongst individuals who had a low 
nadir CD4+ T-cell count before ART. Using cytomegalovirus 
(CMV) as an index antigen, we examined markers relevant 
to the activation or regulation of CD4+ T-cell interferon 
(IFN)-γ responses in HIV patients on ART.
Study groups comprised male, CMV-seropositive HIV 
patients (n=18) and healthy controls (n=10). HIV patients 
were selected to fit three criteria; (1) nadir CD4+ T-cell 
counts <50 cells/µL, (2) at least 3 years on ART and (3) 
plasma HIV RNA <50 copies/mL for at least 2 years. IFN-
γ responses to a crude CMV antigen were measured 
by ELISpot and were shown to arise from CD4+ T-cells. 
Flow cytometry was used to assess expression of CD57, 
CD28, cytotoxic T-lymphocyte antigen (CTLA)-4 and 
programmed death (PD)-1 on CD4+ T-cells. 
Expression of CTLA-4 on CD4+ T-cells was higher overall 
in HIV patients compared to controls (p=0.03) but was 
not correlated with IFN-γ responses to CMV (r=-0.17). 
The expression of PD-1 on CD4+ T-cells in HIV patients 
extended over a wider range than controls (median 
(range) 4.9% (0.2-13.1) vs 2.3% (0.4-4.5), respectively) 
but was also not associated with IFN-γ responses to 
CMV (r=0.26).  The majority of CD4+ T-cells expressed 
CD28 in both patients and controls (median of 90% 
and 93%, respectively) and CD28 expression inversely 
correlated with IFN-γ responses to CMV (r=-0.54, p=0.02) 
in HIV patients. CD4+ T-cells that did not express CD28 
expressed high levels of CD57. The proportion of CD57+ 
CD28- T-cells was directly correlated with IFN-γ responses 
to CMV in HIV patients (r=0.56, p=0.01). 
These data suggest that a substantial proportion of 
CMV-specific effector memory T-cells in previously 
immunodeficient HIV patients receiving long-term 
effective ART are immunosenescent ‘CD28 null” CD4+ 
T-cells, a situation similar to some autoimmune diseases. 
IFN-γ responses to CMV do not appear to be limited by 
CTLA-4 or PD-1.
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PHENOTYPIC	ANALYSES	OF	FOxP3-
ExPRESSING	CD4+	AND	CD8+	T	CELLS	IN	
HIV-INFECTED	PATIENTS
Lim A1, French MA1,2, and Price P1,2
1School of Pathology and Laboratory Medicine, University 
of Western Australia, Nedlands, Western Australia, 
Australia; 2Department of Clinical Immunology and 
Immunogenetics, Royal Perth Hospital, Perth, Western 
Australia, Australia.
Proportions of CD25+CD4+ regulatory T (Treg) cells are 
increased in HIV-infected patients. In untreated HIV disease, 
the proportion of CD4+ Treg cells in blood and tissue may 
be associated with the level of immune activation driven 
by HIV replication. Furthermore, populations of CD4–
CD8– and CD8+ cells expressing FoxP3 are increased in 
the blood, particularly in patients with very low CD4+ T 
cell counts.
FoxP3+ cells have not been extensively phenotyped 
in HIV-infected individuals. We assessed the expression 
of various markers of activation and co-stimulatory 
molecules on FoxP3+CD4+ and FoxP3+CD8+ cells by 
flow cytometry, and compared the expression of these 
markers between untreated and treated patients.
The proportion of CD4-negative FoxP3+ cells was greatest 
in the most immunodeficient patients. This population 
included CD8+ and CD4–CD8– double negative cells. A 
greater proportion of FoxP3+ cells from untreated patients 
(n=20; 5–1,400 CD4+ T cells/µL) exhibited the memory 
(CD45RO+) or activated (HLA-DRHI or Ki-67+) phenotype 
when compared with patients on ART (n=20; 50-1,250 
CD4+ T cells/µL) and uninfected donors (n=14). When 
FoxP3+CD4+ and FoxP3+CD8+ T cells were compared 
in treated/untreated patients and uninfected donors, 
expression of both CD28 and CTLA-4 was higher in the 
CD4+ subset, whereas expression of PD-1 and CD57 was 
higher in the CD8+ subset. 
The data demonstrate major phenotypic differences 
between FoxP3+CD4+ cells and FoxP3+CD8+ cells. 
Proportions of CD4+ Treg cells and the FoxP3+CD8+ 
phenotype are directly related to the level of immune 
activation. A “re-balance” of FoxP3+ cells from the CD8+ 
to the CD4+ compartment may occur in treated patients 
who are able to successfully reconstitute their CD4+ T cell 
compartment and maintain virological control.
IDENTIFICATION	OF	HUMAN	ANTIGEN-
SPECIFIC	REGULATORY	T	CELLS,	
PHENOTYPING	AND	FUNCTIONAL	ANALYSIS
Nabila Seddiki1,2, Kai Brown1,2, Chansavath Phetsouphanh1,2, 
David Cooper1,2,3, John Zaunders1,3 and Anthony Kelleher1,2,3
1Centre for Immunology, St Vincents Hospital, Darlinghurst, 
NSW 2010, Australia; 2National Centre in HIV Epidemiology 
and Clinical Research, University of NSW, Kensington, NSW 
2052, Australia; 3HIV, Immunology and Infectious Diseases 
Clinical Services Unit, St Vincents Hospital, Darlinghurst, 
NSW 2010
CD4+CD25+CD127lowFoxp3+ regulatory T cell (Tregs) 
have a role in maintaining tolerance to self-antigens 
and coordinating immune responses to pathogens. 
More recently, there has been increased interest in 
antigen-specific Tregs as they have potential as a 
novel immunotherapeutic agent in the treatment of 
autoimmune disease and cancer and may also have 
therapeutic role in transplantation and vaccine regimes. 
Using recall responses and a new gating strategy for 
which includes Foxp3, CD134 and CD39, we aimed to 
identify, phenotype and study the function of Tregs 
responding to re-stimulation with epitopes from CMV 
pp65. In healthy CMV+ donors we found that 1.41% 
±0.37% (mean±SEM) of peripheral CD4+ T cells were 
specific for pp65. Surprisingly, a majority of these cells 
(70.80%±1.00%%) were bona-fide Foxp3+ antigen-
specific Tregs. This subpopulation was isolated by FACS 
and studied in suppression assays.  Antigen-specific 
CD39+Foxp3+ Tregs were found to be better suppressors 
than CD39- Foxp3+Tregs. To determine the source of 
these Tregs, the TCRVβ CDR3 region of these subsets 
and other subsets of effector/memory cells is currently 
being amplified for clonotypic analyses. The results will 
determine whether antigen-specific Tregs are derived 
or not from effector/memory cells, which then undergo 
clonal expansion when encounter antigen. 
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REGULATORY	T	CELL	ABNORMALITIES	ARE	
ASSOCIATED	WITH	ABERRANT	CD4+	T-CELL	
RESPONSES	IN	PATIENTS	WITH	IMMUNE	
INFLAMMATORY	SYNDROME	(IRIS)	
Nabila Seddiki1,2, Chansavath Phetsouphanh1,2, 
Kai Brown1,2, John Zaunders1,3, David Cooper1,2,3, 
Anthony Kelleher1,2,3
1Centre for Immunology, St Vincents Hospital, Darlinghurst, 
NSW 2010, Australia; 2National Centre in HIV Epidemiology 
and Clinical Research, University of NSW, Kensington, NSW 
2052, Australia; 3HIV, Immunology and Infectious Diseases 
Clinical Services Unit, St Vincents Hospital, Darlinghurst, 
NSW 2010
Up to 30% of patients with HIV commencing antiretroviral 
therapy (ART) late in the disease, restore a pathogen-
specific cellular immune response that is immuno-
pathological and causes disease referred as immune 
reconstitution inflammatory syndrome or IRIS. We report 
that in HIV-infected patients who developed IRIS to 
mycobacteria, a large expansion of CD4+ T-cells specific 
for M. avium complex (MAC) antigens producing high 
levels of IFN-g and IL-2 (P<0.01) was observed. Surprisingly, 
we found an even larger proportion of expanded 
CD127loFoxp3+CD25+Tregs in these patients compared 
to healthy controls (17.8%±2.51% c/w 6.81%±0.35%, 
p<0.05) or to HIV+ patients before commencing 
(4.5%±2.12%, p<0.01) or 4 weeks after starting ART 
(4.3%±1.61%, p<0.01). However, these Tregs are defective 
in their ability to suppress effector T cell proliferation and 
production of inflammatory cytokines (IL-6, TNF-α).   This 
may explain the aberrant immune responses observed 
in these patients. To further investigate the suppressive 
dysfunction, we assessed CD39 and CD73 expression and 
function. These two ecto-enzymes have been reported 
recently to play a major role in Tregs function. Interestingly 
we found that, although CD39 expression was elevated 
in IRIS patients compared to controls (12.48%±2.069% 
c/w 2.67%±0.38%, p<0.05), CD73 expression was very 
low or absent compared to controls (1.045%±0.18% c/
w 5.028%±1.18%, p<0.01). The imbalance in expression 
of these 2 regulatory ecto-enzymes that normally work 
in tandem may help explain the observed defect in 
suppressive function of Tregs, allowing the excessive 
proliferation and inflammation in IRIS. Experiments are in 
progress attempting to delineate a possible role for CD73 
dysfunction in the immuno-pathology of IRIS.
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A	CRITICAL	ANALYSIS	OF	THE	qUALITY	
AND	TRANSFERABILITY	OF	ECONOMIC	
EVALUATIONS	OF	HIV	INTERVENTIONS	FOR	
AUSTRALIAN	DECISION-MAKING
Anderson JS1, Carter R2, ,Cooper DA1.  
1National Centre in HIV Epidemiology and Clinical 
Research, Darlinghurst NSW 2010. 
2Health Economics, Deakin University, Burwood, Victoria. 
There have been few economic evaluations of HIV 
healthcare and prevention interventions in Australia. 
Decision-makers developing guidelines may use existing 
studies from the pre-HAART era or overseas. However 
findings from these studies may not be valid or relevant 
in an Australian population. This study aimed to examine 
the published literature of economic evaluations in the 
post-HAART era to assess their quality and transferability.
The peer-reviewed literature was searched using 
standard methodologies for publications (post 1996) 
related to economic evaluation of HIV interventions in 
high income countries. A second stage filter was applied 
which assessed the interventions on a number of criteria 
including impact on health and costs; evidence-based; 
on the policy agenda; options for incremental increase 
or decrease in funding; clear program logic for the 
intervention; temporal relevance. Finally the EURONHEED 
consensus instrument, developed by health economists, 
was used to score the quality and generalisability of the 
studies. 
123 peer-review articles were available (1996-2007). Over 
90% were published from North American studies with one 
published study from Australia. 58 related to healthcare 
and 62 prevention (including biomedical prevention). 
19 focused on the prevention of perinatal transmission 
and 13 on the diagnosis, prevention and management of 
opportunistic infections. Quality and transferability scores 
ranged from 96% to less than 50%. Key issues in quality 
and transferability were perspective, study population, 
model design, measurement and valuation of benefit 
and cost data, and statistical analyses. 
While there is extensive published literature on economic 
evaluations, most of it comes from North America and 
some of the findings appear less relevant to clinical 
management and policy making. Study populations 
may differ from an Australian population and values for 
costs and outcomes may not be valid for Australia in 
2008. Decision makers need to consider both the internal 
and external validity of economic evaluations of HIV 
interventions in the post-HAART era.
Planning Requires Economic and 
Quality Review
3.30pm – 5.00pm
COST	EFFECTIVENESS	OF	SCREENING	FOR	
ANAL	CANCER	IN	HIV+	MSM
Hillman R, Botes L   
Sexually Transmitted Infections Research Centre, 
University of Sydney. Sydney, NSW, Australia
Anal Squamous Cell Carcinoma (ASCC) occurs at rates 
of approximately 30 - 92 cases/100,000 in HIV+ MSMs. 
Despite surgery, chemotherapy and radiotherapy, the 
2004 overall five year survival in Australia is 64% (lower 
in HIV+). This compares to 2002 rates of cervical cancer 
among the general Australian female population of 6.9 
cases/100,000, and a five year survival of 74%.
Similarities exist between ASCC and cervical cancer. For 
example, both cancers occur in transitional tissue, both 
are caused by sexual transmission of certain genotypes of 
Human Papilloma Virus and they have similar cytological 
and histological features. Using cervical cancer screening 
as a model, we therefore sought to compare the 
estimated cost parameters of a theoretical anal Pap 
smear intervention to detect anal cancer, with those of 
the existing cervical Pap smear programme.   
The total number of HIV+ MSM in Australia is approximately 
12,700. It can therefore be estimated that 7.5 (range 
3.6 - 11.7) cases of anal cancer will develop per year in 
these men. Anal Pap smears are reported as being 81% 
sensitive. Thus, if all 12,700 HIV+ MSM in Australia were 
screened, 81% of 7.5 cases = 6 cases would be detected. 
In this manner, each case of anal cancer would require 
12,700/6 = 2,116 HIV+ MSM to be screened. 
In comparison, the New South Wales Pap Register 
recorded 681 306 cervical Pap smears in 2005, when the 
incident cervical cancer rate was 238 cases per year. Thus 
681,306/238= 2,862 Pap tests were performed on women 
for each case of cervical cancer detected.
A U.S.A. paper in 1999 estimated the cost per QALy for 
anal cancer screening in HIV+ MSM every 2 years was 
$13,000. In comparison, the most recent Australian figures 
indicate that the cost per QALy for cervical screening is 
significantly higher, at $21,707.
Our preliminary calculations therefore suggest that an 
intervention targeting HIV+MSM with anal Pap smears 
to screen for anal cancer would be of comparable value 
and costs to that of the existing cervical cancer screening 
program. A number of assumptions were made in the 
above calculations, and further work is required to refine 
these figures.
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EFFECTIVE	PARTNERSHIP	AND	ADEqUATE	
INVESTMENT	UNDERPIN	A	SUCCESSFUL	
RESPONSE:	KEY	FACTORS	IN	DEALING	WITH	
HIV	INCREASES
Diana Bernard1, Susan Kippax1, Don Baxter 2
1National Centre for HIV Social research (NCHSR); 
2Australian Federation of AIDS Organisations (AFAO)
 
Background:
 Australia has mounted an effective prevention response 
to HIV/AIDS by investing in policy informed by evidence, 
strong partnerships and adequate investment.  Recently, 
in response to increases in HIV in some Australian states, 
the New South Wales (NSW) Department of Health set up 
a ‘Think Tank’ to examine state-based differences. 
 
Methods:
The National Centre in HIV Social Research (NCHSR) 
undertook key informant interviews with major 
stakeholders to complement behavioural/surveillance 
data. It was hoped to identify how members of 
the partnership (government, non government 
organisations, researchers, gay community) in NSW 
had collaborated to keep HIV notifications in NSW 
stable compared with increases in Victoria and 
Queensland.  In parallel, the Australian Federation 
of AIDS Organisations (AFAO) analysed the strategic 
contexts, government responses and investments 
in prevention of HIV in all jurisdictions in Australia. 
 
Results:
There were significant differences between NSW, 
Queensland and Victoria in the way the HIV partnership 
functioned and was resourced. Whilst the strong 
partnership in NSW enabled a planned, evidence-based 
response, the response in Queensland was hampered 
by competitive tendering that pitched partners against 
each other. In Victoria diminished funding, the inability 
of partners to work together, an inadequate strategic 
framework and a more rigorous application of the 
purchaser-provider model inhibited collaborative 
planning and the optimal resource allocation necessary 
for an effective response. Prevention campaigns in 
Queensland and Victoria were also subject to greater 
government censorship than NSW campaigns.
Conclusions:
Since the Australian strategic response to HIV/AIDS 
has been one of the most successful in the world, an 
understanding of Australian partnership arrangements 
is highly relevant for other countries addressing the 
challenge of HIV/AIDS. Any interpretation of, and response 
to, increases in HIV notifications and unsafe sexual practice 
needs to be cognisant of the crucial nature of strategic 
partnerships and adequate resourcing for successful 
prevention.  
 
Keywords: HIV transmission, evidence based policy, 
partnership
MODELS	OF	ACCESS	AND	CLINICAL	SERVICE	
DELIVERY	IN	AUSTRALIA	TODAY
Dr Jan Savage, ASHM
Mr Peter Canavan NAPWA, Ms Jo Watson, NAPWA, Ms 
Levinia Crooks ASHM
Determining the appropriate nature, level and mechanism 
for delivering care to people living with HIV has been a 
constant challenge in the Australian environment. Since 
the early recognition of HIV and the management of 
opportunistic infection through to the development 
and delivery of very effective antiretroviral agents there 
has been a shifting understanding of what is best, what 
is appropriate, what is manageable and what is affordable 
care.
In Australia much care is provided to PWHIV by general 
practitioners in the community setting. But this care is 
provided in the context of there being a very dispersed 
HIV population nationally. At the same time our health 
workforce is over stretched and asked to take on 
increasing levels of complex management. 
The Models of Access and Clinical Service Delivery Project 
is a joint initiative of NAPWA and ASHM. It is supported 
by DoHA and the States and Territories via AHMAC 
arrangements. The project is exploring the changing 
needs of PLWHA, the range of service models available 
generically to manage chronic care as well as the 
changing nature of HIV management.
The presentation outlines the methodology undertaken 
and presents preliminary data being collected as part 
of the project. It will also act as a discussion point for 
attendees to put forward issues which they see as 
important in the delivery of services to PLWHA as we 
enter the third decade of HIV management.
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REDUCED	RISK	OF	HIV	SEROCONVERSION	
AMONG	CIRCUMCISED	HOMOSExUAL	MEN	
WHO	REPORT	A	PREFERENCE	FOR	THE	
INSERTIVE	ROLE	IN	ANAL	INTERCOURSE
Templeton DJ1,2, Jin F1, Mao L3, Prestage GP1, Donovan B1,4, 
Imrie J3, Kippax SC3,Kaldor JM1, Grulich AE1
1National Centre in HIV Epidemiology and Clinical 
Research, The University of New South Wales, Sydney 
NSW, Australia; 2RPA Sexual Health, Royal Prince Alfred 
Hospital, Sydney NSW, Australia; 3National Centre in HIV 
Social Research, The University of New South Wales, 
Sydney NSW; 4Sydney Sexual Health Centre, Sydney 
Hospital, Sydney NSW, Australia
 
Circumcision substantially lowers the risk of HIV acquisition 
among heterosexual men in Africa, but there are few and 
conflicting data addressing circumcision status as a risk 
factor for HIV among homosexual men. We examined 
circumcision status as an independent risk factor for HIV 
seroconversion in the community-based Health in Men 
(HIM) cohort of homosexual men in Sydney, Australia.
Between 2001 and 2004, 1,426 initially HIV-negative men 
were enrolled. Circumcision status was self-reported at 
baseline and was validated by clinical examination during 
study visits in a sub-sample of participants. All participants 
were tested annually for HIV. Demographic information 
was collected at baseline and detailed information on 
sexual risk behaviours was collected every 6 months. 
At baseline, almost two thirds of participants reported 
being circumcised; mostly as infants. There were 53 HIV 
seroconversions in the HIM cohort, an incidence of 0.78 per 
100Py.  On multivariate analysis controlling for behavioural 
risk factors, being circumcised was not associated with 
HIV seroconversion (HR 0.76, 95% CI 0.41-1.41, p=0.381). 
However, among those with a preference for the insertive 
role in anal intercourse, being circumcised was associated 
with a significant reduction in HIV incidence when 
controlling for age and number of insertive unprotected 
anal intercourse (UAI) acts with HIV positive or status 
unknown (sero-nonconcordant) partners (HR 0.15, 95% 
CI 0.03-0.80, p=0.026). In these men, a median 100% (IQR 
92.1-100%) of UAI acts with sero-nonconcordant partners 
were in the insertive position and reported preference for 
the insertive role was remarkably constant over time. 
Overall, circumcision was not associated with HIV 
incidence in the HIM cohort. However, being circumcised 
was associated with a significant reduction in HIV 
incidence among those participants who reported a 
preference for the insertive role in anal intercourse. As 
most HIV infections in homosexual men occur after 
receptive anal sex, circumcision is likely to have a limited 
impact as an HIV prevention intervention in Australian 
homosexual men. However, circumcision may have a 
role in those men who are predominantly at risk of HIV 
seroconversion through insertive rather than receptive 
anal intercourse. 
Circumcision
5.15pm – 6.15pm
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SMALL	POPULATION	HEALTH	BENEFITS	ON	
HIV	BY	CIRCUMCISING	MEN	WHO	HAVE	SEx	
WITH	MEN
Londish GJ1, Templeton DJ2, Regan D2, Kaldor JM2, 
Murray JM1,2
1School of Mathematics, University of New South 
Wales, Sydney, NSW, Australia; 2National Centre for HIV 
Epidemiology and Clinical Research, Sydney, NSW, 
Australia
Men who have sex with men (MSM) suffer a 
disproportionate burden of HIV in the developed 
world. The recent success of circumcision in reducing 
HIV acquisition among heterosexual African men has 
prompted debate on whether circumcision could be 
effective in reducing HIV acquisition amongst MSM in 
developed countries. We developed a mathematical 
model to estimate the impact of a male circumcision 
intervention on HIV incidence and prevalence in a MSM 
community in a developed country. The model provides 
a simple relationship between the level of circumcision 
and long-term HIV prevalence. The results indicate that 
the decrease in HIV prevalence is much lower than that 
experienced amongst heterosexual men, such that if a 
MSM community initially had no circumcision and 10% 
HIV prevalence, complete circumcision would reduce 
this to 6%. However, it would require decades before a 
substantial drop in HIV prevalence was achieved. HIV 
incidence follows a similar pattern with a drop during 
intervention and then gradual decline over decades. 
Strategic positioning, another risk reduction strategy, 
can provide a slight increase to the effectiveness of 
circumcision reducing prevalence from 6% to 1%. These 
results suggest that circumcision is not a viable option 
to substantially reduce HIV prevalence amongst MSM in 
developed countries.
COST-EFFECTIVENESS	OF	CIRCUMCISION	
FOR	THE	PREVENTION	OF	HIV	IN	GAY	MEN	IN	
AUSTRALIA
Anderson J
 
This study aimed to examine the incremental cost-
effectiveness of a program of male circumcision in 
Australian MSM. 
We used a dynamic model with a hypothetical population 
of 180,000 MSM around Australia with baseline HIV 
prevalence according to age but homogenous sexual 
mixing. Circumcision was assumed to have an efficacy 
of 60% (range 30-82%) in preventing acquisition by an 
insertive MSM.  Baseline circumcision rates ranged from 
50.3% (for <25 y.o.) to 82.6% (for >45 y.o.). The impact of 
antiretroviral therapy, sero-positioning and condom use 
was included. Cost per circumcision was $3,650 including 
pre-operative counseling, assessment and testing, 
operative care and post-operative follow-up. Relevant 
costs and outcomes including quality-adjusted life-years 
were discounted at 3%.
Three strategies for implementation of a circumcision 
intervention were compared with the status quo: 
circumcising all MSM at sexual debut, all insertive MSM 
immediately, and all MSM now. For each strategy the 
number of HIV infections prevented per year is shown in 
the table.
HIV infections 
prevented per year 10 years 25 years 50 years
sexual debut 11 37 72
Insertive 20 34 56
all MSM 37 57 80
All approaches were not cost-effective early post-
intervention but they became cost-effective after 7-14 
years for circumcising just insertive MSM; after 12-27 years 
for all MSM; and after 19-31 years for circumcising all at 
sexual debut. Intervention costs ranged from $14m a year 
for the sexual debut approach, to $196m in the first two 
years for the all MSM approach. 
Sensitivity analyses will be presented that explore changes 
in risk behaviour, uptake and parameter uncertainty .
Targeting the intervention to insertive men would be 
most efficient, but even in the best-case, the benefits of 
an intervention based on male circumcision would not 
be seen for at least a decade and would have significant 
upfront costs. 
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THE	ACCURACY	OF	HIV	INCIDENCE	ASSAYS	
IN	ESTIMATING	THE	POPULATION	RATE	OF	
NEW	INFECTIONS:	A	SYSTEMATIC	REVIEW
Guy R1,2, Gold J2,3, García Calleja JM4, Kaldor J2 on behalf of 
the WHO Working Group on HIV Incidence Assays
1Centre for Epidemiology and Population Health Research, 
Burnet Institute, Melbourne, VIC, Australia; 2National Centre 
in HIV Epidemiology and Clinical Research, Sydney, NSW, 
Australia; 3Department for Epidemiology and Preventive 
Medicine, Monash University, Melbourne, VIC, Australia; 
4World Health Organization, Geneva, Switzerland.
Specialised HIV serological assays have been used in 
many countries to distinguish recent from established 
HIV infections in populations as a basis for estimating 
incidence. However there is recent evidence that the 
BED-CEIA assay overestimates HIV-1 incidence, due to 
misclassification of cases with longstanding HIV infection 
as recent infections, leading to a recommendation by 
UNAIDS that the BED assay not be used for routine 
surveillance, incidence estimates or monitoring incidence 
trends at a population level.
A review was conducted to summarise validation findings 
for all assays. Validation was defined to mean the process 
of comparing estimates of HIV incidence derived from 
use of an assay in a population, to concurrent estimates 
of incidence in the same population obtained by an 
alternative means that is believed to provide a reliable 
measure of incidence (‘gold standard’). PubMed was 
searched to the end of December 2007. 
There were 22 papers identified, reporting 25 overall 
incidence estimates. The most frequently used ‘gold 
standard’ incidence method was a cohort study (13), 
followed by a database of repeat HIV testers (four) and 
mathematical modelling (3). The percentage difference 
between the median assay-derived incidence and ‘gold 
standard’ incidence was 10%. Twelve of the 25 overall 
analyses were based on the comparison of assay-derived 
incidence and ‘gold standard’ incidence on identical 
samples; the median difference for these assessments was 
7.3%, compared to 26% for the 13 validations conducted 
using non-identical populations. The median difference 
was -13.4% for five validations conducted among IDUs, 
13.9% for eight validations in MSM increasing to 166.3% 
for eight validations among heterosexuals from sub-
Saharan Africa. The median difference was 10.3% for three 
validations conducted using the 3A11-LS assay, 7.5% for 
15 validations using the BED assay and 13.9% for the six 
validations using the Vironostika assay.
The review showed incidence assays perform well in 
providing estimates of HIV incidence and assays can be 
reliably used to estimate HIV incidence, as long as due 
consideration is given to the presence of longstanding 
infections and people receiving HIV treatment, with 
their potential to produce “false-recent” findings in the 
population. A variety of validation methods were used, 
highlighting the need for a standard and comprehensive 
framework for the development of incidence assays. 
Diagnostics and Assay Development
5.15pm – 6.15pm
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SENSITIVITY	AND	SPECIFICITY	OF	HIV	
INCIDENCE	ASSAYS:	A	SYSTEMATIC	REVIEW
Gold J1,2, Guy R1,3, García Calleja JM4, Kaldor J3 on behalf of 
the WHO Working Group on HIV Incidence Assays
1Centre for Epidemiology and Population Health Research, 
Burnet Institute, Melbourne, VIC, Australia; 2Department 
for Epidemiology and Preventive Medicine, Monash 
University, Melbourne, VIC, Australia; 3National Centre 
in HIV Epidemiology and Clinical Research, Sydney, 
NSW, Australia; 4World Health Organization, Geneva, 
Switzerland
Reduction in new HIV infections is one of the world’s 
major public health objectives. Specialised serological 
assays have been developed to measure HIV incidence 
at a population level. Assays are developed to have 
an associated ‘estimated window period’ indicating 
the time in which an infection is considered recent. To 
maximise utility, assays must have a high probability of 
correctly detecting recent infections (sensitivity) and a 
low probability of misclassifying established infections as 
recent (specificity). 
Publications reporting on sensitivity and specificity of 
assays measured against specimens of known time of 
infection until the end of 2007 were reviewed. Infections 
were classed as recent or established, as indicated by 
seroconversion before or after the assay window period. 
We also assessed specimens relating to individuals 
(i) known to be HIV infected for one year or more 
(longstanding infections), (ii) diagnosed with AIDS and 
(iii) receiving antiretroviral treatment. 
Thirty two reports related to 16 different assays were 
identified. The 90 sample sets included in the reports were 
most commonly derived from cohorts (47) and sourced 
from the United States (27). Thirty six (40%) sample sets 
specified the subtype of the specimens; 22 were subtype 
B. The number of specimens assessed ranged widely 
(median 123, range 7-2749).  
The median sensitivity for recent infections was 88.8% 
(n=30, range 42.3-100). The median specificity for 
established infections was 93.3% (n=33, range 49.5-100) 
compared to 98.0% for longstanding infections (n=8, 
range 70.0-100) and 91.6% for AIDS cases (n=23, range 
72.2-100). Median specificity for individuals receiving 
antiretroviral treatment for one year was 95.5% (n=4, 
range 91.0-100) and 76.3% for individuals treated for two 
years (n=4, range 72.7-81.8). 
The majority of sensitivity and specificity estimates 
were above 85% for recent and established infections. 
Specificity was lower for AIDS cases compared to 
longstanding infections and specificity appeared 
to decrease with increasing time on antiretroviral 
treatment. However the limited descriptions of sample 
characteristics, and limited number of specimens from 
individuals with longstanding infections and individuals 
receiving antiretroviral treatment, indicates the need for 
established, well-described specimens banks for sensitivity 
and specificity testing during assay development, before 
their application in the field. 
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EVALUATION	OF	THE	NEW	VERSION	3	CAVIDI	
ExAVIR™	LOAD	qUANTITATIVE	HIV	RT	LOAD	
KIT	AS	AN	ALTERNATIVE	HIV	VIRAL	LOAD	
MONITORING	ASSAY	FOR	USE	IN	BOTH	
RESOURCE-CONSTRAINED	AND	DEVELOPED	
COUNTRIES
Greengrass V1, Plate M1, Steele P1, Denholm J2, Morris L1 
and Crowe SM1,2
1Clinical Research Laboratory, Macfarlane Burnet Institute 
for Medical Research and Public Health, Melbourne, 
Australia; 2Infectious Diseases Unit, Alfred Hospital, 
Melbourne, Australia
There is an increasing need for inexpensive and simple 
tests to monitor HIV disease progression in developed and 
resource-constrained countries to facilitate appropriate 
use of antiretroviral therapy. We have extensively 
evaluated the new version 3 (v3) low cost manual reverse 
transcriptase assay, ExaVirTM Load assay from Cavidi AB 
(HIV RT) and compared it to the version 2 (v2) assay and 
the commercially available Roche COBAS Amplicor HIV-1 
Monitor assay version 1.5, which measures HIV RNA (ultra-
sensitive preparation; HIV RNA). 
Frozen plasma samples from HIV-infected individuals with 
previously quantified HIV RNA were also tested for HIV RT 
activity using the v2 (n=411) and the v3 (n=265) assays. 
The HIV RT v3 assay sensitivity has improved significantly 
from v2 with 95% of all samples detectable with HIV 
RNA ≥400 copies/ml compared to 85% with v2. A strong 
positive association was observed between detectable 
samples tested using the HIV RNA assay compared 
to HIV RT v2 and v3 assays (r=0.88; n=176 and r=0.88; 
n=223 respectively). Bland-Altman model was used for 
measuring agreement between the HIV RNA assay and 
the HIV RT v2 and v3 assays (mean difference: -0.19 log10 
and -0.11 log10 respectively) and between the HIV RT v2 
and v3 assays (mean difference: 0.01 log10). 
The HIV RT v3 assay is more sensitive than the v2 assay. 
Other improvements include faster turnaround time 
and fewer consumables required. The HIV RT v3 assay is 
suitable for use in monitoring HIV disease progression in 
both resource-constrained and developed countries. 
PERSISTENCE	OF	HIGH	LEVELS	OF	HIV	
ANTIGEN-SPECIFIC	CD4+	T	CELLS	IN	
UNTREATED	CHRONIC	INFECTION,	
DETECTED	BY	A	NOVEL	FLOW	CYTOMETRIC	
ASSAY
Zaunders J1, Bailey M2, Munier ML2, Seddiki N2, Kim M3, 
Pett S2, Emery S2, Cunningham AL3, Cooper DA1,2 and 
Kelleher AD1,2
1Centre for Immunology, St Vincent’s Hospital, 
Darlinghurst, NSW; 2National Centre in HIV Epidemiology 
and Clinical Research, Darlinghurst, NSW; 3Westmead 
Millenium Institute, Westmead, NSW
HIV antigen-specific CD4+ T cells are preferentially 
targeted and deleted by cytopathic infection. In most 
cases, HIV-1 antigen-specific CD4+ T cells are barely 
detectable by proliferation assays, and at low levels by 
interferon-γ production. We developed a novel assay of 
antigen-specific CD4+ T cells, based on up-regulation 
of CD25 and CD134 (Ox40), and not reliant on either 
proliferation or cytokine production, to reassess the 
level of HIV-specific CD4+ T cells in untreated chronic 
infection.
Samples of whole blood from 15 healthy adult controls 
and 13 consecutive asymptomatic untreated subjects 
with established HIV-1 infection (median: 158 CD4+ T 
cells/µl; 4.7 log10 RNA copies/ ml) were incubated in vitro 
for 40-44 hr with either culture medium alone or with 
various recall antigens including lysates of CMV and M. 
avium; UV-inactivated HSV-1; or a pool of overlapping 15-
mer peptides covering HIV-1 Gag. Cell surface CD25 and 
CD134 were measured on CD4+ T cells by flow cytometry. 
Results for subject groups were expressed as medians.
The background level of CD25+CD134+ CD4+ T cells 
was very low, <0.03% of CD4+ T cells (mean + 3xSD). In 
healthy adult controls, recall responses to CMV, M. avium 
and HSV-1 were a median of 3.9%, 3.6% and 1.1% of CD4+ 
T cells, respectively and correlated with standard assays of 
lymphoproliferation in 7-day cultures. In the cohort of HIV-
infected subjects, responses to CMV, M. avium and HSV-1 
were 4.7%, 5.2% and 2.3% of CD4+ T cells, respectively. 
Responses to HIV-1 Gag peptides were a median of 0.1% 
in healthy adult controls, but in the HIV-infected subjects 
responding cells were a median 0.8% of CD4+ T cells 
(*p<0.001 compared with controls), with 6/13 subjects 
having much higher responses, ranging from 1.7 to 4.8% 
of CD4+ T cells.
This novel assay has revealed relatively large populations 
of antigen-specific CD4+ T cells that respond to recall 
antigens, in both healthy adults and asymptomatic, 
untreated chronically infected HIV-infected subjects. In 
particular, we have discovered that there are 5-10 times 
more HIV Gag-specific CD4+ T cells present in peripheral 
blood than previously estimated by proliferation or IFN-γ 
production.
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Breakfast Session – 
‘Meet the Experts’ – Clinical
7.30am – 8.45am
This is intended to be an interactive session for practitioners 
involved in the clinical care of HIV-infected patients. It 
is assumed that participants will be experienced in the 
assessment and treatment of HIV infection. Presentations 
will elucidate practical and evidence-based clinical 
approaches to the evaluation and management of 
complex clinical scenarios, including
· Life-threatening Immune Reconstitution Inflammatory 
Disease (Prof Martyn French)
· Prevention and Management Strategies for Metabolic 
Syndrome and Cardiovascular Risk in Patients Taking 
Antiretroviral Therapy (Dr David Nolan) 
· Management of Late Presenting Patients with Severe 
Opportunistic Infection (Dr Robin Wood)
· Contemporary Approach to Management of 
Antiretroviral Treatment Failure or Toxicity (Dr Roy Gulick)
Scott-Visser B - see page  255
McGowan A - see page 254
Reeders D - see page 242 
Brown G - see page 236 
Brown G - see page 271
Lake R - see page 239
Clayton S - see page 271
Sarangapany J - see page 256
Oral Poster Session - Social Research, 
International, Community, Indigenous 
Health 8.00am - 8.45am
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NEURODEGENERATION	AND	AGEING	IN	THE	
HAART	ERA
Brew BJ
Departments of Neurology and HIV Medicine St 
Vincent’s Hospital, Sydney Australia
Neurodegeneration and the effects of ageing on the brain 
in HAART treated patients are becoming of increasing 
concern. Existing HIV infected patients are growing 
older as a consequence of suppression of HIV replication 
and the number of older patients newly acquiring HIV 
infection is growing. There is evidence in some patients 
for chronic immune activation and oxidative stress within 
the central nervous system despite effective antiretroviral 
therapy at least as measured in the cerebrospinal 
fluid. Oxidative stress is the “final common pathway” in 
the pathogenesis of a number of neurodegenerative 
diseases. Furthermore, there are particular aspects of 
HIV disease and its therapy that potentially contribute to 
the development of ALzheimers disease or at least a like 
illness. These include hyperlipidaemia, excess amyloid 
production and inhibition of amyloid degradation. 
Emerging evidence for the development of these 
diseases from clinical and neuropathological studies will 
be reviewed. The implications for the early introduction 
of HAART with drugs that have good brain penetration 
will be discussed.
HIV and Ageing
9.00am – 10.30am
GROWING	OLD	DISGRACEFULLY	WITH	HIV
Pitts MK
Australian Research Centre in Sex, Health and Society, 
LaTrobe University
The advent of HAART and improved clinical care means 
that HIV positive people can now expect longevity 
almost equivalent to HIV negative people. This change 
has presented new challenges for positive people, those 
who provide treatment, care and support and those 
who research with them to understand better the lived 
experience. Ageing brings with it new challenges that 
may be related to the ageing process itself, to living 
longer with the virus and living longer on treatments. 
However, ageing is broader than simply facing these 
challenges. We simply do not know what the effects of 
HIV will be in the very long term, there is some evidence 
of premature ageing associated with HIV, but there are 
also indications that older HIV +ve people actually have 
better well being, if not better health than their middle 
aged counterparts. The relationship of identity, HIV status, 
gender and sexuality may also change as one ages. This 
talk will focus on the different ways in which people may 
grow older with HIV, exploring the diversity of experience 
and the highs as well as the lows of being old.
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HIV,	CANCER,	AND	IMMUNE	DEFICIENCY
Grulich AE
National Centre in HIV Epidemiology and Clinical Research, 
UNSW, Sydney, NSW, Australia
Until recently, it was accepted that only a few specific 
types of cancer were associated with the immune 
deficiency associated with HIV infection. Although it is 
known that a number of other cancers occur at increased 
rates, most studies have concluded that these cancers 
occur at increased rates because of lifestyle risk factors for 
cancer in people with HIV, rather than a direct effect of 
immune deficiency. 
In the past year, this paradigm has been challenged by the 
finding that solid organ transplant recipients have a profile 
of increased cancer incidence that is strikingly similar to 
people with HIV. As these two populations share little in 
terms of lifestyle risks for cancer, it appears that immune 
deficiency must underlie these increased risks. Most of 
cancers occurring at increased incidence are those known 
or suspected to be related to oncogenic infective agents 
including Epstein-Barr virus (non-Hodgkin lymphoma 
(NHL), Hodgkin lymphoma), human herpesvirus 8 
(Kaposi’s sarcoma, KS), human papillomavirus  (anogenital 
and head and neck cancers), hepatitis B and C virus (liver 
cancer), and helicobacter pylori (stomach cancer). Most 
epithelial cancers common in the general population (eg 
breast, prostate and ovarian) do not occur at increased 
risk. 
Although it is now clear that immune deficiency causes 
increased incidence of many cancers, there remains 
uncertainty about the level of immune function required 
to prevent increased rates. In transplant recipients, rates 
of many cancers rapidly return towards normal on 
cessation of iatrogenic immune suppression. In people 
with HIV, rates of NHL and KS have declined markedly 
since the widespread use of combination anti-retroviral 
therapy, but rates remain raised above population levels. 
For Hodgkin lymphoma, it incidence is highest when 
immune deficiency is moderate rather than profound. 
For other cancers, there are few data on rates by level of 
immune deficiency. 
Describing cancer rates by level of immune function 
is an important research priority among people with 
HIV. If cancer incidence is raised even in the modestly 
immune deficient, cancer risk may become an important 
consideration in deciding when to start HIV therapy, and 
in the setting of goals for optimal immune recovery.  
HIV	INFECTION	AND	HEALTHY	AGEING:	
IS	THERE	A	NEED	FOR	HIV-SPECIFIC	
MANAGEMENT	GUIDELINES	FOR	THE	
PROTECTION	OF	HEARTS,	BONES,	MINDS	
AND	MORE?				
Nolan DA1,2
1Centre for Clinical Immunology and Biomedical Statistics, 
Murdoch University and Royal Perth Hospital, Perth, 
Western Australia; 2Department of Clinical Immunology, 
Royal Perth Hospital, Perth, Western Australia
The widespread availability of effective first-line and 
salvage HIV treatment regimens has transformed HIV 
infection into a chronic condition that is frequently 
manageable into older age; including among those with 
longstanding HIV infection who were originally given a 
limited prognosis. Hence, long-term HIV treatment now 
incorporates an increased awareness of age-associated 
conditions such as cardiovascular and metabolic diseases, 
osteoporosis, cognitive decline, and risk of malignancy 
– in addition to providing optimally effective and safe 
antiretroviral therapy. 
In this context, several key questions are now directing 
new avenues of clinical research. First, what is the impact 
of HIV infection and associated immune deficiency on 
age-associated diseases? There is now good evidence 
that progressive immune deficiency is associated with 
increased risk of atherogenic dyslipidemia, reduced 
muscle mass and bone density, and ‘non-AIDS-related’ 
malignancies (eg. skin and lung cancer). The potential 
effect of immune activation, irrespective of CD4 T 
cell count, is also being explored as a risk factor for 
cardiovascular disease, dyslipidemia and HIV-associated 
dementia. These factors can inform clinical management 
decisions with regard to patient assessment and 
monitoring, and are fuelling a growing debate regarding 
CD4-guided HIV treatment initiation.
Second, what is the impact of antiretroviral drug treatment 
on age-associated diseases? Here, consideration of 
individual drug toxicity profiles, rather than antiretroviral 
‘class effects’, appears to be the most appropriate 
approach. This is a growing area of interest, particularly in 
light of recent studies suggesting associations between 
NRTI choice and risk of diabetes (stavudine>zidovudine) 
and cardiovascular disease (abacavir>didanosine).
Third - and perhaps most importantly at this stage - to 
what extent are we able to assess disease risk, and apply 
prevention and management strategies, using guidelines 
that have been developed in the general population? 
Here, an awareness of existing guidelines, and their 
incorporation into routine clinical practice, will provide 
a valuable platform for developing clinical experience 
as well as guiding further research. These guidelines also 
reinforce the potent contribution of ‘lifestyle’ factors (eg 
smoking) to chronic disease risk.
These question will be explored, with the goal of 
developing practical approaches to the management of 
healthy ageing in HIV infection. T
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This symposium is aimed at clinicians, epidemiologists, 
public health practitioners and researchers. Three 
presenters will summarise and place in broader context the 
5-10 contributions in HIV basic, clinical, epidemiological 
and social research published over the course of the past 
year that they consider most important, with an emphasis 
on those most likely to result in fundamental practice and 
paradigm change. 
Hot Topics: Top Papers 2008 
11.00am – 12.30pm
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COMMUNITIES	AND	RESEARCH:	THE	
NECESSITY	FOR	DIALOGUE
Bruno Spire1,2, Jean-Marie-Legall1, Franck Barbier1, Christian 
Andreo1 and Vincent Pelletier1
1AIDES, Pantin, France; 2INSERM U912, Marseille, France
In France, AIDES is the largest community-based 
association and contributes through social activism 
both to improve the living conditions of PLWHA and to 
influence policy makers in order to stem the HIV epidemic. 
AIDES promotes a community based approach: “doing 
with people, not for people” by adopting innovative 
approaches and tailoring appropriate actions to meet 
communities’ needs.
Since the introduction of ART, community activists and 
public researchers have worked together in order to 
answer research needs emerging from the community. 
In the field of care and support, one such need is how 
to face therapeutic failure by promoting salvage therapy 
trials combining several new molecules. Another such 
need is how to promote comprehensive care, including 
adherence interventions, justified either by a theoretical 
health psychology framework or on evidence-based 
empirical data. Research needs were also identified in the 
field of quality of life improvement, more particularly in the 
domain of sexual and affective life. Community members 
advocate to promote research on side-effects, including 
those which are all too often neglected, and to take into 
account the patient’s perspective as a possible outcome in 
clinical trials. In the field of social sciences, research needs 
identified by the community raise several questions: i:how 
to influence the negative perception of PLWHA by the 
general public, ii how to decrease stigmatisation which has 
not been strongly impacted by the advent of ART, iii how 
to overcome barriers to disclosure and determine which 
interventions could help in creating greater acceptance 
of PLWHA. Furthermore, research is urgently needed to 
explore in which circumstances promoting “low risk” sex 
practices may reduce the risk of HIV transmission. It is 
also important to determine whether frequent, routine 
testing for people who are often exposed to HIV may 
reduce sexual risks in recently diagnosed HIV cases and 
also reduce HIV incidence. In conclusion, scientists must 
interact with community groups to better tailor research 
issues to real needs. Scientific evidence is an indispensable 
and efficient weapon to support action and lobbying. 
The battle against AIDS can be won only if scientists, field 
actors, community groups and civil society are mobilised 
altogether.
THE	SHOCK	OF	ETHICAL	COMMUNITY	
RESEARCH	
Canavan P
National Association of People Living With HIV/AIDS 
(NAPWA)
                                                                                                                                               
The history of the HIV community’s involvement in clinical 
research has to date largely been driven from the start by 
‘health shocks’. The greatest health shock of them all is to 
be diagnosed with a life threatening disease and to have 
that diagnosis shift to the shock of vulnerability, rapid 
disease progression and death.
Health shocks associated with the HIV crisis have 
necessitated giving priority to the initiation of HIV clinical 
research agendas being driven by biomedical imperatives, 
including the need for effective antiretroviral treatments 
and management strategies.
Research influenced by needs which are foremost dealing 
with ‘crisis avoidance’ present particular challenges 
to communities and to their elected representatives 
in remaining engaged to ensure research is evolving 
in ethically robust, personally relevant, community 
supported and sustainable ways.
This paper seeks to first challenge some of the traditional 
ways community involvement in clinical research occurs 
and in doing so open up discussion on current levels 
of community engagement, discussing difficulties and 
emerging limitations of a representative model.
The HIV crisis has now shifted to occupy centre stage in 
the developing world and in doing so has introduced a 
new ‘health shock risk’ to opportunities for meaningful 
involvement by HIV positive communities in the 
developed world in engaging a research ethic which 
creates opportunities for a revitalized scientific research 
agenda relevant to the needs of HIV positive communities 
in the developed world today. 
In seeking to reinvigorate a broad based community 
engagement with clinical research, this paper proposes 
that there is a concomitant opportunity to reexamine the 
motivations and opportunities of clinical research agendas 
to accommodate a multidisciplinary reflexive approach 
– which embraces diversified and changing health 
needs and perspectives, wider access arrangements, 
strengthened communication processes and guaranteed 
reporting of trial results. 
Finally, ways forward are introduced to assist both 
community and researchers to begin a serious discussion 
on strengthening partnership processes and to avoid 
tendencies of mechanistic engagement with either 
clinical research or consumers.
Community Research and Practice
11.00am – 12.30pm
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THE	FEASIBILITY	OF	A	NATIONAL	GAY	
MEN’S	INTERNET-BASED	COHORT	AND	
PROSPECTIVE	BEHAVIOURAL	SURVEILLANCE	
PLATFORM	IN	AUSTRALIA	–	WHAT	ARE	THE	
ISSUES?	
Imrie J1, Prestage GP2,3, Pitts M3
1National Centre in HIV Social Research, The University 
of New South Wales, Sydney, NSW, Australia; 2National 
Centre in HIV Epidemiology and Clinical Research, The 
University of New South Wales, Sydney, NSW, Australia; 
3Australian Research Centre in Sex Health and Society, La 
Trobe University, Melbourne, VIC, Australia
  
In Australia, concern about rising HIV-notifications, 
diverging epidemics between jurisdictions and increasing 
STIs among homosexually active men (MSM) have 
prompted a re-think of behavioural surveillance research. 
Current surveillance, while of high quality, has notable 
shortcomings – limited coverage outside main cities and 
among hard-to-reach groups, and capacity to evaluate 
prevention effectiveness. 
We are investigating the feasibility of a national internet-
based research platform that would support a longitudinal 
cohort of HIV-positive and HIV-negative men (with data 
linkage to national and state disease registers), and repeat 
cross-sectional behavioural surveys (with monitoring of 
repeat respondents over time). 
A national internet-based platform combining both 
longitudinal and repeat cross-sectional studies would 
be unique. Added benefits of linkage to national and 
state registers would be incidence data on HIV/STIs and 
other health conditions (e.g. cancer, mental illness, etc), 
and potentially, health, pharmaceutical and social care 
service usage. Such a research platform would allow 
comparisons between states/territories, and with the 
general male population. Obvious challenges include 
participant retention, stratified sampling and sample-size 
in small states. But in this new territory there are also new 
issues - multi-level inter-sectoral collaboration, evaluation 
design, ethics, consent requirements, governance and 
data management (e.g. confidentiality, handling and 
ownership). 
Innovations addressing limitations of current behavioural 
surveillance and extending its usefulness are needed, 
particularly in mature MSM HIV epidemics. Internet 
platforms and data linkage offer potentially mechanisms 
to do this, but at a national level, present a range of new 
challenges to the field.
NATIONAL	SAS	PROGRAMS	–	A	REVIEW	OF	
THE	LAST	4	PROGRAMS
Watson J, Whittaker B1, Brown D, Strum A, Paul A
1National Association of People Living with HIV/AIDS 
(NAPWA), 2Janssen-Cilag Australia, 3Merck Sharp & 
Dohme Australia, 4Pfizer Australia
NAPWA is the national peak body representing plwha 
organisations in Australia. As part of its national advocacy 
program, it is the organisation responsible for negotiations 
with individual pharmaceutical companies for the 
development and monitoring of Special Access Scheme 
(SAS) programs for HIV antiretrovirals. NAPWA also 
maintains monitoring of the programs with the individual 
drug manufacturer’s, prior to each drug being submitted 
and registered through the Australian regulatory process 
for listing on the Pharmaceutical Benefits Scheme.
The national SAS programs have been a feature of 
the Australian HIV community based response since 
the early HIV activism movement which established 
compassionate access to the experimental agent AZT, 
in the early 90’s. Since then, there has been a program 
developed for every HIV drug, and over the years there 
has been significant changes to the way in which SAS 
programs have been developed, and how they have 
been utilised by doctors for their patients.
This presentation will review the last 4 programs which 
have been run in Australia, up to the present time. This will 
include a report of the individual program profiles, and 
their specific patient criteria and enrollment numbers. 
Some of the trends noted across state and territory 
jurisdictions, and the changes which can be observed 
across program timelines will be also addressed.
Discussion includes an analysis of the impacts of the 
overlap of some of the programs across specific periods 
of time, and their operation in parallel to several major 
clinical studies in Australia targeting the same patient 
population. The presentation will also cover the principles 
behind the ongoing provision of SAS programs in Australia 
today, and the analysis of trends observed in the patient 
group which is being supported through this mechanism 
for early access to the new agents. 
Finally, some concluding remarks will be focused on the 
potential for improving SAS program parameters in the 
future, including better ways to learn from the “real life” 
information which these programs can provide as part 
of the experience of the patient and their doctors in 
ongoing HIV clinical management developments.
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TOWARDS	MORE	EqUITABLE	ACCESS	TO	HIV	
CLINICAL	TRIALS	
Ogier, A 
National Association of People living With HIV/AIDS 
(NAPWA), Sydney, NSW, Australia
Access to optimal HIV treatments and services should 
not be reserved for those living in key urban centres. But 
where you live in Australia does limit the options of many 
people with HIV.
The Treataware campaign (launched by NAPWA in May 
2008) is an important new health promotion project, 
providing a variety of formats in which all HIV positive 
Australians can access specific HIV treatments information. 
The project is promoted to people with HIV as well as 
their aligned health workers and medical practitioners 
to support a team approach to making informed choices 
regarding HIV treatments. 
A key objective of Treataware is to encourage people 
with HIV to engage more with their medical practitioners 
about treatment developments and to link them to 
relevant clinical trials information regardless of their 
geographic location. 
People with HIV need to be better informed about HIV 
and general health needs, but importantly they need to 
work in partnership with their health providers to produce 
clear, comprehensive and up to date plans for living well 
with HIV. 
The Treataware clinical trials website incorporates the first 
searchable public register of Australian HIV clinical trials, 
providing clinical, technical and medical information 
in a user-friendly format. This database is acting as a 
centralised source of information for both people living 
with HIV and their clinical care providers. 
Adrian Ogier did a lot of different things for a lot of 
different community organisations before achieving his 
most long-winded tour de force coordinating ASHM’s 
prescriber program and short courses in HIV medicine. He 
now works for the National Association of People Living 
with HIV/AIDS in the Health, Treatments and Research 
Unit.
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TAILORING	GLOBAL	RESPONSES	TO	LOCAL	
EPIDEMICS
David Wilson
Curtin University Of Technology And Lead Health 
Specialist, The World Bank                           
The presentation will talk about tailoring global evidence 
and interventions to an understanding of local HIV 
transmission dynamics to ensure global approaches 
tackle the sources of new infections in each local context 
and the role of surveillance, research and good analysis in 
bridging the gap between global policy and local action.
ExPLORING	THE	LINKS	BETWEEN	HIV	AND	
POVERTY:	ARE	THE	ANALYSES	CORRECT
Worth H
National Centre In HIV Social Research
In the developing world, HIV has been constantly 
associated with poverty.  Poor people are said to have 
the greatest vulnerability to HIV and that the economic 
impact epidemic will itself cause poverty to deepen 
and indeed to engender state instability in places with 
the highest prevalence.  yet, is this strictly true, or is the 
picture much more complicated?  
In this paper, using a number of case studies, I will argue 
that it is not poverty per se that is the important association 
with the spread of HIV; rather, it is the incorporation of 
developing countries into the global world that creates 
conditions where the virus rapidly spreads.   
International: Global HIV initiatives vs 
local response
11.00am – 12.30pm
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CAPACITY	BUILDING	THROUGH	LONG-TERM	
PARTNERSHIPS
Bebbington M; Carman M
The HIV Consortium for Capacity Building in Asia and 
the Pacific is a collaboration of nine Australian HIV 
organisations formed to implement the AusAID funded 
Regional Capacity Building Program 2008-2011
The purpose of the Regional Capacity Building Program 
is to foster strategic partnerships and linkages between 
Australia and the Asia-Pacific region that will enable 
sustained performance improvement for individuals 
and organisations working in the HIV/AIDS health care, 
research and community responses.
The Program aims to support a strategic, coordinated and 
complementary use of the expertise and experience of 
organisations which have played important roles in the 
Australian response to HIV.
The Program seeks to build durable and long-standing 
relationships between partners, which can change and 
adjust as capacity develops. Sustainability is supported 
because capacity building takes place in the context of 
broader organisational development. 
This presentation will provide an overview of the HIV 
Consortium’s work plan and outline the HIV Consortium’s 
approach to capacity building and partnerships.
BUILDING	CLINICAL	CAPACITY	TO	MANAGE	
HUMAN	IMMUNODEFICIENCY	VIRUS	(HIV)	
INFECTION	IN	RESOURCE	CONSTRAINED	
ENVIRONMENTS:	REFLECTIONS	FROM	
ExPERIENCE	WITH	CLINICAL	MENTORING	IN	
PAPUA	NEW	GUINEA	(PNG)
Menon A1, Ankus J1, Reis E 1
Australasian Society for HIV Medicine (ASHM)
Since the announcement of the 3x5 initiative there 
has been a scaling up of access to treatments for HIV 
positive people in developing countries. Measures such 
as development of appropriate policies, infrastructure, 
reorientation and reorganization of the STI/HIV program, 
recruitment of staff, and increased funding are necessary 
prerequisites to this effort. Minimum standards, Standard 
Operating Guidelines, training programs and materials 
are widely available to enable clinical teams to deliver the 
continuum of care for HIV positive people.
A key element to this effort is the role of clinical mentoring 
in building clinical capacity within health services. This 
presentation will reflect on successes, constraints and the 
importance of ongoing support of services providing HIV 
treatment and care, based on experience from PNG
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TRENDS	IN	NEWLY	ACqUIRED	HIV	
INFECTION	IN	AUSTRALIA,	1994	–	2007
McDonald A for the National BBV and STI Surveillance 
Committee
National Centre in HIV Epidemiology and Clinical Research, 
Sydney
Introduction: Recent analysis of trends in newly diagnosed 
HIV infection in Australia indicated an increasing 
population rate of HIV diagnosis in Queensland, South 
Australia, Victoria and Western Australia and a stable 
trend in NSW in 2000 – 2006, suggesting differences in 
the extent of HIV transmission by State/Territory.  
Methods: Cases of newly diagnosed HIV infection are 
notifiable in each State/Territory health jurisdiction 
in Australia. State/Territory health authorities forward 
notifications to the National HIV Registry for national 
collation and analysis. Information sought at national HIV 
notification includes evidence of recent HIV acquisition. 
Cases with a previous negative or indeterminate test 
result or a diagnosis of primary HIV infection within 12 
months of HIV diagnosis are defined as cases of newly 
acquired HIV infection.
Results: In 1994 – 2007, 12 248 cases of newly diagnosed 
HIV infection were notified to the National HIV Registry 
including 3 120 (25.5%) with newly acquired HIV 
infection. The age standardised rate of newly acquired 
HIV infection in Australia increased steadily over time to 
1.56 per 100 000 population in 2006. The percentage 
of new HIV diagnoses with evidence of newly acquired 
infection increased significantly from 21.7% in 1994 
– 2000 to 29% in 2001 – 2007 (p<0.0001). Compared with 
the percentage of diagnoses with newly acquired HIV 
infection in 1994 – 2000, significant increases occurred 
in 2001 – 2007 in NSW (p<0.0001), QLD (p<0.0001), VIC 
(p=0.018) and WA (p=0.044). Median age at diagnosis 
of newly acquired HIV infection increased significantly 
among males and females from 34 and 29 years in 1994 
– 2000 to 37 and 31 years, respectively, in 2001 – 2007. 
Among homosexually active men, the percentage of new 
HIV diagnoses with newly acquired infection increased 
significantly from 26.8% in 1994 – 2000 to 37.1% in 2001 
– 2007 (p<0.0001). Significant increases in the percentage 
of diagnoses with newly acquired infection also occurred 
among both males and females whose exposure was 
attributed to heterosexual contact and among males 
with an undetermined exposure.
Discussion: The increasing population rate of diagnoses 
of newly acquired HIV infection suggests increasing HIV 
transmission in Australia, primarily among males with a 
history of homosexual contact.
INCREASING	HIV	TRANSMISSION	THROUGH	
MALE	HOMOSExUAL	AND	HETEROSExUAL	
CONTACT	IN	AUSTRALIA:	RESULTS	FROM	AN	
ExTENDED	BACK-PROJECTION	APPROACH
Handan Wand1, Ping yan2, David Wilson1, Ann McDonald1, 
Melanie Middleton1, John Kaldor1 and Matthew Law1
1National Centre in HIV Epidemiology and Clinical 
Research, UNSW, Sydney, Australia; 2Center for Infectious 
Disease Prevention and Control Population and Public 
Health Branch, Canada    
To reconstruct the HIV epidemic in Australia for selected 
populations categorized by route of exposure, including 
male homosexual transmission, transmission from 
injecting drug use (IDU), and heterosexual transmission for 
men and women in Australia. A modified statistical back-
projection modelling technique was used to estimate 
the expected historical HIV incidence. The method links 
three sources of data from a surveillance system, namely, 
(1) newly diagnosed HIV infection, (2) newly acquired HIV 
infection and (3) AIDS diagnoses. We also ascertained 
sensitivity to changes in various parameter assumptions. 
These analyses estimated that to the end of 2006 a total 
of 19,690, 1050 and 2610 people have been infected with 
HIV through male homosexual contact (MHC), injecting 
drug use (IDU) and heterosexual contact (HC) respectively. 
Of those infected, 13%, 12% and 23% were estimated to 
have not been diagnosed with their HIV infection. HIV 
infections through IDU were estimated to be declining. 
Sensitivity analyses demonstrated that the model was 
robust to major parameter uncertainties. Our analyses 
suggest that sexual transmission of HIV is increasing in 
Australia. The estimated increase in HIV through HC was 
also accompanied with a high estimated proportion 
undiagnosed with their infection. These analyses suggest 
that sexual transmission of HIV, and in particular HC, 
should be the focus of renewed HIV prevention efforts. 
The proportion of new infections attributable to injecting 
drug use decreased since 2002; in contrast, the proportion 
attributable to heterosexual exposure has increased 
slightly. Thus this data provide useful information for 
planning future prevention activities and health structures, 
taking into account the increasing impact of the epidemic 
for selected populations by exposure categories.
Margaret Macdonald Memorial Session 
– Epidemiology Population
11.00am – 12.30pm
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HOW	IS	THE	ABORIGINAL	AND	TORRES	
STRAIT	ISLANDER	POPULATION	FAIRING	
IN	THE	AUSTRALIAN	HIV	EPIDEMIC?-AN	
ANALYSIS	OF	DATA	FROM	1993-2007
Ward J, McDonald A, Middleton M, Kaldor J
National Centre in HIV Epidemiology and Clinical Research, 
University of New South Wales, Sydney Australia 
For many Aboriginal and Torres Strait Islander communities 
in Australia there are higher risks for acquiring HIV 
infection than in the non-Indigenous population due to 
substantially higher rates of bacterial sexually transmissible 
infections (STI). Furthermore, Aboriginal and Torres Strait 
Islander people have poorer access to health services 
compared with non Indigenous people.  
Nationally, information on Aboriginal and TSI status at 
HIV/AIDS diagnosis was sought prospectively from 1995. 
The pattern of newly diagnosed HIV infection in Australia 
is described over the years 1993 – 1999 and 2000 - 2006, 
by Aboriginal and/or TSI status. 
In the Aboriginal and Torres Strait Islander population, 133 
(28% female) and 138 (30% female) cases of HIV infection 
were newly diagnosed in Australia in 1993 – 1999 and in 
2000 – 2006, respectively, whereas 4,737 (8.5% female) 
and 5,457 (10.9% female) were newly diagnosed in 
the non-Indigenous population in each time period, 
respectively.  The declining trend in the age standardised 
rate of newly diagnosed HIV infection in 1993 – 1999 and 
the increasing trend in 2000 – 2006 was similar in the 
Aboriginal and TSI population and the non-Indigenous 
population.  In the years 1993 – 1999 and 2000 – 2006, 
median age at HIV diagnosis increased significantly in 
both populations, from 29 to 33 years among   Aboriginal 
and Torres Strait Islander cases (p=0.004) and from 33 to 
36 years among non-Indigenous cases (p<0.001). Among 
the Aboriginal and Torres Strait Islander cases, exposure to 
HIV was attributed to male homosexual contact, injecting 
drug use, heterosexual contact or mother-to-child 
transmission in 51.9%, 6%, 35.3% and less than 2% of cases 
in 1993 – 1999 and to 44.9%, 19.6%, 32.6% and less than 
1% in 2000 – 2006. In the non-Indigenous population, HIV 
exposure was attributed to male homosexual contact, 
injecting drug use, heterosexual contact and mother-to-
child transmission in 72.5%, 3.3%, 15.3%, and less than 1% 
in 1993 – 1999 and to 71.1%, 3.2%, 19.9% and less than 
1% in 2000 – 2006.  
Although the population rate of HIV/AIDS diagnosis by 
Aboriginal and Torres Strait Islander status were similar the 
risk of HIV transmission in both populations needs to be 
minimized through diagnosis and treatment of bacterial 
STI and adoption of safer sexual and injecting behaviour. 
THE	IMPACT	OF	MIGRATION	ON	THE	
BURDEN	OF	HIV	INFECTION	IN	VICTORIA,	
AUSTRALIA
Horyniak D1, Stoové M1, yohannes K1, Breschkin A², 
Tomnay J³, Carter T³, Hatch B³, Guy R1
1Centre for Epidemiology and Population Health 
Research, Burnet Institute, Melbourne, VIC, Australia. 
²Victorian Infectious Diseases Reference Laboratory, 
North Melbourne, VIC, Australia. ³Department of Human 
Services, Melbourne, VIC, Australia.
Accurate estimates of the number of people diagnosed 
and living with HIV infection provide the basis for planning 
of services. Case reporting of new diagnoses provides 
an incomplete basis for planning, because it does not 
account for migration into and out of a jurisdiction. 
The Victorian passive surveillance system records HIV 
diagnoses in Victoria, and distinguishes between new 
Victorian diagnoses and cases previously diagnosed 
interstate or overseas. Demographic and behavioural 
characteristics are recorded for each case. In order to gain 
an understanding of the impact of population movement 
on the burden of HIV infection in Victoria, we compared 
the characteristics of people first diagnosed with HIV in 
Victoria with those previously diagnosed elsewhere.
Between 1994 and 2007 there were 3,111 HIV notifications 
in Victoria, including 212 cases (6.8%) previously diagnosed 
positive interstate and 124 (4.0%) diagnosed overseas. The 
proportion of cases diagnosed outside Victoria increased 
from 6.4% between 1994 and 2000 to 13.8% between 
2001 and 2007. Most of the previous interstate diagnoses 
were made in NSW (58.5%). Male-to-male sexual contact 
was the most commonly reported HIV exposure (77%) 
among interstate cases, compared to 72% among new 
Victorian diagnoses. The majority of previous diagnoses 
overseas were made in Asia (25%) and New Zealand 
(24%). Heterosexual exposure accounted for 38% of 
cases previously diagnosed overseas, compared to 18% 
of new Victorian diagnoses. Twenty percent of individuals 
diagnosed overseas were born in Asia and 16% in sub-
Saharan Africa, compared to 5% and 9% respectively for 
new Victorian diagnoses.
Around 10% of HIV infections reported in Victoria 
have been previously diagnosed elsewhere. Interstate 
migrants displayed similar characteristics to those 
diagnosed locally, however international migrants 
differed substantially. Changes in the proportion of cases 
diagnosed outside Victoria may reflect trends in testing, 
as well as modifications to the systems used to detect 
previously diagnosed cases. There is currently no way to 
record outward migration of people with HIV infection 
from Victoria. Service planning needs to take account of 
the differing characteristics of people moving to Victoria 
with previously diagnosed HIV, compared to those already 
resident at the time of their initial diagnosis.
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UNExPECTEDLY	HIGH	HIV	PREVALENCE	
AMONG	THAI	SEx	WORKERS	IN	A	
RESPONDENT-DRIVEN	SAMPLING	SURVEY
Manopaiboon C1, Whitehead SJ1, Subhachaturas W2, 
Tanpradech S1, Siangphoe U1, Johnston L3; Thepamnuay 
S1, Anand A4; Sumanapun S5; Fox K1,4
1Thailand MOPH – U.S. CDC Collaboration, Nonthaburi, 
Thailand; 2Bangkok Metropolitan Administration, 
Bangkok, Thailand; 3Tulane University School of Public 
Health and Tropical Medicine, New Orleans, USA; 4Centers 
for Disease Control and Prevention, Atlanta, USA; 5Chiang 
Rai Provincial Health Office, Chiang Rai, Thailand.
Commercial sex has been a major driver of the HIV 
epidemic in Thailand. Recent evidence suggests that the 
highly successful HIV prevention programs of the past 
decade may now be eroding.  The structure of sex work 
has changed substantially, with fewer brothel-based sex 
workers (SW) and more non-venue-based SW who are 
excluded from the annual sentinel surveillance system. We 
conducted a respondent-driven sampling (RDS) survey of 
HIV prevalence and risk behaviors among female SW in 
Bangkok and Chiang Rai.
Initial participants were selected by staff, then recruited 
peers according to RDS methods. Consenting participants 
completed a demographic and behavioral questionnaire 
by handheld computer and provided oral fluid specimens 
for HIV antibody testing (Oral Fluid Vironostika™ HIV-1 
Microelisa, BioMeriux, Durham, NC) and urine specimens 
for Chlamydia trachomatis and Neisseria gonorrhoeae by 
polymerase chain reaction (Amplicor, Roche Molecular 
Systems, Branchburg, NJ). Data were analyzed using 
RDS Analysis Tool (RDSAT) software which adjusts for the 
network properties of respondents. RDSAT-weighted data 
were exported to SAS for multivariate analysis.
A total of 707 women were recruited in Bangkok and 
366 in Chiang Rai. A total of 73% of Bangkok participants 
were non-venue-based compared to 24% in Chiang Rai. 
The RDSAT-adjusted rate of condom use with last client 
was higher in Bangkok (93%; 95% confidence interval (CI): 
90%-95%) than Chiang Rai (69%; 95% CI: 61%-76%); HIV 
prevalence was also higher in Bangkok (20%; 95% CI 16%-
25%) than in Chiang Rai (10%; 95% CI 6%-13%). In a logistic 
regression model for Bangkok participants, HIV infection 
was associated with age>25 (adjusted odds ratio (AOR) 
4.5; 95% CI: 1.3-16.5), price<700 baht (~USD23) (AOR 
3.3; 95% CI: 1.4-8.0), and concurrent sexually transmitted 
infection (AOR 4.5; 95% CI: 1.5-13.0); older age and lower 
price were highly correlated with street-based SW. No 
examined factors were statistically significantly associated 
with HIV infection in Chiang Rai. 
HIV prevalences in this survey were significantly higher 
than 2007 sentinel surveillance findings among SW 
(Bangkok, 2.5%; Chiang Rai, 2.6%). Our findings suggest 
that important high risk groups, especially street-based 
SW in Bangkok, are in urgent need of prevention efforts 
and should be included in routine surveillance. 
THE	MOLECULAR	CHARACTERIzATION	OF	
THE	HIV-1	EPIDEMIC	IN	FIJI
Ryan CE1,2, Kama M3, Darcy A3, Aleksic E1, Mirza T4, 
Chaudhary A5, Rogers G6, Crowe SM1,2 
1Burnet Institute, Melbourne, Australia; 2Dept of Medicine, 
Monash University, Melbourne, Australia; 3Fiji Centre 
for Communicable Disease Control, Suva, Fiji; 4Suva STI 
Clini, Suva, Fiji; 5Lautoka STI Clnic, Lautoka, Fiji; 6Griffith 
University, Brisbane, Australia
The HIV epidemic in Fiji remains largely uncharacterized. 
By the end of 2006, UNAIDS estimates that there were 
219 reported infections, a figure which is thought to be 
a gross under-representation. The majority of infections 
occur among the 20-39 year age group and are reported 
to result from heterosexual contact. There is currently no 
published data concerning the HIV subtype in the Pacific 
Islands, with the exception of Papua New Guinea, which 
has been shown to have a predominantly subtype C 
driven epidemic. 
In 2008, consenting HIV-1 positive individuals are being 
recruited through the hub doctors in Fiji and asked to 
complete a basic demographic and behavioural survey. 
Following this, 50µl of venous blood is spotted onto 
Whatman FTA Elute filter paper and stored at room 
temperature for 1-6 months before transport to the Burnet 
Institute. DNA is extracted using a low cost extraction 
procedure before undergoing a nested PCR designed 
to amplify the HIV-1 envelope region. Additionally, 
the reverse transcriptase and protease regions will be 
amplified using an in-house, low-cost genotyping assay 
to gain information on circulating drug resistance.  All 
resulting sequences undergo phylogenetic analysis with 
published reference sequences to assign a subtype, and 
to assess their relatedness to each other, and to other 
epidemics in the region.
To date, 9 samples have been processed, with 8 yielding 
a PCR product and good envelope sequence. Of the 8 
samples, 4 (50%) are subtype C, 3 (37.5%) are subtype B, 
and 1 (12.5%) subtype A. An additional 20 samples have 
been collected in Fiji and are awaiting transport to the 
Burnet Institute. This data, along with the genotype and 
demographic data will be presented.
This survey offers the first molecular information 
concerning the apparent diverse HIV epidemic in Fiji and 
provides valuable data regarding the movement and 
transmission of HIV-1 in the Pacific Islands. Continued 
surveillance of HIV subtypes throughout the world is 
recommended in order to gain a deeper understanding 
about the diversity of HIV and the impact this has on 
vaccine development and antiretroviral therapy.
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The Annual Consensus Conference is this year 
incorporated into the clinical stream of the main 
ASHM 08 Conference program. Previously, the Annual 
Consensus Conference has been held on the Saturday 
afternoon immediately following the close of the ASHM 
Conference. Feedback from previous years has suggested 
that attendance and participation would be maximised 
if the Australian Antiretroviral Guideline sessions were 
moved into the ASHM program.
This year, the Australian Antiretroviral Guidelines sessions 
will be held on the Thursday 18 and Friday 19 afternoons of 
the ASHM 08 program. These sessions include evidence-
based presentations from international and local experts 
on the latest research and developments in HIV treatment 
and provide the opportunity for discussion. 
Dr Roy Gulick is a member of the US Department of 
Health and Human Services (DHSS) Panel on Antiretroviral 
Guidelines for Adults and Adolescents and will represent 
DHHS at these sessions. The DHSS Guidelines for the 
Use of Antiretroviral Agents HIV-1 Infected Adults and 
Adolescents have been endorsed by Australia and 
form the basis on which the Australian commentary 
is developed. The Australian commentary to the latest 
Guidelines for the Use of Antiretroviral Agents in HIV-1 
Infected Adults and Adolescents is available at: http://
www.ashm.org.au/aust-guidelines/.
Australian Antiretroviral Guidelines: 
Consensus Conference
1.30pm – 3.00pm
NEWER	AGENTS	FOR	TREATMENT-
ExPERIENCED	PATIENTS
Gulick R, MD, MPH
Weill-Cornell Medical College
New york
Recent developments lead to improved management of 
antiretroviral therapy for treatment-experienced patients. 
Newer approved drugs with novel resistance profiles 
(the NNRTI etravirine, the protease inhibitors darunavir 
and tipranavir) or new mechanisms of action (the 
CCR5 antagonist maraviroc and the integrase inhibitor 
raltegravir) offer significant virologic activity even in 
patients with extensive treatment experience and drug 
resistance.  Recognizing these developments, current 
treatment guidelines state that the goal of antiretroviral 
therapy for ALL patients is suppression of HIV RNA to <50 
copies/ml and that the optimal way to do that is to design 
a regimen with 2 (or preferably 3) fully active drugs.
Etravirine, a new NNRTI, demonstrated activity against 
many viral strains with resistance to efavirenz and 
nevirapine and was safe and well-tolerated when used 
with an optimized antiretroviral regimen containing 
darunavir in the phase III DUET studies of treatment-
experienced patients.  Subanalyses revealed that the 
virologic activity of etravirine was impacted only by 
the presence of 3 or more NNRTI-associated mutations 
(excluding K103N).  Additional investigational NNRTIs with 
activity against drug-resistant virus are in development. 
The newer HIV protease inhibitors darunavir and tipranavir 
demonstrated activity against PI-resistant viral strains in 
the POWER and RESIST phase III studies, respectively, and 
are not necessarily cross-resistant to one another.  Safety 
and tolerability considerations, particularly hepatic, favor 
darunavir over tipranavir.  Additionally, because of drug-
drug interactions, tipranavir cannot be co-administered 
with etravirine.
Drugs with new mechanisms of action demonstrate 
virologic activity, even against multi-drug resistant strains. 
Maraviroc, the first approved CCR5 antagonist, blocks HIV 
entry by R5 virus and demonstrated significant virologic 
activity and was well-tolerated in treatment-experienced 
patients with R5 virus (determined with a tropism assay) 
in the phase III MOTIVATE studies.  An investigational CCR5 
antagonist, vicriviroc, currently is under evaluation in phase 
III trials.  Additional investigational chemokine receptor 
inhibitors also are in development.  Raltegravir, the first 
approved HIV integrase inhibitor, inhibits strand transfer of 
viral DNA to host cell DNA and demonstrated significant 
virologic activity and was well-tolerated in treatment-
experienced patients in the phase III BENCHMRK studies. 
Phase III studies of an investigational integrase inhibitor, 
elvitegravir, recently opened.  Additional new agents with 
novel mechanisms of action also are in development, 
including CD4 attachment inhibitors and maturation 
inhibitors. TH
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CASE	PRESENTATIONS
1. Tim Read, sexual health physician at Melbourne Sexual 
Health Centre and Victorian infectious Diseases Service 
(Royal Melbourne Hospital).
 
Managing suspected early virologic failure.
 
A patient with cerebral toxoplasmosis had a viral load 
decrease of only 0.6 log, four weeks after commencing 
tenofovir, emtricitabine and nevirapine. Seeing this 
result at week six, should we have immediately switched 
treatment OR continued this treatment until seeing 
results of a genotypic resistance assay?
 
2. Catriona Ooi, Director of Sexual Health, Hunter New 
England Area Health
 
Juggling antiretroviral therapy and cardiovascular risk.
 
Should a smoker with impaired glucose tolerance, high 
triglycerides and impaired renal function continue to be 
treated with abacavir, lamivudine and efavirenz?
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INCREASING	THE	CONTRIBUTION	OF	
SOCIAL	RESEARCH	TO	HIV	PREVENTION:	
DEVELOPING	AND	TESTING	A	THEORY-
DRIVEN	INTERVENTION	TO	REDUCE	
UNPREMEDITATED	RISK-TAKING	IN	MSM
De Wit, JBF1,2, Adam, PCG1,3
1National Centre in HIV Social Research, University of New 
South Wales, Sydney, NSW, Australia; 2Department of Social 
Psychology, Utrecht University, Utrecht, The Netherlands; 
3 Institute for Prevention and Social Research, Utrecht, The 
Netherlands 
For more than a decade studies conclude that sexual 
risk-taking among MSM is increasing or remains high. 
But what are effective approaches to HIV-prevention in 
this era of HAART? This paper addresses this question 
by drawing on a program of social research concerned 
with the translation of theory-based understanding of 
individual and social processes underlying risky practises 
into effective HIV-prevention. A range of explanations has 
been offerred for increasing trends in risk behavior, STI 
rates and HIV notifications in MSM worldwide, collectively 
emphasizing reduced motivation. However, as expected 
from recent social theorising of behaviour, studies we 
conducted in 5400 French and Dutch MSM showed 
that risk-taking with casual partners, mostly occurs in 
highly motivated men and is mainly unpremeditated. 
As unpremeditated risk-taking is largely unaddressed 
in current HIV-prevention, in collaboration with a major 
French NGO a novel theory-driven online intervention 
was developed and tested. 
In an RCT 331 MSM who engaged in sex with casual 
partners and experienced difficulties in practising 
safer sex were randomly assigned to either a reference 
group not receiving any prevention advice, or one of 
two intervention groups receiving advice to promote 
their vigilance and control over situations related to 
unpremeditated risk-taking (e.g., when strongly aroused). 
Intervention format was either an e-card or a 3 min. 
interactive e-animation. The e-animation had a strong 
impact at immediate post-test and 6 months follow-up, 
while the e-card was generally not effective. In particular, 
the e-animation increased men’s intention to exert 
vigilance and control to prevent unpremeditated risk-
taking at post-test (p<.05), increased effective vigilance 
and control behaviors at follow-up (p=.001), and reduced 
willingness to engage in risk-taking at post-test (p<.01) 
and follow-up (p=.000). Most importantly, 6 months after 
the intervention the e-animation had reduced UAIC by 
23% (adj.OR=.770, p=.001).
The present study illustrates that theory-based 
translational social research holds substantial promise 
for the strengthening of behavioural prevention of HIV, 
in particular when conducted in close collaboration 
between researchers and prevention experts. More 
specifically this study shows that non-premeditated, 
contextual processes that underly risk-taking in MSM 
can effectively be adressed in interventions based 
on innovative theorizing and using state-of-the-art 
intervention delivery. 
Social Research – Desire
1.30pm – 3.00pm
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SEx	PIGS:	A	ROUGH	GUIDE	TO	DIRTY	SEx
Triffitt, K A 
Positive Life NSW, Sydney, Australia
Australian research has identified gay men who practice 
adventurous sex as a priority group for HIV/STI prevention. 
Sexually confident HIV positive gay men are highly 
represented in this subculture. Specifically, the challenge 
was to develop a prevention campaign that adapted 
to participant’s sexual limits and included the way new 
understandings of risk, safety and health are incorporated 
in HIV positive gay men’s sexual lives. 
Drawing on a review of SEx PIGS: DARK AND DIRTy SEx 
AND MANAGING yOUR HEALTH produced by Positive Life 
NSW, this paper will examine campaign development 
and implementation, and incorporate the ways sexually 
adventurous gay men ‘care for self’ and their partners. 
By producing a more sophisticated understanding 
on prevention, adventurous sex is positioned as a 
‘productive’ concept. It highlights values and models of 
behaviour, and harm minimisation applied to condom 
and drug use. While condom use with casual partners of 
unknown HIV status is a key message, the campaign also 
acknowledges gay men continue to redefine the limits of 
risk and safety. 
HIV/STI prevention is not only a behavioural intervention, 
but is also a cultural practice, which engages and 
reproduces community ethics and values. This work 
creates opportunities for sexually adventurous gay men 
to speak through their culture and helps to define the 
sexual and subjective spaces they share. 
GAY	MEN	WHO	ENGAGE	IN	GROUP	SEx	ARE	
AT	INCREASED	RISK	OF	HIV	INFECTION	AND	
ONWARD	TRANSMISSION:	DATA	FROM	THE	
THREE	OR	MORE	STUDY
Prestage G1,2, Hudson J3, Bradley J1, Corrigan N4, Down I4, 
Grulich A1, McInnes D5
1National Centre in HIV Epidemiology & Clinical Research, 
UNSW; 2Australian Research Centre in Sex Health and 
Society, La Trobe University; 3Faculty of Medicine, 
University of Sydney; 4AIDS Council of NSW; 5School of 
Communications, University of Western Sydney.
Background: Group sex has been associated with risk 
behaviour and HIV seroconversion among gay men. We 
examined risk factors for risk behaviour in a community-
based study of homosexually active men who participated 
in group sex activity in Australia.
Methods: The Three or More Study (TOMS) was an 
anonymous self-complete survey of men who had 
engaged in group sex with other men within the previous 
five years. Detailed information about sexual, drug-using 
and other behaviour during their most recent group sex 
encounter was collected. Men who reported group sex in 
the previous six months were included in these analyses.
Results: In broader surveys of Australian gay men, about 
one quarter had engaged in unprotected anal intercourse 
(UAI) with non regular partners in the previous six months, 
whereas among the 746 TOMS participants, 29.4% 
reported UAI with non regular partners at their most recent 
group sex encounter, and 22.4% reported UAI with any 
partners they did not know to be the same HIV serostatus 
as themselves. After controlling for age, education, and 
location, not having a clear intention to use condoms, 
being HIV-positive or HIV status unknown, having more 
men at the group sex encounter, and engaging in group 
sex at least monthly were independently associated with 
UAI.
Conclusion: Gay men who engage in group sex, and 
particularly those who do so regularly and with more 
partners, are much more likely to engage in risk behaviour 
in general than are other gay men, and this risk behaviour 
often occurs in the context of group sex encounters. 
Group sex among gay men should be a high priority in 
HIV-prevention efforts in this population.
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WALKING	AFTER	MIDNIGHT:	TRAJECTORIES	
OF	SEx	ON	PREMISES	VISITS
Grierson J1, Smith A1, Von Doussa H1
1La Trobe University, Australian Research Centre in Sex, 
Health and Society, Melbourne, Australia
Background: Sex on premises venues (SOPV) are a primary 
site for health promotion interventions. Understanding 
the sexual practice of SOPV patrons requires an 
understanding of the ways in which the physical and 
social environments shape, constrain or co-vary with this 
practice.
Methods: Detailed interviews with SOPV patrons capture 
in rich narrative detail the exact nature, duration and 
sequencing of the sexual interactions that occurred 
during the men’s most recent visit to an SOPV. The data 
allow us to describe trajectories of engagement with 
sexual possibilities during visit to an SOPV.
Results: 219 men completed telephone interviews 
within 48 hours of their visit. Interviews detailed the 
pattern of visits to SOPVs using time sequences that 
plotted their venue trajectory. Each sexual episode 
was further detailed in terms of partner characteristics, 
sexual practices and sequencing. 82% of men were 
HIV-negative. 68% of the men described themselves as 
single and 27% had a regular male partner. Most visits 
lasted between one and four hours. The most clearly 
sex-related sites (cruising areas, cubicles and wet areas) 
account for 70% of men’s time. 74% of men’s time does 
not involve a sexual interaction. Sexual encounters lasted 
an average of 26 minutes. Over half of the encounters 
took place in cubicles. Cubicles accounted for 83.9% of 
encounters involving anal intercourse, both protected 
and unprotected. The partner’s age was more likely to be 
undetermined in cruising areas than in other sites such as 
cubicles. Partners’ ages were assessed as somewhat older 
in cruising areas and wet areas compared to cubicles. 
Partner’s HIV status was unrelated to site.
Conclusions: Detailed examination of trajectories of sexual 
practice in SOPVs provides useful contextual direction 
for effective targeting and delivery of health promotion 
interventions. Understanding SOPVs as a complex and 
dynamic social space will enhance outreach efficacy.
SExUAL	DESIRES,	SExUAL	CONTROL	AND	
SExUAL	RISK-TAKING	IN	MEN	WHO	HAVE	
SEx	WITH	MEN
Adam  PCG1,2, De Wit  JBF1,3
1National Centre in HIV Social Research, University of 
New South Wales, Sydney, NSW, Australia; 2Institute for 
Prevention and Social Research, Utrecht, The Netherlands; 
3Department of Social Psychology, Utrecht University, 
Utrecht, The Netherlands 
Sex is about more than preventing risk and a body of 
research shows that some sexual desires, reflected in 
the notion of sexual sensation seeking, are associated 
with risky practises. However, research also suggests that 
individuals can be effective self-regulators who do not 
indiscriminately enact what is considered a personal sexual 
disposition. Based in emergent theorising concerning the 
self-regulation of health behaviors, the aim of this study is 
to go beyond the notion of sexual sensation seeking as 
risk factor, and assess the extent to which any influence 
of sexual sensation seeking on sexual risk-taking among 
MSM is moderated by differences in men’s perceived 
sexual control. Sexual control reflects individuals’ agency 
in sexual contexts that can potentially be promoted to 
support men in having both gratifying and safe sex lives. 
An online survey in The Netherlands recruited 1,613 
MSM; 1,299 men who had sex with casual partners were 
included in this study. Potential sexual risk-taking in the 
preceding 12 months was indexed by number of causal 
partners (1-9 vs. ≥10), unprotected anal intercourse with 
casual partners (UAI-C; no vs. yes), and self-reported 
sexually transmitted infections (no vs. yes). 
Sexual risk-taking with casual partners was highly 
prevalent in this online sample of MSM; 48.5% had had 10 
or more causal sex partners, 39.8% had engaged in UAI-C, 
and 19.2% reported having had a STD. Multivariate logistic 
regression analyses showed that sexual sensation seeking 
was significantly related to more risk-taking according to 
each outcome variables, while all effects of sexual self 
control were significantly protective. As expected, sexual 
self control moderated the effects of sexual sensation 
seeking on behavioral indicators. 
This study is the first to show that, although MSM who 
are higher in sexual sensation seeking are more likely to 
engage in sexual risk-taking, some men can effectively 
self-regulate this sexual disposition. While men high in 
sexual self control may spontaneously control their sexual 
desires, men low in sexual self control may benefit from 
a new generation of prevention methods that, inspired 
by a self-regulation approach, promote planning ahead 
of time.
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MEDICINE,	RISK	FACTOR,	PLEASURE	
ENHANCER	OR	SAFE	SEx	AID?	
THE	USE	OF	VIAGRA	AND	OTHER	
SExUOPHARMACEUTICALS	BY	GAY	MEN
Holt M1, Bernard D1 and Race K2 
1National Centre in HIV Social Research, The University of 
New South Wales; 2The University of Sydney
This paper aims to i) analyse the representations of Viagra 
and other drugs designed to treat erectile dysfunction 
(‘sexuopharmaceuticals’) in the HIV research literature and 
the accounts of gay men, and ii) identify the implications 
of sexuopharmaceutical use for HIV prevention and harm 
reduction among gay men. 
31 gay men were interviewed in Sydney about 
contemporary gay life for the Qualitative Interviews 
Concerning Key Issues and Experiences (QUICKIE) project. 
A discursive analysis of accounts of sexuopharmaceutical 
use is presented here. The HIV research/public health 
literature is also drawn upon to illustrate how Viagra is 
considered a risk factor for HIV transmission.  
Although not all participants had used 
sexuopharmaceuticals, their accounts suggested 
that Viagra and similar drugs are seen as aids to safe 
sex by some gay men; drugs that can offset erectile 
difficulties when using condoms, particularly in 
the context of alcohol or other drug use. Negative 
accounts of sexuopharmaceutical use were rare among 
participants. We suggest that the following contribute 
to a perception among gay men that Viagra and similar 
drugs are benevolent and pose few risks: i) the status of 
sexuopharmaceuticals as beneficial medicines and sexual 
enhancers, ii) gendered expectations that men should be 
able to perform sexually on demand, and iii) the trend 
that encourages biomedical or pharmaceutical fixes to 
behavioural problems.  
Negative outcomes associated with sexuopharmaceutical 
use may be overlooked by gay men, suggesting a need 
for harm reduction information. The idea that problems 
with condom use and safe sex can be solved through 
pharmaceutical intervention requires ongoing and critical 
attention. 
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HETEROGENEITY	IN	PRIMARY	R5	HIV-1	
GP120	STRUCTURES	AFFECTING	CD4	AND	
CCR5	INTERACTIONS	AND	ExPOSURE	OF	
NEUTRALISING	ANTIBODY	EPITOPES.
Paul R. Gorry.
Centre for Virology, Macfarlane Burnet Institute for 
Medical Research and Public Health, Melbourne, Victoria, 
Australia.
CCR5-restricted (R5) HIV-1 variants cause 
immunodeficiency in the majority of HIV-1+ subjects 
who progress to AIDS, but the pathogenic mechanisms 
of R5 HIV-1 are poorly understood. The CD4-bound 
JRFL crystal structure of gp120 containing the V3 loop 
and the b12-bound gp120 crystal structure were used 
as templates to generate 3D models of 17 R5 gp120 
proteins isolated patients with chronic/pre-AIDS (PA-
R5 Envs) HIV-1 infection or AIDS (A-R5 Envs). Structural 
features were correlated to Env functional/genetic data 
including fusogenicity, CD4 binding, CD4-dependence, 
antibody binding and amino acid variations. A more 
open conformation of the CD4 binding site associated 
with movement of the V5 variable loop was present in 
the majority of A-R5 Envs and correlated with reduced 
CD4-dependence, increased CD4 binding and enhanced 
fusogenicity. In addition, the V3 loop of A-R5 Envs was 
more likely to exist in a conformation that brings the 
tip of the V3 loop closer to the co-receptor binding site, 
a conformation associated with enhanced binding of 
the anti-co-receptor binding site antibody 17b, altered 
reliance of CCR5 N-terminal and ECL residues for fusion 
and entry, as well as greater binding of CD4. These 
models suggest structural heterogeneity in R5 Envs may 
affect CD4 and CCR5 interactions and contribute to HIV-
1 pathogenesis in subjects who continue to harbour R5 
viral variants to late stages of infection.
HIV Immunology
1.30pm – 3.00pm
HOW	MIGHT	UNDERSTANDING	OF	THE	CO-
EVOLUTION	OF	HLA	AND	VIRUSES	INFORM	
CONTEMPORARY	CLINICAL	ISSUES
Simon Mallal1, Tomer Hertz2, Mina John1, Silvana 
Guadieri1, Ian James1, Elizabeth Phillips1, David Nolan1 
and Nebojsa Josic2. 
1Institute for Immunology and Infectious Diseases
Royal Perth Hospital and Murdoch University, Perth, 
Australia, 2Microsoft Research, One Microsoft Way, 
Redmond, WA 98052, USA
Class I MHC molecules are under diversifying selection 
but share the preference for binding to conserved areas 
of human proteins, and most target human viruses with 
similar efficiency.  However flaviviruses, such as Hepatitis 
C, are unusual in that non-conserved areas may be 
preferentially targeted.  MHC binding can be considered 
as ‘nature’s estimator of sequence conservation/
functionality’ and MHC targetting acts a fundamental 
force shaping the adaptation of pathogens and different 
viruses have taken different strategies to escape these 
selective pressures.
Some individuals exposed to Hepatitis C clear the virus 
during acute infection while others become chronically 
infected and there is also intra-patent variability in the 
response to therapy.  This is likely to be determined by 
both variability in host alleles and the degree to which the 
infecting virus has adapted to those responses.   However, 
to predict likely clinical outcomes it is also essential 
to first understand which responses are effective and 
constraining the virus from those host responses which 
are being elicited by the virus and are non-effective or 
even harmful to the host.    
The failure of the STEP trial of the Merck developed 
Ad5-based HIV vaccine, which demonstrated that HIV 
acquisition was unexpectedly enhanced in vaccinated 
individuals despite evidence of immunogenicity has 
created new challenges in HIV vaccine research.  We 
have found evidence of characteristic HLA allele-specific 
adaptations that induce T cell responses that are not 
just ineffective or neutral but actively enhancing to 
viral infection and harmful to immune control. These 
responses may appear strong by standard measures but 
they represent the consequence rather than the cause 
of adaptation and as such, serve the interests of the virus 
rather than the host. These findings support the concept 
that the more generally ‘immunogenic’ a vaccine is to 
this highly adaptable pathogen, the greater harm the 
vaccine may do unless the enhancing viral elements 
are pre-emptively identified and excluded from the 
immunogen.
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ROLE	OF	INNATE	IMMUNITY	IN	HIV	
INFECTION
Seema N Desai Ph.D.1, Jeffrey Martinson B.A.1, 
Carlos Montoya M.D.2,and Alan L. Landay Ph.D.1
1Department of Immunology/Microbiology, Rush 
University Medical Center, Chicago, IL; 2Universidad de 
Antioquia, Medellín, Colombia
Innate immunity plays an instrumental role in 
activation and priming of adaptive immune response 
in HIV infection. HIV infection significantly impacts the 
frequency of innate cells mainly natural killer (NK) cells, 
plasmacytoid (p) and myeloid (m) dendritic cells (DCs). 
Highly active antiretroviral therapy (HAART) restores 
the frequency though functional impairment persists 
especially in pDC, the principle interferon-α producing 
cell. pDCs are activated via endosomal toll like receptors 
(TLR) 7 and 9. Our studies indicate that despite reduced 
numbers, pDCs remain responsive to TLR mediated 
activation and to AT-2 inactivated HIV-1 virus that 
induces IFN-α to a higher degree in healthy individuals 
compared to HIV infected. In vitro studies to examine 
the effects of activated innate immune responses in 
HIV infection, indicated that exogenous IFN-α induced 
program death Ligand-1 (PD-L1) on AT-2 HIV-1 activated 
monocytes and T cells which downmodulated T cell 
responses. Activation of pDC via TLR7 and 9 and AT-
2 HIV also resulted in up-regulation of the enzyme, 
indoleamine 2-3 dioxygenase (IDO), which degrades the 
essential amino acid, tryptophan, leading to decreased 
proliferation of antigen specific T cells. Blocking pDC 
activation using chloroquine, a 4-aminoquinoline 
drug that inhibits endosomal fusion and acidification 
completely abrogated TLR7, 7/8 and 9 mediated IFN-
α production and downstream metabolic signaling 
molecules IRF-7 and IRAK-4. Chloroquine impaired IDO 
and its activity. Chloroquine also downmodulated PD-
L1 expression on pDCs and CD38 on T cells. Thus IFN- α 
that exhibits antiviral effects in the acute phase of HIV 
infection has a paradoxical role in the chronic phase that 
is associated with downmodulation of T cell responses 
via PDL1-PD-1 interaction or IDO synthesis. Chloroquine 
reverses the damage by blocking pDC activation in the 
endosome and downstream molecules in the IFN-
α synthesis pathway suggesting its merit in adjuvant 
therapy with HAART.
REASSESSING	VACCINE	RESPONSES
Kelleher AD, NCHECR, UNSW and Centre For Immunology 
St Vincent’s Hospital Darlinghurst, NSW
The recent early completion of the phase IIb proof of 
concept vaccine trial, STEP, because of lack of efficacy, has 
resulted in a reappraisal of what is required for an effective 
HIV vaccine.  In particular these results have raised 
questions about the currently accepted assays used  to 
measure immunogenicity of T cell vaccines: IFN-γ ELIspot 
and ICC.  Further  these results have raised questions  as 
to  whether a T cell based vaccine can prevent or control 
HIV infection.  The increased rate of infection in those with 
higher rates of pre-existing Adenovirus  immunity  also 
highlights the need to more fully understand  immune 
responses to the backbone of  recombinant vectors  as a 
part of vaccine development.  The generation of strong 
mucosal immunity, generally accepted as a desirable 
component of a vaccine for HIV, may be problematical in 
the case of HIV vaccines.  Increasing the pool of  activated 
HIV specific CD4+ T cells in the mucosa may facilitate 
amplification of  the initially transmitted quasispeces, 
encouraging rather than blocking  productive infection.  
A brief review of the STEP trial results will be presented 
as will a review of our current understanding of the 
determinants of T cell immunity and how these impact 
on future vaccine design and development.
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CHANGES	IN	CIRCULATING	CCR5+	T-CELLS	
AND	ANTIGEN-SPECIFIC	CD4+	T-CELLS	
DURING	MONOTHERAPY	WITH	A	SMALL	
MOLECULE	CCR5	ANTAGONIST	SCH532706,	
COMPARED	WITH	COMBINATION	
ANTIRETROVIRAL	THERAPY	(CART)
Pett SL1,2, Zaunders J3, Bailey M3, Murray J1,4, Cooper DA1,2, 
MacRae K2, Emery S1, Kelleher A1,2,3
1National Centre in HIV Epidemiology and Clinical Research, 
University of NSW, Darlinghurst, Sydney, Australia; 2HIV, 
Immunology and Infectious Diseases Clinical Services 
Unit, St. Vincent’s Hospital, Sydney, Australia; 3Centre for 
Immunology, St. Vincent’s Hospital, Sydney, Australia; 
4School of Mathematics and Statistics, University of NSW, 
Sydney, Australia. 
 
We previously found that HIV- and CMV-specific CD4+ T-
cells were CCR5+. 
Therefore we investigated whether levels of these cells 
were altered in HIV-infected subjects given SCH532706 (a 
CCR5-antagonist) with low-dose ritonavir (/r).
 
Subjects received SCH532706/r for 10 days (phase 1), 
followed by a 15-day “washout” (phase 2); cART was 
initiated on day 25. CCR5+ T-cell subsets and CD4+ T-cells 
specific for Mycobacteria tuberculosis and avium (M.TB 
and MAI), cytomegalovirus (CMV), Herpes simplex (HSV) 
and HIV Gag were measured at days 1, 3, 10 (phase 1); 
20, 25 (phase 2) and 28, 35 on cART (phase 3); changes 
were analysed using the Mann-Whitney test. Changes in 
CCR5+ T-cell subsets were assessed by area-under-the-
curve comparisons. 
Ten males, with median 242 CD4+ (range 93-551) and 
783 CD8+ (range 353-1115) T-cells/µL and 4.5 log10 
copies/mL viral load (range 3.8-5.7) were enrolled. At 
baseline, a median 20% of CD4+ and 50% of CD8+ T-cells 
were CCR5+. Antigen-specific CD4+ T-cells for M.TB, MAI, 
CMV, HSV and HIV Gag were 0.45%, 5.7%, 5.0%, 2.3% and 
1.75%, respectively. Median viral load declines for phase 1 
and 3 (SCH532706/r vs. cART) were –1.5 and –1.75 log10 
copies/mL, respectively (p=0.7). 
Median changes in CD4+ T-cells for phases 1, 2, 3 were 
+16, -26, +28 cells/µL respectively (1 vs. 3: p=0.7); CD8+ 
T-cell changes were +91, -142, -71, respectively (1 vs. 
3: p=0.02). Relative to baseline cell counts, changes in 
CCR5+CD4+ T cells for phases 1, 2, 3 were +22%, -24% 
and +24%, respectively (1 vs. 2: p=0.002; 2 vs. 3: p=0.01). 
In contrast, changes for CCR5+CD8+ T-cells were +33%, 
-13% and -10%, respectively (significant for phases 1 vs. 3; 
p=0.01). Declines in M.TB-, CMV-, HSV-, and Gag-specific 
CD4+ T-cells occurred during receipt of SCH532706/r and 
cART. MAI-specific CD4+ T-cells declined significantly on 
cART vs. SCH532706/r (p=0.037). 
  
CD4+ T-cell increases were modest on SCH532706/
r and cART. However, CD8+CCR5+ T cells increased 
substantially during receipt of the CCR5-antagonist, but 
not cART, suggesting alterations in trafficking due to 
CCR5 blockade. Declines in CD4+ T-cells responsive to 
CMV, HSV and HIV Gag were equivalent during use of 
SCH523706/r and subsequent cART. 
Ian Thompson Memorial Session 
– Clinical Anti Retroviral Therapy
3.30pm – 5.00pm
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EFAVIRENz	(EFV)	PLASMA	
CONCENTRATIONS	IN	PATIENTS	STOPPING	
THERAPY	AFTER	AT	LEAST	ONE	MONTH	DUE	
TO	NEUROPSYCHIATRIC	DISTURBANCES:	AN	
INITIO	SUBSTUDY
Read TRH1,2, Mallon P3, Mijch A4, Goodall R5, 
Hudson F5, Wand H6, Carey D6, Emery S6, on behalf of the 
INITIO Coordinating Committee
1Melbourne Sexual Health Centre, Victoria, Australia; 
2Victorian Infectious Diseases Service, Victoria, Australia; 
3Mater Misericordiae, University Hospital Dublin, Ireland; 
4Monash University, Melbourne, Australia; 5Clinical Trials 
Unit, Medical Research Council, London, UK; 6NCHECR/
UNSW, Sydney, NSW, Australia
Neuropsychiatric symptoms, including dreams, dizziness, 
insomnia, somnolence and mood changes can limit EFV 
use. Symptoms usually resolve within several weeks, 
but can persist in some patients necessitating EFV 
cessation. Central nervous system disturbances have 
been associated with elevated EFV concentrations. We 
examined EFV plasma concentrations in a retrospective 
nested case control study of HIV+ adults participating 
in INITIO, a large, international trial of initial antiretroviral 
therapy.
Cases (n=35) were participants who ceased EFV after >4 
weeks therapy due to neuropsychiatric disturbances. 
Controls (n=75), matched for gender, country and time 
since randomisation; continued EFV for >6 months. 
Validated HPLC methods quantitated EFV concentrations 
in plasma collected (at or prior to EFV cessation for cases) 
and stored at -70oC. Cases and controls were compared 
using non-parametric methods.
11 participants (6 cases; 5 controls) had undetectable EFV 
levels and were excluded from analysis. EFV concentrations 
were >500 µg/L in all 99 participants and >1000 µg/L in 
94, indicating acceptable adherence. Baseline age, height, 
weight, body mass index, HIV stage, serum creatinine, 
ALT, CD4 count or HIV RNA did not differ. Concomitant 
protease inhibitor therapy use was not different (p=0.61). 
Cases were more likely to be smokers (62% versus 27%; 
p=0.0011). Median EFV concentrations were not different 
in cases compared to controls (2259 [IQR 1768-2825] 
µg/L vs (2085 [IQR 1684-3336] µg/L respectively; p=0.77). 
EFV concentrations were >3000 µg/L in 17% of cases and 
27% of controls (p=0.30), and >4000 µg/L in 7% and 16% 
respectively (p=0.24). 
In a large randomised trial, EFV plasma concentrations 
did not predict drug cessation due to neuropsychiatric 
disturbances after at least one month of therapy. We 
cannot exclude that differences in adherence and time 
post dose of sample collection may account for our 
findings. It is possible the high prevalence of smokers 
amongst cases may represent individuals with pre-
existing psychiatric disturbances. 
ESPRIT	(EVALUATION	OF	SUBCUTANEOUS	
PROLEUKIN®	IN	A	RANDOMISED	
INTERNATIONAL	TRIAL):	FACTORS	
ASSOCIATED	WITH	ONGOING	CYCLING	WITH	
RECOMBINANT	INTERLEUKIN-2	(RIL-2)
Seneviratne N1, Lin E1, Wentworth D2, 
Courtney-Rodgers D1, Carey C1, Pett SL1, Kearney L1, 
French M3, Finlayson R4, Cooper DA1, Emery S1 for the 
ESPRIT Research Group.
1National Centre in HIV Epidemiology and Clinical 
Research, University of New South Wales, Sydney, Australia, 
2Department of Biostatistics, University of Minnesota, 
Minneapolis, USA; 3Dept Clinical Immunology, Royal Perth 
Hospital, Perth, WA, Australia; 4Taylor Square Private Clinic, 
Sydney, NSW, Australia.  
ESPRIT is an ongoing phase III clinical trial evaluating the 
clinical impact of intermittent SC rIL-2 plus antiretroviral 
therapy (ART) vs. ART alone in HIV-1-infected individuals 
with CD4+ T-cells ≥300 cells/µL. After year 1 rIL-2 
induction further rIL-2 dosing cycles should be given to 
achieve/sustain the CD4+ T-cell target (baseline x2 or 
≥1000 cells/µL when baseline was 300-499 or ≥500 cells/
µL respectively). The aim of the 2007 cycling initiative was 
to encourage all rIL-2 patients not at CD4+ target and 
without medical contraindication to receive further rIL-2. 
The aim was to describe baseline and on-study predictors 
of ongoing rIL-2-cycling.  
The reasons for non-cycling in eligible patients were 
summarised. Multivariate analyses were performed to 
determine the relationship between baseline and on-
study predictors of receipt of ≥ 1 rIL-2 dosing cycle in 
2007. Predictors considered were age, gender, ethnicity, 
geographical location of enrollment, baseline/nadir CD4+ 
T-cell count, prior ADI, previous rIL-2 cycles received and 
recent CD4+ T-cell count.     
In 2007, 1107 patients were eligible to cycle. Median age 
was 40 years, 83.3% male, 76.8%, 10.8%, 8.0% were of 
white, black, Asian ethnicity respectively, 44.1%, 27.5%, 
15.3%, 8.8% and 4.4% were enrolled in Europe/N.Africa, 
N.America, S.America, Asia and Australia respectively. 
Median baseline, nadir and recent CD4+ T-cell counts (in 
2006) were 460, 184 and 568 cells/µL respectively; 26.1% 
had had a prior ADI. 
Only 19.6% (n=217) received ≥1 rIL-2 dosing cycle in 
2007. The main reasons given for non-cycling were 
“patient wish” (62.8%), “other” (17%), “previous rIL2-related 
toxicity” (11.7%) and CD4+ “high enough” (11.5%). Patients 
cycling in 2007 were more likely to have higher CD4+ 
counts in 2006 and had received a greater number of 
previous cycles (p<.001 for each). Geographical location 
of enrolment was also a determinant of cycling, with TH
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the highest and lowest rates in Asia (37.1%) and Europe/
N.Africa (12.9%) respectively.
  
The 2007 rIL-2 cycling initiative was not very successful.  It 
is disappointing that patients with potentially the most to 
gain from further IL-2 cycling – those with lowest recent 
CD4+ counts and little previous IL-2 experience – were 
the least likely to re-cycle. It is unclear why re-cycling rates 
differed across geographical regions.
DEFERRED	MODIFICATION	OF	
ANTIRETROVIRAL	REGIMEN	FOLLOWING	
TREATMENT	FAILURE	IN	ASIA:	RESULTS	
FROM	THE	TREAT	ASIA	HIV	OBSERVATIONAL	
DATABASE	(TAHOD)
Zhou J1, Li PC2, Kumarasamy N3, Boyd M1, Pujari S4, on 
behalf of The TREAT Asia HIV Observational Database
1National Centre in HIV Epidemiology and Clinical 
Research, The University of New South Wales, Sydney, 
Australia; 2Queen Elizabeth Hospital, Hong Kong, China; 
3yRG Centre for AIDS Research and Education, Chennai, 
India; 4Institute of Infectious Diseases, Pune, India
Effective new combination antiretroviral regimens 
(cART) in patients who experience treatment failure 
are not readily available in many Asian countries.. - We 
analysed the rates of treatment failure and antiretroviral 
modification following failure in patients from TAHOD. 
Treatment failure was defined according to WHO 
guidelines. Time to treatment modification following 
cART failure was assessed by person-time method. 
Types of modification were summarised. Countries were 
categorised into high- and low-income by World Bank 
criteria.
Among 2446 patients (71% male) who initiated cART 447 
developed treatment failure (242 immunological failure, 
112 virological failure and 93 clinical failure) over 5697 
person-years (7.8 per 100 person-years, 95% confidence 
interval CI 7.2-8.6). A total of 253 patients (76% male) 
changed at least one drug after treatment failure (51.6 
per 100 person-years, 95% CI 45.6~58.4). There was no 
difference between patients from high- and low-income 
countries (unadjusted hazard-ratio HR 1.03; p=0.829). 
Compared to patients with virological failure, patients 
with either immunological or clinical failure were less 
likely to modify treatment (unadjusted HR 0.55; p<0.001 
and 0.50; p<0.001, respectively). When modifying 
treatment, 24 (10% of 253) patients added one or more 
drug, 92 (36%) changed one and 137 (54%) two or more 
drugs. Compared to patients from low-income countries, 
patients from high-income countries were more likely to 
change two or more drugs (67% vs. 49%; p=0.009) and 
to change to a protease-inhibitor-based regimen (48% vs. 
16%; p<0.001).
We found that among a cohort of HIV patients across 
Asia, nearly half remained on a failing regimen one year 
after treatment failure. Deferred modification of regimen 
following treatment failure in many Asian countries may 
have implications for accumulation of drug resistance 
and response to second-line treatment. There is an urgent 
need to scale up access to second-line regimens and viral 
load monitoring in this region.
McLellan DGJ - see page 230
Byakwaga H - see page 224
Bloch M - see page 223
Chibo D - see page 225
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A	FASTER	DECREASE	IN	CD4+	T	CELL	
COUNTS	AFTER	HIV	INFECTION	FOR	OLDER	
INDIVIDUALS	CONTRIBUTES	TO	LEVELS	OF	
IMMUNOSUPPRESSION	AT	HIV	DIAGNOSIS
Murray JM1,2, Kelleher AD2
1School of Mathematics and Statistics, University of New 
South Wales, Sydney, NSW, Australia; 2National Centre in 
HIV Epidemiology and Clinical Research, University of 
New South Wales, Sydney, NSW, Australia.
It has been observed that older individuals at HIV 
diagnosis are more likely to present with lower CD4+ T cell 
counts, suggesting a longer time between infection and 
diagnosis with older age. We investigated whether this 
same correlation between age and CD4+ T cell numbers 
at diagnosis was also true in Australia. Additionally we 
assessed whether some of the loss in CD4+ T cell counts 
at diagnosis for older individuals could be attributed 
to faster immunosuppression.  CD4+ T cell counts at 
HIV diagnosis (7,244 men and 1,045 women), and at 
primary HIV infection (1,206 men) were determined 
from the HIV Public Access Dataset. CD4+ T cell counts 
for 25 HIV-uninfected individuals were obtained from the 
Sydney AIDS Project, and CD4+ T cell counts for 259 men 
followed from primary HIV infection were obtained from 
the AIEDRP CORE01 Study.
CD4+ T cell counts for 25 HIV-uninfected men aged 
from 23 to 65 exhibited a non-significant increase with 
age. However median CD4+ T cell numbers per mm3 
of blood for men at HIV diagnosis decreased from 500 
for 15 to 24 year olds to 210 for those over 60, while for 
women these decreased from 534 to 175. At primary HIV 
infection men over 60 years of age had median CD4+ T 
cell counts of 352 per mm3 significantly lower than each 
age group younger than 45 where the medians ranged 
from 540 to 510 (p<0.05 Tukey Test). Two years after 
primary HIV infection CD4+ T cell counts for treatment-
naïve men were significantly negatively correlated with 
age (p=0.01).
Although CD4+ T cell counts increase with age in 
uninfected individuals, levels at HIV diagnosis are 
significantly lower for older individuals with many 
presenting with AIDS level immunosuppression. Some of 
this will be due to longer times until diagnosis for older 
individuals, however a significant component is related 
to greater suppression at primary infection and while 
untreated for older HIV-infected individuals. 
PREDICTORS	OF	LONG-TERM	CHANGES	IN	
MEAN	CD4	CELL	COUNTS	AMONGST	HIV	
INFECTED	PATIENTS	FROM	THE	ASIA-PACIFIC	
REGION	DURING	ACTIVE	COMBINATION	
ANTIRETROVIRAL	THERAPY
Egger S1, Petoumenos K2, Kamarulzaman A3, Hoy J4, 
Sungkanuparph S5, Chuah J6, Falster K2,7, Zhou J2, Law MG2, 
on behalf of the Asia Pacific HIV Observational Database 
(APHOD)
1The Cancer Council NSW, Woolloomooloo, NSW 
Australia; 2National Centre in HIV Epidemiology and 
Clinical Research, University of NSW, Sydney, Australia; 
3Department of Medicine, University of Malaya, Lembah 
Pantai, Kuala Lumpur, Malaysia; 4The Alfred Hospital, 
Monash University, Melbourne, Australia; 5Ramathibodi 
Hospital, Mahidol University, Bangkok, Thailand; 6Gold 
Coast Sexual Health Clinic, Queensland, Australia; 7School 
of Public Health and Community Medicine, University of 
NSW, Sydney, Australia
The primary objective of this study is to investigate 
the predictors of long-term changes in mean CD4 cell 
counts among HIV positive patients, up to 6 years after 
the commencement of combination antiretroviral 
treatment (cART) in the Asia-Pacific HIV Observational 
Database (APHOD), a collaboration of the Australian HIV 
Observational Database (AHOD) and the TREAT Asia HIV 
Observational Database (TAHOD).  
Patients in APHOD who first commenced cART after 
January 1 1997, and who had a baseline CD4 cell count 
and viral load measure, and at least one follow-up 
measure between 6 and 24 months were included. CD4 
cell counts were determined at every 6-month period 
following the commencement of cART for up to 6 years. 
Linear random effects models were used to examine the 
change in and predictors of mean CD4 cell counts for 
each of the cohorts over a 6-year study period.
1638 patients fulfilled the inclusion criteria with a 
median follow up time of 58 months. At baseline TAHOD 
patients were slightly younger (37.6 vs 40.1 years), more 
likely to have prior AIDS (44% vs 13%) and substantially 
lower CD4 cell counts (176 vs 386 cells/µL) than AHOD 
patients. Lower post-cART mean CD4 cell counts were 
found to be associated with increasing age (-14 cells/µL 
per 10-year increase in age 95%CI [-21, -7], p<0.001), pre-
cART hepatitis C coinfection (-41 cells/µL 95%CI[-79,-2], 
p=0.038),  prior AIDS (-23 cells/µL 95%CI[-42, -2], p=0.019), 
prior viral load 100,000 copies/ml (-40 cells/µL 95%CI[-56, 
-25], p<0.001), and the Asia-Pacific region (27 cells/µL 
95%CI[-46,-8], p=0.005). Higher absolute post-cART mean 
CD4 cell counts were associated with lower post-cART 
viral load levels and higher baseline CD4 cell counts. 
Higher increments in post-cART mean CD4 cell counts 
was found to be associated with lower baseline CD4 cell 
Epidemiology – Morbidity and 
Mortality
3.30pm – 5.00pm
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counts. Rates of mean CD4+ growth rates plateaued at 6 
years of cART with sustained viral suppression.
Patients with continuously or intermittently sustained 
virological response experience ongoing CD4 cell 
increases for several years after commencing cART, with 
higher increases among patients with lower baseline CD4 
cell counts. This increase was demonstrated in both the 
AHOD and TAHOD cohorts, despite the slightly lower, 
albeit statistically significant, overall absolute CD4 cell 
response in TAHOD over the six years.  
WHO	GETS	AIDS	IN	THE	HAART	ERA?	
Middleton MG1, Jauncey M1, McDonald AM1, Grulich AE1
1National Centre in HIV Epidemiology and Clinical 
Research, The University of New South Wales, Sydney, 
Australia
Objective: To describe demographic, behavioural and 
clinical risk factors for AIDS in the HAART era in Australia.
Methods: AIDS cases diagnosed in three area health 
services in New South Wales in the years 2003 – 2005, 
including deaths in 2001 – 2005, and notified to the 
National AIDS Registry were eligible for inclusion in the 
study. A questionnaire asking for clinical, behavioural and 
demographic information was forwarded to people with 
AIDS (PWA) via the notifying doctor.
Results: Of the 131 PWA who were alive at the time of the 
survey, 36 (27.5%) responded. Twenty-five respondents 
(73.5%) were MSM and 22.2% spoke a language other 
than English at home. There was a high correlation 
between the demographic and risk factor information 
provided by patients and clinicians. Thirty-six percent of 
respondents were diagnosed with HIV ≤ 90 days prior 
to AIDS (late diagnosis), 38.9% had received suboptimal 
HAART, and another 19.4% had not received HAART prior 
to their AIDS diagnosis. Of those with a late HIV diagnosis, 
85% did not consider themselves at risk of HIV infection 
at the time of their diagnosis, 53% reported they had 
never had a previous negative test, and 31% reported 
delaying their HIV-test. The main reasons people did not 
consider themselves at risk of HIV infection were that they 
had never had a sexually transmissible infection (60%), 
had always had safe sex (50%), had not had many sexual 
partners (50%), or thought their sexual partners were HIV 
negative (50%). Sixteen PWA (44.4%) were treated with 
HAART prior to their AIDS diagnosis. Of these, 5 (31.3%) 
did not commence treatment soon enough, 5 (31.3%) 
had difficulty complying with treatment and 4 (25%) had 
a structured treatment interruption. Of the 7 PWA not 
treated prior to their AIDS diagnosis, 3 (42.9%) declined 
treatment and 3 (42.9%) were not offered treatment.
Conclusions: Most PWA with a late HIV diagnosis were 
not tested for HIV because they considered their sexual 
behaviour to be low risk. The majority of people who 
received HAART prior to their AIDS diagnosis received 
suboptimal treatment.
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HIGH	MORTALITY	ASSOCIATED	WITH	HIV	
INFECTION	AMONG	ILLICIT	DRUG	USERS	IN	
THE	HAART	ERA
Grebely J1, Raffa JD2, Lai C3, Krajden M4, Dore GJ1, 
Shannon K3, Kerr T3,5 and Tyndall MW3,5
1National Centre in HIV Epidemiology and Clinical 
Research, Sydney, NSW, Australia; 2Department of 
Statistics and Actuarial Science, University of Waterloo, 
Waterloo, Canada; 3BC Centre for Excellence in HIV/AIDS; 
4British Columbia Centre for Disease Control; 5Department 
of Medicine, University of British Columbia, Vancouver, 
Canada.
Introduction: The impressive decrease in HIV-associated 
morbidity and mortality related to the introduction of 
highly active antiretroviral therapy (HAART) has been 
less dramatic in marginalized populations. This study was 
designed to measure mortality rates among a cohort of 
illicit drug users in Vancouver. 
Methods: CHASE is a cohort study of inner city residents 
recruited from Vancouver, Canada between January 
2003 and June 2004. Participants were then followed 
retrospectively and prospectively through health-related 
database linkages. HIV and HCV status were determined 
through linkage with provincial virology databases. 
Mortality data were derived from the British Columbia 
Vital Statistics registry (2003-2006). Causes of death were 
categorized according to ICD-10 chapter headings. Rates 
of all cause, drug-related, HIV-related and other cause-
related mortality were measured. Factors associated with 
all cause and HIV-related mortality were also assessed 
using Cox proportional hazards models.
 
Results: Of 2913 participants, 305 and 1366 were infected 
with HIV and HCV, respectively. Among 178 deaths, the 
major causes were due to infection (23.0%), external 
causes of morbidity and mortality (18.5%), neoplasms 
(12.4%), respiratory system (11.8%), other ill-defined or 
unspecified causes (11.2%) and circulatory system (10.7%). 
Deaths were HIV-related in 34 (19.1%), drug-related in 30 
(16.9%), liver-related in 12 (6.7%) and other cause-related 
in 102 (57.3%). All cause, HIV-related and drug-related 
mortality rates were 198.2, 37.9 and 33.4 cases/10,000 
p-yrs. All cause mortality remained stable over the study 
period, with observed rates of 239.0, 179.5, 198.4 and 
202.5 cases/10,000 p-yrs from 2003 to 2006, respectively. 
Overall, Cox proportional hazards analyses stratifying on 
age demonstrated that injection drug use in the previous 
6 months (adjusted hazard ratio (AHR) 1.42; 1.03-1.94, 
p=0.030) and HIV infection (AHR 3.14; 2.11-4.66, p<0.001) 
were associated with all cause mortality. HIV-related 
mortality was independently associated with unknown 
HIV status (AHR 5.43; 1.53-19.30, p=0.009). 
Conclusions: In this large retrospective-prospective 
analysis in the HAART era, mortality rates in illicit drug 
users were consistently high. Although injection drug use 
and HIV infection were strongly associated with all cause 
mortality, there were a range of other causes that could be 
prevented through targeted public health interventions.
CANCER	AND	HIV	IN	AUSTRALIA:	A	
COMPARISON	ACROSS	EARLY	AND	LATE	
HAART	PERIODS
Van Leeuwen MT1, Vajdic CM2, Middleton MG1, McDonald 
AM1, Law M1, Kaldor J1, Grulich AE1
1National Centre in HIV Epidemiology and Clinical 
Research, University of New South Wales, Sydney, NSW, 
Australia; 2 University of  New South Wales Cancer Research 
Centre, Prince of Wales Clinical School, University of New 
South Wales, Sydney, Australia.
The epidemiology of cancer in people with HIV infection 
since the introduction of highly active antiretroviral 
therapy (HAART) remains unclear. Using data from 
national, population-based registries, this study examined 
changes in cancer incidence among people with HIV 
infection in Australia post-HAART. 
Probabilistic data linkage between the National HIV 
Registry, the National AIDS Registry and the National 
Cancer Statistics Clearing House (NCSCH), was used to 
ascertain incident cancer diagnoses in adults (16-80 
years) with HIV infection in Australia from 1982-2004. 
Person-years of follow-up were accrued from the date 
of seroconversion or HIV diagnosis, or from 01 Jan 1982, 
until the date of cancer diagnosis, death, or 31 December 
2004. The observed number of cancer diagnoses was 
compared with that expected in the Australian general 
population through the calculation of five-year age-, sex-, 
state- and calendar-year-specific standardised incidence 
ratios (SIRs). SIRs were examined pre- and post-HAART, 
and across ‘early’ (1996 – 1999) and ‘late’ (2000 – 2004) 
HAART periods.  
In total, 2 762 cancers (2 168 AIDS-defining, 594 non-AIDS-
defining) were identified on the NCSCH in 20 232 people. 
Overall, risk for Kaposi sarcoma (KS, SIR 5 379, 95%CI 4 
793 – 6 036) and non-Hodgkin lymphoma (NHL, SIR 
15.3, 95%CI 13.6 – 17.2) remained elevated post-HAART, 
though declined significantly across the early and late 
HAART periods (Ptrend <0.001). Risk for Hodgkin disease 
(HD) peaked during the early HAART period (SIR 17.3, 
95%CI 10.3 – 27.2) but declined significantly thereafter 
(SIR 7.4, 95%CI 3.7 – 13.2; Ptrend<0.023). Risk remained 
significantly elevated for anal cancer in males (SIR 34.4, 
95%CI 22.7 – 50.1), and for leukaemia (SIR 2.0, 95%CI 1.1 – 
3.4), and was non-significantly elevated for cancers of the 
lip, oral cavity and lung. All cases of liver cancer occurred 
post-HAART (SIR 3.5, 95% CI1.7 – 6.2).  
People with HIV infection remain at risk for several cancers 
post-HAART including the AIDS-defining cancers NHL 
and KS, as well as leukaemia, liver, and anal cancer. Risk 
for NHL and KS continued to decline in the late HAART 
period. While the increase in risk for HD post-HAART has 
been previously observed, the recent decline in risk has 
not been elsewhere reported.
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UPDATE	OF	THE	AUSTRALIAN	LONG-TERM	
NON-PROGRESSOR	(LTNP)	COHORT
Gelgor L1, Anderson B2, Baker D3, Finlayson R4, McFarlane 
R3, McMurchie M3, Kelleher A1, Kaldor J1 on behalf of the 
Long Term Non-progressor study group
1National Centre in HIV Epidemiology and Clinical 
Research, University of New South Wales, Sydney NSW, 
Australia; 2St Leonards, Sydney NSW, Australia; 3East 
Sydney Doctors, Darlinghurst, Sydney NSW, Australia; 
4Taylor Square Private Clinic, Darlinghurst, Sydney NSW, 
Australia.
The Australian LTNP cohort was established in 1994 to 
investigate viral, genetic and immunological factors that 
may influence disease progression. Individuals were 
eligible for the study provided they had documented HIV 
infection and remained asymptomatic for at least 8 years 
with a CD4+ count above 500/μl. This cohort has been 
followed clinically on an annual basis, with specimen 
storage for specialised analyses and regular recording of 
CD4+ counts, viral load, clinical disease and therapeutic 
intervention.  Updated analysis of the cohort was 
undertaken to determine what proportion of the cohort 
sustained non-progression and to compare the viral load 
and CD4+ T cells over time with those within the cohort 
who had progressed 
Of 111 people recruited into the cohort 30 are lost to 
follow up, 3 died, 9 developed AIDS, 35 commenced 
antiretroviral treatment, 34 (31%) remain untreated. 
The median duration of infection of the 34 subjects that 
remain untreated is 21 years (Range 8-24 years) with 
those in the treatment group being infected for 22 years 
(Range 12-24 years). Median time to treatment is 13 years 
(Range 9-21 years).  Those who remain untreated had 
lower median viral load of 2300 copies/ml at study entry 
with the most recent median viral load measuring 2700 
copies/ml, compared to 9600 copies/ml in the treated 
group at study entry with the median HIV-1 RNA 32,200 
copies/ml prior to the start of therapy .  The median CD4+ 
T cell counts are within normal range for both the treated 
(550 cells/µL) just prior to treatment start and the most 
recent measured in the untreated (620 cells/µL) group. 
Survival analysis using the Log rank test for comparison 
indicated that a higher CD4+  T cell count (p<0.002) and 
lower HIV-1 RNA (p<0.003) at study entry were significant 
predictors of sustained nonprogression.  
A substantial proportion of this cohort, remain untreated 
20 years after diagnosis and exhibit ongoing viral load 
control with normal CD4+ T cell counts. The mechanisms 
underlying this phenomenon of control of HIV infection 
remains elusive. Continued studies of long-term non-
progression contribute to understanding the pathogenesis 
of HIV-1 infection and for the development of improved 
treatment strategies such as vaccine development.
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SAFE	SEx	NO	REGRETS-	SExUAL	HEALTH	IN	
MAINSTREAM	MEDIA	IN	WA
Crawford G1, Brown G2, Nicholson C2, Langdon T1.
1Western Australian AIDS Council, Perth, WA, Australia
2WA Centre for Health Promotion Research, School of 
Public Health, Curtin University of Technology, Perth, WA, 
Australia
Social marketing focusing on STIs and HIV has been absent 
from WA televisions since the 1990’s, following a shift away 
from broad based marketing strategies. Following the 
success of the Safe Sex No Regrets mass media campaign 
in NSW, the campaign was implemented in WA, for 10 
weeks between December 2007 and February 2008 
incorporating television, print and night venue initiatives. 
Objectives were primarily to increase awareness of safe 
sexual practice, and increase positive attitudes towards 
safe sex, and also increase knowledge of early testing, 
detection and treatment. The campaign, with party 
and nightclub focused imagery targeted sexually active 
heterosexuals under 30 and men who had sex with men 
under 45. Evaluation sought to determine whether the 
campaign has achieved its objectives and to test the 
efficacy of the approaches.
Two hundred pre and post campaign questionnaires were 
administered via telephone to a random cross section 
of the target group. A further 50 venue based intercept 
surveys were administered in night venues frequented 
by the target group. The survey examined campaign 
recall, attitudes, beliefs and risk behaviour toward safe sex, 
condom use, STIs and testing. 
Baseline data indicated low levels of STI testing and 
condom use, but indicated high rates of awareness and 
attitude shifts amongst the target group concerning 
sexual health issues and protective behaviours. The 
evaluation methodology highlighted challenges in 
achieving enough telephone survey participants who 
identified having ‘casual partners’. However a venue based 
sample in nightclubs was achieved with surprising ease.
Television and other media strategies have a role in HIV/
STI prevention to raise awareness and reinforce condom 
use and testing messages. However behaviour change 
requires sustained social marketing as only one part of an 
integrated approach to prevention. Also the high success 
in achieving a venue-based sample may be useful for 
other campaign evaluations. 
DIFFERENT	COMMUNITIES,	DIFFERENT	
NEEDS:	SHAPING	HIV/AIDS	MESSAGES	FOR	
SIx	NEW	SOUTH	WALES	CULTURALLY	AND	
LINGUISTICALLY	DIVERSE	COMMUNITIES	
Shaw MJ1, Sabri W2, McMahon T2, Edwards B3, 
McGowan L4
1HIV & Related Programs Health Promotion Team 
(Inner West), Sydney South West Area Health Service, 
Camperdown, New South Wales, Australia; 2Multicultural 
HIV/AIDS & Hepatitis C Service of NSW, Camperdown, 
New South Wales, Australia; 3HIV & Related Programs Unit, 
South Eastern Sydney & Illawarra Area Health Service, 
Randwick, New South Wales, Australia; 4HIV & Related 
Programs Health Promotion Team (Liverpool), Sydney 
South West Area Health Service, Camperdown, New 
South Wales, Australia
New South Wales has a significant overseas born 
population with almost one third of people born outside 
of Australia.  As part of increasing patterns of international 
mobility, temporary and permanent residents of NSW 
travel to their country of birth to visit friends and family 
or conduct business. To ensure that culturally and 
linguistically diverse (CALD) communities understand 
how HIV/AIDS is transmitted and prevented, as well as the 
particular risks associated with overseas travel, the NSW 
CALD HIV Interagency established a Travel and Mobility 
Working Group to identify health promotion initiatives 
which might address the HIV/AIDS risk posed by overseas 
travel among CALD communities.  
The Working Group is made up of HIV/AIDS health 
promotion stakeholders from Sydney South West Area 
Health Service (SSWAHS), South East Sydney Illawarra 
Area Health Service (SESIAHS) and the Multicultural HIV/
AIDS and Hepatitis C Service (MHAHS).  
The Multicultural HIV/AIDS and Hepatitis C Service, in 
conjunction with the Travel and Mobility Working Group, 
commissioned an assessment of the HIV/AIDS information 
needs of six CALD communities: Chinese (Mandarin 
speaking); Vietnamese; Thai; Cambodian; Indonesian; 
and African communities. These communities have been 
identified by NSW Health as being a high priority among 
CALD communities in NSW. The key findings from the 
needs assessment will be used to inform community 
education campaigns with each community, including 
resource development. 
This paper will discuss these key findings including:
• Current sources of health information
• Gender issues relating to HIV/AIDS messages
• Understanding and perceptions of HIV/AIDS within an 
Australian and overseas context
• Level of interest in information about HIV/AIDS
• Preferred communication mechanism for each 
community
Working with CALD Communities/
Working with Media
3.30pm – 5.00pm
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THE	MAKING	OF	HIV	AS	A	PUBLIC	CONCERN:	
THREE	THEMES	IN	THE	CONTEMPORARY	
AUSTRALIAN	NEWS	MEDIA	COVERAGE	OF	
HIV
Newman CE1, Persson A1 
1National Centre in HIV Social Research, The University of 
New South Wales Sydney NSW Australia
This paper explores how HIV is constituted as a matter of 
public concern in Australia, where – unlike much of the 
rest of the world – there is a continuing low incidence 
of heterosexual transmission. In this context, it is timely 
to explore how the media contributes to the ongoing 
mobilisation of public interest in HIV, and how HIV is 
constituted as a public concern in relation to the past, 
present and future of heterosexual audiences.
This paper identifies three prevailing approaches to 
generating public concern in HIV news stories published 
in The Sydney Morning Herald between 2000 and 2005 
as well as in academic media analysis and HIV education 
and advocacy. The study focused on this period because 
sufficient research had already been conducted on 
Australian HIV media coverage in the previous two 
decades of the HIV epidemic. 
Each of the three themes identified pivots on the question 
of how to generate or regenerate a sense of urgency 
around HIV as a topical and relevant issue for Australian 
audiences. Firstly, reflections on fear revisit the early years 
of the epidemic, distinguishing different generations 
of Australians as either marked or unmarked by the 
1987 Grim Reaper campaign. Secondly, narratives of 
complacency focus on an apparently widespread lack of 
concern or naïvety about HIV in the broadest population 
today. Lastly, projections in risk forecast a multiplication 
of HIV risk environments, incorporating new trends 
such as medical tourism or criminal cases of relationship 
‘betrayal’. 
Together these three themes represent a shared moment 
in the history of public discourses on HIV, constructing 
Australian publics as passive, vulnerable, unaware and 
potentially uncaring. And yet they do little to engage the 
mainstream as more than merely spectators of public 
concern about HIV. This has significance for the future of 
HIV prevention in Australia, specifically in responding to 
changing dynamics in the global and local epidemics.
RADIO	DRAMAS,	HIV/AIDS	&	THE	
VIETNAMESE	COMMUNITY	IN	SYDNEY
Sabri W.
Multicultural HIV/AIDS & Hepatitis C Service
Australia is culturally diverse and HIV infection rates reflect 
this.  Some 21% of national HIV notifications annually are 
among people born in non-English speaking regions of 
the world.  The pattern of HIV infection among culturally 
and linguistically diverse (CALD) communities in Australia 
largely reflects prevalence rates in countries-of-origin. 
The Multicultural HIV/AIDS and Hepatitis C Service 
(MHAHS) implemented a one-year project with the 
Vietnamese community to empower and increase 
their awareness and knowledge using a community 
development framework around crucial, yet sensitive, 
issues of HIV testing and prevention in partnership with 
Vietnamese community organisations.
This paper describes a key strategy of the project - the use 
of “Radio Dramas”  designed to raise HIV/AIDS awareness 
amongst the Vietnamese community in NSW.  It details the 
evaluation process and findings in relation to the reach of 
HIV/AIDS messages among the target communities.  
The paper will also examine how this approach to 
community development demonstrates that community 
engagement, empowerment and partnership can result 
in capacity building and increase social capital around 
HIV/AIDS issues amongst CALD communities.
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REFLECTIONS	ON	IMPROVING	HEALTH	
OUTCOMES
Eisenberg M, Katsaros E
Multicultural HIV/AIDS and Hepatitis C Service, Sydney, 
NSW, Australia
People from culturally and linguistically diverse (CALD) 
backgrounds make up approximately one fifth of HIV 
notifications in NSW and are now recognised as a priority 
population by the NSW HIV/AIDS Strategy.
The Multicultural HIV/AIDS and Hepatitis C Service 
(MHAHS) is a state-wide service providing client support, 
community development, and advocacy for and with 
people from CALD backgrounds affected by HIV and 
hepatitis C.  It currently employs 100 bilingual/bicultural 
workers, known as co-workers, in working with people 
from almost 30 language backgrounds.
This paper uses two complex HIV/AIDS cases to examine 
some factors which contribute to positive and less 
positive outcomes for the client, in particular the values 
and level of commitment of the workforce, both within 
and outside the MHAHS.  It suggests that the practice 
of social inclusion is perhaps not quite what the rhetoric 
of diversity promises and argues that professional 
supervision for all workers is a crucial tool in improving 
health outcomes for all clients. 
ACCULTURATION,	SExUAL	BEHAVIOUR,	RISK	
AND	KNOWLEDGE	IN	VIETNAMESE	MEN	
LIVING	IN	METROPOLITAN	SYDNEY
O’Connor CC1,3, Wen LM2, Shaw M1, Quine S3
1Sexual Health Service, Division of Community Health, 
SSWAHS, Camperdown, Sydney; 2Health Promotion Unit, 
Division of Population Health, SSWAHS, Camperdown, 
Sydney; 3School of Public Health, University of Sydney
 
Objectives: To describe the relationship between 
acculturation, sexual risk and Sexually Transmissible 
Diseases (STDs) and Blood Borne Viruses (BBVs) knowledge 
among Vietnamese men living in inner Sydney and to 
compare this prevalence with national data.
Method: Telephone interviews were completed with 
a random sample of 499 Vietnamese men, selected 
from the electronic phone book using a list of common 
Vietnamese surnames.
Results: Of the 761 eligible men contacted, data were 
obtained from 499 men giving a response rate of 66 %. 
There was an association between lower acculturation 
scores and having more than ten lifetime sexual partners, 
more than 50 lifetime sexual partners, never using a 
condom, ever or recently had commercial sex, ever 
had an STD, were hepatitis B carriers or had ever been 
imprisoned.
Conclusion: There is an association between acculturation 
and many aspects of sexual behaviour 
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ACON  & NSW HEALTH PRESENT:
Prevention And Treatment Issues For Older Gay Men.
A sponsored ASHM conference session on differences in 
risk, behaviour and health promotion need in men over 
40 
The average age of seroconversions is increasing; people 
with HIV are living longer, more men in their 40s and 50s 
are becoming HIV positive. This 90 minute session brings 
together a range of researchers, and service delivery 
and health promotion professionals to explore some 
of the specific issues related to developing appropriate 
responses for older men in terms of HIV prevention and 
health promotion activities.
The session will include an examination of available data 
both nationally and internationally that highlight issues 
in relation to risk behaviour and factors impacting on 
seroconversions amongst this target group. Additionally 
the session will explore aspects of sex cultures and the 
framing of prevention messages, specific interventions 
targeted to older HIV positive men, as well as exploring 
the Implications for an ageing GLBT community, including 
workforce development needs in the medical and aged 
care sectors. 
Chairs: Stevie Clayton ACON &  Geoff Honnor NSW 
Health
Panellists  
Garrett Prestage 
NCHECR
John Imrie 
NCHSR
Dermot Ryan
ACON
Russell Westacott
ACON
Rob Lake 
Positive Life NSW 
RISK,	REALITIES	AND	HIV	
SEROCONVERSIONS	IN	OLDER	GAY	
MEN:	qUALITATIVE	RESULTS	FROM	AN	
INVESTIGATION	OF	SEROCONVERSIONS	
IN	GAY	MEN	WHO	HIV	TEST	IN	ENGLAND	
(INSIGHT	STUDY)
Imrie J1,2, Elam G2, Macdonald N3, Hickson FC4, Power RM5, 
McGarrigle CA6, Fenton KA6,7, Gilbart V6, Ward H3, Evans BG6 
on behalf of the INSIGHT Collaborative Research Team
1National Centre in HIV Social Research, The University 
of New South Wales Sydney, NSW, Australia; 2Centre for 
Sexual Health and HIV Research, Royal Free and University 
College Medical School, London, UK; 3Department of 
Infectious Disease Epidemiology, Imperial College Faculty 
of Medicine, London, UK; 4Sigma Research, University of 
Portsmouth, London, UK; 5Centre for Harm Reduction, 
Burnet Institute, Melbourne, VIC, Australia; 6Department 
of HIV and STIs, Health Protection Agency – Centre for 
Infections, London, UK; 7National Center for HIV, Viral 
Hepatitis, STD, and TB Prevention, Coordinating Center 
for Infectious Diseases, Centers for Disease Control and 
Prevention, Atlanta GA, USA
Gay men in their mid-life have survived the worst years 
of the HIV epidemic, so why are they now acquiring HIV? 
In England, men who have sex with men (MSM) age 35 
to 44 years accounted for over a third (34% 787/2301) of 
all new diagnoses of HIV in 2006.  InSIGHT (Investigation 
into seroconversions in gay men that HIV test) explored 
why gay men continue to acquire new HIV infections. 
This paper reports on one aspect of the qualitative stage 
of the study - our investigation of the context of HIV 
seroconversion among older gay men seeking repeat HIV 
tests at sexual health clinics in England and the factors 
contributing to unprotected anal intercourse (UAI).  
In-depth interviews exploring the context of UAI were 
conducted among 26 recent HIV seroconverters (cases) 
and 22 controls purposively selected from the quantitative 
arm – the InSIGHT case-control study.
We found that older men are more likely to be exposed 
to major relationship and lifestyle changes, bereavement 
and loss.  These factors impact on their sexual lifestyles 
and decisions to engage in higher risk sexual behaviour. 
In addition, among older men, the improved prognosis 
of HIV infection compared to other age related chronic 
health conditions reduces perceptions of the seriousness 
of HIV infection.  
A range of psychosocial reasons led some men to engage 
in high risk UAI, despite high levels of risk awareness. 
The study findings indicate specific factors contributing 
to seroconversion in older men and a relationship 
between sexual and emotional needs, risk perceptions 
and behaviour. More work is required to understand the 
sexual needs and expectations of older men in order to 
inform specific health promotion measures aimed at 
reducing the risk of HIV infection in this group.
Prevention and Treatment Issues For 
Older Gay Men - Sponsored by NSW 
Health and ACON
3.30pm – 5.00pm
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TREATMENT	ISSUES	AND	RESPONSES
Lake, R.
Chief Executive Officer, Positive Life NSW
What kinds of peer support, policy and resource 
interventions are provided to, and valued by, older gay 
men living with HIV? Do newly positive older gay men 
have different issues and needs?
What services provide to people, and what is valued by 
them may be quite different. Positive Life and other HIV 
service providers, have developed services following 
evidence both of need and demand from this group. 
Responses to our targeted peer support and resources 
have been strong, but in identifying and providing for 
a wide range of needs, this may be a starting point, not 
the end. Services have often framed interventions for 
people living longer with Hiv, often older gay men, as 
rehabilitation. Peer support, social opportunities, and re 
engagement are key requests. One of the lessons for us 
is to recognise diverse needs, seek as much evidence as 
possible about those needs, and refine services to meet 
them. 
For newly diagnosed older gay men, whether in their 
forties or sixties, the question is the difference their age 
has on the impact of a diagnosis. Does a positive diagnosis 
heighten existing concerns about ageing, relationships, 
income and the future? Or does the response parallel the 
lack of pessimism often ascribed to younger gay men 
who seroconvert today?
The common point for these groups is ageing. What is 
different for gay men ageing, and how big an impact 
does their Hiv status have? Is their general state of health, 
particularly a poorer state of health over a longer period 
of time, likely to have a more significant impact and direct 
their health, housing, income and community service 
and support needs? Are there are other significant events, 
such as relationship end or partner change, retirement, 
Hiv progression, onset of other critical or chronic health 
conditions? This presentation will include feedback from 
our interventions, evaluations and will highlight research 
needs.
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NEW	POLICIES	FOR	CLINICAL	AND	
OPERATIONS	RESEARCH	IN	RESOURCE	
LIMITED	SETTINGS
Professor David A. Cooper
Director, National Centre in HIV Epidemiology and 
Clinical Research, University of New South Wales, Sydney, 
Australia. 
The delivery of existing HIV interventions to resource 
limited settings has increased dramatically in recent 
years. Although the funding for these initiatives is still 
insufficient, the need for new clinical and operations 
research in these settings is essential to developing 
sustainable interventions and approaches into the future. 
The incorporation of research studies into HIV programs 
is necessary not only to determine the effectiveness 
of specific interventions in these settings but also to 
respond to unique challenges that arise in resource 
limited settings and to examine outcomes that may be 
specific to particular regions. Examples of this may include 
determining the cause of early mortality in patients 
starting antiretroviral therapy in resource limited settings 
or the influence that HIV treatment may have in areas with 
high rates of other infectious diseases like tuberculosis or 
malaria. Collaborations in the Asia-Pacific region have been 
established not only in order to provide counseling and 
clinical care but also to support HIV training and research 
in the region. The HIV-NAT collaboration, between the 
Netherlands, Australia and Thailand, and the Cambodia 
Treatment Access Program have successfully enhanced 
the HIV research capacity and training in the region. 
Additionally, the Sydney Declaration of 2007 highlighted 
the need for and increased awareness of the requirement 
for a firm commitment to sustained research funding in 
order to address HIV in resource limited settings.   
ASHM Plenary – Policy, ‘Australia’s 
response to HIV in Asia and the Pacific: 
new partnerships and collaborations’.
5.00pm – 6.30pm
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EVALUATION	OF	THE	RELATIONSHIP	
BETWEEN	HLA-B*5701	STATUS	AND	HIV	
REVERSE	TRANSCRIPTASE	CODON	245	
VARIATION	IN	SOUTH	AUSTRALIAN	HIV-
INFECTED	INDIVIDUALS
Warner MS1, James HM2, Higgins GD1and Ratcliff RM1 
1Infectious Diseases Laboratories, Institute of Medical and 
Veterinary Science (IMVS), Adelaide, SA Australia; 2Division 
of Human Immunology, IMVS, Frome Rd, Adelaide, South 
Australia
Abacavir hypersensitivity occurs in four to eight percent 
of patients and is strongly associated (greater than 100-
fold increase) with the human leukocyte antigen (HLA)–
B*5701 allele. HLA class I loci can shape viral evolution by 
selecting for HIV viral variants which evade the specific 
cytotoxic T lymphocytes produced.  Investigators in 
Canada recently demonstrated a strong association 
between possessing the HLA-B*5701 allele and variations 
at codon 245 of HIV reverse transcriptase (RT). 
Between June 2004 and January 2007, 40 of 409 (9.8%) 
HIV positive patients screened possessed the HLA B*5701 
allele.   Of patients screened for HLA*B5701, 290 (70.9%) 
had HIV sequence testing performed, and of these, 29 
(10%) were positive for HLA-B*5701. Of these 29 patients, all 
but one had codon substitutions at position 245.  Overall, 
139 (53.1%) of 262 HLA-B*5701-negative and 28 (96.6%) 
of 29 HLA-B*5701–positive isolates had a polymorphism 
at position 245.  The sensitivity and specificity of codon 
245 substitutions for predicting HLA B*5701 were 97% 
and 47% respectively.  The positive predictive value (PPV) 
of a codon 245 substitution was 18% and the negative 
predictive value (NPV) was 99.2%.   
The presence of wild type sequence at RT codon 245 
was highly correlated with the absence of the HLA-
B*5701 allele.  These results are similar to those found by 
Chui et al (2007) although we found significantly more 
codon 245 variants in virus from HLA-B*5701–negative 
individuals than in their study (53.1% versus 24.5%), 
resulting in a lower specificity of codon 245 variation in 
predicting HLA-B*5701 positivity (47% vs 75%). PPV (18% 
vs 20%) and NPV (99.2% vs 96%) were similar.   Given the 
high negative predictive value for detection of wild type 
codon 245 and the possession of the HLA-B*5701 gene, 
RT sequencing  could be used as a simple screening tool 
to identify patients who could safely be treated with 
abacavir.
CHARACTERISATION	OF	TNF	BLOCK	
HAPLOTYPES	AND	GENOTYPES	THAT	
PREDICT	AN	INDIVIDUAL’S	RISK	OF	
STAVUDINE-ASSOCIATED	SENSORY	
NEUROPATHY.
Chew C SN1, Cherry CL2,3,4,Affandi J1 , Valente F5, Imran D6, 
Kamarulzaman A7, Tan Hy7 and Price P1
1Pathology and Laboratory Medicine, University of 
Western Australia, Perth, WA, Australia; 2Burnet Institute, 
Melbourne, VIC, Australia; 3Alfred Hospital, Melbourne, 
VIC, Australia; 4Monash University, Melbourne, VIC, 
Australia; 5University of Denis Diderot, Paris, France; 
6Cipto Mangunkusumo Hospital, University of Indonesia, 
Indonesia; 7Infectious Disease Unit, University of Malaya 
Medical Centre, Malaysia
Sensory Neuropathy (SN) is common in HIV patients 
and is promoted by exposure to the anti-retroviral drug, 
stavudine (“d4T-SN”). Stavudine remains in first-line HIV 
treatment in resource-limited settings as it is effective, 
inexpensive and does not cause anaemia.  We are 
addressing genetic determinants of d4T-SN risk.
Alleles of genes in the TNF haplotype block may 
modulate d4T-SN risk. We associated TNFA-1031*2 
carriage with d4T-SN in both Australian and Indonesian 
HIV patients exposed to d4T.  As linkage disequilibrium 
within the TNF block hampers identification of single 
nucleotide polymorphisms (SNP) responsible for disease 
associations, we are undertaking additional genotyping 
in control donors and d4T-exposed HIV patients from 
various ethnic populations.  We use the PHASE algorithm 
to define haplotypes based on 37 SNP spanning 6 genes 
around TNFA.
We find 15 conserved haplotypes account for >94% of 
healthy Caucasians (n=398). Sixteen haplotypes also 
account for >97% of South East Asian donors (n=247) - 
this includes 8 haplotypes found in Caucasians.  Although 
TNFA-1031*2 is associated with d4T-SN in both Indonesian 
and Australian patients, the underlying haplotypes 
appear different in each population. Haplotype FV10 
can be tagged by IKBL+446*2. FV10 occurs at similar 
frequencies (11-12%) in Caucasian and South East Asian 
controls and hence is a candidate risk haplotype. FV10 
accounts for 52.9% of Australian patients exposed to d4T 
carrying TNFA-1031*2 and may associate with d4T-SN 
in these patients (31% vs 16%, p=0.27), but this requires 
confirmation. 
To date five TNF block SNP have been genotyped in 
d4T-exposed Indonesian patients. Surprisingly, linkage 
disequilibrium was observed between TNF-1031*2 
and IKBL+446*2 in d4T-exposed patients without SN 
(p=0.0009), but not in d4T-SN patients (p=0.76). Carriage 
of TNF-1031*2 and homozygosity for IKBL+446*1 was 
associated with an 8-fold increased risk of d4T-SN in 
Indonesians (p=0.004). This makes it unlikely that FV10 
will associate with risk in Indonesians.
Response & Predictions in ART
5.00pm – 6.30pm
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Taken together, these findings suggest that TNFA-1031*2 
may play a role in the pathogenesis of d4T-SN, rather than 
being a marker for a risk haplotype.  This work is continuing 
with additional genotyping and haplotype analyses, 
including DNA from cohorts of additional ethnicities.
NATURALLY	OCURRING	POLYMORPHISMS	
IN	HIV-1	INTEGRASE:	RELATIONSHIP	TO	
HIV	SUBTYPE,	INTEGRASE	INHIBITOR	
RESISTANCE	AND	IMMUNE	SELECTION
Tschochner M1, Chopra A1, Maiden T1, Ahmad I1, Fordham 
A1, Mallal S1, John M1
1Centre for Clinical Immunology and Biomedical Statistics, 
Royal Perth Hospital and Murdoch University, Perth, 
Western Australia
Integrase inhibitors have emerged as an important new 
class of antiretroviral agents.  A number of resistance 
associated mutations have been described based on 
pre-clinical testing.  In order to determine whether viral 
subtype or HLA-specific immune selection may contribute 
to baseline integrase inhibitor resistance, we examined 
the prevalence of naturally occurring polymorphisms in 
the integrase sequences of 202 HIV-1 infected patients 
in the Western Australian HIV Cohort, all of whom were 
naïve to integrase inhibitors.  We further examined these 
changes in relation to HIV subtype, co-variation patterns 
and established associations with HLA alleles.
Integrase sequences obtained by bulk sequencing and 
4-digit HLA class I genotypes determined by sequence 
based typing were examined at a codon-specific level. 
The subtypes of all samples were assigned on the basis of 
the genome wide sequences using the NCBI genotyping 
tool.
The subtype distribution in the cohort revealed 74.8% 
were subtype B, 4% C, 4.5% CRF01, 0.5% CRF02, 0.5% 
CRF06 and 15.8% inter-subtype recombinants.  Residues 
E92, T97, F121, and y143 were absolutely conserved, 
however at other sites the prevalence of resistance-
associated mutations was as follows: E138K (1.2%), G140S 
(2.3%), V151I (2.9%), M154I (2.4%), N155S (0.6%), E157Q 
(3.6%), G163R (3.0%), y226D (0.6%), D232N (0.6%).  Several 
residues (51, 61, 74, 125, 147, 148, 153, 183 and 230) had 
some degree of polymorphism but none that were drug 
resistance-associated changes. No sequences contained 
the resistance associated T125K.  However, an alternative 
polymorphism T125A occurred in 35.5% of sequences 
and was dominated by non-B subtype sequences (3% of 
sequences with T125 were non-B subtypes versus 62.3% 
with A125).  Notably, this polymorphism corresponds to 
HLA-B*5701/-B*5703 and -B*5801 driven escape within 
the known SW10 epitope. 
In a population-based cohort, most integrase residues 
previously associated with integrase inhibitor resistance 
are highly conserved across and within HIV-1 subtypes, 
in keeping with being sites of significant functional, 
catalytic or structural importance. T125A appears to be 
subtype-specific as well as a result of immune selection 
in individuals expressing HLA-B*57/5801.  Otherwise, the 
low prevalence of natural polymorphism is consistent 
with the lack of overlap between evident immune and 
drug targets in the integrase gene.
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PATIENT	CHARACTERISTICS	AND	
PREDICTORS	OF	TIME	TO	COMMENCE	
ANTIRETROVIRAL	TREATMENT	IN	A	
PROSPECTIVE	COHORT	IDENTIFIED	AT	
PRIMARY	HIV	INFECTION	(PHI).	(THE	
PHAEDRA	COLLABORATIVE	COHORT)
Grey P1, Srasuebkul P1,Finlayson R2, Workman C3, McFarlane 
R4, Bloch M5,Medland N6, Roth N7, Anderson J8, Hoy J9, 
Read T10,Petoumenos K1, Kelleher A1.
1National Centre in HIV Epidemiology and Clinical 
Research, Sydney, Australia; 2Taylor Square Private Clinic, 
Sydney, Australia; 3Aids Research Initiative, Sydney, 
Australia; 4 407 Drs, Sydney, Australia; 5 Holdsworth House 
Medical Practice, Sydney, Australia; 6 The Centre Clinic, 
Melbourne, Australia; 7 Prahran Market Clinic, Melbourne, 
Australia. 8Carlton Clinic, Melbourne, Australia; 9 The Alfred 
Hospital, Melbourne, Australia;10 Melbourne Sexual Health 
Clinic, Melbourne, Australia.
Primary Infection (PHI) presents an opportunity to study 
HIV disease throughout its infection period. The PHAEDRA 
cohort was established to determine immunological, 
virological and therapeutic factors related to disease 
progression. There are a number of theoretical reasons, 
which support early antiretroviral treatment (ART). To 
find out what factors influenced the time to initiation of 
treatment in this cohort, a range of baseline factors were 
assessed. 
From September 2002 to June 2007 data was collected 
on consenting subjects identified with either acute or 
early infection or with known dates of seroconversion. 
Acute and Early infection was defined by standard 
serological criteria. Demographic data plus Western Blot 
ELISA, Viral load, CD4, PHI symptoms and ART history 
were collected.
Of the 341 patients who consented, at the time of analysis, 
79 were never treated (NTx) and 262 commenced 
therapy (103 through clinical trials (CTx), 159 off clinical 
trials (Tx). Median age overall was 36 years. In the NTx 
group 35% were acutely infected compared with 67% in 
the Tx and 62% of CTx. In the NTx group 67%had PHI 
symptoms against 85% of Tx group and 87% of CTx 
patients. Median CD4 and RNA at baseline was 637.5cells/
mm3, 4.6 log10 for NTx respectively, 510cells/mm3, 5.9 
log10 for CTx and for Tx 495cells/mm3, 5.6 log10. The 
median time to commence treatment in CTx group was 
1.5 weeks compared to 6 weeks in Tx group.  Therefore 
despite similar clinical baseline characteristics therapy 
was commenced earlier in CTx patients. In multivariate 
Cox-regression analyses, predictors of time to commence 
treatment were:  Acute status (p = <0.001), the presence 
of PHI symptoms (p =0.037), clinical trial status (p = 
<0.001) and lower CD4 at baseline (p=0.028) with higher 
RNA (p = 0.010).
Having a higher viral load and lower CD4 with PHI 
symptoms at baseline, predicted the uptake of 
antiretroviral treatment at seroconversion. These 
determinants were no different between commencing 
therapy, on or off a trial but the time to start treatment 
was much less in those in the CTx group.
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ASSESSING	ADHERENCE	IN	THAI	PATIENTS	
TAKING	HAART
Kerr SJ1,5, Avihingsanon A1, Putcharoen O2, Chetchotisakd 
P3, Duncombe, C1,5, Teeratakulpisarn S4, Phanuphak N4, 
Ruxrungtham K1,2, Cooper DA,5 Phanuphak P1,4.
1HIV Netherlands Australia Thailand Research 
Collaboration, Bangkok, Thailand; 2Faculty of Medicine, 
Chulalongkorn University, Bangkok, Thailand; 3Faculty of 
Medicine, Khon Kaen University, Khon Kaen, Thailand; 
4Thai Red Cross AIDS Research Centre, Bangkok, Thailand; 
5National Centre in HIV Epidemiology and Clinical 
Research, Sydney, NSW. Australia
Excellent adherence to HAART will maintain viral 
suppression and offset resistance.  We compared two self-
reporting tools that can be used for rapid assessment of 
adherence in a clinical consultation, and assessed predictors 
that might allow early identification of non-adherent 
patients. Tool one was a visual analogue scale (VAS), 
tool two, the 3 question CASE adherence questionnaire 
(CASE). Poor adherence was defined as < 95% on VAS and 
≤ 11 out of a possible 16 on CASE.  224 patients (Male 
63%, age 38 (interquartile range [IQR] 33 – 44) years) from 
3 sites in Thailand and duration of HAART treatment 51 
(IQR 26 – 82) months completed the questionnaires and 
had plasma HIV-RNA (viral load) assessments.  Daily pill 
burden was 4 (IQR 2 – 6) pills; 49 (22%) patients were on 
their first regimen.  24 (11%) patients had poor adherence 
on VAS; 17 patients had poor adherence on CASE.  Six 
patients had poor adherence on both tools.  24 patients 
had plasma viral load detectable at > 50 copies/mL. The 
odds ratio (OR) for poor adherence and detectable viral 
load with VAS was 4.4 (95% confidence interval [CI] 1.6 
– 12.2) and for CASE was 5.7 (95%CI 1.9 – 17.3), and for 
patients who scored with poor adherence on both tools 
was 19.8 (95%CI 3.4 – 114.9).  Time to complete VAS was 
15 (IQR 7 – 28) seconds and 45 (IQR 30 – 60) seconds 
for CASE.  Gender, education, marital status, income, pill 
burden, transmission group, alcohol use, concurrent 
treatment with drugs for opportunistic infections or TB, 
duration of HAART or whether the patient paid for drugs 
themselves were not associated with poor self-reported 
adherence with either tool. Most questions about affect 
and self-esteem were also not associated with poor 
self-reported adherence, but patients indicating at least 
fairly often, felt ‘unable to cope with all the things they 
had to do’, had lower adherence scores.  For patients who 
said they missed at least one dose of medication in the 
previous month, fear of arousing suspicion was cited as an 
important factor.  Both adherence tools could be rapidly 
conducted in a clinical setting and poor scores predicted 
detectable viral load.
SIDE	EFFECTS,	DOSING	SCHEDULES,	
PILL	BURDEN	AND	PERCEIVED	STRESS:	
INTERACTION	AND	INFLUENCE	ON	
MEDICATION	ADHERENCE
Herrmann S1, McKinnon E1, John M1,2,  Nolan D1,2, OP 
Martinez 1,2,3, Phillips E1,2 , Mallal S 1,2
1Centre for Clinical Immunology & Biomedical Statistics, 
Royal Perth Hospital & Murdoch University; 2Department 
of Clinical Immunology & Immunogenetics & PathWest 
Laboratory Medicine, Royal Perth Hospital; 3School of 
Pathology and Laboratory Medicine, University of Western 
Australia. 
 
HIV Cohort research in Royal Perth Hospital (RPH) between 
the years 2002-2005 found that adherence to ART 
predicted viral suppression and CD4 T-cell recovery and 
diminishing adherence was associated with indicators 
of perceived stress, depression and the impact of side 
effects, particularly fatigue and skin itching. Whether 
these variables were associated with a particular regimen 
or dosing schedule was not studied. 
Patients attending the Immunology Outpatient Clinic 
at RPH over a 3 month period in 2008 completed a 
questionnaire on ART (N=156), concomitant medications, 
pill burden, dosing schedule, side effects and perceived 
stress. Doctors verified the regimen and assigned a 
medication score indicating ART adherence. 
The majority of regimens included a nucleoside backbone 
of abacavir/lamivudine (50%), tenofovir/emtricitabine 
(23%) tenofovir/lamivudine (8%) or zidovudine/
lamivudine (7%) combined with either a ritonavir-boosted 
PI (35%; atazanavir 22%), efavirenz (28%) or nevirapine 
(25%). 108 vs 48 patients were on OD vs BD regimens 
respectively. Adherence improved since 2005 with 75% 
vs 55% of patients surveyed reporting 100% adherence 
over the previous month. Neither dosing schedule nor 
pill burden was associated with poorer adherence. Non-
adherent patients reported more coping difficulties 
(p=0.02) than adherent, and the number of side effects 
experienced correlated with higher total perceived stress 
score (p=0.004). 130 patients experienced at least one 
side effect, 36% taking medication for relief. Compared 
with five years ago reported diarrhoea was reduced (34% 
vs 51% of patients), but reported fatigue (59%) muscle 
pain (36%), headache (36%), nausea (32%) and skin itch 
(39%) were comparable. Although boosted PI regimens 
were associated with more frequent side effects than 
NNRTI regimens, including headache (54%),  diarrhoea 
(54%) and fever (atazanavir: 41%),  they did not strongly 
correlate with reduced adherence (p=0.3). 
In our cohort adherence has improved in the last two 
years: simpler dosing schedules and the decreased 
frequency of certain side effects such as diarrhoea 
may have contributed.  In those patients with a higher 
frequency of reported symptoms and perceived stress, 
reduced adherence may be associated with health related 
quality of life (HRQL) issues not measured in this study. 
Further research is needed to understand the interaction 
between HRQL and medication adherence.
Adherence to Antiretroviral Therapy
5.00pm – 6.30pm
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IMPROVED	TREATMENT	ADHERENCE	
ASSOCIATED	WITH	TREATMENT	
SIMPLIFICATION
Baker D1, Vale R1, Doong N2, Bloch M3, Hudson J2, 
McMurchie M1, McFarlane R1
1407 Doctors, Darlinghurst, NSW, Australia; 28 Burwood 
Rd, Burwood, NSW, Australia, 3Holdsworth House Medical 
Practice, Darlinghurst, NSW, Australia
 
Objective: The OneDa study is a randomised, multi-
centre, open-label study in well-controlled treatment-
experienced HIV-infected patients to assess adherence 
to a once-daily regimen of antiretroviral therapy versus 
continuation of current anti-retroviral regimen delivered 
at least twice daily over a 48 week period. 
Method: Adherence with therapy was measured using 
electronic monitoring (MEMS cap), patient self-report 
(MASRI questionnaire), therapeutic drug monitoring 
(TDM) and doctor assessment. Prior to randomisation all 
patients had a one month baseline observation period 
during which their adherence with their current twice-
daily combination therapy was evaluated.  Patients 
were then randomised to continuing current therapy or 
switching to once-daily treatment with any approved 
once-daily regimen. At week 24 patients were switched 
to once-daily therapy.
Results: 96 patients with fully suppressed virus were 
randomised.  94 were males, with an average age of 43 
and average length of HIV infection of 10 years.  Adherence 
(medication prescribed / medication taken) in the baseline 
month, as measured by MEMS cap, was 84.4%.  24 weeks 
adherence (MEMS caps) was significantly higher in the 
once-daily arm at 95.0% versus the continuation arm at 
85.6% (p value 0.019).  No virological failure (VL > 400 
copies/mL) was reported in either arm.
Conclusions: Treatment simplification to once daily 
treatment appears to be an effective and safe approach 
to improving adherence to antiviral therapy.
ADHERENCE	TO	ANTI-RETROVIRAL	THERAPY	
AMONG	PATIENTS	IN	BANGALORE,	INDIA	
Cauldbeck MB1, O’Connor C2,  Saunders JA3, O’Connor 
MB4, Rao B5, Mallesh GV5,  Praveenkumar KN5, Mamtha D5, 
McGolderick C6, Laing RBS6, KS Satish5.
1The School of Medicine, University of Aberdeen, 
Aberdeen, Scotland; 2GU/STD Clinics, Mid-Western 
Regional Hospital, Limerick, Ireland; 3Department of 
Mathematics and Statistics, University of Limerick, 
Ireland. 4Department of Medicine, South Infirmary - 
Victoria University Hospital, Cork Ireland; 5Department of 
Respiratory and HIV Medicine, Rajajinagar and Wockhardt 
Hospital and Heart Institute, Bangalore, India; 6Infection 
Unit, Aberdeen Royal Infirmary, Aberdeen, Scotland.
HIV has an estimated prevalence of 0.9%  in India (5.2 
million).  Anti-retroviral drugs are the treatments of choice 
and non-adherence is an important factor in treatment 
failure and development of resistance, as well as being 
a powerful predictor of survival. This study proposes to 
assess adherence to ART in HIV+ patients in Bangalore, 
India a country where 10% of those who need get 
therapy.
A cross-sectional anonymous questionnaire survey of 
60 HIV+ patients was carried out on patients attending 
HIV outpatient services in Bangalore, India. Consent was 
obtained and translation was carried out when required. 
Data was analysed using SPSS. 
A response rate of 53/60 (88%) was achieved. The mean 
patient age was 39.85 yrs, with 50% aged 30-40 and 
73.6% of participants were male. Mean family size =4.8 
(1-13). 21% lived <50kms & 21% >400kms from clinic. 
60% were fully adherent to their medications. Adherence 
was statistically significantly linked to regular follow-
up attendance (70.5%, p=0.002).  No other results were 
statistically significant but trends were found. Better 
adherence were seen in older patients(>40=50%, 
<40=15%), males, those from larger families, those who 
had AIDS (AIDS=72%, Well= 50%), those taking fewer 
tablets (<5 =76%, 5-9=41%) and without food restrictions 
(Without=70%, With= 48%). Commonest side-effects 
causing non-compliance were metabolic reasons (66%) 
and GIT symptoms (50%). No differences were seen for 
education level, family income, distance travelled to clinic, 
time since diagnosis, or time on ART. 
In conclusion regular attendance for follow up was 
statistically significant for adherence. Positive trends were 
seen in those in larger families, older, those who had 
AIDS, simple regimes, and without side-effects. Education 
income, distance travelled and length of time diagnosed 
or treated had no effect.
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AIDS	DEMENTIA	COMPLEx	(ADC)	AND	
MENTAL	ILLNESS:	THE	ROLE	OF	THE	NSW	
MENTAL	HEALTH	ACT	IN	MANAGING	
COMPLIANCE	WITH	HIGHLY	ACTIVE	ANTI	
RETROVIRAL	THERAPY	(HAART)
Ibrahim D1
1AIDS Dementia and HIV Psychiatry Service (ADAHPS), 
Sydney, NSW, Australia
ADC is a well recognised syndrome that is generally 
associated with advanced HIV disease and is prevalent in 
some 10% of the HIV infected population. It is commonly 
characterised as a ‘frontal-subcortical’ dementia and 
is typified by impairments in cognitive and motor 
functioning, and may be associated with emotional/
personality disturbances.
The level of impairment seen in ADC can compromise 
an individual’s ability to maintain their capacity for 
independent living and their capacity for rational decision 
making. Further compounding this problem is the higher 
incidence of mental illness amongst HIV sufferers and, 
therefore, those with ADC, which can further impinge 
upon competent decision making and the ability of 
individuals to act in the interests of their own health and 
welfare.
A significant health and welfare issue in this population is 
medication adherence. Studies show a strong correlation 
between good HAART compliance and neurological 
improvement in cognitively impaired individuals. 
Cognitively compromised individuals with a concomitant 
mental illness are at further risk, in that poor compliance 
with their non-HAART medications can often lead to a 
relapse of psychotic symptoms. 
In recent times, clients of our service with ADC who have 
been placed on Community Treatment Orders (CTOs), for 
the treatment and management of psychotic symptoms 
related to their mental health issues, have also had HAART 
medications placed on the treatment order. This indicates 
that cognitive health and mental health are seen as 
closely linked, and that the management of mental health 
issues (in this particular client group) cannot be made in 
isolation from the management of cognitive issues.
To date, the effectiveness of CTOs in compelling individuals 
with ADC and mental health issues to take HAART has yet 
to be evaluated. This paper will present a case study, and 
will canvass the views of a number of health & welfare 
practitioners working in the HIV field regarding CTOs & 
HAART. Certain questions will be explored, for instance: 
What would happen if an individual took objection and 
challenged the order? Could an individual be hospitalised 
under the Mental Health Act for not complying with 
HAART treatment in the order? Could CTOs be applied 
to those with cognitive impairment, but without a 
concomitant mental illness?
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Case Presentation Breakfast
7.00am – 8.45am
AUTOIMMUNE	HAEMOLYTIC	ANAEMIA:	
AN	UNUSUAL	PRESENTATION	OF	HIV	
SEROCONVERSION
Sherry NL1, Korman TM1,2
1Department of Infectious Diseases, Monash Medical 
Centre, Melbourne, VIC, Australia; 2Department of 
Medicine, Monash University, Melbourne, VIC, Australia
Autoimmune haemolytic anaemia (AIHA) is uncommon 
is HIV, although positive direct antiglobulin tests (DAT) 
occur quite frequently.  Previous reports describe this 
condition mainly occurring in advanced AIDS.  We 
describe a case of AIHA as a novel presentation of HIV 
seroconversion.  A 54 year-old man presented with 
fever, rash and sore throat, followed by dyspnoea and 
haemoglobinuria one week later.  AIHA was diagnosed, 
characterised by positive DAT with C3b specificity and 
negative cold agglutinins.  The patient’s haemoglobin fell 
to 62g/L, and improved with high-dose corticosteroids 
and intravenous immunoglobulin.  Anti-HIV ELISA was 
positive, and a positive Western blot evolved consistent 
with HIV seroconversion.  Baseline CD4 count was 92 
cells/µL with a HIV viral load of 75,000 copies/mL, and 
antiretroviral therapy was subsequently commenced. 
We review previous published reports, specifically stage 
of HIV, haematological parameters (characteristics of DAT, 
reticulocyte count), management and outcome data.
STEROID	DEPENDENT	CRYPTOCOCCAL	
IMMUNE	RESTORATION	DISEASE	IN	A	HIV	
POSITIVE	PATIENT
Peel T1, McLean C2,3, Cameron P1,3, Hoy J1,3, Wright E1,3,4
1Infectious Diseases Unit, Alfred Hospital, Melbourne, VIC, 
Australia; 2Department of Anatomical Pathology, Alfred 
Hospital, Melbourne, VIC, Australia; 3Faculty of Medicine, 
Nursing and Health Science, Monash University, VIC, 
Australia; 4Burnet Institute, Alfred Medical Research and 
Education Precinct, Melbourne, VIC, Australia
We present the case of a 36 year old HIV positive man with 
the management dilemma of a prolonged Cryptococcal 
Immune Restoration Disease (IRD) managed with highly 
active anti-retroviral therapy (HAART) and corticosteroid 
therapy.
The patient initially presented in September 2006 with 
cryptococcal meningitis, occurring on a background of HIV 
diagnosed in 1997. The patient had ceased HAART several 
years previously but had restarted abacavir, lamivudine 
and boosted atazanavir one week prior to presentation 
wherein his CD4+ cell count was 11.0/uL and plasma HIV 
load was 55, 000 copies/ml.  Cryptococcus neoformans 
was cultured from the CSF and serum and cerebrospinal 
(CSF) cryptococcal antigen titres were  1:4096 and 1:256, 
respectively.  Initial treatment comprised two weeks 
of amphotericin B deoxycholate (0.7mg/kg/day) and 
5-fluorocytosine (2g QID) followed by oral fluconazole 
400mg daily. 
The patient’s course was complicated by multiple 
presentations with headache, fever, seizures, raised 
intracranial pressure and obtundation coinciding with 
attempts to reduce the corticosteroid dose. Serial Magnetic 
Resonance Imaging of brain demonstrated progressive 
leptomeningeal enhancement. A brain biopsy showed 
encapsulated yeast cells; morphologically consistent 
with Cryptococcus however, cultures from tissue and 
CSF failed to isolate the organism. In February 2008, 
the patient presented with cervical lymphadenitis and 
airway compromise. Lymph node biopsy demonstrated 
abundant yeast cells, consistent with Cryptococcus, but 
no organisms were cultured. Of concern, the patient has 
had significant complications secondary to prolonged 
corticosteroid therapy including mood disturbance, 
weight gain, osteoporosis and vertebral crush fractures. 
Adjunctive non-steroidal anti-inflammatory agents did 
not have clinical benefit. 
The patient has remained on HAART throughout with 
virological suppression, but poor restoration of CD4+ 
cell counts. Fluconazole therapy has been maintained 
throughout. Serum and CSF Cryptococcal antigen titres 
have decreased to 1:512 and 1:4, respectively. 
Oral Poster Session - Public Health and 
Epidemiology
7.45am – 8.45am
Roth N - see page 268
Stoove M - see page 269
Allison W - see page 244
Hsu D - see page 228
Jin F - see page 247
Pedrana A - see apge 250 
O’Connor M - see page 249
Prihaswan P - see page 221 
Connelly C - see page  279
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HAART and antifungal therapy. In the setting of severe 
or refractory Cryptococcal IRD corticosteroids may be 
beneficial. In the case described corticosteroids have 
been poorly tolerated however their dose reduction has 
precipitated life-threatening events. Future management 
may require substitution of corticosteroids with other 
immunosuppressive therapy.
A	CASE	OF	TENOFOVIR-ASSOCIATED	RENAL	
TUBULAR	ACIDOSIS	WITH	NEUROLOGICAL	
IMPAIRMENT
Barber B, Denholm J, Fuller A, Hoy J
Department of Infectious Diseases, Alfred Hospital, 
Melbourne, Victoria, Australia.
A 47 year old HIV positive man was admitted to hospital 
in August 2007 with two days of diplopia, expressive 
dysphasia and right sided paraesthesia, on a background 
of several months of lethargy and weight loss.  His HIV 
had been stable since 2002 on tenofovir, emtricitabine 
and delavirdine, with a recent CD4 cell count of 200 cells/
µl and HIV viral load of 450 copies/ml.
On admission, MRI of brain revealed multifocal hyperdense 
lesions of uncertain aetiology.  CSF revealed an elevated 
protein, undetectable HIV viral load, and no lymphocytes 
or other abnormalities.  CSF PCR for HSV, VZV, JC virus, CMV, 
EBV and toxoplasma was negative, as was serum syphilis 
serology.  Pathological examination of a brain biopsy was 
consistent with an active chronic meningoencephalitic 
process.  He was commenced on empirical antibiotics, 
although the diagnosis remained uncertain.
Four days after admission his conscious state deteriorated 
and he developed complete left gaze paresis, 
corresponding with progression of the MRI findings. 
His deterioration corresponded with the development 
of a profound non-anion gap metabolic acidosis (Na+ 
142, Cl- 118, HCO3 4), in addition to hypokalemia, 
hypophosphatemia, proteinuria (0.41g/L), decreased 
creatinine clearance (50mL/min) and urinary biochemistry 
consistent with proximal renal tubular acidosis (RTA).  A 
diagnosis of Fanconi’s syndrome was made and the 
patient was admitted to ICU and commenced on a 
bicarbonate infusion in addition to aggressive fluid 
and electrolyte replacement.  Tenofovir and other 
antiretrovirals were ceased.  The patient responded to 
correction of his acidosis and was discharged one month 
later with significant improvement of his neurological 
symptoms and MRI findings. 
Prior to discharge he was commenced on etravirine, 
darunavir, abacavir, lamivudine and ritonavir.  Six months 
post discharge the patient remains on 30g of sodium 
bicarbonate and 6.5g of potassium citrate daily.  His renal 
function remains impaired with a creatinine clearance of 
56 mL/min.
Proximal RTA is a well recognised adverse effect of 
tenofovir and adefovir.  We describe a case of severe 
Fanconi’s syndrome resulting in irreversible metabolic 
acidosis and renal impairment.  In addition this case raises 
the possibility of neurotoxicity as a result of tenofovir-
associated acidosis.  
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STTHREE’S	A	CROWD:	THE	RELATIONSHIP	
BETWEEN	CA-MRSA,	HIV	AND
MSM
Rogers BA1, Street AC1
1 Victorian Infectious Diseases Service, The Royal 
Melbourne Hospital, Parkville,
Victoria Australia.
Community acquired methicillin resistant Staphylococcus 
aureus (CA-MRSA) infections are increasing in frequency 
in Australia and overseas. Most of these infections are 
confined to the skin, but more serious deep-seated 
infections can occur. Risk groups identified have included 
some indigenous communities, injecting drug users 
and sporting teams. CA-MRSA has also been described 
overseas in association with HIV infection and in men who 
have sex with men (MSM). Sexual transmission of a highly 
resistant CA-MRSA isolate has recently been reported 
amongst MSM in North America. To our knowledge no 
studies have examined the relationship between MSM, 
HIV and CA-MRSA infections in Australia.
We describe the case of a 46 year old gay man with a 
life threatening CA-MRSA infection in the setting of HIV 
infection with a low CD4 cell count (60/microlitre).
The infection originated from multiple skin abscesses. 
Subsequent bacteraemia was complicated by the 
development of a large prostatic abscess and metastatic
pulmonary foci. The isolate was resistant to methicillin, 
ciprofloxacin and erythromycin but it remained susceptible 
to trimethoprim-sulfamethoxazole, rifampicin, fusidic 
acid and vancomycin; it tested positive for the virulence 
factor Panton-Valentine leukocidin. Further molecular 
characterisation is in progress.
Successful management required surgical drainage of 
the prostatic abscess followed by prolonged intravenous 
then oral anti-staphylococcal therapy, totalling 37 days. 
His course was complicated by prolonged fever and 
antibiotic allergies.
Antiretroviral therapy, which had been previously 
discontinued, was restarted, with attention to interactions 
with oral anti-staphylococcal therapy.
To our knowledge, this is the first case of disseminated CA-
MRSA infection reported in association with HIV infection 
in Australia. A high prevalence of CAMRSA among HIV 
positive patients in Australia or the sexual transmission 
of MRSA locally would have significant implications for 
individual health and for the empirical management 
of staphylococcal infections. A study of CA-MRSA to 
delineate the incidence and transmission among HIV 
positive patients and MSM in Australia is needed.
FATAL	ACUTE	VARICELLA-zOSTER	VIRUS	
HAEMORRHAGIC	MENINGOMYELITIS	WITH	
NECROTISING	VASCULITIS	IN	AN	HIV-
INFECTED	PATIENT
Chang CC1, McLean C2, Vujovic O1, Jenney AWJ1, Short M3, 
Lyon S4, Storey E3, Lewin SR1,5
1Infectious Diseases Unit; 2Anatomical Pathology 
Department; 3Neurology Department; 4Radiology 
Department, The Alfred Hospital; 5Department of 
Medicine, Monash University, Commercial Road, Prahran, 
Victoria 3004, Australia.
A 41 year-old woman was transferred from a peripheral 
hospital to our institution with 2 days of fevers, headache, 
neck pain and progressive flaccid quadriparesis.  She had a 
background of HIV infection diagnosed 15 years ago, with 
the most recent CD4 T-cell count (and nadir) of 155 cells/
µl (7%) and HIV RNA of 6000 copies/ml three weeks prior 
to admission.  She had no history of AIDS-defining illness. 
Two weeks prior to her presentation, her antiretroviral 
regime was changed from lamivudine, nevirapine and 
abacavir to lamivudine, raltegravir and ritonavir-boosted-
atazanavir for immunological and virological failure.  
At presentation, she had a flaccid quadriparesis and was 
febrile and drowsy with demonstrable neck stiffness 
and an occasional vesicular lesion over her trunk.  CT 
brain was normal and lumbar puncture revealed bright 
yellow cerebrospinal fluid (CSF) with an opening pressure 
of 15cmH20.  CSF analysis revealed xanthochromia, 
extremely elevated protein of 39.0g/L (normal range 
[NR] 0.15-0.4g/L), glucose of 2 mmol/L (NR 2.5-4.5mmol/
L), 1400 red cells, 40 polymorphs and 2 lymphocytes 
suggestive of necrotising myelitis.  CD4 T-cell count at 
presentation was 83 (9%).  
A clinical diagnosis of VZV-associated necrotising 
meningomyelitis was made.  Empirical intravenous 
dexamethasone 10mg 6-hourly, acyclovir 500mg 8-
hourly, ceftriaxone 2g 12-hourly and benzylpenicillin 
1.8g 4-hourly were immediately administered.  MRI brain 
and spine revealed meningeal enhancement around 
the circle of Willis and brainstem, contiguous with 
marked oedema and expansion of her cervical cord with 
abnormal T2 signal.  “Sugar-coating” of her entire spinal 
cord was noted.  Progressive bulbar palsy and respiratory 
failure ensued and she died 60 hours post arrival to our 
institution.  
Varicella zoster virus (VZV) was detected by PCR in her CSF 
and skin vesicle.  Post-mortem examination confirmed 
extensive infarction and haemorrhagic necrosis of 
the entire spinal cord due to necrotising vasculitis in 
association with a lymphocytic meningitis.  
This is the first case report of VZV-associated fulminant 
haemorrhagic meningomyelitis with necrotising 
vasculitis occurring in a moderately immunosuppressed 
HIV-infected patient in the HAART era.  We believe this is 
potentially related to VZV immune restoration disease.  
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PUBLIC	HEALTH	AND	SOCIAL	SCIENCE	IN	
CLINICAL	RESEARCH:	THE	INTEREST	OF	A	
MULTIDISCIPLINARY	APPROACH
Bruno Spire1, Catherine Leport2, François Raffi3, Geneviève 
Chêne4 and Jean-François Delfraissy5
1INSERM U912/ORS-PACA, Marseille, France; 2Faculté 
xavier Bichat, Paris, France; 3Hôtel-Dieu, Nantes, France
4INSERM U 897, Bordeaux, France; 5French Agency of 
research on HIV and viral hepatitis (ANRS), Paris, France
This presentation aims to summarise almost 10 years of 
results obtained through interactions between social 
scientists and clinical researchers in France since the 
advent of highly active antiretroviral therapy (HAART). 
Such collaborations have been set up in the context 
of cohort studies or clinical trials which included 
collection of both clinical and socio-behavioural data. 
This co-operation conveys several key messages about 
adherence, quality of life and sexual behaviours. One 
major result is the demonstration that adherence to 
HAART is not predictable before treatment initiation. 
Moreover, adherence is a behaviour which changes over 
time. However, the impact of non-adherence on long-
term immuno-virological outcomes is crucial during the 
treatment induction phase and justifies interventions 
at treatment initiation. Interestingly, one randomised 
clinical trial also showed the positive impact of an 
educational and counselling type intervention which 
took into account the cognitive, emotional, social and 
behavioural aspects of patients’ daily lives on virological 
outcomes. Cohort studies have given us the opportunity 
to highlight a specific role of depression, independently 
of non-adherence, on HIV clinical progression. Among 
other important results, it is important to underline the 
role of patient’s perception of HAART-related toxicity: 
the perception of subjective side-effects is detrimental 
to adherence, risky sexual behaviours, patient-provider 
relationships and quality of life. Another randomized trial 
also showed that patients’ quality of life, estimated by the 
number of self-reported side effects, was better with LPV/
r monotherapy when compared with a triple regimen of 
LPV/r+AZT/3TC. Among future perspectives involving 
collaboration between clinicians and social scientists, 
other socio-behavioural issues should be addressed such 
as the level of forgiveness associated with adherence to 
a specific drug combination. The comparison of several 
HAART regimens should be evaluated for joint outcomes 
which could combine for example immuno-virological 
and quality of life outcomes. Answering these research 
questions through a multidisciplinary approach is critical 
for the comprehensive care of PLWHA.
THE	ROLE	OF	T-CELLS	IN	HIV	IMMUNITY:	
LESSONS	FROM	CHINA	AND	WEST	AFRICA
Sarah Rowland-Jones, Nuffield Department of Medicine, 
Oxford University, John Radcliffe Hospital, Oxford Ox3 
9DU, UK
The role of T-cell immunity in controlling HIV infection 
and shaping HIV evolution in the infected individual 
has been controversial. The example of HIV-2 infection 
in West Africa provides a potentially valuable (if under-
appreciated) model of human co-existence with a 
pathogenic retrovirus, in that the majority of HIV-2-
infected people have a normal lifespan with no signs of 
immune deficiency whilst those who develop disease do 
so in a manner identical to AIDS caused by HIV-1. Recent 
studies in the Gambia and Guinea-Bissau have shed light 
on the relative contributions of host and virus in long-
term non-progression in HIV-2 infection.
Whilst initial studies in Perth, WA, suggested that T-cells 
play a major role in determining how HIV evolves under 
selection pressure in an infected person, more recent 
analysis proposed that founder effect is an important 
factor that may have confounded the initial studies. We 
have evaluated the role of HLA-mediated selection in a 
Chinese village where infection with a single or closely-
related virus strain(s) occurred during a plasma donor 
scheme. This study, where founder effect is not a relevant 
factor, suggests that HLA-mediated selection is indeed 
the major cause of viral mutation in this cohort. 
Prevention
9.00am – 10.30am
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UNDERSTANDING	OUR	LAST	1,000	
INFECTIONS	-	KNOWING	OUR	EPIDEMICS	
FOR	MORE	EFFECTIVE	PROGRAMMING	
David Wilson
Lead Health Specialist, the World Bank and Adjunct 
Professor,
Centre for International Health, Curtin University of 
Technology
Introduction: Led by UNAIDS, “Know your epidemic, 
know your response” has become a rallying cry for an 
intensified focus on HIV prevention, spurred by the 
sobering realization that for every two people enrolled 
in antiretroviral treatment programs, five more become 
newly infected. The quest to better understand epidemics 
reflects growing recognition that there is no single global 
HIV epidemic, but rather a multitude of diverse epidemics. 
The era of “standard” global prevention guidance is over. 
However, there is a globally useful distinction between 
concentrated and generalized epidemics, which are 
fundamentally different – not because of arbitrary 
prevalence thresholds, but regarding who gets infected 
and how. 
Methods: Understanding who gets infected and how 
has led to the development of research methods to 
understand incident HIV infection - the figurative last 
1,000 infections in a given context. Methods include 
cohort studies, BED and other assays, modeling of 
incident infection and epidemiological syntheses.
Results: Analysis of the last 1,000 infections illustrates 
the limited extent to which HIV programming is 
matched to epidemic contexts. For too long, the global 
HIV prevention community has pursued generalized 
responses in concentrated epidemics, concentrated 
approaches in generalized epidemics, or hedged their 
bets and done a bit of everything everywhere. Many 
national AIDS strategies are unfocused, developed in the 
face of glaring data and analytic gaps and mismatched to 
epidemic context. Moreover, too few strategies are based 
on proven approaches.
Conclusions: The challenge is clear. For too long, AIDS 
activists, academics and national and international 
institutions have given insufficient emphasis to aligning 
prevention priorities with epidemic transmission 
dynamics, compromising effective prevention with 
unfocused or mismatched responses. The global AIDS 
community in its entirety has been slow to implement 
genuinely proven approaches at adequate scale. With 
the knowledge of HIV transmission dynamics and proven 
prevention approaches we already have, far more should 
have been – and can still be - done to curb HIV globally.
BIOLOGICAL	FACTORS	OF	SExUAL	
TRANSMISSION	OF	HIV
Pietro Vernazza 
St. Gallen, Switzerland
In general, transmission of HIV is rather an unusual event 
during a sexual encounter between two HIV-serodifferent 
partners than the rule. In newly diagnosed cases with HIV-
infection only approximately 20% of the actual steady 
sexual partners are found to be HIV-positive despite a 
longer period of unprotected sexual exposure to the 
infected partner. However, some case reports document 
frequent transmission of HIV from one infected individuals 
to a majority of his sexual partners. Several factors may 
explain this observed heterogeneity in transmission risk. 
The contributing factors could be divided into those 
which modify susceptibity in the non-infected partner 
and others influencing infectiousness in the positive 
partner. Inborn and acquired (specific) immunity will 
affect susceptibility as well as any disruption of the 
mucosal surface in the setting of sexually transmitted 
diseases (STDs) or other inflammatory genital conditions. 
The most potent factor influencing infectiousness of the 
HIV-positive partner is the concentration of HIV-Viral load 
in the blood. However, additional factors – mainly STDs –
are the second important factor influencing transmission 
risk to the non-infected partner. The biologic mechanism 
explaining the epidemiologic evidence of increased 
transmission under STDs might include (among others) 
an increase in the number of infected cells and free virus 
in the genital secretions. 
The presentation will summarizeour knowledge on 
the numerous biological factors contributing to the 
heterogeneity of HIV transmission.
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PROFILE	OF	HIV	ASSOCIATED	TUBERCULOSIS	
IN	THE	SETTING	OF	FREE	ANTI-RETROVIRAL	
THERAPY	AT	A	TUBERCULOSIS	HOSPITAL	IN	
INDIA
Agarwal U1, Kumar A1, Behera D1
1Antiretrviral therapy Centre, Department of Medicine, 
LRS Institute of TB and Respiratory Diseases, New Delhi, 
India 
Human immunodeficiency virus (HIV) associated 
tuberculosis (TB) poses a serious threat to public health. 
With the rollout of the national program, free of cost 
antiretroviral therapy is available to the Indian population 
since 2004. It still remains to be seen, how TB in HIV 
patients changes in terms of presentation, outcome, 
relapse and diagnostic modalities. 
This study was undertaken with the aim to assess the 
presentation and outcome in patients concurrently 
treated for TB and HIV.
Retrospective review of medical records of 251 adult and 
adolescent HIV positive patients, registered between 
January 2006 and June 2007 was performed. Patients 
were said to be concurrently diagnosed with HIV and 
active tuberculosis if the two diseases were diagnosed 
within one month of each other. 
73 (29.1%) of the 251 HIV infected patients, were 
diagnosed with concurrent active tuberculosis. Weight 
loss of more than ten percent and fever were the 
commonest presenting symptoms. Eighty seven per cent 
of the HIV-TB patients presented with CD4 counts less 
than 200 cells/µl. The mean CD4 count at presentation 
was 108.2 cells/µl. 
38.4% patients had purely pulmonary tuberculosis, 39.7% 
had purely extra-pulmonary tuberculosis and 21.9% 
had both. Sputum positivity for acid fast bacilli (AFB) in 
those with pulmonary disease was 34.1 %. Four sputum 
negative patients of disseminated TB, revealed AFB on fine 
needle aspirate of lymph nodes. Immune reconstitution 
inflammatory syndrome (IRIS) was seen in 20.5% patients. 
The mean interval between initiation of ART and IRIS was 
found to be 17.7 days (median 15, range 7- 44). 
Sixty seven per cent patients had a favorable outcome to 
tuberculosis treatment (cure and treatment completed), 
there were four defaulters and two treatment failures. 
There was only one patient of proven multi drug resistant 
(MDR) tuberculosis in this data.  Case fatality of 17.8% was 
observed.  
We concluded, nearly 30% of HIV infected patients 
accessing medical care had concurrent active tuberculosis. 
Despite profound immunosuppression at presentation, 
treatment of both the conditions together lead to an 
improved outcome. Efficient HIV-TB collaboration should 
be an integral component of comprehensive HIV care.
GENERAL	PRACTITIONER	DESCRIPTIONS	
OF	CHALLENGES	IN	THE	MANAGEMENT	OF	
DEPRESSION	IN	GAY	MEN	AND	MEN	WITH	
HIV
Newman CE,1 Kippax SC,1 Mao L,1 Rogers GD,2 Saltman D,3 
Kidd MR4
1National Centre in HIV Social Research, The 
University of New South Wales Sydney NSW 
Australia; 2School of Medicine, Griffith University, 
Gold Coast, QLD Australia; 3Institute of Postgraduate 
Medicine, Brighton and Sussex Medical School 
Brighton, United Kingdom; 4Discipline of General 
Practice, Faculty of Medicine, The University of Sydney 
Balmain NSW Australia
In contrast to the substantial literature on the management 
of depression in the general population in primary 
care settings, little is known about the management of 
depression affecting HIV-positive men and men who 
identify as gay (hereafter ‘gay men’) attending general 
practice clinics, particularly in the Australian context. 
This paper will explore qualitative descriptions of how 
depression in gay men and men with HIV is managed 
by general practitioners (GPs) who are accredited to 
prescribe antiretroviral medications in three Australian 
settings. 
The Primary Health Care Project on HIV and Depression is 
a three year multi-method study funded by the General 
Practice Clinical Research Program of the National Health 
and Medical Research Council (2006-2009). The research 
team represents a unique collaboration between social 
researchers, general practice researchers, GPs and 
community partners. The study employs both qualitative 
and quantitative methods to answer a range of research 
questions including the prevalence and nature of 
depression among gay men (both with and without HIV) 
and heterosexually-identified men attending general 
practice clinics, factors associated with depression in 
these three groups, and the clinical and self-management 
of depression by GPs and patients themselves, especially 
those living with HIV.
As part of the qualitative component, interviews were 
conducted with 16 GPs representing three geographical 
settings and 7 practices: Sydney (4 practices), Adelaide 
(1) and a rural-coastal town in New South Wales (2). 
Participants included 14 male GPs and two female GPs, 
and the number of years each had been working in 
HIV medicine ranged from two to 24. Semi-structured 
face-to-face interviews of around one hour in length 
explored the diagnosis, treatment and management of 
depression, aspects of depression related to HIV, gender 
and sexuality, and reflections on practice. This paper will 
present the results of a thematic analysis that identifies 
strengths (eg. providing supportive counselling, making 
use of specialist support programs) and challenges (eg. 
patients’ experiences of sexual dysfunction, expanding 
GP responsibilities) encountered by GPs in managing 
depression in this population. In doing so, this paper 
provides a unique and timely insight into the primary care 
management of depression by antiretroviral prescribers 
working in general practice settings in different parts of 
Australia.
Peter Meese Memorial Session – Clinical 
– Associated Conditions Complications
11.00am – 12.30pm
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DETERMINATION	OF	THE	UNDERLYING	
CAUSE	OF	DEATH	IN	THREE	MULTICENTER	
INTERNATIONAL	HIV	CLINICAL	TRIALS
Alan R. Lifson1, Waldo H. Belloso2, Cate Carey3, Richard T. 
Davey4, Daniel Duprez1, Wafaa M. El-Sadr5, Jose M. Gatell6, 
Daniela C. Gey7, Jennifer F. Hoy8, Eric A. Krum1, Ray Nelson1, 
Dan Nixon9, Nick Paton10, Court Pedersen11, George 
Perez12, Richard W. Price13, Ronald J. Prineas14, Frank S. 
Rhame15, James Sampson16, John Worley17 on behalf of 
the INSIGHT network
1University of Minnesota, Minneapolis, MN, USA; 2Hospital 
Italiano, Buenos Aires, Argentina; 3University of New 
South Wales, Sydney, Australia; 4National Institutes of 
Health, Bethesda, MD, USA; 5Columbia University, New 
york, Ny, USA; 6University of Barcelona, Barcelona, Spain; 
7Hvidovre University Hospital, Hvidovre, Denmark;  8Alfred 
Hospital and Monash University, Melbourne, Australia; 
9 Richmond AIDS Consortium; Richmond, VA, USA; 
10Medical Research Council Clinical Trials Unit, London, 
United Kingdom; 11Odense University Hospital, Odense, 
Denmark; 12 North Jersey Community Research Initiative, 
Newark, NJ, USA; 13University of California, San Francisco, 
CA, USA ; 14Wake Forest University, Winston-Salem, NC, 
USA; 15Abbott Northwestern Hospital, Minneapolis, MN, 
USA; 16Research and Education Group, Portland, OR, USA; 
17 Park Nicollet Health Services, St. Louis Park, MN, USA
The aim was to describe processes for death reporting 
and to review specified attributions of mortality in large 
international HIV trials according to a uniform set of 
standards for assigning immediate, contributing and 
underlying causes, for large international HIV trials. 
The three international trials were conducted during 
1997-2008, with 11,593 enrollees from multiple sites in 
36 countries. The trials were ESPRIT, SILCAAT and SMART. 
Three Clinical Endpoint Review Committee members 
independently reviewed each death report and 
supporting source documentation to assign underlying 
cause of death (defined as disease or injury initiating 
the train of events leading directly to death, or accident 
or violence producing the fatal injury), and all decisions 
were adjudicated until agreement was achieved.
Of 453 deaths reported through January 14, 2008, the 
underlying causes of death were: 47 (10%) AIDS-defining 
illnesses; 93 (21%) non-AIDS malignancies; 39 (9%) liver 
diseases (excluding malignancy); 40 (9%) cardiac diseases; 
36 (8%) non-AIDS-defining infections; 22 (5%) suicides; 23 
(5%) other trauma-related events or accidents; 20 (4%) 
drug overdoses or acute intoxications; 52 (11%) other 
identified causes; and 74 (18%) cases with “unknown” 
underlying cause. 
For 63 unknown cases, ERC reviewers were specifically 
asked on the death review form about adequacy of 
information and supporting source documentation; in all 
63 cases, one or more reviewers felt there was inadequate 
information and documentation provided to make an 
informed decision about cause of death. Unknown 
cases included 16 persons who were reported as having 
been found dead, and another 15 who were reported as 
suddenly dying with limited details to help identify the 
underlying etiology. 
The underlying cause of death was non-AIDS-defining 
diseases for most deaths (72%), and reflects the changing 
epidemiology of HIV in the HAART era. Accurate 
classification of cause of death requires provision of 
complete information and documentation, and is critically 
important for clinical studies.  
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RE-INITIATION	OF	ANTIRETROVIRAL	
THERAPY	(ART)	IN	THE	CD4	CELL-GUIDED	
CART	INTERRUPTION	GROUP	IN	THE	SMART	
STUDY	LOWERS	RISK	OF	OPPORTUNISTIC	
DISEASE	OR	DEATH
Hoy JF1,2, Drummond FM2, Emery S2, Cooper DAC2 and the 
SMART Study Group
1 Infectious Diseases Unit, Alfred Hospital and Department 
of Medicine Monash University, Melbourne, VIC, Australia.
2 National Centre in HIV Epidemiology and Clinical 
Research, University of NSW, Sydney, NSW, Australia 
The SMART Study established that CD4-guided 
intermittent cART was inferior to continuous cART for 
major clinical outcomes. On January 11, 2006, based on 
the recommendation of the DSMB, ART-experienced 
patients (95.6% of all Drug Conservation (DC) patients) 
in the intermittent cART arm were encouraged to restart 
cART. Follow-up continued to study closure in July 2007 
to assess whether risk associated with intermittent cART 
could be reversed.
5472 patients with CD4 > 350 cells/µl were randomized 
to intermittent CD4 cell-guided cART (stop ART>350 
and start<250 cells/mm3) (DC, n=2720) or continuous 
cART (Viral Suppression [VS] n=2752). Hazard ratios (HR) 
for major clinical outcomes were estimated using Cox 
Proportional Hazards models for 2 time periods: from 
randomisation to January 11, 2006 (pre-January 2006), 
and from January 11, 2006 to July 11, 2007 (post-January 
2006).
Pre-January 2006, DC patients spent 34% of follow-up 
time on cART compared to 94% for VS patients. Post-
January 2006, DC patients spent 71% of time on cART 
compared to 91% for the VS group. Percentage of follow-
up time spent with CD4<350 cells/µl decreased from 
31% pre-January 2006 to 23% post-January 2006 for DC, 
and 8% and 7%, respectively for VS. Pre-January 2006, 
rates for opportunistic disease (OD) or death, death, and 
a composite outcome of serious cardiovascular disease 
(CVD), renal and hepatic events were significantly greater 
for DC compared to VS. Post-January 2006, rates for all 
3 outcomes declined for DC, whilst rates for VS patients 
remained stable. HR (DC/VS) improved for DC patients 
once they restarted cART, but remained significantly 
greater for OD or death post January 2006 (1.37 fold), 
while risk of death and composite outcome were no 
longer significant.
Following the recommendation to reinitiate ART for 
patients in the DC group, the risk of OD or death was 
significantly reduced from 2.52 to1.37 fold. However, less 
than full reversal of risk for DC compared to VS patients 
for OD or death was noted. This may be attributed in part, 
to some patients not initiating cART, and lower CD4 cell 
counts for DC patients post-January 2006. These findings 
reinforce the recommendation not to interrupt cART 
using the CD4 cell-guided strategy evaluated in SMART.
Oral Posters:
Rotty J - see page
Furner V - see page
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MANAGING	DATA	TO	GUIDE	A	LONG-TERM	
STI	CONTROL	RESPONSE	IN	SOME	REMOTE	
CENTRAL	AUSTRALIAN	ABORIGINAL	
COMMUNITIES
 
Huang R1, Torzillo PJ1
1Nganampa Health Council, SA, Australia
Nganampa Health Council (NHC) has managed a data 
collection and surveillance system for monitoring STIs on 
the remote Anangu Pitjantjatjara yankunytjatjara (APy) 
Lands for over twelve years as an important component 
of their comprehensive STI Control and HIV Prevention 
Program.  This customised system provides a method of 
monitoring important indicators of clinical care such as 
participation rate in annual screening, treatment rates 
and time to treatment of various STIs, contact tracing, and 
in recent years population mobility.  
Each year in the month prior to the annual population-
wide screen a consistent population update is 
undertaken.  The population update process is pivotal to 
obtaining comparable cross-sectional prevalence rates 
over thirteen consecutive years of annual population-
wide screening for chlamydia, gonorrhoea and syphilis 
undertaken by NHC.  The trends in these STIs over the 
thirteen year period of screening are discussed.  Marked 
reductions in all three STIs has occurred but there was a 
rise in gonorrhoea over the period 2004-2007.
An appropriate monitoring and evaluation system 
managed within the health service has allowed informed 
and timely choices to be made about many aspects of this 
STI control program.  It has guided choices and provided 
information such as appropriate age groups to test during 
annual population-wide screening, risk factors associated 
with STIs, and uptake of HIV testing. It has provided an 
early alert to the rise in gonorrhoea prevalence 2004-
2007 which has allowed further research into the cause. 
NHC has now commenced using a patient information 
recall system (PIRS) live in all their remote clinics.  The 
application of this system as an adjunct to the current 
data monitoring systems is briefly discussed.
BARRIERS	TO	HEPATITIS	C	SERVICES	FOR	
RURAL	ABORIGINAL	PEOPLE
A, Slater
Hunter New England Population Health Services, Capacity 
Building Service Team, Hunter New England Area Health 
Services, Tamworth, NSW, Australia
Background: Aboriginal people are up to 10 times more 
likely to contract Hepatis C when compared to the broader 
population (Bloodborne viral and sexually transmitted 
infections in Aboriginal and Torres Strait Islander People: 
Surveillance Report 2007). However, treatment statistics 
across the Hunter New England Area Health service 
suggest that Aboriginal people are less likely to access 
specialist Hepatitis C (Hep C) treatment services when 
compared to the broader population. 
Aim: This project aimed: to identify barriers which 
prevent Aboriginal people from accessing specialist Hep 
C services; and to promote opportunities to increase 
Aboriginal people and community groups knowledge of 
the Hep C virus, routes of transmission, testing, treatment, 
care and available support services. 
Method: Working within a cultural context and 
understanding community dynamics, project staff visited 
9 towns and communities across North-West NSW over 
a two month period. The project staff convened Hep 
C discussion groups across a wide representation of 
local community groups, service providers and priority 
population group’s e.g. Aboriginal people in correctional 
facilities. These groups were facilitated by an Aboriginal 
person known to the local community and aimed to 
encourage group discussion around access to specialist 
Hep C services and to deliver advice and information 
sessions to participants. 
Results: Discussion groups identified a poor understanding 
of: available specialist Hep C services; and the Hep C 
virus, routes of transmission, testing, treatment, care 
and available support services. Where appropriate, local 
community members were opportunistically referred 
to specialist Hep C services and other local treatment 
options during the course of the discussion groups.  
Conclusion: Discussion groups convened at a community 
level were an ideal vehicle for providing information to 
community groups, service providers and at risk client 
groups. Working within a cultural context, with an 
understanding of community dynamics and being known 
to the local community is important when encouraging 
the uptake of specialist Hep C services within Aboriginal 
communities. If we are likely to address the growing 
incidence of Hep C within Aboriginal communities future 
projects of this type are required.  
Indigenous Health
11.00am – 12.30pm
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A	CULTURAL	WORLD	AIDS	DAY	IN	THE	
ABORIGINAL	COMMUNITY
David Webb
Aboriginal Sexual Health Worker, Sydney West Area Health 
Service, NSW Australia
The Sydney West Area Health Service (SWAHS) World 
AIDS Day (WAD) event is held at the Holy Family Church 
Emerton, a suburb of Mt Druitt in NSW. This area has a 
large Aboriginal community, and the Church traditionally 
has important links with this community and its’ culture. 
The Holy Family Church has been holding World AIDS 
Day events for the last 10 to 15 years. The Church garden 
area has become a significant place where the ashes of 
Aboriginal People who have passed way with AIDS are 
scattered through out the garden.
SWAHS has been privileged to host a World AIDS Day 
event at the Holy Family Church for the past 3 years as 
a part of its’ wider AIDS awareness programs that have 
been running in the area for the past 16 years. The aims 
of this event, which are in line with the NSW HIV/AIDS, 
STI and Hepatitis C Strategies: Implementation Plan for 
Aboriginal People 2006-2009, are to:
• increase Aboriginal community engagement in HIV/
AIDS issues;
• increase community awareness and knowledge of HIV; 
• find ways of reducing the risk of transmission amongst 
Aboriginal people; and
• For all these to be done in the context of continually 
supporting and affirming the culture and heritage of 
Aboriginal people.
The presentation will focus on the partnerships which 
supported this program and will outline the following 
strategies: 
• a WAD painting representing the families communities 
of those have passed away from AIDS; 
• the “Healing Tree”/”Tree Ochering” to highlight the 
impact of HIV/AIDS on both the indigenous and wider 
community in the Mt Druitt area;
• Women’s business activities; and
• A focus on Aboriginal culture by featuring a traditional 
Welcome to Country in language, and then translated in 
English and a Smoking Ceremony by a local Aboriginal 
Elder. 
BERRIMA	WOMEN’S	PROJECT
Smith M , Tyne M.
HIV & AIDS Related Programs (HARP) Health Promotion, 
Western Zone, Sydney South West Area Health Service 
(SSWAHS) Sydney NSW Australia;
HIV prevalence among people entering the Australian 
prison system in the year 2004 rose primarily within New 
South Wales (NSW) and South Australia (SA). This rise was 
particularly among women. The numbers of HIV+ women 
entering the prison systems are almost 40% higher than 
that of men.
Among new HIV diagnoses in 2002 – 2006, the most 
frequent reported route of transmission in the non-
indigenous population was male homosexual contact 
(65%) heterosexual contact (20%) and injecting drug use 
(3%). In the Aboriginal and Torres Strait Islander population, 
HIV infection was attributed to male homosexual contact 
(37%) in heterosexual contact (34%) and injecting drug 
use (18%).
The Berrima Women’s Project provides Aboriginal inmates 
of the Berrima Women’s Correctional Centre in NSW with 
HIV and sexual health education in a traditional form, 
as identified in the National Aboriginal and Torres Strait 
Islander Sexual Health and Blood Borne Virus Strategy 
2005-2008 (Section 3) and the National HIV/AIDS Strategy 
Revitalising Australia’s Response 2005-2008 (Section 6). 
The Project comprises 18 sessions on sexual health and 
relationship topics. Each session includes interactive 
games on HIV, sexually transmitted infections and health 
topics followed by informal discussions with questions 
and answers. The women contribute to the project 
using traditional learning skills such as painting, craft and 
poetry/song to develop sexual health resources for use in 
other Aboriginal communities.
The project aims to increase to the women’s capacity 
to make informed decisions about their sexual health; 
increase the number undertaking regular health check 
ups and develop knowledge of health/community 
service networks beyond the corrective centre. 
This presentation will discuss partnership building with 
the Department of Corrective Services and Justice Health; 
the development of interactive relationships between 
the HARP health promotion service and the women; and 
among the women themselves. 
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WILLNESS	TO	PAY:	WHAT	IS	THE	TRUE	COST	
OF	PROVIDING	EqUITABLE	HEALTH	CARE		IN	
A	DISADVANTAGED	COMMUNITY?
Gilles MT1, Ferguson C1, Smith P1, Edel M1 
1Western Australian Country Health Service, WA Australia
It has been acknowledged that poor medical outcomes 
in Aboriginal people can be attributed to inequity in the 
delivery of services to this population.  In a recent paper 
reviewing the outcomes of health care to a group of 
socially and geographically disadvantaged women with 
HIV infection. It was demonstrated that if adequately 
resourced and culturally appropriate care is supplied 
similar outcomes to those in non-Aboriginal metropolitan 
based HIV positive people can be achieved. The estimated 
cost per woman for this rural support plus the coordinated 
multidisciplinary care was $57,545 per pregnancy. But 
this took no account of the true investment in this cohort. 
This study seeks to determine how much this level of care 
really cost? 
Staff from the unit providing this rural care will be asked 
to record the duration and type of every interaction with 
their HIV clients for one month.  This will include text 
messages, phone calls, home visits, and appointments. 
Using this diary and the staff salary an economic value will 
be produced for each client. In addition staff will undergo 
semi structured interviews relating to the emotional 
impact this work has on their lives.  
The analysis and final report will incorporate both 
financial and emotional costs. There is no question in the 
team’s mind that this level of care is worth it.  Ironically 
the services success which has prevented the predicted 
HIV holocaust has reduced its visibility and money that 
used to be available for this service is drying up.  This 
paper examines the issue of “willingness to pay” in this 
emotionally charged and important area of health 
delivery. 
THE	PROCESS	OF	MANAGING	AN	HIV	+VE	
INDIGENOUS	WOMAN	WITH	A	CHAOTIC	
LIFESTYLE	IN	A	RURAL	SETTING
Authors: Armstrong, K2, Cain A1, Douglas, C2   
1 Department of Clinical Immunology & Immunogenetics, 
Royal Perth Hospital, WA;  2 WACHS Goldfields- Population 
Health, WA
Indigenous women with HIV face a number of unique 
social and medical issues.  This presentation describes the 
medical, social and legal steps that needed to be taken 
to adequately manage an HIV positive woman originally 
from a remote Aboriginal community but now living in 
Kalgoorlie, and to manage the public health risk that she 
posed.  Supported by the Department of Immunology 
at Royal Perth Hospital and the Case Management Unit 
in Perth, staff from the Goldfields Public Health Unit 
have been actively involved with this patient since her 
diagnosis in April 2006.  
Her history of repeated head injuries, epilepsy and alcohol 
related brain damage have led to cognitive deficits which 
have made education and treatment issues difficult. 
She has been unable to maintain confidentiality of her 
diagnosis, and due to her risk taking behaviour she has 
faced stigmatisation and discrimination by her family, 
community and service providers.  Her lifestyle was 
becoming increasingly chaotic as she had no fixed abode 
and regularly sought company and shelter wherever she 
could find it.  This was frequently associated with groups 
of people who were drinking large amounts of alcohol. 
Often she would disappear for days at a time and the 
Public Health team would only discover her whereabouts 
after she presented to the local hospital emergency 
department having had a convulsion.
Good teamwork has been required between the 
local Public Health Unit and other medical and health 
practitioners in order to maintain her health and 
compliance with medication, and thus the health of the 
wider community.  
Along the way it has been necessary to commence 
directly observed therapy seven days a week, invoke 
the Public Health Act and apply for guardianship and 
administration orders through the Offices of the Public 
Trustee and Public Advocate.  
The presentation includes a timeline that outlines the 
events described above and highlights some of the 
challenges and successes which have allowed her viral 
load to remain undetectable, and the public health risk 
to be minimised.
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RATES	OF	HIV	SEROCONVERSION	IN	
PATIENTS	WHO	HAVE	PREVIOUSLY	USED	
NPEP:	DATA	LINKAGE	OF	THE	VICTORIAN	
NPEP	SERVICE	DATABASE	WITH	THE	
VICTORIAN	HIV	SURVEILLANCE	REGISTRY
Pierce AB1, Stoové MA2, yohannes K2, Guy R3,  Watson K1, 
Armishaw J1,  Price B1, Hoy JF1,4, Wright EJ1,4
1Victorian NPEP Service, Infectious Diseases Unit, The 
Alfred Hospital, Melbourne, Vic, Australia; 2Centre for 
Epidemiology and Population Health Research, The 
Burnet Institute, Melbourne, Vic, Australia; 3National 
Centre in HIV Epidemiology and Clinical Research, The 
University of New South Wales, Sydney, NSW, Australia; 4 
Department of Medicine, Monash University, Melbourne, 
Vic, Australia
The Victorian NPEP Service (VNPEPS) is a state-wide service 
co-ordinated at The Alfred Hospital. Although patients 
are encouraged to return for HIV diagnostic testing three 
months following NPEP, return rates are poor, there is no 
long term follow-up and subsequent HIV diagnoses in 
those who have ever presented for NPEP are unknown. 
The HIM study reported an association between NPEP 
use and subsequent HIV seroconversion. We matched 
the VNPEPS database with the Victorian HIV Surveillance 
Registry to determine the numbers and rates of HIV 
seroconversion among NPEP users in Victoria.  Patients 
in the VNPEPS (N=1595) database between Jan 2001 and 
Feb 2008 were linked with all entries in the Victorian HIV 
surveillance registry up to May 2008 using alpha-numeric 
identifier codes. 
Sixty-one VNPEPS patients were identified as HIV positive, 
giving an incidence rate of 1.54 per 100 Py (95%CI=1.19-
1.87) in those presenting for NPEP. Sixteen were HIV 
positive at baseline, thus giving an HIV incidence rate of 
1.14 (95% CI =0.84-1.51) per 100 Py in those HIV negative 
at first NPEP presentation.  All HIV diagnoses occurred in 
males with a mean age of 33.7 years. Two diagnoses were 
potential NPEP failures occurring within 3 months of NPEP 
prescription. A further eight HIV diagnoses occurred more 
than 3 months post NPEP with no intermediate negative 
HIV test recorded. The majority of HIV positive results 
(84%) occurred in those who presented for NPEP on 
only one occasion with a further 12% occurring among 
patients presenting twice for NPEP. 
The incidence of HIV infection in HIV negative men who 
present to the VNPEPS is similar to the overall rate of 
seroconversion reported in the HIM study, and lower than 
the rate reported in men who had received NPEP in this 
study. Surprisingly, most HIV infections were diagnosed in 
men who had only one presentation for NPEP. Although 
Australian incidence data is limited, these findings 
suggest that HIV incidence among VNPEP presenters 
is comparable to estimates reported among gay male 
populations. Further evaluation including examining risk 
behaviour both before and after NPEP in this population 
is required.
		
RISK	REDUCTION	PATTERNS	OF	
UNPROTECTED	ANAL	INTERCOURSE:	
RELATIVE	RISK	FOR	HIV	ACqUISITION	IN	THE	
HEALTH	IN	MEN	(HIM)	STUDY
Jin F1, Crawford J2,  Prestage GP1, Zablotska I2, Imrie JC2, 
Kaldor JM1, Grulich AE1
1National Centre in HIV Epidemiology and Clinical 
Research; 2National Centre in HIV Social Research, 
University of New South Wales, Australia
A range of so-called risk reduction behaviours (RRBs) 
in which homosexual men practice unprotected anal 
intercourse (UAI) has been described. There are no 
published longitudinal data on the risk of HIV infection of 
these behaviours.  
Between 2001 and 2004, 1,427 men were enrolled. 
They were followed up with 6 monthly behavioural 
interviews and annual HIV testing. Four possible RRBs 
were investigated, namely serosorting, negotiated safety, 
strategic positioning, and withdrawal during receptive 
UAI (UAI-R). These RRBs were defined behaviourally.
RRBs were common in this cohort. In most (88%) follow 
up periods with UAI reported, UAI occurred in the context 
of at least one RRB involved. Compared with those 
who reported no UAI, the risk of HIV infection was not 
raised in negotiated safety (HR=1.67, 95% CI 0.59-4.76) 
and strategic positioning (HR=1.54, 95% CI 0.45-5.26). 
Serosorting outside negotiated safety was associated 
with an intermediate rate of HIV infection.  Withdrawal 
was associated with a higher hazard ratio (5.00, 95% CI 
1.94-12.92), but this was largely because it was commonly 
practiced with HIV positive partners. With such partners, 
withdrawal was associated with a substantially lower 
risk than was UAI-R with ejaculation.  Men who reported 
serosorting were much less likely to report UAI-R with 
withdrawal (OR=0.52, 95% CI 0.43-0.63) or strategic 
positioning (OR=0.44, 95% CI 0.36-0.54).  Overall, men 
who reported any one of these RRBs were more likely 
to seroconvert to HIV than men who reported no UAI 
(HR=3.01, 95% CI 1.31-6.92), but they were much less 
likely to become infected than men who reported UAI 
without any of these RRBs (HR=0.29, 95% CI 0.14-0.54). 
All RRBs were associated with an incidence of HIV 
infection that was intermediate between that in those 
who reported no UAI and higher risk activities suggesting 
that these behaviours did indeed reduce risk. In the 
presence of serosorting (including negotiated safety) 
strategic positioning and withdrawal were very unlikely, 
which suggests that men felt that practicing one RRB 
provided adequate protection. Researchers and policy 
makers need to address the reality that UAI in the context 
of RRB is common among gay men and help inform the 
choices around these behaviours.
Epidemiology – Transmission/ 
Acquisition
11.00am – 12.30pm
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SExUAL	PARTNERS’	AGE	AS	A	RISK	FACTOR	
FOR	HIV	SEROCONVERSION	IN	THE	HEALTH	
IN	MEN	(HIM)	STUDY
Jin F1, Prestage GP1, Mao L2, Imrie JC2, Kippax SC2, Kaldor 
JM1, Grulich AE1
1National Centre in HIV Epidemiology and Clinical 
Research, UNSW; 2National Centre in HIV Social Research, 
UNSW
In Australia, HIV prevalence among homosexual men is 
low in men aged under 30 years and increases with age. 
This gives rise to the possibility that increasing partner 
age may be an important risk factor for HIV infection, 
particularly in younger men.  We aimed to determine 
partners’ age as a risk factor for HIV seroconversion in a 
community-base cohort of HIV negative homosexual 
men in Sydney.
 
Participants were men from the HIM study recruited 
between 2001 and 2004, followed to June 2007. 
Participants responded to “how many of your male sex 
partners were much older than themselves in the last 
6 months” at baseline (none, a few, about half, most). 
In addition, those who were in a regular relationship 
reported the age of that partner at each interview. 
A total of 1427 men were recruited. At baseline, about 
20% of men reported that half or more of their partners 
were much older.  Having more partners who were 
much older was associated with an increased risk of 
HIV seroconversion (p trend=0.002), and this remained 
significant after adjustment for number of episodes of 
sero-non-concordant unprotected anal intercourse (UAI), 
age, and number of casual partners (Hazard ratio for 
those who reported more than half partners were older 
compared to those who reported none older of 2.50, 95% 
CI 1.13-5.53, p trend=0.019). Stratified analysis showed 
that this trend was significant in participants aged both 
under and above the median age of HIV infection (37 
years).  In those who were in a regular relationship, men 
who reported their partner’s age was within 5 years of 
their own were at lowest risk of HIV infection, compared 
with those who reported an older partner, but this was 
not significant. Interestingly, similar although weaker 
and non-significant patterns of increased risk were seen 
for men who reported that more partners were much 
younger. 
Men who reported older partners were at increased risk 
of HIV infection and this was independent of UAI with 
sero-non-concordant partners. 
IMPORTANCE	OF	PROMOTING	HIV	
TESTING	FOR	PREVENTING	SECONDARY	
TRANSMISSIONS:	MODELLING	THE	
AUSTRALIAN	HIV	EPIDEMIC	AMONG	MEN	
WHO	HAVE	SEx	WITH	MEN
Wilson DP, Hoare A, Regan DG, Law MG 
National Centre in HIV Epidemiology and Clinical 
Research, The University of New South Wales, Sydney, 
NSW, Australia
Newly infected people enter the stage of primary HIV 
infection (PHI). In this stage viral loads are higher than at any 
other time during the course of infection. Consequently, 
people in PHI have the greatest infectiousness per sexual 
encounter. Newly-infected people are also generally 
unaware of their new serostatus and potential to cause 
secondary HIV transmissions. In this study we address 
the research questions: (i) what proportion of new HIV 
infections in Australia is transmitted from people who are 
(a) undiagnosed, (b) in PHI, (c) on antiretroviral therapy? 
(ii) what is the expected epidemiological impact of (a) 
increasing rates of early treatment, and (b) increasing HIV 
testing rates? 
We used a mathematical model to simulate HIV 
transmission in men who have sex with men (MSM) in 
Australia. We calibrated the model using established 
biological and clinical data and a wide range of Australian 
MSM epidemiological and behavioural data sources. 
We estimate that ~19% of all new HIV infections are 
transmitted from the ~3% of MSM who are in PHI; ~31% of 
new HIV infections are estimated to be transmitted from 
the ~9% of MSM with undiagnosed HIV. We estimate that 
the average number of transmissions from HIV-infected 
MSM through the duration of PHI is ~0.14-0.28. The 
epidemiological impact of increasing treatment in PHI 
would be modest due to insufficient detection of newly-
infected individuals. In contrast, increases in HIV testing 
could have substantial epidemiological consequences. 
The benefit of testing will also increase over time. 
Promoting increases in the coverage and frequency of 
testing for HIV could be a highly-effective public health 
intervention and could increase the effectiveness of 
any strategy based on treating PHI. Treating PHI requires 
further evaluation of its long-term effects on HIV-infected 
individuals.
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THE	PARADOxICAL	EFFECTS	OF	USING	
ANTIRETROVIRAL-BASED	MICROBICIDES	TO	
CONTROL	HIV	EPIDEMICS
Wilson DP1, Coplan PM2, Wainberg MA3, Blower SM4
1National Centre in HIV Epidemiology and Clinical 
Research, Faculty of Medicine, The University of New South 
Wales; 2Center for Clinical Epidemiology and Biostatistics, 
University of Pennsylvania School of Medicine; 3McGill 
University AIDS Centre, Jewish General Hospital; 4Semel 
Institute for Neuroscience and Human Behavior and 
UCLA AIDS Institute, David Geffen School of Medicine at 
UCLA
Vaginal microbicides, designed to prevent HIV infection 
in women, are one of the most promising biomedical 
interventions. Clinical trials of second-generation 
microbicides have begun; if shown to be effective 
they could be licensed within 5-10 years. Since these 
microbicides contain antiretrovirals (ARVs) they could be 
highly effective. However there is concern that, if used by 
HIV-positive women, ARV resistance may evolve. 
We develop and analyse a novel mathematical model of 
a phase III clinical trial of ARV-based microbicides used by 
women at high risk of HIV infection. We also develop a 
dynamic transmission heterosexual model to investigate 
the potential population-level effects of microbicides 
that contain ARVs that are highly absorbent. The models 
are parameterized using epidemiological, clinical and 
behavioural data to predict the consequences of wide-
scale usage of high-risk microbicides in a heterosexual 
population.
We find that adherence could have both beneficial and 
detrimental effects on trial outcomes. Most importantly 
we show that planned trial designs could mask resistance 
risks and therefore enable high-risk microbicides to pass 
clinical testing. Surprisingly, we show that reducing a 
participant’s risk of resistance during a trial could lead to 
unexpectedly high rates of resistance afterwards when 
microbicides are used in public health interventions. 
We also find that, paradoxically, although microbicides 
will be used by women to protect themselves against 
infection they could provide greater benefit to men. 
More infections in men, than women, will be prevented 
if there is a high probability that ARVs are systemically 
absorbed, microbicides are less than ~50% effective, and/
or adherence is less than ~60%. 
Men will always benefit more than women in terms of 
infections prevented per resistant case; but this advantage 
decreases as the relative fitness of drug-resistant strains 
increases. Interventions that use ARV-based microbicides 
could have surprising consequences.
HIV	RISK	BEHAVIOR	AMONG	HIV-INFECTED	
MEN	WHO	HAVE	SEx	WITH	MEN	IN	
BANGKOK,	THAILAND	
Sirivongrangson P,1 Lolekha R,2 Charoenwatanachokchai 
A,1 Siangphoe U,2 Bollen L,2 Jirarojwattana N,1 yenyarsan 
N,1 Lokpichat S,1 Fox KK,2,3 McConnell M2,3
1 Sexually Transmitted Infection Cluster, Bureau of AIDS/ 
TB/ STIs, Department of Disease Control, Ministry of Public 
Health (MOPH), Bangkok, Thailand; 2 Thailand MOPH - U.S. 
CDC Collaboration, Nonthaburi, Thailand; 3 Global AIDS 
Program, CDC, Atlanta, GA, USA
BACKGROUND: HIV prevalence among men who have 
sex with men (MSM) in Bangkok, Thailand increased from 
17% to 28% between 2003 and 2005. However, limited 
data on sexual risk behaviors are available to guide HIV 
prevention efforts for MSM.  
METHODS:  HIV-infected MSM attending an STI clinic in 
Bangkok were interviewed about sexual risk behaviors 
and evaluated for sexually transmitted infections (STI), 
as part of routine services. Patients were examined for 
genital ulcers and had serologic testing for syphilis and 
urethral PCR testing for chlamydia and gonorrhea. Steady 
partners were defined as regular sexual partners for >2 
months; STI was defined as a positive laboratory test or 
clinician-confirmed genital ulcer. Electronic clinic record 
data were analyzed using SAS. 
RESULTS: During October 2005-October 2007, 154 HIV-
infected MSM were included. Median age was 28 years 
(range, 17-65 years). Sexual intercourse in the last 3 
months was reported by 131 (85%) men. Of these, 79 
(60%), 69 (53%), and 19 (15%) reported sex with steady 
male partners, casual male partners, and female partners, 
respectively. Condoms use during last sex was reported 
by 60% with steady male partners, by 75% with casual 
male partners and by 63% with female partners. Among 
those with steady male partners, 39% had disclosed their 
HIV status, 38% reported their partner had been HIV 
tested and 60% reported the partner tested HIV-negative. 
Among those with discordant steady partners, condoms 
use at last sex was reported by 64%. STIs were found in 
41% of men (10%, chlamydial infection; 13 %, gonorrhea; 
20% reactive syphilis serology; and 10%, genital ulcer). 
Unprotected last sex was more likely among MSM with 
steady male partners than other partner types (OR=2.65, 
95% CI=1.2-5.6). Age, education, time since HIV diagnosis, 
antiretroviral therapy, CD4 count, and current STI were 
not significantly associated with unprotected sex. 
CONCLUSION: Sexual risk behaviors and STIs were 
common among this group of HIV-infected MSM in 
Bangkok. High HIV discordance and low disclosure rates 
with steady partners highlight the need for effective HIV 
prevention strategies for MSM. Increasing condom use 
should be a focus of HIV prevention efforts among HIV-
infected MSM. 
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MINIMUM	STANDARDS	FOR	HIV	
COUNSELLING	AND	TESTING	FOR	THE	
PACIFIC
Ankus JM1, Mac Donald A2, Reis EJ1, Worth H3
 1Australasian Society for HIV Medicine Inc, Sydney, NSW, 
Australia; 2Secretariat of the Pacific Community, Noumea, 
New Caledonia; 3National Centre in HIV Social Research, 
University of New South Wales, Sydney, Australia
In 2008 Secretariat of the Pacific Community (SPC) and 
Global Fund to Fight AIDS, Tuberculosis and Malaria 
(GFATM) commissioned the Australasian Society for HIV 
Medicine and the National Centre in HIV Social Research 
in partnership with SPC to undertake an evaluation of 
existing HIV testing and counselling services in the 11 
Pacific Countries supported by the GFATM: Cook Islands, 
Federated States of Micronesia, Fiji, Kiribati, Niue, Palau, 
Samoa, Solomon Islands, Tonga, Tuvalu and Vanuatu.
This evaluation is in line with A guide to evaluating HIV 
testing and counselling services in the Pacific Island 
Countries and Territories (PICTS) using minimum 
standards devised by the Albion Street Centre Sydney for 
SPC and GFATM in 2007.
The minimum standards for voluntary counselling and 
testing services aim to develop more consistent, better 
quality and effective HIV test counselling services, both at 
country level and across the region. 
The response from sites participating in the evaluation 
has been largely positive and many have been interested 
in determining minimum levels of service provision and 
areas for improvement. Services with identified gaps will 
be supported with follow-up technical expertise, training 
and resource provision.
It has been found that in applying minimum standards 
there needs to be a flexible approach, particularly 
where VCCT services are located within more general 
health services as opposed to stand alone VCCT/HIV 
and STI services. Also, important differences in the pre 
registration training of health professionals across the 
Pacific may mean that counselling skills training and 
ongoing supervision and support requires solutions that 
are country specific. Policy and protocol development 
were also identified as gaps within service provision. 
This paper will discuss the findings of the evaluation of 
HIV testing and counselling services against the Minimum 
Standards and the implications of applying Minimum 
Standards to under resourced health services in low 
prevalence settings in the Pacific.  
International: Where to for testing and 
counselling in resource-poor settings?
11.00am – 12.30pm
POLICING	WOMEN’S	BODIES:	ARE	WE	READY	
TO	MOVE	BEYOND	CRITIqUING	PICT	YET?
Kelly, A.
National Centre in HIV Social Research, UNSW
There is nothing new in the desire to test people and 
determine their HIV status. However, attempts to scale up 
access to ART, and consequent recent shifts in HIV testing 
policy from opt-in to opt-out, has seen a resurgence in 
debates around HIV testing practices. This has been 
especially true in resource poor settings. It is argued that 
testing is the gateway to treatment, yet, with a minority 
of HIV-positive people who already know their status 
receiving treatment, increasing testing as evident in PNG 
does not guarantee access to ART. 
When we examine available surveillance data of vertical 
transmission, it is evident that in PNG the prevention of 
mother to child transmission program (PMTCT) has not 
been successful. In a desperate attempt to stem the 
numbers of children acquiring HIV the government has 
endorsed PICT as a means to address this issue. However, 
this policy shift has occurred without an examination 
of the PMTCT programs and how those already testing 
positive can be better supported to return for the delivery 
of their child, to maintain strict feeding regimes and to 
maintain ongoing connections with health care workers 
at the PMTCT clinics. In addition, we have not examined 
from the health care providers perspectives why they 
have been unable to successfully care for such women 
and babies. It is important that as we continue to critique 
the policy we monitor the practice, especially in relation 
to counseling, consent and confidentiality. Health care 
professionals already yield a great deal of power; we must 
be certain that we do not deny those who seek their care 
any less. As suggested by the PICT guidelines there must 
be a guarantee of an enabling environment; at present, 
this is not the case for women in PNG. Until we can 
improve the social and health outcomes for women, their 
children and families already testing positive with opt-in 
it is not ethical or in the interests of maternal and child 
health to shift direction in HIV testing. While policies and 
practices continue to unfavorably prejudice and police 
women’s bodies then we are not ready to move beyond 
critiquing test practices.  
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PROVIDING	HIV	SERVICES	TO	PRISONERS	IN	
THAILAND:	PEER	OUTREACH,	VOLUNTARY	
COUNSELING	AND	TESTING	(VCT),	AND	
LINKAGES	TO	CARE
Poolsawat M,1 Ngamtrairai N,2 Suwannaraksa P,3 Prajongkit 
C,4 Lertpiriyasuwat C,5 Chiawcharn P,3 Manopaiboon C,1 
Visavakum P,1 Fox K1,6
1Thailand MOPH–U.S. CDC Collaboration, Nonthaburi, 
Thailand; 2Department of Corrections, Bangkok, Thailand; 
3Phuket Provincial Prison, Phuket, Thailand; 4Central 
Correction Institution for young Offenders, Pathumthani, 
Thailand; 5Ministry of Public Health, Nonthaburi, Thailand; 
6CDC, Atlanta, GA, USA
High HIV prevalence has been reported among prisoners 
in Thailand, yet HIV prevention programs and care 
referral systems are limited within Thailand’s prisons. We 
established an HIV peer education program, condom 
access, and counseling and testing (CT) services in Prison 
A (900 male inmates). One year later, we conducted a 
cross-sectional survey to evaluate the intervention and to 
assess needs at Prison B (4000 male inmates).
A simple random sample of male inmates was selected 
in each prison.  Consenting participants completed self-
administered questionnaires using handheld computers. 
We conducted multivariate analysis of factors associated 
with anal sex and condom use.
At the two prisons, 746 male inmates (median age 24) 
were surveyed. Drug offenses were the most common 
reason for incarceration (49%), yet only 4% had ever 
injected drugs. Potential HIV risk behaviors in prison 
included sharing tattoo equipment (64%), penile 
modification (27%), anal sex (14%), and injecting drugs 
(1%). Independent factors associated with having anal 
sex in prison were years incarcerated (adjusted odds 
ratio [ORa] 1.3, 95% confidence interval [CI] 1.1-1.4), 
being unmarried (ORa 2.4, 95% CI 1.2-4.9), receiving a 
tattoo in prison (ORa 2.2, 95% CI 1.1-4.7), and undergoing 
penile modification in prison (ORa 2.4, 95% CI 1.6-3.8). 
Among inmates reporting anal sex, all at Prison A and 
20% at Prison B believed condoms were easy to access 
in prison; perceived easy access to condoms was the 
only independent factor associated with condom use 
(ORa 11.0, 95% CI 3.4-35.6). Most inmates at Prison A had 
been exposed to peer education (82%) and reported 
they trusted the confidentiality of prison CT services 
(70%). Of 171 inmates who accessed CT, 13 (8%) tested 
HIV-positive; all 13 were enrolled in HIV care and 3 have 
begun antiretroviral treatment.
Tattooing, penile modification, and anal sex were common 
behaviors in this population. Easy access to condoms was 
strongly associated with condom use.  Peer education 
and prison CT services were well-received and linked HIV-
infected inmates to care. These services should be key 
components of prison HIV interventions in Thailand.
PROPOSED	APPRAISAL	OF	HIV	TESTING	
STRATEGIES	EMPLOYING	SIMPLE/RAPID	
TESTS
Elizabeth M. Dax and Susan J. Best 
National Serology Reference Laboratory, Australia
The use of HIV testing strategies employing so-called 
simple/rapid tests is gaining momentum internationally. 
The objective is to test larger numbers of people, so that 
those who need antiretroviral treatment can be treated 
as soon as possible.  Increasingly, HIV testing is being 
conducted in non-laboratory settings, by personnel not 
trained in laboratories.  The success of testing programs 
involving simple/raid tests is typically measured by the 
numbers of people being tested, notified of their HIV 
status, or treated with anti-retroviral drugs.  However, 
such measures can be misleading if used in isolation.  The 
effectiveness of new testing strategies will depend on 
whether the quality of testing can be maintained when 
the throughput of testing is increased.  Proper assessments 
of new strategies have often not been made.
The World Health Organization (WHO) is in the process of 
generating a number of revised testing strategies.  These 
strategies, which have become quite complex, should 
not be adopted until and unless their integrity can be 
appropriately substantiated.
When seeking to substantiate new strategies, the 
following should be taken into account:
• Many individual tests have been subject to laboratory 
evaluations, and shown to operate appropriately and 
to accurately define true positive and true negative 
samples;
• However, evaluations of tests when used individually 
do not necessarily allow us to assess their performance 
when used in combination.  A major reason for this is 
that tests may use similar antigens.  As a result, tests 
proposed for use in combination may share either 
common false reactivity or common false negative 
results;
• An initial mathematical assessment of a strategy 
involving a combination of tests can be performed if the 
tests have been individually evaluated, using the basic 
formulae for predictive values of testing to estimate the 
probability that a result obtained from such a strategy 
is a true result.  A model for this assessment has been 
established;
• However, mathematical assessment of any new strategy 
must be supplemented by scientific assessment, 
considering the mechanisms of each of the tests that 
are proposed to be combined;
• After mathematical and scientific assessment, the 
proposed new strategy must also be subject to a 
thorough practical validation in the laboratory e.g. in 
a validation of six HIV simple/rapid tests and enzyme 
immunoassays that was conducted in the same 
samples, four of 43 falsely reactive samples showed 
reactivity in at least two of the tests.
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The increasing emphasis on the use of simple/rapid 
tests for HIV makes it very important to remember these 
principles.  This is because many simple/rapid tests 
employ similar antigens, and sometimes two available 
tests are actually the same product, differently packaged. 
USE	OF	DRY	BLOOD	SPOTS	(DBS)	TO	AID	
HUMAN	IMMUNODEFICIENCY	VIRUS	
(HIV)	DIAGNOSIS	IN	CHILDREN	IN	THE	
ABSENCE	OF	LOCAL	NUCLEIC	ACID	TESTING	
LABORATORY	CAPACITY
Allison WE1, Cunningham P2, Hawkins C2, Kiromat M3, 
Vince J3, Kaldor J1.
1The National Centre in HIV Epidemiology and Clinical 
Research, Sydney, NSW, Australia; 2NSW State Reference 
Laboratory for HIV, St Vincent’s Hospital, Sydney, NSW, 
Australia; 3Department of Paediatrics, Port Moresby 
General Hospital, Port Moresby, Papua New Guinea.
Mortality rates of HIV infected children in Africa have 
been shown to approach 50% within the first two years 
of life.  Early diagnosis is therefore important in order to 
ensure early access to care, treatment and support.  The 
gold standard for diagnosis of HIV in children under 18 
months old is nucleic acid detection via the polymerase 
chain reaction (PCR).  In less resourced settings, including 
Papua New Guinea (PNG), nucleic acid testing often not 
available. 
In the context of a prospective study looking at predicators 
of HIV infection at Port Moresby General Hospital (PMGH) 
dry blood spot samples were collected from children 
on Whatmans Protein Saver #903 cotton based paper. 
These DBS were transported to the laboratory in Sydney 
in individual dessicated airtight pouches.  Blood was 
extracted from the filter paper and HIV-1 DNA amplified 
by PCR (Roche Amplicor HIV-1 test version 1.5, CA USA). 
Of 122 samples analyzed 107 were found to be negative, 
17 reactive and 1 indeterminate.  
Laboratory capacity for nucleic acid testing in PNG is 
under development but in the interim, transport of DBS 
to the NSW State Reference Laboratory can be a feasible 
alternative for diagnosis of HIV infection in children under 
18 months old. The advantages of DBS include use of heel 
or finger prick to obtain blood (venesection in infants can 
be difficult) and ease of transport (less of a biohazard, no 
temperature requirement). With established systems in 
place for sending and receiving samples and reporting of 
results there is the potential for the NSW State Reference 
Laboratory to also offer this diagnostic service to other 
institutions  in the region who as yet do not have the local 
diagnostic capabilities. 
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The Annual Consensus Conference is this year 
incorporated into the clinical stream of the main 
ASHM 08 Conference program. Previously, the Annual 
Consensus Conference has been held on the Saturday 
afternoon immediately following the close of the 
ASHM Conference. Feedback from previous years has 
suggested that attendance and participation would 
be maximised if the Australian Antiretroviral Guideline 
sessions were moved into the ASHM program.
This year, the Australian Antiretroviral Guidelines sessions 
will be held on the Thursday 18 and Friday 19 afternoons of 
the ASHM 08 program. These sessions include evidence-
based presentations from international and local experts 
on the latest research and developments in HIV treatment 
and provide the opportunity for discussion. 
Dr Roy Gulick is a member of the US Department of 
Health and Human Services (DHSS) Panel on Antiretroviral 
Guidelines for Adults and Adolescents and will represent 
DHHS at these sessions. The DHSS Guidelines for the 
Use of Antiretroviral Agents HIV-1 Infected Adults and 
Adolescents have been endorsed by Australia and 
form the basis on which the Australian commentary 
is developed. The Australian commentary to the latest 
Guidelines for the Use of Antiretroviral Agents in HIV-1 
Infected Adults and Adolescents is available at: http://
www.ashm.org.au/aust-guidelines/.
Australian Antiretroviral Guidelines: 
Consensus Conference
1.30pm – 3.00pm
EFFICACY	AND	SAFETY	OF	PREFERRED	ART:		
EMERGING	DATA
Roy M. Gulick, MD, MPH
Weill-Cornell Medical College, New york
Current treatment guidelines recommend specific 
antiretroviral drugs as preferred components of initial 
regimens based on their comparative efficacy, safety, 
tolerability, convenience, and other factors.  Current 
preferred components are:  abacavir/lamivudine and 
tenofovir/emtricitabine (nucleoside analogues); efavirenz 
(NNRTI); and atazanavir/ritonavir, fosamprenavir/ritonavir, 
and lopinavir/ritonavir (protease inhibitors).  Emerging 
data further define the efficacy and safety of these 
preferred ART components.
ACTG 5202 recently demonstrated that abacavir/
lamivudine was virologically inferior to tenofovir/
emtricitabine and also associated with a shorter time to 
severe toxicity in patients with pre-treatment baseline HIV 
RNA levels >100,000 copies/ml.  Abacavir hypersensitivity 
reaction is avoided with the use of baseline HLAB5701 
screening.  Unexpectedly, abacavir was shown to be 
associated with an increased risk of cardiovascular 
events in both the D-A-D cohort and the SMART study, 
although the mechanism is unknown.  Both abacavir and 
tenofovir have favorable lipid profiles compared with 
older nucleoside analogues.  Tenofovir uncommonly is 
associated with renal toxicity in clinical trials and cohort 
studies.  
Efavirenz remains the preferred NNRTI.  A subanalysis of 
ACTG 5095 demonstrated consistent activity of efavirenz-
based regimens across pre-treatment HIV RNA levels and 
CD4 cell counts.  An extension of the 903 study recently 
demonstrated 7-year durability of efavirenz-based 
regimens.  ACTG 5142 demonstrated efavirenz-based 
regimens were virologically superior to lopinavir/ritonavir-
based regimens, although CD4 responses were less good 
and drug resistance at virologic failure occurred more 
commonly.  Newer agents such as maraviroc, raltegravir, 
and the NNRTI rilpivirine, demonstrate comparable 
virologic responses to efavirenz.  A surprising finding 
from A5142 was that lipoatrophy was described more 
frequently with efavirenz than lopinavir/ritonavir.  Long-
term central nervous system side effects with efavirenz 
occur uncommonly.
The preferred protease inhibitors, each boosted with 
ritonavir, are atazanavir, fosamprenavir, and lopinavir and 
head-to-head studies (CASTLE and KLEAN) demonstrate 
their comparable efficacy.  More recently, head-to-head 
studies demonstrate the comparable efficacy to lopinavir/
ritonavir of darunavir (ARTEMIS) and saquinavir (GEMINI). 
Atazanavir/ritonavir is given once-daily and studies 
suggest the activity of once-daily ritonavir-boosted FR
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fosamprenavir and lopinavir.  Atazanavir uncommonly 
is associated with renal stones.  Comparative studies 
demonstrate differences in the lipid profiles of ritonavir-
boosted protease inhibitors; a recent meta-analysis 
suggested ritonavir-boosted fosamprenavir and lopinavir 
were associated with the greatest lipid increases 
compared to atazanavir, darunavir, or saquinavir.
TESTING	FOR	LATENT	TB	IN	HIV	PATIENTS	
–	THE	NEW	OR	THE	OLD?
The risk of reactivation of latent tuberculosis infection is 
significantly increased in the setting of HIV co-infection. 
Interventions to reduce the risk of reactivation of latent 
tuberculosis have been well established. Clinicians need 
to be able to diagnose latent tuberculosis to be able to 
offer these interventions to their patients. The tuberculin 
skin test (based on a delayed type skin hypersensitivity 
reaction to tuberculin) has been the most commonly 
used test to diagnose latent tuberculosis infection. 
However, it has limitations that include specificity, 
sensitivity and practical aspects.  New diagnostic tests 
for latent tuberculosis infection based on the detection 
of interferon gamma that is produced in the presence 
of Mycobacterium tuberculosis antigens have been 
developed and are now recommended as an alternative 
to the tuberculin skin test in the latest iteration of the US 
DHHS antiretroviral treatment guidelines.  These tests 
may be more specific for tuberculosis than the tuberculin 
skin test, but the role of these assays in the HIV setting has 
not been completely defined. This joint presentation will 
highlight the current data that relate to the use of each 
test to diagnose latent tuberculosis infection in people 
with HIV infection.
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I	MET	HIM	AT	THE	CANDY	STORE:
COMMUNITY	ATTITUDES	TO	SEx	ON	
PREMISES	VENUES	AND	THEIR	PATRONS
Smith A1, Grierson J1, Von Doussa H1
1La Trobe University, Australian Research Centre in Sex, 
Health and Society, Melbourne, Australia
Background: In developing health promotion 
interventions for sex on premises venues (SOPVs) it 
is critical to understand the place they have in the 
communities that access them.
Methods: An anonymous, self-complete questionnaire 
was administered to men attending the Midsumma gay 
community carnival in 2007. The survey consisted of 21 
items assessing participant characteristics and knowledge 
and attitudes relating to SOPVs and their patrons.
Results: A total of 287 surveys were returned. Mean age 
was 39 years. 50% were in a regular relationship. 51% 
had had an HIV test in the previous 12 months and 8% 
of the sample was HIV positive. 8% had had an STI in 
the previous 12 months. 46% had met a sexual partner 
at an SOPV in the 12 months prior to survey. Generally 
attitudes indicate little community disapproval of venues 
and their patrons. Respondents tended to disagree with 
statements that characterise patrons of SOPVs negatively. 
There was fairly comprehensive rejection of the premise 
that closing venues would reduce HIV/STI infections or 
reduce the amount of sex gay men had. When asked to 
rate how they might feel telling their gay friends that they 
had met a new boyfriend at a number of different places, 
men were significantly less comfortable reporting SOPVs 
than other settings (including online sites). Generally 
SOPV users were more strongly supportive of SOPVs and 
demonstrated a more nuanced conceptualisation of 
patrons.
Conclusions: Understanding what the peers of SOPV 
patrons believe about the venues and their customers can 
help us to tailor messages that can: address stigmatisation 
of users if this is evident; target specific populations 
in ‘insider’ language; mobilise patron expectations of 
venue standards; suggest approaches that embed SOPV 
practice in broader social and sexual practices; or avoid 
reinforcing typologies that distance patrons from the 
target message.
Social Research – Sexual Risk 
in Space and Time
1.30pm – 3.00pm
HIV/AIDS	AND	AUSTRALIAN	GAY	LIFE:	A	
GENERATIONAL	OVERVIEW
Dr Robert Reynolds
National Centre in HIV Social Research                                          
We are fast approaching the 30th anniversary of the 
emergence of HIV/AIDS in Australia, or, more specifically, 
30 years since the first notification of AIDS in Australia 
(November 1982). Traditionally, a generation spans 30 
years; thus we can now speak historically of a generation 
of HIV/AIDS.
This appellation, however, does not adequately do justice 
to the ebb and flow of HIV/AIDS over 30 years and its 
impact on Australian gay life, including the impact of the 
AIDS epidemic on changing formations of gay identity. 
HIV social researcher Jeffrey Grierson noticed in the late 
1990s three distinct cohorts of gay men: pre-AIDS; Peri-
AIDS; and Post-AIDS.
I think Grierson’s formulation has stood the test of time, 
and in this presentation I want to revisit these three 
cohorts. During 2004-7, I conducted a series of in-depth 
short life history interviews with a group of men ranging 
in age from the mid-50s to the mid-20s. These interviews 
were written up in a monograph which traced three 
decades of gay life in Sydney. While HIV/AIDS was not 
a central pre-occupation of the book, it nevertheless 
shadowed the participants’ narratives of self-identity. In 
this presentation, through a close reading of some of 
these narratives, I hope to show how the AIDS epidemic 
has effected the formation of gay identities, and how this 
has changed over time. 
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AGE	AND	SExUAL	BEHAVIOUR	AMONG	
GAY	MEN	IN	SYDNEY,	MELBOURNE	AND	
BRISBANE
Garrett Prestage,1 Susan Kippax,2 Fengyi Jin,1 Andrew 
Frankland,2 John Imrie,2 Andrew Grulich,1 and Iryna 
Zablotska2
1National Centre in HIV Epidemiology & Clinical Research, 
UNSW; 2National Centre in HIV Social Research, UNSW.
Background: Little attention has been paid to the issue of 
age in relation to HIV risk behaviour in Australia in recent 
years. Since 1996, the average age of new HIV infections 
has been increasing and since 2001 HIV prevalence has 
declined among younger men, particularly in Sydney.
Methods: The Gay Community Periodic Surveys (GCPS) 
are repeated, cross-sectional surveys conducted 
using anonymous, self-complete questionnaires with 
recruitment at gay community venues, clinics and large 
gay community events. Men were asked to report HIV 
testing and sexual behaviour. We included 2007 data 
from Sydney, Melbourne and Brisbane.
Results: Among men aged over thirty, there was little 
difference in terms of behaviours between those aged 
in their thirties, those aged in their forties, or above. The 
main differences were between those aged under and 
above thirty. Men aged over thirty were more likely to 
report being in non-monogamous relationships than 
their younger counterparts (p<0.001), though these 
relationships were of longer duration and the men 
were more likely to know their own or their partners’ 
HIV serostatus (p<0.001). Men aged over thirty reported 
sex with a greater number of casual male partners in 
the previous six months (p<0.001). Approximately one 
quarter of the sample reported engaging in any UAIC in 
the previous six months but there was little age difference 
in the likelihood to report UAIC. Men aged over thirty 
were more likely to engage in group sex.
Conclusion: While age is a consideration in the assessment 
of risk of HIV transmission among gay men, this risk is 
dependent upon the context in which it occurs: Age-
mixing may be important in understanding HIV risk 
among young gay men. Men aged over thirty appear to 
be more sexually active in general and are more likely to 
engage in more adventurous sex play such as group sex.
SEx	BETWEEN	MEN	IN	TIMOR-LESTE:	WHAT	
DOES	IT	MEAN?
Lee J, Rawstorne P, Worth H
National Centre in HIV Social Research                                                                                            
                                                                                                                        
Issues: In Timor-Leste, various socio-cultural factors such 
as political instability and associated violence, mobile 
populations and low condom use have all contributed to 
the increased HIV vulnerability amongst MSM. 
Description: There are no designated venues where MSM 
congregate or socialise in Dili, the capital, or indeed the 
districts. Whilst a well established social network between 
men who identify as being homosexual or MSM (as they 
term themselves) does exist in Dili, the sexual networks 
between MSM and their sexual partners (or clients as they 
are referred to) remain relatively unknown. 
The MSM clients are an even more ‘hidden’ group and 
represent a highly dynamic population. It is difficult 
to quantify the exact number of clients, as each MSM 
may have from 2-20 clients. These clients identify as 
heterosexual and often have girlfriends or wives. For 
the most part, the client appears to hold power in their 
relationships with MSM, only performing anal intercourse 
in the insertive position, and get rewarded by MSM for 
sexual services. Usually these rewards take the form of a 
monetary payment or goods such as mobile phone cards. 
This information was elicited during a mapping exercise 
as part of a larger behavioural surveillance survey. 
Lessons learned: Little is known about the clients of MSM, 
yet they represent a potential link for HIV transmission from 
a more-at-risk group (MSM) to the general population. In 
addition, this is a group that is not well serviced by health 
promotion, largely as the practices of this group are 
clandestine and are yet to be documented. 
Next steps: Utilising the findings of this research, health 
promotions can be designed and tailored to meet the 
specific needs of this hidden population. In addition, a 
greater understanding of the social and sexual dynamics 
of MSM and their clients will inform policies and 
programmes addressing HIV in Timor-Leste.
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‘1	MSG	THEN	SEx’:	TEMPORALITY,	
SPATIALITY,	SAFETY	AND	RISK	IN	GAY	AND	
BISExUAL	MEN’S	ACCOUNTS	OF	ONLINE	
SEx-SEEKING
Holt, M1
1National Centre in HIV Social Research, The University of 
New South Wales, Sydney, New South Wales, Australia.
Online sex-seeking by gay and bisexual men has often 
been characterised as a cause for concern. The use 
of gay chat sites that facilitate the advertising of and 
search for sex partners is seen as a highly efficient way 
for men to find each other. Speed or efficiency, together 
with the abundance of potential partners and relative 
anonymity have been seen as factors that could drive 
unsafe sexual activity or HIV transmission (although direct 
links between internet use and unsafe practice are rarely 
demonstrated). What are often missing in discussions of 
men’s online sex-seeking are the accounts of gay and 
bisexual men themselves. How do men characterise their 
online practice and the ways in which they search for and 
meet partners? Do these accounts trouble narratives of 
risk and online practice?
The e-male survey of Australian gay, bisexual and same-
sex-attracted men provided an opportunity to consider 
these issues. While the majority of participants received a 
quantitative survey, 491 men (10% of eligible participants) 
were directed to a small set of open-ended questions, 
including an item about men’s most recent experience 
of online sex-seeking. Analysis of this item indicates that 
men employ a variety of temporal and spatial strategies 
when looking for partners online, and that accounts of 
safety, care and deliberation are more common than 
those of risk or abandon. While many men’s accounts 
spoke to the speed and efficiency of online sex-seeking 
(e.g. ‘1 msg then sex’), many others referred to the space 
of the internet as territory where they could get to know 
partners before meeting them offline. Intervals of days or 
weeks between first online contact and meeting face-to-
face were not uncommon.
Participants’ accounts also indicated, as expected, that 
most men continue to seek and practice safe sex with 
their online partners. Quickly arranged encounters 
did not always feature anal sex, and men pointed out 
that in these situations HIV disclosure was unlikely or 
unnecessary. Most accounts of anal sex emphasised the 
use of condoms; unprotected anal intercourse was rare 
and usually negotiated. These accounts suggest that the 
majority of men’s sexual encounters initiated online are 
safe, pleasurable and feature planning or deliberation. 
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EDUCATION	SESSIONS	SUPPORT	
ADHERENCE	AND	IMPROVE	CLINICAL	
OUTCOME,	HEDURU	CLINIC	PORT	MORESBY,	
PNG.
Sawiya, G.; Ragagalo, O.; Nauna. T.; Nano, G; Tau,G.
Heduru Clinic, Port Moresby General Hospital, Port 
Moresby, PNG.
Background. Adherence to antiretroviral therapy (>95%) 
predicts HIV outcome. Individual understandings of HIV/
treatments, practical supports to adherence are factors 
predicting adherence in PLWHA. From 2004 (start of ART 
at Heduru) culturally appropriate group HIV education 
sessions on antiretroviral therapy, factors supporting 
adherence and problem solving for individuals on 
treatment have been delivered weekly.
Aim: To describe the development, delivery and evolution 
of education sessions at Heduru and to examine the 
influence of attendance at education sessions on 
outcome.
Results: All patients are invited to attend at least one 
of weekly presentations on: HIV/AIDS, how ART work, 
taking ART; when, how and what to expect, side effects 
management, ARV resistance prevention, adherence 
(how and why) and health maintenance (nutrition, safe 
sex, safe water, safe parenthood, influence of religion), 
follow-up and review protocols.  
The program has evolved including encouragement 
of patient treatment partners to attend (late 2004), 
incorporation in practical National Prescribers Training 
Programs (2005), inclusion of expert patient trainers 
(2006), development of flip charts and modification for 
beginning staff members (2007). 
Education Session Attendance
New registrations(n) HAART (n) Participants(n) 
 Non 
participants(n)
2005 238 199 141                    58
2006 330 269 320 10
2007 489 387 233 154
Of 231 individuals attending first assessment/registration 
January to June 2007, 205 (88%) attended a group 
education session; of 177 individuals commencing ART 94 
(53%) attended education sessions. The attendees did not 
differ from non-attendees by gender, age, marital status 
or baseline WHO clinical stage or performance grade. 
Although 11% have died in each group the proportion 
lost to follow-up at one year was 12 (13%) amongst the 
attendees compared to 22 (26%) in those not attending 
education session.
International: PNG
1.30pm – 3.00pm
Conclusion Nurse delivered culturally appropriate 
education sessions are associated with reduced loss to 
follow-up amongst HIV patients at Heduru. The inclusion 
of volunteer patient educators has a marked impact on 
sessions, encouraging open discussion and reassurance 
concerning outcome of ART.
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HIV/AIDS	AWARENESS	AND	ACCESS	TO	
ANTERETROVIRAL	THERAPY	(ART)	MAKES	
A	DIFFERENCE	IN	PEOPLE’S	LIVES	IN	
SOUTHERN	HIGHLANDS,	PNG
Rondopali, Sr Rose John, Gaudentia Sr. HIV/AIDS Office, 
Diocese of Mendi, SHP, PNG.
Introduction:  Southern Highlands Province (SHP) is 
situated in the interior of mainland PNG. It is divided into 
eight districts where remoteness, lack of infrastructure 
and disparate languages as well as cultural differences 
make response to the increasing burden of HIV/AIDS a 
substantial challenge. 
Aim:  To describe the development of the Mendi 
Catholic HIV/AIDS diocesan network. This aims to ensure 
PLWHA live positively, supported without stigma and 
discrimination to access treatment and care within local 
communities in a context of respect and love.
Methods: A regional approach based on a network of 
parishes will be demonstrated. Activities involved will 
be detailed; establishment of parish HIV Committees, 
community awareness programme, implementation 
of a system of PLWHA follow-up and family education 
and supports within local parishes and ART clinic 
establishment.
Results: SHP Catholic HIV/AIDS programme has been 
based in remote areas where Government services do 
not reach. During 2006, 2007 and to February 2008 the 
Mendi clinical service has provided voluntary counseling 
and testing to 1806 individuals 173 (9.6%) diagnosed 
with HIV infection. ART has become available and forty-
six individuals are receiving treatment and eight-seven 
cotrimoxazole prophylaxis and general care. Antenatal 
Provider Initiated HIV Counseling and Testing (PICT) 
has been provided to more than 2000 women and 
PMTCT have been provided where required (6 women). 
Availability of ART and care has resulted in individuals 
attending for diagnosis and treatment and the associated 
obvious health benefits (return to families and work, 
ability to tend gardens to sustain themselves and their 
families, acceptance into the community activities 
including school and church).
Conclusions:  A decentralized model of HIV/AIDS care 
and follow-up is being established within the network 
of Catholic parishes in Southern Highlands. The lessons 
learnt from our training, awareness, networking and 
clinical/follow-up activities within the responsible 
parishes is the basis for further human rights based 
service development.
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LIFE COACHING – MISSION NOT IMPOSSIBLE
Martinez Cipri
Positive Services Department Western Australian AIDS 
Council
Since the uptake of Highly Active Antiretroviral Therapy 
(HAART) in the mid nineties, the health prospects of 
People Living with HIV (PLWHA) in Australia has become, 
and continues to be, increasingly positive. Whilst this has 
improved their health status and survival overall, some 
have not necessarily enjoyed an improvement in their 
quality of life, particularly those who were diagnosed 
prior to the availability of HAART. 
Many of this group of people have found it difficult to 
move forward and therefore remain on disability support 
pensions, feeling isolated and lacking motivation. They 
are unable to see anything positive in their future and 
continue to have a  perception of their illness that is not 
matched with their clinical results. In other words, their HIV 
is under control on paper, and yet some PLWHAs continue 
to live with a perception that they don’t have a future.
In response to this issue, in 2007 the Western Australian 
AIDS Council (WAAC) introduced the Life Coaching 
project.  The aim of the project is to assist PLWHA to 
improve their quality of life through carefully identifying 
their values, beliefs and goals with the aim of achieving 
their personal vision.  Since the introduction of the Life 
Coaching project, 14 WAAC staff have been trained or 
are in the process of being trained as Life Coaches, with 6 
staff currently having clients.
Since the project started, 21 PLWHAs (16 males and 5 
females) expressed an interest in engaging with the life 
coaching process.  Two thirds (14 people) were assessed 
as being suitable for coaching (9 identifying as gay, 4 as 
heterosexual and 1 as bisexual) and were allocated to 
coaches.  Since the project began 4 people have ceased 
coaching for various reasons.  Of the ten currently being 
coached, their commencement ranged from October 
2006 to January 2008.
This presentation will provide an overview of what Life 
Coaching is, how the model works and what it has to 
offer PLWHA.  The expected and unexpected benefits 
for PLWHA and staff, including how it complements 
other strategies such as therapeutic counselling will be 
discussed.   
Phillip Medcalf Memorial Session 
– Community, Health Choices and 
Communication
1.30pm – 3.00pm
HIV	POSTIVE	SPEAKERS	BUREAUx	
–	A	MODEL	FOR	SUSTAINABILITY	AND	
RELEVANCE	IN	2008	AND	BEYOND
Niggl MR
People Living with HIV/AIDS Victoria Inc, Melbourne, VIC, 
Australia
The People Living with HIV/AIDS Victoria (PLWHA 
Victoria) HIV Positive Speakers Bureau is recognised for its 
management, training and expertise in delivering talks 
about the realities of living with HIV in the 21st century 
contributing to reducing HIV stigma and discrimination 
in the wider community. The Bureau has developed 
a highly successful and sustainable model that strives 
for excellence and consistently delivers talks to more 
than 3500 Victorians per year. The visibility of Victorian 
HIV Positive speakers adheres to the UNAIDS Greater 
Involvement of People Living with HIV/AIDS (GIPA) 
Principle and The Ottawa Charter of Health Promotion.
In other Australian States, Speakers Bureaux have had 
limited success. This paper will illustrate how Victoria 
developed a sustainable model that is still relevant in 
2008. Management methods of funding, recruitment, 
induction, training, administration will be illustrated. Key 
factors of retention and support for speakers from diverse 
backgrounds will be outlined. 
A hallmark of Victoria’s success is the speaker’s 
professionalism and with that professionalism comes a 
recognition that we need to move to sophisticated social 
marketing to attract different audiences and remain 
relevant. An overview of the Victorian Bureau’s innovative 
new campaign will emphasise it’s future sustainability 
and credibility.
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TREATMENT	qUESTIONS?	ANSWERS	BY	
INTERNET	AND	SMS	IN	INDONESIA
Green C1
1Spiritia Foundation, Jakarta
Antiretroviral therapy (ART) has been provided free-of-
charge to people living with HIV (PLHIV) in Indonesia who 
meet the WHO criteria since late 2004. There are now some 
6,000 people on ART, provided through some 200 AIDS 
referral hospitals. Thus each hospital has on average 30 
patients on ART, but the number is much lower in many. 
Although each hospital has at least one doctor trained to 
manage ART, many of these have very little experience, 
and little time to spend educating themselves. For similar 
reasons, doctors can rarely spend more than ten minutes 
with any patient.
As a result, PLHIV frequently have unanswered questions 
about their therapy. The Spiritia Foundation (the national 
peer support for PLHIV) has responded to this challenge 
in two ways. First, by training members of peer support 
groups as treatment educators. But five days training 
cannot provide answers to all these questions, and the 
group educators often feel reluctant to train their peers, 
fearful of difficult questions.
To address this, Spiritia offers two Q&A services. The first 
allows anonymous submission of treatment questions 
to our web site, where they are usually answered within 
36 hours. This is supplemented by a mobile phone SMS 
service, where we attempt to answer more swiftly, usually 
within one hour. 
While Internet access is still not universal, Internet cafes 
are widely available and relatively cheap, so many 
PLHIV can use this service, while also browsing the 
Spiritia site for information. But mobile phone service is 
almost ubiquitous in Indonesia, and SMS messages are 
relatively cheap, offering an alternative for the internet-
challenged.
We now answer an average of more than two questions 
every day on the web site, plus as many as 4-5 via SMS. 
If the SMS question is complex, we offer to call back to 
discuss the matter in more detail.
The main challenge is that there is no equivalent service 
for the ‘worried well’, so some 30% of the questions are of 
the ‘am I infected?’ type.
THE	TREATAWARE	INFOLINE	A	NATIONAL	
HIV	TREATMENT	HEALTH	PROMOTION	
SERVICE	FOR	PEOPLE	LIVING	WITH	HIV
DeMaere K1, Whittaker B1
1National Association of People Living with HIV/AIDS 
(NAPWA), Sydney, NSW, Australia
Increased scientific knowledge and the continuing 
development of better antiretroviral treatments have 
significantly changed the outlook for many Australians 
living with HIV today.  The goal of maximizing health 
and wellbeing of people with HIV over the long-term is 
assisted by a strong doctor/patient partnership in health 
planning.  To support this partnership, people with 
HIV need reliable and accessible treatment and health 
information sources to inform health decision making.
In mid 2008 the National Association of People Living with 
HIV/AIDS (NAPWA) launched a suite of health promotion 
initiatives under the banner of Treataware. This paper will 
focus on the Treataware infoline project, a community-
based service which provides a central place for people 
with HIV to obtain information about treatments, health 
planning and health issues. The Treataware infoline is also 
designed as a useful referral point for doctors and other 
health professionals.
The Treataware infoline offers a free, confidential, 
national telephone information service to HIV positive 
people.  Callers are able to discuss treatment, care, 
health and research issues with trained HIV treatment 
educators.
This paper will present the preliminary results of the 
Treataware infoline; provide an overview of promotional 
activities for the service; describe training, monitoring and 
evaluation arrangements; and highlight future directions 
for this community-based initiative. 
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DANCE,	THEATRE	DRAMA,	HIV/AIDS	&	THE	
AFRICAN	COMMUNITIES	IN	SYDNEY
Sabri W
Multicultural HIV/AIDS & Hepatitis C Service 
The pattern of HIV infection among culturally and 
linguistically diverse (CALD) communities in Australia 
largely reflects prevalence rates in countries-of-origin.  In 
2002-2006, people born overseas accounted for about 
31% of new HIV diagnosis in Australia.  Of these people 
born in Sub-Saharan Africa accounted for up to 18%.
In 2007, the Multicultural HIV/AIDS and Hepatitis C Service 
(MHAHS) implemented a one year project targeted at the 
African communities to build their capacity in relation to 
HIV/AIDS issues including safe sex practices and living 
with HIV/AIDS.  
The paper mainly discusses the use of theatre and dance 
as a creative intervention, designed to raise HIV/AIDS 
awareness and knowledge.  It details the process and 
steps undertaken to involve the African community 
members in the script writing and the performance of 
the “African Dance and Theatre Drama”.   
The paper also describes the community development 
frame work adoted to mobilise community members 
in the development and the implementation of a major 
community event around such a sensitive issue. 
GETTING	ON	WITH	IT	AGAIN	-	RESPONDING	
TO	THE	NEEDS	OF	PEOPLE	LIVING	LONGER	
WITH	HIV
Triffitt, K A , Flanagan,G, Santana H
Positive Life NSW, Sydney, Australia
Research has identified people living longer with HIV as 
a priority group in terms of future needs for both clinical 
services and care. The psychosocial impacts of living longer 
with HIV are only now starting to become clearer through 
research, clinical outcomes and community consultation. 
Those living longer with HIV are a diverse group. While 
many have put their lives on hold, others have made 
significant career choices. Both of these situations are not 
static and can change, sometimes rapidly, in a variety of 
ways. Daily living for many people with HIV also includes 
interactions between ageing, long-term psychosocial 
and clinical experience of treatments, and the long-term 
impact of the virus itself.
Responding to the needs of people living longer with 
HIV, Positive Life NSW has developed work in the areas 
of social marketing, peer support, systemic advocacy 
and health education. These different areas all combine 
to enhance skills, reorient services and create supportive 
environments. This paper will report on policy work, 
focus and group discussions, individual interviews 
and community forums. By incorporating and sharing 
personal strategies for change and enhancing quality 
of life, this work promotes the development of capacity 
at both policy and community level to negotiate the 
challenges of living longer with HIV. 
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ELEVATED	LEVELS	OF	INTERLEUKIN-6	
AND	D-DIMER	ARE	ASSOCIATED	WITH	AN	
INCREASED	RISK	OF	DEATH	IN	PATIENTS	
WITH	HIV
Drummond FM1, Hoy J1, 2, Emery S1, Cooper DA1 and the 
SMART Study Group
1National Centre in HIV Epidemiology and Clinical 
Research, University of NSW, Sydney, NSW, Australia; 
2Infectious Diseases Unit, Alfred Hospital and Department 
of Medicine Monash University, Melbourne, VIC, Australia
In SMART, CD4-guided intermittent antiretroviral 
therapy (ART) as compared to continuous ART resulted 
in an increased risk of cardiovascular disease (CVD) and 
of all-cause mortality, the latter primarily due to non-
AIDS causes. To explore reasons for these increased 
risks, we evaluated four inflammatory (high sensitivity-
C reactive protein [hsCRP], interleukin-6 [IL6], amyloid 
A and amyloid P) and two coagulation (D-dimer and 
prothrombin fragment 1+2 [F1.2]) markers that have high 
laboratory and biological reproducibility and that have 
been associated with mortality and CVD in the general 
population.
Patients with CD4+ count >350 cells/mm3 were 
randomised to viral suppression (VS, continuous ART 
n=2752) or to drug conservation (DC, CD4-guided 
intermittent ART, n=2720). To assess the short-term effect 
of intermittent ART on the biomarkers, stored plasma 
samples at baseline and Month 1 after randomisation 
for a random set of DC (N=249) and VS (N=250) patients 
were analysed. In addition, a nested case control study 
was carried out in which two controls were matched (age, 
gender, country, date of randomisation) to each death 
(N=85) and case of CVD (N=136). Adjusted odds ratios 
(OR) for the 4th versus the 1st quartile for each biomarker 
at baseline were estimated using logistic regression.
IL6 and D-dimer levels increased by 30% and 16%, 
respectively, one month after randomisation in the DC 
group and changed little in the VS group (5% and 0%) 
(p<0.0001 for treatment difference in each biomarker). 
For DC patients, increases in IL6 and D-dimer after one 
month were related in a graded manner to the increases 
in HIV RNA at month 1 (p<0.0001 for each biomarker). 
IL6 and D-dimer determined at baseline were strongly 
related to mortality with ORs greater than 12 for those 
in the 4th versus 1st quartile. Associations with CVD were 
more modest and were significant for IL6 and amyloid P. 
Associations of baseline levels of the biomarkers with all-
cause mortality and with CVD were similar for DC and VS 
patients.
Clinical – Toxicity
3.30pm – 5.00pm
ART interruption results in significant increases in IL6 and 
D-dimer. Elevated levels of D-dimer and IL6 identify a 
sub-group of HIV-infected patients at high risk of death in 
both treatment groups. Increases in IL6 and D-dimer may 
explain, in part, the increased risk of mortality and CVD in 
the DC group.
CARDIOVASCULAR	 DISEASE	 (CVD)	 RISK	 IN	
THE	STEAL	STUDY	COHORT
Bloch M1, Hoy J2, Woolley I3, Hounsfield V4, Humphries A5, 
Amin J5 on behalf of the STEAL investigators
1Holdsworth House Medical Practice Darlinghurst NSW 
Australia; 2The Alfred Hospital Melbourne VIC Australia; 
3Monash Medical Centre Clayton VIC Australia; 4Royal 
North Shore Hospital St Leonards NSW Australia; 5NCHECR 
UNSW Darlinghurst NSW Australia.
Combination antiretroviral therapy (cART) has increased 
survival in HIV patients and shifted attention to broader 
health issues including cardiovascular disease (CVD) risk. 
HIV itself, as well as cART toxicity may increase CVD risk. 
In the STEAL study, 360 participants were randomised 1:1 
to receive fixed-dose abacavir-lamivudine or tenofovir-
emtricitabine.  On entry, all participants had HIV-1 
infection, were on stable cART with plasma RNA <50 
copies/ml for at least 3 months.  Our aim was to assess 
baseline CVD risk in the STEAL study and compare it to 
other Australian cohorts.
All subjects enrolled in the STEAL study were assessed 
for individual CVD risk factors including age, gender, 
smoking status, fasting total and HDL cholesterol, blood 
pressure (at baseline or up to 3 months prior), personal 
history of diabetes, hypertension and CVD.  Framingham 
10-year risk was calculated for those participants with all 
required data (n=272).
The STEAL cohort were 98% male, aged 45±9 years, had 
a mean systolic BP of 125±14mmHg, and diastolic of 
BP 78±10mmHg, total cholesterol 5.3±1.2mmol/L, and 
HDL cholesterol 1.3±0.4mmol/L. 96% had no history of 
diabetes, and 35% were current smokers.  The average 10 
year CVD risk was 8±6%, with 68% in the low risk category 
(<10%); 28% in the moderate risk category (10-20%); 
and 3% in the high risk category (>20%).  These results 
compare favourably with other published HIV cohort data 
but are lower than in Australian population based studies 
(approximately 12-14% CVD risk).  It has been previously 
noted by the D:A:D Study Group, that the Framingham 
equation underestimates observed CVD risk in an HIV 
population.
At the commencement of the STEAL study the cohort 
was representative of an Australian HIV cohort with a 10 
year CVD risk slightly lower then that reported in a non-
HIV Australian cohort.
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POLY-L-LACTIC	ACID	FOR	HIV-1	FACIAL	
LIPOATROPHY:	48-WEEK	FOLLOW-UP
Carey DL1, Baker D2, Petoumenos K1, Chuah J3, Rogers 
G4, Watson J5, Cooper DA1,6, Emery S1, and Carr A6, for 
the FLASH Investigators
1. NCHECR/UNSW, Sydney, NSW, Australia 
2. 407 Doctors, Sydney, NSW, Australia
3. Gold Coast Sexual Health Clinic, Miami, QLD, Australia 
4. Griffith University, Gold Coast, QLD, Australia 
5. National Association of People living with HIV/AIDS, 
Sydney, NSW, Australia
6. St Vincent’s Hospital, Sydney, NSW, Australia
Poly-L-lactic acid (PLA) injections modestly increase 
objectively assessed facial thickness but not facial volume. 
We report the impact of a 24-week delay in PLA injections 
on efficacy, safety and quality of life. Longer term efficacy, 
safety and durability were also evaluated. 
HIV+, lipoatrophic adults were randomised to 4 open-
label PLA treatments administered every two weeks 
from week 0 (immediate group, n=50) or after week 24 
(deferred group, n=50). Endpoints included facial soft 
tissue volume (FSTV) assessed by volumetric computed 
tomography, facial lipoatrophy severity, quality-of-life, 
and safety. Analyses were by intention-to-treat.
PLA treatment adherence was 98%. At 48 weeks, mean 
change in FSTV was 14 (95% confidence interval [CI] –1 to 
29) cm3 in the immediate group and 18 (95% CI 5 to 30) 
cm3 in the deferred group (between-group difference, –
34[95% CI –22, 16] cm3; p=0.71). These represent changes 
of 4% and 5% respectively (between-group difference, 
–1%; p= 0.66). There was no significant between-group 
difference for changes in tissue depth in injection planes 
(base of nasal septum p=0.44; and maxilla p=0.22). Viral 
load, CD4+ cell count, antiretroviral adherence, patient 
and physician-assessed facial lipoatrophy severity, and 
Multidimensional Body-Self Relations Questionnaire-
Appearance Scales (MBSRQ-AS) scores did not differ 
significantly. The Short Form (SF)-36 Health Survey-
assessed mental health score was significantly higher in 
the immediate group than the deferred group (5.2 and –
3.7 respectively; p=0.027). Soft tissue thickness in injection 
planes increased modestly between weeks 24 and 48 in 
early PLA recipients. At week 48, mean change in FSTV 
was 14 (95% CI –1 to 29) cm3 (p=0.06) in immediate 
group participants and increases in tissue thickness were 
observed in both injection planes (p<0.0001). Median 
duration of treatment-related adverse events was 2 
(interquartile range: 1-3) days.
Delaying PLA treatment by 24 weeks did not impact 
change in FSTV or tissue depth in injection planes. FSTV 
and soft tissue thickness were higher at week 48 than at 
week 24 in early PLA recipients suggesting that the PLA 
treatment effect was durable. PLA was safe and well-
tolerated over 48 weeks.
Oral Posters:
Knox D - see page
Mackie K- see page
Hooker D - see page
Russell D - see page
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Network Sex
3.30pm – 5.00pm
IMPACT	OF	A	NON-OCCUPATIONAL	POST-
ExPOSURE	PROPHYLAxIS	PROGRAM	FOR	
HIV	IN	WESTERN	AUSTRALIA
Laing SC1, Dykstra CA2, Marshall LJ3, McCloskey JC2, 
Langdon P4, Brown G5 and Mak DB1
1Communicable Disease Control Directorate, Department 
of Health WA,  Perth, WA, Australia, 2Sexual Health Service, 
Royal Perth Hospital, Perth WA, Australia,  3Infectious 
Diseases Department, Fremantle Hospital, Fremantle, 
WA, Australia, 4WA AIDS Council, Perth, WA, Australia, 5WA 
Centre for Health Promotion Research, Curtin University 
of Technology, Perth, WA, Australia.
Since late 2001, the Department of Health (DOH) has 
monitored provision of non-occupational post-exposure 
prophylaxis (NPEP) for HIV in WA.  Up to 31 December 
2007, 214 cases received NPEP.
Gay Community Periodic Surveys (2002 and 2004) 
showed that the Perth community awareness of NPEP 
availability was low.  
In May 2005, the DOH and the WA AIDS Council 
commenced a targeted campaign to raise awareness of 
NPEP availability and to increase the level of appropriate 
treatment.  The campaign is aimed at health care providers 
and people at high risk of HIV infection - men who have sex 
with men, people in sero-discordant relationships, people 
living with HIV/AIDS, people who inject drugs and people 
who have been sexually assaulted or had unsafe sex with 
a person known to have HIV, or to be strongly suspected 
of being HIV-positive.  Strategies have included resource 
development and distribution (pamphlets, fact sheets, 
posters, press advertisements in gay press and banner 
advertisements on Gaydar), establishment of a 1300 
phone line to triage cases, and provision of information 
for health care providers.
Since the campaign commenced, awareness of NPEP has 
increased.  In 2006, a significantly higher percentage of 
Perth Gay Community Periodic Survey respondents was 
aware that NPEP was readily available compared to the 
two previous surveys (18.5% [2002], 26% [2004], 48.2% 
[2006], χ2 test for trend, p<.001 for both).
The average number of cases receiving NPEP per year 
increased by 16.6% since the campaign commenced (34.3 
cases per year, May 2002 - April 2005; 40 cases per year, 
May 2005 - April 2007).  Evidence from clinicians indicates 
that they receive appropriate referrals from the phone 
line and available data indicates that the proportion of 
patients receiving NPEP who met the recommended 
guidelines has increased from 50% (n = 34) during the 
period May 2002 - April 2003 to 96.7% (n = 30) during the 
period May 2006 - April 2007. 
Initial concerns that a campaign might encourage 
inappropriate and over use of NPEP have not been 
realized.  
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ExTENSIVE	TRANSMISSION	LINKS	
AMONGST	NEWLY	HIV-INFECTED	PATIENTS	
CONTRIBUTE	SIGNIFICANTLY	TO	THE	
INCIDENCE	OF	HIV-1	INFECTION	IN	
MELBOURNE.
Kaye MB1,2, Chibo D1 & Birch CJ1,2.
1HIV Characterisation Laboratory, Victorian Infectious 
Diseases Reference Laboratory, Melbourne, VIC, Australia.
2Microbiology Department, Monash University, 
Melbourne, VIC, Australia.
Primary HIV infection (PHI) and its association with elevated 
viral load is thought to be a critical period for onward 
transmission of the virus, particularly if the individuals 
concerned are unaware of their HIV-positive status.  To 
determine whether such transmission contributes to the 
rates of infection observed in Melbourne, phylogenetics 
was utilised to investigate virological links amongst newly 
HIV-infected patients.
A total of 376 patients (369 males, 7 females) infected with 
HIV-1 subtype B between 1996 and 2006 were investigated 
based on conclusive serological evidence that they had 
become infected within the preceding 12 months.  All 
patient information was de-linked prior to undertaking 
the analysis.  Phylogenetic analysis was performed on 
1035-nucleotide (nt) HIV-1 pol sequences initially using 
distance-based methods.  Monophyletic clusters were 
confirmed using Bayesian methods.  Virological links 
were regarded as likely based on bootstrap values of 
greater than 90%, intra-cluster average genetic distances 
of less than 0.03nt substitutions per site and posterior 
probabilities of 1.0.
Phylogenetic analysis identified 54 transmission clusters 
involving 226 (60%) newly infected patients.  Although 41 
clusters included linkages between only 2 to 4 individuals, 
13 clusters involved 5 or more individuals and accounted 
for 113 (30%) PHIs.  The largest cluster included related 
viral sequences from 22 individuals infected over a period 
spanning 8 years.  Other clusters linked 14, 12 (n=2) and 8 
(n=2) individuals with a maximum period of transmission 
within clusters spanning 9 years.  Within these large 
clusters groupings of 3 or more individuals who had been 
infected within a period of 12 months were frequently 
observed.
This study demonstrated the existence of several large 
clusters of patients infected with related viral strains 
many of which were transmitted within restricted time 
frames.  This suggests transmission of HIV to multiple 
recipients contributes to the number of new infections in 
Melbourne and that onward transmission of HIV during 
early stages of infection is a factor in the continuing 
epidemic.  Phylogenetic surveillance of HIV transmission 
within the local population provides the opportunity to 
identify sources of multiple transmissions and carry out 
targeted education programs aimed at reducing the 
number of new infections.
NON-OCCUPATIONAL	POST	ExPOSURE	
PROPHYLAxIS	AGAINST	HIV	(NPEP)	
AND	SUBSEqUENT	HIV	INFECTION	IN	
HOMOSExUAL	MEN:	FINAL	DATA	FROM	THE	
HIM	COHORT	
Poynten IM1; Jin Fy1; Prestage G1; Mao L2; Kippax S2; Kaldor 
J1; Grulich AE1
1National Centre in HIV Epidemiology and Clinical 
Research, UNSW, Sydney, Australia; 2National Centre in 
HIV Social Research, UNSW, Sydney, Australia
Non-occupational post exposure prophylaxis (NPEP) 
as a means of HIV prevention has yet to be established 
globally. In Australia, guidelines recommending the use 
of NPEP were first released in New South Wales in 1998. 
NPEP is now available in most states. 
In a community-based cohort of HIV negative homosexual 
men, the Health in Men (HIM) study, we aimed to 
determine the awareness of availability of NPEP; the 
frequency and predictors of use of NPEP at baseline and 
during the study and the incidence of HIV seroconversion 
in NPEP users. Annually, men were asked questions about 
NPEP, tested for HIV and detailed quantitative data on 
unprotected anal intercourse (UAI) were collected. NPEP 
awareness, use and predictors of use at baseline were 
analysed using logistic regression. Cox regression models 
examined incident NPEP use, HIV seroconversion and 
time trends in NPEP use. 
1,427 participants were enrolled. Final HIM interviews were 
completed in July 2007. At baseline, 78.5% of participants 
were aware of NPEP and 6.3% reported previous use of 
NPEP. By the fifth annual interview, 97.4% of participants 
had heard of NPEP. 
During follow up, NPEP use increased significantly from 
1.7/100Py in 2002 to 9.9/100Py in 2006 (p < 0.001). 
Previous use of NPEP at baseline was associated with UAI 
in the past 6 months with casual partners (p < 0.001), 
and UAI with partners of unknown or positive HIV status 
(p < 0.001). UAI was a strong predictor of use of NPEP 
during the study. Use approached 25/100 Py in men who 
reported receptive UAI with casual partners if ejaculation 
occurred and exceeded it if the partner was known to be 
HIV positive. By the end of 2006, 49 HIV seroconversions 
were identified (HIV incidence 0.80 per 100 Py (95% CI 
0.60-1.060)).  Men who received NPEP had a significantly 
higher rate of HIV seroconversion during the study 
period.
NPEP use is increasing. Awareness of NPEP among 
HIM participants was almost universal. Use seemed 
appropriate, with many men reporting highest risk 
behaviours also reporting NPEP use. In this setting, men 
who received NPEP were at higher risk of subsequent HIV 
infection.   
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‘SEx	IN	OTHER	CITIES’	–	RESPONDING	TO	
INCREASES	IN	OVERSEAS	ACqUIRED	HIV	
DIAGNOSES	IN	WA
Langdon PA  
Western Australian AIDS Council Inc, West Perth, WA, 
Australia.
Over the past three years, there has been a dramatic 
increase in the number of new HIV diagnoses amongst 
WA men acquiring HIV overseas. New diagnoses 
amongst heterosexual men increased by 212%, (50 in 
2005-2007 compared with 16 in 2002-2004) and by 42% 
amongst homosexual men (20 in 2005-2007 compared 
with 14 in 2002-2004). In the same period, the number 
of heterosexual and homosexual men acquiring HIV in 
Australia remained stable.       
Western Australia is currently experiencing an 
unprecedented resources boom with commensurate 
labour demands, including for temporary 457 visa 
holders. The resource industry labour market is structured 
around fly in fly out workers, which impacts on personal 
relationships and the capacity for service delivery within 
community settings.  Overseas travel for work and leisure 
in nearby high prevalence countries is higher amongst 
Western Australians compared with other Australians. 
These factors combined with poor population health 
infrastructure, in rural and remote WA and high endemic 
rates of STIs in some regions means there is potential 
downstream vulnerability for local populations, 
particularly women and Aboriginal people.
The WA AIDS Council (WAAC) has planned an integrated 
community response to this issue with the aims of 
minimising the number of people acquiring HIV overseas 
and preventing onward HIV transmission in Australia.  The 
strategies are aimed at a population level rather than an 
individual level, including advocacy for specific policy 
development. Tailored research and surveillance is also in 
the pipeline which will inform future service delivery.
  
WAAC is building partnerships with governments, 
resource companies and occupational medicine 
companies with the aim of providing information, training 
and development for professionals.  Targeted social 
marketing is aimed at work and leisure travellers using 
in-flight magazines, mining publications, travel industry 
publications and community newspapers. A new website 
www.sexinothercities.com.au has been developed and 
has applicability for travellers from Australian states and 
territories.   
Targeting people acquiring HIV outside Australia is 
complex. Vulnerable men do not necessarily belong 
to any specific community or groups and are not easily 
accessible. New strategies and different partners are 
required to respond to this growing phenomenon. 
NORTH	qUEENSLAND	TRAVELLERS	
PROJECT:	HETEROSExUAL	HIV	CLUSTER
Harper RE1, Russell D2,3, O’Mullan C3
1Family Planning Queensland, Cairns, QLD, Australia; 
2The University of Melbourne, Melbourne, VIC, Australia; 3 
Cairns Sexual Health Service, Cairns, QLD, Australia
Heterosexual men travelling to Papua New Guinea for 
employment purposes have been identified as a small, 
but significant population at risk of HIV transmission. They 
are also under-represented in service statistics, and less 
likely to identify themselves as at risk.  
In 2007 5/26 of all new HIV diagnoses in Cairns were 
acquired by heterosexual males reporting sexual contact 
in Papua New Guinea, an increase from 1/16 cases 
acquired by this group in high prevalence countries in 
2006.
This spike follows similar national trends, with the 
Northern Territory and Western Australia also recording 
significant increases in diagnoses acquired in high 
prevalence countries. The Far Northern cluster, however, 
has described a unique demographic. The males are all 
heterosexual, aged between 47-66, and based in Cairns 
and/or PNG locations. Three out of the 6 males also had 
a female partner living in Cairns – these women have all 
tested negative for HIV infection.
In response to this cluster, Queensland Health has 
funded Family Planning Queensland to implement 
a social marketing campaign advocating safer sex 
practices amongst those travelling between Cairns and 
neighbouring high prevalence countries, with a particular 
focus on Papua New Guinea. The campaign will measure 
awareness of risk of STI and HIV transmission among the 
target group, awareness of preventive strategies and 
testing options, and the uptake of testing and treatment 
services in the Cairns district among the target group.
This target group poses significant difficulties in health 
promotion. Uptake of information provided through 
brochures, convenience advertising and in-flight 
magazines depends on the target group reading and 
remembering this information. Men in this target group 
may not be interested in reading these resources.
Increased knowledge, awareness of risk and even 
increased intention to use condoms may not be 
sufficient to influence behaviour change. Cultural and 
environmental factors (e.g., being unable to easily acquire 
suitable condoms at the destination, engaging in sexual 
activity spontaneously or while intoxicated, engaging in 
surreptitious sexual activity to conceal the fact from his 
regular partner) may mitigate against men in the target 
group from adopting preventive measures, despite 
increases in knowledge.
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HARM	REDUCTION	IN	ASIA	–	A	CLINICIAN’S	
PERSPECTIVE
A Kamarulzaman
University of Malaya. Kuala Lumpur.
In many parts of Asia, HIV epidemics have been largely 
driven by injection drug use, and transmission among 
sex workers and their clients. HIV rates of greater  than 
20% among injecting drug users have been recorded in 
many countries,  including Indonesia, Malaysia, Myanmar, 
Thailand, and Vietnam. In response to the escalating 
epidemics, several countries in the region have embarked 
on harm reduction efforts but in many instances these 
responses have come somewhat too little and too late. 
Despite recent global initiatives that have increased the 
number of people  receiving antiretroviral therapy in the 
region by almost threefold, injecting drug users remain 
disproportionately less likely to have access to these 
medications. Some of the major obstacles to access to 
antiretrovirals for injecting drug users include legal policies 
surrounding drug use, inadequate health infrastructure, 
cost, and pervasive stigma and discrimination, which 
hinder drug users from coming forward for treatment. 
In some countries, where access to antiretrovirals in the 
community has increased, continued criminalisation of 
drug users has led to periods of treatment interruption for 
HIV-positive IDUs when they are imprisoned. This raises 
the risk for development of antiretroviral resistance.
In Asia, an inadequate health infrastructure and lack of 
healthcare workers with the  relevant skills and training 
to provide treatment are major obstacles to access to 
antiretrovirals, particularly for injecting drug users. The 
complexity of managing HIV infected drug users, who 
often present with multiple medical problems, makes it 
crucial that health professionals are adequately trained. 
High rates of co-infection with hepatitis C and tuberculosis 
increase the risk for antiretroviral-associated toxicities as 
well as complex drug-drug interactions. 
Integrated treatment for substance abuse, general medical 
care, HIV and  psychiatric treatment and psychosocial 
support in non-traditional health care  settings such as 
hospitals and clinics is a model of care that should be 
examined and extensively developed in the region. Finally, 
scaling up antiretroviral and opiate substitution treatment 
must be accompanied by a commitment to improve 
social support services, in order to help integrate people 
back into society, with their families, and into job training 
and placements. Building the capacity of health care 
professionals alone will not be adequate. Peer support, 
peer-based treatment education, patient advocacy, 
case management and social services are other crucial 
services that must be developed for a comprehensive 
and successful management of HIV infected drug users.
International: Harm Reduction in Asia
3.30pm – 5.00pm
RISK	LIFESYLES	OF	DRUG	USERS	IN	PHNOM	
PENH,	CAMBODIA
Dr Vannda Kab
Korsang      
In Cambodia, illicit drug use has increased dramatically in 
the past eight years. The injecting drug use level appears 
to be small but increasing. Amphetamine (yama) appears 
to be the most widely used illicit drug (with regard to HIV 
transmission).
Concern about illicit drug use is increasing in the country 
because there is a possible link between such illicit drug 
use (yama, glue) with increased sexual risk/transmission 
of HIV and other sexually transmitted infections (STIs), 
and yama use has been found among the above highly 
vulnerable groups.We have observed that among the 
vulnerable population there also has been an increase 
in heroin injecting, while the yama users have switched 
from smoking yama to smoking heroin and then injecting 
heroin. 
The injection related infections have been considerably 
high among the injecting drug users (IDUs) because the 
injection equipment has been reused up to 5 or more 
times a day. The sharing of the used syringes and other 
injection equipment with the lack of HIV transmission 
education, the lack of sterile injection equipment and the 
zero knowledge of how to clean injection equipment with 
bleach play very crucial part in the HIV/AIDs epidemic in 
the community. 
Moreover, the zero knowledge of vein care or overdose 
prevention plus the basic lack of over all health care and 
nutrition, this has lead to many preventable deaths. 
Korsang is a small grass roots program located in Phnom 
Penh, Cambodia. It is fairly new program, beginning in 
September 2004. The main component of the Korsang 
team is to engage in intensive, risk reduction based IDU 
and drug user outreach and education through peer 
related connection.  Korsang is targeting Cambodians 
who are engaged in injection drug use and yama use 
who are currently un-served and at serious risk of HIV and 
other health-related hazards that accompany drug use 
and high-risk sexual behavior.  Korsang staff visits areas 
where street based injection drug use is a serious issue 
and sex worker areas where yama and unprotected sex 
go hand in hand.
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HARM	REDUCTION	IN	ASIA	–	AUSTRALIA’S	
ROLE
Professor Nick Crofts
Senior Research Fellow, Nossal Institute for Global Health
HIV among and from injecting drug users is still driving 
the AIDS epidemic in much of Asia, as it has since HIV 
first appeared in the region.  Substantial progress has 
been made in developing supportive environments for 
effective harm reduction responses in many countries in 
the region, and in implementing such responses – and 
Australia has been a major contributor to this progress. 
However, harm reduction programs in Asia are still far 
outweighed by the sheer scale of numbers of the HIV 
epidemics, and are reaching only small proportions of 
those at risk and affected. As well, policy environments 
remain ambiguous at best and openly hostile at worst. 
This session will examine the situation and challenges 
in HIV among and from IDUs in Asia, and the needs and 
opportunities for heightened Australian involvement and 
support.
THIS	IS	THE	REAL	WORLD	-	NOT	AS	WE	
KNOW	IT	
Speed T.
Australian Injecting and Illicit Drug Users League Inc. 
(AIVL) Canberra, ACT, Australia In the context of large 
and growing HIV and hepatitis C epidemics, not to forget 
the impact of coinfection, amongst people who inject 
drugs across the Asia region, AIVL is extending itself to 
tackle what is without a doubt one of the organisation’s 
greatest yet most rewarding challenges - our foray into 
international development work.
Were we ready for the steep learning curve this work 
presented?  Were we ready for the easily established 
rapport, the warmth from our peers in the region, 
enthusiastic to work alongside us?  How is it to work 
in an environment where to be a drug user can mean 
death by firing squad, where government ‘war on drugs’ 
propaganda is not rhetoric?
Whilst not wishing to be too voyeuristic nor perhaps even 
alarmist by way of this presentation, we seek to share our 
experiences and learnings eg what could ‘dry injecting’ 
possibly mean and how do you work with this concept 
without shuddering?  This presentation will share the 
extreme hardships some of our peers face, the context of 
their drug use and drug treatment, and the nature of their 
drug use, what this means to health and humanity.
This presentation will conclude with an exploration of 
some of the key issues and barriers that will need to be 
addressed if an effective response to HIV and hepatitis 
C prevention and treatment among people who inject 
drugs across Asia is to be developed effectively and in line 
with need and their growing proud voices.
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DEVELOPMENT	OF	A	NEW	HEALTH-RELATED	
qUALITY	OF	LIFE	qUESTIONNAIRE	SPECIFIC	
TO	HIV/AIDS:	AN	INTERNATIONAL	AND	
CROSS	CULTURAL	INITIATIVE		
Duracinsky M1, Herrmann S2, Acquadro C3, Berzins B4, 
Lecoeur S5, Hyland N6, Fournier I7, E. McKinnon2, Nolan 
D2,8,  Mallal S2,8, Chassany O3.
1Service de Médecine Interne et de Maladies Infectieuses, 
Hôpital Universitaire de Bicêtre, Paris, France; 2Centre for 
Clinical Immunology & Biomedical Statistics, Royal Perth 
Hospital & Murdoch University, Perth Western Australia; 
3Département de la Recherche Clinique, Hôpital Saint-
Louis, Paris, France; 4Division of Infectious Diseases, 
Northwestern University, Chicago, USA; 5Programs for HIV 
Prevention and Treatment (PHPT), Chiang Mai, Thailand; 
6Sexual Health Services Royal Perth Hospital, Perth 
Western Australia; 7Institut Pasteur du Cambodge, Phnom 
Penh, Cambodia; 8PathWest Laboratory Medicine WA
Health-Related Quality of Life (HRQL) questionnaires (Q’s) 
specific to HIV/AIDS were developed before the advent 
of antiretroviral therapy (ART) and/or before current co-
formulations which have, purportedly, a lower toxicity 
profile. Arguably, these Q’s have diminished sensitivity to 
measure the current impact of HIV disease and treatment 
on People Living With HIV/AIDS (PLWHA). Relevant 
domains important for PLWHA such as sleep, perception 
of treatment and impact of current common side effects, 
including lipodystrophy are missing and the assessment 
of psycho-social impact could be improved. 
The objective is to develop a new Patient-Reported 
Outcomes (PRO) questionnaire to measure the HRQL 
of PLWHA in different countries and cultures, using an 
item bank developed from semi-directive interviews 
which explored the multidimensionality of PLWHA’s 
HRQL with participants. To capture cultural differences in 
perceptions, interviews were held in: Senegal, Brazil, USA, 
Australia, Thailand, China, Cambodia, India and France 
and recorded, transcribed and translated into English and 
French. 
Globally 148 (47% female) individuals consented to the 
interviews from which the domains representing PRO’s 
were identified. Using participants’ verbatim, 300 items 
were generated in French and English and organized 
into a 24-domain item bank. An endpoint model was 
designed to explain the relationship between PRO’s, 
health status, symptoms, side effects and the different 
domains of HRQL. Cultural differences were identified in 
Social Research – Lives Worth Living
3.30pm – 5.00pm
domains such as daily activities, stigma, and relations with 
family and/or friends. Cognitive debriefing was carried out 
at each centre on 5 participants not part of the original 
interview group, using a 70 item questionnaire that had 
been developed—this was subsequently reduced to 60 
items after harmonization.
At the next stage the questionnaire will be administered 
to 100 participants at each centre. In WA the results will be 
correlated with appropriate clinical information from the 
WA HIV Cohort database. It is anticipated that following 
psychometric validation and translation into the target 
languages this questionnaire will be a contemporaneous 
tool to use with WA patients and migrants from high 
prevalence countries. Globally, the new HRQL instrument 
will be used by those who seek to measure the impact of 
HIV and treatment on PLWHA accurately.
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ASSESSING	THE	NEEDS	OF	YOUNGER	HIV	
POSITIVE	MEN
Bavinton B1, Gray J1
1ACON, Sydney, NSW, Australia
The rate of seroconversion amongst gay men aged 29 
years and under in NSW has remained fairly stable for a 
number of years at 80 to 90 each year. At any given time 
there are approximately seven to eight hundred men in 
this category. However, NSW does not have any services 
specifically targeting this age group.  Although there is 
anecdotal evidence suggesting that the needs of this 
group may be different from those of older positive gay 
men, there is very little research focusing on younger 
positive men.
In 2007-08, ACON conducted a needs assessment with 
this target group, which sought to determine whether 
there are unique needs faced by this group, and if so, how 
these might be addressed.
A high level of involvement by the target population 
was an integral component of the needs assessment. 
Volunteers helped to determine areas for further 
discussion and facilitated a series of five discussion 
nights with other young positive men. The discussion 
nights each focused on a different topic – including sex, 
relationships, mental health/emotional wellbeing/drugs 
and alcohol, disclosure, and health/treatments. These 
sessions were complemented by an online survey which 
added quantitative data to the rich qualitative information 
produced by the discussion nights. The young men 
assisted in the analysis of the data.
The needs assessment determined that younger positive 
men have specific needs that can be met through a 
range of programmatic responses. The most significant 
needs that were identified concerned stigma and 
discrimination, peer support, social identification, non-
concordant sex and relationships, and service usage. 
Addressing these issues requires a multifaceted approach 
that works with younger HIV positive men to improve 
skills, reduce social isolation, build a culture of service 
usage, and support these young men around sex and 
relationships. Additionally, a separate focus must be on 
reducing the levels of HIV stigma and discrimination 
amongst HIV negative men.
BEING	HIV	POSITIVE	IN	AOTEAROA	/NEW	
zEALAND:	A	TWO	STUDY	COMPARISON	
2001-2007
Grierson J1, Thorpe R1, Pitts M1, Hughes T2, Saxton P2, Smith 
J3, Smythe E2, Thomas M4
1 La Trobe University, Australian Research Centre in Sex, 
Health and Society, Melbourne, Australia; 2 New Zealand 
AIDS Foundation, Auckland, New Zealand; 3 Eventimento 
NZ Ltd, Auckland, New Zealand; 4Auckland City Hospital, 
Infectious Disease Department, Auckland, New Zealand
Background: Understanding the lived experience of HIV is 
critical for the provision of treatment and support services 
in ways that appropriately reflect the contexts and needs 
of PLWHA.
Methods: HIV Futures New Zealand is an anonymous, 
cross-sectional survey of people living with HV/AIDS. The 
survey covers the domains of HIV testing and counselling; 
health status and management; antiretroviral therapy; 
service use; well being and mental health; social support 
and community engagement; relationships and sex; 
recreational drug use; accommodation; employment; 
finances; and discrimination. First conducted in 2001 
(N=226) it was replicated in 2007 (N=261). Participant 
demographics were generally representative of the 
known HIV positive population in terms of gender age 
and ethnicity.
Results: All results reported are 2001 then 2007. Ratings of 
health status and well being were similar across the two 
surveys. A greater proportion had been diagnosed with 
an AIDS defining illness in the two years prior to survey 
(5%, 14%). Similar proportions had ever used antiretroviral 
treatments (78%, 79%), while current use was higher 
(64%, 73%). Service use was lower across all services at 
HIV organisations in the most recent survey. For example, 
treatments advice (55%, 34%); treatments information 
(26%, 15%); and counselling (48%, 31%). More participants 
owned or were purchasing their own home (37%, 46%). 
Fewer were in public rental accommodation (18%, 13%). 
More reported being in paid employment (53%, 62%). 
Median weekly personal income has increased ($330, 
$486), and this is greater than the change in consumer 
price index. Fewer reported experiencing discrimination 
in relation to accommodation, at health services and in 
relation to obtaining insurance.
Conclusions: A general improvement in the health 
and well being of New Zealand PLWHA can be seen 
from these comparisons. Critical economic and social 
disadvantage still remains when compared with the New 
Zealand population.
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CURRENT CARE AND SUPPORT NEEDS OF 
HIV-POSITIVE GAY MEN: WHAT FACTORS 
LIMIT ACCESS TO AVAILABLE SERVICES?
Zablotska I.B.1, Imrie J.1, Prestage G.2, Frankland A.1, Grulich 
A.2, Sue Kippax2
1 National Centre in HIV Social Research, University of New 
South Wales, Sydney, NSW, Australia; 2National Centre in 
HIV Epidemiology and Clinical Research, University of 
New South Wales, Sydney, NSW, Australia.
Where accessible, effective, simplified treatments 
transformed HIV infection into a chronic condition. The 
changing needs of HIV-positive people have prompted 
health-care systems worldwide to improve and adjust 
services. We consider current access to care among HIV-
positive people. 
Data collected in 2006 from a community-based cohort 
of HIV-positive gay men (Positive Health) in Sydney 
(N=270) were used. Participants were asked about their 
health/clinical and community-based service needs and, 
subsequently, about difficulty in accessing services. We 
report the prevalence of specific needs, barriers, and 
predisposing factors associated with them.  
Participants most commonly used a GP (64%), hospital 
clinic/outpatient services (39%) and sexual health clinics 
(14%) for HIV management. All participants needed at least 
one HIV-related health service (mostly multiple services) 
- doctors experienced in HIV management, dentists, 
antiretroviral prescribers and hospital pharmacies. Most 
were able to use available services without problems. 
However, problems appeared in relation to obtaining 
doctor appointments and opening hours for hospital 
pharmacies. Cost emerged as a substantial barrier to 
dental care (91% of those in need) and psychological 
counselling. Need for one or more community–based 
services was reported by 46% of the men. The most 
difficult to access were income and peer support, public 
housing (supported accommodation); usually due to 
poor services and staff attitudes. Income level was a 
single predisposing factor associated with limited access 
to services. 
Conclusion:  In Australia, health service needs outweigh 
those for social support. Complex medical and social 
support services remain essential to HIV-positive people. 
Worldwide, positive changes in health and life expectancy 
have translated into HIV-infected people with highly 
specific health care needs. This results in growing stress 
on health and social services, some of which are currently 
not meeting the needs of HIV-positive people. The ability 
of society to provide an adequate standard of care 
depends on the adaptability of services to the changing 
needs of HIV-positive people.  
VIRAL	FAMILIES:	ANALYSING	KINSHIP	
DISCOURSE	IN	HIV	TRANSMISSION
Dean Murphy,1 Jeanne Ellard, 1 kylie valentine,2, Jahan 
Tyson1
1National Centre in HIV Social Research, University of New 
South Wales; 2Social Policy Research Centre, University of 
New South Wales
Phylogenetic analysis is the calculation of genetic 
distance between viral strains. This analysis can determine 
the degree of relatedness between two samples of HIV, 
and has been used forensically to prosecute people for 
transmission of HIV. 
The Viral Families project is a pilot qualitative study 
investigating two social and political dimensions of 
this technology: the potential for new forms of social 
connection and belonging; and the potential for new 
forms of biological identity. Its theoretical innovation is 
the use of science and technology studies to explore the 
intra-action of clinical technologies and human actions. 
In this presentation we identify discourses of kinship in 
the narratives of gay men engaging in deliberate HIV 
transmission or acquisition, and in media coverage of HIV 
transmission.
We undertook a content analysis of HIV-related articles 
published in print-based media from 2007 and 2008.  We 
also analysed the public areas of selected gay chat sites 
with a focus on ‘barebacking’ (intentional unprotected 
sex ) for use of familial and genealogical tropes, especially 
in relation to HIV infection, as well as ‘bug-chasing’ and 
‘gift-giving’ (intentional HIV transmission) discourses. 
Our preliminary analysis of chat sites and recent Australian 
media has documented intentional HIV transmission, but 
there is little evidence that people are seeking to become 
transmit or acquire HIV from a particular source in order 
to create kinship connections.  There is also evidence of 
bug-chasing and gift-giving but there is an absence of 
any notion of viral specificity i.e. connectedness based on 
similar virus or origin of infection. 
Nonetheless, kinship and reproductive terms like ‘daddy’, 
‘boy’, ‘breed’ and ‘seed’ are found in print media and 
websites, indicating the importance of genealogical 
constructions in the different social arenas of mainstream 
media and gay sexual culture. The circulation of these 
genealogical constructions between clinical, social and 
criminal discourses is important to the co-constitution of 
scientific and social knowledges of HIV. 
The next phase of the study will involve interviews with 
HIV-positive gay men to explore their understandings of 
the implications of this technology. FR
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NATIONAL	NEEDS	ASSESSMENT	OF	SEx	
WORKERS	WHO	LIVE	WITH	HIV	2008
 
Fawkes J
The one year community based needs assessment 
project sought to identify the needs of HIV positive sex 
workers in Australia through qualitative interviews and 
utilising community development approaches. This 
paper will outline the key recommendations from the 
final report (http://www.scarletalliance.org.au/library/
hiv-needsassessment08/) as well as the process that was 
critical to the projects strong outcomes.
 
Established as a peer-based project, in line with Scarlet 
Alliance’s principles and GIPA (Greater Involvement of 
People Living with HIV/AIDS), the project was designed to 
empower the participants, members of the HIV positive 
sex worker community, to run the project. The project 
involved capacity development for community members 
and community building activities including encouraging 
HIV positive sex workers to share their stories in “proVision” 
the Scarlet Alliance magazine.
 
All approaches were underpinned by a strong sense of 
need to protect participants rights and ensure the project 
followed recognised ethical approaches. Productive ways 
of working with participants individual privacy needs 
were developed to increase participation. Additionally, the 
project had continual reference back to the participants, 
via the project officer, Kane Matthews, and engaged with 
participants about the nature of their contributions and 
their “comfort” with the way the needs assessment was 
carried out and reported.  
 
The process ensured that the written report reflects what 
the contributors offered. This was done in a way which 
valued peer based networks and provided evidence that 
these networks can be productive and generate sound 
knowledge about what the issues and needs are for those 
within the network.
 
The project also included a survey of health care services. 
The responses demonstrate a need for increased training 
of health care workers; the need to address discrimination 
and stigmatising approaches; and improved access to up 
to date information on the legal rights of sex workers 
living with HIV. 
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Swiss Statement
5.15pm – 6.30pm
BACKGROUND	AND	RATIONALE	
-	NORMALISING	SEx	IN	STABLE	
SERODISCORDANT	RELATIONSHIPS
Pietro Vernazza 
St. Gallen, Switzerland
During the past few years, HIV-physicians as well as 
community members have started to question the need 
for barrier protection methods in HIV discordant couples if 
the infected partner was on HAART and some physicians 
have openly talked to patients about the limited risk in 
such situations. In late 2007, several individual physicians 
have given public statements regarding the low risk of 
transmission. 
Based on an evaluation of a Swiss HIV expert group the 
Swiss commission on AIDS has informed Swiss physicians 
in January 2008 that the commission considered it 
adequate to inform their patients about the limited risk 
of transmission under HAART. This step was considered 
necessary to harmonize the information that individual 
physicians have given to their patients. Particularly, it 
was considered important, to inform physicians and the 
community about the potential of interfering risk factors 
which were not considered by most physicians in the 
past. 
Since no randomized controlled trials exist to calculate 
transmission risks in discordant couples and will be 
very unlikely to be available in the near future, the Swiss 
expert’s evaluation of transmission risk was based on 
three methods of approximation: i) estimation based on 
the lack of documented individual cases in Switzerland 
and Europe, ii) extrapolation of a mathematical model for 
transmission risk based on free viral load in semen, and iii) 
support of these estimates by biological studies. 
In summary, all available estimates indicated that 
transmission risk in discordant couples is in a very low 
range. A comparison of the most conservative risk estimate 
with other risks in daily life as well as the risk of condom-
protected sex in the absence of treatment support the 
notion that the residual risk associated with sex in the 
presence of a fully suppressive HAART is negligible. 
The presentation will focus on the background and 
development of the Swiss commission’s statement and 
will discuss the most important arguments that were 
raised against the Swiss statement. 
RELATION BETWEEN HIV VIRAL LOAD AND 
INFECTIOUSNESS
Wilson DP, Law MG, Grulich AE, Cooper DA, Kaldor JM
National Centre in HIV Epidemiology and Clinical 
Research, The University of New South Wales, Sydney, 
NSW, Australia
Abstract
A consensus statement released on behalf of the Swiss 
Federal Commission for HIV/AIDS suggests that people 
receiving effective antiretroviral therapy—ie, those with 
undetectable plasma HIV RNA (<40 copies per mL)—are 
sexually non-infectious. We analysed the implications of 
this statement at a population level.
We used a simple mathematical model, based on 
the empirical data used by the Swiss, to estimate the 
cumulative risk of HIV transmission from effectively 
treated HIV-infected patients (HIV RNA <10 copies per 
mL) over a prolonged period. We investigated the risk of 
unprotected sexual transmission per act and cumulatively 
over many exposures, within couples initially discordant 
for HIV status.
Assuming that each couple had 100 sexual encounters 
per year, the cumulative probability of transmission to the 
serodiscordant partner each year is 0·0022 (uncertainty 
bounds 0·0008–0·0058) for female-to-male transmission, 
0·0043 (0·0016–0·0115) for male-to-female transmission, 
and 0·043 (0·0159–0·1097) for male-to-male transmission. 
In a population of 10 000 serodiscordant partnerships, 
over 10 years the expected number of seroconversions 
would be 215 (80–564) for female-to-male transmission, 
425 (159–1096) for male-to-female transmission, and 
3524 (1477–6871) for male-to-male transmission, 
corresponding to an increase in incidence of four times 
compared with incidence under current rates of condom 
use.
Our analyses suggest that the risk of HIV transmission in 
heterosexual partnerships in the presence of effective 
treatment is low but non-zero and that the transmission 
risk in male homosexual partnerships is high over repeated 
exposures. If the claim of non-infectiousness in effectively 
treated patients was widely accepted, and condom use 
subsequently declined, then there is the potential for 
substantial increases in HIV incidence.
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This session will cover the latest research on bio 
infections from biomedical through to clinical research. 
Presentations will be delivered by experts in their field.  
Breakfast Session – ‘Meet the Experts’ 
– Basic Science/Immunology
7.30am – 8.45am
NATURAL	HISTORY	OF	HEPATITIS	B	
INFECTION
Chris Burrell
SA Pathology/IMVS and University of Adelaide
Hepatitis B virus infects approx. 30 % of the world’s 
population at some point in their lives, and the ~350 
million individuals who remain persistently infected have 
a 20-30% probability of dying from hepatitis B. The natural 
course of infection involves a number of distinct decision 
points in the balance between virus and host defence.  (1) 
the acute infection may be symptomatic or subclinical  (2) 
acute infection may be cleared, or may persist indefinitely 
(3) during persistent infection, patients may progress 
through four distinct and sequential phases, each 
with different virological, immunological and disease 
parameters (4) concurrently, variable progression of liver 
disease through to cirrhosis and liver cancer occurs in a 
proportion of patients. 
Many risk factors or predictors for this progression in 
individual patients have been defined in recent years, 
and indications for antiviral therapy to assist clearance 
are becoming better defined. However, the basic 
immunological and virological drivers of this complex 
progression are still poorly understood. 
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Oral Poster Session - Clinical, Allied 
Health and Basic Science
7.45am – 8.45am
Purnomo J – see page 264
Crooks L – see page 267
Di Guilmi A – see page 260
Di Guilmi A – see page 261
Earle M – see page 261 
Emori R– see page 277
Hoare A – see page 246
Tan D – see page 218
Reddy S – see page 217
Gorton C – see page 244
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HIV,	SYPHILIS	AND	CHLAMYDIA	IN	
MSM	IN	VICTORIA:	RISK	BEHAVIOUR	
AND	PREVALENCE	AT	CLINIC	SENTINEL	
SURVEILLANCE	SITES
Goller JL1, Guy R1, Lim M12 Gold J1, Leslie, D3, BK Tee4, Roth 
N5, Fairley C6, Higgins N7, Hellard ME12
1Centre for Epidemiology and Population Health Research, 
Burnet Institute, Melbourne, VIC, Australia; 2Department 
of Epidemiology and Preventive Medicine, Monash 
University, Melbourne, VIC, Australia; 3Victorian Infectious 
Diseases Reference Laboratory, North Melbourne, VIC, 
Australia,  4The Centre Clinic, St Kilda, VIC, Australia, 5 
Prahran Market Clinic, Prahran, VIC, Australia, 6Melbourne 
Sexual Health Centre, Carlton, VIC, Australia; 7 Department 
of Human Services, VIC, Australia
In Victoria, since early 2000, there has been a steady 
increase in diagnoses of HIV and sexually transmissible 
infections among men who have sex with men (MSM). 
These findings arise from passive surveillance which 
is highly dependant on the extent of testing.  In April 
2006, three sentinel surveillance networks for HIV, syphilis 
and chlamydia commenced operation at five Victorian 
medical practices with a substantial MSM clientele.  The 
system aimed to provide testing rates, prevalence and 
risk behavioural information to assist in interpretation 
of passive surveillance trends. Demographic and 
risk behaviour information were collected through a 
questionnaire from all MSM undergoing routine testing 
and linked with laboratory results.  This paper compares 
results from April-December 2006 and January-June 
2007. Overall 5126 HIV, 5193 syphilis, and 3046 chlamydia 
questionnaires were received in 15 months. In all three 
networks, three quarters (74-77%) of MSM reported casual 
anal sex partners in the last six months and about one 
third (33-36%) reported inconsistent condom use with 
these partners. These behaviours remained consistent 
in both time periods.  The proportion of MSM diagnosed 
with infectious syphilis increased significantly from 1.6% 
of 2858 MSM tested in 2006 (95% CI: 1.2-2.1) to 2.7% of 
2295 MSM tested in 2007 (95% CI: 2.0-3.4; p<0.01). The 
relative risk of an infectious syphilis diagnosis was 6.5 
(95% CI: 3.1-13.7) in HIV positive MSM compared to HIV 
negative MSM.  HIV and chlamydia prevalence remained 
steady over both time periods: HIV - 1.9% in 2006 and 
2.0% in 2007; chlamydia - 5.8% in 2006 and 5.4% in 2007. 
Further demographical and behavioural information will 
be presented and discussed in the context of Victorian 
passive surveillance trends.  The increasing infectious 
syphilis prevalence among those tested highlights the 
need for initiatives aimed at reducing syphilis transmission 
with a particular focus on reducing transmission in HIV 
positive men.
Clinical Epidemiology
9.00am – 10.30am
RISE	IN	SYPHILIS	NOTIFICATIONS	IN	
VICTORIA	−	A	CASE	SERIES	STUDY
Higgins N1, Fairley C2, ReadT2 3, Csutoros D1, Wallis S2, 
McBryde E3  1
1Department of Human Services, Melbourne, VIC; 
2Melbourne Sexual Health Centre, Carlton, VIC, 3Royal 
Melbourne Hospital, Parkville, VIC,  
Annual notifications of infectious syphilis in Victoria have 
risen more than 40-fold from 9 cases in 2000 to 423 
cases in 2007, with men who have sex with men (MSM) 
continuing to comprise a majority of the cases (85% in 
2005-2007). 
A case series study was conducted to examine and better 
understand the cause(s) of the syphilis increase in Victoria. 
Cases notified to the Department of Human Services 
between 1 January and 31 March 2008, aged 18 years or 
older with evidence of infectious syphilis and a Victorian 
postcode of residence were eligible for inclusion. A 
telephone administered questionnaire was used to collect 
data relating to demographic, social/sexual behaviour, 
testing history and health seeking behaviour. 
Of the 103 infectious syphilis cases, 48 males consented 
to participate (response rate of 47%); 88% were in MSM 
and 25% reported co-infection with HIV. Thirty-four cases 
reported casual sexual partners in the preceding month, 
potentially exposing more than 67 persons. Of the cases 
reporting casual sexual partners, nearly all reported 
unprotected oral sex and 66% reported unprotected 
anal sex. Ten of the 48 cases (21%) reported no anal sex 
at all. The most frequent site for meeting sexual partners 
was in a bar/club or over the internet (35% and 31% 
respectively). Thirty-nine cases (81%) were symptomatic 
with an average time to diagnosis of 32 days (median = 
20 days, range: 7 to 119 days). Cases reported hours of 
operation, time and cost as the largest barrier to health 
care (29%, 23% and 21% respectively). 
The results suggests that syphilis cases are not diagnosed 
in a timely way and public health interventions to improve 
health seeking behaviours should be considered. 
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SEROPREVALENCE	AND	INCIDENCE	OF	
HSV-1	AND	HSV-2	IN	AN	HIV	SEROPOSITIVE	
COHORT
Authors:  Srirajalingam M1, Aitken S1, Taylor J2, Dwyer DE2, 
Chuah J1
1Gold Coast Sexual Health Clinic, Miami. Gold Coast, 
Australia; 2Westmead Millennium Institute, Sydney 
University and Westmead Hospital, Westmead, Australia.
background 
Genital herpes is associated with increased rates of 
acquisition and transmission of Human Immunodeficiency 
virus (HIV).
objective:
Determine the prevalence and incidence of Herpes 
Simplex virus type 1 and 2 (HSV-1,-2) infections in an HIV 
positive cohort. 
Methods
Baseline HSV type-specific IgG serology was carried out 
on 256 HIV positive patients attending a Sexual Health 
Clinic.  Follow-up testing was available for 106 subjects 
between 1997-2003.  
results
Prevalence study: Of the 256 subjects (232 males, mean 
age 39 y, range 19-71y and 24 females, mean age 32 y, 
range 18-47 y) 56% (56% of men and 58% of females) 
were HSV-2 seropositive and 83% (84% of men and 71% 
of females) were HSV-1 seropositive.
Longitudinal study: 106 subjects (96 males, 10 females) 
had testing performed on more than one occasion.  
Seven (70%) females were HSV-1 seropositive and 3 (30%) 
were HSV-2 seropositive.  There were no seroconversions 
in this group. 
Among the males baseline seropositivity for HSV-2 and 
HSV-1 were 20.8% (n=20) and 67.8% (n=65) respectively. 
Among the 76 HSV-2-Neg males at baseline there were 
11 HSV-2 seroconversions (52.71/103 P-y).  Among the 
31 HSV-1-Neg males there were 3 HSV-1 seroconversions 
(30.9/103 P-y).
Among the 65 HSV-2-Neg/HSV-1-Pos males there 
were 9 HSV-2 seroconversions (52.79/103 P-y).  Among 
the 11 HSV-2-Neg/HSV-1-Neg males, there were 2 
HSV-2 seroconversions (52.38/103 P-y).  There were 3 
seroconversions among the 31 HSV-1-Neg subjects 
(30.9/103 P-y). 
The Relative Risk of seroconversion to HSV-2-Pos status in 
HSV-1-Pos vs. HSV-1-Neg subjects was 0.76 (95% CI 0.19-
3.07); the Risk Ratio based on incidence rates with person-
years of follow-up was 1.01 (95% CI 0.97-1.03). 
Conclusions 
There was a high prevalence of HSV infection and 
evidence of ongoing HSV-2 acquisition in this group of 
HIV seropositive subjects.  As HIV and HSV have synergistic 
effect on each others transmission, measures to control 
HSV infection may be important.
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CLINICAL	OUTCOME	OF	A	COMMUNITY	
BASED	RESPONSE	TO	A	SYPHILIS	OUTBREAK	
AMONG	GAY	MEN	IN	WA
Bradstreet B, yam SH, Langdon PA
Western Australian AIDS Council Inc, West Perth, WA, 
Australia.
The WA AIDS Council (WAAC) has been operating sexual 
health clinics in the two sex on premises venues (SOPVs) 
in Perth for 14 years.  This very effective model provides 
opportunistic, free, anonymous HIV and STI testing to at-
risk men.  Over half of the clientele attend specifically for 
testing with the rest being sauna patrons at the time of 
the clinic.  The clinics operate for 4 hours per week.
Following a syphilis outbreak among gay men in 2006, 
WAAC undertook a community based response (social 
marketing and editorial in print and web-based media, 
poster, pamphlets and verbal information to sexual, social 
and community groups and cyber-based outreach etc) 
with one of the aims to increase syphilis testing.
We examined the attendance and STI testing data of 
the two SOPV clinics, comparing the 18 months prior to 
the response with the 18 months of the response.  Clinic 
attendance has increased by over 21% (from 263 to 320 
men) with the majority of men citing the increase in 
syphilis infections as the reason for attendance.  In Clinic A 
there was a marked increase (29%) of men attending the 
SOPV clinic specifically for testing.  In Clinic B there was a 
marked increase (41%) of SOPV patrons seeking testing.  
There has been a 36% increase in syphilis tests and nearly 
30% increase in HIV tests, with a significant increase in the 
yield of positive syphilis test results per test completed. 
(0.88% in the eighteen months prior to the intervention 
to 3.88% after the intervention started).  In the same time 
frame, the HIV yield increased from 0 to 1.33%.  There 
has also been a significant increase in the number of 
Chlamydia and gonorrhoea diagnoses.
An integrated community based response has shown 
that at-risk men will respond to a call to be tested and 
that accessible sexual health services are a vital plank in 
achieving a sustained response to an outbreak.  It has 
also shown the value of undertaking comprehensive STI 
screening when the opportunity arises.
THE	ROLE	OF	THE	NURSE	IN	SYPHILIS	
(AND	OTHER	STI)	RISK	ASSESSMENT	IN	
A	SUBACUTE	INPATIENT	SETTING	AT	THE	
ALFRED	HOSPITAL,	MELBOURNE,	VICTORIA
Moyer J1
1Fairfield House, Infectious Diseases Unit, The Alfred 
Hospital, Prahran, VIC, Australia
Fairfield House (FFH) is a sub-acute inpatient ward at 
The Alfred Hospital with fifteen beds dedicated for 
HIV patients.  Syphilis notifications have progressively 
increased in Victoria, predominantly in men who have 
sex with men (MSM), with a significant proportion of 
these notifications occurring in HIV patients.  This paper 
will examine the nurse’s role in the process by which 
these patients are tested for syphilis and other sexually 
transmitted infections (STIs) during admission at Fairfield 
House.  
Syphilis testing on HIV+ inpatients at FFH is currently 
performed either based on presenting symptoms or by 
STI risk assessment.  STI risk assessment may be done on 
admission by the Infectious Diseases medical team but 
may be initiated by nursing staff and then communicated 
to the medical team.  As there is no current protocol at FFH 
for nurse initiated STI risk assessment, STI risk assessment 
by nursing staff and consequent testing of inpatients at 
FFH, particularly syphilis testing, may be inconsistent. 
To examine the current variations in nurse-initiated STI 
risk assessment with a particular emphasis on syphilis, a 
medical record search using an audit tool will be applied 
to all HIV inpatients admitted to FFH over a three month 
period (October-December 2007).  Preliminary data 
indicate 31.6% (25/79) of inpatient visits during the study 
timeframe were tested for syphilis.  
The information from this study will highlight gaps in 
nurse-initiated STI risk assessment at Fairfield House. 
The results of this study will be used towards up-skilling 
nursing staff if inadequate STI risk assessment is noted, 
and to develop protocols for STI risk assessment and 
testing with the FFH multidisciplinary team.
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ZIMBABWE, ADOLESCENT SEXUAL HEALTH 
AND THE POWER OF NARRATIVES  
Power R1, 2Cowan F, Langhaug L2, 3Matudsi M 
1Centre for Harm Reduction, Burnet Institute, Melbourne, 
Australia; 2University College London; 3University of 
Zimbabwe (Funded by the NIH, USA)
The narrative data presented here derive from a 
community-randomised trial of a complex adolescent 
sexual health intervention in rural Zimbabwe. This 
research comprised 30 communities, with a cohort of 
6,600 students, followed up over a four-year period. 
The main outcome measures were reductions in the 
incidence of HIV-1, HSV2 and unintended pregnancy. 
Alongside the quantitative data, qualitative data were 
collected to better understand the contextual and cultural 
issues associated with sexual behaviour and adolescent 
lifestyles. We conducted a series of participatory 
workshops with young people to explore these issues 
further. By means of risk mapping, pair-wise ranking and 
role play, we constructed narratives that depicted some 
of the key risk situations and environments confronting 
these young people. Risk environments and contexts 
included: the family, school, church, the highway, bottle-
shop. These narratives (a selection of which will be played 
during the presentation) were used to imagine more 
positive futures. As a result community-level interventions 
were developed to attain these goals and to improve the 
sexual and reproductive health of rural Zimbabwean 
adolescents.
Social Research – Listen Up: 
International Perspective on Young 
People and HIV Risk
9.00am – 10.30am
PACIFIC	SPECIFIC:	YOUNG	PEOPLE	AND	
CONDOM	USE	IN	TONGA	AND	VANUATU
McMillan K.E.1.
1National Centre in HIV Social Research, University of New 
South Wales, Sydney, Australia.
The Pacific is a region that has not commanded a lot of 
attention in HIV research to date. To a large extent, the 
particularities of Pacific island nations are effaced in a 
consignment to the category ‘Asia- Pacific’; a category 
in which the ‘Pacific’ tends to appear as rim to an Asian 
epicentre. 
This paper reports on data gathered via 62 in-depth 
interviews with 18-25 year olds in Tonga and Vanuatu, 
during March and April 2008. The face to face interviews 
enquired into young people’s personal experiences of, 
and thoughts about, condom access and use.  
 
While the results are largely consistent with international 
data on young people and condom use (e.g. the 
importance of peer networks, and a mismatch between 
knowledge and practice), some of the data highlight issues 
related to social and cultural factors that are common 
to Pacific nations (e.g living in close communities with 
strong traditions, and rapid social change), and other 
results indicate marked differences between the Tongan 
and Ni-Van participants, directing attention to specificities 
of each location, (e.g the community of fakaleiti, and the 
condom positivity of Ni-Van parents) and consequently 
to particular opportunities for condom promotion in 
both Tonga and Vanuatu.
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ADEqUATE	SUPPLY	OF	FOOD	AND	ITS	
IMPACT	ON	ADHERENCE	TO	ART	TREATMENT	
IN	PAPUA	NEW	GUINEA
Akuani F2; Kelly APhD1; Mek  A2; Emori R2;Walizopa L2; Kepa 
B2;Nosi S2; Kupul M2;  Peter B2; Pirpir L2 
1National Centre for HIV Social Research, UNSW, Sydney, 
Australia; 2Papua New Guinea Institute of Medical 
Research, Operational Research Unit, Eastern Highlands; 
Papua New Guinea 
Antiretroviral therapies (ART) are highly concentrated and 
those on treatment are advised to take them with food. 
For most PLWHA in resource poor settings, the availability 
of adequate food supply is not guaranteed. This can 
cause not only challenges for the health and well being 
of PLWHA on treatment, but also for adherence. To date 
no research has been carried out in Papua New Guinea in 
order to examine the relationship between ART and food 
for PLWHA. This paper presents findings of data collected 
in three) of six sites (Lae, Mingendi and Port Moresby from 
a social impact study of ART in PNG.   
A mixed-method approach was taken using survey and 
in-depth interviews with PLWHA on ART. From three 
provinces a total of 152 PLWHA (over the age of sixteen) 
participated in the survey and 28 participated in the in-
depth interviews. Ethics approval was granted by the 
PNG Medical Research Advisory Committee and UNSW.
Three quarters of the PLWHA from all three sites, reported 
having an increased appetite since commencing 
treatment. When asked if they had enough food to satisfy 
their hunger; a total of 49 out of the 152 participants said 
they did not; 36.8% were from Port Moresby while, less 
than 1% were from Mingendi and Lae. Participants were 
further asked if not having enough food was a barrier 
to them not taking their medication. Of the 138 who 
answered, 14.5 % (all of whom were from Port Moresby) 
said yes, while in Lae and in Mingendi no participants 
mentioned this. The qualitative data further validated this 
finding. Fear of resistance, led many who were without 
food, take them with water only or just a scone. Again, 
this was only true for those from Port Moresby.
The availability of an adequate supply of food is an 
important factor influencing PLWHA to adhere to 
treatment in Port Moresby where food and basic 
necessities constantly depends on money rather than 
gardens. 
THE ROLE OF COMFORT IN YOUNG PEOPLE 
TALkING AND LEARNING ABOUT SEX AND 
HIV IN PAPUA NEW GUINEA	
Walizopa LD1, Emori R 1, Nosi S 1, Akuani F 1, Kupul F 1, Kepa 
B 1, Cangah B 1, Mek A1, Pirpir A 1, Keleba K1, Kelly A 2
1Papua New Guinea Institute of Medical Research, 
Operational Research Unit, Goroka, Papua New Guinea; 
2National Center for HIV Social Research, University of 
New South Wales, Sydney, Australia
young people acquire knowledge and attitudes about 
sex and HIV from a variety of sources. During this process, 
young people are receptive to both accurate and 
inaccurate information as well as judgmental and non-
judgmental beliefs. 
Exploring how and where young people acquire 
their knowledge and attitudes is important for 
educators so that programs and campaigns are 
appropriately developed. This paper explores the role 
of comfort in young peoples´ knowledge acquisition 
process towards sex and HIV in secondary schools 
in Eastern Highlands Province, Papua New Guinea. 
Focus group discussions (FGDs) were carried out among 
Grade 12 students attending three secondary schools. A 
guide was developed which involved 5 predetermined 
categories, sex, HIV, discrimination, condoms, sex and HIV 
education. A total number of 73 students participated. 
Eight genders specific FGDs were carried out, 5 males, 
3 females. Informed consent was provided by all 
participants. 
The level of comfort was the primary indicator of 
students´ openness to talking or learning about sex and 
HIV. Students felt most comfortable to share information, 
which may or may not be accurate, their views and 
experiences of sex and HIV with their peers. The extent 
to which students felt comfortable was determined 
by the gender of the person they spoke to, where 
they were talking or listening, the age of the person 
talking, the relationship of the person to them and their 
beliefs in the other persons´ knowledge about sex. 
An atmosphere of comfort is critical to engage students 
in a meaningful and on-going way to talk and learn about 
sex and HIV. Educators must take into account the ´space 
of comfort´ in order to transfer accurate knowledge on 
sex and HIV to young people and enable them to explore 
their attitudes and behaviors.
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ADOLESCENCE	SExUAL	BEHAVIOUR	
AND	RISKS	OF	CONTRACTING	SExUALLY	
TRANSMITTED	INFECTIONS:	A	CROSS-
SECTIONAL	ANALYTICAL	STUDY	IN	NEPAL
Regmi, K. 1, Regmi, S. 2 and Lamichhane G.3
1School of Health & Social Care , University of the West of 
England, Bristol, UK; 2Royal Berks NHS Hospital, Reading, 
UK; 3HIV Prevention and Control Project, Kathmandu, 
Nepal
It has been well documented about importance of sexual 
behaviour and risk of contracting sexually transmitted 
infections (STIs). Growing expansion of urbanisation and 
in/out migration further create positive paradigm, which 
facilitates sexual interactions between different hard 
to reach/risk groups. Over past few decades, despite a 
large gap in socio-cultural stigma, many young people 
are engaged with pre/extra marital sexual relationships 
and becoming inclined to STIs and HIV. This aim of this 
research was to examine and analyse the patterns of 
adolescences’ sexual behaviour and risks of contracting 
STIs and  HIV.
 
Five groups of young people comprised of both sexes, 
15-24 age, were asked to describe their attitudes and 
perceptions using in-depth interview (n=29) and group 
consultations (n=55). To accommodate ‘sensitiveness’ 
in researching process, same sex researchers were 
recruited and used. Respondents were also presented 
statements and they indicated degree of agreement 
or disagreement with each on Likert-type scale. 
 
Discussion revealed that socio-cultural taboos, amongst 
unmarried-adolescence, remain significantly high. 
Majority of the respondents (75.32%) reported that 
poor interaction between sexual health providers and 
unmarried adolescence, fear of stigmatisation and limited 
access, care and support found important barriers to 
initiate discussion on all services related to STIs and HIV. 
Study further demonstrates that, although pre/extra 
marital practices have been discouraged, the level of 
education/awareness and urbanisation have further 
bring associated risks for contracting of STIs and HIV. 
Study suggests that there was inseparable link between 
unmarried young people and increasing risks of STIs and 
HIV - due to change in sex and sexuality; and sexual norms 
and independence. Most of the respondents (56.1%) 
believed that early sexual experimentation with multiple 
partners, alcohol consumption and erratic use of condoms 
considered as ‘high risk’ behaviours contracting for STIs/HIV. 
Implication for sexual health promotion, encompassing 
the sexuality, life skills, and HIV/AIDS education adheres to 
the socio-cultural context would bring positive changes 
in safer sex practices amongst adolescence groups in 
Nepal.
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Program Delivery
9.00am – 10.30am
WHO	IS	DIAGNOSING	HIV	IN	NSW?
Ward K1, Crooks L2, McAnulty J1
1Communicable Disease Branch, NSW Health, Sydney, 
NSW, Australia; 2 Australasian Society for HIV Medicine
Following a positive HIV test result, the diagnosing 
clinician needs to provide support and information to the 
patient and either direct clinical care or referral to relevant 
services. We sought to identify the services that diagnose 
HIV in NSW and in the case of general practitioners, 
determine the level of experience in diagnosing HIV.  
New South Wales doctors must notify demographic and 
epidemiological information on all new HIV diagnoses. 
We analysed the HIV surveillance data collected from 
2000 to 2007 by the health provider making the first 
diagnosis of HIV.
Preliminary results indicate that:
• 70% of HIV patients were diagnosed by a service in their 
local area. 
• 56% were diagnosed by a general practitioner (GP). 
• 78% of all notifying GPs only notified one patient with 
HIV over eight years. This accounted for 34% of all 
patients diagnosed with HIV infections.
Most patients with HIV infections are diagnosed by GPs, 
many of whom have not diagnosed HIV in the recent 
past and therefore may not be familiar with recent 
developments in diagnosis and management. GPs 
require access to up to date resources to help manage 
patients newly diagnosed with HIV.
qUEENSLAND	HIV	MODELS	OF	CARE	
PROJECT	2008
Forrester JM, Boddy G, Kelly M on behalf of the Steering 
Committee
Increasing patient numbers and finite resources threaten 
the capacity of current models of HIV care across the 
country. NAPWA and ASHM have identified this as a critical 
issue and have commissioned an upcoming review. The 
24% increase in the number of HIV cases seeking care in 
Queensland since 2002, the complexity of HIV in relation 
to non-HIV co-morbidities in the HIV population, the 
ageing HIV population and without additional workforce 
prompted a review of the capacity of the models of care 
in Queensland. 
The HIV Models of Care Project commenced on 25 March 
2008 with the employment of the MOC Project Officer for 
3 months.  The aim of the project was to explore the current 
model of care and service integration in Queensland. The 
key focus was to examine the capacity of the models of 
care given the increase in the HIV population over the last 
6 years and the current HIV workforce. The Key objectives 
of the project were:
1. Describe the current models operating in Queensland;
2. Map the gaps in the current clinical model operating in 
Queensland;
3. Compare the current clinical model to models of care 
in other Australian States;
4. Propose recommendations to Queensland Health to 
improve the current clinical model
The project was limited to a clinical focus. Resources did 
not permit thorough evaluation of current model from 
PLWHA or social determinants of health perspective 
although these are integral to models of care. The project 
had a 14 person steering committee comprising of key 
stakeholders.  It was agreed to limit the focus of this 
project to clinical aspects of care with three key areas of 
clinical focus identified:
1. Traditional HIV clinical care;
2. Non-traditional HIV clinical care;
3. HIV workforce issues.
The project has been divided into 3 sections comprising 
of a literature review, interviews with key stakeholders, the 
writing of a report outlining the findings of the interviews, 
the gaps in the model and the recommendations.  35 
clinicians were interviewed across the state, 13 using a 
tailored interview tool. These data will be presented at 
the conference.
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THE	WESTERN	AUSTRALIAN	RURAL	
AND	REMOTE	HIV	PROGRAM:	A	10	YEAR	
ExPERIENCE
Cain A1, Murray R2, Martinez OP1,3, French MAH1,3
1Department of Clinical Immunology & Immunogenetics, 
Royal Perth Hospital & PathWest Laboratory Medicine, 
Perth, Western Australia; 2Department of Microbiology 
& Infectious Diseases, Royal Perth Hospital & PathWest 
Laboratory Medicine, Perth, Western Australia; 3School of 
Pathology & Laboratory Medicine, University of Western 
Australia, Nedlands, Western Australia
A Rural/Remote HIV Program was set up in Western 
Australia in 1998 as a response to the increasing number of 
HIV infected patients in country areas and the increasing 
complexity of treatments and procedures used in the 
management of HIV positive Patients.  The Rural/Remote 
Team is headed by a Consultant Clinical Immunologist, 
assisted by other immunologists and an Infectious Disease 
Physician and includes a Nurse Coordinator who runs the 
program on a daily basis.  The Team provides clinical and 
nursing expertise and liaises closely with regional health 
professionals including Population Community Health 
Units, local GP’s and the Prison Service.
The programme also includes management of pregnant 
women with HIV infection as part of a multidisciplinary 
team of Doctors, Nurses and Social Workers.
There are only two S100 prescribers in regional Western 
Australia.  All HIV medications are prescribed at Royal 
Perth Hospital and are sent to the regional Professionals. 
The Rural/Remote Team conducts clinics and provides 
formal education sessions for local health professionals. 
In addition, telehealth facilities are utilised.
The program has registered a total of 236 regional HIV 
patients since its establishment.  The current enrolment 
is 148 which includes 118 adults, 1 positive child and 
26 uninfected children (24 of which are Aboriginal) 
born to HIV positive mothers.  Of the 118 adults, 78 are 
male including 9 Aboriginal people and 40 are female 
(including 20 Aboriginal people).
77 of the 118 adults are receiving Antiretroviral Therapy. 
Of these, 64 (83%) have 100% adherence and 60 (78.5%) 
have undetectable (<40 copies/ml) HIV RNA in plasma. 
Of the 29 infected adult Aboriginal people (males and 
females), 14 are receiving ART.  Of these, 11 have 100% 
adherence and undetectable HIV RNA in plasma.
Our findings demonstrate that although Western 
Australia is a large state and there is a lack of clinical HIV 
expertise in Regional WA, it is possible to provide a high 
level of care that is culturally appropriate to regional HIV 
patients.  The expertise of the Rural/Remote Team has 
greatly enhanced the activities of local regional health 
professionals to manage HIV infected patients.
COMPARISON	OF	CLINICAL	HIV	
PERFORMACE	INDICATORS	(POST-HAART)	
BETWEEN		AHOD	AND	A	REGIONAL	SExUAL	
HEALTH	CLINIC	1996-2007
Chuah J, Fankhauser W, Page M, Gold Coast Sexual Health 
Clinic,  2019 Gold Coast Highway, Miami, Queensland, 
4220; Dickson B., Ellem S., CaraData,  Parkwood, 
Queensland 4214; Petoumenos K*; National Centre 
for HIV Epidemiology & Clinical Research (NCHECR), 
UNSW, Darlinghurst 2010, *on behalf of AHOD Steering 
Committee and participating centres. 
This study examined the patterns of a minimal set of 
trend  clinical performance indicators from a medium-size, 
regional sexual health (SH) clinic, the Gold Coast Sexual 
Health Clinic (GCSH) in comparison to  a representative 
“national” trend (AHOD - Australian HIV Observational 
Database) during the same period (when available).
Between 01 January 1996 and 31 December 2007, 
epidemiological and utility data were collected at the 
GCSH, using the Sexual Health Information Program (SHIP 
V7.7). The data were collated and expressed in graphs and 
tables formats, in direct comparison to the Australian HIV 
Observation Database (AHOD), representing the “national” 
standard, covering  the period of 01 January 1999 till 31 
December 2007.  
There has been an improvement trend in HIV performance 
at GCSHC, compared to AHOD in recent years, with the 
exception of crude death rate. New indicators suggested 
substantial burden of CVD risks, Depression and Co-
infections at GCSH, reflecting disparity in support services 
& increased complexity of HIV management. This study 
also re-iterated the potential roles of  SHIP and SH 
clinics in the surveillance and monitoring of provision 
of  ambulatory care in HIV management  in Australia, 
especially when regularly bench-marking against a 
representative “national standard”  like AHOD.
Oral Posters:
Saloner KL - see page 265
Lienert TM - see page 240
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Blood-Borne Viruses: Co-Infection
9.00am – 10.30am
controls (p<0.05, ANOVA). The percentage of activated 
NK cells significantly declined in both cases and controls. 
IL-2,-6, -8, -10, TNF-α, IFN-α and -γ were not detectable in 
the majority of case and control sera.
Rises in CxCL-10 (a chemokine induced by IFN-γ) and 
sCD30 (an immune activation marker of the TNFR family) 
correlate with HF following initiation of HBV-active ART in 
HIV-HBV co-infected patients. Also implicated are markers 
of IFN-γ induction (IL-18) and activity (CCL-2). These data 
support our hypothesis that HF in this setting is the result 
of HBV-related IRD in the liver.
IMMUNOPATHOGENESIS	OF	HEPATIC	
FLARE	IN	HIV-HEPATITIS	B	VIRUS	
(HBV)	CO-INFECTED	INDIVIDUALS	
FOLLOWING	INITIATION	OF	HBV-ACTIVE	
ANTIRETROVIRAL	THERAPY
Oliver B.G.1, Crane M2, Avihingsanon A.3, Visvanathan K.2, 
Matthews G.4, Dore G.4, Price P.1,5 French M.1,5, Ruxrungtham 
K.4, Lewin SR.2,6  
1School of Pathology and Laboratory Medicine, University 
of Western Australia, Australia; 2Department of Medicine, 
AMREP, Monash University, Melbourne, Australia; 3HIV 
Netherlands Australia Thailand Research Collaboration 
(HIV-NAT), Bangkok, Thailand; 4National Centre for 
HIV Epidemiology and Clinical Research, University of 
New South Wales, Australia; 5Clinical Immunology and 
Immunogenetics, Royal Perth Hospital, Perth, Australia; 
6Infectious Diseases Unit, Alfred Hospital, Melbourne, 
Australia
Following the initiation of HBV-active combination 
antiretroviral therapy (ART) in HIV-HBV co-infected 
individuals, hepatic flares (HF) are a significant clinical 
problem. We hypothesised that HF in this setting is a form 
of immune restoration disease (IRD). 
We conducted a case-control study of cases with HF 
(n=8; defined as ALT > 5 x the upper limit of normal or 
> 200 IU/L rise from baseline within the first 12 weeks 
of treatment) and controls not having HF. Patients were 
recruited as part of the Tenofovir in Co-infection (TICO) 
study which is a prospective randomized (1:1:1) trial of 
tenofovir (TDF) vs lamivudine (LMV) vs TDF/LMV within 
an efavirenz based ART regimen (n=36). Quantification of 
immune mediators (IL-18, -2, -6, -8, -10, soluble[s] CD26, 
sCD30, CxCL-10, CCL-2, TNF-α, IFN-α and -γ in serum 
was performed by ELISA, antigen capture bioassay or 
cytometric bead array. The percentage of activated NK 
cells (CD56brightTRAIL+) in PBMC samples was determined 
by flow cytometry. In addition, immune mediator levels 
were correlated with ALT, HBV VL, HIV VL and CD4 count 
at each time point (Spearman’s test).
Cases had significantly higher HBV viral loads (p=0.011) 
and ALT (p=0.008) than controls prior to initiation of ART. 
Following ART, CxCL-10 levels significantly decreased 
(p<0.05, Kruskal-Wallis) in controls but not in cases. In 
cases, sCD30 levels increased and peaked at wk 8 (p<0.05, 
ANOVA) while there was no significant change in controls. 
Significant positive correlations were found between ALT 
and CxCL-10, sCD30, CCL-2 and IL-18 at wk 8. There was a 
significant increase in sCD26 over time in both cases and SA
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TENOFOVIR	BASED	HAART	IS	
ASSOCIATED	WITH	HIGH	RATES	OF	
HBV	DNA	SUPPRESSION	AND	HBEAG	
SEROCONVERSION	IN	THAI	HIV-HBV	
COINFECTED	PATIENTS	
Matthews GV1, Avihingsanon A2, Lewin SR 3,4, Sasadeusz J5, 
Thio CL6, Bowden S7, Ayres A7, Locarnini SL 7; Ruxrungtham 
K 2; Dore GJ 1
1National Centre in HIV Epidemiology and Clinical 
Research, University of New South Wales, Sydney, 
Australia; 2 HIV-NAT, Thai Red Cross AIDS Research Centre; 
and Vaccine and Cellular Immunology Laboratory, 
Faculty of Medicine. Chulongkorn University, Bangkok, 
Thailand; 3 Department of Medicine, Monash University, 
Melbourne, Australia; 4 Infectious Diseases Unit, Alfred 
Hospital, Melbourne, Australia; 5 The Royal Melbourne 
Hospital, Melbourne, Australia; 6 John Hopkins University, 
Baltimore, MD, U.S.A; 7 Victorian Infectious Diseases 
Reference Laboratory, Melbourne, Australia
Two randomised clinical trials of HBV-active HAART in 
antiretroviral naive HIV-HBV coinfected subjects were 
initiated in Thailand in 2004-2005. Randomisation was i) 
zidovudine(AZT)/lamivudine(LAM)/efavirenz (EFV) or ii) 
AZT/tenofovir (TDF)/EFV or iii) TDF/LAM/EFV in the TICO 
study (n=36) and to i)AZT/emtricitabine (FTC)/EFV or 
ii)TDF/FTC/EFV in HIV NAT 023 (n=18). Study follow-up 
was to 48 weeks after which all subjects on LAM or FTC 
HBV monotherapy added TDF.
This analysis aimed to determine >48 week HBV virological 
and serological responses in HIV-HBV coinfected subjects 
receiving TDF containing HAART.
47/54 HIVHBV coinfected subjects were followed for 
a median of 27 months (range 14-40m) after HAART 
initiation. Mean age was 38 years and 31/47 (66%) were 
male. They were significantly immunosuppressed pre-
HAART with a median CD4 count of 42 cells/mm3 and 
45% were AIDS-defined. Median HBV DNA was 8.0 log10 
IU/ml (IQR 7.5-8.7 log10 IU/ml) with 30/47 (64%) HBeAg 
positive. All patients were on TDF-containing regimens: 
19 in initial combination (TDF+LAM/FTC), 17 with late 
combination after AZTTDF switch at 48 w, and 11 on 
TDF monotherapy for HBV. Median duration of TDF was 
25, 8 and 32 months respectively.
All patients had HIV RNA suppression < 50 c/ml and 
median CD4 count was higher at 342 cells/mm3. 72% of 
subjects had HBV DNA < 20 IU/ml with 94% HBV DNA 
< 400 IU/ml. No subject had HBV DNA > 1000 IU/ml. No 
significant differences were seen in proportion of patients 
<20 IU/ml by type of TDF-regimen (p=0.236). HBeAg loss 
occurred in 46% of HBeAg positive subjects with an anti-
HBe seroconversion rate of 33%. HBeAg loss was not 
associated with age (p=0.08), CD4 nadir (p=0.71), change 
in CD4 count (p=0.53), or baseline HBV DNA (p=0.48). The 
cumulative rate of HBeAg loss was 13% at 3m, 30% at 6m, 
40% at 12m, 50% at 18m and 67% at 24 months. HBsAg SA
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loss occurred in 12%.
In conclusion TDF-containing HAART is highly successful 
in achieving HIV and HBV-related virological suppression 
in coinfected subjects initiating HAART in Thailand, 
irrespective of regimen. Further work is needed to 
understand the mechanism(s) of the high rates of HBeAg 
loss and HBsAg seroconversion.
SCREENING	FOR	HEPATOCELLULAR	
CARCINOMA	(HCC)	IN	HEPATITIS/HIV	CO-
INFECTION	USING	ULTRASOUND	IMAGING	
AND	ALFA-FETO	PROTEIN	LEVELS
Lo G1, Herrmann S2, Cheng W3, Kontorinis N3, Phillips E 2,4, 
Nolan D2,4, Lucas M3,2
1Royal Perth Hospital; 2Centre for Clinical Immunology 
& Biomedical Statistics Royal Perth Hospital & Murdoch 
University; 3Department of Gastroenterology Royal Perth 
Hospital; 4PathWest Laboratory Medicine WA
 
Hepatocellular carcinoma (HCC) is a serious complication 
of chronic viral hepatitis once cirrhosis has developed. 
Screening for HCC allows for early detection in HCV or 
HBV mono-infection and, if detected, possible treatment. 
Since HIV co-infection is associated with faster progression 
of liver disease in both HBV and HCV infection and non-
AIDS cancers have recently been shown to be more 
common and occur earlier in the setting of HIV, it is likely 
that HIV co-infection increases not only the rapidity of 
hepatocarcinogenesis but also the overall risk of HCC.
Screening for HCC by abdominal ultrasound and alfa-
feto protein (AFP) measurement is recommended at 
6 to 12 month intervals for both HBV and HCV mono-
infected patients. There are multiple treatment modalities 
currently available for HCC including radio-frequency 
ablation, percutaneous ethanol injection, trans-arterial 
chemo-embolisation, resection and liver transplantation. 
Treatment is a feasible option in those individuals with 
hepatitis/HIV co-infection who are successfully treated 
with HAART and otherwise healthy. 
Fifty-one hepatitis/HIV co-infected patients attending the 
Ambulatory HIV Service at Royal Perth Hospital (RPH) were 
identified and their medical records reviewed to identify 
uptake of HCC screening. Since 2000, 21 patients (41%) 
were screened at least once by abdominal ultrasound, 
5 more had ultrasound requested for other reasons 
(e.g. renal failure). One patient was subsequently found 
to have a HCC as an incidental finding. Nine of the 21 
patients (42%) screened since 2000 have had a second 
study performed and 8 more patients (31%) are awaiting 
further follow-up. The mean interval between ultrasound 
screening was 1.0 year (range 0.5-2.2). Thirty patients 
(59%) have been screened for HCC with measurement of 
serum AFP.
There has been poor uptake of initial and follow-up HCC 
screening with abdominal ultrasound and AFP in hepatitis/
HIV co-infected patients at RPH and few patients have had 
regular follow-up scans.  Improved drug treatments have 
resulted in decreased mortality from HIV in countries with 
access to HAART but co-infection with hepatitis poses a 
significant threat to those that might otherwise expect 
a normal lifespan. Improved screening protocols for HCC 
are warranted.
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GBV-C	VS.	HIV-1
SEVERAL	GBV-C	PROTEINS	INHIBIT	
DIFFERENT	HIV	REPLICATION	STEPS
Jung S, Fleckenstein B, Reil H
University Hospital, Department of Virology, Erlangen, 
Germany
GBV-C, discovered during the search for new hepatitis 
viruses displays itself by two extraordinary properties 
confirmed by clinical studies as well as by in vitro 
experiments: Although GBV-C is closely related to HCV 
there is no relation between GBV-C viremia and hepatitis 
or other diseases. Moreover, longterm GBV-C infection 
correlates with a higher survival probability for GBV-C/HIV 
patients. 
By co-infection experiments on PBMC and T-cell lines we 
demonstrate that GBV-C isolates differ in their ability to 
impair replication of different HIV strains and clades. The 
HIV inhibitory phenotype was corroborated by single-
round of infection assays using reporter-HIV pseudo typed 
with HIV specific or heterologous envelops mediating cell 
entry by different mechanisms. Whereas GBV-C isolates, 
predefined as HIV inhibitory isolates, suppress reporter-HIV 
particles independent of the pseudo typed envelope and 
in order that autonomous of the cell entry mechanism, the 
majority of GBV-C HIV non-inhibitory isolates displayed no 
effect on HIV and VSV pseudotype infection. Interestingly, 
some GBV-C isolates have been identified which impair 
exclusively the HIV gp120 mediated entry suggesting 
that more than one GBV-C protein must be involved 
in HIV suppression affecting different replication steps. 
Therefore, each GBV-C protein was cloned and separately 
expressed in T-cell lines and ongoing gene expression 
was detected by FACS and immunofluorescence. 
Infection assays with replication deficient reporter-HIV 
pseudo typed with HIV, SIV, MLV and VSV envelopes were 
performed to determine the inhibitory capacity of each 
GBV-C protein and to differentiate between impairment 
of the gp120/CD4 dependent HIV entry mechanism and 
later HIV replication steps. Indeed, we identified three 
GBV-C proteins with anti-viral properties: Whereas the 
E2 protein blocks exclusively HIV-entry by the induction 
of an unknown soluble factor, the non-structural GBV-
C proteins NS3/4A and NS5A impair HIV post-entry 
replication steps.
Taken together our results arise that the existence of GBV-
C isolates with different HIV inhibitory phenotypes may 
explain the controversial epidemiological data on the 
influence of GBV-C infection for HIV progression in vivo. 
Furthermore, the identification of three proteins derived 
from an non-pathogenic virus reveals an interesting and 
profitable source for the development of innovative, 
antiretroviral drugs based on GBV-C derived peptides.
HIV	AND	HEPATITIS	C	CO-INFECTION:	FROM	
PATIENT	TO	EDUCATOR
Riley R1, Murphy G2
1Immunology and Infectious Diseases Unit, John Hunter 
Hospital, Newcastle, NSW, Australia; 2Hepatitis Service, 
John Hunter Hospital, Newcastle, NSW, Australia
Social Workers at John Hunter Hospital worked with a 
person co-infected with HIV and Hepatitis C through the 
stages of assessment and treatment for Hepatitis C. After 
a successful outcome to treatment the person was re-
engaged to reflect on and capture his experiences. His 
experiences were developed into an educational format 
to inform people in similar situations in the Newcastle 
and Hunter area. The roles of each Social Worker and 
the Non Government Organizations in enabling the 
transformation from patient to educator will be noted. 
The person has allowed his presentation to be included 
within this presentation and it will highlight how he 
prepared for and coped with treatment and it will 
highlight the outcomes for him.
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HIV	AND	TB	CO-INFECTION
Wood, Robin
Desmond Tutu HIV Centre, Department of Medicine, 
University of Cape Town, South Africa
Tuberculosis control programs have failed to contain TB 
incidence in those countries with high HIV-prevalence. 
Sub-Saharan Africa is particularly heavily affected, with 
80% of the global HIV/TB burden. In 2005 the World Heath 
Organization declared HIV/TB to be “a regional emergency, 
requiring urgent and extraordinary actions”. However, the 
interactions between HIV and TB at a population level 
have not been well understood and no new interventions 
have been instituted within the region. The interactions 
between HIV and TB are particularly intense in South 
Africa townships where adult HIV prevalence is >20%, 
TB incidence rates >1000/100,000 cases per annum and 
annual risk of TB infection in children may exceed 4.0% 
per annum. 
Population TB/HIV prevalence studies in communities 
with data on TB incidence and HIV status, allows 
differential estimation of TB case finding proportions 
for HIV-infected and uninfected individuals. Passive case 
finding appears to be a less successful strategy for HIV-
infected individuals. HIV-infection is also associated with 
an increased prevalence of relatively asymptomatic but 
sputum TB culture-positive individuals.  
Observations of HIV-infected individuals from such 
high TB transmission populations during increasing 
immune compromise before initiation of ART, together 
with changes in TB susceptibility during immune 
reconstitution with ART have provided an opportunity to 
gain new insights into the role of immune compromise 
in the development of TB disease. ART decreases the 
long-term susceptibility to TB but may also paradoxically 
increase the severity and quantity of clinical presentations 
of TB soon after treatment initiation. Increased survival 
of HIV-infected individuals with advanced HIV-infection 
with persistently increased susceptibility to TB may 
diminish the potential benefits of earlier initiated ART as 
a TB control measure. Molecular epidemiologic studies 
of TB transmission within high density communities 
identify both reactivation and rapid progression of recent 
TB infection as important contributors to TB transmission 
and specific TB strain association with HIV-infection. 
Interventions to control TB transmission in high HIV-
prevalent settings include, environmental control, 
improving DOTS program performance, active TB case-
finding, isoniazid preventative treatment and antiretroviral 
therapy. Available clinic and population-based data may 
be combined to model the impact of individual and 
combinations of intervention strategies.
Plenary – HIV AND TB Co-infection and 
Conference Closing
11.00am – 12.45pm
RESTORATION OF IMMUNE RESPONSES 
TO M.tuberculosis IN PATIENTS WITH 
HIV AND M.tuberculosis INFECTION IS A 
DOUBLE-EDGED SWORD
French MA. 
Department of Clinical Immunology, Royal Perth Hospital 
and PathWest Laboratory Medicine, and School of 
Pathology and Laboratory Medicine, University of Western 
Australia
Co-infection with HIV and M. tuberculosis is common 
in many resource-poor countries where antiretroviral 
therapy (ART) programmes are currently established or 
being introduced. As HIV and M. tuberculosis both infect 
cells of the immune system, it is not surprising that co-
infection with these pathogens has interacting and 
complex effects on immune responses, especially during 
immune reconstitution induced by ART.
It appears that ‘protective’ immune responses against 
M. tuberculosis are restored by the use of ART as rates of 
tuberculosis generally decline in HIV patients receiving 
therapy. However, disease provoked by M. tuberculosis 
infection can present during the first few months of 
ART and might contribute to the higher mortality rates 
observed during the first 6 months of ART in resource-
poor countries. Two patterns of disease are seen. Firstly, 
10-20% of HIV patients who start ART after receiving 
treatment for tuberculosis (TB) experience a ‘paradoxical 
relapse’ of the TB. It is often characterised by unusual 
or excessive inflammation and is therefore commonly 
referred to as paradoxical TB immune reconstitution 
inflammatory syndrome (TB-IRIS). Secondly, TB may 
present de novo during the first few months of ART. This 
is referred to as ART-associated TB and occurs about 20 
times more frequently in patients from resource-poor 
countries than in those from resource-rich countries.  
Clinico-pathological and immunological studies suggest 
that both TB-IRIS and ART-associated TB are types of 
immune restoration disease (IRD). Tissue inflammation 
often has the characteristics of a Th1 or possibly Th17 
response and circulating interferon-γ+ T cell and/or 
delayed-type hypersensitivity (DTH) skin test responses 
to M. tuberculosis antigens are increased. ART-associated 
TB is particularly associated with an early increase in 
circulating T cells producing interferon-γ (IFN-γ after 
exposure to RD1 antigens of M. tuberculosis whereas 
paradoxical TB-IRIS is associated with a late increase 
in circulating T cells producing IFN-γ after exposure to 
PPD, which is preceded by increased DTH responses to 
PPD. It therefore appears that although TB-IRIS and ART-
associated TB are both manifestations of IRD, there are 
differences in the  immunopathogenesis.
Increased understanding of the immunopathogenesis 
of TB-IRIS and ART-associated TB will improve diagnostic 
methods and management of patients with HIV and M. 
tuberculosis co-infection.
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OPPORTUNISTIC	INFECTIONS	IN	ASIA	–	THE	
UNMET	NEEDS
A Kamarulzaman. University of Malaya
In recent years, access to antiretroviral treatment has 
expanded in every region of the world including East, 
South and Southeast Asia with coverage expanding 
more than 75% in some countries. Whilst this has led to 
significant improvement in the morbidity and mortality 
rates for people living with HIV, opportunistic infections 
continue to be a significant issue in the management of 
the HIV infected in the region.
Delayed presentation and diagnosis of HIV due to a myriad 
of reasons mean that patients in the region continue 
to present with a variety of opportunistic infections. 
Despite advances and development in the science of 
antiretroviral therapy, unfortunately the same cannot be 
said for the diagnosis and management of opportunistic 
infections.  Diagnostic tools for the rapid detection of 
common opportunistic infections such as tuberculosis 
that are simple to use in the field and are inexpensive 
continue to elude us. Access to microbiology laboratory, 
radio-imaging and to less toxic, effective and inexpensive 
medications for many serious opportunistic infections 
can be poor outside of large cities in Asia and the Pacific. 
This often results in inappropriate and delayed therapy 
of these infections resulting in significant morbidity and 
mortality.
Finally, with the emergence of MDR tuberculosis, many 
healthcare centres in the region are ill-equipped to handle 
the infection control needs to minimise the spread of this 
infection to patients and healthcare workers alike.
Whilst the expansion of antiretroviral therapy has been 
met with reasonable success, some attention needs to 
be given to the ongoing need for better diagnostic tools 
and treatment for common opportunistic infections 
complicating HIV in patients living in the Asia and the 
Pacific.
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BASIC	SCIENCE		-	presenters will stand by their posters on Wednesday 17 Sep 12.30-1.30pm
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PROGRESSION	OF	HUMAN	
IMMUNODEFICIENCY	VIRUS	(HIV)	
INFECTION	AND	ACTIVATION	OF	CD4+	T-
LYMPHOCYTES
Chan, M. L. 1, Petravic, J. 1, Ortiz, A. 2, Klatt, N. 2, Silvestri, G. 2, 
Davenport, M. P. 1 
1Centre for Vascular Research, University of New South 
Wales, Kensington, New South Wales, Australia; 2University 
of Pennsylvania School of Medicine, Philadelphia, 
Pennsylvania, USA.
Human immunodeficiency virus (HIV) infection involves 
the progressive decline of CD4+ T-lymphocytes, resulting 
in severe immune deficiency. This in turn leads to 
opportunistic infections and cancers characteristic of 
AIDS, and eventually death. HIV is derived from simian 
immunodeficiency virus (SIV) which infects primates. It 
has been observed that natural hosts of SIV, such as sooty 
mangabeys, are largely asymptomatic when infected. This 
is sharply contrasted with non-natural hosts of SIV, such as 
rhesus macaques, and untreated HIV-infected individuals, 
who experience progressive CD4+ T-cell depletion and 
go on to develop AIDS.
 
Currently, the lack of disease progression in natural 
hosts of SIV is still not clearly understood. A better 
understanding of why SIV is non-pathogenic in natural 
hosts will therefore provide valuable insights into the 
pathogenesis of AIDS in HIV-infected individuals and point 
to new directions in treatment. Recent experimental data 
show that CD4+ T-cells of SIV-infected sooty mangabeys 
exhibit lower levels of the Ki67 activation marker than 
those of rhesus macaques and HIV-infected individuals, 
so that disease progression is apparently associated 
with activation. However, few mathematical models 
have been formulated to relate the levels of activation 
to disease progression. In our study, we have developed 
a model that demonstrates the relationship between 
activation and disease outcome, and helps us understand 
why SIV-infected sooty mangabeys are non-pathogenic 
compared to SIV-challenged rhesus macaques and HIV-
infected individuals. 
We used a deterministic model of viral dynamics to 
characterize the interactions between CD4+ T-cells and 
the virus. Using this model, we can predict the changes 
in the number of resting and activated CD4+ T-cells, the 
number of infected cells and the number of virus particles 
during acute and chronic phases of infection. Our 
preliminary analysis reveals that a lower level of activation, 
as seen in SIV-infected sooty mangabeys, results in 
considerably less depletion of CD4+ T-cells, lower infection 
levels and somewhat lower viral loads, as compared to 
infected rhesus macaques and humans. Moreover, the 
results agree with experimental data obtained from 
our collaborators. Therefore, we conclude that the non-
pathogenicity of SIV-infected sooty mangabeys may be 
attributed to lower levels of activation of CD4+ T-cells.
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ASHM	-	CLINICAL	-	TOxICITY
MONITORING	AND	UNDERSTANDING	
APOPTOSIS	IN	HIV	PATIENTS	BY	LIGATION-
MEDIATED	POLYMERASE	CHAIN	REACTION
Hooker DJ1, Wesselingh SL1,2,3 and Cherry CL1,2,3
1Macfarlane Burnet Institute for Medical Research and 
Public Health, Melbourne Australia; 2Alfred Hospital, 
Melbourne Australia; 3Monash University, Melbourne 
Australia
Increased apoptosis in vivo has been associated with 
serious, persistent antiretroviral drug toxicities, including 
lipoatrophy. A biochemical hallmark of apoptosis, 
internucleosomal DNA fragmentation, has been detected 
in vivo by ligation-mediated polymerase chain reaction 
(LM-PCR). Here we develop LM-PCR to measure apoptosis, 
assess its reliability, validate it against two existing 
apoptosis quantifiers and examine clinical associations 
with LM-PCR results in well-characterized HIV patients. 
Genomic DNA was column-purified from cells. For LM-PCR, 
blunt-ended linkers were ligated to oligonucleosomal 
apoptotic fragments. Removal of one linker strand 
allowed amplification of the apoptotic population using 
the other strand as PCR primer. We converted LM-PCR 
into a comparative quantifier by digital image capture of 
amplified fragmentation then division of trace quantities 
of 600bp apoptotic amplicons into amplicons of the 
single-copy CCR5 gene, generating the LM-PCR ‘value’. 
In validation studies, apoptosis in staurosporine-exposed 
Jurkat cells was measured over time in parallel by active 
caspase-3/ELISA, terminal deoxynucleotidyl transferase-
mediated fluorescence at DNA strand breaks (TUNEL)/
FACS, and LM-PCR. We applied LM-PCR to PBMC samples 
archived from a longitudinal study of HIV patients.
Dynamic range of the LM-PCR value is ≥17-fold (~200-
fold difference in apoptotic fragmentation). Inter-gel 
reliability (reflecting electrophoresis, band detection and 
photography) and intra-gel reliability (reflecting input DNA 
mass, sample loading and trace quantity measurement) 
are both excellent (intra-class correlation coefficients 0.97 
and 0.95 respectively, standard errors of measurement 
0.17 and 0.12 respectively). Validation experiments 
reveal LM-PCR is as sensitive as caspase-3/ELISA and 
more sensitive than TUNEL/FACS for distinguishing 
low degrees of apoptosis (relevant spectrum in vivo). 
In clinical samples, elevated PBMC LM-PCR results are 
independently associated with both current treatment 
exposures and clinical lipoatrophy.
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LM-PCR has been modified, optimised, validated and 
shown to be a reliable apoptosis quantifier able to 
differentiate low degrees of apoptosis. In the validation 
time course, the LM-PCR profile mirrored that of caspase-
3/ELISA (rather than that of TUNEL/FACS) reflecting the 
known correlation between active caspase-3 levels 
and induction of the endonuclease responsible for 
internucleosomal cleavage.  The development and 
validation of LM-PCR to measure apoptosis provides a 
new and versatile tool for monitoring and understanding 
important antiretroviral drug side effects in HIV patients.
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IMMUNODEFICIENCY	VIRUS	ExPLOITATION	
OF	DENDRITIC	CELLS	IN			THE	EARLY	STEPS	
OF	INFECTION
Junior Freddy KANKOU   
University of Bangui (Central African Republic) 
Bernard Frederic University of Bossangoa    (Central African 
Republic)            
The unique capacity of dendritic cells (DCs) to capture 
and process pathogens for presentation to the immune 
system, combined with their capacity to express 
costimulatory and adhesion molecules as well as 
cytokines and chemokines, renders them powerful 
antigen-presenting cells. However, immunodeficiency 
viruses hijack DCs to facilitate virus dissemination while 
subverting effective immune activation. Depending 
on the activation level of the DC subset, human 
immunodeficiency virus can use different receptors (CD4, 
chemokine, and C-type lectin receptors) to bind to DCs. 
These aspects likely impact whether a DC is productively 
infected by or simply carries virus for transmission to more 
permissive targets. DCs efficiently transmit virus to CD4+ 
T cells, driving virus growth as well as providing signals 
to trigger virus expansion in virus-bearing CD4+ T cells. 
There is accumulating evidence that viral determinants 
(nef, tat) selectively modulate immature DC biology, 
fostering DC–T cell interactions and virus replication 
without up-regulating costimulatory molecules for 
effective immune function. In addition, virus-loaded, 
immature DCs activate CD4+ virus-specific T cells, and 
mature DCs stimulate CD4+ and CD8+ T cells. Thus, even if 
immature DCs entrap virus as it crosses the mucosae and 
initiate a CD4+ T cell response, this is likely insufficient to 
control infection. Appreciating how virus modulates DC 
function and what determines whether virus is processed 
for immune stimulation or transmitted between cells will 
unveil the exact role of these cells in the onset of infection 
and advance preventative microbicide and vaccine/
therapeutic approaches.
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POPULATION-BASED	GENETIC	APPROACH	
IDENTIFIES	NOVEL	HEPATITIS	C	TARGETS	OF	
THE	IMMUNE	RESPONSE
Pfafferott K
Human leucocyte antigen (HLA) class-I restricted 
Cytotoxic T Lymphocyte (CTL) responses play an 
important role in the clearance of Hepatitis C virus (HCV) 
infection. Although several HLA class I-restricted epitopes 
within HCV have been described, the true extent of CTL-
driven immune pressure on the virus is likely to be more 
extensive than currently described. This is partly due to 
the use of peptides derived from laboratory strains rather 
than circulating viruses in cellular assays and the focus on 
CTL epitopes restricted by common HLA alleles. 
We previously described a population-based genetic 
approach that identifies sites within the HCV genotype 
(GT) 1 genome that represent in vivo targets of HLA-
driven selection pressure. These sites, and flanking 
sequence, were then further examined using web-based 
programs (syfpheithi and BIMAS) to predict putative HLA 
Class I-restricted epitopes. Sixty one predicted HLA Class 
I-optimal peptides were identified.  These HLA-specific 
peptides along with their potential escape variants were 
then tested using automated IFN-gamma ELISpot assays 
on 50 HCV-infected Haemophilia patients with different 
infection outcomes. Peptides were selected for each 
individual based on their HLA Class I alleles. In addition, 
we adjusted the H77 overlapping peptides (OLPs) to a 
relevant consensus sequence based on our population 
study of individuals with chronic GT1 infection.
CTL responses towards predicted HLA Class I epitopes were 
detected as well as previously unknown escape mutations 
that interfere with CTL recognition. Furthermore, in many 
cases CTL responses against the adjusted OLPs induced a 
CTL response but not the equivalent non-adjusted H77-
derived OLPs. 
In conclusion, the ELISpot assays using H77-derived 
OLPs underestimate the overall breath of the HLA 
Class I-restricted immune response in HCV-infected 
individuals. In order to capture the true extent of HLA-
specific CTL responses we recommend that H77-derived 
overlapping peptides should be adjusted for sequence 
polymorphisms that are present in circulating viruses. 
Furthermore, the population-based genetic approach 
highlights sites within the viral genome that are under 
HLA Class I-restricted selection pressure and can inform 
HLA Class I-epitope predictions and identifies potential 
escape mutations.  
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ASHM	-	ORAL	POSTER	SESSION	-	CLINICAL,	
ALLIED	HEALTH	AND	BASIC	SCIENCE
MOLECULAR	CLONING	AND	
CHARACTERISATION	OF	ENVELOPE	FROM	
HIV-1	PRE-SEROCONVERSION	STRAINS
Reddy S M1, Center R J1, Suzuki K2, Gray L3, Gorry P R3, 
Kelleher A4 &Purcell DFJ1
1Department of Microbiology & Immunology, The 
University of Melbourne, Melbourne, VIC, Australia; 
2Centre for Immunology, St. Vincent’s Hospital, Sydney, 
NSW, Australia; 3Macfarlane Burnet Institute for Medical 
Research and Public Health, Melbourne, VIC, Australia; 
4National Centre in HIV Epidemiology and Clinical 
Research, Sydney, NSW, Australia.
Human trials have shown that HIV-1 vaccines eliciting 
potent T-cell responses without stimulating broadly 
neutralising antibodies (nAb) to HIV-1 envelope 
protein (Env) failed to reduce HIV infections or disease 
progression. Clearly, a better understanding of the nature 
of the Env that supports HIV-1 transmission is required 
to produce vaccines capable of raising broad nAb that 
block HIV-1 at this earliest time.  During the course of 
infection extensive variations arise in Env driving escape 
from humoral immune responses. Therefore, we sought 
to examine Env sequences of transmitting strains derived 
before seroconversion and ensuing selection of Env for 
resistance to nAb. Transmission strain Env may expose 
conserved domains sensitive to antibody neutralization 
and hence studying HIV-1 Env from patients isolates 
obtained before seroconversion may allow identification 
of well-exposed neutralization-sensitive epitopes that 
could inform vaccine design.
Whole blood was collected from patients at high risk for 
HIV-1 infection and five pre-seroconversion (PSC) samples 
were selected that were negative for HIV-1 antibody ELISA 
and western blot, but positive for p24 antigen and HIV-1 
RNA viral load assays. RNA was extracted from cell-free 
virus and reverse transcribed into cDNA. A nested PCR 
approach was used to amplify near full length envelope 
genes. The PCR products were cloned and tested for 
Env-mediated entry by pseudotyping a GFP reporter 
virus and assaying infectivity in permissive cells. Of the 
28 PSC clones tested, 10 (36%) were functional, and 
these were fully sequenced. Within-sample variability 
was very low, indicating limited genetic evolution or drift. 
The number of potential N-linked glycosylation sites was 
consistently lower in PSC clones in comparison with the 
pNL4.3 and AD8 reference sequences. These clones will 
be phenotypically characterized for their affinity for CD4, 
co-receptors and known broadly neutralizing antibodies. 
The clones will be further used for immunogenicity trials 
in animals and the neutralization activity of the resulting 
sera will be assessed.
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ASHM	-	ORAL	POSTER	SESSION	-	CLINICAL,	
ALLIED	HEALTH	AND	BASIC	SCIENCE
DO	NATURAL	KILLER	CELLS	COMPENSATE	
FOR	IMPAIRED	
CD4+	T-CELL	RESPONSES	TO	CMV	IN	HIV	
PATIENTS	RESPONDING	TO	ANTIRETROVIRAL	
THERAPY?
Tan DBA1, Fernandez S1, French M1, 2, Price P1, 2
1School of Pathology and Laboratory Medicine, University 
of Western Australia, Perth, WA, Australia; 2Department of 
Clinical Immunology and Immunogenetics, Royal Perth 
Hospital, Perth, WA, Australia.
Although HIV patients beginning antiretroviral therapy 
(ART) with extreme CD4+ T-cell depletion can achieve 
a stable virological response, recovery of CD4+ T-cell 
and natural killer (NK) cell numbers and function are 
variable. We evaluated whether NK cell function might 
compensate for deficiencies in T-cell responses to a 
common viral pathogen, cytomegalovirus (CMV).
Male patients with nadir CD4+ T-cell counts <50 cells/μl 
and undetectable plasma HIV RNA for >1 year on ART were 
divided into low (CMV-lo, n=8) and high (CMV-hi, n=10) 
responders based on CD4+ T-cell interferon-gamma (IFNγ) 
responses to CMV. NK subsets and perforin expression 
were quantitated cytometrically. NK IFNγ responses to 
K562 cells were assessed by ELISpot. Cytokine receptor 
mRNA was quantitated in unstimulated CD56+ cells.
NK cell IFNγ responses and proportions of CD56+CD16+ 
cells were correlated in patients (p<0.001) and both were 
lower than in controls (p=0.006 and p=0.007, respectively). 
However, NK cell IFNγ responses correlated inversely with 
the expression of IL-10R1 (p=0.002), IL-12Rβ1 (p=0.004) 
and IL-12Rβ2 (p=0.024) mRNA. Expression of these 
transcripts is reduced by exposure to the cytokines, so 
low expression may reflect immune activation.
Proportions of CD56+CD16- NK cells correlated inversely 
with current CD4+ T-cell counts and were weakly inversely 
associated with CD4+ T-cell responses to CMV. Expression 
of perforin in CD56+CD16- NK cells was higher in CMV-
lo patients than controls (p=0.046). Hence increased 
proportions and cytolytic function of CD56+CD16- NK cells 
may compensate for CD4+ T-cell dysfunction, but NK cell 
IFNγ responses remain functionally deficient in patients 
who began ART with extreme immunodeficiency.
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ASSESSMENT	OF	THYMUS-DERIVED	NAÏVE	
T-CELLS	IN	HIV	PATIENTS	WHO	HAVE	
ExPERIENCED	IMMUNE	RECONSTITUTION
Tanaskovic S, Fernandez S, Price P, French M A
Department of Clinical Immunology and Immunogenetics, 
Royal Perth Hospital, and School of Pathology and 
Laboratory Medicine, University of Western Australia, 
Perth, Australia
The expression of CD31 by naive T-cells is known to 
mark a CD4+ T-cell that has recently exited the thymus. 
However CD31 has not been validated for use in other T-
cell populations. Here we correlate expression of CD45RA 
and CD31 on CD4+ T-cells, CD8+ T-cells, regulatory T-cells 
(Tregs) and γδ T-cells with other indicators of thymus 
function. 
PBMC were cryopreserved from 27 previously 
immunodeficient HIV patients with a stable response 
to ART (nadir CD4+ T-cell count <50/μl, age 34-73 years) 
and 23 healthy control donors (age 14-79 years). Flow 
cytometry was used to identify cells co-expressing CD4, 
CD8, FoxP3 (marking Treg) or γδ TCR, with CD45RA and 
CD31. Naïve T-cells were enumerated in whole blood 
using CD45RA and CD62L. TREC levels were quantitated 
using real-time PCR in CD4+ and CD8+ T-cells purified 
using magnetic beads. 
The proportion of CD4+ T-cells co-expressing CD31 and 
CD45RA correlated inversely with age in HIV patients 
(p=0.026) and healthy controls (p<0.0001). In patients 
and controls, co-expression of CD31 and CD45RA 
correlated directly with CD4 TREC content (p=0.016 and 
p=0.001, respectively), naive CD4+ T-cell counts (p=0.002 
and p<0.0001, respectively) and thymus size (p=0.06, only 
assessed in patients). 
In controls, proportions of CD8+ T-cells co-expressing 
CD45RA and CD31 correlated inversely with age (r=-
0.59, p=0.003) and directly with CD8 TREC content 
(r=0.69, p=0.0003) and naive CD8+ T-cell numbers (r=0.47, 
p=0.02). However, these relationships were not observed 
in HIV patients. In controls, the proportion of γδ T-cells 
co-expressing CD45RA and CD31 increased with age 
(r=0.62, p=0.002). CD45RA+ CD31+ γδ T-cells were higher 
in patients than controls (p=0.007) and did not correlate 
with thymus volume.  
These data validate CD31 as a marker of recent thymic 
origin in CD4+ T-cell populations. Although CD31 may 
mark CD8+ thymic emigrants in healthy controls, the 
relationships were not evident in HIV patients. CD31 
expression on γδ T-cells may not indicate a thymic origin of 
these cells. The proportion of circulating CD45RA+ CD31+ 
γδ T-cells appears to increase when the immune system 
is compromised, such as in older individuals and HIV 
patients who have experienced immune reconstitution.  PO
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LONGITUDINAL	PLASMA	ANTIBODY	TITERS	
IN	RELATION	TO	IRD	IN	HIV	PATIENTS	
BEGINNING	ART	IN	KUALA	LUMPUR
yong yK1, Tan Hy1, Tan DBA2, Kamarulzaman A1, Tan LH1, 
French MA2,3, Price P2,3
1 University of Malaya Medical Centre, Kuala Lumpur, 
Malaysia.
2 Pathology and Laboratory Medicine, University of 
Western Australia, Australia.
3 Clinical Immunology & Immunogenetics, Royal Perth 
Hospital, Australia.
A proportion of HIV patients beginning antiretroviral 
therapy (ART) develop an immune restoration disease 
(IRD). To investigate the underlying mechanisms, 
longitudinal changes in plasma antibody titers were 
investigated in relation to IRD in a cohort of HIV patients 
beginning therapy with a range of opportunistic 
infections.
Plasma were collected from 20 male (16 Chinese and 
4 Malay) HIV patients beginning ART with <100 CD4 T-
cells/µl at the University of Malaya Medical Centre, Kuala 
Lumpur, on 5 occasions over the first year of therapy. 10 
patients experienced IRD [2 with cytomegalovirus (CMV) 
retinitis, 1 with Bell’s palsy, 2 with cryptococcal meningitis, 
4 with tuberculosis lymphadenopathy (TB) and 1 with 
varicella zoster virus (VZV)]. Plasma antibodies (IgG) 
reactive with CMV, Cryptococci, PPD and VZV antigens 
were assessed using standard ELISA methods.
 
All patients developed high levels of anti-CMV antibody 
during 1 year on ART, regardless of IRD. Antibody reactive 
to cryptococcal antigen peaked only at the time of 
cryptococcal IRD. Anti-PPD titers were elevated at the 
start of ART in two TB IRD patients and remained high or 
increased further at the time of their IRD. However, the 
other two TB IRD patients retained low to intermediate 
titers throughout first year of ART. Anti-VZV titers were 
detectable in the VZV IRD patient at the start of ART, with 
a marginal increment during IRD. Bell’s palsy followed 
high titers of antibody reactive with CMV and not VZV.
Despite their immunodeficiency, most HIV-infected 
patients display restored antigen-specific IgG antibody 
responses during 12 months of ART. Antibody titers were 
varied considerably between patients but were relatively 
stable over time, suggesting inherent differences in 
immune capacity. The high titers of anti-CMV IgG 
developing in most patients regardless of IRD may reflect 
the reactivation of CMV by chronic immune activation or 
may reflect immune dysregulation associated with the 
restoration of CD4 T-cell numbers and function. 
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TRENDS	OVER	TIME	IN	THAI	GAY	MEN’S	
ACCESS	TO	A	SExUAL	HEALTH	SERVICE	IN	
SYDNEY:	AN	ONGOING	PARTNERSHIP
Dabbhadatta J1,  Wang J2, Moreton R3, Prihaswan P4,  Scott 
S2, Suarez M5, Silveira M4, McGowan L4, Wong S2
1HIV/AIDS and Related Programs Unit, South Eastern 
Sydney and Illawara Area Health Service, NSW, Australia; 
2ACON, Sydney, NSW, Australia; 3Multicultural HIV/AIDS 
and Hepatitis C Service, Sydney, NSW, Australia;  4HIV and 
Related Programs Health Promotion Team, Sydney South 
West Area Health Service, NSW, Australia; 5HIV and Related 
Programs Health Promotion Team, Northern Sydney and 
Central Coast Area Health Service, NSW, Australia
Thai gay men remain a priority group for HIV and sexually 
transmissible infection (STI) prevention in Sydney. Research 
indicates that poor access to sexual health check ups 
may have contributed to undiagnosed HIV transmission 
among  people from culturally and linguistically diverse 
(CALD) communities. 
Working in collaboration with affected communities and 
a range of services is essential in health promotion. A 
media campaign, targeting both ethnic and gay press, to 
increase HIV and STI testing rates among Thai gay men 
has been implemented annually since 2006 through a 
partnership of health services. 
In 2008 the media campaign was reviewed to give a new 
look and better connect with the target audience based 
on the evaluation from previous years. A participation 
strategy was also undertaken to involve Thai gay men in 
the development of new campaign material.  The project 
continued to maintain strong partnerships between 
services and Thai communities resulting in notable 
support from the Thai press, publishing a series of articles 
promoting access to HIV and STI screening for Thai gay 
men.
Evaluation of this new campaign is being conducted. This 
will provide data prior, during and after the campaign 
on Thai gay men’s access to a sexual health clinic. These 
include attendance, proportion of new clients, HIV and 
STI testings and diagnoses, number of asymptomatic 
screens and trends over time.
This paper will describe the findings of the evaluation, 
the process of working in an ongoing partnership, and 
comment on the trends regarding access of Thai gay 
men to sexual health screening.
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ASHM	-	PETER	MEESE	MEMORIAL	SESSION	
-	CLINICAL	-	ASSOCIATED	CONDITIONS	
COMPLICATIONS
THE	TB	+	HIV	CONNECTION
Furner VL1, Moreton R2, Tawil V3, Christensen A4
1 Albion Street Centre, Sydney, NSW; 2Multicultural 
HIV/AIDS and Hepatitis C Service, Sydney, NSW; 3AIDS/
Infectious Diseases Branch, NSW Department of Health, 
4Communicable Diseases Branch, NSW Department of 
Health, NSW, Australia
Background: The NSW HIV/AIDS Strategy 2006-2009 has 
identified people with HIV from CALD backgrounds as 
a priority.  In NSW, there are 350-420 HIV notifications 
annually, with people from CALD backgrounds accounting 
for 1 in 5 notifications. Further, 85% of people with TB 
diagnosed in Australia are born overseas.  However only 
approximately 30% of those diagnosed with TB in NSW 
have documented HIV tests. In November 2005, NSW 
Health formed a NSW CALD Interagency committee to 
enhance inclusion of CALD issues in the work of HIV and 
related sectors.
Outcome: One of the key initiatives of the interagency 
was the establishment of the NSW TB/HIV Working 
Group in recognition of the nexus between TB and HIV 
for people from priority CALD backgrounds.  The working 
group aimed to develop a strategic approach to support 
partnerships and collaboration between the TB and HIV 
sectors across NSW.  The key initiative in 2007-2008 has 
been the development of a state-wide “Roadshow”. 
The purpose of the Roadshow was to bring together HIV, 
sexual health and TB clinicians in each Area Health Service 
to:
• promote the new NSW Health Policy Directives to 
enable statewide standard practice of testing, diagnosis 
and management of TB/HIV; 
• formalise partnerships and strengthen clinical care 
coordination between the TB, HIV and related sectors 
at a local level.
The Roadshow outlined the principles of TB and HIV 
testing, and management within the respective sectors. 
It also highlighted key issues relating to migration, 
settlement and refugee health within NSW.
The development, implementation and outcomes of the 
“Roadshow” initiative will be discussed in detail including 
the enhanced partnerships that have been generated 
between the sectors, and also the lessons learnt in 
developing and implementing the Roadshow at a state 
and local service level.  The model utilised may also be 
relevant in addressing other health challenges in HIV care 
and treatment in the future.   
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	ASHM	-	ORAL	POSTER	SESSION	
-	PUBLIC	HEALTH	AND	EPIDEMIOLOGY
SExO	LATINO.	SExO	CALIENTE.	SExO	
SEGURO.	A	SAFE	SEx	CAMPAIGN	FOR	
SPANISH	SPEAKING	GAY	MEN
Prihaswan P1, Silveira M1, Suarez M2, Moreton R3, 
Dabbhadatta J4, Wang J5, Wong S5, McGowan L1.
1Sydney South West Area Health Service; 2Northern Sydney 
and Central Coast Area Health Service; 3Multicultural 
HIV and Hepatitis C Service; 4South Eastern Sydney and 
Illawara Area Health Service; 5ACON
The Culturally and Linguistically Diverse (CALD) Gay 
Men’s Working Group is a partnership project targeting 
high priority CALD populations to reduce HIV and STI 
transmission. This presentation describes the processes 
and outcomes of the development of a Spanish-speaking 
Gay Men HIV and STI Campaign in metropolitan Sydney.
There is no available research about the sexual health 
needs and behaviours of Spanish-speaking gay men 
in Sydney. To inform the development of strategies a 
series of focus groups and key informant interviews 
were undertaken to explore understandings of HIV and 
STI risk, current service access and testing practices, and 
utilisation of gay and ethnic media.
Strategies have included a social marketing campaign 
as well as a social support initiative. Campaign messages 
were developed in close consultation with Spanish-
speaking gay men. The social support component 
provided an opportunity for Spanish-speaking gay men 
to connect with each other and reduce social isolation for 
those men who are not attached to the gay scene. It will 
also allow for ongoing dialouge between this group and 
service providers regarding their HIV and STI information 
needs. Findings from these consultations and campaign 
development processes will be presented.
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BROTHEL	BASED	ASYMPTOMATIC	
SCREENING	OF	FEMALE	SEx	WORKERS	IN	A	
REGIONAL	SETTING.	
Rose JL, Williamson M.A and Allen. D 
HIV and Sexual Health Service, Northern Sydney Central 
Coast Health, Gosford, NSW, Australia.
A needs assessment was conducted of workers living in 
the regional area of Central Coast NSW Australia in 2005 
- 2006.  17% of sex workers reported that they either do 
not have a regular sexual health checks or have never had 
them.  43% of workers reported having infrequent sexual 
health screening. Vaccination rates for hepatitis B were 
low amongst survey respondents. 
Recommendations were made to explore alternative 
methods to increase the number of sex workers undertaking 
regular sexual health screens.  It was also recommended to 
explore approaches to increase the number of sex workers 
fully vaccinated against Hepatitis B.  
The asymptomatic onsite brothel screening program was 
developed and implemented by the Holden Street clinic 
at Gosford NSW in November 2007. 
An outreach screening and anaphylaxis policy was 
developed.  Letters were sent to all brothel managers 
outlining the program and service provision.   This 
included 7 Asian and 4 English speaking brothels to 
which response was overwhelming. Screening was 
offered to asymptomatic workers who were then 
registered by the clinic, a sexual health history was 
obtained, serology for Hepatitis A, B and C, syphilis, and 
Human Immunodeficiency Virus; self collected vaginal 
swabs, throat swabs for gonorrhoea, first void urine for 
chlamydia.  Follow up with results and vaccination was 
offered 2 weeks post screening.  
Post screening results have indicated that this program 
gives workers an alternative choice to attending the 
Sexual Health Clinic thus increasing uptake in screening 
and education.  Results show 50% of new sex workers 
registered at the sexual health clinic in the past 5 months 
occurred through the outreach program. 
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RELATIVE	SIGNIFICANCE	OF	
PHYSIOTHERAPY	IN	THE	TREATMENT	
OF	ACqUIRED	IMMUNE	DEFICIENCY	
SYNDROME.	A	REVIEW	OF	LITERATURE
Amalnerkar, T.
Masterskill College of nursing & health sciences, Cheras 
{Selangor}, Malaysia.
Objective: Acquired immune deficiency syndrome is 
characterized by depressed and disturbed immune system 
and in long term it leads to psychological symptoms 
like stress, nervousness, anxiety, frustration and worries, 
which in turns leads to a vicious cycle of Persistent pain 
and agony. This review is an attempt to enlighten the 
effectiveness of exercises and other physiotherapeutic 
interventions for reduction in the stress and anxiety 
thereby improvement in the psychological symptoms 
which are commonly manifested in A.I.D.S and are used 
clinically.
Methods: A systematic review has been made by 
MEDLINE, CINHAL, AMED, PUBMED, SCIENCE DIRECT, 
SPORTS DISCUSS, PEDRO, BMJ, COCHRANE LIBRARy 
and other OVID databases. “The awareness of inevitable 
death leads to an irreparable damage to the psychology 
which in turns leads to Psycho morbidity in terms of 
stress, anxiety and depression. Hereby, speed of the 
disease can be altered and moderated well with the 
psychotherapeutic benefits of exercise. As regular active 
exercises like jogging slow running, pace walking, weight 
bearing, walking, resistance training, low impact aerobics, 
bicycling, brisk walk, and muscular strengthening relatively 
keeps the immune level steady, and decreases the speed 
of deterioration. Improvements mostly are caused by 
rhythmic, aerobic exercises, using of large muscle groups 
of moderate and low intensity for example, jogging, 
swimming, cycling, and walking. In addition, life style 
modification and exercises gives feeling of psychological 
well being, and “In addition a reason to live”.
Result: Exercise offers a low-cost alternative treatment 
adjunct which is easy to adapt. Slight reductions in stress, 
anxiety and change in the mood alleviate and reduce these 
symptoms and thereby modulate the immune system. 
Since ancient era exercises is being used successfully as 
a therapeutic adjunct in a variety of psychiatric disorders. 
Enormous strives have made for the treatment but very 
little documentations has been done till now, however 
this concept need’s more evidence based researches and 
studies. In future we can develop specific physiotherapy 
techniques and protocols and to the various stages of 
the diseases which will be specific in terms of intensity 
& duration.
Conclusion: No doubt, an inexpensive approach with 
pain modulation approach is proved effective in treating 
the diseases in specific terms of moderation of psycho-
morbidity. It modulates and reduces it by improving 
function of immune system and positive attitude towards 
the disease. Altered the immune system, may break the 
vicious cycle of anxiety and depressed immune system 
and cause psycho-physiological relaxation.
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RESISTANCE	TO	ANTIRETROVIRAL	DRUGS	IN	
HIV	NAÏVE	PATIENTS	RECRUITED	INTO	THE	
ALTAIR	STUDY
Arriaga ME1, Puls RL1, Emery S1 for the Altair Study Group
1National Centre in HIV Epidemiology and Clinical 
Research, UNSW, Sydney, NSW, Australia
The ALTAIR study is a Phase IIIb/IV, randomised, open 
label study comparing three regimens of combination 
antiretroviral therapy (ART) in treatment-naïve, HIV-
infected subjects over a two-year period. The objective of 
the study is to compare the safety, tolerability and efficacy 
of these regimens based upon a fixed dose combination 
of tenofovir and emtricitabine (Truvada®). The study is 
being conducted at 36 sites in 15 countries across five 
continents.
Evidence of harbouring ART-resistant HIV was an exclusion 
criterion and where available, patients had a genotypic 
resistance test by local service providers at screening. Two 
sites sent samples to Sydney for testing. Point mutations 
were analysed locally and patients were defined as “HIV 
resistant” or “HIV non resistant” according to the current 
International AIDS Society (IAS) guidelines.
Of 441 subjects screened, 24 were excluded because of 
resistance. However, four were subsequently found not 
resistant according to the IAS guidelines, leaving 20 (4.5%) 
subjects with truly resistant HIV. Australia had the highest 
mutation rate (13.6%), followed by Canada (6.2%), Europe 
(4.3%), Latin America (3.4%) and Asia (2.9%). Resistance to 
non-nucleoside reverse transcriptase inhibitors (NNRTI) 
was the most frequent (45.0%), followed by nucleoside 
reverse transcriptase inhibitors (NRTI) (31.0%) and protease 
inhibitors (PI) (12.0%). Three patients were resistant to two 
different classes of ART; two were resistant to NNRTI and 
NRTI and one was resistant to NRTI and PI. When analysed 
by region, Europe presented a different pattern with 
the majority of mutations conferring resistance to NRTI 
(75.0%) and then NNRTI (25.0%).
The prevalence of mutations associated with resistance 
to ART in HIV-naïve subjects varied in different regions 
with highest rates where ART is broadly available. Most 
mutations conferred resistance to NNRTI and NRTI. 
Although low in number, these results confirm the 
importance of testing for ART resistance in patients 
considering initiation of therapy, especially in countries 
where ART is widely available.
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ORAL	POSTER	THURSDAY	18	SEPTEMBER	
1640	–	1645	
ASHM	-	IAN	THOMPSON	
MEMORIAL	SESSION	-	CLINICAL	ARV
TRIPLE	CLASS	HIV	ANTIRETROVIRAL	(ARV)	
FAILURE	IN	AN	AUSTRALIAN	PRIMARY	CARE	
SETTING	
Bloch M1, Farris M2 Tilden D3  Gowers, A1, Hughes, T1
1Holdsworth House Medical Practice, Sydney, NSW, 
Australia; 2Research Development Unit, Merck Sharp & 
Dohme, Australia 3 Dominic Tilden, THEMA Consulting 
Pty Ltd
The prevalence, predictors and outcomes of triple class 
HIV ARV failure in primary care practice in Australia have 
not been evaluated.
In a cross-sectional retrospective ethics-approved study 
we reviewed records of all participants attending a 
high caseload Sydney primary care practice who failed 
triple class ARV virologically, immunologically or due to 
intolerance in each class (NRTI, NNRTI, PI). 
Triple class ARV failure prevalence was 5.1%, all were male 
with a median age of 49. Median age at HIV diagnosis was 
29, 96% of participants were diagnosed prior to 1997. 59% 
initiated monotherapy and 10% dual therapy. At therapy 
initiation, median CD4 T lymphocyte count was 303 cells/
µL, and 30%, 52% and 17% were CDC classification A, B 
and C respectively. 
From diagnosis to ARV initiation was 5.5 years (SD 4.11), 
and time from initiation to triple class failure was 6.76 
years (SD 3.17). Over 85% of participants ceased ARV due 
to intolerance or virologic failure and 31% of participants 
experienced triple class virologic failure. Intolerance was 
experienced equally across NRTI, NNRTI and PI (32%, 
36% and 34% respectively). Virologic failure was more 
common with PIs than NRTI & NNRTI (33% vs 25% & 27% 
respectively)
Resistance information was present for 57% of participants, 
the prevalence of NRTI, NNRTI and PI resistance was 86%, 
76% and 62% respectively. The following independent 
mutations were prevalent in >35% of participants D67N, 
L210W, M184V, M41L, T215y, K103N, L90M, V82A. 
For the 51 participants there were 30 unique regimens 
in current ARV therapy. The median duration of current 
therapy was 1.6 years. 78% of participants were currently 
virologically controlled (VL<50). 
Thus triple class ARV failure in primary care represents 5% of 
patients. The common characteristics of these patients is that 
they had longstanding HIV and were initiated sub-optimally 
however they are currently well controlled.
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IDENTIFICATION	OF	THE	GENETIC	
MARKER	HLA-B*5701	AND	ABACAVIR	
HYPERSENSITIVITY	REACTION	(HSR)	IN	HIV-
1	PATIENTS	IN	SYDNEY,	AUSTRALIA	AND	
DEVELOPMENT	OF	MECHANISMS	FOR	RISK	
REDUCTION
Bloch M, Quan D, Beileiter K and Franic T.
Holdsworth House Medical Practice, Sydney, NSW, 
Australia
The HLA allele, HLA-B*5701, confers susceptibility to 
abacavir HSR, a systemic allergic reaction which resolves 
on abacavir cessation but can be life-threatening on 
abacavir re-challenge. Although abacavir, and abacavir 
containing compounds in conjunction with other NRTI 
as treatment options are efficacious, the need to prevent 
possible HSRs is clear. Hence we measured the prevalence 
of HLA-B*5701 in a sample of HIV patients attending a 
high HIV caseload Sydney primary care practice and used 
this information to design methods of reducing the risk 
of abacavir HSR.
Abacavir treatment naïve or previously clinically 
diagnosed abacavir HSR HIV-1 patients were invited to 
participate in an Ethics-approved cross-sectional study. 
Patients who tolerated abacavir were excluded. 300 
patients were enrolled, 90% were abacavir naïve, 23.3% 
were antiretroviral naïve and 66.7% were on antiretroviral 
therapy that excluded abacavir. All patients were male, 
median age 43 yrs, of Caucasian (91%), Asian (5.3%), 
Hispanic (1.7%), Mixed (1.3%), African and Aboriginal 
(0.3%) ethnicities. The prevalence of HLA-B*5701 in the 
abacavir naïve cohort was 8.5%. 10 percent (30/300) of 
patients enrolled were previously diagnosed as having 
an abacavir HSR. Interestingly, only 50% (15/30) were 
positive for the HLA-B*5701 allele, all being Caucasian. 
The median CD4+ count at the time of diagnosed HSR 
was 580 cells/µL. 96.8% of patients consented to their 
information being entered into a secure web-based 
registry containing de-identified HLA-B*5701 status and 
abacavir HSR details. The registry was created with graded 
access for the treating physician and laboratory.
Successful implementation of a genetic screening 
protocol revealed the prevalence and distribution of HLA-
B*5701 to be as described in previous studies, but the 
clinical diagnosis of abacavir HSR may be a poor predictor 
of HLA-B*5701 status. The acceptability of a secure web 
based registry for retention and result access has potential 
for wider application.
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TOWARDS	EVIDENCE-BASED	GUIDELINES	
FOR	ANAL	CANCER	SCREENING
Botes L P 1, Hillman R 1
1Sexually Transmitted Infections Research Centre, 
University of Sydney, Sydney, NSW, Australia
Anal cancer is a condition with significant morbidity 
and mortality. The early stages of anal cancer and pre-
cancer are typically asymptomatic and thus the majority 
of patients are diagnosed with late-stage disease. As a 
consequence, anal cancer generally has a poor prognosis, 
with five-year survival rates between 20% - 70%.
Anal cancer is rare in the general Australian community, 
with an incidence rate of approximately 1 case/100,000 
per year. Such a relatively low rate may explain the 
comparatively low levels of awareness amongst the 
medical and general communities. However, rates 
among MSM, particularly those with HIV infection, are 
much higher – typically 30-50 cases/100,000.
The introduction of cervical cancer screening programs 
is widely regarded as a major public health success, with 
incident cases of cervical cancer decreasing from 40-50 
cases/100 000 during the last 20 years to the current rate 
of 8 cases/100 000. These programs are based on regular 
cytological screening of ‘at-risk’ women for cervical 
squamous intra-epithelial lesions. Women identified with 
these lesions are then offered the opportunity for early 
intervention, which prevents the development of cervical 
cancer.
The aetiological, epidemiological and cytological 
similarities between cervical and anal cancer have led 
to increasing calls for the introduction of comparable 
screening programs for anal cancer in high-risk 
populations. To date, however, there are no Australian 
data to support such a move 
 
We therefore set out to determine whether anal 
cytological screening was acceptable to HIV positive MSM 
and investigate whether it would lead to a significant 
increase in the detection of individuals with severe anal 
dysplasia and anal cancer
A prospective three-year study of 1000 HIV positive MSM 
attending an HIV outpatient clinic has commenced 
in Sydney. Epidemiological, behavioural, virological, 
immunological, cytological and histological data from 
the first 100 participants will be presented.
Anal cancer is now the third most common tumour 
occurring in the HIV infected, and rates are rising. There is 
increasing evidence that screening for anal cancer is now 
technically possible, and probably desirable. These data 
will help inform the development of evidence-based 
Australian guidelines for the screening of HIV positive 
MSM for anal dysplasia and cancer. 
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CLINICAL	ANTI-RETROVIRAL	THERAPY
HIV	DISEASE	PROGRESSION	IN	HIV-1	
PATIENTS	INITIATING	COMBINATION	
ANTIRETROVIRAL	THERAPY	WITH	
ADVANCED	DISEASE	IN	THE	ASIA-PACIFIC
REGION:	RESULTS	FROM	THE	TREAT	ASIA	HIV	
OBSERVATIONAL	DATABASE	(TAHOD)
1Byakwaga H, 1Petoumenos K, 2Zhang F, 3Ananworanich 
J on behalf of the TREAT Asia HIV Observational Database 
(TAHOD).
1National Centre in HIV Epidemiology and Clinical 
Research, University of New South Wales, Sydney, NSW, 
Australia; 2Beijing Ditan Hospital, Beijing China; 3HIV-
NAT/The Thai Red Cross AIDS Research Centre, Bangkok, 
Thailand
There is little data on HIV disease progression from 
resource-limited settings in patients initiating combination 
antiretroviral therapy (cART) with advanced HIV infection
To examine predictors of AIDS or death in patients 
initiating cART with CD4 cell count ≤ 200 cells/µL in the 
TREAT Asia HIV Observational Database (TAHOD).
Patients who commenced cART after 1 January 1997 in 
TAHOD with a baseline CD4 cell count ≤200 cells/µL were 
included. The main outcome measure was progression 
to either an AIDS defining illness or death occurring 
between 6 months and 2 years after initiation of cART. 
Predictors of HIV disease progression were assessed using 
survival analysis methods.
A total of 1253 patients included in these analyses 
contributed 2056 person years of follow up, during which 
113 patients were diagnosed with AIDS and 9 died. The 
median CD4 count at start of cART was 63 (IQR 25-130) 
cells/µL, the median absolute CD4 cell count six months 
from start of cART was 175 (IQR, 106-268) and the mean 
CD4 T-cell increase was 122 (SD, 105) cells/µL. The rate of 
progression to the combined endpoint (AIDS or death) 
was 5.9 per 100 person years. In univariate analyses gender 
and CD4 count at month 6 were significantly associated 
with HIV disease progression. CD4 count at month 6 was 
the only independent predictor of disease progression 
(HR 0.75, 95% CI 0.62-0.87, P<0.001).
In patients initiating cART with advanced disease (CD4 
count ≤ 200 cells/µL), the CD4 count at month 6 but not 
the baseline CD4 count is strongly associated with the risk 
of HIV disease progression. 
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RESISTANCE	TO	THE	HIV-1	INTEGRASE	
INHIBITOR	RALTEGRAVIR:	A	CASE	STUDY
Chibo D1, Roth N2, Birch C1.
1Victorian Infectious Diseases Reference Laboratory, 
Melbourne, Victoria, Australia; 2Prahran Market Clinic, 
Melbourne, Victoria, Australia 
HIV integrase inhibitors are a new class of antiretroviral 
drugs that target a critical stage in the HIV replication 
cycle by blocking the integration of viral DNA into the 
host cell genome.  Raltegravir, a strand-transfer inhibitor 
of HIV-1 integrase, has been associated with complete 
suppression of viral load when used with an optimised 
background regimen in heavily pre-treated patients. 
However, resistance to the drug has been described in a 
small number of cases.  
Here we describe a case of multidrug class resistant 
HIV, including resistance to raltegravir.  The patient was 
diagnosed HIV positive in October 1993 with a CD4 cell 
count of 66 (8%).  He started on zidovudine monotherapy 
in 1994 and over the next 8 years was treated with dual 
therapy as well as various antiretroviral combination 
regimens.  Throughout this time, his CD4 cell count was 
always less than 100 and HIV viral load greater than 80,000 
copies/mL, suggesting poor adherence.  In 2001 he 
commenced treatment with enfuvirtide on an optimised 
background but with only a transient response.
Raltegravir treatment was commenced in September 
2007, resulting in a viral load reduction of approximately 
3 log10 after 2 months but with a rebound thereafter.  PCR 
amplification and sequencing of the entire integrase 
region in samples with viral loads of 3 log10 HIV copies 
collected during March and April 2008 revealed a wild 
type gene.  Sequencing of the integrase region in a sample 
collected in May with a viral load of 4 log10 HIV copies 
identified an N155N/H mutation.  Previous studies have 
described this mutation as one of two possible genetic 
pathways for development of resistance to raltegravir, the 
other being Q148H.  At this stage no secondary mutations 
have been identified.  The genetic barrier for resistance to 
raltegravir is low. Adherence will be an important issue if 
patients are to benefit optimally from its use.  
    
P124
VACCINATION	RATES	IN	HIV-INFECTED	
PATIENTS	ATTENDING	HOSPITAL	
INFECTIOUS	DISEASES	OUTPATIENT	CLINICS.
Chong S, Ritchie B, Daly L, Shaw D.
Infectious Diseases Unit, Royal Adelaide Hospital, Adelaide, 
South Australia, Australia.
Significant gaps exist between current immunisation 
recommendations for HIV-infected patients and clinical 
practice.
The aim of this study was firstly to determine the extent 
of screening for viral hepatitis and secondly to evaluate 
immunisation uptake of Influenza, Hepatitis A and B in 
HIV-infected patients attending outpatient clinics.
A retrospective review of patient case notes, pharmacy 
records and pathology results was performed. 291 HIV-
infected patients visiting the outpatient department (≥1 
visit) during the 12-month period of 2006 were identified 
from our HIV database.
265 males (91.1%), mean age 46.1 years and 26 females 
(8.9%), mean age 40.7 years, were analysed. Mean CD4 
(cells/mm3) was 476.2 (95% CI: 444.6-507.8) with 196 
(67.4%) having undetectable viral loads (<50 copies/mL). 
Hepatitis C antibody was performed on 90.7% (264/291) 
of patients with 15.9% (42/264) being antibody and PCR 
positive.
From Hepatitis A testing, 28.9% (84/291) of patients were 
non-immune and in 36.1% (105/291) serology status 
was unknown. With Hepatitis B, 31.6% (92/291) patients 
were identified as vaccine eligible but in 24.7% (72/291) 
serology markers were incomplete or absent to fully 
assess vaccine eligibility. 5.3% (14/262) of patients tested 
for Hepatitis B surface antigen were co-infected.
There were no absolute contraindications to vaccination 
in any patient. 24.4% (71/291) received Influenza vaccine; 
36.9% (31/84) of eligible patients received ≥1 or more 
doses of Hepatitis A vaccine, and 31.5% (29/92) of eligible 
patients received ≥1 Hepatitis B vaccine dose. Immune 
response to vaccination was not routinely performed.
Full serology markers for Hepatitis A and B were not 
routinely requested in all HIV patients. Poor vaccine 
uptake among high risk individuals was confirmed from 
this study. Our findings highlight the real problems faced 
with routine immunisation coverage in a busy ambulatory 
HIV practice and emphasise the need for a dedicated and 
proactive approach to identify, vaccinate and follow up 
eligible patients. Having implemented a nurse initiated 
“opt out” immunisation process for 2008, we plan to 
review its impact next year. PO
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A	STUDY	OF	ALDESLEUKIN	WITH	AND	
WITHOUT	ANTIRETROVIRAL	THERAPY	
(STALWART):	DESIGN	AND	BASELINE	
CHARACTERISTICS
Carey C1, Kelly M2, Courtney-Rodgers D1, Wyman N3, on 
behalf of the STALWART Protocol Team and the INSIGHT 
network.
1NCHECR, Sydney, NSW, Australia, 2AIDS Medical Unit, 
Brisbane, Australia, 3Department of Biostatistics, University 
of Minnesota, Minneapolis, USA. 
STALWART is a clinical trial designed to evaluate 
subcutaneous recombinant aldesleukin (rIL-2) as an 
antiretroviral therapy (ART) sparing agent.  
The primary objective of STALWART is to compare change 
from baseline in CD4+ T-lymphocyte count after 32 weeks 
in three groups of patients randomized to receive 
1. 3 cycles of rIL-2 administered as monotherapy; 
2. 3 cycles of rIL-2 with concomitant peri-cycle highly 
active ART; or 
3. neither ART nor rIL-2.  
Patients with HIV-1 infection, CD4+ T lymphocyte count 
≥ 300 cells/mm3 and who have not taken ART for at least 
one year prior to randomization are to be enrolled.
This international, phase II, open label trial is randomizing 
participants equally among the three groups.  Protocol 
implementation is overseen by a multinational team 
and four International Coordinating Centers in Sydney, 
London, Copenhagen and Washington DC.
Enrollment will stop on June 30, 2008.  With at least 70 
patients per treatment group, power exceeds 80% for 
detecting pair-wise differences in CD4+ T lymphocytes 
after 32 weeks of 80 to 100 cells/mm3. 
Through April 2008, 216 participants enrolled in the 
STALWART study at 28 of the planned 35 sites.  The mean 
age is 38 years, 19% are female with a median entry CD4+ 
T-cell count of 414 cells/mL. 75% of participants are ART 
naïve. 
While a substantial phase II database exists on the effect 
of rIL-2 on CD4+ T lymphocyte count with continuous 
ART, data are more limited when rIL-2 is not used with ART 
or with peri-cycle ART.  STALWART will provide important 
information on the potential use of rIL-2 as an ART-sparing 
treatment in a diverse population.
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A RETROSPECTIVE ANALYSIS OF THE 
ORAL HEALTH AND TREAMENT NEEDS IN 
PATIENTS WITH HIV INFECTION
Investigators: Freeman AD1, Logan RM1, Liberali SL1,2, 
Coates EA2
1 School of Dentistry, The University of Adelaide, South 
Australia;2 South Australian Dental Service, Adelaide 
Dental Hospital, South Australia
The introduction of highly-active anti-retroviral therapy 
(HAART) has allowed HIV positive individuals to experience 
a greater life expectancy but with the potential for an 
increased risk of medical co-morbidities including non-HIV 
related oral conditions. Little data is available describing 
prevalence and severity of oral manifestations and little 
evidence available for appropriate dental management 
in a post-HAART cohort of patients.
The Special Needs Unit (SNU) at the Adelaide Dental 
Hospital has provided comprehensive dental treatment 
for patients with HIV since 1998. A retrospective case-note 
analysis with emphasis on identifying the prevalence 
of HIV-related oral lesions was performed, utilising 
electronic and hand-written records. A total of 277 (264M: 
13F) individuals were identified who had attended SNU 
for dental care between 2001 and 2008. 
The majority of patients presented with medical co-
morbidities. There were significant differences observed 
in the prevalence of oral conditions between HAART and 
non-HAART groups, and in comparison to a previous pilot 
study performed in the late 1990s. HAART individuals 
presented with more oral conditions, including 
papillomatous lesions, xerostomia and candidiasis. Further 
analysis of this sample, including the treatment needs of 
these individuals is pending. 
These findings provide information on the prevalence of 
oral conditions and demonstrate the need to identify and 
address oral health needs for people with HIV. 
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KEY	SUCCESSES,	PROCESSES	AND	LESSONS	
LEARNED:	
THE	ISENTRESS	ExPANDED	ACCESS	
PROGRAM
Gaur, D.¹, Strum, A.¹, Opitz, C.¹, Pasfield, C.¹, Aunedi, H.¹, 
Dudek, L.¹, Arnold, G.¹
¹ Merck Sharp & Dohme (Australia) Pty Ltd. 
The Therapeutic Goods Administration (TGA) Act permits 
access to unregistered medication for patients with 
life threatening conditions via Special Access Schemes 
(SAS). Post-registration an SAS changes status to an 
Expanded Access Program (EAP) and EAPs may continue 
until medications achieve listing on the Pharmaceutical 
Benefits Scheme (PBS).
In setting up the ISENTRESS SAS a broad consultative 
process was undertaken with internal and external 
stakeholders.
This consultation process yielded specific decisions.
Australia would run the program as an SAS rather than a 
global research protocol with the following criteria: 
• similar inclusion/exclusion criteria and adverse event 
reporting procedures to the research protocol
• no other patient data would be collected 
• genotype results were removed as part of the inclusion 
criteria as genotype testing was not available on the 
Medicare Benefits Schedule
• a CD4 count restriction of < 200mm³/ml was required 
for each patient enrolment
• any exemptions to the inclusion/exclusion criteria 
would require approval by the Merck Sharp & Dohme 
(MSD Australia) Medical Advisor   
Australia became the first country outside of the United 
States of America to commence an ISENTRESS® access 
program on November 1, 2006.
The transition from SAS to EAP and then preparing for 
PBS launch involves satisfying complex legal, regulatory 
and logistical requirements, and being transparent in 
communication with internal and external stakeholders.
This presentation discusses many of the challenges, 
processes, protocols and successes experienced by 
MSD Australia in initiating and managing the Australian 
ISENTRESS® SAS/EAP.
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CHARACTERISATION	OF	PARTICIPANT	
REACTION	TO	ABACAVIR	IN	THE	STEAL	
STUDY:	A	RANDOMISED,	OPEN	LABEL	TRIAL	
TO	ASSESS	THE	SAFETY	AND	EFFICACY	OF	
SWITCHING	TO	FIxED-DOSE	TENOFOVIR-
EMTRICITABINE	OR	ABACAVIR-LAMIVUDINE.
Davies SC1, Bloch M2, Haskelberg H3, Humphries A3 on 
behalf of the STEAL investigators
1Northern Sydney Sexual Health Service, Royal North 
Shore Hospital, Sydney, NSW, Australia; 2Holdsworth House 
Medical Practice, Darlinghurst, NSW, Australia. 3National 
Centre in HIV Epidemiology and Clinical Research, UNSW, 
Sydney, NSW, Australia
Abacavir causes a potentially severe hypersensitivity 
reaction (HSR) in 5-8% of patients. The symptoms of 
HSR can be non-specific, and in blinded trials HSR was 
reported in 2-7% of participants not receiving abacavir. 
The presence of the HLA-B*5701 allele is a strong predictor 
for HSR and clinical diagnosis of the reaction has reduced 
where screening has been implemented. In the STEAL 
study 360 participants were randomised 1:1 to receive 
either fixed-dose abacavir-lamivudine or tenofovir-
emtricitabine. All were screened for the HLA-B*5701 
allele and excluded if positive (unless previously tolerant 
to abacavir). We aimed to characterise clinical reports of 
HSR against a case definition and perform epicutaneous 
patch tests to determine whether these cases were true 
immunological HSRs. 
Two clinicians reviewed the reports of presumptive 
abacavir HSR against a standardised case definition, and 
classified them as true clinical HSR or not. The case definition 
required at least two intensifying symptoms from a list of 
5 categories (rash, fever, respiratory, gastrointestinal and 
constitutional) within 6 weeks of commencing abacavir, 
and resolving within 72 hours of ceasing abacavir. For 
the skin patch test dilute concentrations of abacavir were 
applied to the skin and reactions were assessed after 24h 
and 48h.  Erythema and vesicular rash limited to the patch 
area characterised a positive result, with no response to 
the control vehicle.
Of 441 participants screened for study eligibility, 28 (6.3%) 
tested HLA-B*5701 positive and all except one (previously 
tolerant to abacavir) were excluded from participation. 
Four participants randomised to the abacavir-lamivudine 
arm reported symptoms and ceased abacavir due to 
presumptive HSR. Two of these met the case definition 
for clinical HSR.  Results from the skin patch test will be 
presented. 
Similar to previous reports, HLA-B*5701 screening resulted 
in less frequent suspected abacavir HSRs. True clinical HSR 
occurred in only two (1.1%) patients. True immunological 
HSR results will be presented.
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COORDINATION OF INTERNATIONAL 
CLINICAL STUDY – SET UP, ETHICS, AND 
LOCAL REGULATIONS	
Haskelberg H1, Puls RL1, Emery S1 for the Altair Study 
Group
1National Centre in HIV Epidemiology and Clinical 
Research, UNSW, Sydney, NSW, Australia
ALTAIR is a Phase IIIb/IV, international, open-label, 
randomised, 96 week clinical trial designed to compare 
the safety, tolerability and efficacy of three initial regimens 
of combination antiretroviral therapy based upon a 
fixed dose combination of tenofovir and emtricitabine 
(Truvada®). This international study has randomised 
329 treatment-naïve subjects at 36 sites in 15 countries. 
This is an investigator-initiated study, sponsored and 
coordinated by the NCHECR/UNSW.
To oversee and coordinate this trial, three structures were 
put in place. Firstly, an Executive structure comprising the 
Protocol Steering Committee (PSC) and the Data Safety 
Monitoring Board (DSMB), secondly, the coordinating 
centres in Sydney and Buenos Aires and thirdly, the site 
base study teams. With this structure, time, distance and 
language differences were overcome, primarily through 
electronic means, including electronic case report 
forms, a study website and teleconferencing/email 
communication.
As Truvada® is not licensed in Singapore, Thailand or 
Malaysia, special importation permits were required. At 
study completion, Truvada® will be available for an extra 
year in these countries.   
Twenty one sites (58.3%) submitted their own ethics 
application, while the sponsor alone and in collaboration 
with a locally contracted lawyer completed 13 (36.1%) and 
two (5.5%) ethics approvals, respectively. Of the 17 sites 
requiring national regulatory approval, two submissions 
were made by the sites, 13 (76.5%) were made by the 
sponsor and two (11.8%) were made by the sponsor with 
legal collaboration. Ethics and regulatory submissions 
took between 35 and 272 days to be approved, with a 
median of 116.0 days. Following approval, sites took 
between seven and 192 days to recruit their first patient, 
with a median of 78.9 days. The main reasons for delay 
include contractual and financial issues, access to few 
naïve patients, importation permit and drug labelling 
delays.
Thus far, the international nature of this trial has provided 
many challenges, nevertheless full recruitment of the 
Altair study was achieved within the expected timeline. 
Overall, good design and careful management were 
required for successful recruitment of the ALTAIR study.   
P131
ORAL	POSTER			FRIDAY	19	SEPTEMBER	
0805	–	0810
CLINICAL	MEDICINE
CLINICAL	AUDIT:	VIROLOGIC	AND	
IMMUNOLOGIC	RESPONSE	TO	
COMBINATION	ANTIRETROVIRAL	
THERAPY	IN	HIV	PATIENTS	AT	A	SYDNEY	
SExUAL	HEALTH	CLINIC
Hsu DC1, Quin JW2
1Department of Immunology, Concord Hospital, 
Sydney South West Area Health Service, Sydney, NSW; 
2Department of Clinical Immunology and HIV medicine/ 
Sexual Health, Liverpool Health Services, Sydney South 
West Area Health Service, Sydney, NSW
Bigge Park Centre (BPC) is a sexual health clinic located 
in a socially disadvantaged area in South West Sydney. 
This study served as a clinical audit, documenting 
the patient demographics of BPC, identifying factors 
associated with virologic, immunologic and discordant 
responses, evaluating the centre’s ability in HIV control 
and investigating changes in practice through time. 
Data including age, gender, ethnicity, mode of 
transmission, hepatitis co-infection, prior AIDS defining 
illness, HIV-1 RNA and CD4 counts were collected from 
medical records of patients on antiretroviral therapy for 
treatment of HIV with at least 1 year follow up at the BPC 
and analysed. 
BPC manages HIV patients from diverse backgrounds. 
Sequential monotherapy was significantly associated 
with poor virologic and immunologic response. When 
only treatment-naïve patients were analysed, Caucasian 
race, high viral load at 1 month and triple-NRTI-regimen 
were associated with lack of virologic control, whereas 
lower baseline viral load and triple-NRTI-regimen were 
associated with reduced CD4 count rise. Lower baseline 
CD4 count and prior diagnosis of AIDS were associated 
with poor immunologic response despite virologic 
control. Virologic control and immunologic response 
achieved were comparable to that documented in 
medical literature. There was no significant change over 
time in terms of timing of HAART initiation, attainment 
of immunologic response or virologic control since the 
late 1990s.
HIV control achieved at the BPC was comparable to that 
reported in medical literature. Enhancement of strategies 
to promote screening and improve adherence will likely 
improve patient care.
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CRYPTOCOCCAL	MENINGITIS	IN		RSCM	
HOSPITAL,	JAKARTA
Imran D1, Irawati M1, Wahyuningsih R2, Jannis J1,yamanie 
N1
1Department of Neurology, University of Indonesia, RSCM 
Hospital, Jakarta, Indonesia; 2Department of Parasitology, 
University of Indonesia, Jakarta, Indonesia
In Indonesia, mortality and clinical characteristics data of 
cryptococcal meningitis in HIV patient was limited. The 
objective of our study was to determine the mortality 
and clinical characteristics of cryptococcal meningitis 
in our hospital. Total of 209 lumbar puncture was done 
from January 2005 to December 2007. Sixty patients 
had cyptococcal meningitis, 52 diagnosed by positive 
cerebrospinal fluid Indian ink stain and 8 had positive 
serology. All of them HIV positive. 92% were males and 
8% females. Age ranged 17-37 years old. CD4 ranged 1-90 
sel/µl. The most common symptom was headache (65%), 
admitted with unconsciousness 30%, neck stiffness 75%, 
and focal brain lesion from CT Scan 13%. Amphotericin 
B was given to 35 patients (59%) patients and among 
them 66% survived. Twenty five patients did not received 
Amphotericin B, of whom 21 (84%) died and 4 patients 
(16%) survived. This was a first report of cryptococcal 
meningitis in Indonesia.
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CORRELATES OF RENAL FUNCTION IN A 
COHORT OF STABLE AND VIROLOGICALLY 
SUPPRESSED HIV PATIENTS ON ART 
SCREENED FOR THE STEAL STUDY.
Kelly M1, Davies SC2, Woolley I3, Amin J4, Jacoby S4, 
Humphries A4 on behalf of the STEAL investigators
1AIDS Medical Unit, Brisbane, QLD, Australia, 2Northern 
Sydney Sexual Health Service, Royal North Shore Hospital, 
Sydney, NSW, Australia; 3Infectious Diseases Department, 
Monash Medical Centre, Clayton, VIC, Australia, 4National 
Centre in HIV Epidemiology and Clinical Research, UNSW, 
Sydney, NSW, Australia
The STEAL study randomised HIV participants to receive 
fixed-dose abacavir-lamivudine or tenofovir-emtricitabine. 
Participants were screened for renal dysfunction by two 
methods: glomerular filtration rate (eGFR) calculated 
by MDRD equation and creatinine clearance (CCrCl) 
calculated by Cockcroft-Gault equation.  The MDRD 
equation has not been validated in an HIV population but 
is reported as more accurate than CCrCl.  Our aim was to 
examine the correlation between the two equations at 
baseline in an HIV cohort and to determine correlates of 
renal impairment.
eGFR and CCrCl were compared by pair-wise correlation. 
Associations between those ineligible to participate 
(n=17) because their eGFR was <70mL/min/1.73m2, and 
biochemical parameters and family history were assessed 
by logistic regression.  Associations between both eGFR 
and CCrCl and the above parameters, as well as HIV 
infection related parameters were assessed by linear 
regression.  Parameters for associations were categorised 
at their median.
Measurements for eGFR and CCrCl were available on 438 
of 441 screened patients.  Despite some variation, there 
was high statistical correlation between the two equations 
(pair-wise correlation co-efficient=0.69, p<0.001).  Only 
three screened patients had eGFR <60mL/min/1.73m2, 
one of which also had CCrCl <50mL/min.  Elevated 
bilirubin (p=0.03) and urea (p=0.04) were more common 
in the 17 participants with eGFR <70mL/min/1.73m2. 
Independent correlates of reduced eGFR were age ≥44 
years (p=0.01), phosphate <1.01mmol/L (p=0.02) and 
urea ≥5.3mmol/L (p<0.001).  Independent correlates of 
reduced CCrCl were age ≥44 years (p<0.001), BMI ≤25 
(p<0.001), amylase ≥62U/L (p=0.012), urea ≥5.3mmol/L 
(p=0.001).  The following previously reported correlates 
of renal impairment were not found to be significantly 
associated in our cohort: HIV parameters, hypertension, 
smoking, dyslipidaemia, diabetes and tenofovir use.
While eGFR and CCrCl were highly correlated, we could 
not evaluate these equations in terms of renal dysfunction 
because very few participants had poor renal function. 
Reduced eGFR and CCrCl were both associated with older 
age and elevated urea, as expected.  Our observations 
regarding bilirubin and phosphate correlations with lower 
eGFR prompt further analyses of STEAL data regarding 
the use and duration of protease inhibitors and tenofovir 
respectively. PO
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WITHDRAWN
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ORAL	POSTER	FRIDAY	19	SEPTEMBER	1625	
–	1635
ASHM	-	CLINICAL	–	TOxICITY
INTERACTION	BETWEEN	INHALED	
CORTICOSTEROIDS	AND	PROTEASE
INHIBITORS	(PI)	IN	HIV-INFECTED	
INDIVIDUALS	-	WHICH	IS	THE	PREFERRED	
INHALED	CORTICOSTEROID?
Mackie K1, Vujovic O2, Topliss D3, Douglass J4, Duncan A1, 
Forrester C1
1Pharmacy Department, Alfred Hospital, Melbourne, 
VIC, Australia; 2Infectious Diseases Unit, Alfred Hospital, 
Melbourne, VIC, Australia; 3Department of Endocrinology, 
Alfred Hospital, Melbourne, VIC, Australia; 4Department 
of General Respiratory, Alfred Hospital, Melbourne, VIC, 
Australia
Iatrogenic Cushing syndrome due to concurrent use 
of inhaled fluticasone propionate and ritonavir is well 
described in the literature and is not uncommon in 
clinical practice. However, there are less, if any, reports of 
the CyP3A4-mediated interaction between ritonavir and 
other inhaled corticosteroids (budesonide, ciclesonide 
and beclomethasone).  The objective of this literature 
review is to ascertain the inhaled corticosteroid causing 
the least adrenal suppression when combined with 
ritonavir boosted protease inhibitors (PIs) based on 
available pharmacokinetic and comparison studies. A 
search using electronic databases, Pubmed and Embase 
was completed and included papers published prior to 
1st March 2008.  
The finding of the review indicates that both inhaled 
budesonide (Pulmicort®, Symbicort®) and ciclesonide 
(Alvesco®) have less systemic corticosteroid effects than 
fluticasone (Flixotide® , Seretide®) however the small levels 
systemically active are also cleared via CyP3A4 pathways, 
therefore the potential still exists for adrenal suppression 
to occur if combining with ritonavir.
Beclomethasone diproprionate (QVAR®) is not 
metabolised by cytochrome P450 enzyme pathway. 
Therefore, any beclomethasone absorbed systemically is 
cleared regardless of ritonavir CyP3A4 inhibition.  Further 
research and clinical experience is required to determine 
if beclomethasone should be considered the inhaled 
corticosteroid of choice in HIV-infected individuals taking 
ritonavir boosted PIs. 
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ORAL	POSTER	THURSDAY	18	SEPTEMBER	
1630	–	1635
ASHM	-	IAN	THOMPSON	MEMORIAL	
SESSION	-	CLINICAL	ARV
EFAVIRENz	AND	POSITIVE	URINARY	DRUG	
SCREEN	FOR	CANNABINOIDS
Mclellan DGJ1,2, Libertino SL1,  Kerth JM1,  Dyer JR1, Wilson 
MA1, Clark BM1 and Edwards T2 
1Infectious Diseases Department, Fremantle Hospital, 
FREMANTLE, WESTERN AUSTRALIA 6160; 2Western 
Diagnostic Pathology, MyAREE, WESTERN AUSTRALIA 
6154
We have observed two patients on long term efavirenz 
therapy as part of an anti-retroviral regimen test positive 
for urinary cannabinoids following routine employment 
drug screening. In both cases use of cannabis was denied 
but the positive results led to employment termination. 
It is now recognised that a side chain of efavirenz can 
interact with commercial drug assays resulting in a false 
positive result. As drugs of abuse screening is now routine 
in many employment sectors this interaction may have a 
significant impact on employment choices and prospects 
for those individuals receiving an efavirenz containing anti-
retroviral regimen. To explore this further, urine samples 
from 15 individuals receiving efavirenz were assayed 
by the cloned enzyme donor immunoassay (CEDIA, 
Microgenics) for the presence of cannabinoids. A control 
group of 20 individuals on non-efavirenz containing 
regimens were also assayed. Confirmatory testing with gas 
chromatography was performed on all positive samples. 
Correlation between plasma efavirenz concentrations 
and drug screen results was also determined. Our analysis 
suggests that patients receiving Efavirenz should expect 
a false positive urinary cannabinoid result when tested by 
the CEDIA method.  Additional confirmatory testing by 
gas chromatography is required to clarify the result. This 
information may be important in some individuals when 
selecting anti-retroviral drugs.
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BASELINE	DATA	FROM	THE	ALTAIR	STUDY:	
A	RANDOMISED,	OPEN-LABEL,	96-
WEEK	STUDY	COMPARING	THE	SAFETY	
AND	EFFICACY	OF	THREE	DIFFERENT	
COMBINATION	ANTIRETROVIRAL	REGIMENS	
AS	INITIAL	THERAPY	FOR	HIV	INFECTION.
Puls, RL1, Arriaga, ME1, Satchell C1, Dazo C1, Haskelberg H1, 
Boesecke C1, Drummond F1, Srasuebkul, P1, Emery S1, for 
the Altair Study Group.
1 National Centre in HIV Epidemiology and Clinical 
Research, Sydney, NSW, Australia. 
ALTAIR is a Phase IIIb/IV, international, randomised, open 
label study comparing three regimens of combination 
antiretroviral therapy (cART) in treatment-naïve, HIV-
infected subjects at 36 sites in 15 countries on five 
continents. Patients were randomised in a 1:1:1 ratio to 
each cART regimen containing a fixed dose formulation 
of tenofovir and emtricitabine (TDF/FTC), with either 
efavirenz (EFV) or ritonavir boosted atazanavir (r/ATV) 
or zidovudine (ZDV) plus abacavir (ABC). The primary 
objective of this study is to compare safety and virological 
efficacy, as measured by the time-weighted mean change 
from baseline plasma HIV-RNA over 96 weeks.
Of 441 patients screened, 87 were ineligible, one died 
before randomisation, eleven were outside the screening 
period and 13 chose not to continue into the study. Of 329 
randomised patients, two were incorrectly randomised. 
Of those correctly randomised, 100 (30.6%) patients were 
from Asia, 74 (22.6%) from Europe/Israel/Canada, 120 
(36.7%) from Latin America and 33 (10.1%) from Australia. 
Among ineligible patients, 20 (4.5%) were ineligible due to 
genotypic resistance, 12 (2.7%) to HLA-B57*01 positivity, 
20 (4.5%) to low creatinine clearance and 22 (5.0%) to 
other laboratory parameters, including six (1.4%) with low 
CD4 count and six (1.4%) with low plasma HIV viral load. 
Patients were predominately male (76.6%), with category 
A HIV infection (72.0%) and infected by homosexual 
(52.0%) or heterosexual (45.9%) sex, respectively. 
At randomisation, mean (SD) CD4+ T cell count was 229 
+ 116 cells/µL and 11.3% of patients had >350 cells/
µL; mean (SD) plasma HIV viral load was 4.7 + 0.7 log10 
copies/mL and 54.4% of patients had > 100,000 copies/
mL. Fasting glucose was 5.0 + 1.0 mmol/L, cholesterol 
was 4.0 + 0.9, HDL was 0.9 + 0.3 and LDL was 2.5 + 0.8 
mmol/L, triglycerides were 1.6 + 1.7 mmol/L. Baseline 
Framingham cardiovascular disease risk was calculated for 
304 patients and the mean score was 3.9 (3.5); 286 (94.1%) 
were at < 10%, 16 (5.3%) were at between 10% and 20% 
and 2 (0.6%) patients were at > 10% risk of cardiovascular 
disease within ten years.
The study continues and the last patient will complete 96 
weeks on therapy in February 2010.
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ASHM	-	PETER	MEESE	MEMORIAL	SESSION	
-	CLINICAL	-	ASSOCIATED	CONDITIONS	
COMPLICATIONS
INCIDENCE	AND	CHARACTERISTICS	OF	
HIV-ASSOCIATED	LYMPHOMA	IN	THE	ERA	
OF	HAART	AT	FOUR	MAJOR	AUSTRALIAN	
TREATMENT	CENTRES
Rotty J1, Clezy K2, Hoy J1,3, van Leeuwen M2, Grulich AE2 
1Infectious Disease Unit, Alfred Hospital, Melbourne, VIC, 
Australia,; 2National Centre in HIV Epidemiology and Clinical 
Research, Darlinghurst, NSW, Australia; 3Department of 
Medicine, Monash University, Melbourne, VIC, Australia
Since the introduction of highly active antiretroviral 
therapy (HAART) a decrease in incidence of AIDS-defining 
malignancies including non-Hodgkin’s lymphoma (NHL) 
has been described. Whether the incidence of Hodgkin’s 
lymphoma (HD) has decreased is unclear. In order to assess 
incidence and characteristics of HIV-associated lymphoma 
(HAL) in Australia we have collected longitudinal data 
since 2003 from four major HIV-treatment centres. 
During this five year period a total of 79 HALs were 
observed. There was no apparent increase in HAL 
diagnoses over time with an average of 13 new cases 
per year (except 25 in 2005). The majority of HALs (n=64, 
84%) was NHL with diffuse large B-cell lymphoma as 
the predominant histological type (n= 38). Extra-nodal 
involvement was common (n=64). The incidence for HD 
was lower than for NHL with a total of 12 cases and no 
increase over time. 
For the majority of NHL-patients (76%) lymphoma was 
the first AIDS-defining illness. The mean CD4-cell count 
at HAL-diagnosis was relatively high with 258 cells/ul. 
The mean nadir was 147 cells/ul. The majority of patients 
(n=51) was ARV treatment-experienced and 42 patients 
(53%) were on HAART at time of HAL-diagnosis. Of patients 
on HAART 24 (57%) had achieved virological suppression 
(< 500 copies/ml). There was no significant difference for 
NHL and HD in viral load (VL) at HAL-diagnosis, CD4 nadir 
and current CD4-cell count. The majority of patients (79%) 
received HAART during chemotherapy. 42% achieved 
complete response. 24% had a partial response. 21% 
experienced progression of disease and 13% had stable 
disease.  Of 79 patients in this 5 year period 17 have died. 
Due to the small number of cases we are limited to 
making general observations only. However, this is 
the first longitudinal cohort that will provide more 
information about the natural history and incidence of 
HAL in Australia. 
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ASHM	-	CLINICAL	-	TOxICITY
	
TRANSIENT	SICK	SINUS	SYNDROME	
RELATED	TO	LOPINAVIR-RITONAVIR	IN	A	
PATIENT	WITH	AIDS
Santosh Chaubey1,  Ashim Sinha1 ,Darren Russell2,3  ,  Henrik 
Falhammar1, ,4
1Department of Medicine, Cairns Base Hospital; 2 Cairns 
Sexual Health Service; 3University of Melbourne; 
4Department of Molecular Medicine and Surgery, 
Karolinska Institute
A 42-year-old northern Thai man who recently migrated 
to Australia developed transient sick sinus syndrome 
soon after institution of treatment with Kaletra (liponavir/
ritonavir) and Kivexa (abacavir/lamivudine) is presented. 
His most recent CD4 count was 390 cells/l, and he was 
taking no other medications, nor any herbal medicines. He 
presented with dizziness to the Emergency Department 
after 3 doses of Kaletra (and 2 of Kivexa). There was no 
history of any cardiac conditions and the only other 
history of note is a positive VDRL test, and Herpes Zoster 
6 months ago. 
On admission he was bradycardic with pulse rate of 42/
minute. His ECG demonstrated sinus arrest with junctional 
escape rhythm which later changed into atrial fibrillation 
followed by sinus bradycardia. Three days after stopping 
his medications he reverted to normal sinus rhythm. To 
our knowledge only 4 similar cases have been described 
in the literature, and 3 occurred in Japanese individuals. 
All of these cases were associated with the introduction 
of lopinavir/ritonavir. In contrast to our patient, however, 
all of the previously described cases were on various 
other medications apart from antiretrovirals, and the 
mechanism of cardiac conduction defects with these 
agents has not yet been elucidated. 
Our case occurred in a man who is HLAB57-negative, and 
it is proposed that lopinavir/ritonavir is the cause of this 
mans sinus arrhythmia.
Even though the numbers of affected individuals are 
small, 3 out of 4 individuals were of Asian origin which 
raises the question about genetic propensity to this 
particular manifestation of this particular combination of 
antiretroviral (liponavir/ritonavir). 
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HIV-TB	CO-INFECTION:	A	SOUTH	
AUSTRALIAN	ExPERIENCE
Sehu MM1, Stapledon R2, Shaw D3
1Mater Misericordiae Health Services Brisbane, South 
Brisbane, Queensland, Australia; 2South Australia 
Tuberculosis Service, Adelaide, South Australia, Australia; 
3Royal Adelaide Hospital, Adelaide, South Australia, 
Australia.
Tuberculosis (TB) is the most common opportunistic 
infection in Human Immunodeficiency Virus (HIV) / 
Acquired Immunodeficiency Syndrome (AIDS).  The 
accessibility of global travel, increasing migration as 
well as displacement of communities due to conflict, 
war and famine has led to increased human movement 
throughout the world.  
TB incidence had been falling in developed countries 
until recently.  However, with the rise of HIV infection, 
TB has become a diagnostic and management issue for 
clinicians worldwide.  We present three recent cases of 
HIV-TB co-infection which highlight practice points in this 
setting.
The diagnosis of TB was made after the diagnosis of HIV 
in all three of the cases.  The possible place of acquisition 
differed in all three patients.  Two had typical radiological 
findings consistent with TB.  One was treated for TB prior to 
HIV whilst the remaining had HIV treatment commenced 
prior to TB treatment.  All three had similar triple therapy 
for HIV.  Two had confirmed Mycobacterium tuberculosis 
on culture with one showing partial resistance to 
isoniazid.  All three were commenced on standard 
quadruple therapy; moxifloxacin and streptomycin was 
added until microbiological confirmation for the third. 
Intravenous therapy was needed in one patient due to 
drug malabsroption.  Treatment was halted temporarily in 
two due to adverse drug reaction and for complications 
arising from HIV/TB.  Directly Observed Therapy was 
utilized in two patients to ensure adherence to therapy. 
The duration of therapy ranged from six months to two 
years.  
The HIV/AIDS pandemic is threatening to destabilize 
control of TB, especially in areas of the world lacking 
the resources to combat the burgeoning numbers of 
HIV-TB co-infected individuals.  Despite the relatively 
low numbers of individuals co-infected with TB and HIV, 
Australia is not immune to the effects of this growing 
world trend  The complexities associated with treatment 
of HIV-TB co-infection should not prevent appropriate 
and adequate treatment.
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SEqUENTIAL	TRANSMISSION	OF	3-CLASS	
DRUG-RESISTANT	HIV	
Tong WWy1, McAllister J2, White PA3, Kelleher AD2, 
Carr A2
1Department of Clinical Immunology, Royal Prince Alfred 
Hospital, Sydney, NSW, Australia; 2HIV, Immunology 
and Infectious Diseases Unit, St Vincent’s Hospital, 
Sydney, NSW, Australia; 3School of Biotechnology and 
Biomolecular Sciences, University of New South Wales, 
Sydney, NSW, Australia.
Patient A presented in February 2007 requesting non-
occupational post-exposure prophylaxis (nPEP) for human 
immunodeficiency virus (HIV).  HIV testing confirmed 
previously unknown established HIV-1 infection. A 
negative HIV test was documented in October 2005.  On 
history he may have experienced seroconversion illness 
during winter of 2006.  Baseline HIV genotype testing 
showed resistance to nucleoside reverse transcriptase 
inhibitors (NRTIs), non-NRTIs and protease inhibitors.  The 
resistance associated reverse transcriptase mutations 
detected were A98G, K103N, V108I and T215C.  The major 
and minor resistance associated protease mutations 
detected were L10V, M46I, I54V, Q58E, A71V, L76V, V82F 
and L90M.  Subsequent contact tracing identified a 
possible source patient (patient B) who was highly 
treatment experienced with multi-drug resistant HIV 
on antiretroviral therapy.  Phylogenetic comparison of 
the two patients’ HIV reverse transcriptase and protease 
sequences confirmed a high (100%) probability of 
transmission from patient B to patient A.  Patient A was 
counselled about the need for protected sex and relevant 
disclosure of his serostatus. A third HIV-infected patient 
(patient C) was identified in 2008 with a highly similar, if 
not identical, antiretroviral resistance pattern to that of 
patients A and B.  Patient C had serology consistent with 
recent HIV seroconversion. Patient A may be a more likely 
source of HIV transmission to patient C, as the plasma viral 
load of patient B has been nearly undetectable (but not 
completely so) since starting a new antiretroviral regimen 
in 2007.
We postulate that a multi-drug resistant strain of HIV-1 
has been sequentially transmitted to two patients.
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PREVALENCE	OF	INTEGRASE	INHIBITOR	
RESISTANCE	MUTATIONS	IN	TREATMENT	
NAÏVE	AND	TREATMENT	ExPERIENCED	HIV	
INFECTED	PATIENTS.
Van Hal SJ¹, Deris Z¹,Chew CB¹, Wang B2, Shaw CO¹, Saksena 
NK2, Dwyer DE¹.
¹Centre for Infectious Diseases and Micbrobiology (ICPMR) 
Westmead Hospital, NSW, Australia; 2Centre for Virus 
Research, Westmead Millennium Institute, Westmead, 
NSW, Australia
In two Phase III trials (BENCHMARK-1 & 2), raltegravir (RAL), 
an HIV-1 integrase inhibitor (INI), was documented to be 
effective in treating patients with triple-class resistant 
virus. RAL failure was associated with INI resistant virus 
secondary to 3 distinct resistance pathways:
N155H; Q148H and y143K each accompanied by 
secondary resistance mutations.
RAL will be available in Australia in June 2008 for use 
in treatment experienced patients. However, baseline 
resistance remains largely unknown.
Methods: Following extraction of HIV RNA from the 
patient’s plasma a one step RT-PCR (primers bpol2: 5’-
AGCTTTCCCGAAATATACATATGGT-3’ & Pol 1937
5’-AGAAGTAAACATAGTAACAGACTCAC-3’) followed by a 
2nd round nested PCR was performed (primers: Pol-6: 5’-
ATGGTGTTTTACTAAACTTTTCCATG -3’ & Pol 1976:
5’-AATCATTCAAGCACAACCA-3’). Following purification, 
the amplicons were sequenced (Applied Bioscience 
Systems®).
Results: Of the 104 INI naïve isolates, 88% (n=91) were 
clade B. The non-B
(n=13) isolates included 4 clade A; 4 clade C; 3 clade G 
and one each of CRF02-AG and CRF01-AE. 51% (n=53) of 
the isolates were from treatment experienced patients 
with triple and double class resistant virus.
Compared to the IN clade B consensus sequence, 
polymorphisms were observed in 43% (122/288) of all 
amino acid positions. V30I; F100y; L101I; T113V; K136Q; 
V201I; T206S; T125A/V; and S283G were significantly 
more likely to occur in non-B HIV clades. The presence 
of V72I was significantly associated with RT and PI drug 
resistant virus whilst L101I and A265V were significantly 
associated with viruses from treatment naïve virus. 
Previous antiretroviral therapy was significantly (p<0.01) 
associated with greater genetic variability (mean 4.6%) on 
distance matrix studies of integrase
(IN) gene (for clade B only) compared to ARV naïve isolates 
(mean 3.8%).
No primary mutations were documented in any samples. 
Secondary RAL associated mutations were observed in 
9% (n=11) of samples, with G140S (n=2); L74I (n=5) and 
I203M (n=4) detected.
Conclusion: Failure of previous antiretroviral therapy 
selects for IN gene polymorphisms; some of which may 
be secondary INI resistance mutations. No primary RAL 
mutations were detected; secondary RAL mutations were 
observed in 9% of HIV-1 isolates. It would be reasonable 
that all patients have INI resistance genotyping prior to 
the commencement of RAL P
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BASELINE	RESISTANCE	TO	ETRAVIRINE	(TMC	
125)	IN	ANTIRETROVIRAL	ExPERIENCED	AND	
NAÏVE	HIV	INFECTED	PATIENTS.	
Chew CB1, van Hal SJ1,  Shaw CO1, Wang B2,  Lau K2,  Deris 
Z3,  Saksena NK2,  Dwyer DE1
1Centre for Infectious Diseases and Microbiology Laboratory 
Services, ICPMR, Westmead Hospital, Westmead, NSW 
2145, Australia; 2Retroviral Genetics Laboratory, Centre for 
Virus Research, Westmead Millennium Institute, University 
of Sydney, Westmead, NSW 2145, Australia; 3Department 
of Medical Microbiology, Faculty of Medicine, University 
of Science Malaysia, Kota Baru, Kelantan, Malaysia.
The first generation of NNRTIs (nevirapine, efavirenz) can 
rapidly select resistant HIV, with extensive cross-resistance 
within the class. Significant NNRTIs resistance can be 
mediated  by a single mutation. Etravirine (TMC125), is 
a second generation NNRTI that is active against HIV-1 
resistant to the first generation NNRTI, including viruses 
with the K103N RT mutations. TMC125 resistance may 
occur with the accumulation of the NNRTI mutations; 
V90L, L100I, V106I/A, y181C/I/V, A98G, K101E/P, V179D/
F and G190A/S, with three or more of these mutations 
required for full resistance.  
Aim: To evaluate the potential role of etravirine in 
antiretroviral experienced HIV infected patients who may 
have K103N or other NNRTI mutations.
Methods
ARV resistance genotyping were performed on HIV-1 
protease and RT regions from 730 HIV-1 infected patients: 
74% (543/730) were ARV-experienced. Following RNA 
extraction from plasma, RT (750 base pairs) and protease 
(300bp) were amplified by nested PCR using gene-specific 
primers, and sequenced. Interpretations of sequence for 
primary and secondary RT and protease mutations were 
directly adopted from the Stanford University HIV Drug 
Resistance database. 
Results
Of the 543 ARV-experienced patients 22% (117/543) had 
the K103N mutation. Etravirine associated mutations were 
detected in 40% (47/117) of these patients. However, only 
4 (0.9%) patients had ≥ 3 associated mutations (V106A, 
V179D and G190A), 18 (15.4%) had 2   and 28 samples had 
a single mutation. 
In ARV-naive patients (n=187), 10% had first generation 
NNRTI resistant virus with K103N as the most prevalent 
mutation (74%; 17 of 23). One patient (0.5%) had 3 
associated mutations; 5 (3%) had 2 mutations and 13 (7%) 
patients had a single associated mutation. 
Conclusions
In ARV experienced and naive patients, etravirine efficacy 
would be compromised in 0.9% (n=4) and 0.5% (n=1) 
patients respectively. Care must be taken, with the use of 
the first generation NNRTIs as the accumulation of 3 or 
more mutations may limit TMC125 efficacy. 
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THE	ACCEPTABILITY	OF	A	WEB-BASED	
ELECTRONIC	CASE	REPORT	FORM	(ECRF)	
FOR	USE	IN	CLINICAL	TRIALS.
Vulcao JAV, Courtney-Vega K, Humphries A, Jacoby S, 
Haskelberg H on behalf of the STEAL Study Group
National Centre in HIV Epidemiology and Clinical Research 
(NCHECR), UNSW, Darlinghurst NSW, Australia.
The electronic Case Report Form (eCRF) is a web-based, 
interactive data collection tool that has recently been 
introduced into clinical trials conducted by NCHECR. The 
aim of this paper is to examine the acceptability of this 
new system by the site coordinator, and if the acceptability 
has changed over 2 years.
The STEAL study was the first NCHECR trial to use eCRF. The 
Inform eCRF was launched in 2006 at which time the first 
acceptability survey was sent to all coordinators (n=34). In 
2008 the same survey was sent again to all coordinators. 
In 2008 20/29 (69%) responded, 13 of whom completed 
the survey in 2006.
Overall, in 2008 there were significantly more coordinators 
that prefer eCRF to paper CRF (from 53% in 2006 to 85% in 
2008). For those coordinators (n=13) that completed both 
surveys their preference for eCRF increased from 54% to 
69% over the 2 years of the study. Overall preference for 
the Inform product for future studies was 75% in 2008, 
compared to 68% in 2006. Satisfaction with the eCRF 
features, functionality, quality, reliability and ease of use 
improved from approx 74% to 96% over the two years. 
Overall comments included user-friendliness, faster 
and cleaner data collection, quick query management 
processing and better on environment. 
Overwhelmingly study coordinators preferred entering 
clinical trial data into internet-based eCRFs as compared 
to paper-based forms. The poor overall response rate 
of 69% may have skewed the results. Although this 
was the first time NCHECR utilised an eCRF, there was 
overwhelming positive support for it’s continued use. 
For NCHECR the advantages include real-time access to 
data, more efficient study monitoring and elimination of 
storing paper-based CRF. 
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HIV/AIDS	PREVENTION	IN	PAKISTAN:	
DYNAMICS	OF	CONDOM	USE	AMONG	MEN	
HAVING	SEx	WITH	MEN
Akhtar MM, Punjab AIDS Control Programme, Lahore, 
Pakistan.
HIV/AIDS is at an early stage in Pakistan and patterns of 
risk behaviors facilitating rapid spread of infection are 
widespread. Majority of clients buying sex commercially 
do not use condom. Condom promotion among men 
having sex with men was a major component in service 
delivery package under World Bank funded Enhanced 
HIV/AIDS Control Programme, implemented with men 
having sex with men in Lahore, Pakistan. Out reach 
workers visited the targeted population at Gurus’ houses 
where clients were provided with information about HIV/
AIDS, motivated to have safe sex and offered condoms. 
Selected information on condom use was collected from 
500 clients. Majority of clients were unmarried and were 
carrying condoms at the time of interview. Clients on 
average had anal sex at least once a day. Condom use 
rate was lower among married clients than unmarried. 
Condom use rate declined with increase in age. Major 
reasons for non-use of condom were decrease in sexual 
gratification and non-affordability. In future, follow-up 
visits to targeted clients would be increased and condoms 
would be provided to non-affording clients.
P146
EMPOWERING	WOMEN	GROUP	FOR	HIV	
PREVENTION
Aryal, K
Nepal Red Cross Society
Due to the little access to information Women in 
communities are really out from different health facilities 
and are found more vulnerable than males to HIV/AIDS 
due to social and physiological reasons. So, Nepal Red 
Cross Society (NRCS) started HIV prevention intervention 
for women since 2002 aiming to reduce HIV transmission 
rate by enhancing knowledge and skills among women 
and to empower women through active participation 
as a result they can take responsible decision regarding 
Reproductive Health (RH), HIV/AIDS, STIs. 
Women from low economical background marginalized 
groups and excluded from the society, have no other 
access of information regarding HIV and AIDS, who practice 
relatively high risk behaviors are selected after orientation. 
Selected women of aged 16-39 years are trained on 
HIV/AIDS, RH, STIs and leadership skills and mobilized to 
disseminate information in communities through peer to 
peer sharing, organizing home visits, orientation sessions, 
competition during different festivals and performance 
of street drama. One of the major responsibilities of the 
trained women groups is to organize a monthly meeting 
aiming to enhance knowledge and skill regarding RH, 
HIV/AIDS and STIs.These meetings are designed as the 
input sessions so as to empower the women group 
.They have to submit report containing activities carried 
out, lesson learned, the impact of the programme and 
feedback for the improvement. They collect address of 
migrated people and send letter containing information 
on HIV/AIDS. 
Although it has been not a long time, NRCS addressed 
women group on its HIV prevention programme but 
it has able to achieve successful result. The number of 
women visiting health facilities for STIs treatment has 
been increased; they are empowered to take a responsible 
decision after project implementation in communities. 
1460 women Peer Educators are developed. Increased 
demand of condom indicates that service seeking 
behavior among women has improved. They can talk 
openly about HIV/AIDS, STI and RH.
Empowerment of women is essential to reduce the 
risks of HIV/AIDS and STI. Similarly, activities have to be 
designed focused on problems like, illiteracy and lack 
of employment opportunities which are contributing 
factors to weaken women status in the community and 
should cover the women from high risk group.
COMMUNITY	PROGRAM
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PEER	EDUCATORS	CONFERENCE;	TO	
CONSOLIDATE	LEARNING	&	ExPERIENCES	
WORKING	AS	A	PEER	EDUCATOR
Aryal, K 
Nepal Red Cross Society             
With the motto “I serve” Junior/youth Red Cross (J/
yRC) was established in 1965. Nepal Red Cross Society 
through J/yRC from 1994 has been implementing HIV/
AIDS Prevention and Reproductive Health Program. 
Annually 2297 Peer Educators (PEs) are developed. They 
are instrumental to disseminate knowledge and skill 
around HIV/AIDS amongst peer. Packing into account 
the need to recognize their contribution to the program 
Peer Conference was held with the objectives; to bring 
the scattered PEs in one place in order to share their 
experiences, lesson learned and obstacles of the program 
period, to update their leadership skill and knowledge, to 
develop independently problem solving skill. 
Altogether 49 participants from different regions 
i.e. terai, mid-hill, far and mid eastern and western 
areas representing 13 districts of Nepal participated 
in the conference. Gender balance was ensured in 
the participation, the number of female participants 
was equivalent so as to male. Participatory learning 
methods like group discussions, question answers, 
situation discussions, practical work, were applied. Media 
presentation and models were used to make the sessions 
more effective and educative. The participants made 
presentation highlighting prominent issues around 
youth PEs.  Altogether 33 abstracts were prepared by 
the youths with the back up support of teacher sponsor. 
Teacher Sponsors participated in the conference for the 
encouragement of the PEs. To update knowledge of the 
participants, input sessions were organized.
The conference concluded with adopting Deceleration. 
The deceleration reads:
Realizing HIV/AIDS 
• a global and local concern
• has a large-scale social, economic and health impacts
•  the young people are the most sufferers 
Participants  express commitments to; act actively to 
raise awareness among youth and community at large, 
support youth for positive behavioral changes ,engage in 
the care and support to positive people and  creating an 
enabling environment to them, advocacy for increased 
access to age-specific appropriate knowledge .
"This program has helped me in developing my skills, 
now I am confident that I can express my self even in the 
large gathering". Santi Tamang
Peer conference is essential to share experience, lesson 
learned, obstacles of PEs, which automatically help to 
reduce risk and burden of HIV/AIDS and STIs.
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EVALUATION	OF	A	HEALTH	PROMOTION	
SHORT	COURSE	FOR	THE	HIV	
COMMUNITY	SECTOR
Brown G1, Donohoe, S2
1Western Australian Centre for Health Promotion 
Research, Curtin University Perth, Australia
2Australian Federation of AIDS Organisations, Sydney, 
Australia
The Australian Federation of AIDS Organisations and the 
WA Centre for Health Promotion Research collaborated 
in conducting a 3-day short course in Health Promotion 
for those working within the HIV community sector. The 
course was designed for people in the HIV community 
sector with an emphasis on AIDS Councils, People Living 
with HIV/AIDS Organisations, Sex Worker Organisations, 
and other partner organisations.
After the trial of a two day condensed course with 
Education Managers from the state AIDS Councils, a 
broader 3 day course was developed to be conducted in 
Melbourne, Sydney, Brisbane, Adelaide, Darwin and Perth. 
Driven by the results of an online survey, the course took 
a very hands-on and pragmatic approach.
The course aimed to develop or improve skills in health 
promotion planning; community participation; achieving 
the right strategy mix; and effective evaluation within 
an HIV community response context. It was assumed 
that there was a range of experience and skills in health 
promotion amongst the participants of the workshop. 
Over 100 participants have completed the course to 
date. 
A key aspect of the course was the understanding and 
application of behaviour and social theories to planning 
and evaluating strategies for the individual, group, 
community and population level. 
Impact evaluation of the course consisted of pre-course 
online survey and post course survey with an emphasis 
on self efficacy in applying key content areas, and then 
a follow-up survey of participants two to three months 
later to determine application of the knowledge, skills 
and momentum created by the course. 
Initial results show: increases in self efficacy regarding the 
use of theory to support looking at a health issue and PO
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potential responses from different angles or perspectives 
and guiding strategy development; more confidence in 
applying evaluation approaches that are practice- and 
theory-driven; and benefits from the opportunity to 
participate in a planning and decision making process 
with a real scenario with colleagues working in a similar 
area. Full results of the follow up survey will be available at 
the time of presentation.
P149
GETTING THE BEST HIV CARE
THE CHECkLIST GUIDE: A UNIQUE 
RESOURCE FOR PEOPLE WITH HIV
Canavan P, Ogier A, Whittaker B
National Association of People Living With HIV/AIDS 
(NAPWA), Sydney, NSW, Australia
HIV treatment and care have changed a lot over recent 
years. The development of better treatments have meant 
that more Australians with HIV can expect to live longer 
and enjoy better health. Knowledge about HIV clinical 
management has also increased, and today the focus is 
on keeping people with HIV well over the long term.
Health and wellbeing requires careful planning, as HIV 
and its treatment often complicates general health 
management. The experience of living with HIV is different 
for each HIV positive person. For people newly diagnosed 
with HIV, adjusting to being HIV positive can be a stressful 
time. Some people find that HIV has a serious impact on 
their health and well being. Many other people enjoy 
long periods of good health and live full and active lives.
Making decisions about health and HIV treatment 
options can be challenging, but NAPWA believes that 
people should be supported in taking an active role in 
their health decision making. If people with HIV better 
understand their own treatment and care choices 
then they can actively participate in their healthcare 
management with their doctors, and this can lead to 
better health outcomes.
In May 2008 NAPWA launched Treataware – a national 
health and treatment campaign for HIV positive 
Australians. One arm of the campaign is a printed resource 
called “Getting the best HIV care: a checklist guide for 
people with HIV.”
The guide gives people with HIV a checklist of issues 
they can work through with their doctor when planning 
their health and treatment. The booklet lists main tests 
and health checks they should expect to receive as part 
of comprehensive health care as well as support and 
information services to access for living long-term with 
HIV.
An outline of the development process of this important 
resource is presented, acknowledging the collaboration 
with HIV positive contributors and a number of HIV 
clinicians. A final discussion point will be next steps in 
ongoing evaluation of this interactive resource for use by 
patients with their doctors in the clinic setting.
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INTEGRATED	COMMUNITY	HIV/AIDS	
PREVENTION	PROGRAM
Chola BM
OBJECTIVE(S):
• Increased access to reproductive health services
• Increased access to HIV/AIDS and STI diagnostic and 
treatment services
• To empower community with life coping skills
METHODOLOGy
The Peer Education strategy is employed where young 
people aged between 13 and 18 are trained as Peer 
Educators and reach out to fellow young people in 
the community through one on one basis, group 
discussions, drama performances, sports and drop-in-
shops that include barber shops, hair saloons, roadside 
stalls, bars and markets. Through these activities, people 
in the community have access to reproductive health 
information, condoms, HIV/AIDS/STI diagnostic and 
treatment services through the Community Health 
Clinic and training in life coping skills that include critical 
thinking, analytical skills, problem solving, negotiation 
skills, assertiveness and decision making skills among 
others.
SUMMARy OF RESULTS
• Well informed community
• Increased number of young people seeking Voluntary 
Counseling and Testing for HIV
• Reduced incidences of STIs and unplanned for 
pregnancies
• Reduced stigma and discrimination of PLWHAs
• Improved access to ART
CONCLUSION
Integration of Community HIV/AIDS initiatives ensures 
increased access to services, a continuum of services and 
a sound base for program sustainability beyond donor 
support.
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POPULAR	APPROACHES	TO	MANAGING	
HEPATITIS	C	INFECTION	AMONG	
INDOCHINESE	INJECTING	DRUG	USERS:	“IT’S	
ALL	UP	TO	YOU”
Coupland H1, Day C2, Maher L1.
1 National Centre in HIV Epidemiology and Clinical 
Research and the School of  Public Health and Community 
Medicine, University of New South Wales, Sydney, NSW, 
Australia; 2 Drug Health Services, Faculty of Medicine, 
University of Sydney, NSW, Australia
Popular perceptions of the management of hepatitis 
C (HCV) can provide important insights into decision-
making about seeking HCV treatment. Little is known 
about these approaches among culturally and 
linguistically diverse groups. This ethnographic study 
explores these approaches among Indochinese injecting 
drug users (IDUs).
Ethnographic fieldwork and in-depth interviews were 
conducted with Cambodian, Lao and Vietnamese IDUs 
(n=72), to identify explanatory models of hepatitis C 
(HCV) prevention and management and their influence 
on health-seeking behaviours. Participants were recruited 
using theoretical and snowball sampling based on peer 
and street networks.  A grounded theory approach was 
used to identify emergent themes. 
Popular approaches focussed on maintaining body 
“strength” to “fight” HCV. This was achieved by “looking 
after yourself” by eating a “healthy” diet, adequate 
exercise and sleep and avoidance of drug and alcohol 
use. For Vietnamese participants this also involved the 
consumption of “cooling” foods or drinks, consisting of 
fruits, vegetables or herbs, to restore humoral balance and 
avoid becoming “weak”. The origins of these approaches 
will be explored.
These approaches could “maintain” or “stabilize” HCV 
and prevent disease progression. However, while most 
participants subscribed to these beliefs, applying them 
in practice was described as difficult for IDUs and they 
were rarely adopted. Awareness of potential outcomes 
of HCV treatment, particularly that treatment could clear 
the virus, was also limited. Participants expressed anxiety 
about how “bad” their HCV had become and reported 
being “scared” to undergo further monitoring, such as 
liver function testing.
Data indicate the importance of promoting the need 
for regular monitoring of liver function and disease 
progression among this group, as well as potential HCV 
treatment outcomes. Inclusion of information in post-
test counselling and peer education activities, regarding 
the role of diet, drug use and lifestyle in HCV disease 
progression is also necessary to encourage testing and 
treatment seeking. 
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TB	CO-INFECTION:	WHY	DO	INDONESIAN	
PLHIV	STILL	DIE?
Green C1
1Spiritia Foundation, Jakarta
TB is curable and preventable; yet TB remains the prime 
cause of mortality for people living with HIV (PLHIV) in 
the developing world. To respond to this in Indonesia, 
the Spiritia Foundation (the national peer support for 
PLHIV) has implemented a number of interventions: 
informing PLHIV about TB-HIV co-infection; treatment 
education; promoting infection control in peer group 
and counselling settings; raising awareness of healthcare 
workers; advocating for implementation of preventive 
therapy;  pressing for surveillance, including of MDR-
TB; encouraging integration of HIV and TB services; and 
supporting efforts by partner organizations working in 
related fields.
As a result, PLHIV are more aware of their vulnerability. 
There have been advances in the healthcare sector, 
particularly with an increasing number of primary 
healthcare centres implementing one-stop shops that 
provide TB and antiretroviral therapies.
Major challenges continue to exist, particularly in 
encouraging doctors in the private sector to adhere to 
the International Standards of TB Care, and raising the 
level of suspicion about possible HIV co-infection in cases 
of TB. Diagnosing TB among PLHIV is still delayed, with the 
result that antiretroviral therapy is started late. In addition, 
infection control in many hospitals and clinics is lacking.
In Papua, which is experiencing a generalized HIV 
epidemic together with high rates of TB, the spitting 
which accompanies the widespread habit chewing of 
betel nut, even in hospitals, clearly raises the risk of active 
TB, and a long-term campaign will be needed to address 
this.
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ARE	HOSPITALS	BIOHAzARDS	FOR	PEOPLE	
WITH	HIV?
Lake, R, 
Positive Life NSW
Preventable admissions and avoidable mortality are two 
key features of the health systems advocacy agenda 
proposed by Positive Life NSW for the period 2008-
2010.  A renewed Federal Government focus on health 
prevention presents an opportunity to consider more 
active prevention, screening and early intervention 
approaches to prevent hospital admissions. 
In addition to adverse events experienced generally by 
hospital inpatients, patients with HIV face an increased 
likelihood of privacy breaches, disclosure of HIV status 
and in some cases, discrimination from other patients, 
their visitors or allied health care staff when this occurs. 
This presentation will detail some of these events using 
case studies. There is growing awareness of screening 
and other prevention strategies to consider the benefits, 
particularly psycho social, to people with HIV of more 
active and earlier health interventions to prevent hospital 
admission or consider the use of innovative outpatient 
options more frequently used with older people.
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LIVING LONG TERM WITH HIV IN THE RAINBOW 
REGION  
Lienert TM1, Starkey RJ2, McKellar-Stewart NP3, Scott-Visser 
B4,,Santana H5 
123 ACON Northern Rivers, Lismore NSW, Australia; 4 SHAIDS 
sexual health clinic, North Coast Area Health Service, 
Lismore, NSW, Australia; 5 Positive Life NSW.
The Northern Rivers, including the Rainbow Region 
of NSW, hosts a large number of people with HIV who 
moved to the area from Sydney in the critical early days 
of the epidemic, facing limited life expectancy. While their 
goal was to experience a more relaxed quality of life, many 
faced new problems inherent to rural communities such 
as the need to travel long distances and a lack of transport, 
limited access to specialised medical practitioners, 
employment and housing, and limited social networks.
 
The advent of HAART brought unexpected challenges 
to this group of people who, now ageing, had to swiftly 
adapt to potentially long-term rural lifestyles. 
 
In this paper we will explore the role that ACON’s Client 
Services and HIV Health Maintenance staff, along with 
the NCAHS HIV/AIDS Enhanced Primary Care (EPC) Co-
ordinator, other partner agencies and local positive 
people have played in addressing the complex needs of 
people living long term with HIV in the region.
P155
ENHANCED	PRIMARY	CARE	(EPC)	AND	
CARE	CO-ORDINATION	AS	A	CO-OPERATIVE	
MODEL
Scott-Visser BR 1, Starkey R 2, Lienert T
SHAIDS, Lismore, NSW, Australia
 ACON, Lismore, NSW, Australia
The terms empowerment and self determination can 
become clichéd. Case management means many things 
to many people. How can these values and perspectives 
effectively be implemented to produce positive outcomes 
for positive people, especially those with complex needs 
living in a rural setting? 
In this presentation, we discuss our unique roles, the theory 
behind our work (differentiating case management and 
care co-ordination), why we use these models and how 
we have developed an effective partnership model.
The two presenters work in differing services in differing 
roles, however they have developed a partnership 
approach to initiate productive outcomes for positive 
people, especially those with complex needs living in 
rural Australia.
1  SHAIDS, Lismore, NSW, Australia
2  ACON, Lismore, NSW, Australia
The terms empowerment and self determination can 
become clichéd. Case management means many things 
to many people. How can these values and perspectives 
effectively be implemented to produce positive outcomes 
for positive people, especially those with complex needs 
living in a rural setting? 
In this presentation, we discuss our unique roles, the theory 
behind our work (differentiating case management and 
care co-ordination), why we use these models and how 
we have developed an effective partnership model.
The two presenters work in differing services in differing 
roles, however they have developed a partnership 
approach to initiate productive outcomes for positive 
people, especially those with complex needs living in 
rural Australia.
PO
ST
ER
	A
BS
TR
A
C
TS
	
CO
M
M
U
N
IT
Y	
PR
O
G
RA
M
17-20 SepteMber 2008 @ pertH ConVentIon Centre, WeStern AuStrAlIA                           241
P156
MULITDISCIPLINARY	HIV	COMMUNITY	
HEALTH	TEAM	USES	AN	AREA-WIDE	
APPROACH	TO	PROVIDE	EFFECTIVE	
REFERRAL	AND	CARE	
COORDINATION	SERVICES	IN	SOUTH	
EASTERN	SYDNEY	ILLAWARRA	AREA	HEALTH	
SERVICE	
Murray KJ1 
1HIV Community Team, South Eastern Sydney Illawarra 
Area Health Service (SESIAHS), Sydney Australia
SESIAHS covers a large geographical area including 
Sydney’s Central Business District (CBD), East and Southern 
suburbs, the Illawarra and South. Traditionally HIV funded 
community health services have been concentrated in 
the inner-east, with little or no service provision outside 
this area. A new multidisciplinary Community Health 
Team was established in November 2007 to provide 
outreach services across SESIAHS..  The team comprises 
nurses, social workers and a dietitian.  Members of the 
team have specialist experience in mental health, alcohol 
and other drugs, HIV and primary care 
People living with HIV/AIDS (PLWHA) may experience a 
range of acute or chronic health problems and require 
a number of different services to manage their needs. 
Challenges for service providers can include issues with 
medications, mental health, physical health, nutrition, 
housing, finances and alcohol and other drugs. The 
HIV Community Team provides advocacy and support 
around these issues and works in partnership with other 
health programs and agencies. 
The service’s goals are to provide a strong consumer-
focused model of care, strengthen partnerships with 
other health services and agencies and avoid duplication 
by providing services that compliment those of existing 
service providers.   A key focus is providing more equitable 
and integrated service delivery across the SISIAHS.
Partnership arrangements to date include dietetic support 
to Pt Kembla Sexual Health Clinic, care coordination 
services through ACON, effective referral pathways 
with mental health services and support to HIV/AOD 
Integrated Service Model for Homeless People.
P157
ANY	qUESTIONS...WHAT	DOES	MY	PATIENT	
REALLY	WANT	TO
KNOW?
Perri, V
People Living With HIV/AIDS Victoria
Melbourne, Victoria, Australia
As part of People Living With HIV/AIDS Victoria’s Health 
Promotion work and through one of it’s courses/
workshops, participants are given the opportunity to 
explore the many questions they can think of when 
choosing a suitable General Practitioner with whom they 
feel not only meets their medical needs but someone 
they can talk to and trust without feeling embarrassed or 
fearful when discussing intimate details.
In this conference workshop aimed at General Practitioners, 
Nurses and other Health Professionals working with HIV 
positive people, we will conduct this activity in order for 
the participants to gain a sense of what their clients are 
thinking and wanting out of their session.  
P158
POWER	OF	POSITIVE	DIGITAL	STORY	
TELLING
Jeffrey Robertson
Straight Arrows Inc    
Digital story project and its value in being used as an 
educational tool in relation of infection, transmission and 
prevention and also the power of personal stories to relay 
their struggles around HIV medications and also living 
well with HIV  
                                        
This would be about a half hour presentation and the 20 
minutes for questions and answers
Hopefully to point out relevant issues of people living 
with HIV today
1 Living with HIV in 2008
2 Medication and how they improve people life 
3 Travel and HIV among young people and their journeys
4    Personal perspective of HIV 
Outcomes would hopefully give real life perspective to 
people in the sector about progress made by people 
who have overcome the issues in relation to HIV and how 
this would give abeter insight into people living with HIV 
not dying from aids 
Attached is a pdf of the journeys into the unknown launch 
and I would have permission to use some of these stories 
in our presentation PO
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PROVIDING	ON-LINE	SUPPORT	FOR	
TEACHERS	IN	DELIVERING	SExUALITY	
EDUCATION	IN	WESTERN	AUSTRALIA
McKay E1   , Baker M1 
1Sexual Health and Blood-borne Virus Program, 
Department of Health, Perth, WA, 
Sexual health education is a subject that teachers are 
frequently required to teach often without any prior 
training. Some teachers view the subject as a priority 
while others may feel uncomfortable or insufficiently 
prepared to teach it. 
A priority of the Department of Health’s (DOH) policy and 
programming in public health is to work with the school 
education sector to promote and support the conduct of 
quality sexual health education.  In addition to parents, the 
DOH regards teachers and schools to be a fundamental 
partner in providing sexual health education to student.
Since 2002, The DOH has funded the development and 
implementation of set of resources for teachers called the 
“Growing and Developing Healthy Relationships” (GDHR) 
Curriculum Support Materials, and corresponding in-
person professional development courses for teachers. 
In 2005, an audit of the uptake of the GDHR materials 
found that the materials are having a positive impact on 
school sexual health education. 
An impact evaluation is currently underway to examine 
the influence on teacher and school nurse practise 
from participation in the professional development and 
training. The results will be available by mid-2008. 
The DOH, in partnership with the Department of 
Education and Training are moving towards providing 
on-line support for teachers in order to increase their 
access to up-to-date curriculum resources, training and 
support.
The Project involves two components:
1. Development of an interactive website based on 
updated GDHR content. This will incorporate a range 
of age-appropriate learning activities, links to resources, 
statistics, background information, and an on-line 
question box for teachers. 
2. Development of a corresponding on-line training 
course. This course is designed to increase teachers’ 
confidence, comfort, knowledge and skills using on-
line learning techniques such as asynchronous learning, 
podcasts, video clips, discussion forums, interactive 
games, and professional facilitation. 
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USER-CENTRED	DESIGN	IN	A	RESOURCE	FOR	
POSITIVE	TRAVELLERS
Malhotra S1 and Reeders D1
1PLWHA Victoria Inc, Melbourne, VIC, Australia
As a discipline, User-Centred Design (UCD) responds to 
the challenge of finding intuitive conventions for interface 
design to help users of online and print resources access 
complex information according to their needs. PLWHA 
Victoria adopted this approach during the development 
of Up Up & Away – A Guide for Positive Travellers. Faced 
with “apples vs. oranges” information about entry 
restrictions against HIV-positive travellers, positing a thirty-
day maximum visit allowed the generation of simple 
categories: no restrictions, possible restrictions, known 
restrictions, which are represented using an intuitive 
traffic light metaphor. A dynamic, searchable companion 
website makes full use of hypertext markup conventions 
to highlight information updated after printing, and links 
to source material and further reading.
The project offers a best-practice model for the 
collaborative development of resources to communicate 
complex information, which can be applied in other 
contexts including clinical and pharmacy settings. 
Supported by Roche Products over a period of six years, 
the project grew from a collection of fact sheets into 
print and now online resource formats. Contributing 
organisations include NAPWA, ATPA, ACON, Positive Life 
NSW and PLWHA Victoria, and a network of educators is 
being established to maintain the companion website 
(www.positivetravel.info) and reply to questions received 
from visitors. 
The presentation will introduce the UCD approach, 
discuss its application to the positive travel project and 
argue for its adoption in public health education. 
EDUCATION
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SECONDARY		SCHOOL	NURSES’	AND	THEIR	
WORK	PROVIDING	SCHOOL-BASED	SExUAL	
AND	REPRODUCTIVE	HEALTH	PROGRAMS	IN	
VICTORIAN	SCHOOLS
Towers C
Secondary school nurses provide a broad range of school 
nursing services in public, private and independent 
schools in all Australian states and territories.  However, 
the role of Victorian Department of Human Service (DHS) 
secondary school nurses (SSNs) in providing sexual and 
reproductive health (SRH) education and services to 
students is relatively unclear.  Key focus areas developed 
for SSNs by DHS required SSNs to play a key role in 
reducing negative outcomes and risk taking behaviours 
among students.  Evidence is emerging that SSNs are 
developing a key role in school-based SRH programs. 
Therefore, evidence about SSNs work in sexual health is 
required.
A cross-sectional survey of DHS secondary school nurses 
(N=129) was conducted using self-completed anonymous 
questionnaires.  Seventy four SSNs responded, giving 
a response rate of 57.4%.  Over 90% of respondents 
provided a diverse range of health promoting SRH 
programs ranging from classroom programs, individual 
and small group student consultations, and wider school 
community programs.
Most respondents believed SRH was a major practice area 
of SSNs.  SSN readiness to provide sexual education and 
student consultations regarding sexual health depended 
on their qualifications, nursing experience, participation 
in professional development, networks, and interest 
in sexual health.  Schools, policies, and the Secondary 
School Nursing Program guidelines also affected their 
ability to provide SRH education and care to students.
Significantly, SSNs appear to have been overlooked as a 
key stakeholder in school-based sexual education and 
care of students.  Sexual health is a DHS Victorian health 
promotion priority area for 2007-2012 and SSNs need to 
assert their right as a key SRH stakeholder, and participate 
in key government groups developing strategies and 
frameworks to guide sexual education and care of young 
people.
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MOLECULAR	EPIDEMIOLOGY	OF	
MYCOBACTERIUM	TUBERCULOSIS	IN	
KIRIBATI
Aleksic E1, Cox H1, Ryan C1,4, Globan M3, Reiher B2, Toatu T2, 
O’Connor J5, Crowe S1,4 
1Burnet Institute, Melbourne, Victoria 2Tunguru Hospital, 
Tarawa, Kiribati 3Victorian Infectious Diseases Reference 
Laboratory, Melbourne, Victoria 4Department of Medicine, 
Monash University, Clayton, Victoria, 5Secretariat of the 
Pacific Community, Noumea, New Caledonia
With an incidence of 348 cases/100,000 people, Kiribati 
has the highest TB burden in the Western Pacific region. 
Current data indicate there are 21 diagnosed cases/
month, a figure that has increased substantially over the 
past 5 years, where incidence was 250 cases/100,000 in 
2000.  As HIV testing services are not well established 
and data concerning prevalence are limited, the extent 
of the effect HIV has on the incidence of TB is not fully 
understood.  A high proportion of the population are 
highly mobile fisherman, among whom the prevalence 
of STIs is high and condom use is low, thus providing a 
perfect transmission environment for HIV.
We have designed a study to address the molecular and 
epidemiologic factors associated with the recent increase 
in cases in Kiribati. To date, we have enrolled 48 patients 
with newly diagnosed TB.  Epidemiological data are 
gathered, sputum collected and both sent to Australia for 
culture, DST and identification of MTb (IMVS, Adelaide). 
DNA extracted from the MTb (VIDRL, Melbourne) is sent 
to Burnet Institute for genotype analysis.  Median time 
from specimen collection to receipt in Australia is 29 days 
(8-54).  
Using two genotyping techniques, MIRU-VNTR and 
spoligotyping we have examined the relatedness of 
strains from 30 patients, with an additional 18 in progress. 
Molecular mapping has shown that >40% of strains 
within our participants are of the Beijing genotype. There 
is a high proportion of fishermen, administration workers 
and students with a mean age of 34 (9-68). Approximately 
half the participants are female (44%) and the median 
number of people living per house is 8 (3–16).  Nine (19%) 
patients had a previous instance of TB in their family and 
there were 6 (13%) individuals who reported prior TB. 
Ten patients have been tested for HIV with; 8 (80%) of 
respondents not knowing their result.
The finding of multiple strains of TB suggests that 
there is a diverse TB epidemic occurring in Kiribati, with 
overcrowding and mobility as contributors. The presence 
of the Beijing genotype is of concern as this genotype is 
often associated with multi-drug resistance.  Currently, 
patients with TB are not routinely tested for HIV, and those 
that are do not necessarily return for their results. 
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CLINICAL	FEATURES	ASSOCIATED	WITH	HIV	
INFECTION	IN	CHILDREN	AT	PORT	MORESBY	
GENERAL	HOSPITAL	-	INTERIM	ANALYSIS	
OF	A	PROSPECTIVE	STUDY	TO	ASCERTAIN	
PREDICTORS	OF	HIV	INFECTION
Allison WE1, Kiromat M2, Vince J2, Cunnigham P3,Kaldor J1.
1The National Centre in HIV Epidemiology and Clinical 
Research, Sydney, NSW, Australia; 2Department of 
Paediatrics, Port Moresby General Hospital, Port Moresby, 
Papua New Guinea, 3NSW State Reference Laboratory for 
HIV, St Vincent’s Hospital, Sydney, NSW, Australia;
A number of clinical signs and symptoms are common 
in both children infected with HIV and sick but HIV 
uninfected children, particularly in resource-limited 
settings.  In settings where hospital prevalence of HIV 
infection is high all admitted children may be tested 
for HIV serostatus.  In Papua New Guinea (PNG), where 
prevalence estimates are much lower than Sub-Saharan 
Africa, clinicians are faced with the challenge of which 
children to select for testing based on clinical criteria. 
We randomly recruited children who fitted the inclusion 
criteria of all admitted children aged 0-16 years. Exclusion 
criteria were children who were confirmed HIV serostatus 
positive (HIV+) and ≥ 2 years old, children of any age on 
antiretroviral treatment and refusal of informed consent 
by the primary carer of the child.  Recruited children were 
tested for HIV infection by dry blood spot nucleic acid 
testing and specific information was collected on clinical 
history and physical examination.
Of the first 122 children recruited, 17 were found to be 
HIV+ and 1 had an indeterminate result.  History and 
physical examination were analysed separately and 
subjects with aspects of history or examination missing 
from the data collected were excluded from the relevant 
analysis.  On history, chronic ear infection was found to 
be significantly associated with HIV infection [p: 0.001, OR 
(95% CI): 13.6 (3.1-59.9)].  On examination, oral thrush was 
found to be significantly associated with HIV infection [p: 
0.001, OR (95% CI): 9.2 (2.2-33.2)]
These early results are encouraging as to achievement 
of the objective of the study which is to establish a firm 
evidence base leading to guidelines in the use of clinical 
criteria to select children for testing for suspected HIV 
infection in PNG.
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UNDERSTANDING	THE	EPIDEMIOLOGY	
OF	HEPATITIS	C	IN	VICTORIA:	REVIEW	OF	
CURRENT	SURVEILLANCE	MECHANISMS	
Goller JL1, Lim M12, Horyniak D1, Aitken C1, Stoove M1, 
Samuel King J3; Brown J4, Fairley C5, Higgins N6, Hellard 
ME12  
1Centre for Epidemiology and Population Health Research, 
Burnet Institute, Melbourne, VIC, Australia; 2Department 
of Epidemiology and Preventive Medicine, Monash 
University, Melbourne, VIC, Australia; 3 Access Health, St 
Kilda, VIC, Australia, 4 Healthworks, Footscray, VIC, Australia, 
5Melbourne Sexual Health Centre, Carlton, VIC, Australia; 6 
Department of Human Services, VIC, Australia
In Australia, an estimated 200,000 people are living 
with hepatitis C virus (HCV), 13,000-20,000 individuals 
are diagnosed annually with HCV; injecting drug use 
(IDU) is the main route of transmission. Around three 
quarters of infected individuals progress to chronic 
HCV with long term sequelae for a minority of these 
including liver failure and hepatocellular carcinoma. 
The current Victorian Hepatitis C Strategy identifies 
epidemiological surveillance as a core component of 
the response to the epidemic. The Strategy recommends 
enhanced notification systems that integrate prevalence, 
incidence and disease outcome data in conjunction with 
behavioural data, which focuses on transmission risk in key 
populations. Up until a few years ago three HCV-related 
surveillance systems existed in Victoria; (i) passive HCV 
surveillance, (ii) annual surveillance of HCV and injecting 
risk behaviour through the National NSP survey and (iii) 
the annual Illicit Drug Reporting System (IDRS) which also 
examines injecting behaviour. These systems provide 
useful data but have several limitations, including being 
unable to measure HCV incidence. In recent years, three 
new data collection approaches have provided more 
comprehensive and integrated HCV surveillance data in 
Victoria; (i) targeted enhanced surveillance (established 
2002), involving follow up of diagnoses with clinical or 
laboratory indicators to identify incident HCV infections 
and describe associated demographic and risk factors, (ii) 
a sentinel network of nine primary health care clinics (GPs, 
prisons, sexual health clinics) (established 2005) to monitor 
HCV testing rates, prevalence and incidence among 
people routinely tested for HCV, and (iii) a community-
based longitudinal cohort study of IDUs conducted 
between 2001-2003 and 2005-2007 to provide detailed 
information about injecting risk behaviour, injecting 
networks, HCV subtypes and estimates of HCV incidence 
and prevalence. We will describe epidemiological results, 
running costs and strengths and weaknesses of these 
initiatives. Recommendations will be made for future 
Victorian HCV surveillance and research initiatives.  
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HEPATITIS	B	AND	C	PREVALENCE	AMONG	
PATIENTS	INFECTED	WITH	HUMAN	
IMMUNODEFICIENCY	VIRUS	IN	MOROCCO
Benjelloun S1, Akil A1, Bensghir R2, Wakrim L1, Oulad Lahcen 
A2, Hassar M1, Ezzikouri S1, Himmich H2 
1Viral Hepatitis Laboratory, Institut Pasteur du Maroc, 
Casablanca, Morocco; 2Service of Infectious Diseases, CHU 
Ibn Rochd, Casablanca, Morocco
In HIV-infected persons, an estimated 2–4 million have 
chronic HBV co-infection and 4–5 million have HCV 
co-infection. HBV, HCV and HIV share common routes 
of transmission, but they differ in their prevalence by 
geographic region and the efficiency by which certain 
types of exposures transmit them. The aims of the present 
study were to determine the prevalence of HBV and HCV 
infection among 309 Moroccan HIV infected patients. 
Chronic HBV infection has been found in 2.2%, including 
71.4% of heterosexuals. Two genotypes were found (D2 
and B). HCV infection has been found in 9.4% of HIV-positive 
persons overall; 13.3% of injection drug users, 3.3% of men 
who have sex with men and 56.7% of heterosexuals. Most 
of anti-HCV positive patients were positive for viral RNA 
(67%) and 4 genotypes were detected (1a, 1b, 2c and 3a) 
with predominance of genotype 1. The characteristics of 
HIV infected persons differ according to the co-infecting 
hepatitis virus, their epidemiologic patterns may change 
over time, and surveillance systems are needed to monitor 
their infection patterns in order to ensure that prevention 
measures are targeted appropriately.
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ORAL	POSTER	SATURDAY	20	SEPTEMBER	
0850	–	0855
ASHM	-	ORAL	POSTER	SESSION	-	SOCIAL	
RESEARCH,	INTERNATIONAL,	COMMUNITY,	
INDIGENOUS
HIV	IN	THE	TROPICS:	AN	ANALYSIS	OF	
NEW	HIV	INFECTIONS	IN	FAR	NORTH	
qUEENSLAND	DECEMBER	2006	–	MARCH	
2008
Ms Carla Gorton1, Ms Joanne Leamy1, Dr Darren Russell1. 
1Cairns Sexual Health Service, Cairns, QLD.
In March 2008 a small scale study of all new HIV infections 
managed at Cairns Sexual Health Service (The Dolls 
House) was conducted. A total of 35 clients were newly 
diagnosed as HIV positive at the Dolls House between 
December 1, 2006 and March 31, 2008. Of these 33 
(94%) were male and 2 (6%) were female. The mean age 
of males was 38.8yrs and the mean age of females was 
33.5yrs. 2 (6%) of the clients were Aboriginal and Torres 
Strait Islanders. 
24 (68%) of the clients had same sex partners, 9 (26%) 
had opposite sex partners, 1 (3%) had partners of both 
sexes and in one case (3%) partners were unknown. 9 
(26%) clients had a regular partner who was HIV positive, 
10 (28%) had a regular partner who was HIV negative, 7 
(20%) were unsure of the status of their regular partner 
and 9 (26%) had no regular partner.
6 (18%) of the clients had contracted HIV via heterosexual 
sex in a high prevalence country (5 in PNG and 1 in 
Malaysia). These clients were all male and their mean age 
was 58yrs.
9 (26%) clients were co-infected with an STI at the time of 
their HIV diagnosis, 18 (51%) tested negative for an STI at 
the time of diagnosis and 8 (23%) declined STI testing.
Occupational background, additional risk factors 
(including IDU), PEP awareness and Gay community 
connectedness were also noted and all data will be 
graphed or described on the poster.
The study has implications for education and prevention 
messages and is informing a planned Syphilis Testing 
month in Cairns during June 2008.
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ORAL	POSTER	SATURDAY	20	SEPTEMBER	
0835	–	0840
ASHM	-	ORAL	POSTER	SESSION	-	CLINICAL,	
ALLIED	HEALTH	AND	BASIC	SCIENCE
MODELLING	THE	EMERGENCE	OF	DRUG-
RESISTANT	HIV	IN	BANGKOK
Hoare A, Kerr S, Wilson DP
National Centre in HIV Epidemiology and Clinical 
Research, Faculty of Medicine, University of New South 
Wales, Sydney, Australia 
Thailand has been successful in scaling up access to 
antiretroviral therapy (ART).  However, second-line and 
third-line therapy options are relatively scarce, limiting 
options once a patient experiences treatment failure. 
Continued use of a failed regime may select for drug-
resistant strains of HIV and these resistant strains may 
be transmitted to susceptible individuals. The potential 
emergence of transmitted drug-resistant HIV in Thailand 
is of considerable concern.  
We have investigated ART scale-up plans in Thailand in 
order to predict the degree of acquisition and transmission 
of drug resistant HIV. We also forecasted the impact of 
treatment plans on future HIV incidence. We address 
this issue through the development of a mathematical 
model, calibrated to match the HIV epidemic in Bangkok 
and the planned scale-up of therapy.  The model tracks 
transmission of susceptible individuals through the 
stratification of seven different population groups across 
thirteen different disease stages.  This allows the model 
to track the number of individuals that acquire drug 
resistance through treatment failure, and those who 
become newly infected with drug-resistant virus.  
We show that high levels of treatment over a sustained 
number of years without alternative treatment options, 
has the potential to lead to large rates of transmitted 
resistance. We predict low-to-moderate levels in the short 
term, of ~5% transmitted drug resistance after 5 years, but 
sustained treatment rates could lead to very high levels of 
drug resistance in the longer term (of over 10% within 10 
years).  This work highlights the great need for accessibility 
to second- and third-line antiretroviral therapies and drug 
resistance monitoring in the region.
PO
ST
ER
	A
BS
TR
A
C
TS
	
EP
ID
EM
IO
LO
G
Y
17-20 SepteMber 2008 @ pertH ConVentIon Centre, WeStern AuStrAlIA                           247
P168
ORAL	POSTER	FRIDAY	19	SEPTEMBER	0820	
–	0825
ASHM	-	ORAL	POSTER	SESSION	-	PUBLIC	
HEALTH	AND	EPIDEMIOLOGY
RENEWING	THE	SEROCONVERSION	STUDY	
Jin F1, Bradley J1, Slavin S2, Ellard J3, Grulich A1, Prestage 
G1,2
1National Centre in HIV Epidemiology and Clinical 
Research, UNSW
2Australian Research Centre in Sex Health and Society, La 
Trobe University
3National Centre in HIV Social Research, UNSW
The previous two waves of the Seroconversion Study 
provided crucial information on circumstances that might 
put gay men at higher risk of HIV infection in Australia, and 
helped enormously in framing HIV prevention campaigns. 
The last few years have seen a significant increase in HIV 
notifications in homosexual men in some states and 
changes in the forms of risk behaviour among gay men. 
We have re-developed the Seroconversion Study to 
continue monitoring risk factors for HIV infection.
 
To achieve optimal participation and expand recruitment 
options beyond high-caseload clinics, the study 
now allows enrolment through community-based 
organisations as well as clinics in other settings. Further, 
the reliance on clinic-based interviews has been reduced 
by allowing for participants’ online enrolment and self-
completion of the questionnaire.  
Through to April 2008, 22 participants were recruited 
through this new scheme. The questionnaire was 
administered by interviewers in 16 men, and 6 men 
completed the survey online. The mean age of the 
participants was 35 years, and over 90% were gay/
homosexual self-identified. A quarter (26%) completed 
a tertiary or higher degree and the majority (73%) were 
recruited from Queensland. A high risk event (HRE) 
which they thought had led to their HIV seroconversion 
was identified by 19 (86%), and in 15 (79%) the source 
person was reported as a casual partner. Among these 
casual partners, 10 (67%) were previously known to the 
participants, including 3 whom participants reported 
having sex with before the HRE. Nearly 40% reported 
that they met the source partner through the internet. 
At the HRE, receptive unprotected anal intercourse 
was reported by 15 (79%).  Drug and alcohol use was 
common at the high risk event. Four men (21%) reported 
having more than 5 drinks of alcohol and amyl was the 
most frequently reported recreational drug used (21%), 
followed by crystal/meth (16%). 
The new wave of the seroconversion is up and running. 
Preliminary results have indicated that participants 
recruited under the new scheme are similar to those who 
were recruited from clinics in the previous rounds.
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UNDERTREATMENT	OF	PAIN	IN	HIV-POSITIVE	
SOUTH	AFRICANS
Mphahlele NR, Mitchell D, Kamerman PR
Brain Function Research Group, School of Physiology, 
University of the Witwatersrand, Johannesburg, South 
Africa 
Pain is a common complication of HIV infection and its 
treatment. However, most studies investigating HIV-
related pain and its treatment have taken place in first-
world countries, with predominantly male and white 
patients. Because ethnic and cultural background may 
affect pain perception, and female HIV-positive patients 
have been shown to be more likely to receive inadequate 
pain management, we have investigated the prevalence, 
intensity and treatment of pain in HIV-positive patients in 
a predominantly female, and black, cohort of patients in 
South Africa. 
We recruited 392 adult outpatients (298 black females, 94 
black male), in the day wards of a hospital in Johannesburg, 
South Africa. Patients completed the Wisconsin Brief 
Pain Questionnaire to assess the prevalence, severity 
and location of pain, and what medications were being 
taken to alleviate pain. The adequacy of analgesia 
achieved by patients was assessed by calculating the Pain 
Management Index, which compares pain intensity to 
the analgesic potency (based on the WHO Pain Ladder) 
of the medications that patients took. 
Three-hundred and two (77%) of the patients were in 
pain (30% had mild pain, 36% had moderate pain, and 
11% had severe pain). Sixty-eight percent of patients in 
pain had pain at multiple sites, with the most common 
sites of pain being the feet (30%), abdomen (10%) 
and head (20%). Only paracetamol and nonsteroidal 
anti-inflammatory drugs were taken for pain control, 
irrespective of pain severity, with no patients in moderate 
to severe pain achieving adequate pain control. Therefore, 
there is a high prevalence of pain in South African HIV-
positive outpatients, which is similar to the prevalence 
reported in European and North American studies, and 
it is poorly treated. 
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TRIPLE	CLASS	ExPERIENCE	IN	THE	
AUSTRALIAN	HIV	OBSERVATIONAL	
DATABASE	(AHOD)
Marashi Pour,S1, Petoumenos,K1, and Chuah,J2, on behalf 
of the Australian HIV Observational Database 
1. National Centre in HIV Epidemiology and Clinical 
Research, University of NSW, Sydney, Australia
2. Gold Coast Sexual Health Clinic, Queensland, Australia
The management of HIV disease for patients who become 
triple class experienced (TCE), is an important and 
ongoing challenge. The aim of this study is to describe 
the characteristics of patients who become TCE in the 
Australian HIV Observational Database (AHOD). 
Patients recruited to AHOD up to March 2007 who 
commenced combination antiretroviral treatment (cART) 
from 1 January 1997, for more than 14 days, and were 
experienced to the three major ARV classes were included 
in these analyses. Patients were defined as TCE at the time 
they stopped or changed the regimen the third class of 
ARV was first introduced. Patient characteristics including 
age, sex, prior AIDS, CD4 cell count, and viral load at the 
time of becoming TCE, and mortality rates after becoming 
TCE are summarised.
A total of 2066 patients were recruited to AHOD by 
March 2007. Of these, 1168 commenced cART, 737 (63%) 
patients commenced cART between 1 January 1997 and 
31 December 1999; and a further 431 (37 %) since January 
2000. During follow-up 386 patients (33%) became TCE; 
359 (93%) were male, mean age was 44 years (SD:10.2), 
and 91 (23.6%) had a prior AIDs defining illness diagnosed. 
272 patients had a viral load measure available at the time 
of becoming TCE, with 68% having a undetectable viral 
load (<=400 copies/mL). The mean CD4 was 555 (SD: 
376). The median time on treatment from commencing 
cART to becoming TCE was 2.8 years (IQR: 1.4-5.2). Among 
patients with follow-up after becoming TCE (n=386), 27 
patients died, yielding an overall crude mortality rate of 
1.67 per 100 person years. More than half (55.6%) were 
non-AIDS related deaths. 
While the majority of patients in AHOD who become 
TCE are stopping or changing treatments for various 
reasons including toxicities, approximately one third of 
patients continue to stop treatment due to virological 
failure. Despite become TCE, the rate of death in these 
patients is similar to that previously shown in AHOD 
overall. These results illustrate the complexities of treating 
experienced patients and the challenges faced in 
developing appropriate treatment regimens for the long-
term management of HIV positive patients, particularly 
in the era of continuous therapy once treatment is 
commenced.
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PROJECTION	DEATHS	FOLLOWING	AIDS	IN	
AUSTRALIA	TO	THE	END	OF	2010	BY	USING	
PARAMETRIC	SURVIVAL	MODELS	
 
Nakhaee F1,2, Law M1, McDonald A1, Black D3
1 National Centre in HIV Epidemiology and Clinical 
Research, UNSW, Sydney, Australia.
2 School of Health, Kerman University of Medical Sciences, 
Kerman, Iran.
3 School of Public Health and Community Medicine, 
Faculty of Medicine, UNSW, Sydney, Australia.
Information on AIDS mortality is needed for health care 
planning and resource allocation in upcoming years. 
There has been little work projecting mortality following 
AIDS in Australia.
Parametric models including exponential, Weibull, 
lognormal and log-logistic were used to model survival 
following AIDS between 1980 and 2003. Likelihood based 
goodness-of-fit criteria were used to select the best fitting 
parametric model. In order to project mortality to the end 
of 2010, AIDS diagnoses over the period from 2006 to 
2010 were generated based on the average number of 
AIDS diagnoses reported to the National AIDS Registry in 
2005. Covariate values for additional dummy diagnoses 
required for projecting mortality were generated based 
on the average values of those covariates among AIDS 
diagnoses from 2001 to 2005. Three scenarios for trends 
in highly active antiretroviral therapy (HAART) use for the 
period between 2006 and 2010 were considered; that 
HAART remained stable at, increased from, or decreased 
from 2005 levels. Predicted number of deaths was 
estimated by calculation of cumulative risk of death for 
each individual and then summing over all individuals by 
calendar year from 2006 to 2010.
The Weibull model was found to be the best fitting model 
for survival following AIDS and consequently was used 
to project deaths into the future. The number of deaths 
after AIDS is projected to increase from 175 in 2005 to 213 
and 252 in 2010 if HAART remains stable at 2005 levels 
or decreases respectively. Deaths after AIDS are projected 
to decrease from 175 in 2005 to 171 if HAART usage 
increases to 100% of all AIDS diagnoses by 2010. 
Deaths after AIDS is projected to increase if HAART usage 
remains stable or decreases and to decrease if HAART 
usage increases to 100 percent of AIDS diagnoses.
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A	STUDY	OF	NEEDLE	STICK	INJURIES	
AMONG	NON-CONSULTANT	HOSPITAL	
DOCTORS	IN	IRELAND
O’Connor MB1, Hannon MJ2*, Cagney D3*, Harrington U4*, 
O’Brien F5*, O’Connor R5*, Courtney K6*, O’Connor C7.
1 The Department of Surgery, Cork University Hospital, Cork, 
Ireland; 2The Department of Medicine, Cork University 
Hospital, Cork, Ireland; 3The Department of Surgery, 
Mercy University Hospital, Cork, Ireland; 4The Department 
of Surgery, South Infirmary – Victoria University Hospital, 
Cork, Ireland; 5The Department of Surgery, Mid-Western 
Regional Hospital, Limerick, Ireland; 6The Department 
of Surgery, Bon Secours Hospital, Cork, Ireland; 7The 
Department of GU/STD Medicine, Mid-Western Regional 
Hospital, Limerick, Ireland.
* Joint second authors
In a time of increasing blood borne infection prevalence 
and global travelling, NCHDs are thus being exposed to 
a greater number and wider variation of blood borne 
infections. Needle stick injuries (NI) are possibly the 
main route of acquiring such infections from a non-
consultant hospital doctors (NCHDs) perspective. This 
study examines NCHDs experiences surrounding NI, 
blood/needle handling training received, infection fears 
and NCHDs demographics.
A cross-sectional self-administered anonymous 
questionnaire survey was conducted on 185 NCHDs 
working in 7 teaching hospitals. NI history along with 
training, fears and demographics were examined. Ethical 
approval was prospectively received.
A response rate of 85.4% (158/185) was achieved, with 
58% of participants being medical NCHDs and 42% 
surgical. The mean age was 27.7, with Interns (46%), 
SHOs (33%) and Registrars (20%) taking part. 58% have 
experienced a NI with a mean number of 2.77 accidents 
(range:1-13). Venopuncture (47%) was the commonest 
type of injury. Only 31% report wearing gloves when 
dealing with needles or blood products. 37% have had 
sharps handling training, while 37% have reported their 
NI to the relevant departments. HIV (60%) followed by 
HCV (28%) and HBV (11%) are the infections most feared.
As a consequence of this study we conclude that a NI 
history is greater among the surgical NCHDs than the 
medical NCHDs. The level of disposable glove usage 
is worryingly poor. Training in sharps handling and in 
dealing with a NI needs to be addressed. HIV is the blood 
borne infection most fear of being contracting as a 
consequence of a NI.
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A COMPARATIVE STUDY OF HUMAN 
IMMUNODEFICIENCY VIRUS ANTIBODY 
POSITIVE PATIENTS IN IRELAND & 
AUSTRALIA
O’Connor MB1, O’Connor C2, Saunders JA3, Sheehan C4, 
Murphy E4, Horgan M1, 4,  Carr A5, Cooper DA5, 6.
1 The School of Medicine, University College Cork, Cork, 
Ireland. 2 Department of GU/STD Medicine, Mid Western 
Regional Hospital, Limerick, Ireland. 3 Department of 
Mathematics and Statistics, University of Limerick, 
Limerick, Ireland. 4 Department of Infectious Diseases, 
Cork University Hospital, Cork, Ireland. 5 HIV, Immunology 
and Infectious Diseases Clinical Services Unit, St Vincent’s 
Hospital, Sydney, Australia. 6 National Centre for HIV 
Epidemiology and Clinical Research, University for New 
South Wales, Sydney, Australia
Differences between HIV+ patients in developed and 
third world countries are publicised. This study proposes 
to compare patients demographically, medically and 
therapeutically in Ireland & Australia.
A confidential cross-sectional self-administered 
anonymous questionnaire survey of HIV antibody 
positive patients attending HIV outpatient services in 
both countries was carried out. Data was analysed for 
variations within cohorts and between cohorts using 
SPSS. Ethical approval was prospectively received in both 
countries.
A response rate of 71%(93/131)[Ire] & 76%(148/194)[Aus] 
was achieved, with a mean age of 36(20-67)[Ire] & 
45(20-71)[Aus]. Mean time diagnosed was 4.5yrs[Ire] & 
11.8yrs[Aus], with a reported diagnostic CD4 <200 in 
35%[Ire] & 22%[Aus]. A total of 64%[Ire] & 85%[Aus] are 
currently receiving HAART medications. Resistance in 
patient started ART post-HAART is 0%[Ire] & 2%[Aus]. 
Statistically significant findings included: 1) having a 
history of Gonorrhoea and Syphilis (a) in all subgroups 
in both countries, (b) is more likely with CD4 <200 at 
diagnosis(p=0.035). 2) Recreational drug use is higher 
in (a) younger people(p=0.021), (b) males(p=0.007), 
(c) homosexuals(p=0.05). 3) Alcohol use more likely in 
males(p=0.03). 4) Patients with HIV+ partners are less 
likely to use condoms(p=0.012). 5) Mean lifetime partner 
numbers predictive of number in last 6 months. 6) 
Doctor requesting a test is associated with no previous 
test(p=0.038). 
There were no factors associated with place of diagnosis, 
being “ill” at diagnosis, currently receiving ART, having a 
regular sexual partner, or sharing diagnosis with others.
As a consequence of this study we conclude that 
resistance post-HAART is minimal. Improvements are 
needed in STI prevention, doctors being proactive in 
testing, condom use with HIV antibody positive partners, 
addictive substance habits in younger male homosexuals, 
and the number of sexual partners of HIV antibody 
positive patients post-diagnosis.
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MEASURES	OF	COUNTRY	AND	SITE	
RESOURCING	PREDICT	VIROLOGIC	
SUPPRESSION,	IMMUNOLOGIC	RESPONSE	
AND	DISEASE	PROGRESSION	IN	THE	TREAT	
ASIA	HIV	OBSERVATIONAL	DATABASE	
(TAHOD).
Oyomopito R
The study’s objective  
HIV viral load (VL) and CD4 diagnostics are not routinely 
available in resource-limited settings despite improved 
access to antiretrovirals (ARVs). We aim to determine 
whether measures of country income, based on World 
Bank criteria or site-reported frequency of diagnostic 
testing, predicted post HAART treatment outcomes. 
Methodology
Analyses were based on 2333(69.7%) eligible patients 
starting HAART from 2000 onwards. Sites were categorized 
by country income (high/low) and annual frequency of 
VL(>=3/1-2/<1) or CD4(>=3/<3) testing. Endpoints were 
VL suppression (<400copies/ml) and change in CD4 count 
at 12months and time to AIDS/death. Demographics, CDC 
classification, baseline VL/CD4, Hepatitis B/C coinfections 
and HAART regimen were covariates.
Effects of the country income measures were adjusted 
for significant baseline patient covariates. VL and CD4 
endpoints were analysed using logistic and linear 
regression, respectively. Time to AIDS/death was analysed 
by proportional hazards models.
Summary of results
Patients from low income countries had lower CD4 
counts, less asymptomatic infection and fewer hepatitis 
B/C and VL results available at (p<0.001). 
785(33.7%) patients were analysed for VL 
suppression. Patients from sites with <1/year VL 
testing (OR=0.30;p<0.001) and reporting “Other” HIV 
source exposures including IDU and blood products 
(OR=0.28;p<0.001) experienced reduced suppression. 
1120(48.2%) patients had change in CD4 data. Smaller 
increases were associated with older age (p=0.001) and 
“Other” exposure (p=0.033). Patients from high income 
sites had lower increases in CD4 count (p=0.005). Patients 
from sites with VL testing <1/year had higher increases 
(p<0.001). 
For time to AIDS/death analyses, Hepatitis C coinfection 
(HR=1.7;p<0.02) and severely symptomatic HIV infection 
(HR=1.4;p=0.008) increased disease progression. Female 
gender (HR=0.8;p=0.03) and baseline CD4 count 
>=100cells/μL were protective (p<0.001). VL testing <1/
year was associated with increased disease progression 
(HR=1.4;p=0.032).
Conclusion
Measures of country income, including site-reported 
availability of diagnostic testing, were associated with 
virological and clinical outcomes following HAART.
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ORAL	POSTER	FRIDAY	19	SEPTEMBER	0825	
–	0830
ASHM	-	ORAL	POSTER	SESSION	-	PUBLIC	
HEALTH	AND	EPIDEMIOLOGY
ESTIMATING	HIV	PREVALENCE	OF	HIV	
AMONG	MEN	WHO	HAVE	SEx	WITH	MEN	
(MSM);	A	REVIEW	OF	METHODOLOGICAL	
OPTIONS
Pedrana A1, 2, Stoovè M1, von Doussa H3, Guy R4, Hellard 
H1  
1Centre for Epidemiology and Population Health Research, 
Burnet Institute, Melbourne, Vic, Australia; 2Department of 
Epidemiology and Preventive Medicine, Melbourne, Vic, 
Australia; 3Australian Research Centre in Sex, Health and 
Society; La Trobe University, Melbourne, Vic, Australia; 
4National Centre for Epidemiology and Clinical Research, 
Sydney, NSW, Australia
HIV prevalence estimates are required to support the 
planning of health services, monitor the long-term impact 
of interventions and inform models of HIV transmission. 
In Victoria, like most other parts of Australia, the HIV 
epidemic has been concentrated among men who 
have sex with men (MSM), suggesting that prevalence 
estimates should initially be focussed in this population. 
Estimating HIV prevalence requires determination of 
the number of people with HIV infection (numerator) 
in a representative sample of the population of interest 
(denominator).  In order to identify a repeatable and 
accurate strategy for estimating HIV prevalence among 
MSM in Victoria we considered four methodological 
strategies, and compared them against the criteria of 
repeatability, accuracy, cost and representativeness. 
Passive surveillance is based on reports of new HIV 
diagnoses and can serve as a numerator in prevalence 
estimates, with the denominator being the number of 
people tested. Although representative of diagnosis rates, 
these data do not provide true prevalence estimates 
because the population tested does not include those 
previously diagnosed, those not undergoing testing, and 
does not account for in or outward migration. A second 
option is estimating prevalence through census type 
surveys to provide numerators and denominators. This 
approach is expensive and theoretically representative, 
but may be subject to high degrees of underreporting 
of both quantities.  Another approach to deriving HIV 
prevalence is to use self-reported HIV status reported in 
surveys such as Gay Community Periodic Survey which 
takes place annually at community events, venues and 
bars. This approach is relatively cheap, but can not be 
assumed to provide valid prevalence estimates because 
of its dependence on self-report and an inability to 
detect unrecognised infections. A related, fourth 
approach is to incorporate HIV testing into these types 
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of surveys, ideally using some form of minimally invasive 
specimen collection, such as oral fluids. This approach 
does not provide for greater representativeness, but is 
more accurate than self-report while being simple and 
repeatable.  On the basis of the criteria, an oral fluid, 
venue-based approach was selected for Victoria and will 
be piloted in June 2008. 
P176
DEMOGRAPHIC CHARACTERISTICS OF CLIENTS 
ACCESSING PUBLIC SEXUAL HEALTH CLINICS IN 
NEW SOUTH WALES
Ramanathan V2, Sarangapany J 1,3, Kang M 2
1. Albion Street Centre, NSW, Australia
2. University of Sydney, NSW, Australia
3. University of Wollongong, NSW, Australia
We aimed to describe the demographics of an adult 
population accessing public sexual health clinics (PSHCs) 
in New South Wales (NSW). Demographic data was 
collected as part of a larger study determining accessibility 
and acceptability of PSHCs 
The study was a survey using a self-administered, 
anonymous questionnaire and was conducted between 
December 2005 and February 2006 in four PSHCs in 
different geographical locations – Sydney city (SC), 
Sydney suburban (SS), Sydney outer metropolitan (SOM) 
and NSW rural areas (NSWRA). An accredited health 
interpreter was offered for non-English speaking clients 
who required assistance completing the questionnaire. 
Three hundred and two adults (68% male, 32% female) 
participated, a response rate of 89%.. Thirty six refused 
participation for reasons of:  time constraints 6 (17%), 
no interest 18 (50 %), and 12 (33%) gave no reasons.. 
The Majority (82%) of the participants were from the SC 
(n=110) and SS (n=139) clinics with 53 (18%) from SOM 
and NSWRA. Pooled data found 26.5% were aged 18 – 25 
years, 56% were aged 26-49 years and 17.5% were over 50 
years. Eighty-two percent of the sample was Caucasian, 
69% were born in Australia and 88% spoke English as their 
main language. Ninety six percent of the participants had 
at least a secondary education. Of these, 65% had a tertiary 
level education. Only 38% reported full-time employment 
with 28 % being unemployed or retired. Seventy nine 
percent of the respondents reported multiple visits to the 
clinics. No differences were found in educational status 
or SHC users. However, significant differences were found 
in age (p<0.001), gender (p<0.001), employment status 
(p<0.001), ethnicity (p=0.023), country of birth (p=0.02), 
and language spoken at home (p=0.007) between sites.
The demographics of clients attending PSHCs varied from 
site to site. SC clients were more likely to be Caucasian, 
male age between 26-50 years. In contrast SS clients 
were more culturally and linguistically diverse. SOM and 
NSWRA were similar to SC but had equal distribution of 
male and female clients born predominantly in Australia. 
This reflects local demographic variation to some extent, 
but may also reflect the nature of the clinical services 
provided at PHSCs. 
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PREVALENCE	TOxOPLASMA	IN	WOMEN	
PREGNANTE	IN	zANJAN	CITY	,IRAN	2006-
2007
H.shoaei , Z.laghaei , M.jalalian , Z.afshar
Emam Hossein hospital Zanjan ,Iran.
Abstract
The aims of the present study were to determine the 
prevalence of toxoplasmosis in pregnant women 
.Prevalence toxoplasma was determine by ELISA 
method.Serum samples belonge to women pregnant 
refer to hospital. Five hundred and fourty woman 
pregnant presented.Overall IgG seroprevalence rate of 
toxoplasmosis was (47.5%) , only egith women  (1.5%) 
were found to have IgM antibodies. No significant 
difference was between ,job,abort, meat,based of Chi-
squar test but a significant difference was between 
educatin ,contact with cat,dog ,vegetable and water 
(P<0.001).Intervention programs including health 
education and environment sanitation are recommended. 
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SHORT-TERM	CLINICAL	DISEASE	
PROGRESSION	IN	HIV-1-POSITIVE	PATIENTS	
TAKING	COMBINATION	ANTIRETROVIRAL	
THERAPY:	TAHOD	RESULTS
Srasuebkul P1, Lim PL2, Lee MP3, Kumarasamy N4, Zhou J1, 
Law M1
1 National Centre in HIV Epidemiology and Clinical 
Research, UNSW, Sydney, Australia 2 Tan Tock Seng Hospital, 
Singapore, 3 Queen Elizabeth Hospital Hong Kong, China, 
4 yRG Centre for AIDS Research and Education, Chennai, 
India
The aim is to develop short-term predictive risk equations 
of AIDS or death in Asian populations based on simple 
clinical data.
Inclusion criteria were HAART initiation and completion 
of required laboratory tests.  Predictors for short term 
clinical disease progression defined as AIDS or death, 
were assessed. Poisson regression was used with three 
different models: (1) clinical data only, (2) clinical data and 
CD4 counts, and (3) clinical data and CD4 and viral load 
(VL). 
Body mass index (BMI) and anaemia were predictive in all 
three models. Others were age and female, CD4 (Models2 
and 3) and detectable VL (Model3). We separated patients 
into patient risk groups; low(L), high(H) and very high(VH). 
For Model1 patients with severe anaemia or BMI < 18 were 
at very high risk, while patients with (age < 40 or male) 
and mild anaemia were at high risk. For Model2, patients 
with CD4 < 50 or severe anaemia or BMI < 18 were at very 
high risk, patients at high risk were patients with (CD4 51 
– 200 or Age < 40 or male) and mild anaemia. For Model3, 
patients with CD4 < 50 or detectable viral load or severe 
anaemia or BMI < 18 were at very high risk, and patients 
with CD4 51 – 200 and mild anaemia were at high risk.
The incidences from Model1 were 2.4%, 7.6% and 17.7 
% from L, H and VH risk groups, respectively. The Model2 
incidences were 1.0%, 3.8% and 18.6 % from L, H and VH 
risk groups, respectively. Finally, the Model3 incidences 
were 1.6%, 4.3% and 6.3 % from L, H and VH risk groups, 
respectively
These models are simple enough for widespread use 
in busy clinics. These models should allow clinicians to 
identify patients at highest risk of the outcome, with a 
view if possible to intervention.
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COST-EFFECTIVENESS	OF	DARUNAVIR/
RITONAVIR	600/100	MG	BID	VERSUS	
COMPARATOR	PIS	IN	HIGHLY	TREATMENT	
ExPERIENCED,	HIV-INFECTED	ADULTS	IN	
AUSTRALIA
Warren E¹, Schrover R¹
¹Janssen-Cilag Pty Ltd   
Introduction: 
We evaluated, from an Australian perspective, the cost-
effectiveness of ritonavir-boosted darunavir (DRV/r) 
600/100 mg BID plus an optimised background regimen 
(OBR) compared with investigator-selected control PIs 
(CPIs) +OBR used in the DRV POWER 1&2 trials in highly 
treatment experienced HIV-infected adults, in line with the 
currently reimbursed indication for DRV/r in Australia. We 
also examined the cost-effectiveness of DRV/r compared 
to tipranavir/ritonavir (TPV/r), which recently received 
Pharmaceutical Benefits Scheme reimbursement for this 
patient group in Australia.
Methods:
We extracted mean CD4 count and viral load data for 
DRV/r and CPI-based HAART from weeks 0-72 from the 
POWER 1&2 studies. We projected viral load from week 
73 onwards over a 10 year time horizon with exponential 
regression curves for each treatment group. Using the 
relationship between CD4 count and viral load reported 
in the PLATO collaboration, we estimated the monthly 
mean CD4 counts in each group over this time horizon 
from these projected viral load data. We then used a 
Markov model with monthly transition probabilities as 
reported in the EuroSIDA Cohort to predict AIDS defining 
events, deaths and related costs based upon monthly 
CD4 counts over this horizon. We also performed a cost-
effectiveness analysis of DRV/r + OBR versus TPV/r + OBR 
based upon an indirect comparison and data from the 
POWER and RESIST studies. We assumed that patients 
would switch to salvage therapy after virological failure 
with DRV/r, CPIs or TPV/r-based HAART. 
Results:
Our analysis of DRV/r + OBR versus CPIs + OBR in highly 
treatment experienced patients found a discounted 
Incremental Cost-Effectiveness Ratio (ICER) of AUD$36,776 
per life year gained and a discounted cost per Quality 
Adjusted Life year (QALy) gained of AUD$39,019 for DRV/
r. Our analysis of DRV/r versus TPV/r found a discounted 
ICER for DRV/r of AUD$40,595 per life year gained and 
AUD$42,284 per QALy gained.
Conclusion:
DRV/r 600/100mg BID-based HAART is cost-effective 
compared to both CPI and TPV/r based regimens in 
highly treatment experienced, HIV-infected adults in 
Australia. A lower, once daily dose of DRV/r (800/100 mg 
QD) is currently being evaluated in treatment naïve and 
early treatment experienced HIV-infected patients. PO
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PROMOTION	OF	HPV	VACCINES	TO	
FACILITATE	SExUAL	HEALTH	EDUCATION	
WITHIN	A	HOLISTIC	HEALTH	FRAMEWORK	IN	
ABORIGINAL	COMMUNITIES	
Stacey Donovan
Aboriginal Sexual Health Worker, Biripi Aboriginal Medical 
Service, Taree NSW Australia
The occurrences of cervical cancer in Aboriginal women, 
is 5 times greater then that of Non- Aboriginal women. 
The role of the Human Papilloma Virus (HPV) and cervical 
cancer are well established.
It has been identified that being infected with HPV is a 
normal part of being sexually active, thus is of particular 
concern for girls and young Women, in the Aboriginal 
communities, due to sexual activity commencing at a 
younger age.
In 2006, the Therapeutic Goods Administration, approved 
Gardasil™ which is a vaccine that protects women by 90-
100%. The vaccine was made available and subsidised 
by the Australian Government, targeting females aged 
between 9-26 years of age. From 2007 this became a 
school based Vaccination Program.
The role of an Aboriginal Sexual Health Worker is 
promoting health, providing health education on safe sex 
practices and raising awareness of sexually transmissible 
infections (STI), and blood bourne viruses (BBV). 
The NSW HIV/AIDS, STI and Hepatitis C Strategies: 
Implementation Plan for Aboriginal People 2006-2009 
states that HIV/AIDS, STI and hepatitis C programs may 
be more acceptable to Aboriginal people, and therefore 
more accessible, when delivered within a holistic health 
framework.  
In line with the above NSW Plan and the National 
Aboriginal and Torres Strait Islander Sexual Health 
and BBV Strategy 2005-2008, the Aboriginal sexual 
health worker at Biripi Aboriginal Medical Service (AMS) 
promotes HPV Vaccine part of their sexual health role. 
This ensures Aboriginal girls and women receive this 
preventative treatment, in an effort to reduce the statistics 
around cervical cancer in Aboriginal communities, while 
at the same time facilitating HIV/AIDS, STI and hepatitis C 
education within a holistic health framework.
The presentation will focus on the strategies implemented 
undertaken at Biripi AMS, and their results. 
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‘WE	HAVE	INFECTIONS	zAPPED!’	
OFFERING	TESTING	FOR	CHLAMYDIA	
AND	GONORRHOEA	IN	TARGETED	YOUTH	
SETTINGS
McGowan AC1, Shaw MJ1, Prihaswan P1
1HIV & Related Programs Health Promotion Team, Sydney 
South West Area Health Service, Camperdown, New 
South Wales, Australia
Chlamydia is the most common STI in Australia and 
is particularly high in young people 15 to 30 years old. 
Aboriginal young people in NSW are recognised as 
suffering from a higher burden of sexually transmitted 
infections (STIs) and blood-borne viruses than non–
Aboriginal young people and have been identified as a 
priority population for Sexual Health Services across the 
state by the NSW Department of Health.
young people however, do not access health services as 
extensively as adults and seldom discuss sexual health 
issues when they do. Research has noted that barriers to 
accessing health care include financial concerns, lack of 
knowledge, lack of confidentiality and other emotional 
concerns. young people traditionally do not perceive 
themselves at risk of STIs. This supports the need to 
actively engage young people in settings where they feel 
more comfortable and secure engaging with health care 
staff. 
In response to these issues, the HIV & Related Programs 
(HARP) Health Promotion Team (SSWAHS) has initiated an 
outreach testing program as a strategy to improve access 
for young clients, particularly young Aboriginal clients, 
to sexual health clinical services. In line with the NSW 
Sexually Transmissible Infections Strategy 2006-2009, the 
program will trial an active outreach approach to sexual 
health clinical services and promote collection of urine 
for chlamydia and gonorrhoea testing. 
This program is being delivered as a collaboration 
between the HARP Health Promotion Team and the RPA 
Sexual Health Clinic team. Of particular importance is the 
role of the Aboriginal Sexual Health Workers (ASHWs) 
in maintaining relationships with services and working 
directly with Aboriginal young people. STI testing is 
offered by both ASHWs and nursing staff.
This paper will discuss the process of:
• selecting two local youth services as sites for outreach 
testing
• developing and formalising partnerships with these 
services
• developing a series of project resources, including an 
information pamphlet and safe sex packs
• delivering the program and preliminary results
INDIGENOUS	HEALTH
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ORAL	POSTER	THURSDAY	18	SEPTEMBER	
0800		-	0805
ASHM	-	ORAL	POSTER	SESSION	-	SOCIAL	
RESEARCH,	INTERNATIONAL,	COMMUNITY,	
INDIGENOUS
ENHANCED	PRIMARY	CARE	(EPC)	AND	
CARE	CO-ORDINATION	AS	A	CO-OPERATIVE	
MODEL
Scott-Visser BR 3, Starkey RJ 4
1  SHAIDS, Lismore, NSW, Australia
2  ACON, Lismore, NSW, Australia
The terms empowerment and self determination can 
become clichéd. Case management means many things 
to many people. How can these values and perspectives 
effectively be implemented to produce positive outcomes 
for positive people, especially those with complex needs 
living in a rural setting? 
In this presentation, we discuss our unique roles, the theory 
behind our work (differentiating case management and 
care co-ordination), why we use these models and how 
we have developed an effective partnership model.
The two presenters work in differing services in differing 
roles, however they have developed a partnership 
approach to initiate productive outcomes for positive 
people, especially those with complex needs living in 
rural Australia.
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POTENTIAL	DIFFICULTIES	AND	CONFLICTS:	
FINDINGS	FROM	A	KNOWLEDGE,	ATTITUDES	
AND	PRACTICE	SURVEY	OF	HEALTH	CARE	
WORKERS	IN	PAPUA	NEW	GUINEA
Hill R1, Ryan B2, Sadler S1, Sarangapany J1, Begley K1, 
Wyndham H1, Cousins
J2, Nicol K2, Kalinoe M2 and Miria R2
1Albion Street Centre, Surry Hills, NSW, Australia
2Anglicare StopAIDS, Port Moresby, Papua New Guinea
The social and cultural impact of twin HIV and STI epidemics 
in Papua New Guinea (PNG) is widely acknowledged. 
Responding to these diseases using a multi-sectorial 
approach is a Government of PNG (GoPNG) priority. The 
PNG and Australia Sexual Health Improvement Program 
(PASHIP) is a partnership between the Australian and PNG 
governments, and a number of local and international 
organisations. The purpose of the program is to reduce 
the prevalence of STIs through the provision of sexual 
health services.
The study was a questionnaire based survey of knowledge 
and attitudes of Health Care Workers (HCWs) in a single 
health care facility in Port Moresby. The survey was 
divided into two sections: 1) knowledge and 2) attitudes, 
with each section containing three separate sub-sections. 
A total of 19 forms were returned, four from nursing staff 
and fifteen from counselling staff. For the knowledge 
section of the survey overall scores were higher among 
the nursing participants than among counselling staff, 
90% correct compared with 69% correct respectively. 
Basic knowledge of transmission was similar between 
both groups. There were differences in specific knowledge 
about STI’s between nurses and counsellors, and this 
accounted for differences in the overall knowledge score. 
Despite the overall sound knowledge of the HCWs, three 
reported that there was a cure for HIV with one person 
witnessing a ‘faith healing’ that cured HIV. Attitudes 
towards condom use had positive response from both 
groups. The survey indicated a strong perception that 
those most vulnerable to STI’s, such as men who have 
sex with men (MSM) and commercial sex workers (CS) 
deserved access to health care. However, more than half 
(8/15) of the counsellors felt that knowing a colleagues 
HIV positive status would give them a better chance to 
protect themselves against HIV.
The study found that the overall level of knowledge 
was high and there was a high level of commitment 
and motivation to care for people living with HIV in this 
PNG HCW cohort. There were, however some myths and 
beliefs that could potentially be barriers to the delivery of 
care which need to be addressed.
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NEW	MARRIAGES,	NEW	PREGNANCYS	AND	
KNOWLEDGE	OF	SPOUSE	HIV	STATUS	AT	AN	
HIV	TREATMENT	FACILITY	IN	CAMBODIA.
Roeun M1,  Pouv S1, Phorn S1, Khem C 1, Keo S1, Song S1, 
Taing S1, Eng L1,  Huffam S1,2, Saphonn V1,  Kaldor J2, Cooper 
D A2, Mean CV1.
1National Center for HIV/AIDS, Dermatology and STIs 
(NCHADS) Ministry of Health Cambodia, 2 The National 
Center in HIV Epidemiology and Clinical Research 
(NCHECR), University of New South Wales, Sydney, NSW, 
Australia.
The NCHADS Social Health Clinic (SHC) is an outpatient 
facility providing care, including antiretroviral therapy 
(ART), to people living with HIV in Phnom Penh, 
Cambodia.  
Patients’ spouse status (single, married, divorced, widowed, 
and HIV/ART status) are recorded by counsellors and 
peer support workers at enrolment, and entered into an 
observational clinic database. All current patients’ data 
were reviewed and updated in early 2008, and compared 
with baseline.
Of 1989 ever enrolled patients 1411 were current at 
April 30th 2008, with a median time of enrolment of 22.8 
months, and 1047/1411(75%) on ART. At enrolment 
479/677(71%) men, and 419/734(57%) women were 
married, and 27/677(4%) men and 116/734(16%) women 
widowed. Spouse status was “missing” for 106/734(14%) 
women and 30/677(4%) men. At review, spouse status 
rates are similar to at enrolment except 213/734 women 
(29%) were subsequently recorded as widowed, with 
data missing data for only 2 women. 
New marriages (or stable partnerships) occurred for 
56(8%) male patients and 58(8%) women, including 14 
patients who entered more than one marriage since 
enrolment. After enrolment 39/734(5%) women became 
pregnant including 8(14%) of the 58 women with a new 
marriage.
HIV status was recorded as unknown for 181/524(35%) 
spouses of male patients, and 179/492(36%) spouses of 
female patients at enrolment. At review, HIV status are 
recorded unknown for 116/540(21%) current spouses 
of male patients, and 144/504(29%) spouses of female 
patients, including 9/50(18%) spouses of men, and 
16/50(32%) spouses of women in new marriages. Overall 
260/1044(25%) patients’ current spouse’s HIV status are 
recorded as unknown, 492/1044(47%) HIV +ve, (including 
39/100(39%) newly married), and 292/1044(28%) HIV 
–ve (including 36/100(36%) newly married). Of HIV +ve 
spouses, 278/492(56%) are on ART. 
These data give some insight into changes in marital 
status, knowledge of spouse HIV status, and occurrence 
of pregnancies in a cohort of PLHA over time. To prevent 
20  HIV transmission, HIV clinics must acknowledge their 
patients’ relationships and family life and encourage 
and facilitate honest communication between couples, 
disclosure of HIV status, HIV testing of partners, use of HIV 
prevention methods, and ensure family planning and 
sexual heath services are available to patients and their 
partners. 
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COMMUNITY	CAPACITY	ENHANCEMENT	
FOR	HIV	RESILIENCE	IN	A	GENERALISED	
EPIDEMIC:	A	COMPARISON	STUDY	OF	
A	SOCIAL	CHANGE	COMMUNICATION	
APPROACH	IN	RURAL	ETHIOPIA
Tadesse Z1, Afework S1, Claxton A2, Duffy SM3
1World Vision Ethiopia, 2World Vision HIV and AIDS Hope 
Initiative Africa Region, 3World Vision Australia
Community capacity enhancement (CCE) is an approach 
developed by the United Nations Development 
Programme to assist communities to address social, 
cultural, and gender factors contributing to HIV 
vulnerability.  It utilises the ‘community conversation’ 
methodology pioneered by the Salvation Army and Hope 
Worldwide.  CCE can be categorised as a ‘social change 
communication’ intervention, defined in November 
2007 by the Joint United nations Programme on HIV and 
AIDS (UNAIDS) Technical Consultation on Social Change 
Communication as “…the strategic use of advocacy, 
communication and social mobilization to systematically 
facilitate and accelerate change in the underlying drivers 
of HIV risk, vulnerability and Impact.”  
As an international non-governmental organisation, 
World Vision’s challenge is to identify evidence-
informed and theory-based HIV response approaches 
that are viable for scale-up and yet flexible enough to 
be adapted for a range of epidemiological and social 
contexts.  World Vision is moving toward incorporating 
a CCE approach into a ‘core model’ for HIV prevention 
in generalised epidemic settings in sub-Saharan Africa 
with predominantly sexual transmission.  In 2007 World 
Vision Ethiopia commenced a four-year pilot project to 
test the viability and effectiveness of a CCE approach in 
the context of broad-based, long-term, multi-sectoral 
community development programmes. The project 
operates in one district in Tigray Region and three districts 
in the Southern Nations and Nationalities People’s Region. 
The CCE approach is employed in combination with other 
behaviour change interventions: life-skills education in 
schools, child peer education for in-school and out-of-
school youth, and the ‘Channels of Hope’ methodology 
for mobilising faith communities.  Baseline, mid-term and 
final evaluations will employ a combination of qualitative 
and quantitative methodologies to compare results 
against comparison sites, which will use the same set of 
interventions, excluding the community conversations 
methodology.  
This presentation will discuss the project’s implementation 
approach and research methodology, and present 
relevant baseline findings.  
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IMPLEMENTATION	ISSUES	ARISING	FROM	
THE	2008	WHO/ILO	POST	ExPOSURE	
PROPHYLAxIS	GUIDELINES
Tomkins M, Gold J
The Albion Street Centre, Sydney, NSW, Australia
The World Health Organization (WHO) and International 
Labour Organization (ILO) recently published Joint WHO/
ILO guidelines on post-exposure prophylaxis (PEP) to 
prevent HIV infection. Personnel from the Albion Street 
Centre were involved in drafting  the document.
The Guidelines include policy and clinical guidelines for 
PEP for occupational exposure and non-occupational 
exposure (primarily after sexual assault) and are intended 
to be able to be used in any setting in any country. 
Although the guidelines are designed to ensure equitable 
and appropriate access to PEP in resource constrained 
settings issues with implementation are forseen.
Key delivery issues include: 
- Is the provision of PEP after occupational exposure or 
sexual assault beneficial in terms of effectiveness and/
or cost?
- How can PEP be seen as a priority in the context of 
inadequate treatment resources? 
- How can PEP be provided without affecting resources 
available for antiretroviral therapy or prevention?
- Is there a link between provision of PEP and subsequent 
sexual, drug use and occupational practices?
- What are the minimum requirements (in terms of other 
support services) needed to be able to offer PEP?
- Is there a reliable risk assessment algorithm that ensures 
PEP is not given for low risk exposures?
- What is the role of source assessment? Should PEP only 
be given if the source is known to be HIV antibody or 
HBV antigen positive?
- Which drugs should be recommended?
- How can PEP accessibility be made equitable in all 
settings?
The provision of international  PEP guidelines raises 
important concerns regarding implementation and 
should include mechanisms for an evaluation of their 
impact on HIV care delivery and prevention programs. 
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SHARP	PRACTICE:	THIRTEEN	YEARS	OF	THE	
NSW	NEEDLESTICK	INJURY	HOTLINE
Cherry R, Melling P, Wyndham H
Albion Street Centre, NSW, Australia
The New South Wales (NSW) Needlestick Injury Hotline 
was launched in September 1995.  The Hotline was 
developed in response to a 1994 NSW Health Department 
report  which identified a crucial need for a coordinated 
approach to the treatment of health care workers 
sustaining needlestick injuries in NSW health care facilities. 
The Hotline was designed to augment, not supplant, 
local policies and protocols for managing exposures.  The 
objective was to provide immediate information, risk 
assessment, support and referral to injured health care 
workers and the emergency services (i.e. police, fire and 
ambulance personnel), their supervisors and clinicians, 24 
hours a day, 365 days a year.
In 2008 occupational exposures remain a common 
cause for concern among health care workers. Exposures 
continue to occur despite the introduction of new safety 
equipment such as needle-less systems.  Knowledge 
deficits among health care professionals providing direct 
management of needlestick injuries persist, and the 
uptake of hepatitis B vaccination among some groups of 
health care workers remains inconsistent.
The Needlestick Hotline has established a database 
capturing valuable information about trends in 
needlestick injuries and occupational exposures.  This 
poster will identify key trends and provide an overview 
of the service.
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ORAL	POSTER	SATURDAY	20	SEPTEMBER	
0805	-	0810
ASHM	-	ORAL	POSTER	SESSION	-	CLINICAL,	
ALLIED	HEALTH	AND	BASIC	SCIENCE
VALIDATING	A	TWO-qUESTION	DEPRESSION	
SCREENING	TOOL	IN	AN	HIV-POSITIVE	
POPULATION	TO	USE	IN	IMPROVING	
NUTRITION	OUTCOMES	AND	PROGNOSIS	
Di Guilmi, A. 1, 2, Sarangapany, J. 1, 3, Houtzager, L. 1, 3, young, 
J. 1, 3, Purnomo, J. 1, Begley, K. 1 
1 The Albion Street Centre, Prince of Wales Hospital, 
Sydney, NSW, Australia.
2 The University of Sydney, Sydney, NSW, Australia.
3 The University of Wollongong, Wollongong, NSW, 
Australia.
Depression is a treatable disorder which is prevalent 
amongst people infected with HIV with rates as high as 
20-32%. Concurrent depression can result in increased 
symptoms and accelerated progression to AIDS. Studies 
have found associations between nutrient intake 
and depression. Poor diet quality and micronutrient 
deficiencies, particularly folate and omega-3 fatty acids, 
may propagate depressive symptoms. This study aims 
to validate a two-question depression screen, previously 
validated within a veteran’s population, in HIV-1 infected 
patients.  The overall goal is to incorporate the tool within 
nutritional screening to improve nutritional outcomes and 
prognosis through identifying and treating depression. 
A convenience sample of 32 participants (30 male, 2 
female) was recruited for the study. The mean age of the 
participants was 44 ± 10 years and the mean duration of 
HIV-infection was 12 ± 7 years. Participants completed 
the two-question depression screen and the Centre 
for Epidemiologic Studies Depression Scale (CESD-10), 
to assess the validity of the tool. The scoring system for 
both the CESD-10 and two-question depression screen 
remained the same as in the original study. Validity 
testing was performed by bi-variate correlation analysis 
using Spearman’s (rho) correlation coefficient. A strong 
correlation was found between the two measures, 
rho=0.78 (p<0.001). These results indicated that the 
abridged screening tool was valid for detecting individuals 
at risk of depression. The proportion of participants 
classified as depressed by the CESD-10 was 9/32 (28%) 
and with the abridged tool was 12/32 (38%). The abridged 
questions overestimated depressed participants, which is 
acceptable for a screening tool. 
As screening tools improve potential case identification, 
further confirmatory assessment and appropriate 
interventions such as cognitive behaviour therapy and 
nutrition counselling can be initiated in a timely fashion 
to improve outcomes. Effective treatment can reduce 
major depression in 80-90% of patients. Greater attention 
to nutritional factors in mental health is warranted given 
that nutrition interventions are inexpensive, safe and easy 
to administer. The depression screening questions should 
be incorporated into a larger nutrition screening criteria 
to assist in detecting and treating comorbidities relating 
to HIV-infection and treatment.
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ORAL	POSTER	SATURDAY	20	SEPTEMBER	
0810	-	0815
ASHM	-	ORAL	POSTER	SESSION	-	CLINICAL,	
ALLIED	HEALTH	AND	BASIC	SCIENCE
VALIDATING	AN	ABRIDGED	SYMPTOMS	
DISTRESS	qUESTIONNAIRE	IN	AN	HIV-
POSITIVE	POPULATION	TO	FACILITATE	
DIETETIC	REFERRAL	AND	IMPROVE	
NUTRITION	OUTCOMES
Di Guilmi, A. 1, 2, Sarangapany, J. 1, 3, Houtzager, L. 1, 3, young, 
J. 1, 3,   Purnomo, J1.
1 The Albion Street Centre, Prince of Wales Hospital, 
Sydney, NSW, Australia.
2 The University of Sydney, Sydney, NSW, Australia.
3 The University of Wollongong, Wollongong, NSW, 
Australia.
HIV infection, secondary infections and treatment with 
antiretroviral (ARV) medications can result in complicated 
health and nutritional issues for individuals. There is 
increasing evidence to suggest that nutrition interventions 
can influence future health outcomes and prognosis. 
HIV infection and/or ARV treatment may induce various 
side effects including nausea, vomiting, diarrhoea, taste 
changes, weight loss and micronutrient deficiencies. 
These symptoms may propagate more serious 
comorbidities such as malnutrition, muscle wasting and 
reduced functional status. Nutrition screening allows for 
early detection of symptoms and encourages treatment 
with nutritional counselling.
This study aims to validate an abridged symptoms 
distress questionnaire in a HIV-1 infected sample against 
the Symptoms Distress Module (NIAID Adults AIDS 
Clinical Trials Group), a validated questionnaire used in 
HIV clinical trials. The overall goal is to increase symptom 
detection and improve nutrition outcomes through 
appropriate dietetic referral. A convenience sample of 
32 (30 male, 2 female) participants was recruited for the 
study. The mean age of the participants was 44 ± 10 
years and the mean duration of HIV-infection was 12 ± 
7 years. Participants completed both the abridged and 
complete symptoms distress questionnaires. Validity 
testing was performed by bi-variate correlation analysis 
using Spearman’s (rho) correlation coefficient. A strong 
correlation was found between the two measures, 
rho=0.86 (p<0.001), indicating the abridged questionnaire 
was valid for detecting patients with a high symptoms 
score. The questionnaire indicated that a dietetic referral 
was required in 28 (87%) participants. A high frequency of 
symptoms was observed in the sample; 28 (88%) reported 
fatigue, 23 (73%) diarrhoea, 21 (66%) bloating, 18 (56%) 
fat deposits or weight gain, and 17 (53%) reported weight 
loss or muscle wasting. 
Nutrition management is integral to the care of HIV-
infected individuals as they may be at nutritional risk 
at any point in their illness. Nutritional counselling can 
assist in alleviating nutrition related symptoms, and 
improve nutrition status, immune function and survival. 
The abridged symptom distress questions should be 
incorporated into a larger nutrition screening criteria to 
assist in detecting and treating symptoms related to HIV-
infection and treatment.  
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DEVELOPMENT	AND	RELIABILITY	TESTING	
OF	NUTRITION	SCREENING	CRITERIA	FOR	
USE	IN	HIV-1	INFECTED	PATIENTS
Di Guilmi, A. 1, 2, Sarangapany, J. 1, 3, Houtzager, L. 1, 3, young, 
J. 1, 3, Purnomo, J. 1, Begley, K. 1
1 The Albion Street Centre, Prince of Wales Hospital, 
Sydney, NSW, Australia.
2 The University of Sydney, Sydney, NSW, Australia.
3 The University of Wollongong, Wollongong, NSW, 
Australia.
Targeted nutrition screening provides a quick, reliable 
and cost-effective alternative to complete assessment, to 
identify individuals who have one or more indicators of 
poor nutritional status or disease risk. Early identification 
allows for timely intervention and management with 
nutritional counselling, support and supplementation to 
improve nutritional status. 
There have been few nutrition screening tools used 
in the screening of HIV-positive patients and most 
do not incorporate risk factors for multiple nutritional 
issues, nor do they consistently take into account the 
chronic nature of the disease or long-term antiretroviral 
therapy. Hence, a multi-parameter tool is indicated for 
nutrition screening amongst people living with HIV. We 
have identified evidence-based risk factors that would 
contribute to diabetes and cardiovascular disease; and 
nutritional deficiencies in this population, including; 
symptoms, malnutrition, food insecurity, poor oral health 
and depression. 
The aim of this study was to develop and pilot a nutrition 
screening criteria using validated questionnaires and 
evidence-based risk factors for disease, and to test 
the inter-rater reliability of the tool in a HIV-positive 
population. A convenience sample of 32 participants (30 
male, 2 female) was recruited for the study. The mean 
age of the participants was 44 ± 10 years and the mean 
duration of HIV-infection was 12 ± 7 years. Reliability of 
referrals between two health practitioners was tested 
using the kappa-test statistics. Two of either a medical 
officer, registered nurse or dietitian scored the completed 
screening criteria and indicated an appropriate referral to a 
dietitian, dentist or psychologist. Referral to a dietitian was 
concordant in 93%, a dentist in 76% (k=0.66, p<0.001), and 
a psychologist in 86% (k=0.73, p<0.001) of cases. Of the 
32 participants; 29 (91%) required a referral to a dietitian, 
15 (47%) to a dentist and 16 (41%) to a psychologist.  
The screening criteria developed were found to be reliable 
between examiners, and further testing is undertaken to 
validate the tool and assess sensitivity and specificity. A 
panel of experts within the centre concluded that the 
tool was adequate and reliable for a referral pathway. 
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ORAL	POSTER	SATURDAY	20	SEPTEMBER	
0810	–	0815
ASHM	-	ORAL	POSTER	SESSION	-	CLINICAL,	
ALLIED	HEALTH	AND	BASIC	SCIENCE
COMPLEx	PSYCHOLOGICAL	FACTORS	
CONTRIBUTING	TO	SExUAL	RISK	BEHAVIOUR	
AMONG	HIV	NEGATIVE	MEN	WHO	HAVE	SEx	
WITH	MEN	(MSM):	INFORMING	SExUAL	RISK-
REDUCTION	INITIATIVES	FOR	THE	FUTURE.				
Earle, M, Hoy, J., Price, B. 
Victorian HIV Service, The Alfred, Melbourne, Victoria, 
Australia. 
Predictors of sexual risk behaviour potentiating HIV or 
STI infection among HIV negative Men who have Sex 
with Men (MSM), have been extensively researched. 
An illuminating body of literature has accumulated 
describing the demographics and health status of MSM 
engaging in sexual risk behaviour along with many social 
and contextual variables surrounding it. Though some 
contributing mental health conditions such as substance 
abuse, depression or anxiety have also been studied, 
comparatively less attention has been given to complex 
psychological factors such as impulsivity, affect regulation 
or interpersonal relating difficulties. Given these factors 
have repeatedly been identified in the mental health 
literature as contributing to other forms of risk-taking 
behaviour such as binge-drinking, substance or gambling 
addiction, they warrant closer attention.  
In response to this need, the Psychology Unit within the 
Victorian HIV Service began systematically collecting data 
regarding these psychological factors from HIV negative 
MSM attending the service for assistance reducing sexual 
risk behaviour. Clients were referred from the Victorian Non 
Occupational Post-Exposure Prophylaxis (NPEP) program 
and from general practice clinics in the community, after 
seeking medical help regarding a sexual risk event. Clients 
completed the Sexual Sensation-Seeking and Sexual 
Compulsivity Scales (Kalichman & Rompa, 1995) and 
the Personality Assessment Inventory (PAI, Morey, 2007). 
Both of these psychological assessment instruments are 
valid and reliable measures of sexual excitement-seeking, 
sexual compulsivity, depression and anxiety along with 
propensities toward impulsivity, self-harming behaviour, 
difficulties with affect regulation and negotiating 
interpersonal relationships.  
Trends in the data collected to date will be presented 
and discussed in light of relevant research from within 
the HIV Prevention and Mental Health fields. Applications 
of this data will also be discussed, including it’s use as an 
evidence-base for developing psychological interventions 
aimed at helping HIV negative MSM engaging in sexual 
risk behaviour increase their sexual safety, and ways it 
might inform preventative education campaigns 
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NURSE	ROLE	IN	PROVIDER-INITIATED	
HIV	TESTING	AND	COUNSELING	IN	RSIJ	
HOSPITAL,	JAKARTA
Hari Atikasari1, Husna Ihsanil3, Sumiwi Riris1, Umayah Siti1, 
Imran Darma2
1Department of Nursing Jakarta Islamic Hospital (RSIJ); 
2Department of Neurology University of Indonesia; 3AIDS 
Working Group Jakarta Islamic Hospital (RSIJ)
Nurse role as a counselor for human immunodeficiency 
virus (HIV) suspected patients based on admission 
symptom was very important to diagnose HIV. We 
determined patient or family response to provider-
initiated HIV testing and counseling by nurses in our 
hospital. We conducted a cross sectional study from 
August 23rd to May 10th 2008. Fifty four patients were 
included and majority of patients were males 41 (76%). 
The age of patients ranged from 20 to 44 years with mean 
value 28 years. Marital status was  57% single, 30% married 
and 13% widow. Eleven (20%) patients had education 
degree lower than high school. Thirty two (59%) of the 
patients employee and 41 % unemployee. HIV risk factor 
was intravenous drug users (IDU) 61%, heterosexual 6% 
and others 33%. Admission symptoms were prolonged 
fever 54%, chronic diarrhea 13%, unconsciousness 11% 
and others 22%. Fourty (74%) patients showed a positive 
response attitude when  nurse asked for HIV testing and 
14 (26%) showed a negative response attitude. Marital 
and job status had significant value to patients response 
(p=0,037 and p=0,042). Almost all of the provider-initiated 
HIV testing and counseling in our hospital by nurses had 
positive response, and factors which influenced their 
response was marital and job status. 
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UNDERSTANDING	DOMESTIC	VIOLENCE	
AND	SAME	SEx	DOMESTIC	VIOLENCE	IN	A	
HIV	AMBULATORY	CARE	SETTING	
Hennessy R
Domestic Violence (DV) and Same Sex Domestic Violence 
(SSDV) has been recognised as a serious issue.  Overseas 
and anecdotal reporting suggests that DV in same-
gender relationships is comparable to the rates of DV 
against heterosexual women.  As in opposite-gendered 
couples, the issue is presumably underreported.  Being 
afraid of revealing the nature of the sexual relationship, an 
unsympathetic justice system and inadequate resources 
for male victims are some of the barriers to reporting.  
Purportedly HIV in an abusive relationship may add 
to the complexity of concerns.  Perpetrators of DV 
ostensibly could use HIV status as a means of coercion or 
intimidation in their relationships.  Victims may fear that 
their abusive partner may reveal their HIV status to others 
and thus face HIV discrimination and potentially outing of 
sexual orientation due to HIV’s association with sexuality 
in Australia.  Alternatively abusive HIV positive partners 
may coerce partners to risk HIV infection and should 
HIV transmission occur this sero-concordance itself may 
make separation more difficult due to the fears previously 
noted.  
Currently within the SESIAHS sector data on DV and SSDV 
is not uniformly collected.  Understanding how HIV may 
affect DV has rarely been considered.  In addition to other 
approaches the Albion Street Centre’s (ASC) Psychology 
Unit acknowledged the need to develop a strategic plan 
to address DV and SSDV service delivery.  Promoting 
awareness and improving our understanding of DV and 
SSDV within our HIV positive client’s relationships were 
identified as essential first steps.  
Information regarding client’s experiences of DV both 
in current and past relationships will be collected over a 
one month period.  Identifying if HIV features in any abuse 
experienced and what help or barriers to help, if any, 
clients will be considered.  Data on a planned recruitment 
of 30 clients will be presented.  
Gaining an insight into the incidence and type of DV 
issues facing clients will potentially enable psychosocial 
based services to better assist people to leave an abusive 
relationship.  Such information can assist professional 
providers, who may have inadequate levels of experience 
and training to work with victims, to highlight what the 
professional development and resource needs are to 
improve service delivery. 
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MENTAL	HEALTH	DIAGNOSES	IN	
FREMANTLE’S	HIV-POSITIVE	PATIENTS	
Libertino S1, Kerth J1, Wilson M1, McLellan D1, Marshall L1, 
Dyer J1, Clark B1.
1Department of Infectious Diseases, Fremantle Hospital, 
Western Australia.
Previous studies have shown the incidence of psychiatric 
and substance abuse disorders are generally higher in 
people infected with HIV than in the general population. 
It has also been shown that improving treatment in those 
with both HIV and mental health disorders can improve 
quality of life and treatment outcomes. In order to 
improve the provision of mental health care amongst the 
cohort of HIV patients attending Fremantle’s Infectious 
diseases department, we performed an audit examining 
mental health diagnoses and the care accessed by these 
persons.
A retrospective case note review was performed. 
Demographic data, risk factors for HIV transmission, CD4 
count at HIV diagnosis, current mental health diagnoses 
(MHD), previous MHD, HIV treatment outcomes, current 
psychiatric treatment, and health services accessed were 
recorded.
 
In February 2008, 90 HIV-positive patients (males N= 
69, females N=21) were registered on the department’s 
database. Of these 34% (38/90) were found to have a 
current MHD, and another 13% (14/90) had a past history. 
Men were more likely to have a MHD and present later 
with advanced HIV disease. Of the 11 indigenous patients 
attending the clinic, 9 had a current MHD.
Only 51% of those with a current MHD were accessing a 
General practitioner (GP) and 23% Mental health services. 
67% were recorded as being prescribed antidepressants, 
19% antipsychotics, and 14% were on both medications. 
Of these, 55% of patients had their psychiatric medications 
prescribed by the Infectious diseases department. 
Reassuringly all patients with a mental health diagnosis 
who required HIV treatment were taking HAART (highly 
active antiretroviral treatment), and the majority had 
undetectable HIV viral loads.
We have subsequently secured funding for a psychiatric 
outpatient’s session in our HIV clinic and are actively 
seeking GP’s for patients who are not registered with 
a general practice. We are also a developing a mental 
health assessment tool to be used within our clinics, in 
order to identify patients who require early intervention 
and referral to specialist services.
P199
ANzANAC	VICTORIAN	BRANCH:	RESPECTING	
OUR	HISTORY,	CAPTURING	OUR	ExPERTISE	
AND	LOOKING	TO	THE	FUTURE.
Crock L1, Gellie K1, Moyer J1, Tomnay J1. 
1. Australian & New Zealand Association of Nurses in 
AIDS Care (ANZANAC) Victorian Branch Committee, 
Melbourne, Victoria
ANZANAC (Victorian Branch) began as the Victorian AIDS 
Nurses Resource Group in 1986 when a group of nurses 
recognised the need to support and educate nurses 
working in HIV/AIDS.  Whilst the group has had name 
changes over the years, its purpose and core functions 
have been maintained, with a small but dedicated group 
of active members.  Now in its 22nd year, the group is 
led by a volunteer committee.  Although it receives no 
funding, ANZANAC (Victorian Branch) produces a regular 
journal and holds education and networking events for 
members.  It advocates and responds to issues relevant to 
Victorian HIV nurses, and people living with HIV/AIDS. 
A strong sense of the historical importance among group 
members is balanced by recognition of how a dynamic 
epidemic impacts on the needs of Victorian nurses.  In 
2007, ANZANAC (Victorian Branch) conducted a survey 
of members to explore and document the diversity and 
expertise within the group, to establish the current needs 
of members, and to plan for the future.  
An email requesting members to fill in an online survey 
was sent in three waves. Also, non participating members 
attending a subsequent education session were invited 
to fill in a hard copy of the survey.  Results were entered 
into “Survey Monkey” and analysis performed.
86% (19/22) of members participated. 90% of participants 
worked in public health, community nursing, research or 
a public hospital.  All participants (100%) had or did work 
in an HIV related position. 70% (14/20) respondents had 
a combined 204 years experience in HIV nursing. 94% of 
respondents were Division 1 nurses, with 90% having 
post graduate qualifications (52% graduate diploma, 32% 
Masters, 11% PhD). 78% of respondents indicated that 
ANZANAC’s education sessions, journal, peer support and 
networking were good or very good. Members stated 
that, in the future, ANZANAC (Victorian Branch) should 
focus on increasing its profile among nurses in Victoria 
and provide more educational opportunities such as 
journal/book clubs, refresher courses on HIV, blood borne 
viruses and sexually transmissible infections. ANZANAC 
(Victorian Branch) also needed stronger networking 
within Australia.
We conclude that ANZANAC (Victorian Branch) is meeting 
the current membership needs. PO
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A	STUDY	OF	FACTORS	AFFECTING	LONG-
TERM	ADHERENCE	TO	ENFUVIRTIDE	(ENF)	
THERAPY	IN	HIV-1	INFECTED	INDIVIDUALS
Norris R.1, Fraser H.2, Hales G.3
1St Vincent’s Hospital, HIV Ambulatory Care Unit, Sydney, 
Australia, 2St Vincent’s Hospital, Research Office, Sydney, 
Australia, 3Roche Products, Medical, Sydney, Australia
Text: Objective: To describe issues for patients related to 
long term adherence to ENF and to identify strategies 
that affect adherence to twice daily injections. 
Methods: 17 subjects provided informed consent; 
structured interviews were undertaken at an HIV 
Ambulatory Care Clinic. The interviews were tape-
recorded and transcribed verbatim. Transcripts were 
analyzed using an interpretative phenomenological 
approach. Themes were identified which reflected 
the subjects’ experience of self administrating ENF. 
Results: 
Demographics N = 17
Mean Age (years) 47
Mean time taking Anti Retroviral 
Therapy (ART) (years)
13
Mean time taking ENF (Months) 24
Mean CD4+ Cells/mm3 287
% HIV Viral Load <50 71
% Currently on ENF 82
% Male 94
[Demographics]
The main findings were that adherence to ENF takes 
self discipline, commitment and a sustainable routine 
combined with an understanding of the process for self 
administering a twice daily injection. Improved HIV clinical 
surrogate markers were powerful motivators for long term 
use. Lifestyle readjustment was also required for successful 
long term use. High levels of satisfaction with training and 
confidence in the ability to self inject were important for 
adherence. Injection site reactions (ISR) posed significant 
problems for many patient however choice in the delivery 
method (27, 31 gauge needles and biojector) provided 
patients with options to manage the impact of ISR. 
Conclusion: Study participants recognized that taking 
ENF required additional commitment to adherence 
compared to oral ART. Patient education needs to focus 
on ways to develop routines, management of ISRs and 
identification of suitable injection sites. Patients taking 
ENF long term would benefit from annual training 
sessions, targeting ISR management and updated self 
administration education.
Country of research: Australia
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ORAL	POSTER	SATURDAY	20	SEPTEMBER	
0800	–	0805
ASHM	-	ORAL	POSTER	SESSION	-	CLINICAL,	
ALLIED	HEALTH	AND	BASIC	SCIENCE
REDUCED	ENERGY	AND	INCREASED	
SATURATED	FAT	INTAKE	IN	A	COHORT	OF	
HIV	POSITIVE	CLIENTS	IN	SYDNEY
Purnomo J1, young J1,2, Sarangapany J1,2, Houtzager L1,2, Di 
Guilmi A1,3
1Albion St Centre, Surry Hills, Sydney, NSW, Australia; 
2University of Wollongong, Wollongong, NSW, Australia; 
3University of Sydney, Sydney, NSW, Australia
Balanced nutrition is essential for people living with 
HIV (PLHIV) as it helps in managing symptoms, reduce 
toxicities associated with anti retroviral therapy, delay 
disease progression and maintain immune responses 
leading to a better quality of life. 
Thirty two subjects (30 males, 2 females) participated in 
the study to evaluate dietary intake among HIV-1 infected 
patients. Dietary intake was analysed using Food Works 
Nutrient Analysis Software Version 5. Comparisons were 
made to current Recommended Dietary Intakes (RDI), 
the Australian Guide to Healthy Eating (AGTHE), National 
Cholesterol Education Program (NCEP) and National 
Nutrition Survey (1995). 
Mean age was 44 ± 10 years and mean duration of HIV-
infection was 12 ± 7 years. Mean actual energy intake was 
9618.2 ± 4697.1 kJ/day which was -890.7 ± 3498.3 kJ/day 
lower than estimated energy requirements (EER). The 
majority of subjects (72%) did not meet EER. Macronutrient 
breakdown was 20% protein, 45% carbohydrate and 34% 
fat. Total fat included 44% saturated fat contributing to 
13% of total energy intake. Mean fibre intake was 23.2 
± 12.4 g/day and was inadequate in 24 (75%) subjects. 
Mean intakes of magnesium and folate in 25 (78%) 
subjects, and zinc in 19 (59%) were found to be lower 
than the RDI.  Twenty nine (91%) did not meet the AGTHE 
recommendation for consumption of vegetables; 27 
(84%) for fruits and; 21 (66%) for bread, cereal, rice and 
pasta. Mean percentage energy from saturated fat in 27 
(84%) and dietary cholesterol in 17 (53%) were higher 
than the NCEP guidelines. Mean cholesterol and sugar 
intake were 356.0 ± 190.9 mg/day and 123.7 ± 83.6 g/day 
respectively which were higher than that reported in the 
general population in New South Wales.
This study found that despite high sugar and saturated fat 
intake, energy intake was still lower than recommended. 
The pattern of food consumption in these patients was not 
consistent with the AGTHE guidelines with participants 
consuming food of low nutritional value resulting in low 
energy intake. Clinicians need to be aware of nutritional 
deficiencies and to consider nutritional referral and 
intervention in the management HIV-1 infected patients.PO
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ARE	WE	MISSING	AN	OPPORTUNITY	TO	
IMPACT	BMI’S	IN	PEOPLE	WHO	ARE	HIV	+VE?
Roney J1, Bryant M1, Downs C1, Giddings E1, Hoy J1, 
Liddle R1, Rotty J1.  1Clinical Research Unit, Infectious 
Diseases, The Alfred Hospital, Melbourne, VIC, Australia
Excess body weight contributes to risk for a variety of 
conditions such as diabetes, cardiovascular disease (CVD), 
osteoarthritis, hypertension, and dyslipidemia, (WHO 
2003). The most recent National Health Survey taken in 
2004-2005 reported an increased number of Australians 
classified as overweight (BMI score 25  to 29.99) and obese 
(Body Mass Index or BMI score > 30), over the last 15 years, 
4.6 million in 1989/90 to 7.4 million in 2004-005. 
In the pre HAART era, the average BMI in the HIV 
positive population was lower than normal.  However 
with effective anti-retroviral treatment, the HIV-infected 
population is now at risk of disease associated with higher 
BMIs. In 2003, the D:A:D study analysis identified that 3.5% 
of the study population were considered obese.
In April 2008, all HIV-infected patients attending 
the Infectious Diseases Outpatient clinic (OP), were 
approached to have their BMI calculated. 191 patients 
agreed.   The purpose of this cross-sectional survey was to 
examine the prevalence of obesity, and to assess whether 
this had previously been identified and appropriate 
interventions had been put in place. The Alfred Hospital 
has 1191 HIV-infected people regularly attending the OP 
for HIV clinical care. Of these 1093 are male, with a mean 
age 46 years (range 21.2 to 83.3) and 98 are female, with a 
mean age of 40.9 years (range 19.6 to 72.9).  
Of the patients assessed in April 2008, 183 were male 
with an average age of 46.6 (range 23-79),). The mean 
male BMI was 24.26 (range 16.44 to 38.96) with 4% (n=8) 
underweight, 33% (n=61) being considered overweight 
and 6% (n=11) obese. Only 8 women participated in the 
survey therefore not providing a sufficient data set for 
analysis
 
This data is similar to data collected on 159 males 
presenting to OP and enrolled in a lipodystrophy 
prevalence study. The mean BMI was 24.1 (range 18.1 to 
34.6) in 1998. 
However, 39% of patients assessed in the cross-sectional 
study in 2008 had a BMI > 25. The paper will explore other 
risk factors such as duration of HIV infection, duration and 
type of ART, VL suppression and CD4 cell count (current 
and changes over time). 
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ASHM	-	PROGRAM	DELIVERY			
																													
ENHANCING	THE	GP’S	PRIMARY	CARE:	
ACON	SYDNEY’S	ENHANCED	PRIMARY	CARE	
PROJECT
Saloner KL¹
Barr NJ¹
¹ACON
ACON’s Enhanced Primary Care (EPC) Project is a model 
that can be adopted by a number of non-government 
organizations (NGOs) and GP offices for wider practice. 
The aim of this paper is to showcase the model currently 
being revitalized by ACON Sydney which is possibly 
underutilized by services working with clients who could 
benefit immensely from a more immediate and accessible 
level of psycho-social intervention, particularly where a 
relationship and high degree of trust already exists.  
The EPC project sees social workers, who are employed 
by ACON, work onsite at high HIV caseload GP surgeries 
assisting the GPs’ care provision. 
A unique aspect of service delivery through the EPC 
method is the maintenance of two very different types 
of relationships. The first is the relationship with a range 
of time-restricted GPs who have often had a long-term 
relationship with the client. The second is a client group 
who frequently has a history of involvement with health 
care services, often characterized by experiences of 
homophobia for GLBT clients and/or clients with “anger 
management issues”. For clients, the interface with 
systems is one that they frequently do not feel equipped 
to negotiate with ease. The EPC officer’s role is to create a 
harmonious outcome for the client and the GP. 
In the 2007-2008 fiscal year, EPC workers saw approximately 
13 clients per month. The majority (approximately 80%) 
of these clients receive care co-ordination, whilst the 
remainder might only seek information. On average 
each care co-ordinated client receives seven occasions of 
service from the EPC worker. 
Historically, EPC officers were required to be experts in 
relation to Medicare’s system of developing Team Care 
Arrangements and GP Management Plans. Today, 2 out 
of 3 GP surgeries utilise social workers’ professional skills 
and knowledge to provide key services such as short-
term interventions to help clients realize their goals and 
potential with particular emphasis on whole-of-person 
care. With the GP looking after the medical aspects, social 
workers can look after the psycho-social aspects so that a 
complementary relationship results. 
PO
ST
ER
	A
BS
TR
A
C
TS
	
N
U
RS
IN
G
	&
	A
LL
IE
D
	H
EA
LT
H
266                17-20 SepteMber 2008 @ pertH ConVentIon Centre, WeStern AuStrAlIA
P205
CERVICAL	SCREENING	(PAP	SMEARS)	
ATTENDENCE	IN	HIV	POSITIVE	WOMEN:	A	
NURSING	AUDIT
Smith M L
Division of Nursing Albion Street 
 NSW, Australia
Studies suggest that cervical Low and High Grade 
Intraepithelial Lesions (LSIL/HSIL) are more common and 
potentially progress to higher grade cellular changes 
faster in HIV positive women .The National Cervical 
Screening Program Guidelines recommend annual Pap 
smears for immunosuppressed women, which includes 
HIV positive women. 
An audit of HIV positive women attending Albion Street 
Centre for their HIV care was commenced in March 
2008 to ascertain the rate of women who adhere to 
this recommendation. Of the 39 files reviewed 11(28%) 
women have had documented Pap smears here or at 
their GPs  in the last 12 months, with no abnormal cells 
detected ,  2 (5%) women have had hysterectomies and 
will require no further Pap smears, and 2(5%) women 
are transgender  and do not require Pap smears. Of the 
remaining women, 6 (15%)have had Pap smears attended 
in the past 2 years and the remainder of the women will 
require clarification to identify if they have had Pap smears 
attended elsewhere.
This poster aims to provide an overview of the results of 
this audit and a review of the centre’s recall system. It is 
anticipated that the findings from this audit will highlight 
the need for a proactive recall system for these client’s 
and to identify client’s awareness of the need for their Pap 
smears. The results of this audit will potentially assist other 
services in improving their care for HIV positive women. 
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VALIDATION	OF	AN	ABRIDGED	FOOD	
SECURITY	TOOL	AND	EVALUATION	OF	ORAL	
HEALTH	RISK	IN	A	HIV-1	INFECTED	COHORT
young J1,2, Sarangapany J1,2, Houtzager L1,2, Di Guilmi A1,3 
and Purnomo J1
1. Albion St Centre, Surry Hills, NSW, Australia
2. University of Wollongong,NSW, Australia
3. University of Sydney, NSW, Australia
Food security (FS) and oral Health (OH) screening tools 
have been used in the general population. However this 
is the first time OH and FS have been screened together in 
people living with HIV (PLHIV). The FS nutrition screening 
tool (NST) was developed using two questions from the 
FS questionnaire (FSQ). The OH NST included a question 
on mouth pain, dry mouth and time since last dental visit 
as these were the main OH issues identified in a HIV-1 
infected cohort. Each participant completed three forms: 
FSQ vs. FS NST and OH NST. 
Thirty two (30 male, 2 female) participated in the study. 
The mean age of participants was 44 ± 10 years, with a 
mean duration of HIV infection of 12 ± 7 years. A highly 
significant correlation was found between the abridged 
FS NST and the FSQ (rho = 0.845, p <0.001). The proportion 
of PLHIV reporting food insecurity was 11 (34%) and 12 
(37.5%) with the FS NST and FSQ respectively indicating 
that the FS NST accurately detected food insecurity. From 
the OH NST 15 (50%) PLHIV were identified as being at 
high risk of OH issues. A significant correlation was also 
found between the OH NST and FS NST (rho = 0.471, p 
=0.007). 
The strong relationships found between the FS NST 
and the FSQ suggest that the NST adequately screens 
PLHIV for FS issues. Therefore the abridged food security 
tool (FS NST) could be incorporated into a NST for a 
multidisciplinary approach to the nutrition management 
of PLHIV. The OH NST requires further investigation to 
determine the true extent of OH issues in a HIV-1 infected 
cohort. A relationship exists between oral health and food 
security but the true cause and effect requires further 
research. 
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KNOWLEDGE	OF	HIV/AIDS	AMONG	
‘PRIMARY	HEALTH	CARE	PROVIDER’S	AND	
IMPACT	OF	TRAINING.’
Badhan S
Objective:  
India is ill prepared for ‘Provider- Initiated Testing and 
Counselling (PITC)’ as per UNAIDS guidelines for HIV 
testing because of the lack of knowledge about various 
aspects of HIV/AIDS among the primary health care 
providers. Thus, objective of present study was to assess 
the level of knowledge about HIV/AIDS among the private 
practitioners who are supposed to identify suspected 
cases of HIV/AIDS, counsel and refer them for testing. 
Methods: 
 The study was conducted in North East Delhi from 
15th Dec. 06 to 15th Feb. 2007 among primary health 
care service providers. A pre-tested, semi-structured 
questionnaire was used to collect the information about 
sexually transmitted diseases, presence of HIV in human 
body, categorization of some of the risk categories for 
HIV transmission, modes of transmission and prevention 
of HIV/AIDS and the conditions for initiating treatment. 
This was followed by one day workshop for training 
and education for risk reduction practices. A purposive 
sample of 350 private practitioners was taken for time 
constraints. 
Results:   
Out of 350 study subjects contacted 278 responded 
(79.42 %).  Majority of these were males (87.05%), aged 
below 40 years (81.40%) having no recognized medical 
degree (82.02 %). Surprisingly only 27.33% study subjects 
could name all the four modes of transmission viz. 
sexual intercourse, blood transfusion, parent to child 
and I/V Injections, correctly and there was significant 
improvement at the end of workshop. There was no 
significant difference between males and females 
except in relation to the window period where females 
outnumbered the males
Conclusion:          
 The knowledge about the STD’s, HIV/AIDS among the 
study subjects was found to be very poor which improved, 
a bit but not significantly, after the workshop, highlighting 
the need of vigorous awareness campaigning before 
they take up the responsibility of PITC as per UNAIDS 
guidelines.
      Male (%)
     242   (87.05)
    Female (%)
     36    (12.94)
       Total
       278
Correctly 
named 
transmission 
mode
Pre Post Pre Post Pre Post
                    
          4
64 
(26.44)
92  
(38.01)
12 
(33.33)
18  
(50.0)
76 
(27.33)
110  
(39.56)
                    
          3   
58 
(23.96)
128  
(52.89)
8 
(22.22)
13  
(36.11)
66 
(23.74)
141  
(50.71)
                    
          2
43 
(17.76)
22  
(9.09)
6 
(16.66)
5  
(13.88)
49 
(17.62)
27  
(11.15)
                    
          1
77 
(31.81) 0
10 
(27.77) 0
87 
(31.29) 0
Window 
Period:                         
yes
52 
(21.48)
126 
(52.06)
15 
(41.66)
21 
(58.33)
67 
(24.10)
147 
(52.87)
CD 4 
– Count: 
yes
28 
(11.57) 
54  
(22.31)
7 
(19.44)
12 
(33.33)
35 
(12.58)
66  
(23.74)
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THE	SUPPORT	FOCUS	IS	ON	INDEPENDENT	
LIVING!
Crooks L, Chair, NSW HIV/AIDS Supported Accommodation 
Plan Implementation Working Group
Over the last twenty years, the NSW AIDS Program 
established a range of supported accommodation 
services for people with HIV/AIDS. Originally the services 
provided respite care and support in a context of acute 
illness and limited life expectancy. A range of graded 
services were later developed for people with AIDS 
Dementia Complex and other complex support needs.
With improved HIV/AIDS treatments supported 
accommodation needs have changed. In particular a 
greater number of people with HIV/AIDS require longer 
term support and commonly support that is complex 
in its provision because of co morbidities such as drug 
and alcohol problems, mental illness and cognitive or 
intellectual disabilities. Factors arising from ageing have 
also become a consideration. 
In an environment where HIV/AIDS is now a chronic 
illness and where congregate types of supported 
accommodation arrangements are no longer considered 
the most appropriate model for service delivery, NSW has 
changed its approach to the supported accommodation 
provided through the AIDS Program for the purpose of 
improving the coordination of services, the prioritisation of 
access, the focus on individual needs and the partnerships 
between HIV/AIDS services and other agencies. 
This paper focuses on the NSW changes to policies and 
models of care and the essential involvement of service 
providers and other stakeholders in a process that 
supports a philosophy of independent living. 
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GENERAL	PRACTITIONER	UNDERSTANDINGS	
OF	HOW	DEPRESSION	AFFECTS	GAY	AND	
HIV	POSITIVE	MEN	IN	AUSTRALIA
Newman CE,1 Kippax SC,1 Mao L,1 Saltman D,2 Kidd MR3
1National Centre in HIV Social Research, 
The University of New South Wales Sydney 
NSW Australia; 2Institute of Postgraduate 
Medicine, Brighton and Sussex Medical School 
Brighton, United Kingdom; 3Discipline of General 
Practice, Faculty of Medicine, The University of Sydney 
Balmain NSW Australia
This paper explores how Australian general practitioners 
(GPs) who are accredited to prescribe antiretroviral 
medications understand the relationship between 
depression, gender and sexuality in gay men, including 
those living with HIV.
The Primary Health Care Project on HIV and Depression is 
a three year multi-method study funded by the General 
Practice Clinical Research Program of the National Health 
and Medical Research Council (2006-2009). The research 
team represents a unique collaboration between social 
researchers, general practice researchers, GPs and 
community partners. The study employs both qualitative 
and quantitative methods to answer a range of research 
questions including the prevalence and nature of 
depression among gay men (both with and without HIV) 
and heterosexually-identified men attending general 
practice clinics, factors associated with depression in 
these three groups, and the clinical and self-management 
of depression by GPs and patients themselves, especially 
those living with HIV.
As part of the qualitative component, interviews were 
conducted with 16 GPs representing three geographical 
settings and 7 practices: Sydney (4 practices), Adelaide 
(1) and a rural-coastal town in New South Wales (2). 
Participants included 14 male GPs and two female GPs, 
and the number of years each had been working in HIV 
medicine ranged from two to 24. Semi-structured face-
to-face interviews of around one hour in length explored 
the diagnosis, treatment and management of depression, 
aspects of depression related to HIV, gender and sexuality, 
and reflections on practice. 
This paper will present the results of a thematic analysis 
that identifies recurrent themes in the understandings (eg. 
perceptions, attitudes and beliefs) of GPs regarding how 
depression affects the gay men they see in their practices, 
in comparison with heterosexual men. Both the differences 
(eg. ways of seeking help, attitudes to treatment) and 
similarities (eg. forms of emotional expression, excessive 
time spent on work) that they identified are understood 
to directly shape the management of depression in these 
populations. Broader social issues (eg. ageing, social 
isolation, poverty) are understood to also complicate 
and exacerbate individual experiences of depression. GPs 
with less experience in treating gay and HIV positive men 
can benefit from these insights to ensure that depression 
is accurately detected and effectively treated in these 
populations. 
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HEALTH	AND	EPIDEMIOLOGY
A	COMPARATIVE	STUDY	OF	SYPHILIS	&	HIV	
FROM	A	MELBOURNE	GENERAL	PRACTICE	
PERSPECTIVE.
Roth N, Nicolson J
Prahran Market Clinic, South yarra, Victoria, Australia.
Since ~2000, there has been a resurgence of syphilis, 
particularly in homosexual men (MSM) and in HIV positive 
men. With an apparent rise in the rate of new HIV infections 
(particularly in Victoria) there has been speculation that 
this signified a rise in risk-taking behaviour among MSM 
and/or confirmation that syphilis-associated ulceration 
and inflammation increases the risk of HIV acquisition.
Our clinic has a predominantly gay patient population, 
with a significant HIV caseload. We conducted a 
retrospective case review of all diagnoses of syphilis, with 
the aim of describing the differences, if any, between HIV 
positive and negative men in the presentation, treatment 
response and follow-up of syphilis cases.
The clinic uses a computerised medical record system 
(CMRS). All patients with positive syphilis serology were 
identified. By manual review, cases of previous treated 
syphilis were removed, focussing this study on de novo 
syphilis cases. The CMRS was then reviewed for all 
identified cases to identify the parameters of interest.
187 diagnoses of syphilis were identified: 86 in HIV negative 
men, 101 in HIV positive men. Differences were found in 
the presentation, treatment regime, occurrence of Jarisch-
Herxheimer reaction and adequacy of serological follow-
up in the HIV positive vs. negative groups. Response to 
treatment was the same in both groups. In 7 cases, a 
possible relationship was observed between the syphilis 
diagnosis and subsequent HIV seroconversion. Follow-up 
serology was significantly more consistently performed 
in HIV-positive patients.
The clinical presentation of syphilis in HIV positive men 
is associated with more florid clinical symptoms and 
signs and better clinical follow-up, but a similar treatment 
response to HIV negative men. Better documentation of 
a past history of syphilis in medical records is needed to 
optimise follow-up.
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HEALTH	AND	EPIDEMIOLOGY
LOCAL	HIV	INFORMATION	TESTING	
AND	SUPPORT	(HITS)	PILOT	PROGRAM:	
IMPROVING	THE	CAPACITY	OF	GENERAL	
PRACTITIONERS.
Stoove M1, Jenkinson R1, Hellard M1
1 Centre for Epidemiology and Population Health Research, 
The Burnet Institute, Melbourne, VIC, Australia.
In Victoria, around one third of the men who have sex 
with men (MSM) diagnosed with HIV each year have 
their testing and diagnosis preformed at “low case load” 
GP clinics. These low case load clinics are responsible for 
the diagnosis of less than three HIV cases per year. MSM 
diagnosed by these GP clinics have been shown to have 
lower CD4 counts compared to those diagnosed at high 
case load clinics. Low CD4 counts are indicative of late 
diagnostic presentations, suggesting that men attending 
low case load GP clinics may have been infected with 
HIV for longer. These patients have a greater potential to 
transmit HIV infection to others by not being aware of 
their infection and through potentially higher viral loads. 
The purpose of the HITS pilot program is to improve the 
capacity of GPs working in low case load clinics to discuss 
issues of sexual health and sexual risk behaviour with 
MSM, improve HIV/STI testing, management and referral, 
and develop clinical practices that are MSM welcoming. 
The program includes: a review of existing HIV/STI 
information; interviews with GPs/practice nurses; a sexual 
health update session; development of a sexual health 
education package; implementation of a system for 
distribution of educational material; and a consultation 
service for GPs to access support, advice and/or referral 
information.
A process and impact evaluation will be conducted 
to assess the objectives of this program, including pre- 
and post-program surveys and interviews with MSM. 
Findings from the HITS pilot program and evaluation will 
be presented.
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NPEP	REPEAT	PRESENTERS	MODEL	OF	CARE
Armishaw J 1, Earle M 2, Pierce A 1 Wright EJ1
1. Victorian NPEP Service, Infectious Diseases Unit, Alfred 
Hospital, Melbourne, Victoria, Australia
2. Sex Health and Wellbeing Service, Victorian HIV Service, 
Infectious Diseases Unit, Alfred Hospital, Melbourne, 
Victoria, Australia
Non-occupational post-exposure prophylaxis (NPEP) is a 
course of antiretroviral medications commenced within 
72 hours of exposure to HIV and taken for 28 days in order 
to reduce the risk of acquiring HIV infection. NPEP has been 
available at The Alfred Hospital in Melbourne since 2000. 
The Victorian NPEP Service was established in August 
2005 and NPEP availability has been rolled out into the 
community, with NPEP now available at 9 metropolitan 
centres and in 5 rural areas. Approval to maintain a 
database of individuals presenting for NPEP was granted 
by The Alfred Research and Ethics Committee. Consent 
for coded information to be sent to the Victorian NPEP 
Service for inclusion on the database is obtained.
From 10 August 2005 to 31 Dec 2007 (28 months), 
1022 patients have presented on 1207 occasions of 
service, with 204 patients (20.0%) presenting on 383 
occasions. Of the 204 patients who have had repeat NPEP 
presentations, 116 patients (56.9%) presented twice, 46 
(22.5%) presented 3 times and 22 (10.8%) had 4 or more 
presentations. Repeat presentations made up 31.7% of all 
consultations. Data from the Health in Men (HIM) Cohort 
shows that those who presented for NPEP were 2.2 times 
more likely to sero-convert to HIV. NPEP presentation is a 
marker of HIV risk, which if not addressed, may lead to HIV 
acquisition from future exposures.
The Repeat Presenter Model of Care was implemented 
in February 2008 and targets those who have presented 
for NPEP 3 or more times in the previous 2 years. The 
model of care has 3 components. Patients are asked to 
nominate a GP/clinic where they will attend for any future 
NPEP presentations and to consent for a summary of their 
NPEP history to be sent to the nominated GP/clinic. These 
2 interventions aim to support a therapeutic relationship 
between the patient and the doctor where risk reduction 
can be approached from a more informed position. The 
third intervention is for the patient to agree to a referral 
to the Sex Health and Wellbeing Service, a psychology 
service at The Alfred Hospital focussed on men’s sexual 
health.
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USING	FINANCIAL	INCENTIVES	TO	INCREASE	
HEPATITIS	B	IMMUNISATION	COMPLETION	
IN	INJECTING	DRUG	USERS:	A	RANDOMISED	
CONTROLLED	TRIAL
Barnes K, van Beek I, Day C, Topp L, Shanahan M, Wand 
H, Maher L (on behalf of the Hepatitis Acceptability and 
Vaccine Incentives Trail (HAVIT) Group*) 
Using financial incentives to increase hepatitis B 
immunisation completion in injecting drug users: A 
randomised controlled trial
While injecting drug users (IDUs) are at high risk of 
hepatitis B virus (HBV) infection, studies have documented 
low rates of immunisation uptake, completion and 
vaccination-induced immunity. The HAVIT trial seeks to 
identify strategies to improve HBV vaccine completion and 
seroconversion. The study will also gather important data 
on acceptability and IDU attitudes towards immunisation 
which will inform preparedness for candidate HCV 
vaccine trials.  
The primary objective is to compare the proportion 
of participants who complete the vaccine series in an 
incentive payment arm relative to a standard care arm. 
Secondary objectives are to assess the incremental cost 
effectiveness of standard care compared to incentive 
payments as methods of improving series completion; 
identify the correlates of immune response (HBsAb≥10 
mIU/ml) week 12; and determine the acceptability of 
vaccines, barriers to immunisation uptake and willingness 
to participate in vaccine trials.
Results have the potential to reduce the burden of disease 
associated with HBV infection, and potentially, other 
vaccine-preventable infections, in IDUs by providing data 
on the efficacy and cost-effectiveness of contingency 
management in this group. Results in relation to 
acceptability, attitudes and willingness to participate will 
inform preparedness for future HCV clinical trials. 
* Lisa Maher, Ingrid van Beek, Carolyn Day, Libby Topp, 
Marian Shanahan, Handan Wand, Craig Rodgers, Greg 
Dore, Andrew Lloyd, Paul Haber, Nicholas Walsh.
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ASHM	-	ORAL	POSTER	SESSION	-	
SOCIAL	RESEARCH,	INTERNATIONAL,	
COMMUNITY,	INDIGENOUS
NETREACH:	ONLINE	PEER	OUTREACH	
TO	VIRTUAL	COMMUNITIES	ACROSS	
AUSTRALIA
Brown G1, Keen P2, Maycock B1, Hyde Z1
1Western Australian Centre for Health Promotion 
Research, Curtin University Perth, Australia
2Australian Federation of AIDS Organisations, Sydney, 
Australia
NetReach was a peer-based sexual health promotion 
outreach program targeting Australian men who have 
sex with men (MSM) via Internet chat rooms and profile 
sites.  It was a collaborative effort of the AIDS Councils of 
Western Australia, South Australia, Victoria, Queensland 
and Tasmania and the Australian Federation of AIDS 
Organisations.  
In essence peer volunteers and staff entered existing 
commercial online chat rooms in a similar way to peer 
outreach at social, community and sexual venues. The 
program was implemented in a way that aimed to 
respect and support the users of this virtual environment 
and the online community they had created. During 
the brief development and trial period there were 304 
outreach shifts, with exposure to 27,672 people and 460 
in depth online discussions. 18 months after the end of 
the trial period AIDS Councils were interviewed to discuss 
the sustainability of the program and why some had 
maintained the interventions and why some had ceased 
Internet outreach in this format.
The online environment may change significantly in 
as little as six months, requiring the delivery of online 
outreach programs to be modified.  Planning, funding and 
evaluation arrangements need to reflect this.  Involving 
participants from the online community in the project 
was critical to maintain a level of cultural acceptance 
and credibility, adapt to rapid changes inn culture 
and technology, and to sustain a reflexive approach. 
Feedback from AIDS Councils 18 months after the trial 
period focused around the challenges of sustaining 
outreach with limited numbers of participants or capacity 
to track direct impact verses the need to be part of the 
developing context of online communities. 
Organisations looking at online outreach need to consider 
their infrastructure, connections to online cultures, and 
flexibility of funding requirements before embarking on 
an investment into online outreach.
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ORAL	POSTER	THURSDAY	18	SEPTEMBER	
0840	–	0845
ASHM	-	ORAL	POSTER	SESSION	-	SOCIAL	
RESEARCH,	INTERNATIONAL,	COMMUNITY,	
INDIGENOUS
SERO-SORTING:	WHAT	IS	THE	IMPACT	ON	
HIV	TRANSMISSION	IN	GAY	MEN	AND	HOW	
DO	WE	REDUCE	IT?
Stevie Clayton, CEO, ACON (AIDS Council of NSW)
Dermot Ryan, Manager Education, ACON (AIDS Council 
of NSW)
Research among Sydney gay men conducted by Australia’s 
National HIV Research Centres since 2001 shows an overall 
decline in partner numbers and in UAIC, an increase in 
disclosure of HIV status to sexual partners, and increased 
reporting of partners of the same sero-status. Disclosure 
of sero-status and negotiation around condom use often 
occurs in a context of trust and familiarity between players 
which could indicate an increase in sero-sorting or simply 
a greater willingness to discuss HIV status. 
Sero-sorting is the practice of consciously choosing sexual 
partners of the same HIV status to facilitate unprotected 
anal intercourse while minimizing HIV transmission. 
Recent studies have shown an increase in sero-sorting 
amongst both HIV positive and HIV negative Sydney gay 
men. 
With a population as highly educated about HIV as 
Sydney gay men, provision of information about risk may 
not be sufficient to effect behaviour change as there are 
complex analyses of relative risk versus potential pleasure 
being undertaken, which require greater understanding 
of motivation for effective interventions.
Based on this evidence ACON developed a culturally 
appropriate, multi-faceted campaign encouraging gay 
men to reflect on assumptions and beliefs which influence 
their decisions around condom use in the context of 
their knowledge, or presumed knowledge, about the HIV 
status of themselves and their partners. 
This paper will examine the current research, reflect on 
the campaign and consider the evaluation results.
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AVOIDING	HEPATITIS	C	INFECTION	DESPITE	
LONG	TERM	INJECTING:	BEHAVIOURAL,	
SOCIAL	OR	IMMUNOLOGICAL?	
Peter Higgs 1, Campbell Aitken 2, Margaret Hellard 2  and 
Lisa Maher 1
1Viral Hepatitis Epidemiology & Prevention Program, 
National Centre in HIV Epidemiology & Clinical Research, 
UNSW ; 2Centre for Epidemiology & Population Health 
Research, The Burnet 
Abstract: 
Transmission of hepatitis C (HCV) in injecting drug users 
primarily occurs as a result of exposure to the virus during 
injection. There is some evidence that previous infection 
with HCV may be protective for future infection of the 
same genotype but not against other genotypes.  If this 
is true and HCV infection occurs at similar or higher rate 
in previously exposed compared to naïve individuals 
this poses significant challenges for HCV vaccine 
development. 
The Networks II study is an ongoing cohort study of HCV 
among injecting drug users (IDUs) being conducted in 
Melbourne, Australia. Three hundred and ninety-five IDUs 
were recruited between July 2005 and November 2007 
and most were interviewed and tested for HCV markers 
at least twice.  
Fifty IDUs remained HCV antibody and RNA negative at 
their last test, and 10 people initially lacking evidence 
of exposure to HCV tested RNA-positive during the 
study.  Initial analyses indicate that people who reported 
injecting with five or more others in the three months 
prior to  baseline were significantly more likely to be 
infected with HCV at any time than people who reported 
injecting with fewer than five others.  
However,  there may not be specific injecting risk 
behaviours that markedly increase or decrease an IDU’s 
risk of HCV exposure and infection. Some IDUs may 
simply be lucky, others may unknowingly only inject or 
share with other HCV negative IDUs; alternatively, some 
individuals’ immune systems may protect them from 
infection.
The ability of some IDUs to escape or reject HCV infection 
despite repeated and often long-term exposure has 
been previously noted by ourselves and others, and is the 
subject of an ongoing international collaboration. 
P219
COUNSELORS’	PERSPECTIVE	AND	qUALITY	
OF	COUNSELING	IN	VOLUNTARY	HIV	
COUNSELING	AND	TESTING	CENTERS	IN	
DELHI
Kant S
Background: Confidential counseling process is a crucial 
step towards providing prevention, care and support 
services. It empowers the client to make informed choice 
about getting tested to know their HIV sero-status. With 
rapid scale of counseling and testing services in India, 
ensuring quality of counseling becomes very important. 
We have assessed quality of counseling provided and 
satisfaction level of counselors working in Voluntary 
Counseling and Testing Centers (VCTC) of Delhi.  
Methods: A cross-sectional health-facility survey was 
conducted in 10 randomly selected VCTC of Delhi. 
The observations of counseling sessions were carried 
out by investigator through personal presence during 
counseling using checklist. Counselors were interviewed 
using a semi-structured interview schedule that assessed 
counselors’ perception as HIV counselor, trainings received; 
availability and need of support and supervision; their 
job satisfaction in present set up. It’s a semi-structured 
interview schedule administered to the counselors. 
Qualitative analysis of statements was done by coding 
of themes, domain identification and calculation of 
frequencies. 
Results: Ten out of 18 VCT centers were selected randomly 
(3/6, 5/8 and 5/8 from teaching, non-teaching and 
specialized hospitals respectively). Fifty-one counseling 
sessions were observed and 17 counselors interviewed. 
Six out of 17 counselors were Masters in Social Work. 
Counselors demonstrated good interpersonal skills 
but needed in-service training to further improve their 
counseling skills. Majority (9/17) of counselors believed 
a positive career prospect as counselor. Few (5/17) felt 
insecure due to low salary structure and temporary nature 
of the job. The counselors reported the need of in-service 
training that should be practically oriented (10/17). 
 
Conclusion: The quality of counseling was found to be at 
par with other studies and the counselors were overall 
satisfied with their job profile. The nature of training 
being received by the counselors has to be reviewed with 
particular emphasis on frequency of in-service training, 
eligibility of trainers and practical orientation of courses.  
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ORAL	POSTER		FRIDAY	19	SEPTEMBER	1615	
–	1625
ASHM	-	CLINICAL	-	TOxICITY	
																												
A	PUBLIC	ACCESS	PROGRAM	OF	SCULPTRA®	
POLYLACTIC	THERAPY	TO	TREAT	PEOPLE	
WITH	FACIAL	LIPOATROPHY	
Knox D1, Carr A2, Conway D3, Edwards B 1, Flanagan G4, 
Furner V5, Heslop J6, Honnor G4, Lake R4, McKellar-Stewart 
N7, McMurchie M8 and Pollard A7.
1 HIV/AIDS & Related Programs (HARP) Unit, South Eastern 
Sydney and Illawarra Area Health Service, Sydney, NSW, 
Australia, 2 St Vincent’s Hospital, Sydney, 3 Australasian 
Society for HIV Medicine, 4 Positive Life NSW (previously 
PLWHA NSW), 5 Albion Street Centre SESIH, 6 HARP Unit 
North Coast Area Health Service, 7 ACON, 8 East Sydney 
Doctors (formerly 407 Doctors) East Sydney NSW.
Around half of people living with HIV in Australian report 
some degree of lipodystrophy, with most reporting 
consequent stigmatisation and poor body image. 
A number of cosmetic treatment options for facial 
lipoatrophy are available through private clinics.  In 2006 
NAPWA negotiated with a major pharmaceutical company 
to provide polylactic therapy as part of a compassionate 
access scheme for the delivery of Sculptra® to a defined 
number of HIV positive people in Australia for no charge. 
In New South Wales, the HARP Unit of South Eastern 
Sydney and Illawarra Area Health Service, in collaboration 
with a multidisciplinary Steering Committee and with 
funding from NSW Health, developed and implemented 
a Sculptra® Program.  The Program was for eligible HIV-
positive adults in NSW to be assessed by their S100 
prescribing doctors to receive therapy.  Access was based 
on severity and financial need.
NSW received Sculptra® for 205 individuals to receive 8 
vials (4 treatments). Allocations of places into the program 
were made to S100 Prescribers based on antiretroviral 
prescription numbers per service.
Plastic and cosmetic surgeons across the state who are 
able to provide Sculptra® were contacted and 12 agreed 
to be part of the Program.   Prescribers referred clients to 
these proceduralists.
205 individuals were enrolled into the program which 
ran from April 2007 until June 2008. Clients were offered 
up to four treatments, each about 2 weeks apart, and 
a survey evaluation of the program was conducted 
with the patients, the referring prescribing doctors and 
proceduralists.
187 clients received treatment, with 53 of these returning 
the evaluation survey so far (28%).  Clients were asked to 
indicate ‘yes’ or ‘no’ to the question of satisfaction with 
treatment, with 52 indicating they were satisfied, with 1 
writing that they would ‘wait and see’.
Of the 12 proceduralists engaged, 10 saw clients as part 
of the program and were sent evaluations.  Of these 8 
have returned completed surveys (80%), with 3 reporting 
minor nodules or bruising.
49 prescribers referred patients to the program and were 
sent surveys.  26 surveys have been returned (53%), with 
25 reported no adverse reactions and 1 noting ‘expected 
local reactions’.
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CAUSES	OF	DEATH	OF	HIV	_	INFECTED	
PATIENTS	RECEIVING	HAART	IN	UGANDA
Author Waiswa Moses, John Muwanga.
The African child care and Mother Development: (ACMD) 
Kampala- Uganda
Background: HAART has had a dramatic impact in the HIV 
epidemic in Uganda. With a clear decline in morbidity 
and mortality, although even in development countries, 
with a wide spread use of effective treatment HIV- related 
deaths are still occurring.
Methods: We review the charts of all Hiv - infected patients 
who have died from march 2004 through August 2007. 
we evaluate the basic epidemiologic data, immunologic 
and virologic status, treatments received, and causes of 
death of every patient.
Results: of the 865 patients of our cohort, a total of 50 
(5.5%) have died in the study period. SD of age at the 
time of death is 35_+ 6years, 40, (85%)are male, 36 (77%) 
are women, medium of CD4 Cell count is 79permm, and 
medium of HIV RNA is 4.9log: 6patients(13%)had never 
received anti-retroviral therapy although they should 
have received according to guidelines, and 20 patients 
are receiving suboptimal treatment or no treatment at 
all. Cirrhosis of the liver is the cause of death in 18 pati
ents(38%),progressive multifocal koencephalopathy in 
6 (13%),wasting syndrome in 12(23%),and pneumonia 
in 3(6%).compared with the rest of the cohort, patients 
who have died are commonly men, are more commonly 
HCV-infected, have lower CD4 count, and have higher 
HIV RNA(all differences p<.0.1).
Conclusion: in the era of HAART, the first causes of death 
in patients with Hiv infection is Cirrhosis of the liver, in 
adequate treatment is common among patients who 
die.
P223
AN	ExAMINATION	OF	A	NUMBER	OF	RECENT	
HIGH-PROFILE	AUSTRALIAN	CRIMINAL	
CASES,	TO	HIGHLIGHT	THE	COMPLEx	
RELATIONSHIP	BETWEEN	THE	LEGAL	
REGULATION	OF	HIV	TRANSMISSION	AND	
ExPOSURE,	AND	EFFECTIVE	PUBLIC	HEALTH	
OUTCOMES
David Scamell, Policy Manager, AIDS Council of NSW
Sally Cameron, Policy Consultant to Australian Federation 
of AIDS Organisations
Description 
There is a growing international trend towards the 
employment of criminal law in relation to HIV transmission 
and exposure despite a lack of evidence to demonstrate its 
effectiveness in reducing the incidences of HIV infection. 
The type of laws that are enacted and the manner in 
which they are used present a number of considerable 
challenges to established public health HIV prevention 
practices based on individual responsibility, voluntary 
testing, and access to treatment, care and support.  
Recently a number of HIV-related prosecutions in Australia 
have occurred, attracting significant political and media 
attention. These cases have coincided with a rise in HIV 
infections across the country. The confluence between 
these cases and the rise in infections has resulted in 
public and government debate about the role of law in 
Australia’s response to the epidemic and the effectiveness 
of the response more generally.  
Lessons learned 
While the debate to date has reinforced the broad public 
health approach to HIV prevention, certain aspects 
reinforced the need for HIV policy to be guided by 
comprehensive evidence, particularly given the impact 
criminal penalties for HIV transmission may have in 
relation to increasing stigma and decreasing levels of 
testing and willingness to access health services.  
Next steps 
Further research is needed across multiple jurisdictions 
and within differing epidemics (generalized or within 
specific population groups) as to the impact and 
effectiveness of criminalization on HIV prevention. 
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MEN’S	qUICK	qUIz:	ANNUAL	SNAPSHOT	
OF	STI	KNOWLEDGE	AT	A	GAY	COMMUNITY	
EVENT
Prihaswan P1, Shaw MJ1, Silveira M1.
1HIV & Related Programs Health Promotion Team 
(Inner West), Sydney South West Area Health Service, 
Camperdown, New South Wales, Australia.
As the Sydney Mardi Gras Season’s biggest daytime event, 
Mardi Gras Fair Day provides an opportunity to promote 
local sexual health services to gay men and to check their 
sexual health and service knowledge.
Since 2004, we have been coordinating the administration 
of a ‘Quick Quiz’ to gay men attending Fair Day. The quiz 
includes a series of questions on STIs which are revised 
annually. Questions generally address the asymptomatic 
nature of STIs, current STI testing recommendations and 
treatment for STIs. The quiz also asks about access to 
sexual health clinics and general practice for regular sexual 
health check-ups. Information on age and postcodes are 
also collected. 
The quiz is also useful as a tool to engage respondents in 
discussion about sexual health and is administered from 
an information stall shared by metropolitan Area Health 
Services. 
Each year, about half of the respondents have 
demonstrated good understanding of the asymptomatic 
nature of STIs. The majority have also demonstrated good 
knowledge of current STI testing recommendations and 
were generally aware of treatment for STIs. 
A smaller proportion of respondents reported accessing 
GPs for sexual health care. For those men accessing GPs, 
the majority reported visiting a GP in the Darlinghurst 
area.
 
This paper will focus on the results of respondents from 
Sydney’s inner-west. A detailed analysis of the quiz results 
from 2005 to 2008, including attendance at public sexual 
health services and general practice, will be presented. 
Recommendations for future STI campaigns and capacity 
building programs for health care workers, including GPs, 
will also be discussed.
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SExUAL	BEHAVIOUR	IN	FIJI	ISLANDS.	A	
RETROSPECTIVE	K.A.P	SURVEY	ON	SExUAL	
BEHAVIOUR	IN	FIJI
Chaudhary A
The Western Health Hub Centre in Fiji caters for around 250 
000 people. Since the inception of the clinic in 2004, 5367 
clients seeking STI and HIV related out-patient services 
have been seen. History from clients is recorded in a set 
template and upon seeking verbal consent, question on 
personal sexual behaviour is asked and recorded. The 
clients were also informed that the information will be 
used to draw up statistics on sexual behaviour in Fiji and 
also that their names would be kept confidential.  
Of the 5367, 133 did not qualify and 82 declined to answer 
personal question.
The records of the 5152 clients was analysed and a 
comprehensive report on sexual behaviour [wich 
included age of first sex, number of sexual partners, 
use of condoms, and failure to use of condoms,  sexual 
orientation and knowledge and attitude towards sex] 
Correlations between the ethnic groups, social status, 
marital and education level with the sexual behaviour 
was elicited. 
P227
CAMP	GOODTIME:	CATERING	FOR	THE	
DADS!	
SOCIAL	RESEARCH	INTO	THE	
IMPLEMENTATION	AND	EVALUATION	OF	
SPECIFIC	GROUP	PROGRAMS	FROM	2002-
2007	AS	PART	OF	A	UNIqUE	NATIONAL	
SERVICE	TO	FAMILIES	LIVING	WITH	HIV/AIDS
CoadyJF1
1Short Street Clinic St George Hospital KOGARAH NSW 
2217
Camp Goodtime is an annual four day camp facilitated 
by the Paediatric HIV service at Sydney Children’s Hospital 
providing support to children and families living with 
HIV/AIDS. Operating since 1990, this unique service 
provides medical management, psychological support, 
consultation and education in framework aimed at 
reducing isolation experienced by these families. Trained 
volunteers are assigned to care for the children while two 
social workers cater to the needs of the parents.
Social work input for parents had previously been on 
an ad hoc basis, usually with a different worker each 
year. The last five years however has seen a continuous 
social work service to fathers allowing the development 
of a formalised group program. This program focused 
on developing connection, sharing experiences and 
information, providing client support and nurturing peer 
and self support. It was envisaged that this knowledge 
and experience would benefit the fathers and their 
families in self management strategies long after they left 
the camp. 
Apart from annual evaluation reports garnered by the 
service, there had been no research done as to the 
efficacy of the range of benefits received from the group 
programs by attending families, and in particular by 
the fathers. A qualitative research project was initiated 
in 2007 to provide and evaluate written and recorded 
data to research the lived experience of this unique 
client group over a five year period. A detailed analysis 
of the specialized service was undertaken to ascertain 
what impact it has made in the lives of these families. 
Initial findings indicate the programs have been highly 
desirable, with further details to be presented. 
Information provided from this research will assist social 
workers and other allied health professionals involved in 
HIV care to adapt their client centred approach to improve 
outcomes in working with specific populations such as 
these families from diverse parts of Australia.
SOCIAL	RESEARCH
PO
ST
ER
	A
BS
TR
A
C
TS
	
SO
C
IA
L	
RE
SE
A
RC
H
17-20 SepteMber 2008 @ pertH ConVentIon Centre, WeStern AuStrAlIA                           277
P228
ORAL	POSTER	SATURDAY	20	SEPTEMBER	
0815	–	0820
ASHM	-	ORAL	POSTER	SESSION	-	CLINICAL,	
ALLIED	HEALTH	AND	BASIC	SCIENCE
PHYSICAL	AND	SOCIAL	BENEFITS	OF	
ANTIRETROVIRAL	THERAPY	(ART)	ON	THE	
LIVES	OF	PEOPLE	LIVING	WITH	HIV	AND	
AIDS	(PLWHA)	IN	PAPUA	NEW	GUINEA	(PNG)	
Emori R1, Kelly A2, Akuani F1, Nosi S1, Peter B1, Kupul M1, 
Walizopa L1, Mek A1 , Pirpir L1,Worth H2 and Siba P1. 
1PNG Institute of Medical Research, Goroka, Eastern 
Highlands Province, Papua New Guinea; 2 National Centre 
in HIV Social Research, University of New South Wales, 
Sydney, Australia. 
In the past three years, there has been an increase in efforts 
to roll out ART in PNG. While there is some knowledge of 
the clinical impact of ART in PNG in terms of morbidity, 
little is known of the social impacts of these treatments. 
In an effort to understand these social impacts, this study 
has sought to explore these impacts of ART on PLWHA 
in PNG. 
This study used a multi-method approach to examine the 
social impacts of ART for PLWHA. A total of 152 people 
were surveyed and 28 participated in in-depth interviews. 
Ethics approval was granted by the PNG Medical Research 
Advisory Committee and University of New South Wales, 
Australia. 
Since taking ART, the majority of people reported that 
their health status improved. 90.8% of participants’ rated 
their physical health as good to excellent whereas before 
ART only 8.5% participants had good health. In the last 
month on treatment 94.1% of people rated their mental 
health as good to excellent where in the month before 
treatment only 15.7% rated their mental health as good. 
Prior to commencing ART 44.1% indicated that their 
quality of life was poor.  On treatment 50.7% people 
experienced an improvement in the quality of life. 
The qualitative data shows similar results with most 
participants experiencing improvements in physical and 
social aspects of their lives. These included regaining 
strength and appetite; being able to work; tend to chores 
and work in the gardens; and walk long distances again. 
Other physical improvements included gaining of weight 
and the re-growing of hair.  The social benefits of these 
physical consequences of ART were considered of high 
importance because they meant that they were no 
longer recognizable as someone with HIV.  
ART has provided physical and social benefits to PLWHA. 
Their health and well-being has improved and their 
capacity to engage with family and the community has 
benefited. While these results don’t disprove any of the 
real negative impacts of ART such as side effects, these 
physical and social benefits are significant as ART rolls out 
and the country monitors the success of ART in its socio-
cultural context.  
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VISUAL	RESPRESENTATION	OF	PEOPLE	
LIVING	WITH	HIV	IN	PAPUA	NEW	GUINEA
Mek A1, Kelly A2, Akuani F1, Kepa B1,  Kupul M1, Emori R1, 
Peter B1, Nosi S1, Pirpir L1 & Walizopa L1
1Operational Research Unit, Papua New Guinea Institute 
of Medical Research, Goroka, Eastern Highlands Province, 
Papua New Guinea 
2National Centre for HIV Social Research, University of 
New South Wales, Sydney, NSW, Australia 
Participatory visual methods are used in social research 
to better understand people’s experiences of health, 
illnesses, death and dying including the everyday lives of 
people living with HIV. Such methods offer an alternative 
to the spoken and written word, and the statistical 
representation of life. The use of visual methods was 
chosen to understand how people pictorially perceive 
themselves living with HIV in Papua New Guinea (PNG) 
and to pilot the use of such methods here. The data 
analysis is based on these drawings of self-image of 
the body at various stages in the lives of people living 
with HIV and the shift from imminent death to a life on 
antiretroviral therapy (ART). 
The visual data is drawn from a larger mixed-methods 
study on the social impacts of ART on PLWHA in 3 
provinces of PNG. Of those who participated in the 
qualitative interviews, eight participants illustrated on 
paper their routine daily activities and the meanings of 
HIV prior to and after treatment. 
The images contrast the difference between suffering 
bodies confronting imminent death (prior to ART) with 
healing, healthy bodies (post-ART). Before going on ART, 
people positioned HIV as inseparable from who they were. 
In contrast, in drawing life after antiretroviral treatment 
they displayed drastic bodily changes leading to social 
interaction and a new relationship to death. People drew 
themselves interacting with others; with healthy bodies; 
with their hair growing; with flesh on skeletons, and; being 
able to participate in life again. ART transformed people’s 
lives from one of inevitable death to one of renewed life. 
For HIV-positive people, the images they drew are 
powerful tools that offer researchers an alternative 
method of grasping what it means to live with HIV and 
a method that can be applied in contexts where visual 
imagery has a particular importance - such as PNG.
P230
TRANSLATION:	PAPUA	NEW	GUINEAN	
RESEARCHER’S	PERSPECTIVE
By Pirpir Lawrencia 1, Kelly Angela 2, Nosi Somu 1, Walizopa 
Lucy 1, Mek1 Agnes, Emori Rebecca 1, Akuani Frances 1, 
Kupul Martha 1, Peter Cangah Brenda 1, Kepa Barbara 1 & 
Keleba Kritoe 1
1 Papua New Guinea Institute of Medical Research
2 University of New South Wales National Centre for HIV 
Social Research
The philosophy that underpins the Strengthening HIV 
Social and Behavioural Research Cadetship Program at 
the Papua New Guinea Institute of Medical Research is 
one of ‘learning by doing’, carrying out ‘real life’ research 
projects. After completing a study on the attitudes of 
young people towards sex and HIV the issue of language 
and translation became a real life scenario which the 
cadets had to become skilled in.
In HIV social and behavioural research the role of language 
is critical. How questions are asked can influence the way 
a person responds. But more than this, in international 
research, the role of translating one language into another 
is pivotal. Simply knowing the words of a language is not 
sufficient to translate that language into another.
This paper highlights how translation requires the careful 
recreation of meaning from one language to another, 
not a literal word for word exchange. Learning to capture 
meaning in this way is a skill and one that requires capacity 
building, as has been the experience of the HIV social and 
behavioural research cadets in PNG.
We cannot expect that because someone is fluent in 
their own language that they will be automatically able 
to translate it. Translation is a complex skill that social 
researchers need to develop. This entails understanding 
local differences in the use of language, for example 
the metaphor ‘kol kaukau’ in Tok Pisin literally means 
‘cold sweet potato’. However, the meaning of this in its 
speech context was that the introverted girls are those 
who go around and have sex. Thus, an English translation, 
metaphorically, could be ‘still waters run deep’.
The skill of translation needs to be seen as an important 
priority in capacity building of social researchers who 
work across languages in setting where training has been 
limited.
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DOES	COMMUNITY	TESTING	FOR	HIV	PROVE	
EFFECTIVE?	
[A	CROSS-SECTIONAL	STUDY	IN	NEPAL]
Regmi K
Background: HIV epidemic continues to pose a major 
public health challenge. National strategy for HIV aims to 
decrease the number of HIV through increased testing for 
disadvantaged and hard to reach group i.e. sex between 
men, sex between men and women and injecting drug 
users. Fear of stigmatisation and lack of peer supports 
found major barriers to attend sexual health and HIV 
screening. In order to further de-stigmatised HIV testing, 
a service for HIV has been offered and managed as part 
of a general health screen where urine tested for raised 
sugar and Chlamydia as well as blood pressure screening 
and advice on maintaining a healthy life style. The 
purpose of the present study was to examine the effects 
of community testing for HIV.
Methods: Standard 2 steps HIV testing is limited by poor 
return for results rates and misses high risk individuals 
who do not access conventional testing facilities. We, 
therefore, describe a community testing programme 
among people who had  difficultly in accessing and 
utilising of government local heath care services due 
to stigma and challenging socio-cultural circumstances 
using Abbort Rapid Determine HIV-1/2 test among three 
primary health centres in rural part of Nepal, in 2005/6.
Results: over 6 months, 200 adults were invited to 
participate and 180 (90%) underwent testing. HIV 
seroprevalence was 17.2% (31 of 180) overall and 3.9% 
amongst hard to reach individuals reporting no previous 
testing, a prior negative test of previous testing without 
result disclosure. All 180 patients received their results. Of 
15 newly diagnosed persons who received confirmatory 
results, 7 (47%) reported at least one contact with a health 
provider in four months following diagnosis. Individuals 
who reluctant to use hospital services were also attended 
for testing, which enabled them to access treatment 
and care for long term health benefits. General and test-
specific counselling, mobilising health care professionals, 
found important in dealing with positive and negative 
results.
Conclusion: limited evidence suggest that routine HIV 
testing in hospital setting has a part to play in increasing 
uptake of testing and thus preventing deaths. This study 
concludes that community testing for HIV is feasible, 
acceptable and effective based on the number of high 
risk persons tested over a short period, the participation 
rate, the prevalence of new infection the rate of result 
disclosure and the proportion linked to care and support. 
Increasing update of HIV testing will have both individuals 
and public health benefits.
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HEALTH	AND	EPIDEMIOLOGY
THE	EFFECT	OF	INTRODUCING	SPECIALIST	
BLOOD	BORNE	VIRUS	(BBV)	NURSES	INTO	
PRISON	HEALTH	CENTRES.	
Connelly C 1, Patterson KL 1 , McNulty L 1 .
1Department of Corrective Services, Hakea Prison, Perth, 
WA, Australia
Socio economic challenges and psychiatric illness can 
affect the physical health and well being of an individual 
and inadvertently, access to adequate medical care. Many 
prisoners report low employment rates, mental health 
issues and substance abuse prior to imprisonment. 
Imprisonment allows health care workers to take 
advantage of the opportunity provided by incarceration 
to offer health screening- including BBVs - and assessment 
to individuals who do not otherwise access a medical 
service.
Approximately half of all prisoners in Australia have a 
history of injecting drug use. BBV screening has become 
a priority for prison health services. Currently such 
screening is not compulsory upon reception to WA 
prisons though many prisoners have taken up the offer 
of testing after routine admission. Specialist BBV nurses 
conduct detailed screening of risk behaviour, Pre- and 
Post-Test Counselling, provide ongoing education and 
discuss treatment options. Currently the main focus is on 
Hepatitis C.
The creation of the specialist BBV nurse role has allowed 
significant health care benefits to patients in the custodial 
setting including:
• Increased rates of BBV screening 
• Access to support & harm reduction counselling and 
treatments.
• More prisoners will have treatment for their BBV thus 
reducing the public health burden of the disease.
Recent improvements in screening as a result of BBV 
nurses have led to the following outcomes;
• Screening of an average of 22 new patients per week.
• A current register of 76 people who are Hepatitis C 
antibody positive of whom 64 are also RNA positive.
• Of these 76 patients, eight were newly diagnosed 
cases of Hepatitis C detected in the current intensive 
screening program.
In conclusion, the introduction of specialist BBV nurses 
has resulted in improved care being provided to prisoners 
with, or at risk of contracting, Hepatitis C.
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SHOULD	WE	BE	VACCINATING	BOYS	AS	WELL	
AS	GIRLS	WITH	THE	HPV	VACCINE?
Regan DR1, Law MG1, Philp DJ2, Hocking JS3
1National Centre in HIV Epidemiology and Clinical 
Research, UNSW, Sydney: 2National Centre for 
Epidemiology and Population Health, ANU, Canberra: 
3Key Centre for Women’s Health in Society, University of 
Melbourne, Melbourne
HPV vaccination has been shown to be effective 
in preventing cervical cancer in females. While 
immunogenicity has been shown in males, trials are 
underway to demonstrate HPV vaccination is clinically 
effective.
Mathematical modeling of HPV transmission in Australia 
suggested that for a vaccine with 100% effectiveness 
and conferring lifelong immunity, then with coverage 
over 80%, vaccinating 12-year old males in addition to 
12-year old females had only a modest impact on HPV 
incidence among females. Vaccinating 12-year olds only 
was estimated to take long periods to take effect, with 
an estimated 7 years to achieving 50% of the effect on 
HPV incidence. A catch-up campaign, vaccinating 13-25 
year old females, was estimated to decrease this time to 
under 2 years. The models suggested that vaccination of 
males and females would not eradicate HPV with realistic 
vaccine coverage rates.
These models suggest that for a HPV vaccine of 100% 
effectiveness and conferring lifelong immunity, there is at 
most modest effect on cervical cancer risk in vaccinating 
males in addition to females. Vaccinating 12-year old 
males with such a vaccine would only be cost-effective if 
this resulted in appreciable reductions in HPV-associated 
disease in men, such as anal or penile warts, and anal or 
head/neck cancer. Vaccinating 12-year old males may 
be cost-effective in preventing cervical cancer among 
females if herd-immunity effects become important in 
the case that vaccination coverage rates are low, or that 
the vaccines prove to be only partially effective or confer 
limited duration of immunity. To answer these questions, 
it is important that the current HPV vaccination schedule 
in Australia is monitored, both in terms of coverage rates 
and conferred immunity.
Sexual Health Plenary 5: 
A Mixed Bag of Jewels
9.00am – 10.30am
IS	YOUR	CLITORIS	IN	YOUR	VAGINA	OR	THE	
VULVA!	WHAT	IS	A	VULVA!		
A Woman’s Personal Perspective and Experience of what 
is missing in sexual health and society, The Vulva 
Kath Mazzella 
This presentation aims to bring life to the vulva, bringing 
it out from the unknown or un-mentionable and giving it 
the recognition and the status it deserves. 
It will highlight the stigmas, misconceptions and taboos 
that surround the vulva and ask how women, educator’s, 
health professionals and society can break down these 
barriers and move to a healthy and accurate knowledge 
of this vital part of female genitalia. These questions will 
be posed and related to you through the perspective of 
one woman. 
A woman who’s experience of gynaecological cancer has 
taken her on an inspiring journey. A woman who went 
from knowing nothing about down there, to one who is 
now an empowered, assertive, understanding individual. 
The presenter will relate how her own experience altered 
her to how women in the community suffer in silence 
and of the need to give these women a voice. 
She will take you through her quest to raise the profile of 
this issue within Australia, 
Her successes – which include the establishment of the 
Gynaecological Awareness Information Network (GAIN), 
National Gynaecological Awareness Day – the lessons 
learned and the work that is yet to be done. She was 
also involved with the Australian Senate Gynaecological 
Cancer Enquiry. Key themes of the presentation include:
i.  Giving women better knowledge of, and responsibility 
for their sexual health 
ii.  Educators seeing it from a health consumers point of 
  view. Working together. 
iii. Calling a spade a spade, a vagina a vagina, and a vulva 
a vulva. How by not speaking about or acknowledging 
this part of the body can suppress emotions, dis-
empower women and cause significant psychological 
and physical health problems. 
iv. Encouraging women to be proud of their vulva 
instead of calling it something it is not: a vagina. Come 
and get inVULed!
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Sexual Health Plenary 6: Drugs and Sex
11.00am – 12.30pm
NATURAL	HISTORY	OF	HPV	IN	THE	ANAL	
CANAL:	EVERYONE’S	GETTING	INTO	THE	ACT
Palefsky JM1
1Department of Medicine, University of California, San 
Francisco, San Francisco CA USA 94143
A high proportion of anal cancers are associated with 
human papillomavirus (HPV), most commonly HPV16. 
The incidence of anal cancer is increasing annually in the 
general population among both men and women but 
has increased most dramatically among HIV-positive men 
and women. 
Among HIV-negative men who have sex with men (MSM), 
the epidemiology of anal HPV infection resembles that of 
penile infection more than that of cervical infection with 
approximately 60% having anal HPV infection throughout 
a wide age range.  In contrast nearly all HIV-positive MSM 
have anal HPV infection.  Other high-risk groups include 
HIV-positive women and high-risk HIV-negative women, 
in whom anal HPV infection is more common than cervical 
infection.  Anal HPV infection may also be as common or 
more common than cervical HPV infection in sexually 
active but healthy, lower risk women.  Finally, more than 
20% of heterosexual men have anal HPV infection. 
The key consequence of anal HPV infection is anal cancer- 
some but not all individuals with anal HPV infection will 
develop anal intrraepithelial neoplasia  (AIN) and fewer 
still will develop anal cancer.  The main risk factors for 
progression to high-grade AIN (HGAIN) are HIV-positivity 
with lower CD4+ level and oncogenic anal infection but 
risk factors for progression from HGAIN to anal cancer 
are not understood.   ART has not reduced the incidence 
of HGAIN  nor of anal cancer implying that the immune 
response plays a less prominent role in progression to 
anal cancer than in development of HGAIN.  The data 
suggest that the incidence of anal cancer will continue 
to grow in the future, raising questions about whether at-
risk individuals should be screened for HGAIN and/or anal 
HPV infection.  Additional questions relate to the effect of 
anal HPV in women on the biology and natural history of 
cervical cancer and its precursors.  
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ANAL	DYSPLASIA	AND	CANCER.	AN	
AUSTRALIAN	ExPERIENCE
Richard Hillman
Australian rates of anal cancer are rising in both males and 
females, with approximately 260 new cases being reported 
annually. Precursor lesions are typically asymptomatic, 
leading to frequent late-stage presentation and poor 
five year survival rates (typically 60 -70%). Furthermore, 
symptoms of anal cancer & associated treatments are 
often extremely unpleasant. 
Anal cancer occurs as a consequence of sexually 
transmitted infection and has an unusual epidemiology. 
Overall, rates in women are generally slightly higher than 
in men. However, within the two sexes, the distribution 
varies markedly. In women, anal cancer typically presents 
over the age of 60 years, in smokers, and in those with 
a history of cervical cancer & receptive anal intercourse. 
In men, it presents at a younger age, in men who have 
sex with men, and in the HIV-infected. Indeed, rates in the 
latter group are approximately 100 times higher than in 
the general population.
This presentation will review what we know of the 
epidemiology of anal cancer & precancerous lesions in 
Australia, the potential value of screening programs and 
the possible public health impacts of HPV prophylactic 
vaccination.
Sexual Health Plenary 7: 
Out of Sight Out of Mind 
1.30pm – 3.00pm
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IT’S	ONLY	A	COLD	SORE,	LOVE…
B Donovan. 
National Centre in HIV Epidemiology and Clinical Research, 
University of New South Wales, Level 2, 376 Victoria Street, 
Darlinghurst NSW 2010, Australia; and Sydney Sexual 
Health Centre, Sydney Hospital.
Over recent generations oral sexual practices have grown 
in incidence while re-positioning themselves in our 
society, with variations within different sub-populations. 
For many teenagers, oral sex is the new abstinence (in 
the Clintonesque sense), and its contraceptive effect is 
a bonus.  For men who have sex with men (MSM), the 
near-universal practice of fellatio is a pretty effective HIV 
prevention strategy.  Indeed, sexual safety codes within 
MSM relationships are often seen as being honoured if 
oral sex is the only sex that takes place with third parties. 
Oro-anal sex (‘rimming’) with casual partners has gone 
from being a minority practice among MSM in Australia 
in the 1980s to a majority practice by the 2000s.
Oral sex brings with it advantages and dangers.  Certainly, 
among MSM only anal sex and oral sex rate as ‘highly 
valued’ as a source of pleasure, with the widespread use of 
oral sex probably reducing the individual- and population-
level risk of HIV transmission.  And oral sex is one of the 
most efficacious and use-effective contraceptives. 
On the public health down-side, oral sex is logistically 
easier to organise than anal or vaginal sex so it enables 
rapid and furtive sexual encounters.  Only in commercial 
contexts is oral sex protected with a condom.  Promoted 
since the 1980s, everyone talks about dental dams for 
cunnilingus and rimming, but hardly anybody has ever 
used one.  Some of the diseases that have been linked to 
oral sex include ano-genital HSV-1 infection, gonorrhoea, 
syphilis, hepatitis A, shigellosis, giardiasis, amoebiasis, 
and ocular and oro-pharyngeal cancers.  While unusual, 
there are occasional traumatic consequences to oral sex, 
though these are rarely fatal.  
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THE	LAW	AND	SExWORKER	HEALTH	(LASH)	
PROJECT
Donovan B1,2, O’Connor JL1, Harcourt C1,2, Egger S3, 
Wand H1, Chen My4,5, Tabrizi S6, Marshall L7, Kaldor JM1, 
Fairley CK4,5
1National Centre in HIV Epidemiology and Clinical 
Research, University of New South Wales, Sydney NSW; 
2Sydney Sexual Health Centre, Sydney Hospital NSW; 
3Faculty of Law, UNSW; 4School of Population Health, 
University of Melbourne VIC; 5Melbourne Sexual Health 
Centre, The Alfred Hospital, Melbourne VIC; 6Microbiology 
Department, Royal Women’s Hospital, Melbourne 
VIC; 7Fremantle Sexual Health Centre, Fremantle WA, 
AUSTRALIA.
objective: Based on the hypothesis that restrictive or 
punitive laws could have adverse consequences, we 
explored the impact of various prostitution laws on the 
health and welfare of the sex workers working in three 
jurisdictions.
Methods: Key informants, searches of advertisements, 
agency lists, and site visits enabled us to map the female 
brothel-based sex industries in Perth (where all forms of 
sex work were criminalised), Melbourne (decriminalised, 
but regulated), and Sydney (decriminalised and 
deregulated).  Representative samples of sex workers 
were invited to self-complete a questionnaire (available in 
5 languages) and to provide a vaginal tampon for testing 
for chlamydia, gonorrhoea, Mycoplasma genitalium, and 
Trichomonas vaginalis by multiplex PCR.
results: All 3 cities had thriving and diverse sex industries, 
though the unregistered premises in Melbourne 
proved to be the most difficult to access. Questionnaire 
participation rates were high (>80%) when access was 
gained: 175 women in Perth, 229 in Melbourne, and 201 
in Sydney. The Melbourne women were a median of 4 
years older and had been working 2-3 times longer.  Only 
27% of the Sydney women had been born in Australia (cf 
51% in Perth and 67% in Melbourne, p<0.001), while more 
Perth women had injected drugs (14%) in the last 12m (cf 
2% in Sydney and 10% in Melbourne, p<0.001). There was 
no significant difference in mental health scores (K10) 
between the women in the 3 cities. Despite vastly more 
frequent screening of the Melbourne women as required 
by the law (72% monthly cf 12% in Sydney and 15% in 
Perth, p<0.001) STI prevalences were similarly low in each 
city. However, the under-sampling of unregulated sex 
workers in Melbourne limited the interpretation of these 
findings.
Sexual Health Conference Closing
3.30pm – 5.00pm
Conclusions: The demographic differences between the 
sex industries in the 3 cities may be partially explained 
by their legal frameworks. The policy of compulsory 
monthly STI screening of sex workers in Victoria should 
be reviewed.
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